cord_uid,title,abstract,authors,journal,publish_time,source_x,doi,pmcid,url,publication_year,publication_month,title_length,title_word_count,has_abstract,abstract_length,abstract_word_count,has_journal
cord-000000,Analysis of transmission and pneumonia in clinical settings,This study examines transmission with 121 word abstract...,,,2021-07-08,Medline,,PMC1000000,https://example.com/paper_0,2021.0,7.0,59,8,True,58.0,8.0,False
cord-000001,Analysis of COVID-19 and treatment and public health and antibody in clinical settings,This study examines COVID-19 with 363 word abstract...,"Author1_1, Author1_2",Science,2019-12-30,Medline,10.1000/sample.1,,https://example.com/paper_1,2019.0,12.0,86,13,True,54.0,8.0,True
cord-000002,Analysis of coronavirus and COVID-19 and treatment in clinical settings,This study examines coronavirus with 479 word abstract...,"Author2_1, Author2_2",Nature,,PMC,10.1000/sample.2,,,,,71,10,True,57.0,8.0,True
cord-000003,Analysis of antiviral and public health and clinical and pandemic in clinical settings,This study examines antiviral with 326 word abstract...,"Author3_1, Author3_2",New England Journal of Medicine,2021-10-16,WHO,10.1000/sample.3,PMC1000003,https://example.com/paper_3,2021.0,10.0,86,13,True,55.0,8.0,True
cord-000004,Analysis of epidemiology and symptoms and COVID-19 and transmission in clinical settings,This study examines epidemiology with 127 word abstract...,"Author4_1, Author4_2",Journal of Virology,2019-12-13,medRxiv,10.1000/sample.4,PMC1000004,https://example.com/paper_4,2019.0,12.0,88,12,True,58.0,8.0,True
cord-000005,Analysis of antiviral and immunity and lockdown and SARS-CoV-2 in clinical settings,This study examines antiviral with 212 word abstract...,Author5_1,Science,2020-08-20,WHO,,PMC1000005,https://example.com/paper_5,2020.0,8.0,83,12,True,55.0,8.0,True
cord-000006,Analysis of symptoms and antiviral and respiratory and diagnosis in clinical settings,,"Author6_1, Author6_2",BMJ,2021-07-17,PMC,10.1000/sample.6,PMC1000006,https://example.com/paper_6,2021.0,7.0,85,12,False,,,True
cord-000007,Analysis of epidemiology and clinical and outbreak and pandemic in clinical settings,This study examines epidemiology with 215 word abstract...,"Author7_1, Author7_2",Lancet,2021-10-25,WHO,10.1000/sample.7,PMC1000007,https://example.com/paper_7,2021.0,10.0,84,12,True,58.0,8.0,True
cord-000008,Analysis of treatment and symptoms in clinical settings,This study examines treatment with 257 word abstract...,"Author8_1, Author8_2",PLoS ONE,2020-06-11,Medline,10.1000/sample.8,PMC1000008,https://example.com/paper_8,2020.0,6.0,55,8,True,55.0,8.0,True
cord-000009,Analysis of clinical and SARS-CoV-2 and lockdown and symptoms in clinical settings,This study examines clinical with 290 word abstract...,"Author9_1, Author9_2",Cell,2020-10-30,PMC,10.1000/sample.9,PMC1000009,https://example.com/paper_9,2020.0,10.0,82,12,True,54.0,8.0,True
cord-000010,Analysis of antibody and therapeutic and vaccination and pandemic in clinical settings,This study examines antibody with 412 word abstract...,"Author10_1, Author10_2",Emerging Infectious Diseases,2019-12-18,medRxiv,10.1000/sample.10,,https://example.com/paper_10,2019.0,12.0,86,12,True,54.0,8.0,True
cord-000011,Analysis of coronavirus and antibody and SARS-CoV-2 and lockdown in clinical settings,This study examines coronavirus with 407 word abstract...,"Author11_1, Author11_2",Emerging Infectious Diseases,,bioRxiv,10.1000/sample.11,,,,,85,12,True,57.0,8.0,True
cord-000012,Analysis of public health and therapeutic and pneumonia in clinical settings,This study examines public health with 384 word abstract...,"Author12_1, Author12_2",,2021-05-09,WHO,10.1000/sample.12,PMC1000012,,2021.0,5.0,76,11,True,59.0,9.0,False
cord-000013,Analysis of treatment and diagnosis and therapeutic in clinical settings,This study examines treatment with 277 word abstract...,Author13_1,Cell,2020-10-15,medRxiv,10.1000/sample.13,PMC1000013,https://example.com/paper_13,2020.0,10.0,72,10,True,55.0,8.0,True
cord-000014,Analysis of antiviral and treatment and vaccination in clinical settings,This study examines antiviral with 475 word abstract...,"Author14_1, Author14_2",Lancet,2020-04-04,PMC,10.1000/sample.14,PMC1000014,https://example.com/paper_14,2020.0,4.0,72,10,True,55.0,8.0,True
cord-000015,Analysis of SARS-CoV-2 and respiratory and symptoms and clinical in clinical settings,This study examines SARS-CoV-2 with 364 word abstract...,"Author15_1, Author15_2",Lancet,2020-04-05,ArXiv,,PMC1000015,https://example.com/paper_15,2020.0,4.0,85,12,True,56.0,8.0,True
cord-000016,Analysis of respiratory and lockdown in clinical settings,This study examines respiratory with 221 word abstract...,"Author16_1, Author16_2",,2021-02-08,ArXiv,10.1000/sample.16,PMC1000016,https://example.com/paper_16,2021.0,2.0,57,8,True,57.0,8.0,False
cord-000017,Analysis of clinical and lockdown in clinical settings,This study examines clinical with 290 word abstract...,Author17_1,JAMA,2021-10-02,Medline,,PMC1000017,,2021.0,10.0,54,8,True,54.0,8.0,True
cord-000018,Analysis of epidemiology and pneumonia and antiviral and clinical in clinical settings,This study examines epidemiology with 472 word abstract...,"Author18_1, Author18_2",PLoS ONE,2022-08-17,Medline,10.1000/sample.18,PMC1000018,https://example.com/paper_18,2022.0,8.0,86,12,True,58.0,8.0,True
cord-000019,Analysis of symptoms and pandemic in clinical settings,,Author19_1,Journal of Medical Virology,2020-07-19,ArXiv,10.1000/sample.19,PMC1000019,https://example.com/paper_19,2020.0,7.0,54,8,False,,,True
cord-000020,Analysis of symptoms and pandemic and lockdown and therapeutic in clinical settings,This study examines symptoms with 465 word abstract...,"Author20_1, Author20_2",Emerging Infectious Diseases,2020-04-14,Medline,10.1000/sample.20,,https://example.com/paper_20,2020.0,4.0,83,12,True,54.0,8.0,True
cord-000021,Analysis of COVID-19 and symptoms in clinical settings,This study examines COVID-19 with 407 word abstract...,Author21_1,Virology,2021-09-25,Medline,10.1000/sample.21,PMC1000021,,2021.0,9.0,54,8,True,54.0,8.0,True
cord-000022,Analysis of outbreak and public health in clinical settings,This study examines outbreak with 254 word abstract...,"Author22_1, Author22_2",Cell,,ArXiv,10.1000/sample.22,PMC1000022,,,,59,9,True,54.0,8.0,True
cord-000023,Analysis of SARS-CoV-2 and diagnosis and outbreak in clinical settings,This study examines SARS-CoV-2 with 313 word abstract...,"Author23_1, Author23_2",PLoS ONE,2021-02-15,Medline,,,https://example.com/paper_23,2021.0,2.0,70,10,True,56.0,8.0,True
cord-000024,Analysis of public health and clinical and SARS-CoV-2 in clinical settings,This study examines public health with 245 word abstract...,"Author24_1, Author24_2",Journal of Medical Virology,2021-10-01,PMC,10.1000/sample.24,PMC1000024,https://example.com/paper_24,2021.0,10.0,74,11,True,59.0,9.0,True
cord-000025,Analysis of outbreak and SARS-CoV-2 in clinical settings,This study examines outbreak with 319 word abstract...,"Author25_1, Author25_2",Nature,2021-11-11,WHO,10.1000/sample.25,PMC1000025,https://example.com/paper_25,2021.0,11.0,56,8,True,54.0,8.0,True
cord-000026,Analysis of antiviral and clinical in clinical settings,This study examines antiviral with 112 word abstract...,"Author26_1, Author26_2",New England Journal of Medicine,,PMC,10.1000/sample.26,PMC1000026,https://example.com/paper_26,,,55,8,True,55.0,8.0,True
cord-000027,Analysis of pneumonia and symptoms and diagnosis in clinical settings,This study examines pneumonia with 177 word abstract...,"Author27_1, Author27_2",Science Translational Medicine,2022-08-24,WHO,10.1000/sample.27,PMC1000027,https://example.com/paper_27,2022.0,8.0,69,10,True,55.0,8.0,True
cord-000028,Analysis of antiviral and vaccination and SARS-CoV-2 and therapeutic in clinical settings,This study examines antiviral with 388 word abstract...,"Author28_1, Author28_2",New England Journal of Medicine,2021-11-05,PMC,10.1000/sample.28,PMC1000028,https://example.com/paper_28,2021.0,11.0,89,12,True,55.0,8.0,True
cord-000029,Analysis of COVID-19 and diagnosis in clinical settings,This study examines COVID-19 with 402 word abstract...,"Author29_1, Author29_2",Clinical Infectious Diseases,2021-05-16,Medline,10.1000/sample.29,,https://example.com/paper_29,2021.0,5.0,55,8,True,54.0,8.0,True
cord-000030,Analysis of therapeutic and respiratory and coronavirus and immunity in clinical settings,This study examines therapeutic with 498 word abstract...,Author30_1,Science Translational Medicine,2021-10-20,ArXiv,10.1000/sample.30,,https://example.com/paper_30,2021.0,10.0,89,12,True,57.0,8.0,True
cord-000031,Analysis of coronavirus and transmission in clinical settings,This study examines coronavirus with 162 word abstract...,Author31_1,Clinical Infectious Diseases,2021-12-13,bioRxiv,10.1000/sample.31,PMC1000031,https://example.com/paper_31,2021.0,12.0,61,8,True,57.0,8.0,True
cord-000032,Analysis of clinical and symptoms and epidemiology and transmission in clinical settings,This study examines clinical with 465 word abstract...,Author32_1,,2020-10-12,Medline,10.1000/sample.32,PMC1000032,https://example.com/paper_32,2020.0,10.0,88,12,True,54.0,8.0,False
cord-000033,Analysis of diagnosis and outbreak in clinical settings,This study examines diagnosis with 410 word abstract...,"Author33_1, Author33_2",Nature,2020-09-11,bioRxiv,10.1000/sample.33,PMC1000033,https://example.com/paper_33,2020.0,9.0,55,8,True,55.0,8.0,True
cord-000034,Analysis of clinical and symptoms and diagnosis in clinical settings,This study examines clinical with 314 word abstract...,Author34_1,Nature,2021-01-11,Medline,10.1000/sample.34,,,2021.0,1.0,68,10,True,54.0,8.0,True
cord-000035,Analysis of diagnosis and coronavirus and therapeutic in clinical settings,This study examines diagnosis with 233 word abstract...,"Author35_1, Author35_2",Nature Medicine,2021-04-19,Medline,10.1000/sample.35,PMC1000035,https://example.com/paper_35,2021.0,4.0,74,10,True,55.0,8.0,True
cord-000036,Analysis of transmission and therapeutic and antiviral and antibody in clinical settings,,"Author36_1, Author36_2",Nature,2020-11-05,ArXiv,10.1000/sample.36,PMC1000036,https://example.com/paper_36,2020.0,11.0,88,12,False,,,True
cord-000037,Analysis of transmission and COVID-19 in clinical settings,This study examines transmission with 429 word abstract...,Author37_1,Emerging Infectious Diseases,2020-05-08,bioRxiv,10.1000/sample.37,PMC1000037,https://example.com/paper_37,2020.0,5.0,58,8,True,58.0,8.0,True
cord-000038,Analysis of pandemic and epidemiology and SARS-CoV-2 and coronavirus in clinical settings,This study examines pandemic with 181 word abstract...,"Author38_1, Author38_2",Science,2021-03-30,PMC,10.1000/sample.38,PMC1000038,https://example.com/paper_38,2021.0,3.0,89,12,True,54.0,8.0,True
cord-000039,Analysis of respiratory and clinical and epidemiology and vaccination in clinical settings,This study examines respiratory with 373 word abstract...,"Author39_1, Author39_2",,,ArXiv,10.1000/sample.39,PMC1000039,https://example.com/paper_39,,,90,12,True,57.0,8.0,False
cord-000040,Analysis of symptoms and clinical and treatment in clinical settings,This study examines symptoms with 239 word abstract...,"Author40_1, Author40_2",Journal of Virology,2022-09-23,WHO,10.1000/sample.40,PMC1000040,https://example.com/paper_40,2022.0,9.0,68,10,True,54.0,8.0,True
cord-000041,Analysis of pandemic and respiratory in clinical settings,This study examines pandemic with 198 word abstract...,Author41_1,Science Translational Medicine,2020-03-12,Medline,10.1000/sample.41,,https://example.com/paper_41,2020.0,3.0,57,8,True,54.0,8.0,True
cord-000042,Analysis of treatment and diagnosis in clinical settings,This study examines treatment with 325 word abstract...,"Author42_1, Author42_2",,2020-03-29,Medline,10.1000/sample.42,PMC1000042,,2020.0,3.0,56,8,True,55.0,8.0,False
cord-000043,Analysis of pneumonia and diagnosis and immunity in clinical settings,This study examines pneumonia with 444 word abstract...,"Author43_1, Author43_2",JAMA,2021-10-28,ArXiv,10.1000/sample.43,PMC1000043,,2021.0,10.0,69,10,True,55.0,8.0,True
cord-000044,Analysis of treatment and coronavirus in clinical settings,This study examines treatment with 173 word abstract...,"Author44_1, Author44_2",Virology,2020-12-28,ArXiv,10.1000/sample.44,PMC1000044,https://example.com/paper_44,2020.0,12.0,58,8,True,55.0,8.0,True
cord-000045,Analysis of respiratory and antiviral in clinical settings,This study examines respiratory with 157 word abstract...,,Science,2019-12-27,PMC,10.1000/sample.45,PMC1000045,https://example.com/paper_45,2019.0,12.0,58,8,True,57.0,8.0,True
cord-000046,Analysis of SARS-CoV-2 and antiviral and transmission in clinical settings,This study examines SARS-CoV-2 with 114 word abstract...,"Author46_1, Author46_2",,2020-10-14,medRxiv,10.1000/sample.46,PMC1000046,https://example.com/paper_46,2020.0,10.0,74,10,True,56.0,8.0,False
cord-000047,Analysis of clinical and transmission in clinical settings,This study examines clinical with 418 word abstract...,"Author47_1, Author47_2",PLoS ONE,2020-04-02,ArXiv,10.1000/sample.47,PMC1000047,https://example.com/paper_47,2020.0,4.0,58,8,True,54.0,8.0,True
cord-000048,Analysis of vaccination and antibody in clinical settings,This study examines vaccination with 324 word abstract...,"Author48_1, Author48_2",,2021-01-11,Medline,10.1000/sample.48,,https://example.com/paper_48,2021.0,1.0,57,8,True,57.0,8.0,False
cord-000049,Analysis of antibody and COVID-19 and immunity and vaccination in clinical settings,This study examines antibody with 487 word abstract...,"Author49_1, Author49_2",Cell,,medRxiv,10.1000/sample.49,,,,,83,12,True,54.0,8.0,True
cord-000050,Analysis of respiratory and therapeutic and COVID-19 and outbreak in clinical settings,This study examines respiratory with 301 word abstract...,"Author50_1, Author50_2",,,PMC,10.1000/sample.50,,https://example.com/paper_50,,,86,12,True,57.0,8.0,False
cord-000051,Analysis of COVID-19 and public health and epidemiology in clinical settings,This study examines COVID-19 with 230 word abstract...,"Author51_1, Author51_2",Cell,2021-08-08,medRxiv,10.1000/sample.51,,https://example.com/paper_51,2021.0,8.0,76,11,True,54.0,8.0,True
cord-000052,Analysis of vaccination and symptoms and respiratory in clinical settings,,"Author52_1, Author52_2",Clinical Infectious Diseases,2020-11-20,bioRxiv,10.1000/sample.52,PMC1000052,https://example.com/paper_52,2020.0,11.0,73,10,False,,,True
cord-000053,Analysis of antiviral and SARS-CoV-2 and outbreak and coronavirus in clinical settings,This study examines antiviral with 229 word abstract...,"Author53_1, Author53_2",Clinical Infectious Diseases,2021-05-13,bioRxiv,10.1000/sample.53,PMC1000053,https://example.com/paper_53,2021.0,5.0,86,12,True,55.0,8.0,True
cord-000054,Analysis of COVID-19 and coronavirus in clinical settings,This study examines COVID-19 with 107 word abstract...,Author54_1,Clinical Infectious Diseases,2020-10-02,ArXiv,10.1000/sample.54,,https://example.com/paper_54,2020.0,10.0,57,8,True,54.0,8.0,True
cord-000055,Analysis of SARS-CoV-2 and antiviral and outbreak in clinical settings,This study examines SARS-CoV-2 with 319 word abstract...,"Author55_1, Author55_2",Nature,2020-04-23,ArXiv,10.1000/sample.55,PMC1000055,https://example.com/paper_55,2020.0,4.0,70,10,True,56.0,8.0,True
cord-000056,Analysis of antibody and respiratory and outbreak in clinical settings,This study examines antibody with 415 word abstract...,Author56_1,Nature,2020-05-11,WHO,,PMC1000056,https://example.com/paper_56,2020.0,5.0,70,10,True,54.0,8.0,True
cord-000057,Analysis of COVID-19 and antibody in clinical settings,This study examines COVID-19 with 463 word abstract...,"Author57_1, Author57_2",Journal of Virology,,ArXiv,10.1000/sample.57,,https://example.com/paper_57,,,54,8,True,54.0,8.0,True
cord-000058,Analysis of antiviral and transmission in clinical settings,This study examines antiviral with 362 word abstract...,"Author58_1, Author58_2",Journal of Medical Virology,2019-12-21,PMC,10.1000/sample.58,,https://example.com/paper_58,2019.0,12.0,59,8,True,55.0,8.0,True
cord-000059,Analysis of pandemic and vaccination and treatment in clinical settings,This study examines pandemic with 159 word abstract...,Author59_1,,2021-06-22,PMC,10.1000/sample.59,,https://example.com/paper_59,2021.0,6.0,71,10,True,54.0,8.0,False
cord-000060,Analysis of COVID-19 and pandemic in clinical settings,This study examines COVID-19 with 340 word abstract...,,Emerging Infectious Diseases,2020-05-28,Medline,10.1000/sample.60,PMC1000060,https://example.com/paper_60,2020.0,5.0,54,8,True,54.0,8.0,True
cord-000061,Analysis of public health and symptoms in clinical settings,This study examines public health with 229 word abstract...,"Author61_1, Author61_2",Cell,2021-03-14,WHO,10.1000/sample.61,PMC1000061,,2021.0,3.0,59,9,True,59.0,9.0,True
cord-000062,Analysis of clinical and transmission and SARS-CoV-2 in clinical settings,This study examines clinical with 330 word abstract...,"Author62_1, Author62_2",JAMA,2021-11-07,ArXiv,,PMC1000062,https://example.com/paper_62,2021.0,11.0,73,10,True,54.0,8.0,True
cord-000063,Analysis of transmission and antiviral in clinical settings,This study examines transmission with 257 word abstract...,"Author63_1, Author63_2",Cell,2020-09-05,medRxiv,10.1000/sample.63,PMC1000063,,2020.0,9.0,59,8,True,58.0,8.0,True
cord-000064,Analysis of lockdown and therapeutic and diagnosis in clinical settings,This study examines lockdown with 178 word abstract...,"Author64_1, Author64_2",Virology,2020-07-24,WHO,10.1000/sample.64,,https://example.com/paper_64,2020.0,7.0,71,10,True,54.0,8.0,True
cord-000065,Analysis of pandemic and treatment and therapeutic in clinical settings,This study examines pandemic with 179 word abstract...,Author65_1,BMJ,2019-12-11,ArXiv,10.1000/sample.65,PMC1000065,https://example.com/paper_65,2019.0,12.0,71,10,True,54.0,8.0,True
cord-000067,Analysis of antibody and outbreak and public health and clinical in clinical settings,This study examines antibody with 196 word abstract...,"Author67_1, Author67_2",PLoS ONE,2020-11-03,bioRxiv,10.1000/sample.67,PMC1000067,https://example.com/paper_67,2020.0,11.0,85,13,True,54.0,8.0,True
cord-000068,Analysis of public health and SARS-CoV-2 and treatment and pandemic in clinical settings,This study examines public health with 465 word abstract...,"Author68_1, Author68_2",BMJ,2021-06-22,bioRxiv,10.1000/sample.68,,https://example.com/paper_68,2021.0,6.0,88,13,True,59.0,9.0,True
cord-000069,Analysis of vaccination and immunity and therapeutic and antiviral in clinical settings,This study examines vaccination with 365 word abstract...,"Author69_1, Author69_2",Science,2020-02-07,ArXiv,10.1000/sample.69,PMC1000069,https://example.com/paper_69,2020.0,2.0,87,12,True,57.0,8.0,True
cord-000070,Analysis of treatment and clinical and SARS-CoV-2 in clinical settings,This study examines treatment with 248 word abstract...,"Author70_1, Author70_2",BMJ,2020-09-29,bioRxiv,10.1000/sample.70,PMC1000070,https://example.com/paper_70,2020.0,9.0,70,10,True,55.0,8.0,True
cord-000071,Analysis of transmission and SARS-CoV-2 and pneumonia and antibody in clinical settings,This study examines transmission with 235 word abstract...,Author71_1,Cell,2021-08-01,bioRxiv,10.1000/sample.71,PMC1000071,https://example.com/paper_71,2021.0,8.0,87,12,True,58.0,8.0,True
cord-000072,Analysis of public health and diagnosis in clinical settings,This study examines public health with 411 word abstract...,"Author72_1, Author72_2",Clinical Infectious Diseases,2021-03-07,Medline,10.1000/sample.72,PMC1000072,https://example.com/paper_72,2021.0,3.0,60,9,True,59.0,9.0,True
cord-000073,Analysis of immunity and COVID-19 and transmission in clinical settings,This study examines immunity with 159 word abstract...,"Author73_1, Author73_2",,2021-02-07,ArXiv,10.1000/sample.73,PMC1000073,https://example.com/paper_73,2021.0,2.0,71,10,True,54.0,8.0,False
cord-000074,Analysis of epidemiology and immunity and SARS-CoV-2 and vaccination in clinical settings,This study examines epidemiology with 174 word abstract...,"Author74_1, Author74_2",Nature Medicine,2021-12-16,Medline,10.1000/sample.74,,,2021.0,12.0,89,12,True,58.0,8.0,True
cord-000075,Analysis of respiratory and immunity and diagnosis and treatment in clinical settings,This study examines respiratory with 228 word abstract...,"Author75_1, Author75_2",JAMA,2020-12-02,medRxiv,10.1000/sample.75,PMC1000075,https://example.com/paper_75,2020.0,12.0,85,12,True,57.0,8.0,True
cord-000076,Analysis of vaccination and lockdown and COVID-19 in clinical settings,This study examines vaccination with 106 word abstract...,"Author76_1, Author76_2",,2020-12-29,medRxiv,10.1000/sample.76,PMC1000076,https://example.com/paper_76,2020.0,12.0,70,10,True,57.0,8.0,False
cord-000077,Analysis of treatment and respiratory and diagnosis in clinical settings,This study examines treatment with 388 word abstract...,"Author77_1, Author77_2",Virology,2021-06-14,PMC,10.1000/sample.77,PMC1000077,https://example.com/paper_77,2021.0,6.0,72,10,True,55.0,8.0,True
cord-000078,Analysis of transmission and COVID-19 and vaccination in clinical settings,This study examines transmission with 131 word abstract...,"Author78_1, Author78_2",Lancet,2021-01-05,WHO,,,https://example.com/paper_78,2021.0,1.0,74,10,True,58.0,8.0,True
cord-000079,Analysis of vaccination and lockdown and transmission in clinical settings,This study examines vaccination with 367 word abstract...,"Author79_1, Author79_2",Lancet,2020-06-16,PMC,10.1000/sample.79,PMC1000079,https://example.com/paper_79,2020.0,6.0,74,10,True,57.0,8.0,True
cord-000080,Analysis of lockdown and immunity and SARS-CoV-2 and pneumonia in clinical settings,This study examines lockdown with 374 word abstract...,"Author80_1, Author80_2",BMJ,2021-09-20,ArXiv,10.1000/sample.80,PMC1000080,https://example.com/paper_80,2021.0,9.0,83,12,True,54.0,8.0,True
cord-000081,Analysis of diagnosis and therapeutic and outbreak and antiviral in clinical settings,This study examines diagnosis with 463 word abstract...,"Author81_1, Author81_2",JAMA,2021-09-04,medRxiv,10.1000/sample.81,,,2021.0,9.0,85,12,True,55.0,8.0,True
cord-000082,Analysis of epidemiology and respiratory in clinical settings,This study examines epidemiology with 165 word abstract...,"Author82_1, Author82_2",JAMA,2019-12-01,medRxiv,10.1000/sample.82,,,2019.0,12.0,61,8,True,58.0,8.0,True
cord-000083,Analysis of antiviral and pneumonia and clinical and vaccination in clinical settings,This study examines antiviral with 241 word abstract...,"Author83_1, Author83_2",Emerging Infectious Diseases,2021-05-23,bioRxiv,10.1000/sample.83,,https://example.com/paper_83,2021.0,5.0,85,12,True,55.0,8.0,True
cord-000084,Analysis of outbreak and SARS-CoV-2 and treatment in clinical settings,,"Author84_1, Author84_2",Journal of Virology,2020-03-23,PMC,10.1000/sample.84,PMC1000084,,2020.0,3.0,70,10,False,,,True
cord-000085,Analysis of immunity and treatment and COVID-19 in clinical settings,This study examines immunity with 492 word abstract...,Author85_1,,2021-04-20,ArXiv,10.1000/sample.85,,https://example.com/paper_85,2021.0,4.0,68,10,True,54.0,8.0,False
cord-000086,Analysis of transmission and public health and COVID-19 in clinical settings,This study examines transmission with 361 word abstract...,"Author86_1, Author86_2",Virology,2020-05-26,bioRxiv,10.1000/sample.86,,https://example.com/paper_86,2020.0,5.0,76,11,True,58.0,8.0,True
cord-000087,Analysis of symptoms and coronavirus and therapeutic and transmission in clinical settings,This study examines symptoms with 481 word abstract...,"Author87_1, Author87_2",Nature,2020-05-21,bioRxiv,10.1000/sample.87,PMC1000087,,2020.0,5.0,90,12,True,54.0,8.0,True
cord-000088,Analysis of lockdown and treatment and transmission and immunity in clinical settings,This study examines lockdown with 314 word abstract...,"Author88_1, Author88_2",Science,2020-11-28,PMC,10.1000/sample.88,PMC1000088,,2020.0,11.0,85,12,True,54.0,8.0,True
cord-000089,Analysis of vaccination and public health and antiviral and pneumonia in clinical settings,This study examines vaccination with 192 word abstract...,"Author89_1, Author89_2",Nature,2021-08-31,medRxiv,10.1000/sample.89,PMC1000089,https://example.com/paper_89,2021.0,8.0,90,13,True,57.0,8.0,True
cord-000090,Analysis of immunity and COVID-19 and outbreak in clinical settings,This study examines immunity with 459 word abstract...,"Author90_1, Author90_2",JAMA,2019-12-21,PMC,10.1000/sample.90,PMC1000090,,2019.0,12.0,67,10,True,54.0,8.0,True
cord-000092,Analysis of epidemiology and public health and clinical in clinical settings,This study examines epidemiology with 225 word abstract...,"Author92_1, Author92_2",JAMA,2020-02-20,ArXiv,10.1000/sample.92,PMC1000092,,2020.0,2.0,76,11,True,58.0,8.0,True
cord-000094,Analysis of coronavirus and outbreak in clinical settings,This study examines coronavirus with 253 word abstract...,"Author94_1, Author94_2",JAMA,2020-03-31,Medline,10.1000/sample.94,PMC1000094,https://example.com/paper_94,2020.0,3.0,57,8,True,57.0,8.0,True
cord-000095,Analysis of SARS-CoV-2 and clinical in clinical settings,This study examines SARS-CoV-2 with 424 word abstract...,"Author95_1, Author95_2",BMJ,,WHO,10.1000/sample.95,PMC1000095,https://example.com/paper_95,,,56,8,True,56.0,8.0,True
cord-000096,Analysis of outbreak and clinical and treatment in clinical settings,This study examines outbreak with 331 word abstract...,"Author96_1, Author96_2",Journal of Medical Virology,2020-07-22,bioRxiv,10.1000/sample.96,,https://example.com/paper_96,2020.0,7.0,68,10,True,54.0,8.0,True
cord-000097,Analysis of diagnosis and public health and vaccination in clinical settings,This study examines diagnosis with 112 word abstract...,"Author97_1, Author97_2",BMJ,2019-12-04,WHO,10.1000/sample.97,,,2019.0,12.0,76,11,True,55.0,8.0,True
cord-000098,Analysis of COVID-19 and transmission in clinical settings,This study examines COVID-19 with 359 word abstract...,"Author98_1, Author98_2",Virology,2021-06-07,WHO,10.1000/sample.98,PMC1000098,https://example.com/paper_98,2021.0,6.0,58,8,True,54.0,8.0,True
cord-000099,Analysis of antibody and immunity and pandemic in clinical settings,This study examines antibody with 182 word abstract...,"Author99_1, Author99_2",Nature,2020-08-28,Medline,10.1000/sample.99,PMC1000099,https://example.com/paper_99,2020.0,8.0,67,10,True,54.0,8.0,True
cord-000101,Analysis of pneumonia and vaccination in clinical settings,This study examines pneumonia with 127 word abstract...,"Author101_1, Author101_2",New England Journal of Medicine,2022-01-16,bioRxiv,10.1000/sample.101,PMC1000101,https://example.com/paper_101,2022.0,1.0,58,8,True,55.0,8.0,True
cord-000102,Analysis of pneumonia and lockdown and epidemiology in clinical settings,This study examines pneumonia with 477 word abstract...,"Author102_1, Author102_2",BMJ,2020-03-14,PMC,10.1000/sample.102,PMC1000102,,2020.0,3.0,72,10,True,55.0,8.0,True
cord-000103,Analysis of public health and immunity and clinical and epidemiology in clinical settings,This study examines public health with 406 word abstract...,"Author103_1, Author103_2",BMJ,2019-12-27,ArXiv,10.1000/sample.103,PMC1000103,,2019.0,12.0,89,13,True,59.0,9.0,True
cord-000104,Analysis of immunity and antibody and symptoms and respiratory in clinical settings,This study examines immunity with 493 word abstract...,"Author104_1, Author104_2",New England Journal of Medicine,2020-07-23,medRxiv,10.1000/sample.104,PMC1000104,https://example.com/paper_104,2020.0,7.0,83,12,True,54.0,8.0,True
cord-000105,Analysis of symptoms and antiviral in clinical settings,This study examines symptoms with 376 word abstract...,"Author105_1, Author105_2",JAMA,2021-07-07,WHO,10.1000/sample.105,PMC1000105,,2021.0,7.0,55,8,True,54.0,8.0,True
cord-000106,Analysis of lockdown and vaccination in clinical settings,This study examines lockdown with 118 word abstract...,"Author106_1, Author106_2",Science Translational Medicine,,medRxiv,10.1000/sample.106,PMC1000106,https://example.com/paper_106,,,57,8,True,54.0,8.0,True
cord-000108,Analysis of immunity and therapeutic in clinical settings,This study examines immunity with 212 word abstract...,"Author108_1, Author108_2",Science,2020-12-29,ArXiv,10.1000/sample.108,PMC1000108,https://example.com/paper_108,2020.0,12.0,57,8,True,54.0,8.0,True
cord-000109,Analysis of public health and antiviral and therapeutic and diagnosis in clinical settings,This study examines public health with 381 word abstract...,"Author109_1, Author109_2",Journal of Medical Virology,2020-12-30,Medline,10.1000/sample.109,PMC1000109,https://example.com/paper_109,2020.0,12.0,90,13,True,59.0,9.0,True
cord-000110,Analysis of SARS-CoV-2 and pneumonia in clinical settings,This study examines SARS-CoV-2 with 123 word abstract...,"Author110_1, Author110_2",Nature Medicine,2020-04-25,ArXiv,10.1000/sample.110,PMC1000110,,2020.0,4.0,57,8,True,56.0,8.0,True
cord-000111,Analysis of antiviral and COVID-19 and outbreak in clinical settings,This study examines antiviral with 268 word abstract...,"Author111_1, Author111_2",Emerging Infectious Diseases,2021-09-06,PMC,10.1000/sample.111,,,2021.0,9.0,68,10,True,55.0,8.0,True
cord-000112,Analysis of antibody and vaccination and diagnosis in clinical settings,This study examines antibody with 201 word abstract...,"Author112_1, Author112_2",Lancet,2021-01-16,Medline,10.1000/sample.112,PMC1000112,https://example.com/paper_112,2021.0,1.0,71,10,True,54.0,8.0,True
cord-000113,Analysis of public health and antibody in clinical settings,This study examines public health with 370 word abstract...,"Author113_1, Author113_2",Cell,2021-05-06,bioRxiv,,PMC1000113,https://example.com/paper_113,2021.0,5.0,59,9,True,59.0,9.0,True
cord-000114,Analysis of SARS-CoV-2 and antiviral in clinical settings,This study examines SARS-CoV-2 with 247 word abstract...,"Author114_1, Author114_2",PLoS ONE,2020-11-10,PMC,10.1000/sample.114,,https://example.com/paper_114,2020.0,11.0,57,8,True,56.0,8.0,True
cord-000115,Analysis of symptoms and diagnosis in clinical settings,This study examines symptoms with 478 word abstract...,"Author115_1, Author115_2",Nature,2022-07-29,WHO,10.1000/sample.115,,https://example.com/paper_115,2022.0,7.0,55,8,True,54.0,8.0,True
cord-000116,Analysis of diagnosis and outbreak and antiviral in clinical settings,This study examines diagnosis with 486 word abstract...,Author116_1,Science,2022-10-07,Medline,10.1000/sample.116,,https://example.com/paper_116,2022.0,10.0,69,10,True,55.0,8.0,True
cord-000117,Analysis of diagnosis and antiviral and pneumonia in clinical settings,,"Author117_1, Author117_2",Science Translational Medicine,2021-02-10,bioRxiv,10.1000/sample.117,PMC1000117,https://example.com/paper_117,2021.0,2.0,70,10,False,,,True
cord-000118,Analysis of public health and epidemiology in clinical settings,This study examines public health with 343 word abstract...,"Author118_1, Author118_2",Journal of Medical Virology,2021-10-11,ArXiv,10.1000/sample.118,PMC1000118,https://example.com/paper_118,2021.0,10.0,63,9,True,59.0,9.0,True
cord-000120,Analysis of epidemiology and pandemic and respiratory and therapeutic in clinical settings,This study examines epidemiology with 222 word abstract...,"Author120_1, Author120_2",Science,2021-08-26,ArXiv,10.1000/sample.120,PMC1000120,https://example.com/paper_120,2021.0,8.0,90,12,True,58.0,8.0,True
cord-000121,Analysis of public health and outbreak and therapeutic and symptoms in clinical settings,This study examines public health with 208 word abstract...,"Author121_1, Author121_2",New England Journal of Medicine,,medRxiv,10.1000/sample.121,PMC1000121,https://example.com/paper_121,,,88,13,True,59.0,9.0,True
cord-000123,Analysis of antibody and diagnosis and clinical and pandemic in clinical settings,This study examines antibody with 237 word abstract...,"Author123_1, Author123_2",Nature Medicine,2020-02-15,bioRxiv,10.1000/sample.123,,https://example.com/paper_123,2020.0,2.0,81,12,True,54.0,8.0,True
cord-000124,Analysis of antiviral and pandemic and diagnosis and lockdown in clinical settings,This study examines antiviral with 147 word abstract...,"Author124_1, Author124_2",PLoS ONE,2020-05-31,ArXiv,10.1000/sample.124,PMC1000124,https://example.com/paper_124,2020.0,5.0,82,12,True,55.0,8.0,True
cord-000125,Analysis of pandemic and outbreak and respiratory in clinical settings,This study examines pandemic with 217 word abstract...,"Author125_1, Author125_2",Cell,2020-08-28,ArXiv,10.1000/sample.125,,https://example.com/paper_125,2020.0,8.0,70,10,True,54.0,8.0,True
cord-000126,Analysis of pneumonia and coronavirus and symptoms in clinical settings,,"Author126_1, Author126_2",PLoS ONE,2020-02-17,WHO,10.1000/sample.126,PMC1000126,,2020.0,2.0,71,10,False,,,True
cord-000127,Analysis of antiviral and treatment in clinical settings,This study examines antiviral with 128 word abstract...,"Author127_1, Author127_2",Virology,2021-03-03,Medline,10.1000/sample.127,PMC1000127,https://example.com/paper_127,2021.0,3.0,56,8,True,55.0,8.0,True
cord-000128,Analysis of vaccination and lockdown and respiratory in clinical settings,This study examines vaccination with 323 word abstract...,"Author128_1, Author128_2",Journal of Medical Virology,2021-03-03,bioRxiv,10.1000/sample.128,PMC1000128,https://example.com/paper_128,2021.0,3.0,73,10,True,57.0,8.0,True
cord-000129,Analysis of SARS-CoV-2 and coronavirus and antiviral and transmission in clinical settings,This study examines SARS-CoV-2 with 169 word abstract...,"Author129_1, Author129_2",Virology,,Medline,10.1000/sample.129,PMC1000129,https://example.com/paper_129,,,90,12,True,56.0,8.0,True
cord-000130,Analysis of public health and antibody and therapeutic in clinical settings,,"Author130_1, Author130_2",Emerging Infectious Diseases,2021-03-18,ArXiv,10.1000/sample.130,,https://example.com/paper_130,2021.0,3.0,75,11,False,,,True
cord-000131,Analysis of epidemiology and diagnosis and treatment and clinical in clinical settings,This study examines epidemiology with 209 word abstract...,"Author131_1, Author131_2",Journal of Virology,2021-07-26,ArXiv,10.1000/sample.131,PMC1000131,https://example.com/paper_131,2021.0,7.0,86,12,True,58.0,8.0,True
cord-000132,Analysis of pneumonia and lockdown and SARS-CoV-2 in clinical settings,This study examines pneumonia with 308 word abstract...,"Author132_1, Author132_2",,2021-07-08,PMC,10.1000/sample.132,PMC1000132,https://example.com/paper_132,2021.0,7.0,70,10,True,55.0,8.0,False
cord-000133,Analysis of respiratory and transmission and antibody in clinical settings,This study examines respiratory with 439 word abstract...,"Author133_1, Author133_2",BMJ,2021-07-03,bioRxiv,10.1000/sample.133,,https://example.com/paper_133,2021.0,7.0,74,10,True,57.0,8.0,True
cord-000134,Analysis of public health and coronavirus in clinical settings,This study examines public health with 197 word abstract...,"Author134_1, Author134_2",Journal of Virology,2022-07-31,WHO,10.1000/sample.134,,https://example.com/paper_134,2022.0,7.0,62,9,True,59.0,9.0,True
cord-000135,Analysis of respiratory and coronavirus and treatment and SARS-CoV-2 in clinical settings,This study examines respiratory with 265 word abstract...,"Author135_1, Author135_2",JAMA,2021-03-13,bioRxiv,10.1000/sample.135,PMC1000135,,2021.0,3.0,89,12,True,57.0,8.0,True
cord-000136,Analysis of clinical and therapeutic and immunity in clinical settings,This study examines clinical with 318 word abstract...,"Author136_1, Author136_2",Journal of Medical Virology,2021-12-21,WHO,10.1000/sample.136,PMC1000136,https://example.com/paper_136,2021.0,12.0,70,10,True,54.0,8.0,True
cord-000137,Analysis of clinical and SARS-CoV-2 and outbreak and lockdown in clinical settings,This study examines clinical with 219 word abstract...,"Author137_1, Author137_2",Cell,2020-07-14,Medline,10.1000/sample.137,PMC1000137,https://example.com/paper_137,2020.0,7.0,82,12,True,54.0,8.0,True
cord-000138,Analysis of epidemiology and outbreak and public health in clinical settings,This study examines epidemiology with 375 word abstract...,Author138_1,Nature,2020-01-06,ArXiv,,PMC1000138,https://example.com/paper_138,2020.0,1.0,76,11,True,58.0,8.0,True
cord-000139,Analysis of coronavirus and epidemiology and antibody and pandemic in clinical settings,This study examines coronavirus with 437 word abstract...,"Author139_1, Author139_2",BMJ,2019-12-14,bioRxiv,10.1000/sample.139,PMC1000139,https://example.com/paper_139,2019.0,12.0,87,12,True,57.0,8.0,True
cord-000140,Analysis of vaccination and antiviral and diagnosis in clinical settings,This study examines vaccination with 470 word abstract...,"Author140_1, Author140_2",Nature,2020-06-28,ArXiv,10.1000/sample.140,PMC1000140,https://example.com/paper_140,2020.0,6.0,72,10,True,57.0,8.0,True
cord-000141,Analysis of therapeutic and treatment and symptoms and antiviral in clinical settings,This study examines therapeutic with 127 word abstract...,"Author141_1, Author141_2",Lancet,2020-07-10,Medline,10.1000/sample.141,PMC1000141,https://example.com/paper_141,2020.0,7.0,85,12,True,57.0,8.0,True
cord-000142,Analysis of vaccination and transmission and lockdown in clinical settings,This study examines vaccination with 283 word abstract...,"Author142_1, Author142_2",Nature Medicine,2021-07-07,bioRxiv,10.1000/sample.142,PMC1000142,https://example.com/paper_142,2021.0,7.0,74,10,True,57.0,8.0,True
cord-000143,Analysis of COVID-19 and epidemiology in clinical settings,This study examines COVID-19 with 228 word abstract...,"Author143_1, Author143_2",Science Translational Medicine,2021-11-19,medRxiv,10.1000/sample.143,,https://example.com/paper_143,2021.0,11.0,58,8,True,54.0,8.0,True
cord-000144,Analysis of public health and transmission and symptoms in clinical settings,This study examines public health with 299 word abstract...,"Author144_1, Author144_2",Science Translational Medicine,2020-05-22,ArXiv,10.1000/sample.144,PMC1000144,https://example.com/paper_144,2020.0,5.0,76,11,True,59.0,9.0,True
cord-000145,Analysis of lockdown and antibody and coronavirus in clinical settings,This study examines lockdown with 151 word abstract...,Author145_1,PLoS ONE,2019-12-16,PMC,10.1000/sample.145,PMC1000145,https://example.com/paper_145,2019.0,12.0,70,10,True,54.0,8.0,True
cord-000146,Analysis of pandemic and SARS-CoV-2 and transmission in clinical settings,This study examines pandemic with 105 word abstract...,"Author146_1, Author146_2",Nature Medicine,2021-07-27,ArXiv,10.1000/sample.146,,https://example.com/paper_146,2021.0,7.0,73,10,True,54.0,8.0,True
cord-000147,Analysis of symptoms and vaccination and SARS-CoV-2 in clinical settings,,"Author147_1, Author147_2",Journal of Virology,2020-09-05,bioRxiv,10.1000/sample.147,PMC1000147,https://example.com/paper_147,2020.0,9.0,72,10,False,,,True
cord-000148,Analysis of immunity and clinical and vaccination in clinical settings,This study examines immunity with 463 word abstract...,"Author148_1, Author148_2",Cell,2020-08-26,WHO,10.1000/sample.148,PMC1000148,https://example.com/paper_148,2020.0,8.0,70,10,True,54.0,8.0,True
cord-000149,Analysis of public health and COVID-19 and clinical in clinical settings,This study examines public health with 436 word abstract...,"Author149_1, Author149_2",PLoS ONE,2021-12-16,WHO,10.1000/sample.149,PMC1000149,https://example.com/paper_149,2021.0,12.0,72,11,True,59.0,9.0,True
cord-000150,Analysis of respiratory and therapeutic and SARS-CoV-2 and lockdown in clinical settings,This study examines respiratory with 124 word abstract...,"Author150_1, Author150_2",,2022-03-17,PMC,,,https://example.com/paper_150,2022.0,3.0,88,12,True,57.0,8.0,False
cord-000151,Analysis of respiratory and antibody and pandemic and epidemiology in clinical settings,This study examines respiratory with 338 word abstract...,"Author151_1, Author151_2",Lancet,2019-12-11,Medline,,PMC1000151,https://example.com/paper_151,2019.0,12.0,87,12,True,57.0,8.0,True
cord-000152,Analysis of transmission and coronavirus in clinical settings,This study examines transmission with 498 word abstract...,"Author152_1, Author152_2",Clinical Infectious Diseases,2020-03-03,ArXiv,10.1000/sample.152,,,2020.0,3.0,61,8,True,58.0,8.0,True
cord-000153,Analysis of immunity and epidemiology and pneumonia in clinical settings,This study examines immunity with 434 word abstract...,Author153_1,Science,2020-08-11,medRxiv,10.1000/sample.153,PMC1000153,,2020.0,8.0,72,10,True,54.0,8.0,True
cord-000154,Analysis of treatment and COVID-19 and SARS-CoV-2 in clinical settings,This study examines treatment with 229 word abstract...,Author154_1,Emerging Infectious Diseases,,bioRxiv,10.1000/sample.154,,,,,70,10,True,55.0,8.0,True
cord-000155,Analysis of public health and transmission in clinical settings,This study examines public health with 281 word abstract...,"Author155_1, Author155_2",Emerging Infectious Diseases,2021-07-28,medRxiv,10.1000/sample.155,,https://example.com/paper_155,2021.0,7.0,63,9,True,59.0,9.0,True
cord-000156,Analysis of coronavirus and lockdown and treatment and outbreak in clinical settings,This study examines coronavirus with 138 word abstract...,Author156_1,Lancet,2021-02-11,bioRxiv,10.1000/sample.156,PMC1000156,https://example.com/paper_156,2021.0,2.0,84,12,True,57.0,8.0,True
cord-000157,Analysis of coronavirus and antiviral in clinical settings,This study examines coronavirus with 263 word abstract...,"Author157_1, Author157_2",Clinical Infectious Diseases,2021-12-25,bioRxiv,10.1000/sample.157,PMC1000157,,2021.0,12.0,58,8,True,57.0,8.0,True
cord-000158,Analysis of clinical and symptoms in clinical settings,This study examines clinical with 182 word abstract...,"Author158_1, Author158_2",PLoS ONE,2020-12-02,medRxiv,10.1000/sample.158,PMC1000158,,2020.0,12.0,54,8,True,54.0,8.0,True
cord-000159,Analysis of antiviral and vaccination and SARS-CoV-2 and respiratory in clinical settings,This study examines antiviral with 436 word abstract...,"Author159_1, Author159_2",Clinical Infectious Diseases,2020-11-20,PMC,10.1000/sample.159,,https://example.com/paper_159,2020.0,11.0,89,12,True,55.0,8.0,True
cord-000160,Analysis of COVID-19 and immunity and diagnosis and symptoms in clinical settings,This study examines COVID-19 with 176 word abstract...,"Author160_1, Author160_2",BMJ,2021-09-17,WHO,,,https://example.com/paper_160,2021.0,9.0,81,12,True,54.0,8.0,True
cord-000161,Analysis of antiviral and therapeutic in clinical settings,This study examines antiviral with 408 word abstract...,Author161_1,Clinical Infectious Diseases,2020-08-17,PMC,10.1000/sample.161,PMC1000161,https://example.com/paper_161,2020.0,8.0,58,8,True,55.0,8.0,True
cord-000162,Analysis of vaccination and SARS-CoV-2 and diagnosis in clinical settings,This study examines vaccination with 192 word abstract...,"Author162_1, Author162_2",Cell,,bioRxiv,10.1000/sample.162,PMC1000162,https://example.com/paper_162,,,73,10,True,57.0,8.0,True
cord-000163,Analysis of therapeutic and coronavirus in clinical settings,This study examines therapeutic with 317 word abstract...,"Author163_1, Author163_2",Nature Medicine,2019-12-23,ArXiv,10.1000/sample.163,,https://example.com/paper_163,2019.0,12.0,60,8,True,57.0,8.0,True
cord-000164,Analysis of outbreak and epidemiology in clinical settings,This study examines outbreak with 352 word abstract...,"Author164_1, Author164_2",Science Translational Medicine,2021-06-05,WHO,10.1000/sample.164,PMC1000164,https://example.com/paper_164,2021.0,6.0,58,8,True,54.0,8.0,True
cord-000165,Analysis of coronavirus and antibody and respiratory in clinical settings,This study examines coronavirus with 309 word abstract...,"Author165_1, Author165_2",Virology,,Medline,10.1000/sample.165,,https://example.com/paper_165,,,73,10,True,57.0,8.0,True
cord-000166,Analysis of pandemic and public health and antiviral and clinical in clinical settings,This study examines pandemic with 477 word abstract...,"Author166_1, Author166_2",,2020-06-20,Medline,10.1000/sample.166,PMC1000166,,2020.0,6.0,86,13,True,54.0,8.0,False
cord-000167,Analysis of outbreak and therapeutic and symptoms and COVID-19 in clinical settings,This study examines outbreak with 100 word abstract...,"Author167_1, Author167_2",Nature,2021-01-08,medRxiv,10.1000/sample.167,PMC1000167,https://example.com/paper_167,2021.0,1.0,83,12,True,54.0,8.0,True
cord-000168,Analysis of diagnosis and therapeutic and lockdown and outbreak in clinical settings,This study examines diagnosis with 422 word abstract...,"Author168_1, Author168_2",BMJ,2020-10-05,ArXiv,10.1000/sample.168,,https://example.com/paper_168,2020.0,10.0,84,12,True,55.0,8.0,True
cord-000169,Analysis of SARS-CoV-2 and epidemiology and antibody and lockdown in clinical settings,This study examines SARS-CoV-2 with 374 word abstract...,"Author169_1, Author169_2",Virology,2021-06-24,bioRxiv,10.1000/sample.169,,,2021.0,6.0,86,12,True,56.0,8.0,True
cord-000170,Analysis of pneumonia and symptoms and pandemic in clinical settings,This study examines pneumonia with 163 word abstract...,"Author170_1, Author170_2",Emerging Infectious Diseases,2021-06-17,Medline,10.1000/sample.170,,https://example.com/paper_170,2021.0,6.0,68,10,True,55.0,8.0,True
cord-000171,Analysis of pneumonia and epidemiology and antibody and coronavirus in clinical settings,This study examines pneumonia with 127 word abstract...,Author171_1,Nature Medicine,2021-10-30,PMC,10.1000/sample.171,,https://example.com/paper_171,2021.0,10.0,88,12,True,55.0,8.0,True
cord-000172,Analysis of diagnosis and clinical in clinical settings,This study examines diagnosis with 428 word abstract...,"Author172_1, Author172_2",Virology,2020-12-20,Medline,10.1000/sample.172,PMC1000172,https://example.com/paper_172,2020.0,12.0,55,8,True,55.0,8.0,True
cord-000173,Analysis of SARS-CoV-2 and treatment and vaccination and clinical in clinical settings,This study examines SARS-CoV-2 with 178 word abstract...,"Author173_1, Author173_2",Lancet,2021-02-08,Medline,10.1000/sample.173,,https://example.com/paper_173,2021.0,2.0,86,12,True,56.0,8.0,True
cord-000174,Analysis of COVID-19 and treatment and antibody and lockdown in clinical settings,This study examines COVID-19 with 440 word abstract...,"Author174_1, Author174_2",New England Journal of Medicine,2020-04-26,PMC,10.1000/sample.174,PMC1000174,,2020.0,4.0,81,12,True,54.0,8.0,True
cord-000175,Analysis of SARS-CoV-2 and therapeutic and antibody in clinical settings,This study examines SARS-CoV-2 with 457 word abstract...,"Author175_1, Author175_2",Nature Medicine,2021-08-08,WHO,10.1000/sample.175,,https://example.com/paper_175,2021.0,8.0,72,10,True,56.0,8.0,True
cord-000176,Analysis of vaccination and lockdown and antiviral and outbreak in clinical settings,This study examines vaccination with 177 word abstract...,"Author176_1, Author176_2",BMJ,2021-01-07,bioRxiv,10.1000/sample.176,PMC1000176,https://example.com/paper_176,2021.0,1.0,84,12,True,57.0,8.0,True
cord-000177,Analysis of therapeutic and vaccination and lockdown in clinical settings,This study examines therapeutic with 264 word abstract...,"Author177_1, Author177_2",New England Journal of Medicine,2021-11-08,bioRxiv,10.1000/sample.177,,https://example.com/paper_177,2021.0,11.0,73,10,True,57.0,8.0,True
cord-000178,Analysis of transmission and therapeutic and symptoms and antiviral in clinical settings,This study examines transmission with 471 word abstract...,Author178_1,,2021-09-30,WHO,10.1000/sample.178,PMC1000178,https://example.com/paper_178,2021.0,9.0,88,12,True,58.0,8.0,False
cord-000179,Analysis of diagnosis and respiratory and COVID-19 in clinical settings,This study examines diagnosis with 229 word abstract...,"Author179_1, Author179_2",JAMA,2021-02-07,PMC,10.1000/sample.179,PMC1000179,https://example.com/paper_179,2021.0,2.0,71,10,True,55.0,8.0,True
cord-000180,Analysis of lockdown and immunity in clinical settings,This study examines lockdown with 315 word abstract...,"Author180_1, Author180_2",Journal of Virology,2019-12-08,PMC,10.1000/sample.180,,,2019.0,12.0,54,8,True,54.0,8.0,True
cord-000181,Analysis of antibody and transmission and pandemic in clinical settings,This study examines antibody with 347 word abstract...,"Author181_1, Author181_2",JAMA,2020-03-27,medRxiv,10.1000/sample.181,PMC1000181,,2020.0,3.0,71,10,True,54.0,8.0,True
cord-000182,Analysis of clinical and vaccination and SARS-CoV-2 and transmission in clinical settings,This study examines clinical with 311 word abstract...,"Author182_1, Author182_2",Science,2020-09-07,WHO,,,https://example.com/paper_182,2020.0,9.0,89,12,True,54.0,8.0,True
cord-000183,Analysis of transmission and immunity and outbreak in clinical settings,This study examines transmission with 160 word abstract...,"Author183_1, Author183_2",Nature,2020-04-19,bioRxiv,,PMC1000183,https://example.com/paper_183,2020.0,4.0,71,10,True,58.0,8.0,True
cord-000184,Analysis of coronavirus and public health and epidemiology in clinical settings,This study examines coronavirus with 144 word abstract...,"Author184_1, Author184_2",BMJ,2022-07-25,bioRxiv,10.1000/sample.184,,,2022.0,7.0,79,11,True,57.0,8.0,True
cord-000185,Analysis of clinical and vaccination and outbreak in clinical settings,This study examines clinical with 204 word abstract...,"Author185_1, Author185_2",JAMA,2021-02-24,Medline,10.1000/sample.185,PMC1000185,https://example.com/paper_185,2021.0,2.0,70,10,True,54.0,8.0,True
cord-000186,Analysis of treatment and epidemiology and antiviral and coronavirus in clinical settings,This study examines treatment with 302 word abstract...,"Author186_1, Author186_2",New England Journal of Medicine,2020-07-09,ArXiv,10.1000/sample.186,,https://example.com/paper_186,2020.0,7.0,89,12,True,55.0,8.0,True
cord-000188,Analysis of antiviral and lockdown and clinical and treatment in clinical settings,This study examines antiviral with 154 word abstract...,"Author188_1, Author188_2",JAMA,2019-12-13,WHO,10.1000/sample.188,,https://example.com/paper_188,2019.0,12.0,82,12,True,55.0,8.0,True
cord-000189,Analysis of antiviral and lockdown and outbreak in clinical settings,This study examines antiviral with 101 word abstract...,"Author189_1, Author189_2",Science Translational Medicine,2020-04-27,ArXiv,10.1000/sample.189,PMC1000189,https://example.com/paper_189,2020.0,4.0,68,10,True,55.0,8.0,True
cord-000190,Analysis of vaccination and treatment and COVID-19 in clinical settings,This study examines vaccination with 291 word abstract...,"Author190_1, Author190_2",Journal of Virology,2020-03-06,ArXiv,10.1000/sample.190,PMC1000190,https://example.com/paper_190,2020.0,3.0,71,10,True,57.0,8.0,True
cord-000191,Analysis of pandemic and antibody and respiratory and epidemiology in clinical settings,This study examines pandemic with 480 word abstract...,"Author191_1, Author191_2",Science Translational Medicine,2021-10-31,medRxiv,,PMC1000191,https://example.com/paper_191,2021.0,10.0,87,12,True,54.0,8.0,True
cord-000192,Analysis of antibody and outbreak and diagnosis and respiratory in clinical settings,This study examines antibody with 366 word abstract...,"Author192_1, Author192_2",Science,2022-09-14,bioRxiv,10.1000/sample.192,PMC1000192,https://example.com/paper_192,2022.0,9.0,84,12,True,54.0,8.0,True
cord-000193,Analysis of coronavirus and clinical and antiviral in clinical settings,,"Author193_1, Author193_2",PLoS ONE,2021-09-10,ArXiv,10.1000/sample.193,PMC1000193,https://example.com/paper_193,2021.0,9.0,71,10,False,,,True
cord-000194,Analysis of epidemiology and vaccination in clinical settings,This study examines epidemiology with 163 word abstract...,Author194_1,Science,2020-08-07,ArXiv,,PMC1000194,https://example.com/paper_194,2020.0,8.0,61,8,True,58.0,8.0,True
cord-000195,Analysis of lockdown and antibody in clinical settings,This study examines lockdown with 409 word abstract...,"Author195_1, Author195_2",New England Journal of Medicine,2020-03-28,Medline,10.1000/sample.195,PMC1000195,https://example.com/paper_195,2020.0,3.0,54,8,True,54.0,8.0,True
cord-000196,Analysis of transmission and symptoms and coronavirus and COVID-19 in clinical settings,This study examines transmission with 429 word abstract...,Author196_1,Science,2020-03-30,medRxiv,10.1000/sample.196,PMC1000196,,2020.0,3.0,87,12,True,58.0,8.0,True
cord-000197,Analysis of coronavirus and symptoms and treatment in clinical settings,This study examines coronavirus with 452 word abstract...,"Author197_1, Author197_2",Lancet,2020-01-11,bioRxiv,10.1000/sample.197,PMC1000197,https://example.com/paper_197,2020.0,1.0,71,10,True,57.0,8.0,True
cord-000198,Analysis of public health and respiratory and lockdown in clinical settings,This study examines public health with 435 word abstract...,Author198_1,Science,2021-02-11,bioRxiv,10.1000/sample.198,PMC1000198,https://example.com/paper_198,2021.0,2.0,75,11,True,59.0,9.0,True
cord-000199,Analysis of treatment and epidemiology in clinical settings,This study examines treatment with 189 word abstract...,"Author199_1, Author199_2",Lancet,2021-09-17,PMC,10.1000/sample.199,,https://example.com/paper_199,2021.0,9.0,59,8,True,55.0,8.0,True
cord-000200,Analysis of vaccination and antibody and symptoms and diagnosis in clinical settings,This study examines vaccination with 410 word abstract...,"Author200_1, Author200_2",Journal of Medical Virology,2021-06-17,WHO,10.1000/sample.200,,https://example.com/paper_200,2021.0,6.0,84,12,True,57.0,8.0,True
cord-000201,Analysis of symptoms and COVID-19 in clinical settings,,Author201_1,New England Journal of Medicine,2020-02-06,Medline,10.1000/sample.201,PMC1000201,,2020.0,2.0,54,8,False,,,True
cord-000203,Analysis of pandemic and SARS-CoV-2 in clinical settings,This study examines pandemic with 271 word abstract...,"Author203_1, Author203_2",BMJ,2020-06-30,ArXiv,10.1000/sample.203,PMC1000203,,2020.0,6.0,56,8,True,54.0,8.0,True
cord-000204,Analysis of epidemiology and antiviral and clinical in clinical settings,This study examines epidemiology with 487 word abstract...,"Author204_1, Author204_2",,2021-07-10,ArXiv,10.1000/sample.204,PMC1000204,https://example.com/paper_204,2021.0,7.0,72,10,True,58.0,8.0,False
cord-000205,Analysis of SARS-CoV-2 and antibody and symptoms in clinical settings,This study examines SARS-CoV-2 with 146 word abstract...,"Author205_1, Author205_2",JAMA,2021-01-17,WHO,,PMC1000205,https://example.com/paper_205,2021.0,1.0,69,10,True,56.0,8.0,True
cord-000206,Analysis of COVID-19 and public health and therapeutic in clinical settings,This study examines COVID-19 with 303 word abstract...,"Author206_1, Author206_2",BMJ,2020-03-12,ArXiv,,,https://example.com/paper_206,2020.0,3.0,75,11,True,54.0,8.0,True
cord-000207,Analysis of lockdown and clinical and epidemiology in clinical settings,This study examines lockdown with 218 word abstract...,,Clinical Infectious Diseases,2020-05-19,WHO,10.1000/sample.207,PMC1000207,https://example.com/paper_207,2020.0,5.0,71,10,True,54.0,8.0,True
cord-000208,Analysis of vaccination and treatment and clinical in clinical settings,This study examines vaccination with 310 word abstract...,"Author208_1, Author208_2",Journal of Virology,2020-01-03,medRxiv,10.1000/sample.208,,https://example.com/paper_208,2020.0,1.0,71,10,True,57.0,8.0,True
cord-000209,Analysis of outbreak and therapeutic and public health in clinical settings,This study examines outbreak with 466 word abstract...,"Author209_1, Author209_2",Science Translational Medicine,2021-11-20,ArXiv,10.1000/sample.209,PMC1000209,https://example.com/paper_209,2021.0,11.0,75,11,True,54.0,8.0,True
cord-000210,Analysis of outbreak and COVID-19 in clinical settings,This study examines outbreak with 165 word abstract...,"Author210_1, Author210_2",Nature Medicine,2022-12-19,PMC,10.1000/sample.210,,https://example.com/paper_210,2022.0,12.0,54,8,True,54.0,8.0,True
cord-000211,Analysis of coronavirus and therapeutic and symptoms in clinical settings,This study examines coronavirus with 237 word abstract...,"Author211_1, Author211_2",Science,2020-08-25,WHO,10.1000/sample.211,PMC1000211,https://example.com/paper_211,2020.0,8.0,73,10,True,57.0,8.0,True
cord-000212,Analysis of epidemiology and therapeutic and pandemic and COVID-19 in clinical settings,This study examines epidemiology with 278 word abstract...,"Author212_1, Author212_2",Clinical Infectious Diseases,2020-11-20,PMC,10.1000/sample.212,,https://example.com/paper_212,2020.0,11.0,87,12,True,58.0,8.0,True
cord-000213,Analysis of public health and symptoms and epidemiology and vaccination in clinical settings,This study examines public health with 168 word abstract...,"Author213_1, Author213_2",Clinical Infectious Diseases,2020-03-06,Medline,10.1000/sample.213,PMC1000213,,2020.0,3.0,92,13,True,59.0,9.0,True
cord-000214,Analysis of public health and lockdown in clinical settings,This study examines public health with 285 word abstract...,"Author214_1, Author214_2",Journal of Virology,2020-08-05,PMC,10.1000/sample.214,,,2020.0,8.0,59,9,True,59.0,9.0,True
cord-000215,Analysis of diagnosis and coronavirus and SARS-CoV-2 in clinical settings,This study examines diagnosis with 258 word abstract...,Author215_1,Nature Medicine,2021-10-03,ArXiv,,PMC1000215,https://example.com/paper_215,2021.0,10.0,73,10,True,55.0,8.0,True
cord-000216,Analysis of antiviral and immunity and epidemiology in clinical settings,This study examines antiviral with 165 word abstract...,"Author216_1, Author216_2",Virology,2021-05-15,medRxiv,10.1000/sample.216,,https://example.com/paper_216,2021.0,5.0,72,10,True,55.0,8.0,True
cord-000217,Analysis of diagnosis and vaccination and SARS-CoV-2 and treatment in clinical settings,This study examines diagnosis with 348 word abstract...,Author217_1,Cell,2021-04-15,ArXiv,10.1000/sample.217,PMC1000217,https://example.com/paper_217,2021.0,4.0,87,12,True,55.0,8.0,True
cord-000218,Analysis of immunity and public health and antibody and treatment in clinical settings,This study examines immunity with 134 word abstract...,"Author218_1, Author218_2",BMJ,2020-08-02,Medline,10.1000/sample.218,,https://example.com/paper_218,2020.0,8.0,86,13,True,54.0,8.0,True
cord-000219,Analysis of epidemiology and pneumonia in clinical settings,This study examines epidemiology with 148 word abstract...,"Author219_1, Author219_2",,2022-12-22,PMC,10.1000/sample.219,PMC1000219,https://example.com/paper_219,2022.0,12.0,59,8,True,58.0,8.0,False
cord-000220,Analysis of treatment and symptoms and pneumonia and transmission in clinical settings,This study examines treatment with 199 word abstract...,"Author220_1, Author220_2",Clinical Infectious Diseases,2020-07-29,PMC,10.1000/sample.220,PMC1000220,,2020.0,7.0,86,12,True,55.0,8.0,True
cord-000221,Analysis of therapeutic and epidemiology and lockdown and transmission in clinical settings,This study examines therapeutic with 151 word abstract...,"Author221_1, Author221_2",New England Journal of Medicine,2021-06-21,ArXiv,10.1000/sample.221,,https://example.com/paper_221,2021.0,6.0,91,12,True,57.0,8.0,True
cord-000222,Analysis of treatment and immunity and clinical in clinical settings,This study examines treatment with 451 word abstract...,"Author222_1, Author222_2",Science Translational Medicine,2020-05-10,bioRxiv,10.1000/sample.222,PMC1000222,https://example.com/paper_222,2020.0,5.0,68,10,True,55.0,8.0,True
cord-000223,Analysis of epidemiology and coronavirus and immunity in clinical settings,This study examines epidemiology with 354 word abstract...,"Author223_1, Author223_2",Nature Medicine,2021-01-03,bioRxiv,10.1000/sample.223,PMC1000223,https://example.com/paper_223,2021.0,1.0,74,10,True,58.0,8.0,True
cord-000224,Analysis of respiratory and treatment and lockdown and pneumonia in clinical settings,This study examines respiratory with 276 word abstract...,"Author224_1, Author224_2",Virology,2020-08-02,PMC,10.1000/sample.224,,https://example.com/paper_224,2020.0,8.0,85,12,True,57.0,8.0,True
cord-000225,Analysis of immunity and coronavirus and public health in clinical settings,This study examines immunity with 361 word abstract...,"Author225_1, Author225_2",JAMA,2021-08-29,Medline,10.1000/sample.225,PMC1000225,,2021.0,8.0,75,11,True,54.0,8.0,True
cord-000226,Analysis of therapeutic and antibody and vaccination in clinical settings,This study examines therapeutic with 193 word abstract...,Author226_1,Journal of Medical Virology,2020-02-21,medRxiv,,PMC1000226,https://example.com/paper_226,2020.0,2.0,73,10,True,57.0,8.0,True
cord-000227,Analysis of vaccination and outbreak and treatment and pandemic in clinical settings,This study examines vaccination with 433 word abstract...,Author227_1,JAMA,2020-12-21,PMC,10.1000/sample.227,,,2020.0,12.0,84,12,True,57.0,8.0,True
cord-000228,Analysis of pandemic and antibody in clinical settings,This study examines pandemic with 260 word abstract...,"Author228_1, Author228_2",,2020-02-13,bioRxiv,10.1000/sample.228,,https://example.com/paper_228,2020.0,2.0,54,8,True,54.0,8.0,False
cord-000229,Analysis of pneumonia and antibody in clinical settings,This study examines pneumonia with 431 word abstract...,"Author229_1, Author229_2",Clinical Infectious Diseases,,WHO,10.1000/sample.229,PMC1000229,https://example.com/paper_229,,,55,8,True,55.0,8.0,True
cord-000230,Analysis of treatment and COVID-19 and respiratory in clinical settings,This study examines treatment with 418 word abstract...,Author230_1,Science,2021-07-31,medRxiv,10.1000/sample.230,,https://example.com/paper_230,2021.0,7.0,71,10,True,55.0,8.0,True
cord-000231,Analysis of therapeutic and transmission and treatment and outbreak in clinical settings,This study examines therapeutic with 288 word abstract...,"Author231_1, Author231_2",Cell,2021-09-27,Medline,10.1000/sample.231,,https://example.com/paper_231,2021.0,9.0,88,12,True,57.0,8.0,True
cord-000232,Analysis of immunity and outbreak in clinical settings,This study examines immunity with 236 word abstract...,"Author232_1, Author232_2",Lancet,2020-08-05,PMC,10.1000/sample.232,PMC1000232,https://example.com/paper_232,2020.0,8.0,54,8,True,54.0,8.0,True
cord-000233,Analysis of coronavirus and antiviral and COVID-19 in clinical settings,This study examines coronavirus with 427 word abstract...,"Author233_1, Author233_2",Emerging Infectious Diseases,2020-04-30,bioRxiv,10.1000/sample.233,PMC1000233,https://example.com/paper_233,2020.0,4.0,71,10,True,57.0,8.0,True
cord-000234,Analysis of epidemiology and COVID-19 and outbreak and diagnosis in clinical settings,This study examines epidemiology with 293 word abstract...,"Author234_1, Author234_2",Science,2021-01-15,Medline,,PMC1000234,https://example.com/paper_234,2021.0,1.0,85,12,True,58.0,8.0,True
cord-000235,Analysis of outbreak and public health and respiratory and transmission in clinical settings,This study examines outbreak with 245 word abstract...,"Author235_1, Author235_2",Nature,2021-03-19,Medline,10.1000/sample.235,,https://example.com/paper_235,2021.0,3.0,92,13,True,54.0,8.0,True
cord-000236,Analysis of COVID-19 and transmission and pandemic and diagnosis in clinical settings,This study examines COVID-19 with 143 word abstract...,"Author236_1, Author236_2",,2020-12-02,ArXiv,10.1000/sample.236,PMC1000236,,2020.0,12.0,85,12,True,54.0,8.0,False
cord-000237,Analysis of coronavirus and therapeutic and diagnosis in clinical settings,This study examines coronavirus with 191 word abstract...,"Author237_1, Author237_2",Emerging Infectious Diseases,2020-07-28,WHO,10.1000/sample.237,PMC1000237,https://example.com/paper_237,2020.0,7.0,74,10,True,57.0,8.0,True
cord-000238,Analysis of treatment and vaccination and pandemic and pneumonia in clinical settings,,Author238_1,BMJ,2021-08-11,bioRxiv,,PMC1000238,https://example.com/paper_238,2021.0,8.0,85,12,False,,,True
cord-000239,Analysis of pandemic and lockdown and immunity in clinical settings,This study examines pandemic with 299 word abstract...,"Author239_1, Author239_2",JAMA,2022-08-28,ArXiv,10.1000/sample.239,PMC1000239,https://example.com/paper_239,2022.0,8.0,67,10,True,54.0,8.0,True
cord-000240,Analysis of lockdown and COVID-19 in clinical settings,This study examines lockdown with 394 word abstract...,Author240_1,PLoS ONE,2022-09-21,bioRxiv,,PMC1000240,https://example.com/paper_240,2022.0,9.0,54,8,True,54.0,8.0,True
cord-000241,Analysis of antibody and outbreak in clinical settings,This study examines antibody with 493 word abstract...,Author241_1,Emerging Infectious Diseases,2021-08-09,ArXiv,10.1000/sample.241,PMC1000241,,2021.0,8.0,54,8,True,54.0,8.0,True
cord-000242,Analysis of symptoms and antibody and therapeutic and vaccination in clinical settings,This study examines symptoms with 453 word abstract...,"Author242_1, Author242_2",Nature Medicine,2020-10-12,PMC,10.1000/sample.242,PMC1000242,https://example.com/paper_242,2020.0,10.0,86,12,True,54.0,8.0,True
cord-000243,Analysis of SARS-CoV-2 and antiviral and lockdown in clinical settings,This study examines SARS-CoV-2 with 426 word abstract...,"Author243_1, Author243_2",BMJ,2021-02-02,Medline,10.1000/sample.243,PMC1000243,https://example.com/paper_243,2021.0,2.0,70,10,True,56.0,8.0,True
cord-000244,Analysis of transmission and therapeutic and immunity in clinical settings,,"Author244_1, Author244_2",Journal of Medical Virology,2020-07-22,Medline,10.1000/sample.244,PMC1000244,https://example.com/paper_244,2020.0,7.0,74,10,False,,,True
cord-000245,Analysis of clinical and antiviral and COVID-19 and symptoms in clinical settings,This study examines clinical with 169 word abstract...,"Author245_1, Author245_2",Science Translational Medicine,2020-08-23,WHO,10.1000/sample.245,,https://example.com/paper_245,2020.0,8.0,81,12,True,54.0,8.0,True
cord-000246,Analysis of pneumonia and pandemic in clinical settings,,"Author246_1, Author246_2",Emerging Infectious Diseases,2019-12-07,Medline,10.1000/sample.246,PMC1000246,https://example.com/paper_246,2019.0,12.0,55,8,False,,,True
cord-000247,Analysis of antiviral and lockdown and coronavirus and diagnosis in clinical settings,This study examines antiviral with 419 word abstract...,,PLoS ONE,2020-06-25,medRxiv,10.1000/sample.247,PMC1000247,https://example.com/paper_247,2020.0,6.0,85,12,True,55.0,8.0,True
cord-000248,Analysis of SARS-CoV-2 and treatment in clinical settings,This study examines SARS-CoV-2 with 328 word abstract...,Author248_1,BMJ,2020-11-06,ArXiv,10.1000/sample.248,PMC1000248,https://example.com/paper_248,2020.0,11.0,57,8,True,56.0,8.0,True
cord-000249,Analysis of clinical and pandemic and transmission and immunity in clinical settings,This study examines clinical with 160 word abstract...,Author249_1,JAMA,2020-12-24,bioRxiv,10.1000/sample.249,PMC1000249,,2020.0,12.0,84,12,True,54.0,8.0,True
cord-000250,Analysis of transmission and diagnosis in clinical settings,This study examines transmission with 408 word abstract...,"Author250_1, Author250_2",BMJ,2021-06-02,medRxiv,10.1000/sample.250,PMC1000250,https://example.com/paper_250,2021.0,6.0,59,8,True,58.0,8.0,True
cord-000251,Analysis of treatment and antiviral in clinical settings,This study examines treatment with 249 word abstract...,"Author251_1, Author251_2",New England Journal of Medicine,2020-06-15,bioRxiv,10.1000/sample.251,,https://example.com/paper_251,2020.0,6.0,56,8,True,55.0,8.0,True
cord-000252,Analysis of immunity and symptoms and antiviral and coronavirus in clinical settings,This study examines immunity with 142 word abstract...,"Author252_1, Author252_2",Clinical Infectious Diseases,2020-02-17,PMC,10.1000/sample.252,PMC1000252,,2020.0,2.0,84,12,True,54.0,8.0,True
cord-000253,Analysis of transmission and pneumonia and clinical in clinical settings,This study examines transmission with 413 word abstract...,Author253_1,BMJ,2021-06-25,Medline,10.1000/sample.253,PMC1000253,https://example.com/paper_253,2021.0,6.0,72,10,True,58.0,8.0,True
cord-000255,Analysis of transmission and outbreak and coronavirus in clinical settings,,Author255_1,,2021-10-13,medRxiv,10.1000/sample.255,,https://example.com/paper_255,2021.0,10.0,74,10,False,,,False
cord-000256,Analysis of coronavirus and clinical and pneumonia in clinical settings,This study examines coronavirus with 455 word abstract...,"Author256_1, Author256_2",,2020-02-11,WHO,10.1000/sample.256,,,2020.0,2.0,71,10,True,57.0,8.0,False
cord-000257,Analysis of respiratory and therapeutic in clinical settings,This study examines respiratory with 352 word abstract...,"Author257_1, Author257_2",Science Translational Medicine,2021-09-29,medRxiv,10.1000/sample.257,PMC1000257,https://example.com/paper_257,2021.0,9.0,60,8,True,57.0,8.0,True
cord-000258,Analysis of antibody and lockdown and public health and symptoms in clinical settings,This study examines antibody with 169 word abstract...,"Author258_1, Author258_2",Clinical Infectious Diseases,2020-04-20,medRxiv,10.1000/sample.258,PMC1000258,https://example.com/paper_258,2020.0,4.0,85,13,True,54.0,8.0,True
cord-000259,Analysis of coronavirus and therapeutic and public health and lockdown in clinical settings,This study examines coronavirus with 204 word abstract...,"Author259_1, Author259_2",Science,2021-07-23,Medline,10.1000/sample.259,PMC1000259,https://example.com/paper_259,2021.0,7.0,91,13,True,57.0,8.0,True
cord-000260,Analysis of pandemic and treatment and antibody and epidemiology in clinical settings,This study examines pandemic with 129 word abstract...,"Author260_1, Author260_2",Nature Medicine,2020-08-10,PMC,10.1000/sample.260,PMC1000260,https://example.com/paper_260,2020.0,8.0,85,12,True,54.0,8.0,True
cord-000261,Analysis of antiviral and coronavirus and transmission and public health in clinical settings,This study examines antiviral with 246 word abstract...,"Author261_1, Author261_2",Journal of Virology,2020-10-16,ArXiv,10.1000/sample.261,PMC1000261,https://example.com/paper_261,2020.0,10.0,93,13,True,55.0,8.0,True
cord-000262,Analysis of epidemiology and SARS-CoV-2 and transmission in clinical settings,This study examines epidemiology with 155 word abstract...,"Author262_1, Author262_2",Science Translational Medicine,2020-06-07,ArXiv,10.1000/sample.262,PMC1000262,,2020.0,6.0,77,10,True,58.0,8.0,True
cord-000263,Analysis of clinical and antiviral in clinical settings,This study examines clinical with 137 word abstract...,Author263_1,Science,2020-10-13,PMC,10.1000/sample.263,PMC1000263,https://example.com/paper_263,2020.0,10.0,55,8,True,54.0,8.0,True
cord-000264,Analysis of diagnosis and SARS-CoV-2 and pneumonia in clinical settings,This study examines diagnosis with 390 word abstract...,"Author264_1, Author264_2",PLoS ONE,2022-06-19,medRxiv,10.1000/sample.264,PMC1000264,https://example.com/paper_264,2022.0,6.0,71,10,True,55.0,8.0,True
cord-000265,Analysis of outbreak and clinical and SARS-CoV-2 and immunity in clinical settings,This study examines outbreak with 365 word abstract...,"Author265_1, Author265_2",Nature,2019-12-21,medRxiv,,,https://example.com/paper_265,2019.0,12.0,82,12,True,54.0,8.0,True
cord-000266,Analysis of diagnosis and SARS-CoV-2 and immunity in clinical settings,This study examines diagnosis with 378 word abstract...,Author266_1,Journal of Medical Virology,2022-05-24,medRxiv,,PMC1000266,https://example.com/paper_266,2022.0,5.0,70,10,True,55.0,8.0,True
cord-000267,Analysis of therapeutic and coronavirus and treatment and pandemic in clinical settings,This study examines therapeutic with 230 word abstract...,"Author267_1, Author267_2",Journal of Medical Virology,2020-06-05,bioRxiv,10.1000/sample.267,PMC1000267,https://example.com/paper_267,2020.0,6.0,87,12,True,57.0,8.0,True
cord-000268,Analysis of treatment and antibody and antiviral and COVID-19 in clinical settings,This study examines treatment with 406 word abstract...,Author268_1,Nature,2020-05-12,bioRxiv,10.1000/sample.268,PMC1000268,https://example.com/paper_268,2020.0,5.0,82,12,True,55.0,8.0,True
cord-000269,Analysis of pneumonia and coronavirus in clinical settings,This study examines pneumonia with 225 word abstract...,"Author269_1, Author269_2",Lancet,2019-12-14,WHO,10.1000/sample.269,PMC1000269,https://example.com/paper_269,2019.0,12.0,58,8,True,55.0,8.0,True
cord-000270,Analysis of immunity and pandemic and treatment in clinical settings,This study examines immunity with 427 word abstract...,"Author270_1, Author270_2",New England Journal of Medicine,2021-04-28,PMC,,PMC1000270,https://example.com/paper_270,2021.0,4.0,68,10,True,54.0,8.0,True
cord-000271,Analysis of immunity and vaccination and epidemiology and coronavirus in clinical settings,This study examines immunity with 393 word abstract...,"Author271_1, Author271_2",,2020-07-10,medRxiv,10.1000/sample.271,,https://example.com/paper_271,2020.0,7.0,90,12,True,54.0,8.0,False
cord-000272,Analysis of treatment and public health and therapeutic and COVID-19 in clinical settings,This study examines treatment with 317 word abstract...,"Author272_1, Author272_2",Emerging Infectious Diseases,2021-09-10,Medline,10.1000/sample.272,PMC1000272,https://example.com/paper_272,2021.0,9.0,89,13,True,55.0,8.0,True
cord-000273,Analysis of treatment and pneumonia and immunity and outbreak in clinical settings,This study examines treatment with 324 word abstract...,"Author273_1, Author273_2",Journal of Medical Virology,2020-08-21,bioRxiv,10.1000/sample.273,PMC1000273,https://example.com/paper_273,2020.0,8.0,82,12,True,55.0,8.0,True
cord-000274,Analysis of pandemic and outbreak in clinical settings,This study examines pandemic with 455 word abstract...,Author274_1,Clinical Infectious Diseases,2020-07-28,ArXiv,10.1000/sample.274,PMC1000274,https://example.com/paper_274,2020.0,7.0,54,8,True,54.0,8.0,True
cord-000275,Analysis of pneumonia and lockdown and symptoms in clinical settings,This study examines pneumonia with 201 word abstract...,Author275_1,New England Journal of Medicine,2020-07-16,bioRxiv,10.1000/sample.275,PMC1000275,https://example.com/paper_275,2020.0,7.0,68,10,True,55.0,8.0,True
cord-000277,Analysis of lockdown and therapeutic and transmission in clinical settings,This study examines lockdown with 286 word abstract...,"Author277_1, Author277_2",Science Translational Medicine,2021-01-24,ArXiv,10.1000/sample.277,PMC1000277,https://example.com/paper_277,2021.0,1.0,74,10,True,54.0,8.0,True
cord-000279,Analysis of public health and antiviral in clinical settings,This study examines public health with 230 word abstract...,"Author279_1, Author279_2",Science,2020-02-25,Medline,10.1000/sample.279,PMC1000279,https://example.com/paper_279,2020.0,2.0,60,9,True,59.0,9.0,True
cord-000280,Analysis of symptoms and pandemic and public health in clinical settings,This study examines symptoms with 234 word abstract...,"Author280_1, Author280_2",Journal of Medical Virology,2019-12-29,medRxiv,10.1000/sample.280,PMC1000280,https://example.com/paper_280,2019.0,12.0,72,11,True,54.0,8.0,True
cord-000281,Analysis of diagnosis and therapeutic and lockdown in clinical settings,This study examines diagnosis with 255 word abstract...,"Author281_1, Author281_2",Science,2020-12-26,WHO,10.1000/sample.281,PMC1000281,https://example.com/paper_281,2020.0,12.0,71,10,True,55.0,8.0,True
cord-000282,Analysis of public health and respiratory and lockdown and COVID-19 in clinical settings,This study examines public health with 302 word abstract...,"Author282_1, Author282_2",Nature,2021-03-13,ArXiv,10.1000/sample.282,PMC1000282,https://example.com/paper_282,2021.0,3.0,88,13,True,59.0,9.0,True
cord-000283,Analysis of clinical and public health and antibody and epidemiology in clinical settings,This study examines clinical with 356 word abstract...,"Author283_1, Author283_2",Journal of Virology,2021-05-14,ArXiv,10.1000/sample.283,,https://example.com/paper_283,2021.0,5.0,89,13,True,54.0,8.0,True
cord-000284,Analysis of clinical and treatment in clinical settings,This study examines clinical with 166 word abstract...,"Author284_1, Author284_2",,,ArXiv,10.1000/sample.284,,,,,55,8,True,54.0,8.0,False
cord-000285,Analysis of antibody and respiratory in clinical settings,This study examines antibody with 478 word abstract...,Author285_1,Nature,2020-12-06,bioRxiv,10.1000/sample.285,PMC1000285,https://example.com/paper_285,2020.0,12.0,57,8,True,54.0,8.0,True
cord-000286,Analysis of treatment and public health and diagnosis and vaccination in clinical settings,This study examines treatment with 347 word abstract...,"Author286_1, Author286_2",BMJ,2019-12-16,WHO,10.1000/sample.286,,https://example.com/paper_286,2019.0,12.0,90,13,True,55.0,8.0,True
cord-000288,Analysis of therapeutic and symptoms and pandemic in clinical settings,This study examines therapeutic with 171 word abstract...,Author288_1,Nature,2021-01-16,WHO,10.1000/sample.288,PMC1000288,https://example.com/paper_288,2021.0,1.0,70,10,True,57.0,8.0,True
cord-000289,Analysis of diagnosis and symptoms and antiviral in clinical settings,This study examines diagnosis with 480 word abstract...,Author289_1,JAMA,2020-07-14,medRxiv,10.1000/sample.289,,https://example.com/paper_289,2020.0,7.0,69,10,True,55.0,8.0,True
cord-000290,Analysis of antibody and diagnosis and pandemic and symptoms in clinical settings,This study examines antibody with 104 word abstract...,"Author290_1, Author290_2",Nature,2019-12-30,ArXiv,10.1000/sample.290,,https://example.com/paper_290,2019.0,12.0,81,12,True,54.0,8.0,True
cord-000291,Analysis of symptoms and SARS-CoV-2 in clinical settings,This study examines symptoms with 328 word abstract...,Author291_1,PLoS ONE,2020-06-26,PMC,10.1000/sample.291,PMC1000291,https://example.com/paper_291,2020.0,6.0,56,8,True,54.0,8.0,True
cord-000292,Analysis of COVID-19 and transmission and public health in clinical settings,This study examines COVID-19 with 432 word abstract...,"Author292_1, Author292_2",New England Journal of Medicine,2020-07-28,PMC,10.1000/sample.292,,https://example.com/paper_292,2020.0,7.0,76,11,True,54.0,8.0,True
cord-000293,Analysis of coronavirus and antibody and SARS-CoV-2 and respiratory in clinical settings,This study examines coronavirus with 307 word abstract...,"Author293_1, Author293_2",Journal of Medical Virology,2020-09-01,ArXiv,10.1000/sample.293,PMC1000293,https://example.com/paper_293,2020.0,9.0,88,12,True,57.0,8.0,True
cord-000295,Analysis of COVID-19 and therapeutic and pneumonia in clinical settings,This study examines COVID-19 with 432 word abstract...,"Author295_1, Author295_2",PLoS ONE,2019-12-23,ArXiv,10.1000/sample.295,,https://example.com/paper_295,2019.0,12.0,71,10,True,54.0,8.0,True
cord-000296,Analysis of COVID-19 and pneumonia and diagnosis in clinical settings,This study examines COVID-19 with 380 word abstract...,"Author296_1, Author296_2",Nature,2020-07-06,medRxiv,10.1000/sample.296,,https://example.com/paper_296,2020.0,7.0,69,10,True,54.0,8.0,True
cord-000297,Analysis of pneumonia and pandemic and symptoms in clinical settings,This study examines pneumonia with 128 word abstract...,"Author297_1, Author297_2",Science Translational Medicine,2021-01-18,Medline,10.1000/sample.297,PMC1000297,https://example.com/paper_297,2021.0,1.0,68,10,True,55.0,8.0,True
cord-000299,Analysis of treatment and pandemic and immunity and symptoms in clinical settings,This study examines treatment with 153 word abstract...,"Author299_1, Author299_2",Journal of Virology,2020-01-18,PMC,10.1000/sample.299,PMC1000299,,2020.0,1.0,81,12,True,55.0,8.0,True
cord-000300,Analysis of pandemic and immunity and lockdown and treatment in clinical settings,This study examines pandemic with 397 word abstract...,"Author300_1, Author300_2",Cell,2020-07-09,Medline,10.1000/sample.300,PMC1000300,https://example.com/paper_300,2020.0,7.0,81,12,True,54.0,8.0,True
cord-000301,Analysis of antibody and public health and vaccination in clinical settings,This study examines antibody with 103 word abstract...,"Author301_1, Author301_2",,2020-08-10,PMC,10.1000/sample.301,PMC1000301,https://example.com/paper_301,2020.0,8.0,75,11,True,54.0,8.0,False
cord-000302,Analysis of epidemiology and SARS-CoV-2 and outbreak and symptoms in clinical settings,This study examines epidemiology with 196 word abstract...,"Author302_1, Author302_2",Journal of Medical Virology,,bioRxiv,10.1000/sample.302,,https://example.com/paper_302,,,86,12,True,58.0,8.0,True
cord-000303,Analysis of SARS-CoV-2 and public health and vaccination and outbreak in clinical settings,This study examines SARS-CoV-2 with 228 word abstract...,"Author303_1, Author303_2",Nature,2019-12-16,medRxiv,10.1000/sample.303,PMC1000303,https://example.com/paper_303,2019.0,12.0,90,13,True,56.0,8.0,True
cord-000304,Analysis of coronavirus and pneumonia in clinical settings,This study examines coronavirus with 357 word abstract...,"Author304_1, Author304_2",,2020-05-06,WHO,10.1000/sample.304,PMC1000304,https://example.com/paper_304,2020.0,5.0,58,8,True,57.0,8.0,False
cord-000305,Analysis of pneumonia and COVID-19 and antibody in clinical settings,,Author305_1,New England Journal of Medicine,,ArXiv,10.1000/sample.305,,https://example.com/paper_305,,,68,10,False,,,True
cord-000306,Analysis of diagnosis and COVID-19 and respiratory in clinical settings,This study examines diagnosis with 252 word abstract...,"Author306_1, Author306_2",Nature,2020-11-15,PMC,10.1000/sample.306,,https://example.com/paper_306,2020.0,11.0,71,10,True,55.0,8.0,True
cord-000307,Analysis of public health and vaccination and COVID-19 and immunity in clinical settings,This study examines public health with 230 word abstract...,"Author307_1, Author307_2",Lancet,2019-12-31,Medline,10.1000/sample.307,,https://example.com/paper_307,2019.0,12.0,88,13,True,59.0,9.0,True
cord-000308,Analysis of respiratory and vaccination and epidemiology in clinical settings,This study examines respiratory with 134 word abstract...,"Author308_1, Author308_2",Nature Medicine,2020-08-30,PMC,10.1000/sample.308,PMC1000308,https://example.com/paper_308,2020.0,8.0,77,10,True,57.0,8.0,True
cord-000310,Analysis of immunity and antibody and epidemiology in clinical settings,This study examines immunity with 358 word abstract...,"Author310_1, Author310_2",Journal of Medical Virology,2020-09-21,bioRxiv,10.1000/sample.310,PMC1000310,https://example.com/paper_310,2020.0,9.0,71,10,True,54.0,8.0,True
cord-000311,Analysis of vaccination and pneumonia and epidemiology in clinical settings,This study examines vaccination with 472 word abstract...,"Author311_1, Author311_2",Nature Medicine,2022-11-09,WHO,10.1000/sample.311,PMC1000311,https://example.com/paper_311,2022.0,11.0,75,10,True,57.0,8.0,True
cord-000312,Analysis of outbreak and diagnosis and antibody in clinical settings,This study examines outbreak with 418 word abstract...,"Author312_1, Author312_2",Clinical Infectious Diseases,2021-01-05,bioRxiv,10.1000/sample.312,PMC1000312,,2021.0,1.0,68,10,True,54.0,8.0,True
cord-000313,Analysis of therapeutic and clinical and outbreak in clinical settings,This study examines therapeutic with 410 word abstract...,Author313_1,PLoS ONE,2020-06-19,bioRxiv,,,,2020.0,6.0,70,10,True,57.0,8.0,True
cord-000314,Analysis of therapeutic and clinical in clinical settings,This study examines therapeutic with 117 word abstract...,"Author314_1, Author314_2",Emerging Infectious Diseases,2020-11-07,PMC,,PMC1000314,,2020.0,11.0,57,8,True,57.0,8.0,True
cord-000315,Analysis of public health and pandemic in clinical settings,This study examines public health with 185 word abstract...,"Author315_1, Author315_2",New England Journal of Medicine,2021-09-09,ArXiv,10.1000/sample.315,,https://example.com/paper_315,2021.0,9.0,59,9,True,59.0,9.0,True
cord-000316,Analysis of COVID-19 and transmission and lockdown and immunity in clinical settings,This study examines COVID-19 with 253 word abstract...,Author316_1,Nature Medicine,2021-10-01,ArXiv,,,https://example.com/paper_316,2021.0,10.0,84,12,True,54.0,8.0,True
cord-000317,Analysis of clinical and outbreak and epidemiology and pneumonia in clinical settings,This study examines clinical with 364 word abstract...,"Author317_1, Author317_2",Science,2019-12-12,ArXiv,10.1000/sample.317,,,2019.0,12.0,85,12,True,54.0,8.0,True
cord-000318,Analysis of pneumonia and outbreak in clinical settings,This study examines pneumonia with 307 word abstract...,"Author318_1, Author318_2",Journal of Virology,2021-04-02,ArXiv,10.1000/sample.318,PMC1000318,https://example.com/paper_318,2021.0,4.0,55,8,True,55.0,8.0,True
cord-000319,Analysis of symptoms and therapeutic and COVID-19 and SARS-CoV-2 in clinical settings,This study examines symptoms with 288 word abstract...,"Author319_1, Author319_2",New England Journal of Medicine,2020-02-27,bioRxiv,10.1000/sample.319,,,2020.0,2.0,85,12,True,54.0,8.0,True
cord-000320,Analysis of lockdown and outbreak and public health and antiviral in clinical settings,This study examines lockdown with 158 word abstract...,Author320_1,JAMA,2019-12-01,medRxiv,10.1000/sample.320,PMC1000320,https://example.com/paper_320,2019.0,12.0,86,13,True,54.0,8.0,True
cord-000321,Analysis of treatment and pandemic in clinical settings,This study examines treatment with 321 word abstract...,"Author321_1, Author321_2",Clinical Infectious Diseases,2020-03-05,bioRxiv,10.1000/sample.321,PMC1000321,https://example.com/paper_321,2020.0,3.0,55,8,True,55.0,8.0,True
cord-000322,Analysis of coronavirus and transmission and SARS-CoV-2 and COVID-19 in clinical settings,,"Author322_1, Author322_2",Journal of Medical Virology,2020-04-21,bioRxiv,10.1000/sample.322,,https://example.com/paper_322,2020.0,4.0,89,12,False,,,True
cord-000323,Analysis of SARS-CoV-2 and transmission and diagnosis in clinical settings,This study examines SARS-CoV-2 with 306 word abstract...,"Author323_1, Author323_2",,2021-07-16,Medline,10.1000/sample.323,PMC1000323,https://example.com/paper_323,2021.0,7.0,74,10,True,56.0,8.0,False
cord-000324,Analysis of treatment and pandemic and clinical in clinical settings,This study examines treatment with 408 word abstract...,"Author324_1, Author324_2",Cell,,PMC,,,,,,68,10,True,55.0,8.0,True
cord-000325,Analysis of coronavirus and public health in clinical settings,This study examines coronavirus with 344 word abstract...,"Author325_1, Author325_2",Science,2021-10-05,ArXiv,10.1000/sample.325,,https://example.com/paper_325,2021.0,10.0,62,9,True,57.0,8.0,True
cord-000326,Analysis of antiviral and COVID-19 in clinical settings,This study examines antiviral with 233 word abstract...,"Author326_1, Author326_2",,2022-09-03,medRxiv,10.1000/sample.326,PMC1000326,https://example.com/paper_326,2022.0,9.0,55,8,True,55.0,8.0,False
cord-000327,Analysis of public health and pneumonia in clinical settings,This study examines public health with 151 word abstract...,"Author327_1, Author327_2",Virology,2019-12-03,ArXiv,,PMC1000327,https://example.com/paper_327,2019.0,12.0,60,9,True,59.0,9.0,True
cord-000328,Analysis of COVID-19 and respiratory and coronavirus and pneumonia in clinical settings,This study examines COVID-19 with 398 word abstract...,"Author328_1, Author328_2",Lancet,2021-03-04,Medline,10.1000/sample.328,PMC1000328,https://example.com/paper_328,2021.0,3.0,87,12,True,54.0,8.0,True
cord-000329,Analysis of lockdown and SARS-CoV-2 in clinical settings,This study examines lockdown with 381 word abstract...,"Author329_1, Author329_2",Nature Medicine,2020-10-16,bioRxiv,10.1000/sample.329,PMC1000329,https://example.com/paper_329,2020.0,10.0,56,8,True,54.0,8.0,True
cord-000330,Analysis of lockdown and public health and pneumonia and diagnosis in clinical settings,This study examines lockdown with 330 word abstract...,"Author330_1, Author330_2",JAMA,2022-11-10,WHO,10.1000/sample.330,,https://example.com/paper_330,2022.0,11.0,87,13,True,54.0,8.0,True
cord-000331,Analysis of symptoms and treatment and coronavirus and clinical in clinical settings,This study examines symptoms with 207 word abstract...,"Author331_1, Author331_2",Clinical Infectious Diseases,2020-05-22,medRxiv,10.1000/sample.331,,https://example.com/paper_331,2020.0,5.0,84,12,True,54.0,8.0,True
cord-000332,Analysis of vaccination and COVID-19 in clinical settings,This study examines vaccination with 130 word abstract...,"Author332_1, Author332_2",Cell,2020-07-05,medRxiv,10.1000/sample.332,PMC1000332,https://example.com/paper_332,2020.0,7.0,57,8,True,57.0,8.0,True
cord-000333,Analysis of public health and antibody and transmission in clinical settings,This study examines public health with 365 word abstract...,"Author333_1, Author333_2",JAMA,2021-01-22,ArXiv,10.1000/sample.333,PMC1000333,,2021.0,1.0,76,11,True,59.0,9.0,True
cord-000334,Analysis of pneumonia and lockdown in clinical settings,This study examines pneumonia with 406 word abstract...,"Author334_1, Author334_2",Science Translational Medicine,2021-09-07,ArXiv,10.1000/sample.334,PMC1000334,https://example.com/paper_334,2021.0,9.0,55,8,True,55.0,8.0,True
cord-000335,Analysis of antibody and outbreak and lockdown in clinical settings,This study examines antibody with 433 word abstract...,"Author335_1, Author335_2",Lancet,2020-03-18,PMC,10.1000/sample.335,PMC1000335,,2020.0,3.0,67,10,True,54.0,8.0,True
cord-000336,Analysis of pandemic and coronavirus and epidemiology in clinical settings,This study examines pandemic with 461 word abstract...,"Author336_1, Author336_2",Clinical Infectious Diseases,2020-08-22,ArXiv,10.1000/sample.336,,,2020.0,8.0,74,10,True,54.0,8.0,True
cord-000337,Analysis of antibody and pneumonia and vaccination in clinical settings,This study examines antibody with 133 word abstract...,"Author337_1, Author337_2",BMJ,2021-09-07,WHO,10.1000/sample.337,,,2021.0,9.0,71,10,True,54.0,8.0,True
cord-000338,Analysis of transmission and antiviral and therapeutic and SARS-CoV-2 in clinical settings,This study examines transmission with 202 word abstract...,"Author338_1, Author338_2",Emerging Infectious Diseases,2020-08-27,PMC,10.1000/sample.338,PMC1000338,https://example.com/paper_338,2020.0,8.0,90,12,True,58.0,8.0,True
cord-000339,Analysis of immunity and clinical and therapeutic and SARS-CoV-2 in clinical settings,This study examines immunity with 349 word abstract...,"Author339_1, Author339_2",Emerging Infectious Diseases,2020-01-05,ArXiv,10.1000/sample.339,PMC1000339,https://example.com/paper_339,2020.0,1.0,85,12,True,54.0,8.0,True
cord-000340,Analysis of epidemiology and coronavirus and lockdown in clinical settings,This study examines epidemiology with 498 word abstract...,"Author340_1, Author340_2",Journal of Virology,2021-06-24,medRxiv,,,https://example.com/paper_340,2021.0,6.0,74,10,True,58.0,8.0,True
cord-000341,Analysis of coronavirus and COVID-19 in clinical settings,This study examines coronavirus with 160 word abstract...,Author341_1,Virology,2020-11-06,bioRxiv,10.1000/sample.341,PMC1000341,,2020.0,11.0,57,8,True,57.0,8.0,True
cord-000342,Analysis of outbreak and transmission and respiratory in clinical settings,This study examines outbreak with 442 word abstract...,"Author342_1, Author342_2",New England Journal of Medicine,2021-10-06,medRxiv,10.1000/sample.342,,https://example.com/paper_342,2021.0,10.0,74,10,True,54.0,8.0,True
cord-000343,Analysis of SARS-CoV-2 and coronavirus and pandemic in clinical settings,This study examines SARS-CoV-2 with 249 word abstract...,Author343_1,Journal of Medical Virology,2021-03-09,WHO,10.1000/sample.343,,https://example.com/paper_343,2021.0,3.0,72,10,True,56.0,8.0,True
cord-000344,Analysis of treatment and pneumonia and diagnosis and pandemic in clinical settings,This study examines treatment with 371 word abstract...,"Author344_1, Author344_2",Nature,2021-06-22,medRxiv,10.1000/sample.344,PMC1000344,https://example.com/paper_344,2021.0,6.0,83,12,True,55.0,8.0,True
cord-000345,Analysis of therapeutic and pandemic and public health in clinical settings,This study examines therapeutic with 452 word abstract...,"Author345_1, Author345_2",Cell,2020-02-03,medRxiv,10.1000/sample.345,PMC1000345,https://example.com/paper_345,2020.0,2.0,75,11,True,57.0,8.0,True
cord-000347,Analysis of pandemic and outbreak and symptoms in clinical settings,This study examines pandemic with 389 word abstract...,"Author347_1, Author347_2",,2021-03-03,ArXiv,10.1000/sample.347,PMC1000347,https://example.com/paper_347,2021.0,3.0,67,10,True,54.0,8.0,False
cord-000349,Analysis of coronavirus and respiratory and vaccination in clinical settings,This study examines coronavirus with 407 word abstract...,"Author349_1, Author349_2",Science Translational Medicine,2020-10-30,ArXiv,10.1000/sample.349,PMC1000349,https://example.com/paper_349,2020.0,10.0,76,10,True,57.0,8.0,True
cord-000350,Analysis of treatment and clinical and public health in clinical settings,This study examines treatment with 316 word abstract...,"Author350_1, Author350_2",JAMA,2020-01-21,bioRxiv,10.1000/sample.350,,https://example.com/paper_350,2020.0,1.0,73,11,True,55.0,8.0,True
cord-000351,Analysis of public health and immunity in clinical settings,This study examines public health with 460 word abstract...,Author351_1,Nature Medicine,2021-12-31,bioRxiv,10.1000/sample.351,PMC1000351,https://example.com/paper_351,2021.0,12.0,59,9,True,59.0,9.0,True
cord-000352,Analysis of clinical and transmission and public health in clinical settings,This study examines clinical with 424 word abstract...,Author352_1,,2020-06-28,bioRxiv,10.1000/sample.352,PMC1000352,https://example.com/paper_352,2020.0,6.0,76,11,True,54.0,8.0,False
cord-000353,Analysis of respiratory and diagnosis and vaccination in clinical settings,This study examines respiratory with 206 word abstract...,"Author353_1, Author353_2",Virology,2020-07-08,medRxiv,10.1000/sample.353,PMC1000353,https://example.com/paper_353,2020.0,7.0,74,10,True,57.0,8.0,True
cord-000354,Analysis of SARS-CoV-2 and public health and transmission and outbreak in clinical settings,This study examines SARS-CoV-2 with 365 word abstract...,Author354_1,,2020-05-25,ArXiv,10.1000/sample.354,PMC1000354,https://example.com/paper_354,2020.0,5.0,91,13,True,56.0,8.0,False
cord-000355,Analysis of symptoms and coronavirus in clinical settings,This study examines symptoms with 141 word abstract...,"Author355_1, Author355_2",Emerging Infectious Diseases,2021-11-30,PMC,10.1000/sample.355,PMC1000355,https://example.com/paper_355,2021.0,11.0,57,8,True,54.0,8.0,True
cord-000356,Analysis of antibody and lockdown in clinical settings,This study examines antibody with 126 word abstract...,"Author356_1, Author356_2",Science,2022-02-05,bioRxiv,10.1000/sample.356,PMC1000356,https://example.com/paper_356,2022.0,2.0,54,8,True,54.0,8.0,True
cord-000357,Analysis of antibody and diagnosis and outbreak and public health in clinical settings,This study examines antibody with 230 word abstract...,"Author357_1, Author357_2",Nature,2020-07-25,WHO,10.1000/sample.357,,https://example.com/paper_357,2020.0,7.0,86,13,True,54.0,8.0,True
cord-000358,Analysis of COVID-19 and immunity in clinical settings,This study examines COVID-19 with 205 word abstract...,"Author358_1, Author358_2",Journal of Medical Virology,2020-06-04,medRxiv,,,https://example.com/paper_358,2020.0,6.0,54,8,True,54.0,8.0,True
cord-000359,Analysis of lockdown and outbreak and antibody and clinical in clinical settings,This study examines lockdown with 313 word abstract...,"Author359_1, Author359_2",,2021-02-18,bioRxiv,10.1000/sample.359,,https://example.com/paper_359,2021.0,2.0,80,12,True,54.0,8.0,False
cord-000360,Analysis of clinical and immunity and antiviral in clinical settings,This study examines clinical with 426 word abstract...,"Author360_1, Author360_2",Nature,2020-12-15,PMC,10.1000/sample.360,,https://example.com/paper_360,2020.0,12.0,68,10,True,54.0,8.0,True
cord-000361,Analysis of immunity and transmission in clinical settings,This study examines immunity with 253 word abstract...,"Author361_1, Author361_2",Lancet,2022-02-26,WHO,10.1000/sample.361,,https://example.com/paper_361,2022.0,2.0,58,8,True,54.0,8.0,True
cord-000362,Analysis of SARS-CoV-2 and immunity and transmission and diagnosis in clinical settings,This study examines SARS-CoV-2 with 115 word abstract...,"Author362_1, Author362_2",Virology,2020-01-21,ArXiv,10.1000/sample.362,PMC1000362,https://example.com/paper_362,2020.0,1.0,87,12,True,56.0,8.0,True
cord-000363,Analysis of antibody and symptoms and pneumonia in clinical settings,This study examines antibody with 394 word abstract...,"Author363_1, Author363_2",New England Journal of Medicine,2020-05-31,bioRxiv,10.1000/sample.363,PMC1000363,https://example.com/paper_363,2020.0,5.0,68,10,True,54.0,8.0,True
cord-000364,Analysis of diagnosis and pneumonia and transmission in clinical settings,This study examines diagnosis with 146 word abstract...,"Author364_1, Author364_2",Science Translational Medicine,2020-01-07,medRxiv,10.1000/sample.364,,https://example.com/paper_364,2020.0,1.0,73,10,True,55.0,8.0,True
cord-000365,Analysis of vaccination and outbreak and pneumonia and treatment in clinical settings,This study examines vaccination with 185 word abstract...,"Author365_1, Author365_2",Journal of Medical Virology,2021-06-06,bioRxiv,10.1000/sample.365,PMC1000365,https://example.com/paper_365,2021.0,6.0,85,12,True,57.0,8.0,True
cord-000366,Analysis of antiviral and transmission and treatment in clinical settings,This study examines antiviral with 271 word abstract...,"Author366_1, Author366_2",Journal of Medical Virology,2020-04-03,Medline,10.1000/sample.366,PMC1000366,https://example.com/paper_366,2020.0,4.0,73,10,True,55.0,8.0,True
cord-000367,Analysis of immunity and pneumonia and therapeutic in clinical settings,This study examines immunity with 480 word abstract...,"Author367_1, Author367_2",New England Journal of Medicine,2020-01-18,medRxiv,10.1000/sample.367,,https://example.com/paper_367,2020.0,1.0,71,10,True,54.0,8.0,True
cord-000368,Analysis of outbreak and lockdown and public health and therapeutic in clinical settings,This study examines outbreak with 262 word abstract...,"Author368_1, Author368_2",Lancet,2020-10-10,bioRxiv,10.1000/sample.368,PMC1000368,https://example.com/paper_368,2020.0,10.0,88,13,True,54.0,8.0,True
cord-000369,Analysis of lockdown and pandemic and transmission in clinical settings,This study examines lockdown with 378 word abstract...,"Author369_1, Author369_2",Science Translational Medicine,2020-09-15,Medline,10.1000/sample.369,PMC1000369,https://example.com/paper_369,2020.0,9.0,71,10,True,54.0,8.0,True
cord-000370,Analysis of lockdown and SARS-CoV-2 and diagnosis in clinical settings,This study examines lockdown with 327 word abstract...,"Author370_1, Author370_2",Journal of Virology,2020-03-13,Medline,10.1000/sample.370,PMC1000370,,2020.0,3.0,70,10,True,54.0,8.0,True
cord-000371,Analysis of public health and antiviral and treatment in clinical settings,This study examines public health with 490 word abstract...,"Author371_1, Author371_2",Journal of Virology,2020-01-03,WHO,10.1000/sample.371,PMC1000371,https://example.com/paper_371,2020.0,1.0,74,11,True,59.0,9.0,True
cord-000372,Analysis of antibody and symptoms in clinical settings,This study examines antibody with 209 word abstract...,"Author372_1, Author372_2",Nature Medicine,2020-03-26,medRxiv,10.1000/sample.372,,https://example.com/paper_372,2020.0,3.0,54,8,True,54.0,8.0,True
cord-000373,Analysis of therapeutic and SARS-CoV-2 and respiratory and pneumonia in clinical settings,This study examines therapeutic with 326 word abstract...,"Author373_1, Author373_2",Virology,2021-03-21,WHO,10.1000/sample.373,,https://example.com/paper_373,2021.0,3.0,89,12,True,57.0,8.0,True
cord-000374,Analysis of respiratory and therapeutic and antiviral and symptoms in clinical settings,This study examines respiratory with 246 word abstract...,"Author374_1, Author374_2",BMJ,,medRxiv,10.1000/sample.374,PMC1000374,https://example.com/paper_374,,,87,12,True,57.0,8.0,True
cord-000375,Analysis of symptoms and antibody in clinical settings,This study examines symptoms with 251 word abstract...,"Author375_1, Author375_2",Nature Medicine,2021-04-15,Medline,10.1000/sample.375,,https://example.com/paper_375,2021.0,4.0,54,8,True,54.0,8.0,True
cord-000376,Analysis of COVID-19 and SARS-CoV-2 and outbreak and clinical in clinical settings,This study examines COVID-19 with 115 word abstract...,"Author376_1, Author376_2",BMJ,2020-08-11,ArXiv,10.1000/sample.376,,,2020.0,8.0,82,12,True,54.0,8.0,True
cord-000377,Analysis of clinical and public health and outbreak and treatment in clinical settings,This study examines clinical with 248 word abstract...,"Author377_1, Author377_2",JAMA,2020-03-26,PMC,10.1000/sample.377,PMC1000377,https://example.com/paper_377,2020.0,3.0,86,13,True,54.0,8.0,True
cord-000378,Analysis of public health and vaccination in clinical settings,This study examines public health with 388 word abstract...,"Author378_1, Author378_2",Science,2020-05-21,WHO,10.1000/sample.378,,https://example.com/paper_378,2020.0,5.0,62,9,True,59.0,9.0,True
cord-000379,Analysis of vaccination and SARS-CoV-2 in clinical settings,This study examines vaccination with 349 word abstract...,"Author379_1, Author379_2",Lancet,2021-03-28,PMC,10.1000/sample.379,PMC1000379,https://example.com/paper_379,2021.0,3.0,59,8,True,57.0,8.0,True
cord-000382,Analysis of COVID-19 and epidemiology and therapeutic in clinical settings,This study examines COVID-19 with 246 word abstract...,"Author382_1, Author382_2",Emerging Infectious Diseases,2020-11-20,WHO,,PMC1000382,https://example.com/paper_382,2020.0,11.0,74,10,True,54.0,8.0,True
cord-000384,Analysis of vaccination and epidemiology and diagnosis and outbreak in clinical settings,This study examines vaccination with 107 word abstract...,Author384_1,Cell,2021-10-17,bioRxiv,10.1000/sample.384,,,2021.0,10.0,88,12,True,57.0,8.0,True
cord-000386,Analysis of vaccination and antiviral and outbreak in clinical settings,This study examines vaccination with 463 word abstract...,"Author386_1, Author386_2",Journal of Medical Virology,2020-08-18,PMC,10.1000/sample.386,,https://example.com/paper_386,2020.0,8.0,71,10,True,57.0,8.0,True
cord-000387,Analysis of vaccination and treatment and epidemiology in clinical settings,,"Author387_1, Author387_2",Journal of Virology,2020-11-08,ArXiv,10.1000/sample.387,PMC1000387,,2020.0,11.0,75,10,False,,,True
cord-000389,Analysis of vaccination and outbreak in clinical settings,This study examines vaccination with 297 word abstract...,"Author389_1, Author389_2",,2020-02-04,Medline,10.1000/sample.389,PMC1000389,https://example.com/paper_389,2020.0,2.0,57,8,True,57.0,8.0,False
cord-000390,Analysis of epidemiology and treatment and symptoms and diagnosis in clinical settings,This study examines epidemiology with 374 word abstract...,"Author390_1, Author390_2",Cell,2021-08-20,bioRxiv,10.1000/sample.390,,https://example.com/paper_390,2021.0,8.0,86,12,True,58.0,8.0,True
cord-000391,Analysis of transmission and therapeutic in clinical settings,This study examines transmission with 363 word abstract...,,Nature Medicine,2020-09-09,Medline,10.1000/sample.391,,https://example.com/paper_391,2020.0,9.0,61,8,True,58.0,8.0,True
cord-000392,Analysis of vaccination and respiratory and immunity and epidemiology in clinical settings,This study examines vaccination with 421 word abstract...,Author392_1,Virology,2021-10-28,medRxiv,10.1000/sample.392,,https://example.com/paper_392,2021.0,10.0,90,12,True,57.0,8.0,True
cord-000394,Analysis of symptoms and transmission and pneumonia in clinical settings,This study examines symptoms with 238 word abstract...,"Author394_1, Author394_2",Science Translational Medicine,2020-08-31,WHO,,,,2020.0,8.0,72,10,True,54.0,8.0,True
cord-000396,Analysis of public health and coronavirus and vaccination and antiviral in clinical settings,,"Author396_1, Author396_2",Lancet,2020-12-04,PMC,10.1000/sample.396,,https://example.com/paper_396,2020.0,12.0,92,13,False,,,True
cord-000397,Analysis of clinical and SARS-CoV-2 and immunity in clinical settings,This study examines clinical with 370 word abstract...,"Author397_1, Author397_2",Emerging Infectious Diseases,2020-09-19,medRxiv,10.1000/sample.397,PMC1000397,https://example.com/paper_397,2020.0,9.0,69,10,True,54.0,8.0,True
cord-000398,Analysis of treatment and COVID-19 and public health and pneumonia in clinical settings,This study examines treatment with 251 word abstract...,Author398_1,Nature Medicine,2020-08-20,bioRxiv,10.1000/sample.398,PMC1000398,https://example.com/paper_398,2020.0,8.0,87,13,True,55.0,8.0,True
cord-000399,Analysis of treatment and public health and vaccination and outbreak in clinical settings,This study examines treatment with 327 word abstract...,"Author399_1, Author399_2",JAMA,2020-02-09,bioRxiv,10.1000/sample.399,,https://example.com/paper_399,2020.0,2.0,89,13,True,55.0,8.0,True
cord-000400,Analysis of vaccination and outbreak and transmission in clinical settings,,,Cell,2020-06-01,PMC,10.1000/sample.400,,https://example.com/paper_400,2020.0,6.0,74,10,False,,,True
cord-000401,Analysis of pneumonia and antiviral in clinical settings,This study examines pneumonia with 283 word abstract...,"Author401_1, Author401_2",Journal of Virology,2021-07-10,WHO,,PMC1000401,https://example.com/paper_401,2021.0,7.0,56,8,True,55.0,8.0,True
cord-000403,Analysis of public health and SARS-CoV-2 and antibody and clinical in clinical settings,This study examines public health with 198 word abstract...,"Author403_1, Author403_2",Emerging Infectious Diseases,,ArXiv,10.1000/sample.403,PMC1000403,https://example.com/paper_403,,,87,13,True,59.0,9.0,True
cord-000404,Analysis of antiviral and public health in clinical settings,This study examines antiviral with 465 word abstract...,"Author404_1, Author404_2",Journal of Virology,2021-05-26,medRxiv,10.1000/sample.404,PMC1000404,,2021.0,5.0,60,9,True,55.0,8.0,True
cord-000405,Analysis of COVID-19 and clinical and immunity and diagnosis in clinical settings,This study examines COVID-19 with 183 word abstract...,"Author405_1, Author405_2",Nature Medicine,,medRxiv,10.1000/sample.405,PMC1000405,,,,81,12,True,54.0,8.0,True
cord-000406,Analysis of public health and outbreak and diagnosis and COVID-19 in clinical settings,This study examines public health with 131 word abstract...,"Author406_1, Author406_2",JAMA,2021-09-19,ArXiv,10.1000/sample.406,,https://example.com/paper_406,2021.0,9.0,86,13,True,59.0,9.0,True
cord-000407,Analysis of lockdown and clinical and vaccination in clinical settings,This study examines lockdown with 200 word abstract...,"Author407_1, Author407_2",Virology,2021-01-28,WHO,10.1000/sample.407,PMC1000407,https://example.com/paper_407,2021.0,1.0,70,10,True,54.0,8.0,True
cord-000408,Analysis of COVID-19 and antiviral and immunity in clinical settings,This study examines COVID-19 with 317 word abstract...,"Author408_1, Author408_2",,2021-05-24,Medline,10.1000/sample.408,PMC1000408,https://example.com/paper_408,2021.0,5.0,68,10,True,54.0,8.0,False
cord-000409,Analysis of SARS-CoV-2 and symptoms and antibody and vaccination in clinical settings,This study examines SARS-CoV-2 with 441 word abstract...,"Author409_1, Author409_2",PLoS ONE,2020-03-26,Medline,10.1000/sample.409,PMC1000409,,2020.0,3.0,85,12,True,56.0,8.0,True
cord-000410,Analysis of epidemiology and clinical and transmission and pneumonia in clinical settings,This study examines epidemiology with 329 word abstract...,Author410_1,Emerging Infectious Diseases,2020-10-30,PMC,10.1000/sample.410,,https://example.com/paper_410,2020.0,10.0,89,12,True,58.0,8.0,True
cord-000411,Analysis of antibody and therapeutic and clinical in clinical settings,This study examines antibody with 151 word abstract...,"Author411_1, Author411_2",Journal of Virology,2020-07-07,Medline,10.1000/sample.411,,https://example.com/paper_411,2020.0,7.0,70,10,True,54.0,8.0,True
cord-000412,Analysis of public health and SARS-CoV-2 and immunity and treatment in clinical settings,This study examines public health with 276 word abstract...,"Author412_1, Author412_2",New England Journal of Medicine,2019-12-28,Medline,10.1000/sample.412,PMC1000412,https://example.com/paper_412,2019.0,12.0,88,13,True,59.0,9.0,True
cord-000413,Analysis of diagnosis and public health and pneumonia in clinical settings,,"Author413_1, Author413_2",Nature Medicine,2020-04-08,ArXiv,10.1000/sample.413,PMC1000413,,2020.0,4.0,74,11,False,,,True
cord-000414,Analysis of antiviral and immunity and COVID-19 in clinical settings,This study examines antiviral with 302 word abstract...,"Author414_1, Author414_2",PLoS ONE,2020-11-11,Medline,10.1000/sample.414,,https://example.com/paper_414,2020.0,11.0,68,10,True,55.0,8.0,True
cord-000415,Analysis of COVID-19 and pneumonia and clinical and symptoms in clinical settings,This study examines COVID-19 with 221 word abstract...,"Author415_1, Author415_2",Lancet,2021-06-18,Medline,10.1000/sample.415,PMC1000415,https://example.com/paper_415,2021.0,6.0,81,12,True,54.0,8.0,True
cord-000418,Analysis of COVID-19 and antiviral and symptoms in clinical settings,This study examines COVID-19 with 149 word abstract...,"Author418_1, Author418_2",Emerging Infectious Diseases,2021-06-29,medRxiv,10.1000/sample.418,PMC1000418,,2021.0,6.0,68,10,True,54.0,8.0,True
cord-000419,Analysis of transmission and public health in clinical settings,This study examines transmission with 430 word abstract...,"Author419_1, Author419_2",Journal of Virology,2021-04-10,bioRxiv,10.1000/sample.419,,https://example.com/paper_419,2021.0,4.0,63,9,True,58.0,8.0,True
cord-000420,Analysis of lockdown and treatment and transmission and pneumonia in clinical settings,This study examines lockdown with 429 word abstract...,Author420_1,Cell,2020-11-26,medRxiv,10.1000/sample.420,PMC1000420,https://example.com/paper_420,2020.0,11.0,86,12,True,54.0,8.0,True
cord-000421,Analysis of SARS-CoV-2 and diagnosis and public health in clinical settings,This study examines SARS-CoV-2 with 470 word abstract...,"Author421_1, Author421_2",Journal of Virology,2020-11-21,medRxiv,10.1000/sample.421,PMC1000421,https://example.com/paper_421,2020.0,11.0,75,11,True,56.0,8.0,True
cord-000422,Analysis of transmission and antibody and lockdown and COVID-19 in clinical settings,,"Author422_1, Author422_2",JAMA,2020-03-27,medRxiv,10.1000/sample.422,,https://example.com/paper_422,2020.0,3.0,84,12,False,,,True
cord-000423,Analysis of outbreak and pneumonia and coronavirus in clinical settings,This study examines outbreak with 117 word abstract...,Author423_1,Journal of Medical Virology,2022-12-08,WHO,10.1000/sample.423,PMC1000423,,2022.0,12.0,71,10,True,54.0,8.0,True
cord-000424,Analysis of antiviral and antibody in clinical settings,This study examines antiviral with 432 word abstract...,"Author424_1, Author424_2",Journal of Medical Virology,2021-08-18,PMC,10.1000/sample.424,PMC1000424,https://example.com/paper_424,2021.0,8.0,55,8,True,55.0,8.0,True
cord-000425,Analysis of public health and COVID-19 in clinical settings,This study examines public health with 105 word abstract...,"Author425_1, Author425_2",Cell,,Medline,10.1000/sample.425,PMC1000425,https://example.com/paper_425,,,59,9,True,59.0,9.0,True
cord-000426,Analysis of treatment and immunity in clinical settings,This study examines treatment with 175 word abstract...,"Author426_1, Author426_2",Science,2019-12-05,bioRxiv,10.1000/sample.426,PMC1000426,https://example.com/paper_426,2019.0,12.0,55,8,True,55.0,8.0,True
cord-000427,Analysis of epidemiology and outbreak and antiviral in clinical settings,This study examines epidemiology with 306 word abstract...,"Author427_1, Author427_2",Clinical Infectious Diseases,2020-03-30,medRxiv,10.1000/sample.427,PMC1000427,https://example.com/paper_427,2020.0,3.0,72,10,True,58.0,8.0,True
cord-000428,Analysis of transmission and SARS-CoV-2 and treatment in clinical settings,This study examines transmission with 345 word abstract...,"Author428_1, Author428_2",,2020-03-26,WHO,10.1000/sample.428,PMC1000428,https://example.com/paper_428,2020.0,3.0,74,10,True,58.0,8.0,False
cord-000429,Analysis of transmission and diagnosis and public health and pneumonia in clinical settings,,"Author429_1, Author429_2",Science,2020-07-16,ArXiv,10.1000/sample.429,,,2020.0,7.0,91,13,False,,,True
cord-000430,Analysis of respiratory and pandemic and antiviral in clinical settings,This study examines respiratory with 294 word abstract...,"Author430_1, Author430_2",Journal of Virology,2019-12-18,bioRxiv,,PMC1000430,https://example.com/paper_430,2019.0,12.0,71,10,True,57.0,8.0,True
cord-000431,Analysis of SARS-CoV-2 and pandemic and coronavirus and respiratory in clinical settings,This study examines SARS-CoV-2 with 129 word abstract...,Author431_1,Journal of Virology,2021-02-07,medRxiv,10.1000/sample.431,PMC1000431,https://example.com/paper_431,2021.0,2.0,88,12,True,56.0,8.0,True
cord-000433,Analysis of outbreak and vaccination in clinical settings,This study examines outbreak with 290 word abstract...,"Author433_1, Author433_2",Journal of Medical Virology,2021-05-31,Medline,10.1000/sample.433,PMC1000433,https://example.com/paper_433,2021.0,5.0,57,8,True,54.0,8.0,True
cord-000435,Analysis of SARS-CoV-2 and immunity and clinical and epidemiology in clinical settings,This study examines SARS-CoV-2 with 202 word abstract...,"Author435_1, Author435_2",,2020-01-12,medRxiv,10.1000/sample.435,PMC1000435,https://example.com/paper_435,2020.0,1.0,86,12,True,56.0,8.0,False
cord-000437,Analysis of antibody and symptoms and therapeutic in clinical settings,This study examines antibody with 396 word abstract...,"Author437_1, Author437_2",JAMA,2021-09-10,PMC,10.1000/sample.437,,https://example.com/paper_437,2021.0,9.0,70,10,True,54.0,8.0,True
cord-000438,Analysis of respiratory and transmission and coronavirus and therapeutic in clinical settings,This study examines respiratory with 316 word abstract...,"Author438_1, Author438_2",Lancet,2021-09-16,bioRxiv,10.1000/sample.438,,https://example.com/paper_438,2021.0,9.0,93,12,True,57.0,8.0,True
cord-000439,Analysis of therapeutic and lockdown in clinical settings,This study examines therapeutic with 266 word abstract...,Author439_1,Virology,2021-07-18,PMC,10.1000/sample.439,,https://example.com/paper_439,2021.0,7.0,57,8,True,57.0,8.0,True
cord-000440,Analysis of pneumonia and SARS-CoV-2 and public health and coronavirus in clinical settings,This study examines pneumonia with 407 word abstract...,"Author440_1, Author440_2",Clinical Infectious Diseases,2020-04-25,ArXiv,10.1000/sample.440,PMC1000440,https://example.com/paper_440,2020.0,4.0,91,13,True,55.0,8.0,True
cord-000441,Analysis of diagnosis and lockdown and epidemiology in clinical settings,This study examines diagnosis with 343 word abstract...,"Author441_1, Author441_2",Lancet,2021-06-10,ArXiv,10.1000/sample.441,PMC1000441,,2021.0,6.0,72,10,True,55.0,8.0,True
cord-000443,Analysis of therapeutic and symptoms and coronavirus and treatment in clinical settings,This study examines therapeutic with 473 word abstract...,"Author443_1, Author443_2",Cell,2022-04-30,ArXiv,10.1000/sample.443,PMC1000443,https://example.com/paper_443,2022.0,4.0,87,12,True,57.0,8.0,True
cord-000444,Analysis of symptoms and COVID-19 and antiviral in clinical settings,This study examines symptoms with 291 word abstract...,"Author444_1, Author444_2",Emerging Infectious Diseases,2020-10-17,ArXiv,10.1000/sample.444,PMC1000444,https://example.com/paper_444,2020.0,10.0,68,10,True,54.0,8.0,True
cord-000446,Analysis of coronavirus and vaccination and public health in clinical settings,This study examines coronavirus with 438 word abstract...,"Author446_1, Author446_2",Clinical Infectious Diseases,2021-11-27,Medline,,,https://example.com/paper_446,2021.0,11.0,78,11,True,57.0,8.0,True
cord-000447,Analysis of vaccination and epidemiology in clinical settings,This study examines vaccination with 286 word abstract...,"Author447_1, Author447_2",Clinical Infectious Diseases,2020-06-07,Medline,10.1000/sample.447,PMC1000447,https://example.com/paper_447,2020.0,6.0,61,8,True,57.0,8.0,True
cord-000448,Analysis of SARS-CoV-2 and COVID-19 in clinical settings,This study examines SARS-CoV-2 with 399 word abstract...,"Author448_1, Author448_2",Journal of Medical Virology,2020-06-20,WHO,10.1000/sample.448,PMC1000448,https://example.com/paper_448,2020.0,6.0,56,8,True,56.0,8.0,True
cord-000449,Analysis of public health and treatment and coronavirus in clinical settings,This study examines public health with 373 word abstract...,"Author449_1, Author449_2",Journal of Medical Virology,2022-05-25,PMC,10.1000/sample.449,PMC1000449,https://example.com/paper_449,2022.0,5.0,76,11,True,59.0,9.0,True
cord-000450,Analysis of epidemiology and diagnosis and SARS-CoV-2 and vaccination in clinical settings,,Author450_1,Clinical Infectious Diseases,2020-01-21,ArXiv,10.1000/sample.450,PMC1000450,https://example.com/paper_450,2020.0,1.0,90,12,False,,,True
cord-000451,Analysis of symptoms and immunity and antibody and pandemic in clinical settings,This study examines symptoms with 353 word abstract...,"Author451_1, Author451_2",Virology,2022-12-31,ArXiv,10.1000/sample.451,PMC1000451,https://example.com/paper_451,2022.0,12.0,80,12,True,54.0,8.0,True
cord-000452,Analysis of treatment and public health and epidemiology in clinical settings,This study examines treatment with 319 word abstract...,"Author452_1, Author452_2",Clinical Infectious Diseases,2022-06-25,ArXiv,10.1000/sample.452,,,2022.0,6.0,77,11,True,55.0,8.0,True
cord-000453,Analysis of COVID-19 and immunity and coronavirus and therapeutic in clinical settings,This study examines COVID-19 with 266 word abstract...,"Author453_1, Author453_2",Science Translational Medicine,2022-09-12,Medline,10.1000/sample.453,,https://example.com/paper_453,2022.0,9.0,86,12,True,54.0,8.0,True
cord-000454,Analysis of COVID-19 and symptoms and clinical in clinical settings,This study examines COVID-19 with 267 word abstract...,"Author454_1, Author454_2",PLoS ONE,2020-06-01,PMC,,PMC1000454,https://example.com/paper_454,2020.0,6.0,67,10,True,54.0,8.0,True
cord-000455,Analysis of outbreak and public health and treatment and pandemic in clinical settings,This study examines outbreak with 304 word abstract...,"Author455_1, Author455_2",BMJ,2020-09-16,medRxiv,10.1000/sample.455,PMC1000455,https://example.com/paper_455,2020.0,9.0,86,13,True,54.0,8.0,True
cord-000457,Analysis of transmission and pneumonia and outbreak and vaccination in clinical settings,This study examines transmission with 467 word abstract...,"Author457_1, Author457_2",Journal of Medical Virology,2020-08-16,Medline,,,https://example.com/paper_457,2020.0,8.0,88,12,True,58.0,8.0,True
cord-000459,Analysis of diagnosis and COVID-19 and immunity and antibody in clinical settings,This study examines diagnosis with 358 word abstract...,"Author459_1, Author459_2",,,bioRxiv,10.1000/sample.459,PMC1000459,,,,81,12,True,55.0,8.0,False
cord-000460,Analysis of therapeutic and antibody and respiratory and treatment in clinical settings,This study examines therapeutic with 253 word abstract...,Author460_1,Nature Medicine,2020-11-15,bioRxiv,10.1000/sample.460,PMC1000460,https://example.com/paper_460,2020.0,11.0,87,12,True,57.0,8.0,True
cord-000461,Analysis of pneumonia and symptoms and public health in clinical settings,This study examines pneumonia with 234 word abstract...,"Author461_1, Author461_2",Journal of Virology,2022-07-22,bioRxiv,10.1000/sample.461,PMC1000461,https://example.com/paper_461,2022.0,7.0,73,11,True,55.0,8.0,True
cord-000462,Analysis of antiviral and therapeutic and immunity and vaccination in clinical settings,This study examines antiviral with 172 word abstract...,Author462_1,Virology,2020-11-14,WHO,10.1000/sample.462,PMC1000462,,2020.0,11.0,87,12,True,55.0,8.0,True
cord-000463,Analysis of immunity and pandemic and vaccination and respiratory in clinical settings,This study examines immunity with 152 word abstract...,Author463_1,Cell,2020-09-21,bioRxiv,10.1000/sample.463,,,2020.0,9.0,86,12,True,54.0,8.0,True
cord-000464,Analysis of transmission and diagnosis and pneumonia in clinical settings,This study examines transmission with 277 word abstract...,"Author464_1, Author464_2",Emerging Infectious Diseases,2021-10-04,WHO,10.1000/sample.464,PMC1000464,,2021.0,10.0,73,10,True,58.0,8.0,True
cord-000465,Analysis of therapeutic and diagnosis in clinical settings,This study examines therapeutic with 248 word abstract...,"Author465_1, Author465_2",Science Translational Medicine,2021-12-29,PMC,10.1000/sample.465,PMC1000465,https://example.com/paper_465,2021.0,12.0,58,8,True,57.0,8.0,True
cord-000466,Analysis of clinical and vaccination and lockdown and public health in clinical settings,This study examines clinical with 307 word abstract...,,JAMA,2020-09-02,WHO,,PMC1000466,https://example.com/paper_466,2020.0,9.0,88,13,True,54.0,8.0,True
cord-000467,Analysis of antibody and treatment and transmission and SARS-CoV-2 in clinical settings,This study examines antibody with 176 word abstract...,"Author467_1, Author467_2",New England Journal of Medicine,2020-08-05,ArXiv,10.1000/sample.467,PMC1000467,https://example.com/paper_467,2020.0,8.0,87,12,True,54.0,8.0,True
cord-000468,Analysis of public health and pandemic and lockdown and treatment in clinical settings,This study examines public health with 137 word abstract...,Author468_1,Nature,2021-09-04,bioRxiv,10.1000/sample.468,PMC1000468,https://example.com/paper_468,2021.0,9.0,86,13,True,59.0,9.0,True
cord-000469,Analysis of immunity and coronavirus in clinical settings,This study examines immunity with 228 word abstract...,Author469_1,,2021-04-25,bioRxiv,10.1000/sample.469,PMC1000469,https://example.com/paper_469,2021.0,4.0,57,8,True,54.0,8.0,False
cord-000470,Analysis of public health and outbreak and treatment and vaccination in clinical settings,This study examines public health with 206 word abstract...,"Author470_1, Author470_2",PLoS ONE,2021-01-04,bioRxiv,10.1000/sample.470,PMC1000470,https://example.com/paper_470,2021.0,1.0,89,13,True,59.0,9.0,True
cord-000471,Analysis of pandemic and lockdown and therapeutic in clinical settings,This study examines pandemic with 251 word abstract...,"Author471_1, Author471_2",Journal of Virology,2020-07-10,medRxiv,10.1000/sample.471,PMC1000471,https://example.com/paper_471,2020.0,7.0,70,10,True,54.0,8.0,True
cord-000472,Analysis of epidemiology and pandemic and pneumonia and treatment in clinical settings,This study examines epidemiology with 419 word abstract...,"Author472_1, Author472_2",New England Journal of Medicine,,PMC,10.1000/sample.472,PMC1000472,https://example.com/paper_472,,,86,12,True,58.0,8.0,True
cord-000473,Analysis of respiratory and therapeutic and treatment and transmission in clinical settings,This study examines respiratory with 196 word abstract...,Author473_1,BMJ,2020-03-03,Medline,10.1000/sample.473,PMC1000473,,2020.0,3.0,91,12,True,57.0,8.0,True
cord-000474,Analysis of antibody and diagnosis in clinical settings,This study examines antibody with 297 word abstract...,"Author474_1, Author474_2",Science Translational Medicine,2021-05-07,WHO,10.1000/sample.474,PMC1000474,,2021.0,5.0,55,8,True,54.0,8.0,True
cord-000475,Analysis of lockdown and pandemic and coronavirus in clinical settings,This study examines lockdown with 341 word abstract...,"Author475_1, Author475_2",,,ArXiv,10.1000/sample.475,,,,,70,10,True,54.0,8.0,False
cord-000476,Analysis of treatment and pandemic and diagnosis and lockdown in clinical settings,This study examines treatment with 225 word abstract...,"Author476_1, Author476_2",,2020-05-05,Medline,,PMC1000476,https://example.com/paper_476,2020.0,5.0,82,12,True,55.0,8.0,False
cord-000478,Analysis of vaccination and respiratory and antibody in clinical settings,This study examines vaccination with 498 word abstract...,"Author478_1, Author478_2",Science,2021-07-17,bioRxiv,10.1000/sample.478,PMC1000478,,2021.0,7.0,73,10,True,57.0,8.0,True
cord-000479,Analysis of symptoms and pandemic and transmission in clinical settings,This study examines symptoms with 379 word abstract...,"Author479_1, Author479_2",New England Journal of Medicine,2022-07-31,bioRxiv,10.1000/sample.479,PMC1000479,https://example.com/paper_479,2022.0,7.0,71,10,True,54.0,8.0,True
cord-000480,Analysis of immunity and epidemiology and treatment in clinical settings,This study examines immunity with 272 word abstract...,"Author480_1, Author480_2",Lancet,2021-04-21,bioRxiv,10.1000/sample.480,PMC1000480,https://example.com/paper_480,2021.0,4.0,72,10,True,54.0,8.0,True
cord-000483,Analysis of vaccination and symptoms and diagnosis in clinical settings,This study examines vaccination with 120 word abstract...,Author483_1,JAMA,2020-01-04,medRxiv,10.1000/sample.483,PMC1000483,,2020.0,1.0,71,10,True,57.0,8.0,True
cord-000484,Analysis of antiviral and respiratory in clinical settings,This study examines antiviral with 491 word abstract...,"Author484_1, Author484_2",Journal of Medical Virology,2019-12-22,Medline,10.1000/sample.484,PMC1000484,https://example.com/paper_484,2019.0,12.0,58,8,True,55.0,8.0,True
cord-000485,Analysis of treatment and respiratory and COVID-19 and pneumonia in clinical settings,This study examines treatment with 461 word abstract...,"Author485_1, Author485_2",,2020-06-09,WHO,10.1000/sample.485,PMC1000485,https://example.com/paper_485,2020.0,6.0,85,12,True,55.0,8.0,False
cord-000486,Analysis of therapeutic and vaccination in clinical settings,This study examines therapeutic with 351 word abstract...,"Author486_1, Author486_2",Journal of Medical Virology,2020-11-23,medRxiv,10.1000/sample.486,,https://example.com/paper_486,2020.0,11.0,60,8,True,57.0,8.0,True
cord-000488,Analysis of pandemic and antiviral and public health and pneumonia in clinical settings,This study examines pandemic with 449 word abstract...,"Author488_1, Author488_2",Lancet,2020-01-24,PMC,10.1000/sample.488,,,2020.0,1.0,87,13,True,54.0,8.0,True
cord-000489,Analysis of public health and treatment in clinical settings,This study examines public health with 170 word abstract...,"Author489_1, Author489_2",JAMA,2021-05-02,ArXiv,10.1000/sample.489,,https://example.com/paper_489,2021.0,5.0,60,9,True,59.0,9.0,True
cord-000490,Analysis of public health and therapeutic and diagnosis in clinical settings,This study examines public health with 473 word abstract...,"Author490_1, Author490_2",Lancet,2020-08-05,PMC,10.1000/sample.490,PMC1000490,https://example.com/paper_490,2020.0,8.0,76,11,True,59.0,9.0,True
cord-000491,Analysis of outbreak and transmission in clinical settings,This study examines outbreak with 122 word abstract...,"Author491_1, Author491_2",Nature Medicine,2020-09-07,WHO,10.1000/sample.491,,https://example.com/paper_491,2020.0,9.0,58,8,True,54.0,8.0,True
cord-000492,Analysis of immunity and treatment and diagnosis and vaccination in clinical settings,This study examines immunity with 373 word abstract...,"Author492_1, Author492_2",Journal of Medical Virology,2020-04-18,PMC,10.1000/sample.492,PMC1000492,https://example.com/paper_492,2020.0,4.0,85,12,True,54.0,8.0,True
cord-000493,Analysis of antibody and outbreak and respiratory in clinical settings,This study examines antibody with 175 word abstract...,"Author493_1, Author493_2",Lancet,2021-05-26,WHO,10.1000/sample.493,PMC1000493,,2021.0,5.0,70,10,True,54.0,8.0,True
cord-000494,Analysis of outbreak and antiviral in clinical settings,This study examines outbreak with 442 word abstract...,"Author494_1, Author494_2",Virology,2019-12-10,PMC,10.1000/sample.494,PMC1000494,https://example.com/paper_494,2019.0,12.0,55,8,True,54.0,8.0,True
cord-000495,Analysis of COVID-19 and symptoms and public health in clinical settings,This study examines COVID-19 with 446 word abstract...,Author495_1,BMJ,2022-05-18,Medline,,,https://example.com/paper_495,2022.0,5.0,72,11,True,54.0,8.0,True
cord-000497,Analysis of outbreak and SARS-CoV-2 and public health and lockdown in clinical settings,This study examines outbreak with 310 word abstract...,"Author497_1, Author497_2",Emerging Infectious Diseases,2019-12-23,WHO,10.1000/sample.497,PMC1000497,,2019.0,12.0,87,13,True,54.0,8.0,True
cord-000498,Analysis of pneumonia and treatment and lockdown in clinical settings,,"Author498_1, Author498_2",Science Translational Medicine,2021-09-03,PMC,10.1000/sample.498,PMC1000498,https://example.com/paper_498,2021.0,9.0,69,10,False,,,True
cord-000499,Analysis of coronavirus and immunity and therapeutic and epidemiology in clinical settings,This study examines coronavirus with 450 word abstract...,"Author499_1, Author499_2",Lancet,2021-10-02,PMC,10.1000/sample.499,PMC1000499,https://example.com/paper_499,2021.0,10.0,90,12,True,57.0,8.0,True
cord-000500,Analysis of lockdown and diagnosis and therapeutic and public health in clinical settings,,Author500_1,Science Translational Medicine,2020-03-16,medRxiv,10.1000/sample.500,PMC1000500,https://example.com/paper_500,2020.0,3.0,89,13,False,,,True
cord-000503,Analysis of antiviral and respiratory and treatment in clinical settings,This study examines antiviral with 229 word abstract...,Author503_1,JAMA,2020-04-09,bioRxiv,10.1000/sample.503,,https://example.com/paper_503,2020.0,4.0,72,10,True,55.0,8.0,True
cord-000504,Analysis of symptoms and clinical and antiviral and diagnosis in clinical settings,This study examines symptoms with 114 word abstract...,"Author504_1, Author504_2",BMJ,2020-06-03,PMC,10.1000/sample.504,,https://example.com/paper_504,2020.0,6.0,82,12,True,54.0,8.0,True
cord-000505,Analysis of respiratory and immunity and pandemic and epidemiology in clinical settings,This study examines respiratory with 358 word abstract...,"Author505_1, Author505_2",Journal of Virology,2021-04-29,WHO,,PMC1000505,https://example.com/paper_505,2021.0,4.0,87,12,True,57.0,8.0,True
cord-000506,Analysis of therapeutic and respiratory and SARS-CoV-2 and antiviral in clinical settings,This study examines therapeutic with 140 word abstract...,"Author506_1, Author506_2",,2021-05-11,medRxiv,10.1000/sample.506,PMC1000506,https://example.com/paper_506,2021.0,5.0,89,12,True,57.0,8.0,False
cord-000507,Analysis of antibody and pneumonia and lockdown in clinical settings,This study examines antibody with 389 word abstract...,Author507_1,Lancet,2020-01-10,PMC,10.1000/sample.507,,,2020.0,1.0,68,10,True,54.0,8.0,True
cord-000508,Analysis of coronavirus and vaccination in clinical settings,This study examines coronavirus with 325 word abstract...,"Author508_1, Author508_2",Cell,,ArXiv,10.1000/sample.508,PMC1000508,https://example.com/paper_508,,,60,8,True,57.0,8.0,True
cord-000509,Analysis of lockdown and respiratory and COVID-19 in clinical settings,This study examines lockdown with 496 word abstract...,"Author509_1, Author509_2",Science,2021-03-04,bioRxiv,10.1000/sample.509,,https://example.com/paper_509,2021.0,3.0,70,10,True,54.0,8.0,True
cord-000510,Analysis of coronavirus and clinical and COVID-19 in clinical settings,This study examines coronavirus with 342 word abstract...,"Author510_1, Author510_2",Science,2021-03-21,PMC,10.1000/sample.510,PMC1000510,https://example.com/paper_510,2021.0,3.0,70,10,True,57.0,8.0,True
cord-000511,Analysis of respiratory and therapeutic and pandemic and clinical in clinical settings,This study examines respiratory with 296 word abstract...,Author511_1,,2020-03-07,medRxiv,10.1000/sample.511,PMC1000511,https://example.com/paper_511,2020.0,3.0,86,12,True,57.0,8.0,False
cord-000512,Analysis of COVID-19 and symptoms and therapeutic in clinical settings,,"Author512_1, Author512_2",Science Translational Medicine,2020-12-03,ArXiv,10.1000/sample.512,PMC1000512,https://example.com/paper_512,2020.0,12.0,70,10,False,,,True
cord-000513,Analysis of coronavirus and diagnosis and transmission in clinical settings,This study examines coronavirus with 429 word abstract...,"Author513_1, Author513_2",Virology,2021-10-06,medRxiv,10.1000/sample.513,PMC1000513,https://example.com/paper_513,2021.0,10.0,75,10,True,57.0,8.0,True
cord-000514,Analysis of antiviral and outbreak and diagnosis and immunity in clinical settings,This study examines antiviral with 303 word abstract...,"Author514_1, Author514_2",Journal of Virology,2022-10-27,Medline,10.1000/sample.514,PMC1000514,https://example.com/paper_514,2022.0,10.0,82,12,True,55.0,8.0,True
cord-000515,Analysis of diagnosis and therapeutic and pandemic and outbreak in clinical settings,This study examines diagnosis with 458 word abstract...,"Author515_1, Author515_2",Science Translational Medicine,2020-03-29,medRxiv,10.1000/sample.515,PMC1000515,https://example.com/paper_515,2020.0,3.0,84,12,True,55.0,8.0,True
cord-000516,Analysis of lockdown and therapeutic and diagnosis and transmission in clinical settings,This study examines lockdown with 430 word abstract...,"Author516_1, Author516_2",Science Translational Medicine,2019-12-06,ArXiv,10.1000/sample.516,PMC1000516,https://example.com/paper_516,2019.0,12.0,88,12,True,54.0,8.0,True
cord-000517,Analysis of epidemiology and pandemic and clinical in clinical settings,,"Author517_1, Author517_2",,2021-11-22,bioRxiv,10.1000/sample.517,PMC1000517,,2021.0,11.0,71,10,False,,,False
cord-000518,Analysis of symptoms and transmission and epidemiology in clinical settings,This study examines symptoms with 163 word abstract...,"Author518_1, Author518_2",Science Translational Medicine,2019-12-02,medRxiv,10.1000/sample.518,PMC1000518,,2019.0,12.0,75,10,True,54.0,8.0,True
cord-000519,Analysis of antibody and epidemiology and pandemic and COVID-19 in clinical settings,This study examines antibody with 279 word abstract...,"Author519_1, Author519_2",Emerging Infectious Diseases,2021-03-30,ArXiv,10.1000/sample.519,PMC1000519,https://example.com/paper_519,2021.0,3.0,84,12,True,54.0,8.0,True
cord-000520,Analysis of vaccination and antiviral in clinical settings,This study examines vaccination with 174 word abstract...,"Author520_1, Author520_2",Journal of Virology,2020-06-08,Medline,10.1000/sample.520,PMC1000520,,2020.0,6.0,58,8,True,57.0,8.0,True
cord-000521,Analysis of pneumonia and antiviral and immunity in clinical settings,This study examines pneumonia with 448 word abstract...,Author521_1,Cell,,ArXiv,10.1000/sample.521,PMC1000521,https://example.com/paper_521,,,69,10,True,55.0,8.0,True
cord-000522,Analysis of symptoms and immunity and antibody in clinical settings,This study examines symptoms with 187 word abstract...,"Author522_1, Author522_2",JAMA,2022-11-11,WHO,10.1000/sample.522,PMC1000522,https://example.com/paper_522,2022.0,11.0,67,10,True,54.0,8.0,True
cord-000523,Analysis of diagnosis and symptoms in clinical settings,This study examines diagnosis with 455 word abstract...,"Author523_1, Author523_2",BMJ,2021-08-06,bioRxiv,10.1000/sample.523,,,2021.0,8.0,55,8,True,55.0,8.0,True
cord-000524,Analysis of lockdown and pandemic in clinical settings,This study examines lockdown with 368 word abstract...,"Author524_1, Author524_2",PLoS ONE,2021-11-25,Medline,10.1000/sample.524,PMC1000524,https://example.com/paper_524,2021.0,11.0,54,8,True,54.0,8.0,True
cord-000525,Analysis of antiviral and respiratory and symptoms in clinical settings,,"Author525_1, Author525_2",Nature,2021-06-08,bioRxiv,10.1000/sample.525,PMC1000525,,2021.0,6.0,71,10,False,,,True
cord-000526,Analysis of pandemic and therapeutic in clinical settings,This study examines pandemic with 293 word abstract...,"Author526_1, Author526_2",,2021-12-22,PMC,10.1000/sample.526,PMC1000526,https://example.com/paper_526,2021.0,12.0,57,8,True,54.0,8.0,False
cord-000527,Analysis of antiviral and pandemic and therapeutic in clinical settings,This study examines antiviral with 461 word abstract...,"Author527_1, Author527_2",Emerging Infectious Diseases,2021-04-17,ArXiv,10.1000/sample.527,PMC1000527,https://example.com/paper_527,2021.0,4.0,71,10,True,55.0,8.0,True
cord-000528,Analysis of clinical and pandemic and antiviral and lockdown in clinical settings,This study examines clinical with 365 word abstract...,Author528_1,Science,2022-01-17,medRxiv,10.1000/sample.528,,https://example.com/paper_528,2022.0,1.0,81,12,True,54.0,8.0,True
cord-000529,Analysis of lockdown and outbreak and diagnosis and pandemic in clinical settings,This study examines lockdown with 103 word abstract...,"Author529_1, Author529_2",Emerging Infectious Diseases,2022-11-06,medRxiv,10.1000/sample.529,PMC1000529,https://example.com/paper_529,2022.0,11.0,81,12,True,54.0,8.0,True
cord-000530,Analysis of SARS-CoV-2 and therapeutic and treatment in clinical settings,This study examines SARS-CoV-2 with 131 word abstract...,"Author530_1, Author530_2",Science Translational Medicine,2020-08-14,bioRxiv,10.1000/sample.530,,https://example.com/paper_530,2020.0,8.0,73,10,True,56.0,8.0,True
cord-000531,Analysis of immunity and diagnosis in clinical settings,This study examines immunity with 227 word abstract...,"Author531_1, Author531_2",Clinical Infectious Diseases,2020-02-10,WHO,10.1000/sample.531,,https://example.com/paper_531,2020.0,2.0,55,8,True,54.0,8.0,True
cord-000532,Analysis of coronavirus and immunity and diagnosis and antiviral in clinical settings,This study examines coronavirus with 453 word abstract...,"Author532_1, Author532_2",Science Translational Medicine,2020-08-01,PMC,10.1000/sample.532,PMC1000532,https://example.com/paper_532,2020.0,8.0,85,12,True,57.0,8.0,True
cord-000534,Analysis of public health and symptoms and lockdown in clinical settings,This study examines public health with 100 word abstract...,"Author534_1, Author534_2",Clinical Infectious Diseases,2020-06-07,Medline,10.1000/sample.534,PMC1000534,https://example.com/paper_534,2020.0,6.0,72,11,True,59.0,9.0,True
cord-000535,Analysis of vaccination and treatment in clinical settings,This study examines vaccination with 296 word abstract...,"Author535_1, Author535_2",JAMA,2021-08-09,medRxiv,10.1000/sample.535,PMC1000535,https://example.com/paper_535,2021.0,8.0,58,8,True,57.0,8.0,True
cord-000536,Analysis of antibody and pandemic and lockdown and pneumonia in clinical settings,This study examines antibody with 498 word abstract...,"Author536_1, Author536_2",Lancet,2020-03-18,Medline,10.1000/sample.536,,https://example.com/paper_536,2020.0,3.0,81,12,True,54.0,8.0,True
cord-000537,Analysis of respiratory and diagnosis and pandemic and immunity in clinical settings,This study examines respiratory with 261 word abstract...,"Author537_1, Author537_2",Cell,2020-02-19,medRxiv,10.1000/sample.537,PMC1000537,,2020.0,2.0,84,12,True,57.0,8.0,True
cord-000538,Analysis of pandemic and diagnosis and coronavirus in clinical settings,This study examines pandemic with 498 word abstract...,"Author538_1, Author538_2",BMJ,2021-12-05,PMC,10.1000/sample.538,PMC1000538,https://example.com/paper_538,2021.0,12.0,71,10,True,54.0,8.0,True
cord-000539,Analysis of symptoms and immunity in clinical settings,This study examines symptoms with 405 word abstract...,"Author539_1, Author539_2",Cell,2021-05-06,Medline,10.1000/sample.539,,https://example.com/paper_539,2021.0,5.0,54,8,True,54.0,8.0,True
cord-000540,Analysis of transmission and symptoms and clinical in clinical settings,This study examines transmission with 364 word abstract...,"Author540_1, Author540_2",Science,2020-04-15,Medline,10.1000/sample.540,,https://example.com/paper_540,2020.0,4.0,71,10,True,58.0,8.0,True
cord-000541,Analysis of immunity and antibody in clinical settings,This study examines immunity with 370 word abstract...,"Author541_1, Author541_2",JAMA,2021-10-26,WHO,10.1000/sample.541,PMC1000541,,2021.0,10.0,54,8,True,54.0,8.0,True
cord-000542,Analysis of antibody and diagnosis and epidemiology in clinical settings,This study examines antibody with 157 word abstract...,"Author542_1, Author542_2",Nature Medicine,2020-02-07,bioRxiv,10.1000/sample.542,PMC1000542,https://example.com/paper_542,2020.0,2.0,72,10,True,54.0,8.0,True
cord-000543,Analysis of respiratory and immunity in clinical settings,This study examines respiratory with 408 word abstract...,Author543_1,Lancet,2020-08-30,WHO,10.1000/sample.543,PMC1000543,https://example.com/paper_543,2020.0,8.0,57,8,True,57.0,8.0,True
cord-000544,Analysis of epidemiology and antiviral in clinical settings,This study examines epidemiology with 445 word abstract...,"Author544_1, Author544_2",Emerging Infectious Diseases,2020-12-30,ArXiv,,,https://example.com/paper_544,2020.0,12.0,59,8,True,58.0,8.0,True
cord-000545,Analysis of symptoms and vaccination and pandemic in clinical settings,This study examines symptoms with 382 word abstract...,"Author545_1, Author545_2",Science,2021-12-29,PMC,10.1000/sample.545,PMC1000545,https://example.com/paper_545,2021.0,12.0,70,10,True,54.0,8.0,True
cord-000546,Analysis of outbreak and vaccination and immunity and COVID-19 in clinical settings,This study examines outbreak with 466 word abstract...,"Author546_1, Author546_2",Science Translational Medicine,2020-09-16,ArXiv,,,https://example.com/paper_546,2020.0,9.0,83,12,True,54.0,8.0,True
cord-000547,Analysis of transmission and treatment and coronavirus and vaccination in clinical settings,This study examines transmission with 272 word abstract...,"Author547_1, Author547_2",Emerging Infectious Diseases,2021-09-08,ArXiv,10.1000/sample.547,,https://example.com/paper_547,2021.0,9.0,91,12,True,58.0,8.0,True
cord-000548,Analysis of transmission and diagnosis and clinical and pandemic in clinical settings,This study examines transmission with 179 word abstract...,"Author548_1, Author548_2",Nature,2019-12-07,PMC,10.1000/sample.548,PMC1000548,https://example.com/paper_548,2019.0,12.0,85,12,True,58.0,8.0,True
cord-000549,Analysis of vaccination and immunity and therapeutic in clinical settings,This study examines vaccination with 220 word abstract...,"Author549_1, Author549_2",BMJ,2021-04-10,medRxiv,10.1000/sample.549,PMC1000549,https://example.com/paper_549,2021.0,4.0,73,10,True,57.0,8.0,True
cord-000550,Analysis of antibody and clinical and therapeutic in clinical settings,This study examines antibody with 300 word abstract...,"Author550_1, Author550_2",Journal of Medical Virology,2020-08-15,bioRxiv,10.1000/sample.550,PMC1000550,https://example.com/paper_550,2020.0,8.0,70,10,True,54.0,8.0,True
cord-000551,Analysis of therapeutic and symptoms and respiratory and immunity in clinical settings,This study examines therapeutic with 396 word abstract...,"Author551_1, Author551_2",BMJ,,medRxiv,10.1000/sample.551,PMC1000551,https://example.com/paper_551,,,86,12,True,57.0,8.0,True
cord-000552,Analysis of transmission and coronavirus and clinical and diagnosis in clinical settings,This study examines transmission with 150 word abstract...,"Author552_1, Author552_2",JAMA,2019-12-16,PMC,10.1000/sample.552,,https://example.com/paper_552,2019.0,12.0,88,12,True,58.0,8.0,True
cord-000553,Analysis of pandemic and COVID-19 in clinical settings,This study examines pandemic with 368 word abstract...,"Author553_1, Author553_2",JAMA,2020-12-29,Medline,10.1000/sample.553,PMC1000553,https://example.com/paper_553,2020.0,12.0,54,8,True,54.0,8.0,True
cord-000554,Analysis of clinical and lockdown and COVID-19 and coronavirus in clinical settings,This study examines clinical with 146 word abstract...,"Author554_1, Author554_2",Nature Medicine,2020-07-16,Medline,10.1000/sample.554,PMC1000554,https://example.com/paper_554,2020.0,7.0,83,12,True,54.0,8.0,True
cord-000555,Analysis of therapeutic and public health and treatment and antibody in clinical settings,This study examines therapeutic with 457 word abstract...,"Author555_1, Author555_2",New England Journal of Medicine,2019-12-02,Medline,10.1000/sample.555,PMC1000555,https://example.com/paper_555,2019.0,12.0,89,13,True,57.0,8.0,True
cord-000557,Analysis of pandemic and outbreak and antiviral in clinical settings,This study examines pandemic with 147 word abstract...,"Author557_1, Author557_2",New England Journal of Medicine,2020-01-13,bioRxiv,10.1000/sample.557,PMC1000557,https://example.com/paper_557,2020.0,1.0,68,10,True,54.0,8.0,True
cord-000558,Analysis of antiviral and COVID-19 and coronavirus in clinical settings,This study examines antiviral with 188 word abstract...,"Author558_1, Author558_2",Lancet,2022-09-23,medRxiv,10.1000/sample.558,,,2022.0,9.0,71,10,True,55.0,8.0,True
cord-000559,Analysis of public health and respiratory in clinical settings,This study examines public health with 469 word abstract...,Author559_1,Emerging Infectious Diseases,2020-09-30,PMC,10.1000/sample.559,,https://example.com/paper_559,2020.0,9.0,62,9,True,59.0,9.0,True
cord-000560,Analysis of public health and pneumonia and COVID-19 in clinical settings,This study examines public health with 342 word abstract...,Author560_1,,2021-07-17,bioRxiv,10.1000/sample.560,,https://example.com/paper_560,2021.0,7.0,73,11,True,59.0,9.0,False
cord-000562,Analysis of epidemiology and immunity and vaccination and antibody in clinical settings,This study examines epidemiology with 413 word abstract...,"Author562_1, Author562_2",BMJ,2022-11-17,bioRxiv,,PMC1000562,,2022.0,11.0,87,12,True,58.0,8.0,True
cord-000563,Analysis of antiviral and COVID-19 and clinical in clinical settings,This study examines antiviral with 201 word abstract...,Author563_1,Emerging Infectious Diseases,2020-06-19,bioRxiv,10.1000/sample.563,,https://example.com/paper_563,2020.0,6.0,68,10,True,55.0,8.0,True
cord-000564,Analysis of coronavirus and therapeutic in clinical settings,This study examines coronavirus with 193 word abstract...,"Author564_1, Author564_2",Clinical Infectious Diseases,2019-12-11,PMC,10.1000/sample.564,,,2019.0,12.0,60,8,True,57.0,8.0,True
cord-000565,Analysis of SARS-CoV-2 and immunity in clinical settings,This study examines SARS-CoV-2 with 227 word abstract...,"Author565_1, Author565_2",BMJ,2021-06-26,PMC,10.1000/sample.565,,https://example.com/paper_565,2021.0,6.0,56,8,True,56.0,8.0,True
cord-000566,Analysis of pneumonia and clinical and treatment in clinical settings,This study examines pneumonia with 264 word abstract...,"Author566_1, Author566_2",Virology,2020-05-20,Medline,10.1000/sample.566,PMC1000566,https://example.com/paper_566,2020.0,5.0,69,10,True,55.0,8.0,True
cord-000567,Analysis of public health and antiviral and epidemiology and antibody in clinical settings,This study examines public health with 392 word abstract...,"Author567_1, Author567_2",Lancet,2021-01-30,bioRxiv,10.1000/sample.567,,https://example.com/paper_567,2021.0,1.0,90,13,True,59.0,9.0,True
cord-000568,Analysis of coronavirus and transmission and outbreak in clinical settings,This study examines coronavirus with 218 word abstract...,"Author568_1, Author568_2",Emerging Infectious Diseases,2020-09-28,Medline,10.1000/sample.568,PMC1000568,https://example.com/paper_568,2020.0,9.0,74,10,True,57.0,8.0,True
cord-000569,Analysis of diagnosis and symptoms and pandemic in clinical settings,This study examines diagnosis with 447 word abstract...,"Author569_1, Author569_2",Clinical Infectious Diseases,2021-05-13,ArXiv,10.1000/sample.569,,https://example.com/paper_569,2021.0,5.0,68,10,True,55.0,8.0,True
cord-000570,Analysis of SARS-CoV-2 and immunity and treatment and therapeutic in clinical settings,This study examines SARS-CoV-2 with 434 word abstract...,"Author570_1, Author570_2",,2020-02-24,PMC,10.1000/sample.570,,https://example.com/paper_570,2020.0,2.0,86,12,True,56.0,8.0,False
cord-000571,Analysis of vaccination and coronavirus and antibody in clinical settings,This study examines vaccination with 465 word abstract...,"Author571_1, Author571_2",Science,2020-07-20,Medline,10.1000/sample.571,,https://example.com/paper_571,2020.0,7.0,73,10,True,57.0,8.0,True
cord-000572,Analysis of respiratory and coronavirus and COVID-19 and immunity in clinical settings,This study examines respiratory with 153 word abstract...,"Author572_1, Author572_2",Virology,2021-09-03,PMC,10.1000/sample.572,PMC1000572,https://example.com/paper_572,2021.0,9.0,86,12,True,57.0,8.0,True
cord-000573,Analysis of transmission and clinical in clinical settings,This study examines transmission with 328 word abstract...,"Author573_1, Author573_2",Nature,2021-06-16,PMC,10.1000/sample.573,,,2021.0,6.0,58,8,True,58.0,8.0,True
cord-000574,Analysis of antiviral and SARS-CoV-2 and antibody and treatment in clinical settings,This study examines antiviral with 344 word abstract...,"Author574_1, Author574_2",,2021-06-02,Medline,10.1000/sample.574,PMC1000574,https://example.com/paper_574,2021.0,6.0,84,12,True,55.0,8.0,False
cord-000575,Analysis of SARS-CoV-2 and transmission and pneumonia in clinical settings,This study examines SARS-CoV-2 with 337 word abstract...,"Author575_1, Author575_2",Science,2020-03-27,WHO,10.1000/sample.575,PMC1000575,https://example.com/paper_575,2020.0,3.0,74,10,True,56.0,8.0,True
cord-000576,Analysis of pneumonia and therapeutic in clinical settings,,"Author576_1, Author576_2",Cell,2020-11-20,Medline,10.1000/sample.576,PMC1000576,https://example.com/paper_576,2020.0,11.0,58,8,False,,,True
cord-000577,Analysis of therapeutic and antiviral and public health in clinical settings,,Author577_1,BMJ,2021-06-12,ArXiv,10.1000/sample.577,,https://example.com/paper_577,2021.0,6.0,76,11,False,,,True
cord-000578,Analysis of COVID-19 and diagnosis and outbreak in clinical settings,This study examines COVID-19 with 134 word abstract...,"Author578_1, Author578_2",Clinical Infectious Diseases,2020-03-28,bioRxiv,10.1000/sample.578,PMC1000578,https://example.com/paper_578,2020.0,3.0,68,10,True,54.0,8.0,True
cord-000579,Analysis of respiratory and vaccination and clinical and transmission in clinical settings,,"Author579_1, Author579_2",New England Journal of Medicine,2019-12-27,ArXiv,10.1000/sample.579,,https://example.com/paper_579,2019.0,12.0,90,12,False,,,True
cord-000580,Analysis of pandemic and therapeutic and clinical and treatment in clinical settings,This study examines pandemic with 113 word abstract...,"Author580_1, Author580_2",Journal of Medical Virology,2020-09-12,PMC,,PMC1000580,https://example.com/paper_580,2020.0,9.0,84,12,True,54.0,8.0,True
cord-000581,Analysis of pandemic and therapeutic and epidemiology in clinical settings,This study examines pandemic with 176 word abstract...,"Author581_1, Author581_2",Clinical Infectious Diseases,2019-12-31,bioRxiv,10.1000/sample.581,PMC1000581,https://example.com/paper_581,2019.0,12.0,74,10,True,54.0,8.0,True
cord-000582,Analysis of treatment and antibody and antiviral and clinical in clinical settings,,"Author582_1, Author582_2",JAMA,2020-02-25,PMC,10.1000/sample.582,PMC1000582,https://example.com/paper_582,2020.0,2.0,82,12,False,,,True
cord-000583,Analysis of SARS-CoV-2 and antibody and COVID-19 in clinical settings,This study examines SARS-CoV-2 with 241 word abstract...,"Author583_1, Author583_2",,2021-03-09,Medline,10.1000/sample.583,PMC1000583,https://example.com/paper_583,2021.0,3.0,69,10,True,56.0,8.0,False
cord-000584,Analysis of immunity and symptoms and treatment in clinical settings,This study examines immunity with 152 word abstract...,"Author584_1, Author584_2",Nature,2020-05-19,WHO,10.1000/sample.584,,https://example.com/paper_584,2020.0,5.0,68,10,True,54.0,8.0,True
cord-000585,Analysis of public health and therapeutic and outbreak and lockdown in clinical settings,This study examines public health with 380 word abstract...,"Author585_1, Author585_2",,2020-06-28,WHO,,,https://example.com/paper_585,2020.0,6.0,88,13,True,59.0,9.0,False
cord-000586,Analysis of antibody and coronavirus in clinical settings,This study examines antibody with 103 word abstract...,"Author586_1, Author586_2",Lancet,2021-07-17,medRxiv,10.1000/sample.586,PMC1000586,https://example.com/paper_586,2021.0,7.0,57,8,True,54.0,8.0,True
cord-000588,Analysis of antiviral and outbreak and clinical in clinical settings,This study examines antiviral with 241 word abstract...,"Author588_1, Author588_2",PLoS ONE,2021-06-18,bioRxiv,10.1000/sample.588,,https://example.com/paper_588,2021.0,6.0,68,10,True,55.0,8.0,True
cord-000589,Analysis of respiratory and pneumonia and vaccination in clinical settings,,"Author589_1, Author589_2",PLoS ONE,2021-11-22,ArXiv,,PMC1000589,https://example.com/paper_589,2021.0,11.0,74,10,False,,,True
cord-000590,Analysis of pandemic and coronavirus in clinical settings,This study examines pandemic with 368 word abstract...,"Author590_1, Author590_2",Clinical Infectious Diseases,2021-08-21,bioRxiv,10.1000/sample.590,,https://example.com/paper_590,2021.0,8.0,57,8,True,54.0,8.0,True
cord-000591,Analysis of antibody and immunity and therapeutic in clinical settings,This study examines antibody with 310 word abstract...,"Author591_1, Author591_2",Lancet,2021-05-23,bioRxiv,10.1000/sample.591,,https://example.com/paper_591,2021.0,5.0,70,10,True,54.0,8.0,True
cord-000592,Analysis of antibody and immunity in clinical settings,This study examines antibody with 439 word abstract...,"Author592_1, Author592_2",Science Translational Medicine,2022-11-29,WHO,10.1000/sample.592,,,2022.0,11.0,54,8,True,54.0,8.0,True
cord-000593,Analysis of lockdown and epidemiology and treatment and coronavirus in clinical settings,This study examines lockdown with 406 word abstract...,"Author593_1, Author593_2",Clinical Infectious Diseases,2021-07-12,Medline,,PMC1000593,,2021.0,7.0,88,12,True,54.0,8.0,True
cord-000594,Analysis of respiratory and symptoms in clinical settings,This study examines respiratory with 237 word abstract...,"Author594_1, Author594_2",BMJ,2020-07-09,PMC,10.1000/sample.594,,https://example.com/paper_594,2020.0,7.0,57,8,True,57.0,8.0,True
cord-000595,Analysis of diagnosis and antibody and therapeutic in clinical settings,This study examines diagnosis with 498 word abstract...,"Author595_1, Author595_2",BMJ,2020-04-22,PMC,10.1000/sample.595,,https://example.com/paper_595,2020.0,4.0,71,10,True,55.0,8.0,True
cord-000596,Analysis of immunity and clinical and respiratory in clinical settings,This study examines immunity with 301 word abstract...,"Author596_1, Author596_2",Nature,2022-04-30,medRxiv,10.1000/sample.596,PMC1000596,https://example.com/paper_596,2022.0,4.0,70,10,True,54.0,8.0,True
cord-000597,Analysis of diagnosis and respiratory and therapeutic and transmission in clinical settings,This study examines diagnosis with 260 word abstract...,Author597_1,BMJ,2021-09-17,ArXiv,10.1000/sample.597,,,2021.0,9.0,91,12,True,55.0,8.0,True
cord-000598,Analysis of lockdown and diagnosis and treatment and pandemic in clinical settings,This study examines lockdown with 194 word abstract...,"Author598_1, Author598_2",New England Journal of Medicine,2020-09-05,PMC,10.1000/sample.598,PMC1000598,https://example.com/paper_598,2020.0,9.0,82,12,True,54.0,8.0,True
cord-000599,Analysis of therapeutic and diagnosis and SARS-CoV-2 in clinical settings,This study examines therapeutic with 369 word abstract...,"Author599_1, Author599_2",JAMA,2021-07-21,PMC,10.1000/sample.599,PMC1000599,https://example.com/paper_599,2021.0,7.0,73,10,True,57.0,8.0,True
cord-000600,Analysis of pandemic and antiviral and pneumonia and symptoms in clinical settings,This study examines pandemic with 103 word abstract...,Author600_1,Clinical Infectious Diseases,2020-02-18,WHO,10.1000/sample.600,PMC1000600,https://example.com/paper_600,2020.0,2.0,82,12,True,54.0,8.0,True
cord-000601,Analysis of lockdown and COVID-19 and coronavirus and pandemic in clinical settings,,"Author601_1, Author601_2",Journal of Virology,2021-01-10,PMC,10.1000/sample.601,PMC1000601,https://example.com/paper_601,2021.0,1.0,83,12,False,,,True
cord-000602,Analysis of pandemic and antiviral and respiratory in clinical settings,This study examines pandemic with 184 word abstract...,"Author602_1, Author602_2",,2021-10-10,ArXiv,10.1000/sample.602,,https://example.com/paper_602,2021.0,10.0,71,10,True,54.0,8.0,False
cord-000603,Analysis of antiviral and vaccination in clinical settings,This study examines antiviral with 149 word abstract...,"Author603_1, Author603_2",Emerging Infectious Diseases,2021-04-17,WHO,10.1000/sample.603,PMC1000603,https://example.com/paper_603,2021.0,4.0,58,8,True,55.0,8.0,True
cord-000604,Analysis of COVID-19 and diagnosis and vaccination and SARS-CoV-2 in clinical settings,This study examines COVID-19 with 269 word abstract...,"Author604_1, Author604_2",BMJ,2021-07-05,medRxiv,10.1000/sample.604,PMC1000604,https://example.com/paper_604,2021.0,7.0,86,12,True,54.0,8.0,True
cord-000605,Analysis of vaccination and clinical in clinical settings,This study examines vaccination with 180 word abstract...,"Author605_1, Author605_2",Lancet,2020-04-06,PMC,10.1000/sample.605,,https://example.com/paper_605,2020.0,4.0,57,8,True,57.0,8.0,True
cord-000607,Analysis of SARS-CoV-2 and respiratory in clinical settings,This study examines SARS-CoV-2 with 278 word abstract...,"Author607_1, Author607_2",Virology,2022-08-04,PMC,10.1000/sample.607,PMC1000607,https://example.com/paper_607,2022.0,8.0,59,8,True,56.0,8.0,True
cord-000608,Analysis of outbreak and treatment in clinical settings,This study examines outbreak with 305 word abstract...,Author608_1,JAMA,2020-03-18,Medline,10.1000/sample.608,PMC1000608,https://example.com/paper_608,2020.0,3.0,55,8,True,54.0,8.0,True
cord-000609,Analysis of vaccination and SARS-CoV-2 and treatment in clinical settings,This study examines vaccination with 448 word abstract...,"Author609_1, Author609_2",Clinical Infectious Diseases,2020-05-19,bioRxiv,10.1000/sample.609,PMC1000609,https://example.com/paper_609,2020.0,5.0,73,10,True,57.0,8.0,True
cord-000610,Analysis of vaccination and treatment and antiviral in clinical settings,This study examines vaccination with 322 word abstract...,"Author610_1, Author610_2",,2020-04-04,ArXiv,10.1000/sample.610,PMC1000610,,2020.0,4.0,72,10,True,57.0,8.0,False
cord-000611,Analysis of therapeutic and immunity in clinical settings,This study examines therapeutic with 204 word abstract...,"Author611_1, Author611_2",New England Journal of Medicine,2020-03-03,Medline,10.1000/sample.611,,,2020.0,3.0,57,8,True,57.0,8.0,True
cord-000612,Analysis of symptoms and pneumonia in clinical settings,This study examines symptoms with 485 word abstract...,"Author612_1, Author612_2",Virology,2019-12-22,PMC,10.1000/sample.612,PMC1000612,https://example.com/paper_612,2019.0,12.0,55,8,True,54.0,8.0,True
cord-000613,Analysis of SARS-CoV-2 and coronavirus and lockdown in clinical settings,This study examines SARS-CoV-2 with 482 word abstract...,"Author613_1, Author613_2",JAMA,2020-01-16,bioRxiv,,PMC1000613,https://example.com/paper_613,2020.0,1.0,72,10,True,56.0,8.0,True
cord-000614,Analysis of treatment and antibody and clinical and antiviral in clinical settings,This study examines treatment with 449 word abstract...,"Author614_1, Author614_2",BMJ,2020-10-05,WHO,10.1000/sample.614,,https://example.com/paper_614,2020.0,10.0,82,12,True,55.0,8.0,True
cord-000615,Analysis of symptoms and antiviral and COVID-19 and transmission in clinical settings,This study examines symptoms with 490 word abstract...,"Author615_1, Author615_2",Science,2020-08-17,ArXiv,,PMC1000615,https://example.com/paper_615,2020.0,8.0,85,12,True,54.0,8.0,True
cord-000616,Analysis of pneumonia and antiviral and diagnosis and immunity in clinical settings,This study examines pneumonia with 131 word abstract...,"Author616_1, Author616_2",Science,2021-05-28,PMC,10.1000/sample.616,PMC1000616,https://example.com/paper_616,2021.0,5.0,83,12,True,55.0,8.0,True
cord-000617,Analysis of immunity and diagnosis and symptoms and COVID-19 in clinical settings,This study examines immunity with 132 word abstract...,"Author617_1, Author617_2",Clinical Infectious Diseases,2020-07-25,WHO,10.1000/sample.617,PMC1000617,https://example.com/paper_617,2020.0,7.0,81,12,True,54.0,8.0,True
cord-000618,Analysis of symptoms and transmission and pandemic and outbreak in clinical settings,This study examines symptoms with 333 word abstract...,"Author618_1, Author618_2",Lancet,2021-08-08,ArXiv,10.1000/sample.618,PMC1000618,https://example.com/paper_618,2021.0,8.0,84,12,True,54.0,8.0,True
cord-000619,Analysis of outbreak and pneumonia and public health in clinical settings,This study examines outbreak with 493 word abstract...,"Author619_1, Author619_2",Emerging Infectious Diseases,2022-08-11,Medline,10.1000/sample.619,PMC1000619,https://example.com/paper_619,2022.0,8.0,73,11,True,54.0,8.0,True
cord-000620,Analysis of pneumonia and diagnosis and COVID-19 in clinical settings,This study examines pneumonia with 451 word abstract...,"Author620_1, Author620_2",Nature Medicine,2020-03-04,ArXiv,10.1000/sample.620,PMC1000620,https://example.com/paper_620,2020.0,3.0,69,10,True,55.0,8.0,True
cord-000621,Analysis of clinical and epidemiology in clinical settings,This study examines clinical with 136 word abstract...,"Author621_1, Author621_2",Journal of Medical Virology,2019-12-21,Medline,10.1000/sample.621,,https://example.com/paper_621,2019.0,12.0,58,8,True,54.0,8.0,True
cord-000622,Analysis of outbreak and lockdown and pneumonia and therapeutic in clinical settings,This study examines outbreak with 223 word abstract...,"Author622_1, Author622_2",Virology,,medRxiv,10.1000/sample.622,PMC1000622,https://example.com/paper_622,,,84,12,True,54.0,8.0,True
cord-000623,Analysis of lockdown and vaccination and transmission in clinical settings,This study examines lockdown with 391 word abstract...,"Author623_1, Author623_2",Science,2021-08-05,ArXiv,10.1000/sample.623,PMC1000623,https://example.com/paper_623,2021.0,8.0,74,10,True,54.0,8.0,True
cord-000624,Analysis of respiratory and antibody in clinical settings,This study examines respiratory with 343 word abstract...,"Author624_1, Author624_2",Cell,2020-02-20,ArXiv,,PMC1000624,https://example.com/paper_624,2020.0,2.0,57,8,True,57.0,8.0,True
cord-000625,Analysis of respiratory and pandemic and COVID-19 in clinical settings,This study examines respiratory with 174 word abstract...,,Science Translational Medicine,2022-11-15,medRxiv,10.1000/sample.625,PMC1000625,,2022.0,11.0,70,10,True,57.0,8.0,True
cord-000626,Analysis of respiratory and lockdown and SARS-CoV-2 in clinical settings,This study examines respiratory with 440 word abstract...,Author626_1,Cell,2021-06-28,Medline,10.1000/sample.626,PMC1000626,https://example.com/paper_626,2021.0,6.0,72,10,True,57.0,8.0,True
cord-000627,Analysis of epidemiology and diagnosis and public health and antiviral in clinical settings,This study examines epidemiology with 161 word abstract...,"Author627_1, Author627_2",Lancet,2020-02-24,Medline,10.1000/sample.627,,https://example.com/paper_627,2020.0,2.0,91,13,True,58.0,8.0,True
cord-000628,Analysis of pandemic and epidemiology and lockdown in clinical settings,This study examines pandemic with 134 word abstract...,"Author628_1, Author628_2",Cell,2019-12-17,WHO,10.1000/sample.628,PMC1000628,,2019.0,12.0,71,10,True,54.0,8.0,True
cord-000629,Analysis of antiviral and coronavirus and COVID-19 in clinical settings,This study examines antiviral with 281 word abstract...,"Author629_1, Author629_2",Lancet,2021-07-29,WHO,10.1000/sample.629,,https://example.com/paper_629,2021.0,7.0,71,10,True,55.0,8.0,True
cord-000630,Analysis of lockdown and transmission and epidemiology in clinical settings,This study examines lockdown with 361 word abstract...,"Author630_1, Author630_2",Journal of Medical Virology,2021-03-18,WHO,10.1000/sample.630,PMC1000630,https://example.com/paper_630,2021.0,3.0,75,10,True,54.0,8.0,True
cord-000631,Analysis of epidemiology and coronavirus and COVID-19 in clinical settings,This study examines epidemiology with 498 word abstract...,"Author631_1, Author631_2",Cell,2020-11-30,WHO,10.1000/sample.631,PMC1000631,https://example.com/paper_631,2020.0,11.0,74,10,True,58.0,8.0,True
cord-000632,Analysis of COVID-19 and SARS-CoV-2 and transmission in clinical settings,This study examines COVID-19 with 489 word abstract...,"Author632_1, Author632_2",Nature,2020-01-17,bioRxiv,10.1000/sample.632,PMC1000632,https://example.com/paper_632,2020.0,1.0,73,10,True,54.0,8.0,True
cord-000633,Analysis of coronavirus and public health and antiviral in clinical settings,This study examines coronavirus with 412 word abstract...,"Author633_1, Author633_2",Science,2020-10-02,WHO,10.1000/sample.633,PMC1000633,https://example.com/paper_633,2020.0,10.0,76,11,True,57.0,8.0,True
cord-000635,Analysis of pneumonia and clinical and antibody in clinical settings,This study examines pneumonia with 339 word abstract...,"Author635_1, Author635_2",New England Journal of Medicine,2021-11-23,bioRxiv,,PMC1000635,,2021.0,11.0,68,10,True,55.0,8.0,True
cord-000636,Analysis of pandemic and diagnosis and vaccination in clinical settings,This study examines pandemic with 396 word abstract...,"Author636_1, Author636_2",JAMA,2020-04-05,Medline,10.1000/sample.636,PMC1000636,,2020.0,4.0,71,10,True,54.0,8.0,True
cord-000637,Analysis of antibody and diagnosis and antiviral in clinical settings,This study examines antibody with 138 word abstract...,"Author637_1, Author637_2",PLoS ONE,2020-07-01,PMC,10.1000/sample.637,PMC1000637,https://example.com/paper_637,2020.0,7.0,69,10,True,54.0,8.0,True
cord-000638,Analysis of vaccination and SARS-CoV-2 and lockdown in clinical settings,This study examines vaccination with 365 word abstract...,"Author638_1, Author638_2",JAMA,2020-08-20,Medline,10.1000/sample.638,PMC1000638,https://example.com/paper_638,2020.0,8.0,72,10,True,57.0,8.0,True
cord-000639,Analysis of treatment and symptoms and coronavirus in clinical settings,This study examines treatment with 162 word abstract...,"Author639_1, Author639_2",Cell,2020-05-29,bioRxiv,10.1000/sample.639,PMC1000639,https://example.com/paper_639,2020.0,5.0,71,10,True,55.0,8.0,True
cord-000640,Analysis of antiviral and transmission and vaccination and coronavirus in clinical settings,This study examines antiviral with 224 word abstract...,"Author640_1, Author640_2",Journal of Virology,2020-07-22,PMC,10.1000/sample.640,PMC1000640,https://example.com/paper_640,2020.0,7.0,91,12,True,55.0,8.0,True
cord-000641,Analysis of clinical and symptoms and public health in clinical settings,This study examines clinical with 238 word abstract...,"Author641_1, Author641_2",Nature Medicine,2021-06-01,medRxiv,10.1000/sample.641,,https://example.com/paper_641,2021.0,6.0,72,11,True,54.0,8.0,True
cord-000642,Analysis of coronavirus and outbreak and symptoms in clinical settings,This study examines coronavirus with 117 word abstract...,"Author642_1, Author642_2",Journal of Virology,2020-03-03,WHO,10.1000/sample.642,PMC1000642,https://example.com/paper_642,2020.0,3.0,70,10,True,57.0,8.0,True
cord-000643,Analysis of transmission and pandemic and pneumonia in clinical settings,This study examines transmission with 176 word abstract...,Author643_1,Cell,2021-08-18,medRxiv,10.1000/sample.643,,https://example.com/paper_643,2021.0,8.0,72,10,True,58.0,8.0,True
cord-000644,Analysis of outbreak and therapeutic and epidemiology in clinical settings,,"Author644_1, Author644_2",,2020-12-04,Medline,10.1000/sample.644,,https://example.com/paper_644,2020.0,12.0,74,10,False,,,False
cord-000645,Analysis of public health and immunity and lockdown in clinical settings,This study examines public health with 211 word abstract...,"Author645_1, Author645_2",JAMA,2021-12-22,medRxiv,10.1000/sample.645,,https://example.com/paper_645,2021.0,12.0,72,11,True,59.0,9.0,True
cord-000646,Analysis of symptoms and antiviral and SARS-CoV-2 in clinical settings,This study examines symptoms with 463 word abstract...,"Author646_1, Author646_2",Emerging Infectious Diseases,2019-12-08,ArXiv,10.1000/sample.646,PMC1000646,https://example.com/paper_646,2019.0,12.0,70,10,True,54.0,8.0,True
cord-000647,Analysis of immunity and respiratory in clinical settings,This study examines immunity with 157 word abstract...,"Author647_1, Author647_2",BMJ,2021-10-31,medRxiv,,PMC1000647,https://example.com/paper_647,2021.0,10.0,57,8,True,54.0,8.0,True
cord-000648,Analysis of pneumonia and epidemiology and symptoms and transmission in clinical settings,This study examines pneumonia with 146 word abstract...,"Author648_1, Author648_2",Nature,2020-02-27,bioRxiv,10.1000/sample.648,PMC1000648,https://example.com/paper_648,2020.0,2.0,89,12,True,55.0,8.0,True
cord-000649,Analysis of COVID-19 and transmission and therapeutic and respiratory in clinical settings,This study examines COVID-19 with 232 word abstract...,"Author649_1, Author649_2",Journal of Virology,2020-07-18,Medline,10.1000/sample.649,PMC1000649,https://example.com/paper_649,2020.0,7.0,90,12,True,54.0,8.0,True
cord-000650,Analysis of COVID-19 and immunity and antiviral and antibody in clinical settings,This study examines COVID-19 with 378 word abstract...,Author650_1,BMJ,2020-04-25,WHO,,PMC1000650,https://example.com/paper_650,2020.0,4.0,81,12,True,54.0,8.0,True
cord-000651,Analysis of respiratory and symptoms and lockdown in clinical settings,This study examines respiratory with 123 word abstract...,"Author651_1, Author651_2",Cell,2019-12-21,bioRxiv,10.1000/sample.651,PMC1000651,https://example.com/paper_651,2019.0,12.0,70,10,True,57.0,8.0,True
cord-000652,Analysis of diagnosis and immunity and COVID-19 in clinical settings,This study examines diagnosis with 390 word abstract...,"Author652_1, Author652_2",,2021-09-04,medRxiv,10.1000/sample.652,PMC1000652,https://example.com/paper_652,2021.0,9.0,68,10,True,55.0,8.0,False
cord-000653,Analysis of lockdown and treatment in clinical settings,This study examines lockdown with 218 word abstract...,"Author653_1, Author653_2",Clinical Infectious Diseases,2021-09-19,medRxiv,10.1000/sample.653,,https://example.com/paper_653,2021.0,9.0,55,8,True,54.0,8.0,True
cord-000654,Analysis of pandemic and symptoms and lockdown in clinical settings,This study examines pandemic with 472 word abstract...,"Author654_1, Author654_2",Nature,2021-02-09,PMC,10.1000/sample.654,PMC1000654,,2021.0,2.0,67,10,True,54.0,8.0,True
cord-000655,Analysis of respiratory and treatment in clinical settings,This study examines respiratory with 133 word abstract...,"Author655_1, Author655_2",Nature Medicine,2021-11-13,ArXiv,10.1000/sample.655,,https://example.com/paper_655,2021.0,11.0,58,8,True,57.0,8.0,True
cord-000656,Analysis of epidemiology and diagnosis in clinical settings,This study examines epidemiology with 428 word abstract...,"Author656_1, Author656_2",Virology,2021-10-25,ArXiv,10.1000/sample.656,PMC1000656,,2021.0,10.0,59,8,True,58.0,8.0,True
cord-000657,Analysis of treatment and respiratory and SARS-CoV-2 in clinical settings,This study examines treatment with 234 word abstract...,"Author657_1, Author657_2",Journal of Medical Virology,2022-04-08,WHO,10.1000/sample.657,,https://example.com/paper_657,2022.0,4.0,73,10,True,55.0,8.0,True
cord-000658,Analysis of SARS-CoV-2 and transmission in clinical settings,This study examines SARS-CoV-2 with 266 word abstract...,"Author658_1, Author658_2",Journal of Medical Virology,2021-07-08,WHO,10.1000/sample.658,PMC1000658,https://example.com/paper_658,2021.0,7.0,60,8,True,56.0,8.0,True
cord-000659,Analysis of pandemic and therapeutic and outbreak and lockdown in clinical settings,This study examines pandemic with 476 word abstract...,"Author659_1, Author659_2",JAMA,2022-11-26,WHO,,PMC1000659,https://example.com/paper_659,2022.0,11.0,83,12,True,54.0,8.0,True
cord-000660,Analysis of coronavirus and COVID-19 and antibody and clinical in clinical settings,This study examines coronavirus with 185 word abstract...,"Author660_1, Author660_2",Nature,2020-04-24,Medline,10.1000/sample.660,PMC1000660,,2020.0,4.0,83,12,True,57.0,8.0,True
cord-000661,Analysis of public health and antiviral and immunity and transmission in clinical settings,This study examines public health with 293 word abstract...,"Author661_1, Author661_2",Journal of Medical Virology,2019-12-23,bioRxiv,10.1000/sample.661,,https://example.com/paper_661,2019.0,12.0,90,13,True,59.0,9.0,True
cord-000662,Analysis of therapeutic and COVID-19 in clinical settings,,"Author662_1, Author662_2",Nature,2021-01-30,medRxiv,10.1000/sample.662,PMC1000662,https://example.com/paper_662,2021.0,1.0,57,8,False,,,True
cord-000663,Analysis of outbreak and vaccination and pneumonia in clinical settings,This study examines outbreak with 183 word abstract...,"Author663_1, Author663_2",BMJ,2020-09-29,WHO,10.1000/sample.663,PMC1000663,https://example.com/paper_663,2020.0,9.0,71,10,True,54.0,8.0,True
cord-000664,Analysis of pandemic and epidemiology in clinical settings,This study examines pandemic with 431 word abstract...,"Author664_1, Author664_2",BMJ,2020-06-07,medRxiv,10.1000/sample.664,PMC1000664,,2020.0,6.0,58,8,True,54.0,8.0,True
cord-000665,Analysis of lockdown and immunity and clinical and coronavirus in clinical settings,This study examines lockdown with 450 word abstract...,"Author665_1, Author665_2",Cell,2019-12-27,WHO,10.1000/sample.665,PMC1000665,https://example.com/paper_665,2019.0,12.0,83,12,True,54.0,8.0,True
cord-000667,Analysis of lockdown and transmission and coronavirus and antiviral in clinical settings,This study examines lockdown with 375 word abstract...,"Author667_1, Author667_2",Cell,2020-09-13,bioRxiv,10.1000/sample.667,PMC1000667,https://example.com/paper_667,2020.0,9.0,88,12,True,54.0,8.0,True
cord-000668,Analysis of pandemic and diagnosis and COVID-19 in clinical settings,This study examines pandemic with 275 word abstract...,"Author668_1, Author668_2",Virology,2021-03-24,Medline,,PMC1000668,https://example.com/paper_668,2021.0,3.0,68,10,True,54.0,8.0,True
cord-000669,Analysis of vaccination and lockdown in clinical settings,This study examines vaccination with 239 word abstract...,"Author669_1, Author669_2",Lancet,2021-09-10,PMC,,,https://example.com/paper_669,2021.0,9.0,57,8,True,57.0,8.0,True
cord-000670,Analysis of COVID-19 and therapeutic in clinical settings,This study examines COVID-19 with 208 word abstract...,"Author670_1, Author670_2",,2021-12-07,ArXiv,10.1000/sample.670,PMC1000670,https://example.com/paper_670,2021.0,12.0,57,8,True,54.0,8.0,False
cord-000671,Analysis of antibody and clinical in clinical settings,This study examines antibody with 324 word abstract...,"Author671_1, Author671_2",Clinical Infectious Diseases,2021-02-19,Medline,10.1000/sample.671,PMC1000671,,2021.0,2.0,54,8,True,54.0,8.0,True
cord-000672,Analysis of diagnosis and transmission in clinical settings,This study examines diagnosis with 389 word abstract...,"Author672_1, Author672_2",Nature,2021-01-12,bioRxiv,10.1000/sample.672,PMC1000672,https://example.com/paper_672,2021.0,1.0,59,8,True,55.0,8.0,True
cord-000673,Analysis of SARS-CoV-2 and antibody and lockdown in clinical settings,This study examines SARS-CoV-2 with 373 word abstract...,"Author673_1, Author673_2",Science Translational Medicine,,bioRxiv,10.1000/sample.673,,https://example.com/paper_673,,,69,10,True,56.0,8.0,True
cord-000674,Analysis of clinical and antiviral and outbreak in clinical settings,This study examines clinical with 245 word abstract...,"Author674_1, Author674_2",Nature,2021-01-05,Medline,10.1000/sample.674,,https://example.com/paper_674,2021.0,1.0,68,10,True,54.0,8.0,True
cord-000675,Analysis of coronavirus and antibody and epidemiology and treatment in clinical settings,This study examines coronavirus with 285 word abstract...,Author675_1,Clinical Infectious Diseases,2020-02-21,Medline,10.1000/sample.675,PMC1000675,https://example.com/paper_675,2020.0,2.0,88,12,True,57.0,8.0,True
cord-000676,Analysis of respiratory and COVID-19 and transmission and therapeutic in clinical settings,This study examines respiratory with 138 word abstract...,Author676_1,Emerging Infectious Diseases,2021-08-05,Medline,10.1000/sample.676,PMC1000676,https://example.com/paper_676,2021.0,8.0,90,12,True,57.0,8.0,True
cord-000677,Analysis of antiviral and epidemiology and outbreak and diagnosis in clinical settings,This study examines antiviral with 440 word abstract...,Author677_1,Science,2021-10-01,Medline,10.1000/sample.677,,https://example.com/paper_677,2021.0,10.0,86,12,True,55.0,8.0,True
cord-000678,Analysis of treatment and symptoms and lockdown and diagnosis in clinical settings,This study examines treatment with 179 word abstract...,"Author678_1, Author678_2",Cell,2019-12-10,bioRxiv,10.1000/sample.678,PMC1000678,https://example.com/paper_678,2019.0,12.0,82,12,True,55.0,8.0,True
cord-000679,Analysis of vaccination and outbreak and respiratory and COVID-19 in clinical settings,This study examines vaccination with 111 word abstract...,"Author679_1, Author679_2",BMJ,2020-07-28,bioRxiv,10.1000/sample.679,PMC1000679,,2020.0,7.0,86,12,True,57.0,8.0,True
cord-000680,Analysis of treatment and diagnosis and lockdown and outbreak in clinical settings,This study examines treatment with 191 word abstract...,Author680_1,Clinical Infectious Diseases,2020-07-25,ArXiv,10.1000/sample.680,,https://example.com/paper_680,2020.0,7.0,82,12,True,55.0,8.0,True
cord-000681,Analysis of SARS-CoV-2 and coronavirus and therapeutic in clinical settings,This study examines SARS-CoV-2 with 490 word abstract...,Author681_1,Journal of Medical Virology,2020-06-30,PMC,,PMC1000681,https://example.com/paper_681,2020.0,6.0,75,10,True,56.0,8.0,True
cord-000682,Analysis of public health and lockdown and symptoms and COVID-19 in clinical settings,This study examines public health with 476 word abstract...,"Author682_1, Author682_2",Journal of Virology,2021-09-05,Medline,10.1000/sample.682,PMC1000682,https://example.com/paper_682,2021.0,9.0,85,13,True,59.0,9.0,True
cord-000683,Analysis of COVID-19 and therapeutic and symptoms in clinical settings,This study examines COVID-19 with 226 word abstract...,"Author683_1, Author683_2",Science Translational Medicine,2021-04-03,Medline,10.1000/sample.683,PMC1000683,https://example.com/paper_683,2021.0,4.0,70,10,True,54.0,8.0,True
cord-000684,Analysis of respiratory and epidemiology in clinical settings,This study examines respiratory with 458 word abstract...,"Author684_1, Author684_2",BMJ,2022-06-28,ArXiv,10.1000/sample.684,PMC1000684,https://example.com/paper_684,2022.0,6.0,61,8,True,57.0,8.0,True
cord-000686,Analysis of respiratory and COVID-19 and epidemiology and clinical in clinical settings,This study examines respiratory with 328 word abstract...,"Author686_1, Author686_2",Journal of Medical Virology,2022-08-25,bioRxiv,10.1000/sample.686,PMC1000686,https://example.com/paper_686,2022.0,8.0,87,12,True,57.0,8.0,True
cord-000687,Analysis of pneumonia and epidemiology and transmission and therapeutic in clinical settings,This study examines pneumonia with 222 word abstract...,Author687_1,New England Journal of Medicine,2020-09-21,ArXiv,10.1000/sample.687,,https://example.com/paper_687,2020.0,9.0,92,12,True,55.0,8.0,True
cord-000688,Analysis of pandemic and symptoms in clinical settings,This study examines pandemic with 480 word abstract...,"Author688_1, Author688_2",,2020-11-27,PMC,10.1000/sample.688,PMC1000688,https://example.com/paper_688,2020.0,11.0,54,8,True,54.0,8.0,False
cord-000689,Analysis of immunity and coronavirus and treatment in clinical settings,This study examines immunity with 378 word abstract...,"Author689_1, Author689_2",,2021-01-11,ArXiv,10.1000/sample.689,,,2021.0,1.0,71,10,True,54.0,8.0,False
cord-000692,Analysis of antiviral and respiratory and pneumonia in clinical settings,This study examines antiviral with 487 word abstract...,"Author692_1, Author692_2",Nature,2019-12-27,WHO,10.1000/sample.692,,https://example.com/paper_692,2019.0,12.0,72,10,True,55.0,8.0,True
cord-000693,Analysis of immunity and clinical and transmission in clinical settings,This study examines immunity with 495 word abstract...,"Author693_1, Author693_2",Journal of Medical Virology,2021-06-21,PMC,10.1000/sample.693,PMC1000693,https://example.com/paper_693,2021.0,6.0,71,10,True,54.0,8.0,True
cord-000694,Analysis of antibody and pneumonia in clinical settings,This study examines antibody with 264 word abstract...,"Author694_1, Author694_2",Journal of Medical Virology,2021-01-04,PMC,,PMC1000694,https://example.com/paper_694,2021.0,1.0,55,8,True,54.0,8.0,True
cord-000695,Analysis of treatment and respiratory and symptoms and pneumonia in clinical settings,This study examines treatment with 147 word abstract...,"Author695_1, Author695_2",,2019-12-27,WHO,10.1000/sample.695,PMC1000695,,2019.0,12.0,85,12,True,55.0,8.0,False
cord-000696,Analysis of transmission and therapeutic and treatment in clinical settings,This study examines transmission with 273 word abstract...,"Author696_1, Author696_2",Clinical Infectious Diseases,2021-12-09,ArXiv,10.1000/sample.696,PMC1000696,https://example.com/paper_696,2021.0,12.0,75,10,True,58.0,8.0,True
cord-000697,Analysis of epidemiology and transmission and respiratory and COVID-19 in clinical settings,This study examines epidemiology with 336 word abstract...,"Author697_1, Author697_2",Nature,2020-03-09,WHO,,PMC1000697,https://example.com/paper_697,2020.0,3.0,91,12,True,58.0,8.0,True
cord-000698,Analysis of symptoms and epidemiology and respiratory and antiviral in clinical settings,This study examines symptoms with 494 word abstract...,Author698_1,Cell,2020-06-22,bioRxiv,10.1000/sample.698,,https://example.com/paper_698,2020.0,6.0,88,12,True,54.0,8.0,True
cord-000699,Analysis of diagnosis and treatment in clinical settings,This study examines diagnosis with 457 word abstract...,"Author699_1, Author699_2",Nature Medicine,2020-10-17,ArXiv,10.1000/sample.699,PMC1000699,https://example.com/paper_699,2020.0,10.0,56,8,True,55.0,8.0,True
cord-000700,Analysis of epidemiology and antibody and pneumonia in clinical settings,This study examines epidemiology with 410 word abstract...,"Author700_1, Author700_2",Nature Medicine,2021-03-05,PMC,10.1000/sample.700,,https://example.com/paper_700,2021.0,3.0,72,10,True,58.0,8.0,True
cord-000702,Analysis of therapeutic and antibody and diagnosis in clinical settings,,Author702_1,JAMA,2020-03-06,bioRxiv,10.1000/sample.702,PMC1000702,https://example.com/paper_702,2020.0,3.0,71,10,False,,,True
cord-000703,Analysis of public health and lockdown and immunity in clinical settings,This study examines public health with 456 word abstract...,"Author703_1, Author703_2",Nature,2021-09-04,WHO,10.1000/sample.703,,https://example.com/paper_703,2021.0,9.0,72,11,True,59.0,9.0,True
cord-000705,Analysis of outbreak and treatment and coronavirus in clinical settings,This study examines outbreak with 486 word abstract...,"Author705_1, Author705_2",Nature,2022-01-13,ArXiv,,PMC1000705,,2022.0,1.0,71,10,True,54.0,8.0,True
cord-000708,Analysis of treatment and pneumonia and COVID-19 in clinical settings,This study examines treatment with 376 word abstract...,"Author708_1, Author708_2",New England Journal of Medicine,2020-11-10,Medline,10.1000/sample.708,PMC1000708,https://example.com/paper_708,2020.0,11.0,69,10,True,55.0,8.0,True
cord-000709,Analysis of vaccination and diagnosis in clinical settings,This study examines vaccination with 151 word abstract...,"Author709_1, Author709_2",Clinical Infectious Diseases,2020-05-02,ArXiv,10.1000/sample.709,,https://example.com/paper_709,2020.0,5.0,58,8,True,57.0,8.0,True
cord-000710,Analysis of lockdown and COVID-19 and coronavirus in clinical settings,This study examines lockdown with 199 word abstract...,"Author710_1, Author710_2",Nature,2020-04-29,medRxiv,10.1000/sample.710,,https://example.com/paper_710,2020.0,4.0,70,10,True,54.0,8.0,True
cord-000711,Analysis of SARS-CoV-2 and vaccination and outbreak in clinical settings,This study examines SARS-CoV-2 with 118 word abstract...,"Author711_1, Author711_2",Cell,2020-03-02,PMC,10.1000/sample.711,,https://example.com/paper_711,2020.0,3.0,72,10,True,56.0,8.0,True
cord-000712,Analysis of pandemic and clinical and outbreak and coronavirus in clinical settings,This study examines pandemic with 109 word abstract...,"Author712_1, Author712_2",Nature,2020-11-27,medRxiv,10.1000/sample.712,PMC1000712,https://example.com/paper_712,2020.0,11.0,83,12,True,54.0,8.0,True
cord-000713,Analysis of symptoms and clinical in clinical settings,This study examines symptoms with 140 word abstract...,"Author713_1, Author713_2",Nature Medicine,2021-02-21,bioRxiv,10.1000/sample.713,,https://example.com/paper_713,2021.0,2.0,54,8,True,54.0,8.0,True
cord-000714,Analysis of treatment and symptoms and COVID-19 and antibody in clinical settings,This study examines treatment with 293 word abstract...,"Author714_1, Author714_2",New England Journal of Medicine,2020-02-21,PMC,10.1000/sample.714,PMC1000714,https://example.com/paper_714,2020.0,2.0,81,12,True,55.0,8.0,True
cord-000715,Analysis of vaccination and therapeutic and lockdown in clinical settings,This study examines vaccination with 257 word abstract...,"Author715_1, Author715_2",Emerging Infectious Diseases,2020-09-12,Medline,10.1000/sample.715,PMC1000715,https://example.com/paper_715,2020.0,9.0,73,10,True,57.0,8.0,True
cord-000716,Analysis of clinical and pneumonia and transmission and respiratory in clinical settings,This study examines clinical with 161 word abstract...,"Author716_1, Author716_2",Journal of Medical Virology,2019-12-14,bioRxiv,10.1000/sample.716,PMC1000716,https://example.com/paper_716,2019.0,12.0,88,12,True,54.0,8.0,True
cord-000717,Analysis of transmission and pneumonia and pandemic in clinical settings,This study examines transmission with 218 word abstract...,"Author717_1, Author717_2",New England Journal of Medicine,2021-03-22,ArXiv,10.1000/sample.717,PMC1000717,https://example.com/paper_717,2021.0,3.0,72,10,True,58.0,8.0,True
cord-000718,Analysis of coronavirus and respiratory and vaccination and epidemiology in clinical settings,This study examines coronavirus with 174 word abstract...,Author718_1,Journal of Medical Virology,2019-12-03,PMC,,,https://example.com/paper_718,2019.0,12.0,93,12,True,57.0,8.0,True
cord-000719,Analysis of respiratory and public health in clinical settings,This study examines respiratory with 458 word abstract...,"Author719_1, Author719_2",Lancet,2021-04-29,medRxiv,10.1000/sample.719,PMC1000719,https://example.com/paper_719,2021.0,4.0,62,9,True,57.0,8.0,True
cord-000720,Analysis of public health and transmission and therapeutic and clinical in clinical settings,This study examines public health with 274 word abstract...,Author720_1,PLoS ONE,2020-12-19,ArXiv,10.1000/sample.720,PMC1000720,https://example.com/paper_720,2020.0,12.0,92,13,True,59.0,9.0,True
cord-000722,Analysis of COVID-19 and vaccination in clinical settings,This study examines COVID-19 with 485 word abstract...,"Author722_1, Author722_2",Lancet,2019-12-20,WHO,,,,2019.0,12.0,57,8,True,54.0,8.0,True
cord-000723,Analysis of treatment and lockdown in clinical settings,This study examines treatment with 239 word abstract...,Author723_1,BMJ,2020-08-27,bioRxiv,10.1000/sample.723,PMC1000723,https://example.com/paper_723,2020.0,8.0,55,8,True,55.0,8.0,True
cord-000725,Analysis of COVID-19 and public health and lockdown and pandemic in clinical settings,This study examines COVID-19 with 281 word abstract...,"Author725_1, Author725_2",Science Translational Medicine,2020-03-17,PMC,10.1000/sample.725,PMC1000725,https://example.com/paper_725,2020.0,3.0,85,13,True,54.0,8.0,True
cord-000726,Analysis of lockdown and public health and epidemiology in clinical settings,This study examines lockdown with 377 word abstract...,"Author726_1, Author726_2",Science Translational Medicine,2020-08-18,Medline,10.1000/sample.726,PMC1000726,https://example.com/paper_726,2020.0,8.0,76,11,True,54.0,8.0,True
cord-000727,Analysis of transmission and epidemiology in clinical settings,This study examines transmission with 329 word abstract...,"Author727_1, Author727_2",,2020-08-06,WHO,10.1000/sample.727,PMC1000727,,2020.0,8.0,62,8,True,58.0,8.0,False
cord-000728,Analysis of public health and transmission and coronavirus and vaccination in clinical settings,This study examines public health with 203 word abstract...,"Author728_1, Author728_2",Journal of Medical Virology,2021-04-13,WHO,10.1000/sample.728,PMC1000728,https://example.com/paper_728,2021.0,4.0,95,13,True,59.0,9.0,True
cord-000729,Analysis of public health and outbreak and antiviral and lockdown in clinical settings,This study examines public health with 128 word abstract...,"Author729_1, Author729_2",Virology,2020-12-08,bioRxiv,10.1000/sample.729,PMC1000729,https://example.com/paper_729,2020.0,12.0,86,13,True,59.0,9.0,True
cord-000730,Analysis of coronavirus and respiratory and transmission and public health in clinical settings,This study examines coronavirus with 238 word abstract...,"Author730_1, Author730_2",New England Journal of Medicine,2019-12-27,WHO,10.1000/sample.730,PMC1000730,https://example.com/paper_730,2019.0,12.0,95,13,True,57.0,8.0,True
cord-000731,Analysis of coronavirus and outbreak and antibody in clinical settings,This study examines coronavirus with 342 word abstract...,"Author731_1, Author731_2",New England Journal of Medicine,2021-11-20,medRxiv,10.1000/sample.731,PMC1000731,https://example.com/paper_731,2021.0,11.0,70,10,True,57.0,8.0,True
cord-000732,Analysis of epidemiology and public health and immunity in clinical settings,This study examines epidemiology with 489 word abstract...,"Author732_1, Author732_2",Science,2020-11-10,bioRxiv,10.1000/sample.732,PMC1000732,https://example.com/paper_732,2020.0,11.0,76,11,True,58.0,8.0,True
cord-000733,Analysis of pneumonia and transmission and outbreak and therapeutic in clinical settings,This study examines pneumonia with 399 word abstract...,"Author733_1, Author733_2",Lancet,2020-09-24,medRxiv,10.1000/sample.733,PMC1000733,https://example.com/paper_733,2020.0,9.0,88,12,True,55.0,8.0,True
cord-000734,Analysis of COVID-19 and treatment and respiratory and antibody in clinical settings,This study examines COVID-19 with 308 word abstract...,"Author734_1, Author734_2",Nature,2020-06-14,bioRxiv,10.1000/sample.734,,https://example.com/paper_734,2020.0,6.0,84,12,True,54.0,8.0,True
cord-000735,Analysis of epidemiology and pneumonia and antibody and coronavirus in clinical settings,This study examines epidemiology with 498 word abstract...,"Author735_1, Author735_2",Emerging Infectious Diseases,2020-08-31,Medline,10.1000/sample.735,,https://example.com/paper_735,2020.0,8.0,88,12,True,58.0,8.0,True
cord-000736,Analysis of SARS-CoV-2 and vaccination in clinical settings,This study examines SARS-CoV-2 with 273 word abstract...,"Author736_1, Author736_2",Virology,2020-01-15,bioRxiv,10.1000/sample.736,PMC1000736,,2020.0,1.0,59,8,True,56.0,8.0,True
cord-000737,Analysis of transmission and pandemic in clinical settings,This study examines transmission with 493 word abstract...,"Author737_1, Author737_2",Science,2022-02-27,medRxiv,10.1000/sample.737,PMC1000737,,2022.0,2.0,58,8,True,58.0,8.0,True
cord-000738,Analysis of respiratory and pandemic and lockdown and diagnosis in clinical settings,This study examines respiratory with 365 word abstract...,Author738_1,New England Journal of Medicine,2022-02-04,PMC,10.1000/sample.738,,https://example.com/paper_738,2022.0,2.0,84,12,True,57.0,8.0,True
cord-000739,Analysis of transmission and pneumonia and antiviral in clinical settings,This study examines transmission with 122 word abstract...,"Author739_1, Author739_2",Virology,2020-09-14,WHO,10.1000/sample.739,PMC1000739,https://example.com/paper_739,2020.0,9.0,73,10,True,58.0,8.0,True
cord-000740,Analysis of antiviral and respiratory and SARS-CoV-2 in clinical settings,This study examines antiviral with 435 word abstract...,"Author740_1, Author740_2",Nature,,medRxiv,10.1000/sample.740,PMC1000740,https://example.com/paper_740,,,73,10,True,55.0,8.0,True
cord-000741,Analysis of symptoms and pandemic and treatment and therapeutic in clinical settings,This study examines symptoms with 260 word abstract...,"Author741_1, Author741_2",JAMA,2021-09-01,medRxiv,10.1000/sample.741,PMC1000741,https://example.com/paper_741,2021.0,9.0,84,12,True,54.0,8.0,True
cord-000742,Analysis of respiratory and therapeutic and antiviral in clinical settings,This study examines respiratory with 402 word abstract...,Author742_1,Lancet,2021-12-13,PMC,10.1000/sample.742,PMC1000742,https://example.com/paper_742,2021.0,12.0,74,10,True,57.0,8.0,True
cord-000743,Analysis of symptoms and therapeutic and treatment and COVID-19 in clinical settings,This study examines symptoms with 479 word abstract...,Author743_1,Emerging Infectious Diseases,2020-10-13,Medline,,PMC1000743,https://example.com/paper_743,2020.0,10.0,84,12,True,54.0,8.0,True
cord-000744,Analysis of pneumonia and epidemiology in clinical settings,This study examines pneumonia with 355 word abstract...,"Author744_1, Author744_2",,2020-08-06,medRxiv,10.1000/sample.744,,https://example.com/paper_744,2020.0,8.0,59,8,True,55.0,8.0,False
cord-000745,Analysis of treatment and antiviral and antibody and clinical in clinical settings,This study examines treatment with 148 word abstract...,"Author745_1, Author745_2",Cell,2020-07-27,Medline,10.1000/sample.745,PMC1000745,,2020.0,7.0,82,12,True,55.0,8.0,True
cord-000746,Analysis of diagnosis and treatment and antibody in clinical settings,This study examines diagnosis with 167 word abstract...,Author746_1,,2020-07-14,bioRxiv,10.1000/sample.746,PMC1000746,https://example.com/paper_746,2020.0,7.0,69,10,True,55.0,8.0,False
cord-000748,Analysis of antibody and treatment and lockdown in clinical settings,This study examines antibody with 469 word abstract...,"Author748_1, Author748_2",Science,2022-08-31,ArXiv,10.1000/sample.748,PMC1000748,https://example.com/paper_748,2022.0,8.0,68,10,True,54.0,8.0,True
cord-000750,Analysis of diagnosis and symptoms and transmission and SARS-CoV-2 in clinical settings,This study examines diagnosis with 115 word abstract...,"Author750_1, Author750_2",,2022-08-02,ArXiv,10.1000/sample.750,PMC1000750,https://example.com/paper_750,2022.0,8.0,87,12,True,55.0,8.0,False
cord-000751,Analysis of COVID-19 and antibody and SARS-CoV-2 in clinical settings,This study examines COVID-19 with 327 word abstract...,"Author751_1, Author751_2",BMJ,2020-05-15,ArXiv,10.1000/sample.751,,,2020.0,5.0,69,10,True,54.0,8.0,True
cord-000753,Analysis of pneumonia and pandemic and treatment and symptoms in clinical settings,This study examines pneumonia with 406 word abstract...,"Author753_1, Author753_2",JAMA,2020-02-01,PMC,10.1000/sample.753,PMC1000753,https://example.com/paper_753,2020.0,2.0,82,12,True,55.0,8.0,True
cord-000757,Analysis of symptoms and COVID-19 and therapeutic in clinical settings,This study examines symptoms with 464 word abstract...,"Author757_1, Author757_2",BMJ,2020-03-22,Medline,10.1000/sample.757,,https://example.com/paper_757,2020.0,3.0,70,10,True,54.0,8.0,True
cord-000758,Analysis of SARS-CoV-2 and pneumonia and epidemiology in clinical settings,This study examines SARS-CoV-2 with 288 word abstract...,"Author758_1, Author758_2",PLoS ONE,2020-03-24,Medline,10.1000/sample.758,PMC1000758,https://example.com/paper_758,2020.0,3.0,74,10,True,56.0,8.0,True
cord-000759,Analysis of epidemiology and pandemic in clinical settings,,"Author759_1, Author759_2",BMJ,2021-04-06,Medline,,PMC1000759,https://example.com/paper_759,2021.0,4.0,58,8,False,,,True
cord-000760,Analysis of vaccination and clinical and SARS-CoV-2 and outbreak in clinical settings,This study examines vaccination with 403 word abstract...,"Author760_1, Author760_2",Cell,2020-06-23,bioRxiv,10.1000/sample.760,PMC1000760,https://example.com/paper_760,2020.0,6.0,85,12,True,57.0,8.0,True
cord-000762,Analysis of COVID-19 and lockdown and outbreak and therapeutic in clinical settings,This study examines COVID-19 with 422 word abstract...,Author762_1,Lancet,2020-11-29,ArXiv,10.1000/sample.762,PMC1000762,https://example.com/paper_762,2020.0,11.0,83,12,True,54.0,8.0,True
cord-000763,Analysis of lockdown and antiviral and treatment and COVID-19 in clinical settings,This study examines lockdown with 277 word abstract...,"Author763_1, Author763_2",Science Translational Medicine,2021-09-10,ArXiv,10.1000/sample.763,PMC1000763,https://example.com/paper_763,2021.0,9.0,82,12,True,54.0,8.0,True
cord-000764,Analysis of vaccination and symptoms and pandemic in clinical settings,This study examines vaccination with 286 word abstract...,"Author764_1, Author764_2",Virology,2020-12-04,medRxiv,10.1000/sample.764,PMC1000764,https://example.com/paper_764,2020.0,12.0,70,10,True,57.0,8.0,True
cord-000767,Analysis of respiratory and lockdown and transmission and diagnosis in clinical settings,This study examines respiratory with 232 word abstract...,"Author767_1, Author767_2",Science,2021-09-30,ArXiv,10.1000/sample.767,PMC1000767,,2021.0,9.0,88,12,True,57.0,8.0,True
cord-000769,Analysis of public health and pandemic and therapeutic and lockdown in clinical settings,,"Author769_1, Author769_2",Emerging Infectious Diseases,2020-12-10,bioRxiv,10.1000/sample.769,PMC1000769,,2020.0,12.0,88,13,False,,,True
cord-000770,Analysis of immunity and antiviral and symptoms and diagnosis in clinical settings,This study examines immunity with 405 word abstract...,"Author770_1, Author770_2",Journal of Virology,2020-06-16,ArXiv,10.1000/sample.770,PMC1000770,https://example.com/paper_770,2020.0,6.0,82,12,True,54.0,8.0,True
cord-000771,Analysis of diagnosis and antiviral in clinical settings,This study examines diagnosis with 481 word abstract...,"Author771_1, Author771_2",Cell,2022-12-21,WHO,10.1000/sample.771,PMC1000771,https://example.com/paper_771,2022.0,12.0,56,8,True,55.0,8.0,True
cord-000772,Analysis of coronavirus and COVID-19 and vaccination in clinical settings,This study examines coronavirus with 164 word abstract...,Author772_1,Science,2021-10-06,Medline,10.1000/sample.772,PMC1000772,https://example.com/paper_772,2021.0,10.0,73,10,True,57.0,8.0,True
cord-000773,Analysis of outbreak and treatment and transmission in clinical settings,This study examines outbreak with 249 word abstract...,"Author773_1, Author773_2",Clinical Infectious Diseases,2021-10-13,PMC,10.1000/sample.773,PMC1000773,https://example.com/paper_773,2021.0,10.0,72,10,True,54.0,8.0,True
cord-000775,Analysis of pandemic and pneumonia and lockdown and diagnosis in clinical settings,This study examines pandemic with 130 word abstract...,"Author775_1, Author775_2",Journal of Medical Virology,2020-12-06,WHO,10.1000/sample.775,PMC1000775,https://example.com/paper_775,2020.0,12.0,82,12,True,54.0,8.0,True
cord-000777,Analysis of COVID-19 and respiratory and immunity and epidemiology in clinical settings,This study examines COVID-19 with 459 word abstract...,"Author777_1, Author777_2",JAMA,2021-03-24,medRxiv,10.1000/sample.777,,https://example.com/paper_777,2021.0,3.0,87,12,True,54.0,8.0,True
cord-000778,Analysis of COVID-19 and pneumonia and outbreak in clinical settings,,"Author778_1, Author778_2",Journal of Medical Virology,2020-10-08,PMC,10.1000/sample.778,PMC1000778,,2020.0,10.0,68,10,False,,,True
cord-000779,Analysis of COVID-19 and pneumonia and respiratory in clinical settings,This study examines COVID-19 with 370 word abstract...,"Author779_1, Author779_2",Cell,,WHO,10.1000/sample.779,PMC1000779,https://example.com/paper_779,,,71,10,True,54.0,8.0,True
cord-000781,Analysis of pneumonia and symptoms and SARS-CoV-2 in clinical settings,This study examines pneumonia with 453 word abstract...,"Author781_1, Author781_2",Virology,2021-11-27,PMC,10.1000/sample.781,PMC1000781,https://example.com/paper_781,2021.0,11.0,70,10,True,55.0,8.0,True
cord-000784,Analysis of therapeutic and clinical and SARS-CoV-2 in clinical settings,This study examines therapeutic with 139 word abstract...,"Author784_1, Author784_2",BMJ,2021-09-18,medRxiv,10.1000/sample.784,PMC1000784,,2021.0,9.0,72,10,True,57.0,8.0,True
cord-000785,Analysis of COVID-19 and public health in clinical settings,This study examines COVID-19 with 374 word abstract...,"Author785_1, Author785_2",Lancet,2021-02-02,PMC,,,https://example.com/paper_785,2021.0,2.0,59,9,True,54.0,8.0,True
cord-000786,Analysis of diagnosis and immunity and clinical and COVID-19 in clinical settings,This study examines diagnosis with 260 word abstract...,Author786_1,Emerging Infectious Diseases,2022-08-31,ArXiv,10.1000/sample.786,PMC1000786,https://example.com/paper_786,2022.0,8.0,81,12,True,55.0,8.0,True
cord-000787,Analysis of epidemiology and pneumonia and transmission and COVID-19 in clinical settings,This study examines epidemiology with 480 word abstract...,"Author787_1, Author787_2",Science Translational Medicine,2020-11-20,PMC,,PMC1000787,https://example.com/paper_787,2020.0,11.0,89,12,True,58.0,8.0,True
cord-000789,Analysis of symptoms and public health in clinical settings,This study examines symptoms with 107 word abstract...,Author789_1,Science,2020-03-15,Medline,10.1000/sample.789,PMC1000789,https://example.com/paper_789,2020.0,3.0,59,9,True,54.0,8.0,True
cord-000790,Analysis of treatment and respiratory and SARS-CoV-2 and epidemiology in clinical settings,This study examines treatment with 450 word abstract...,"Author790_1, Author790_2",Cell,2020-08-20,WHO,10.1000/sample.790,PMC1000790,https://example.com/paper_790,2020.0,8.0,90,12,True,55.0,8.0,True
cord-000791,Analysis of coronavirus and epidemiology and SARS-CoV-2 in clinical settings,This study examines coronavirus with 315 word abstract...,,JAMA,2021-11-23,ArXiv,10.1000/sample.791,PMC1000791,https://example.com/paper_791,2021.0,11.0,76,10,True,57.0,8.0,True
cord-000792,Analysis of SARS-CoV-2 and public health in clinical settings,This study examines SARS-CoV-2 with 430 word abstract...,"Author792_1, Author792_2",Nature Medicine,2020-01-09,PMC,10.1000/sample.792,PMC1000792,,2020.0,1.0,61,9,True,56.0,8.0,True
cord-000793,Analysis of clinical and COVID-19 and public health in clinical settings,This study examines clinical with 220 word abstract...,"Author793_1, Author793_2",Nature Medicine,2020-10-11,ArXiv,10.1000/sample.793,PMC1000793,https://example.com/paper_793,2020.0,10.0,72,11,True,54.0,8.0,True
cord-000794,Analysis of coronavirus and transmission and treatment and lockdown in clinical settings,This study examines coronavirus with 463 word abstract...,"Author794_1, Author794_2",Nature,2020-04-21,medRxiv,10.1000/sample.794,PMC1000794,https://example.com/paper_794,2020.0,4.0,88,12,True,57.0,8.0,True
cord-000795,Analysis of therapeutic and antibody in clinical settings,This study examines therapeutic with 221 word abstract...,"Author795_1, Author795_2",Clinical Infectious Diseases,2021-01-04,medRxiv,10.1000/sample.795,PMC1000795,https://example.com/paper_795,2021.0,1.0,57,8,True,57.0,8.0,True
cord-000796,Analysis of respiratory and lockdown and epidemiology in clinical settings,This study examines respiratory with 225 word abstract...,"Author796_1, Author796_2",Journal of Medical Virology,2020-01-22,WHO,10.1000/sample.796,PMC1000796,,2020.0,1.0,74,10,True,57.0,8.0,True
cord-000797,Analysis of clinical and coronavirus in clinical settings,This study examines clinical with 229 word abstract...,"Author797_1, Author797_2",Journal of Virology,2020-02-01,bioRxiv,10.1000/sample.797,,https://example.com/paper_797,2020.0,2.0,57,8,True,54.0,8.0,True
cord-000798,Analysis of antibody and COVID-19 and therapeutic and treatment in clinical settings,This study examines antibody with 488 word abstract...,"Author798_1, Author798_2",Nature Medicine,2022-06-26,Medline,10.1000/sample.798,PMC1000798,https://example.com/paper_798,2022.0,6.0,84,12,True,54.0,8.0,True
cord-000799,Analysis of transmission and coronavirus and pneumonia and vaccination in clinical settings,This study examines transmission with 301 word abstract...,"Author799_1, Author799_2",Science Translational Medicine,,medRxiv,10.1000/sample.799,PMC1000799,https://example.com/paper_799,,,91,12,True,58.0,8.0,True
cord-000800,Analysis of therapeutic and diagnosis and coronavirus and pandemic in clinical settings,This study examines therapeutic with 233 word abstract...,"Author800_1, Author800_2",Virology,2021-11-25,Medline,10.1000/sample.800,,https://example.com/paper_800,2021.0,11.0,87,12,True,57.0,8.0,True
cord-000801,Analysis of clinical and public health in clinical settings,This study examines clinical with 329 word abstract...,Author801_1,Virology,2020-11-01,medRxiv,10.1000/sample.801,,https://example.com/paper_801,2020.0,11.0,59,9,True,54.0,8.0,True
cord-000802,Analysis of clinical and immunity in clinical settings,This study examines clinical with 199 word abstract...,Author802_1,Virology,2020-06-08,Medline,10.1000/sample.802,PMC1000802,https://example.com/paper_802,2020.0,6.0,54,8,True,54.0,8.0,True
cord-000803,Analysis of treatment and transmission and SARS-CoV-2 in clinical settings,This study examines treatment with 207 word abstract...,"Author803_1, Author803_2",Science,2021-12-27,PMC,,,https://example.com/paper_803,2021.0,12.0,74,10,True,55.0,8.0,True
cord-000805,Analysis of transmission and SARS-CoV-2 in clinical settings,This study examines transmission with 169 word abstract...,"Author805_1, Author805_2",Clinical Infectious Diseases,2020-04-12,ArXiv,10.1000/sample.805,,https://example.com/paper_805,2020.0,4.0,60,8,True,58.0,8.0,True
cord-000806,Analysis of diagnosis and clinical and coronavirus in clinical settings,This study examines diagnosis with 138 word abstract...,"Author806_1, Author806_2",Lancet,2020-07-24,ArXiv,,PMC1000806,,2020.0,7.0,71,10,True,55.0,8.0,True
cord-000807,Analysis of diagnosis and lockdown in clinical settings,This study examines diagnosis with 256 word abstract...,"Author807_1, Author807_2",Nature Medicine,2022-03-23,ArXiv,10.1000/sample.807,,,2022.0,3.0,55,8,True,55.0,8.0,True
cord-000809,Analysis of immunity and coronavirus and diagnosis in clinical settings,This study examines immunity with 432 word abstract...,"Author809_1, Author809_2",BMJ,2020-12-05,PMC,10.1000/sample.809,PMC1000809,,2020.0,12.0,71,10,True,54.0,8.0,True
cord-000810,Analysis of pneumonia and transmission and immunity and treatment in clinical settings,This study examines pneumonia with 229 word abstract...,"Author810_1, Author810_2",New England Journal of Medicine,2019-12-12,medRxiv,10.1000/sample.810,,https://example.com/paper_810,2019.0,12.0,86,12,True,55.0,8.0,True
cord-000811,Analysis of antibody and public health in clinical settings,This study examines antibody with 350 word abstract...,"Author811_1, Author811_2",Journal of Medical Virology,,PMC,10.1000/sample.811,PMC1000811,https://example.com/paper_811,,,59,9,True,54.0,8.0,True
cord-000812,Analysis of antiviral and therapeutic and lockdown and antibody in clinical settings,This study examines antiviral with 421 word abstract...,,Nature Medicine,,Medline,10.1000/sample.812,,https://example.com/paper_812,,,84,12,True,55.0,8.0,True
cord-000813,Analysis of antibody and coronavirus and symptoms in clinical settings,This study examines antibody with 331 word abstract...,"Author813_1, Author813_2",Lancet,2020-03-06,bioRxiv,10.1000/sample.813,,https://example.com/paper_813,2020.0,3.0,70,10,True,54.0,8.0,True
cord-000814,Analysis of outbreak and COVID-19 and SARS-CoV-2 in clinical settings,This study examines outbreak with 329 word abstract...,"Author814_1, Author814_2",Nature Medicine,,PMC,10.1000/sample.814,,,,,69,10,True,54.0,8.0,True
cord-000815,Analysis of respiratory and pneumonia and lockdown and therapeutic in clinical settings,This study examines respiratory with 108 word abstract...,"Author815_1, Author815_2",PLoS ONE,2021-03-09,medRxiv,10.1000/sample.815,,https://example.com/paper_815,2021.0,3.0,87,12,True,57.0,8.0,True
cord-000816,Analysis of clinical and antiviral and vaccination and immunity in clinical settings,,Author816_1,BMJ,2019-12-14,PMC,10.1000/sample.816,PMC1000816,https://example.com/paper_816,2019.0,12.0,84,12,False,,,True
cord-000817,Analysis of symptoms and outbreak and respiratory in clinical settings,This study examines symptoms with 221 word abstract...,,Clinical Infectious Diseases,2020-11-12,Medline,10.1000/sample.817,PMC1000817,https://example.com/paper_817,2020.0,11.0,70,10,True,54.0,8.0,True
cord-000818,Analysis of public health and diagnosis and symptoms and pandemic in clinical settings,This study examines public health with 387 word abstract...,"Author818_1, Author818_2",Lancet,2021-03-24,WHO,10.1000/sample.818,,https://example.com/paper_818,2021.0,3.0,86,13,True,59.0,9.0,True
cord-000819,Analysis of immunity and COVID-19 in clinical settings,This study examines immunity with 332 word abstract...,"Author819_1, Author819_2",Virology,2020-12-20,Medline,10.1000/sample.819,PMC1000819,https://example.com/paper_819,2020.0,12.0,54,8,True,54.0,8.0,True
cord-000820,Analysis of respiratory and coronavirus and antiviral and transmission in clinical settings,This study examines respiratory with 259 word abstract...,"Author820_1, Author820_2",Science Translational Medicine,2020-12-16,Medline,10.1000/sample.820,PMC1000820,https://example.com/paper_820,2020.0,12.0,91,12,True,57.0,8.0,True
cord-000821,Analysis of epidemiology and pandemic and SARS-CoV-2 in clinical settings,This study examines epidemiology with 394 word abstract...,"Author821_1, Author821_2",,2020-10-23,ArXiv,10.1000/sample.821,,https://example.com/paper_821,2020.0,10.0,73,10,True,58.0,8.0,False
cord-000822,Analysis of therapeutic and clinical and treatment in clinical settings,This study examines therapeutic with 321 word abstract...,"Author822_1, Author822_2",,2019-12-09,ArXiv,10.1000/sample.822,PMC1000822,https://example.com/paper_822,2019.0,12.0,71,10,True,57.0,8.0,False
cord-000823,Analysis of SARS-CoV-2 and coronavirus and clinical and antiviral in clinical settings,This study examines SARS-CoV-2 with 160 word abstract...,"Author823_1, Author823_2",Clinical Infectious Diseases,2020-06-11,WHO,10.1000/sample.823,PMC1000823,https://example.com/paper_823,2020.0,6.0,86,12,True,56.0,8.0,True
cord-000824,Analysis of antiviral and immunity and respiratory and pneumonia in clinical settings,This study examines antiviral with 252 word abstract...,"Author824_1, Author824_2",Journal of Virology,2020-06-24,medRxiv,,,https://example.com/paper_824,2020.0,6.0,85,12,True,55.0,8.0,True
cord-000826,Analysis of diagnosis and clinical and transmission and antibody in clinical settings,This study examines diagnosis with 283 word abstract...,Author826_1,,2020-03-13,Medline,10.1000/sample.826,,https://example.com/paper_826,2020.0,3.0,85,12,True,55.0,8.0,False
cord-000827,Analysis of antiviral and diagnosis in clinical settings,This study examines antiviral with 255 word abstract...,Author827_1,BMJ,2021-06-18,PMC,10.1000/sample.827,,https://example.com/paper_827,2021.0,6.0,56,8,True,55.0,8.0,True
cord-000828,Analysis of clinical and COVID-19 and antiviral and lockdown in clinical settings,This study examines clinical with 151 word abstract...,"Author828_1, Author828_2",Nature Medicine,2022-10-24,PMC,10.1000/sample.828,PMC1000828,,2022.0,10.0,81,12,True,54.0,8.0,True
cord-000829,Analysis of outbreak and public health and lockdown in clinical settings,This study examines outbreak with 373 word abstract...,"Author829_1, Author829_2",Virology,2019-12-14,Medline,10.1000/sample.829,PMC1000829,https://example.com/paper_829,2019.0,12.0,72,11,True,54.0,8.0,True
cord-000830,Analysis of epidemiology and pneumonia and coronavirus and outbreak in clinical settings,This study examines epidemiology with 348 word abstract...,"Author830_1, Author830_2",BMJ,2021-03-09,Medline,,PMC1000830,,2021.0,3.0,88,12,True,58.0,8.0,True
cord-000832,Analysis of transmission and antiviral and treatment in clinical settings,This study examines transmission with 148 word abstract...,"Author832_1, Author832_2",Nature Medicine,2021-01-22,medRxiv,10.1000/sample.832,PMC1000832,https://example.com/paper_832,2021.0,1.0,73,10,True,58.0,8.0,True
cord-000833,Analysis of SARS-CoV-2 and vaccination and coronavirus in clinical settings,This study examines SARS-CoV-2 with 297 word abstract...,"Author833_1, Author833_2",BMJ,2021-05-21,medRxiv,10.1000/sample.833,PMC1000833,,2021.0,5.0,75,10,True,56.0,8.0,True
cord-000835,Analysis of pneumonia and transmission and vaccination in clinical settings,This study examines pneumonia with 185 word abstract...,"Author835_1, Author835_2",Nature Medicine,2020-11-11,WHO,10.1000/sample.835,,https://example.com/paper_835,2020.0,11.0,75,10,True,55.0,8.0,True
cord-000836,Analysis of clinical and coronavirus and SARS-CoV-2 in clinical settings,This study examines clinical with 463 word abstract...,"Author836_1, Author836_2",Nature,2021-04-12,bioRxiv,10.1000/sample.836,PMC1000836,,2021.0,4.0,72,10,True,54.0,8.0,True
cord-000837,Analysis of lockdown and antiviral and symptoms and epidemiology in clinical settings,This study examines lockdown with 374 word abstract...,"Author837_1, Author837_2",,2022-10-08,ArXiv,10.1000/sample.837,PMC1000837,https://example.com/paper_837,2022.0,10.0,85,12,True,54.0,8.0,False
cord-000838,Analysis of COVID-19 and treatment and transmission in clinical settings,This study examines COVID-19 with 499 word abstract...,Author838_1,Clinical Infectious Diseases,2021-06-11,ArXiv,10.1000/sample.838,PMC1000838,https://example.com/paper_838,2021.0,6.0,72,10,True,54.0,8.0,True
cord-000840,Analysis of pneumonia and antibody and immunity in clinical settings,This study examines pneumonia with 358 word abstract...,"Author840_1, Author840_2",Nature,2021-02-21,medRxiv,10.1000/sample.840,PMC1000840,,2021.0,2.0,68,10,True,55.0,8.0,True
cord-000844,Analysis of public health and SARS-CoV-2 and epidemiology in clinical settings,This study examines public health with 330 word abstract...,Author844_1,Virology,2022-08-02,ArXiv,10.1000/sample.844,PMC1000844,https://example.com/paper_844,2022.0,8.0,78,11,True,59.0,9.0,True
cord-000845,Analysis of diagnosis and COVID-19 and respiratory and outbreak in clinical settings,This study examines diagnosis with 200 word abstract...,"Author845_1, Author845_2",Cell,2021-01-28,PMC,10.1000/sample.845,,https://example.com/paper_845,2021.0,1.0,84,12,True,55.0,8.0,True
cord-000846,Analysis of vaccination and therapeutic and pneumonia and SARS-CoV-2 in clinical settings,This study examines vaccination with 169 word abstract...,"Author846_1, Author846_2",Nature,2022-03-30,Medline,10.1000/sample.846,PMC1000846,https://example.com/paper_846,2022.0,3.0,89,12,True,57.0,8.0,True
cord-000847,Analysis of coronavirus and epidemiology and immunity and vaccination in clinical settings,This study examines coronavirus with 178 word abstract...,"Author847_1, Author847_2",Science,2022-08-24,ArXiv,,PMC1000847,https://example.com/paper_847,2022.0,8.0,90,12,True,57.0,8.0,True
cord-000848,Analysis of SARS-CoV-2 and epidemiology and antiviral and treatment in clinical settings,This study examines SARS-CoV-2 with 435 word abstract...,"Author848_1, Author848_2",JAMA,2022-05-05,medRxiv,10.1000/sample.848,PMC1000848,https://example.com/paper_848,2022.0,5.0,88,12,True,56.0,8.0,True
cord-000849,Analysis of therapeutic and outbreak and treatment in clinical settings,This study examines therapeutic with 244 word abstract...,"Author849_1, Author849_2",JAMA,2020-03-24,WHO,10.1000/sample.849,,,2020.0,3.0,71,10,True,57.0,8.0,True
cord-000850,Analysis of vaccination and respiratory and COVID-19 and lockdown in clinical settings,This study examines vaccination with 238 word abstract...,Author850_1,Nature Medicine,2020-12-14,ArXiv,10.1000/sample.850,PMC1000850,https://example.com/paper_850,2020.0,12.0,86,12,True,57.0,8.0,True
cord-000851,Analysis of epidemiology and pandemic and therapeutic and COVID-19 in clinical settings,This study examines epidemiology with 120 word abstract...,"Author851_1, Author851_2",Nature,2021-10-07,ArXiv,10.1000/sample.851,PMC1000851,https://example.com/paper_851,2021.0,10.0,87,12,True,58.0,8.0,True
cord-000852,Analysis of treatment and therapeutic in clinical settings,This study examines treatment with 326 word abstract...,"Author852_1, Author852_2",Science Translational Medicine,2019-12-01,WHO,10.1000/sample.852,PMC1000852,https://example.com/paper_852,2019.0,12.0,58,8,True,55.0,8.0,True
cord-000854,Analysis of antibody and therapeutic in clinical settings,This study examines antibody with 372 word abstract...,Author854_1,Nature Medicine,2020-12-18,ArXiv,,PMC1000854,https://example.com/paper_854,2020.0,12.0,57,8,True,54.0,8.0,True
cord-000855,Analysis of coronavirus and therapeutic and vaccination in clinical settings,This study examines coronavirus with 457 word abstract...,"Author855_1, Author855_2",New England Journal of Medicine,2022-08-27,WHO,10.1000/sample.855,PMC1000855,https://example.com/paper_855,2022.0,8.0,76,10,True,57.0,8.0,True
cord-000856,Analysis of immunity and pneumonia and antiviral in clinical settings,This study examines immunity with 420 word abstract...,Author856_1,Nature Medicine,2020-01-19,ArXiv,10.1000/sample.856,PMC1000856,https://example.com/paper_856,2020.0,1.0,69,10,True,54.0,8.0,True
cord-000857,Analysis of transmission and antiviral and epidemiology and SARS-CoV-2 in clinical settings,This study examines transmission with 432 word abstract...,"Author857_1, Author857_2",Science Translational Medicine,2020-11-28,medRxiv,10.1000/sample.857,PMC1000857,https://example.com/paper_857,2020.0,11.0,91,12,True,58.0,8.0,True
cord-000858,Analysis of pandemic and lockdown and public health in clinical settings,This study examines pandemic with 324 word abstract...,"Author858_1, Author858_2",Emerging Infectious Diseases,2020-12-07,WHO,10.1000/sample.858,PMC1000858,,2020.0,12.0,72,11,True,54.0,8.0,True
cord-000859,Analysis of respiratory and diagnosis in clinical settings,This study examines respiratory with 132 word abstract...,Author859_1,Nature,2021-06-25,WHO,10.1000/sample.859,PMC1000859,,2021.0,6.0,58,8,True,57.0,8.0,True
cord-000860,Analysis of antibody and COVID-19 and SARS-CoV-2 and pneumonia in clinical settings,,"Author860_1, Author860_2",BMJ,2020-05-17,bioRxiv,10.1000/sample.860,PMC1000860,https://example.com/paper_860,2020.0,5.0,83,12,False,,,True
cord-000861,Analysis of lockdown and therapeutic in clinical settings,This study examines lockdown with 132 word abstract...,"Author861_1, Author861_2",Nature Medicine,2021-10-11,WHO,10.1000/sample.861,PMC1000861,https://example.com/paper_861,2021.0,10.0,57,8,True,54.0,8.0,True
cord-000862,Analysis of treatment and outbreak and SARS-CoV-2 in clinical settings,,"Author862_1, Author862_2",Science Translational Medicine,2020-08-02,ArXiv,10.1000/sample.862,PMC1000862,https://example.com/paper_862,2020.0,8.0,70,10,False,,,True
cord-000863,Analysis of COVID-19 and therapeutic and symptoms and clinical in clinical settings,This study examines COVID-19 with 458 word abstract...,Author863_1,Lancet,2021-08-02,medRxiv,10.1000/sample.863,,https://example.com/paper_863,2021.0,8.0,83,12,True,54.0,8.0,True
cord-000864,Analysis of treatment and antibody in clinical settings,This study examines treatment with 400 word abstract...,Author864_1,Emerging Infectious Diseases,2020-06-01,WHO,10.1000/sample.864,PMC1000864,https://example.com/paper_864,2020.0,6.0,55,8,True,55.0,8.0,True
cord-000865,Analysis of respiratory and SARS-CoV-2 in clinical settings,This study examines respiratory with 482 word abstract...,"Author865_1, Author865_2",Journal of Medical Virology,2022-03-23,PMC,10.1000/sample.865,PMC1000865,https://example.com/paper_865,2022.0,3.0,59,8,True,57.0,8.0,True
cord-000866,Analysis of diagnosis and clinical and public health in clinical settings,This study examines diagnosis with 187 word abstract...,"Author866_1, Author866_2",New England Journal of Medicine,2019-12-29,bioRxiv,10.1000/sample.866,PMC1000866,https://example.com/paper_866,2019.0,12.0,73,11,True,55.0,8.0,True
cord-000869,Analysis of epidemiology and treatment and SARS-CoV-2 and pandemic in clinical settings,This study examines epidemiology with 480 word abstract...,"Author869_1, Author869_2",Science,2020-03-24,medRxiv,10.1000/sample.869,,https://example.com/paper_869,2020.0,3.0,87,12,True,58.0,8.0,True
cord-000870,Analysis of clinical and COVID-19 in clinical settings,This study examines clinical with 345 word abstract...,"Author870_1, Author870_2",New England Journal of Medicine,2020-04-26,bioRxiv,10.1000/sample.870,PMC1000870,https://example.com/paper_870,2020.0,4.0,54,8,True,54.0,8.0,True
cord-000871,Analysis of public health and lockdown and coronavirus and pandemic in clinical settings,This study examines public health with 163 word abstract...,Author871_1,JAMA,2021-06-16,bioRxiv,10.1000/sample.871,PMC1000871,,2021.0,6.0,88,13,True,59.0,9.0,True
cord-000872,Analysis of SARS-CoV-2 and transmission and outbreak in clinical settings,This study examines SARS-CoV-2 with 497 word abstract...,"Author872_1, Author872_2",,2021-07-22,WHO,10.1000/sample.872,,https://example.com/paper_872,2021.0,7.0,73,10,True,56.0,8.0,False
cord-000873,Analysis of coronavirus and pandemic and pneumonia and transmission in clinical settings,This study examines coronavirus with 410 word abstract...,"Author873_1, Author873_2",Virology,2021-06-06,Medline,10.1000/sample.873,PMC1000873,,2021.0,6.0,88,12,True,57.0,8.0,True
cord-000874,Analysis of antiviral and lockdown in clinical settings,This study examines antiviral with 173 word abstract...,"Author874_1, Author874_2",Science Translational Medicine,2022-07-29,WHO,10.1000/sample.874,PMC1000874,https://example.com/paper_874,2022.0,7.0,55,8,True,55.0,8.0,True
cord-000876,Analysis of diagnosis and therapeutic in clinical settings,This study examines diagnosis with 116 word abstract...,Author876_1,JAMA,2020-08-22,PMC,10.1000/sample.876,PMC1000876,https://example.com/paper_876,2020.0,8.0,58,8,True,55.0,8.0,True
cord-000877,Analysis of public health and clinical and epidemiology and antiviral in clinical settings,This study examines public health with 247 word abstract...,"Author877_1, Author877_2",Nature,2020-11-24,ArXiv,10.1000/sample.877,PMC1000877,,2020.0,11.0,90,13,True,59.0,9.0,True
cord-000878,Analysis of public health and SARS-CoV-2 and antibody and lockdown in clinical settings,This study examines public health with 269 word abstract...,Author878_1,BMJ,2020-02-22,PMC,10.1000/sample.878,,,2020.0,2.0,87,13,True,59.0,9.0,True
cord-000879,Analysis of pandemic and transmission and COVID-19 and vaccination in clinical settings,This study examines pandemic with 469 word abstract...,"Author879_1, Author879_2",Nature Medicine,2021-10-31,medRxiv,10.1000/sample.879,PMC1000879,,2021.0,10.0,87,12,True,54.0,8.0,True
cord-000880,Analysis of immunity and symptoms and epidemiology and outbreak in clinical settings,This study examines immunity with 288 word abstract...,"Author880_1, Author880_2",Science Translational Medicine,2020-02-11,WHO,10.1000/sample.880,PMC1000880,https://example.com/paper_880,2020.0,2.0,84,12,True,54.0,8.0,True
cord-000882,Analysis of coronavirus and clinical and diagnosis in clinical settings,This study examines coronavirus with 364 word abstract...,"Author882_1, Author882_2",BMJ,2021-10-12,ArXiv,10.1000/sample.882,,https://example.com/paper_882,2021.0,10.0,71,10,True,57.0,8.0,True
cord-000883,Analysis of diagnosis and epidemiology and antibody and clinical in clinical settings,This study examines diagnosis with 451 word abstract...,"Author883_1, Author883_2",Virology,2020-08-14,WHO,10.1000/sample.883,PMC1000883,https://example.com/paper_883,2020.0,8.0,85,12,True,55.0,8.0,True
cord-000884,Analysis of lockdown and symptoms and epidemiology and outbreak in clinical settings,This study examines lockdown with 468 word abstract...,Author884_1,Science Translational Medicine,2020-04-25,PMC,10.1000/sample.884,PMC1000884,,2020.0,4.0,84,12,True,54.0,8.0,True
cord-000886,Analysis of pandemic and diagnosis in clinical settings,This study examines pandemic with 244 word abstract...,"Author886_1, Author886_2",Virology,2020-12-30,medRxiv,10.1000/sample.886,PMC1000886,https://example.com/paper_886,2020.0,12.0,55,8,True,54.0,8.0,True
cord-000887,Analysis of transmission and symptoms in clinical settings,This study examines transmission with 449 word abstract...,"Author887_1, Author887_2",,,medRxiv,10.1000/sample.887,PMC1000887,,,,58,8,True,58.0,8.0,False
cord-000888,Analysis of public health and COVID-19 and immunity in clinical settings,This study examines public health with 111 word abstract...,Author888_1,New England Journal of Medicine,2021-01-09,Medline,10.1000/sample.888,,https://example.com/paper_888,2021.0,1.0,72,11,True,59.0,9.0,True
cord-000889,Analysis of coronavirus and pneumonia and immunity and therapeutic in clinical settings,This study examines coronavirus with 399 word abstract...,"Author889_1, Author889_2",JAMA,2021-04-16,WHO,10.1000/sample.889,PMC1000889,https://example.com/paper_889,2021.0,4.0,87,12,True,57.0,8.0,True
cord-000891,Analysis of treatment and clinical in clinical settings,This study examines treatment with 219 word abstract...,"Author891_1, Author891_2",,2020-04-06,medRxiv,10.1000/sample.891,PMC1000891,https://example.com/paper_891,2020.0,4.0,55,8,True,55.0,8.0,False
cord-000892,Analysis of immunity and pandemic in clinical settings,This study examines immunity with 325 word abstract...,"Author892_1, Author892_2",PLoS ONE,2021-09-30,Medline,10.1000/sample.892,PMC1000892,https://example.com/paper_892,2021.0,9.0,54,8,True,54.0,8.0,True
cord-000893,Analysis of antibody and public health and COVID-19 in clinical settings,This study examines antibody with 397 word abstract...,"Author893_1, Author893_2",Cell,2021-11-21,PMC,10.1000/sample.893,PMC1000893,https://example.com/paper_893,2021.0,11.0,72,11,True,54.0,8.0,True
cord-000894,Analysis of antibody and SARS-CoV-2 in clinical settings,This study examines antibody with 215 word abstract...,"Author894_1, Author894_2",Virology,2021-05-04,PMC,,,https://example.com/paper_894,2021.0,5.0,56,8,True,54.0,8.0,True
cord-000895,Analysis of respiratory and therapeutic and vaccination in clinical settings,This study examines respiratory with 252 word abstract...,"Author895_1, Author895_2",Journal of Virology,2021-11-08,WHO,10.1000/sample.895,,https://example.com/paper_895,2021.0,11.0,76,10,True,57.0,8.0,True
cord-000898,Analysis of lockdown and public health and antiviral and diagnosis in clinical settings,This study examines lockdown with 249 word abstract...,Author898_1,Cell,2020-09-12,Medline,10.1000/sample.898,PMC1000898,https://example.com/paper_898,2020.0,9.0,87,13,True,54.0,8.0,True
cord-000899,Analysis of outbreak and treatment and pneumonia in clinical settings,This study examines outbreak with 475 word abstract...,"Author899_1, Author899_2",Cell,2020-04-13,ArXiv,10.1000/sample.899,PMC1000899,https://example.com/paper_899,2020.0,4.0,69,10,True,54.0,8.0,True
cord-000900,Analysis of therapeutic and clinical and COVID-19 and pneumonia in clinical settings,This study examines therapeutic with 342 word abstract...,,Clinical Infectious Diseases,2020-05-17,bioRxiv,10.1000/sample.900,PMC1000900,https://example.com/paper_900,2020.0,5.0,84,12,True,57.0,8.0,True
cord-000901,Analysis of therapeutic and respiratory and clinical and antiviral in clinical settings,This study examines therapeutic with 305 word abstract...,"Author901_1, Author901_2",Lancet,2021-10-24,PMC,10.1000/sample.901,PMC1000901,https://example.com/paper_901,2021.0,10.0,87,12,True,57.0,8.0,True
cord-000902,Analysis of transmission and epidemiology and SARS-CoV-2 in clinical settings,This study examines transmission with 210 word abstract...,Author902_1,New England Journal of Medicine,2022-04-16,WHO,10.1000/sample.902,PMC1000902,https://example.com/paper_902,2022.0,4.0,77,10,True,58.0,8.0,True
cord-000905,Analysis of antiviral and COVID-19 and epidemiology and respiratory in clinical settings,This study examines antiviral with 134 word abstract...,"Author905_1, Author905_2",PLoS ONE,2021-01-30,PMC,10.1000/sample.905,,https://example.com/paper_905,2021.0,1.0,88,12,True,55.0,8.0,True
cord-000906,Analysis of clinical and public health and transmission in clinical settings,This study examines clinical with 461 word abstract...,"Author906_1, Author906_2",Cell,2020-12-17,medRxiv,10.1000/sample.906,PMC1000906,https://example.com/paper_906,2020.0,12.0,76,11,True,54.0,8.0,True
cord-000907,Analysis of transmission and treatment and pneumonia and clinical in clinical settings,This study examines transmission with 236 word abstract...,"Author907_1, Author907_2",Virology,2020-03-03,PMC,10.1000/sample.907,PMC1000907,,2020.0,3.0,86,12,True,58.0,8.0,True
cord-000908,Analysis of symptoms and lockdown in clinical settings,This study examines symptoms with 166 word abstract...,Author908_1,New England Journal of Medicine,2022-02-10,PMC,10.1000/sample.908,PMC1000908,,2022.0,2.0,54,8,True,54.0,8.0,True
cord-000909,Analysis of pneumonia and antiviral and antibody and epidemiology in clinical settings,This study examines pneumonia with 451 word abstract...,"Author909_1, Author909_2",New England Journal of Medicine,2021-09-26,PMC,,PMC1000909,,2021.0,9.0,86,12,True,55.0,8.0,True
cord-000910,Analysis of antibody and antiviral in clinical settings,This study examines antibody with 284 word abstract...,"Author910_1, Author910_2",,2020-10-26,PMC,10.1000/sample.910,PMC1000910,https://example.com/paper_910,2020.0,10.0,55,8,True,54.0,8.0,False
cord-000911,Analysis of SARS-CoV-2 and diagnosis and lockdown and immunity in clinical settings,This study examines SARS-CoV-2 with 283 word abstract...,"Author911_1, Author911_2",Science Translational Medicine,2021-02-11,ArXiv,10.1000/sample.911,PMC1000911,https://example.com/paper_911,2021.0,2.0,83,12,True,56.0,8.0,True
cord-000912,Analysis of pneumonia and SARS-CoV-2 and epidemiology and antiviral in clinical settings,,"Author912_1, Author912_2",Journal of Medical Virology,2020-04-18,Medline,10.1000/sample.912,PMC1000912,https://example.com/paper_912,2020.0,4.0,88,12,False,,,True
cord-000914,Analysis of public health and outbreak and respiratory in clinical settings,This study examines public health with 241 word abstract...,"Author914_1, Author914_2",Science Translational Medicine,2020-11-04,medRxiv,10.1000/sample.914,PMC1000914,https://example.com/paper_914,2020.0,11.0,75,11,True,59.0,9.0,True
cord-000915,Analysis of lockdown and COVID-19 and immunity and transmission in clinical settings,This study examines lockdown with 384 word abstract...,"Author915_1, Author915_2",Cell,2022-05-17,bioRxiv,10.1000/sample.915,,https://example.com/paper_915,2022.0,5.0,84,12,True,54.0,8.0,True
cord-000916,Analysis of outbreak and epidemiology and pandemic and coronavirus in clinical settings,This study examines outbreak with 100 word abstract...,"Author916_1, Author916_2",Journal of Virology,2020-11-02,PMC,10.1000/sample.916,PMC1000916,https://example.com/paper_916,2020.0,11.0,87,12,True,54.0,8.0,True
cord-000917,Analysis of treatment and transmission and clinical and outbreak in clinical settings,This study examines treatment with 308 word abstract...,Author917_1,Emerging Infectious Diseases,2021-04-05,PMC,10.1000/sample.917,PMC1000917,https://example.com/paper_917,2021.0,4.0,85,12,True,55.0,8.0,True
cord-000918,Analysis of pneumonia and diagnosis in clinical settings,This study examines pneumonia with 345 word abstract...,Author918_1,PLoS ONE,2022-06-18,Medline,10.1000/sample.918,PMC1000918,https://example.com/paper_918,2022.0,6.0,56,8,True,55.0,8.0,True
cord-000919,Analysis of antiviral and immunity in clinical settings,This study examines antiviral with 450 word abstract...,"Author919_1, Author919_2",Nature,2021-04-13,bioRxiv,10.1000/sample.919,PMC1000919,https://example.com/paper_919,2021.0,4.0,55,8,True,55.0,8.0,True
cord-000921,Analysis of pandemic and transmission in clinical settings,This study examines pandemic with 485 word abstract...,"Author921_1, Author921_2",,2019-12-20,Medline,10.1000/sample.921,PMC1000921,https://example.com/paper_921,2019.0,12.0,58,8,True,54.0,8.0,False
cord-000922,Analysis of antiviral and symptoms and clinical in clinical settings,This study examines antiviral with 255 word abstract...,"Author922_1, Author922_2",PLoS ONE,2020-07-21,PMC,10.1000/sample.922,PMC1000922,,2020.0,7.0,68,10,True,55.0,8.0,True
cord-000923,Analysis of diagnosis and outbreak and antibody and lockdown in clinical settings,This study examines diagnosis with 217 word abstract...,"Author923_1, Author923_2",Lancet,2020-09-21,bioRxiv,10.1000/sample.923,PMC1000923,https://example.com/paper_923,2020.0,9.0,81,12,True,55.0,8.0,True
cord-000924,Analysis of antibody and SARS-CoV-2 and public health and respiratory in clinical settings,This study examines antibody with 124 word abstract...,"Author924_1, Author924_2",Clinical Infectious Diseases,2021-02-07,bioRxiv,,PMC1000924,https://example.com/paper_924,2021.0,2.0,90,13,True,54.0,8.0,True
cord-000925,Analysis of treatment and lockdown and epidemiology in clinical settings,This study examines treatment with 352 word abstract...,"Author925_1, Author925_2",Nature,2020-07-13,WHO,10.1000/sample.925,,https://example.com/paper_925,2020.0,7.0,72,10,True,55.0,8.0,True
cord-000926,Analysis of outbreak and COVID-19 and symptoms and pneumonia in clinical settings,This study examines outbreak with 336 word abstract...,"Author926_1, Author926_2",Science Translational Medicine,2021-02-21,WHO,,PMC1000926,,2021.0,2.0,81,12,True,54.0,8.0,True
cord-000927,Analysis of therapeutic and public health and symptoms and COVID-19 in clinical settings,This study examines therapeutic with 125 word abstract...,Author927_1,Science,2021-07-11,medRxiv,10.1000/sample.927,PMC1000927,https://example.com/paper_927,2021.0,7.0,88,13,True,57.0,8.0,True
cord-000928,Analysis of respiratory and symptoms and vaccination in clinical settings,This study examines respiratory with 339 word abstract...,Author928_1,PLoS ONE,2022-05-03,PMC,10.1000/sample.928,PMC1000928,,2022.0,5.0,73,10,True,57.0,8.0,True
cord-000929,Analysis of pneumonia and antiviral and therapeutic and transmission in clinical settings,This study examines pneumonia with 185 word abstract...,"Author929_1, Author929_2",PLoS ONE,2021-06-19,PMC,,PMC1000929,,2021.0,6.0,89,12,True,55.0,8.0,True
cord-000930,Analysis of public health and COVID-19 and SARS-CoV-2 and immunity in clinical settings,This study examines public health with 417 word abstract...,"Author930_1, Author930_2",Clinical Infectious Diseases,2020-10-24,WHO,10.1000/sample.930,,https://example.com/paper_930,2020.0,10.0,87,13,True,59.0,9.0,True
cord-000931,Analysis of treatment and vaccination and diagnosis and respiratory in clinical settings,This study examines treatment with 446 word abstract...,"Author931_1, Author931_2",,2021-07-02,PMC,10.1000/sample.931,,https://example.com/paper_931,2021.0,7.0,88,12,True,55.0,8.0,False
cord-000932,Analysis of antiviral and symptoms and antibody and public health in clinical settings,This study examines antiviral with 437 word abstract...,"Author932_1, Author932_2",New England Journal of Medicine,2021-06-11,WHO,10.1000/sample.932,PMC1000932,https://example.com/paper_932,2021.0,6.0,86,13,True,55.0,8.0,True
cord-000933,Analysis of clinical and diagnosis in clinical settings,This study examines clinical with 232 word abstract...,"Author933_1, Author933_2",Journal of Virology,2020-02-07,PMC,10.1000/sample.933,PMC1000933,https://example.com/paper_933,2020.0,2.0,55,8,True,54.0,8.0,True
cord-000934,Analysis of symptoms and antibody and antiviral in clinical settings,This study examines symptoms with 441 word abstract...,"Author934_1, Author934_2",,2019-12-14,bioRxiv,10.1000/sample.934,PMC1000934,https://example.com/paper_934,2019.0,12.0,68,10,True,54.0,8.0,False
cord-000935,Analysis of pneumonia and clinical in clinical settings,This study examines pneumonia with 414 word abstract...,"Author935_1, Author935_2",Lancet,2020-01-19,PMC,,PMC1000935,https://example.com/paper_935,2020.0,1.0,55,8,True,55.0,8.0,True
cord-000936,Analysis of immunity and epidemiology and pneumonia and therapeutic in clinical settings,This study examines immunity with 414 word abstract...,"Author936_1, Author936_2",Clinical Infectious Diseases,2021-02-05,PMC,10.1000/sample.936,,https://example.com/paper_936,2021.0,2.0,88,12,True,54.0,8.0,True
cord-000937,Analysis of vaccination and pneumonia and pandemic and public health in clinical settings,This study examines vaccination with 410 word abstract...,"Author937_1, Author937_2",Lancet,2020-10-25,Medline,10.1000/sample.937,,,2020.0,10.0,89,13,True,57.0,8.0,True
cord-000938,Analysis of epidemiology and antibody in clinical settings,This study examines epidemiology with 460 word abstract...,"Author938_1, Author938_2",Science,2021-04-01,PMC,10.1000/sample.938,PMC1000938,https://example.com/paper_938,2021.0,4.0,58,8,True,58.0,8.0,True
cord-000939,Analysis of pneumonia and coronavirus and antiviral in clinical settings,This study examines pneumonia with 273 word abstract...,"Author939_1, Author939_2",JAMA,2021-01-26,ArXiv,10.1000/sample.939,PMC1000939,https://example.com/paper_939,2021.0,1.0,72,10,True,55.0,8.0,True
cord-000940,Analysis of outbreak and antibody and coronavirus in clinical settings,This study examines outbreak with 448 word abstract...,"Author940_1, Author940_2",BMJ,2020-12-02,medRxiv,10.1000/sample.940,PMC1000940,https://example.com/paper_940,2020.0,12.0,70,10,True,54.0,8.0,True
cord-000941,Analysis of therapeutic and clinical and immunity in clinical settings,This study examines therapeutic with 158 word abstract...,"Author941_1, Author941_2",Lancet,2021-11-03,WHO,10.1000/sample.941,PMC1000941,,2021.0,11.0,70,10,True,57.0,8.0,True
cord-000942,Analysis of antiviral and pandemic in clinical settings,This study examines antiviral with 434 word abstract...,"Author942_1, Author942_2",Nature,2020-11-30,ArXiv,10.1000/sample.942,PMC1000942,https://example.com/paper_942,2020.0,11.0,55,8,True,55.0,8.0,True
cord-000943,Analysis of diagnosis and immunity and COVID-19 and therapeutic in clinical settings,This study examines diagnosis with 320 word abstract...,"Author943_1, Author943_2",,2022-12-30,PMC,10.1000/sample.943,PMC1000943,https://example.com/paper_943,2022.0,12.0,84,12,True,55.0,8.0,False
cord-000944,Analysis of SARS-CoV-2 and treatment and outbreak in clinical settings,This study examines SARS-CoV-2 with 128 word abstract...,"Author944_1, Author944_2",Journal of Medical Virology,2019-12-20,PMC,10.1000/sample.944,,https://example.com/paper_944,2019.0,12.0,70,10,True,56.0,8.0,True
cord-000945,Analysis of epidemiology and pneumonia and pandemic and immunity in clinical settings,This study examines epidemiology with 246 word abstract...,"Author945_1, Author945_2",Clinical Infectious Diseases,2021-04-19,ArXiv,10.1000/sample.945,PMC1000945,,2021.0,4.0,85,12,True,58.0,8.0,True
cord-000946,Analysis of respiratory and therapeutic and pandemic in clinical settings,This study examines respiratory with 364 word abstract...,"Author946_1, Author946_2",,2020-07-28,WHO,10.1000/sample.946,PMC1000946,https://example.com/paper_946,2020.0,7.0,73,10,True,57.0,8.0,False
cord-000947,Analysis of lockdown and respiratory and coronavirus in clinical settings,This study examines lockdown with 137 word abstract...,Author947_1,Virology,2020-06-20,ArXiv,10.1000/sample.947,,https://example.com/paper_947,2020.0,6.0,73,10,True,54.0,8.0,True
cord-000948,Analysis of pneumonia and respiratory in clinical settings,This study examines pneumonia with 169 word abstract...,"Author948_1, Author948_2",Journal of Medical Virology,2020-12-16,PMC,10.1000/sample.948,PMC1000948,,2020.0,12.0,58,8,True,55.0,8.0,True
cord-000949,Analysis of pneumonia and outbreak and respiratory and antiviral in clinical settings,This study examines pneumonia with 476 word abstract...,"Author949_1, Author949_2",Cell,2020-12-12,medRxiv,10.1000/sample.949,,https://example.com/paper_949,2020.0,12.0,85,12,True,55.0,8.0,True
cord-000950,Analysis of antibody and transmission and respiratory in clinical settings,This study examines antibody with 131 word abstract...,"Author950_1, Author950_2",Nature Medicine,2020-09-14,ArXiv,10.1000/sample.950,PMC1000950,https://example.com/paper_950,2020.0,9.0,74,10,True,54.0,8.0,True
cord-000952,Analysis of COVID-19 and SARS-CoV-2 in clinical settings,This study examines COVID-19 with 132 word abstract...,"Author952_1, Author952_2",,2020-03-14,bioRxiv,10.1000/sample.952,PMC1000952,https://example.com/paper_952,2020.0,3.0,56,8,True,54.0,8.0,False
cord-000953,Analysis of symptoms and antiviral and treatment and therapeutic in clinical settings,This study examines symptoms with 235 word abstract...,"Author953_1, Author953_2",PLoS ONE,2019-12-06,Medline,10.1000/sample.953,,https://example.com/paper_953,2019.0,12.0,85,12,True,54.0,8.0,True
cord-000955,Analysis of respiratory and antiviral and pneumonia and pandemic in clinical settings,This study examines respiratory with 308 word abstract...,,Lancet,2022-04-04,bioRxiv,10.1000/sample.955,,https://example.com/paper_955,2022.0,4.0,85,12,True,57.0,8.0,True
cord-000956,Analysis of antiviral and public health and vaccination in clinical settings,This study examines antiviral with 132 word abstract...,"Author956_1, Author956_2",Virology,2020-11-21,WHO,10.1000/sample.956,PMC1000956,https://example.com/paper_956,2020.0,11.0,76,11,True,55.0,8.0,True
cord-000957,Analysis of public health and coronavirus and clinical and immunity in clinical settings,This study examines public health with 330 word abstract...,Author957_1,Clinical Infectious Diseases,2020-10-08,medRxiv,10.1000/sample.957,,https://example.com/paper_957,2020.0,10.0,88,13,True,59.0,9.0,True
cord-000958,Analysis of SARS-CoV-2 and epidemiology and transmission and therapeutic in clinical settings,This study examines SARS-CoV-2 with 456 word abstract...,"Author958_1, Author958_2",BMJ,2020-09-23,medRxiv,10.1000/sample.958,,,2020.0,9.0,93,12,True,56.0,8.0,True
cord-000959,Analysis of immunity and clinical and symptoms in clinical settings,This study examines immunity with 238 word abstract...,"Author959_1, Author959_2",Nature,2020-09-03,medRxiv,10.1000/sample.959,PMC1000959,https://example.com/paper_959,2020.0,9.0,67,10,True,54.0,8.0,True
cord-000961,Analysis of coronavirus and COVID-19 and SARS-CoV-2 and vaccination in clinical settings,This study examines coronavirus with 470 word abstract...,"Author961_1, Author961_2",Journal of Medical Virology,2022-08-11,medRxiv,10.1000/sample.961,PMC1000961,,2022.0,8.0,88,12,True,57.0,8.0,True
cord-000962,Analysis of public health and COVID-19 and diagnosis in clinical settings,This study examines public health with 170 word abstract...,Author962_1,,2019-12-28,bioRxiv,10.1000/sample.962,PMC1000962,https://example.com/paper_962,2019.0,12.0,73,11,True,59.0,9.0,False
cord-000963,Analysis of outbreak and pandemic and immunity in clinical settings,,"Author963_1, Author963_2",New England Journal of Medicine,2021-03-08,PMC,10.1000/sample.963,,https://example.com/paper_963,2021.0,3.0,67,10,False,,,True
cord-000965,Analysis of public health and outbreak in clinical settings,This study examines public health with 104 word abstract...,"Author965_1, Author965_2",Science,2021-11-29,ArXiv,10.1000/sample.965,PMC1000965,https://example.com/paper_965,2021.0,11.0,59,9,True,59.0,9.0,True
cord-000966,Analysis of respiratory and antibody and vaccination and outbreak in clinical settings,This study examines respiratory with 226 word abstract...,"Author966_1, Author966_2",Nature Medicine,2021-02-28,medRxiv,,PMC1000966,https://example.com/paper_966,2021.0,2.0,86,12,True,57.0,8.0,True
cord-000967,Analysis of epidemiology and outbreak and immunity in clinical settings,This study examines epidemiology with 442 word abstract...,"Author967_1, Author967_2",Nature Medicine,2020-01-17,Medline,10.1000/sample.967,PMC1000967,https://example.com/paper_967,2020.0,1.0,71,10,True,58.0,8.0,True
cord-000968,Analysis of lockdown and therapeutic and pneumonia and antibody in clinical settings,This study examines lockdown with 479 word abstract...,"Author968_1, Author968_2",Science Translational Medicine,2020-01-16,Medline,,PMC1000968,,2020.0,1.0,84,12,True,54.0,8.0,True
cord-000969,Analysis of SARS-CoV-2 and symptoms and antiviral and COVID-19 in clinical settings,This study examines SARS-CoV-2 with 498 word abstract...,Author969_1,Journal of Virology,2022-06-14,medRxiv,10.1000/sample.969,PMC1000969,https://example.com/paper_969,2022.0,6.0,83,12,True,56.0,8.0,True
cord-000970,Analysis of clinical and diagnosis and antibody and pneumonia in clinical settings,This study examines clinical with 461 word abstract...,"Author970_1, Author970_2",Virology,2020-09-14,medRxiv,10.1000/sample.970,PMC1000970,,2020.0,9.0,82,12,True,54.0,8.0,True
cord-000971,Analysis of pandemic and antiviral in clinical settings,This study examines pandemic with 254 word abstract...,"Author971_1, Author971_2",Virology,2020-02-25,medRxiv,,,,2020.0,2.0,55,8,True,54.0,8.0,True
cord-000973,Analysis of transmission and symptoms and vaccination and immunity in clinical settings,This study examines transmission with 455 word abstract...,"Author973_1, Author973_2",Emerging Infectious Diseases,2020-12-22,bioRxiv,10.1000/sample.973,,https://example.com/paper_973,2020.0,12.0,87,12,True,58.0,8.0,True
cord-000974,Analysis of epidemiology and coronavirus and vaccination in clinical settings,This study examines epidemiology with 121 word abstract...,"Author974_1, Author974_2",Science,2020-08-14,Medline,10.1000/sample.974,PMC1000974,https://example.com/paper_974,2020.0,8.0,77,10,True,58.0,8.0,True
cord-000975,Analysis of diagnosis and clinical and outbreak in clinical settings,This study examines diagnosis with 229 word abstract...,"Author975_1, Author975_2",JAMA,2020-04-03,bioRxiv,10.1000/sample.975,PMC1000975,https://example.com/paper_975,2020.0,4.0,68,10,True,55.0,8.0,True
cord-000976,Analysis of outbreak and lockdown and vaccination in clinical settings,This study examines outbreak with 318 word abstract...,"Author976_1, Author976_2",Journal of Virology,2019-12-24,ArXiv,10.1000/sample.976,PMC1000976,https://example.com/paper_976,2019.0,12.0,70,10,True,54.0,8.0,True
cord-000977,Analysis of therapeutic and treatment and diagnosis in clinical settings,This study examines therapeutic with 192 word abstract...,"Author977_1, Author977_2",,2020-07-04,medRxiv,10.1000/sample.977,PMC1000977,https://example.com/paper_977,2020.0,7.0,72,10,True,57.0,8.0,False
cord-000979,Analysis of pandemic and coronavirus and antiviral and respiratory in clinical settings,This study examines pandemic with 194 word abstract...,"Author979_1, Author979_2",Journal of Medical Virology,,Medline,10.1000/sample.979,PMC1000979,,,,87,12,True,54.0,8.0,True
cord-000980,Analysis of therapeutic and coronavirus and lockdown and pandemic in clinical settings,This study examines therapeutic with 394 word abstract...,"Author980_1, Author980_2",Cell,2020-01-04,ArXiv,10.1000/sample.980,PMC1000980,https://example.com/paper_980,2020.0,1.0,86,12,True,57.0,8.0,True
cord-000981,Analysis of transmission and lockdown in clinical settings,This study examines transmission with 133 word abstract...,"Author981_1, Author981_2",,2020-07-11,bioRxiv,,PMC1000981,https://example.com/paper_981,2020.0,7.0,58,8,True,58.0,8.0,False
cord-000982,Analysis of vaccination and pneumonia in clinical settings,This study examines vaccination with 248 word abstract...,"Author982_1, Author982_2",BMJ,2021-11-15,bioRxiv,10.1000/sample.982,PMC1000982,,2021.0,11.0,58,8,True,57.0,8.0,True
cord-000983,Analysis of antibody and transmission and coronavirus in clinical settings,This study examines antibody with 362 word abstract...,Author983_1,New England Journal of Medicine,2020-05-29,medRxiv,10.1000/sample.983,PMC1000983,https://example.com/paper_983,2020.0,5.0,74,10,True,54.0,8.0,True
cord-000984,Analysis of transmission and respiratory and SARS-CoV-2 in clinical settings,This study examines transmission with 429 word abstract...,"Author984_1, Author984_2",Nature,2021-03-11,Medline,10.1000/sample.984,PMC1000984,,2021.0,3.0,76,10,True,58.0,8.0,True
cord-000985,Analysis of treatment and COVID-19 and therapeutic and antibody in clinical settings,This study examines treatment with 416 word abstract...,"Author985_1, Author985_2",BMJ,2020-12-01,medRxiv,10.1000/sample.985,PMC1000985,https://example.com/paper_985,2020.0,12.0,84,12,True,55.0,8.0,True
cord-000987,Analysis of antiviral and antibody and respiratory and treatment in clinical settings,This study examines antiviral with 224 word abstract...,"Author987_1, Author987_2",,2021-09-30,medRxiv,10.1000/sample.987,,https://example.com/paper_987,2021.0,9.0,85,12,True,55.0,8.0,False
cord-000988,Analysis of vaccination and COVID-19 and antiviral in clinical settings,This study examines vaccination with 331 word abstract...,"Author988_1, Author988_2",Science,2020-06-18,ArXiv,10.1000/sample.988,PMC1000988,https://example.com/paper_988,2020.0,6.0,71,10,True,57.0,8.0,True
cord-000989,Analysis of antibody and lockdown and SARS-CoV-2 in clinical settings,This study examines antibody with 217 word abstract...,"Author989_1, Author989_2",New England Journal of Medicine,2020-10-24,medRxiv,10.1000/sample.989,PMC1000989,https://example.com/paper_989,2020.0,10.0,69,10,True,54.0,8.0,True
cord-000990,Analysis of respiratory and epidemiology and antibody in clinical settings,This study examines respiratory with 358 word abstract...,"Author990_1, Author990_2",Emerging Infectious Diseases,2020-12-29,bioRxiv,10.1000/sample.990,PMC1000990,https://example.com/paper_990,2020.0,12.0,74,10,True,57.0,8.0,True
cord-000992,Analysis of therapeutic and SARS-CoV-2 and transmission in clinical settings,This study examines therapeutic with 128 word abstract...,"Author992_1, Author992_2",JAMA,2021-07-07,Medline,10.1000/sample.992,PMC1000992,https://example.com/paper_992,2021.0,7.0,76,10,True,57.0,8.0,True
cord-000993,Analysis of vaccination and coronavirus in clinical settings,This study examines vaccination with 164 word abstract...,"Author993_1, Author993_2",Emerging Infectious Diseases,2020-07-22,ArXiv,10.1000/sample.993,,,2020.0,7.0,60,8,True,57.0,8.0,True
cord-000994,Analysis of transmission and clinical and SARS-CoV-2 in clinical settings,This study examines transmission with 230 word abstract...,"Author994_1, Author994_2",Nature Medicine,2020-01-15,ArXiv,10.1000/sample.994,,https://example.com/paper_994,2020.0,1.0,73,10,True,58.0,8.0,True
cord-000997,Analysis of diagnosis and respiratory in clinical settings,This study examines diagnosis with 407 word abstract...,"Author997_1, Author997_2",Science Translational Medicine,,WHO,10.1000/sample.997,,,,,58,8,True,55.0,8.0,True
cord-000999,Analysis of public health and symptoms and vaccination in clinical settings,This study examines public health with 201 word abstract...,"Author999_1, Author999_2",Journal of Virology,2019-12-07,PMC,10.1000/sample.999,,,2019.0,12.0,75,11,True,59.0,9.0,True
cord-001000,Analysis of vaccination and antiviral and respiratory and outbreak in clinical settings,This study examines vaccination with 388 word abstract...,"Author1000_1, Author1000_2",Science,2019-12-14,PMC,10.1000/sample.1000,PMC1001000,https://example.com/paper_1000,2019.0,12.0,87,12,True,57.0,8.0,True
cord-001001,Analysis of respiratory and treatment and antibody in clinical settings,This study examines respiratory with 134 word abstract...,"Author1001_1, Author1001_2",PLoS ONE,2020-06-16,Medline,10.1000/sample.1001,PMC1001001,https://example.com/paper_1001,2020.0,6.0,71,10,True,57.0,8.0,True
cord-001002,Analysis of SARS-CoV-2 and symptoms and epidemiology and pneumonia in clinical settings,This study examines SARS-CoV-2 with 439 word abstract...,"Author1002_1, Author1002_2",Nature Medicine,2022-09-18,PMC,,,https://example.com/paper_1002,2022.0,9.0,87,12,True,56.0,8.0,True
cord-001003,Analysis of lockdown and symptoms and coronavirus and transmission in clinical settings,This study examines lockdown with 498 word abstract...,"Author1003_1, Author1003_2",Virology,2020-08-25,medRxiv,10.1000/sample.1003,PMC1001003,https://example.com/paper_1003,2020.0,8.0,87,12,True,54.0,8.0,True
cord-001004,Analysis of outbreak and COVID-19 and immunity and SARS-CoV-2 in clinical settings,This study examines outbreak with 217 word abstract...,"Author1004_1, Author1004_2",Nature,2020-03-22,ArXiv,10.1000/sample.1004,,https://example.com/paper_1004,2020.0,3.0,82,12,True,54.0,8.0,True
cord-001005,Analysis of transmission and immunity and antiviral and pneumonia in clinical settings,This study examines transmission with 181 word abstract...,"Author1005_1, Author1005_2",Lancet,2021-12-27,bioRxiv,10.1000/sample.1005,,https://example.com/paper_1005,2021.0,12.0,86,12,True,58.0,8.0,True
cord-001006,Analysis of pandemic and vaccination and public health and outbreak in clinical settings,This study examines pandemic with 326 word abstract...,"Author1006_1, Author1006_2",Lancet,2020-05-17,WHO,10.1000/sample.1006,PMC1001006,https://example.com/paper_1006,2020.0,5.0,88,13,True,54.0,8.0,True
cord-001007,Analysis of treatment and therapeutic and vaccination and symptoms in clinical settings,This study examines treatment with 442 word abstract...,"Author1007_1, Author1007_2",Virology,2021-01-08,Medline,10.1000/sample.1007,PMC1001007,https://example.com/paper_1007,2021.0,1.0,87,12,True,55.0,8.0,True
cord-001008,Analysis of transmission and immunity and public health in clinical settings,This study examines transmission with 447 word abstract...,"Author1008_1, Author1008_2",Journal of Medical Virology,2021-04-27,medRxiv,10.1000/sample.1008,,https://example.com/paper_1008,2021.0,4.0,76,11,True,58.0,8.0,True
cord-001009,Analysis of outbreak and respiratory in clinical settings,This study examines outbreak with 250 word abstract...,"Author1009_1, Author1009_2",Clinical Infectious Diseases,2021-05-17,ArXiv,10.1000/sample.1009,PMC1001009,https://example.com/paper_1009,2021.0,5.0,57,8,True,54.0,8.0,True
cord-001010,Analysis of epidemiology and coronavirus in clinical settings,This study examines epidemiology with 473 word abstract...,"Author1010_1, Author1010_2",Virology,2020-03-14,medRxiv,10.1000/sample.1010,PMC1001010,https://example.com/paper_1010,2020.0,3.0,61,8,True,58.0,8.0,True
cord-001011,Analysis of transmission and respiratory and therapeutic in clinical settings,This study examines transmission with 200 word abstract...,"Author1011_1, Author1011_2",BMJ,2019-12-21,WHO,10.1000/sample.1011,,https://example.com/paper_1011,2019.0,12.0,77,10,True,58.0,8.0,True
cord-001012,Analysis of pneumonia and SARS-CoV-2 and epidemiology in clinical settings,This study examines pneumonia with 460 word abstract...,"Author1012_1, Author1012_2",,2020-12-29,PMC,10.1000/sample.1012,PMC1001012,https://example.com/paper_1012,2020.0,12.0,74,10,True,55.0,8.0,False
cord-001013,Analysis of epidemiology and pneumonia and treatment and therapeutic in clinical settings,This study examines epidemiology with 485 word abstract...,"Author1013_1, Author1013_2",Science Translational Medicine,2021-04-05,medRxiv,10.1000/sample.1013,,,2021.0,4.0,89,12,True,58.0,8.0,True
cord-001014,Analysis of SARS-CoV-2 and therapeutic in clinical settings,This study examines SARS-CoV-2 with 451 word abstract...,"Author1014_1, Author1014_2",New England Journal of Medicine,2020-04-13,bioRxiv,10.1000/sample.1014,PMC1001014,https://example.com/paper_1014,2020.0,4.0,59,8,True,56.0,8.0,True
cord-001015,Analysis of coronavirus and antiviral and clinical and respiratory in clinical settings,This study examines coronavirus with 235 word abstract...,"Author1015_1, Author1015_2",Science,2021-04-01,medRxiv,10.1000/sample.1015,PMC1001015,https://example.com/paper_1015,2021.0,4.0,87,12,True,57.0,8.0,True
cord-001016,Analysis of antibody and clinical and lockdown in clinical settings,This study examines antibody with 161 word abstract...,"Author1016_1, Author1016_2",Virology,2022-12-21,WHO,10.1000/sample.1016,PMC1001016,https://example.com/paper_1016,2022.0,12.0,67,10,True,54.0,8.0,True
cord-001017,Analysis of COVID-19 and treatment in clinical settings,This study examines COVID-19 with 368 word abstract...,Author1017_1,JAMA,2021-01-05,medRxiv,,,https://example.com/paper_1017,2021.0,1.0,55,8,True,54.0,8.0,True
cord-001018,Analysis of epidemiology and antiviral and antibody in clinical settings,This study examines epidemiology with 336 word abstract...,"Author1018_1, Author1018_2",Science Translational Medicine,2022-05-15,medRxiv,10.1000/sample.1018,,https://example.com/paper_1018,2022.0,5.0,72,10,True,58.0,8.0,True
cord-001019,Analysis of pandemic and immunity in clinical settings,This study examines pandemic with 251 word abstract...,"Author1019_1, Author1019_2",Virology,2021-05-29,Medline,10.1000/sample.1019,PMC1001019,https://example.com/paper_1019,2021.0,5.0,54,8,True,54.0,8.0,True
cord-001020,Analysis of transmission and lockdown and clinical and symptoms in clinical settings,This study examines transmission with 467 word abstract...,"Author1020_1, Author1020_2",Clinical Infectious Diseases,2020-09-22,medRxiv,10.1000/sample.1020,PMC1001020,https://example.com/paper_1020,2020.0,9.0,84,12,True,58.0,8.0,True
cord-001022,Analysis of public health and outbreak and vaccination and therapeutic in clinical settings,,"Author1022_1, Author1022_2",PLoS ONE,2021-06-09,medRxiv,10.1000/sample.1022,PMC1001022,https://example.com/paper_1022,2021.0,6.0,91,13,False,,,True
cord-001023,Analysis of symptoms and antibody and COVID-19 and lockdown in clinical settings,,Author1023_1,Journal of Medical Virology,2020-10-19,medRxiv,10.1000/sample.1023,PMC1001023,https://example.com/paper_1023,2020.0,10.0,80,12,False,,,True
cord-001024,Analysis of public health and coronavirus and vaccination and immunity in clinical settings,This study examines public health with 322 word abstract...,,BMJ,2021-09-30,medRxiv,10.1000/sample.1024,PMC1001024,https://example.com/paper_1024,2021.0,9.0,91,13,True,59.0,9.0,True
cord-001026,Analysis of outbreak and lockdown and pandemic and treatment in clinical settings,This study examines outbreak with 433 word abstract...,"Author1026_1, Author1026_2",Emerging Infectious Diseases,2021-07-31,PMC,10.1000/sample.1026,PMC1001026,https://example.com/paper_1026,2021.0,7.0,81,12,True,54.0,8.0,True
cord-001027,Analysis of therapeutic and pneumonia in clinical settings,This study examines therapeutic with 286 word abstract...,Author1027_1,Cell,2020-08-30,ArXiv,10.1000/sample.1027,PMC1001027,https://example.com/paper_1027,2020.0,8.0,58,8,True,57.0,8.0,True
cord-001028,Analysis of coronavirus and clinical and SARS-CoV-2 in clinical settings,This study examines coronavirus with 364 word abstract...,"Author1028_1, Author1028_2",Science Translational Medicine,2019-12-16,Medline,10.1000/sample.1028,PMC1001028,https://example.com/paper_1028,2019.0,12.0,72,10,True,57.0,8.0,True
cord-001029,Analysis of lockdown and clinical and immunity in clinical settings,This study examines lockdown with 166 word abstract...,"Author1029_1, Author1029_2",PLoS ONE,2021-04-17,ArXiv,10.1000/sample.1029,PMC1001029,https://example.com/paper_1029,2021.0,4.0,67,10,True,54.0,8.0,True
cord-001030,Analysis of public health and SARS-CoV-2 in clinical settings,This study examines public health with 395 word abstract...,"Author1030_1, Author1030_2",Journal of Medical Virology,2021-10-26,PMC,10.1000/sample.1030,PMC1001030,https://example.com/paper_1030,2021.0,10.0,61,9,True,59.0,9.0,True
cord-001031,Analysis of therapeutic and coronavirus and symptoms in clinical settings,This study examines therapeutic with 317 word abstract...,"Author1031_1, Author1031_2",New England Journal of Medicine,2021-12-01,ArXiv,10.1000/sample.1031,,https://example.com/paper_1031,2021.0,12.0,73,10,True,57.0,8.0,True
cord-001032,Analysis of therapeutic and coronavirus and outbreak in clinical settings,This study examines therapeutic with 165 word abstract...,"Author1032_1, Author1032_2",JAMA,2022-01-06,WHO,10.1000/sample.1032,PMC1001032,https://example.com/paper_1032,2022.0,1.0,73,10,True,57.0,8.0,True
cord-001033,Analysis of antiviral and respiratory and outbreak and symptoms in clinical settings,This study examines antiviral with 389 word abstract...,"Author1033_1, Author1033_2",,2021-02-06,bioRxiv,10.1000/sample.1033,PMC1001033,,2021.0,2.0,84,12,True,55.0,8.0,False
cord-001034,Analysis of immunity and public health in clinical settings,This study examines immunity with 167 word abstract...,"Author1034_1, Author1034_2",Science,,bioRxiv,10.1000/sample.1034,PMC1001034,https://example.com/paper_1034,,,59,9,True,54.0,8.0,True
cord-001035,Analysis of clinical and diagnosis and transmission and COVID-19 in clinical settings,This study examines clinical with 155 word abstract...,"Author1035_1, Author1035_2",Science,2020-09-02,Medline,10.1000/sample.1035,PMC1001035,https://example.com/paper_1035,2020.0,9.0,85,12,True,54.0,8.0,True
cord-001036,Analysis of immunity and pandemic and COVID-19 in clinical settings,This study examines immunity with 437 word abstract...,"Author1036_1, Author1036_2",Science Translational Medicine,2019-12-24,ArXiv,,PMC1001036,https://example.com/paper_1036,2019.0,12.0,67,10,True,54.0,8.0,True
cord-001037,Analysis of outbreak and symptoms and respiratory in clinical settings,This study examines outbreak with 110 word abstract...,"Author1037_1, Author1037_2",Nature Medicine,2021-10-08,Medline,,,https://example.com/paper_1037,2021.0,10.0,70,10,True,54.0,8.0,True
cord-001038,Analysis of SARS-CoV-2 and symptoms and transmission and clinical in clinical settings,This study examines SARS-CoV-2 with 385 word abstract...,Author1038_1,,2021-11-08,Medline,10.1000/sample.1038,PMC1001038,https://example.com/paper_1038,2021.0,11.0,86,12,True,56.0,8.0,False
cord-001039,Analysis of vaccination and respiratory and public health in clinical settings,This study examines vaccination with 320 word abstract...,"Author1039_1, Author1039_2",Nature Medicine,2020-01-31,Medline,10.1000/sample.1039,PMC1001039,https://example.com/paper_1039,2020.0,1.0,78,11,True,57.0,8.0,True
cord-001040,Analysis of coronavirus and therapeutic and outbreak in clinical settings,This study examines coronavirus with 110 word abstract...,"Author1040_1, Author1040_2",Journal of Medical Virology,,PMC,10.1000/sample.1040,PMC1001040,https://example.com/paper_1040,,,73,10,True,57.0,8.0,True
cord-001042,Analysis of symptoms and diagnosis and pneumonia and SARS-CoV-2 in clinical settings,This study examines symptoms with 440 word abstract...,"Author1042_1, Author1042_2",JAMA,2022-04-03,bioRxiv,10.1000/sample.1042,,https://example.com/paper_1042,2022.0,4.0,84,12,True,54.0,8.0,True
cord-001045,Analysis of vaccination and immunity and pneumonia in clinical settings,This study examines vaccination with 395 word abstract...,"Author1045_1, Author1045_2",Emerging Infectious Diseases,,WHO,10.1000/sample.1045,PMC1001045,https://example.com/paper_1045,,,71,10,True,57.0,8.0,True
cord-001047,Analysis of antiviral and immunity and vaccination in clinical settings,,"Author1047_1, Author1047_2",Journal of Virology,2021-04-11,bioRxiv,10.1000/sample.1047,PMC1001047,https://example.com/paper_1047,2021.0,4.0,71,10,False,,,True
cord-001048,Analysis of public health and treatment and epidemiology and antibody in clinical settings,This study examines public health with 248 word abstract...,"Author1048_1, Author1048_2",Journal of Virology,2020-11-12,bioRxiv,10.1000/sample.1048,PMC1001048,https://example.com/paper_1048,2020.0,11.0,90,13,True,59.0,9.0,True
cord-001049,Analysis of coronavirus and SARS-CoV-2 and outbreak and immunity in clinical settings,This study examines coronavirus with 365 word abstract...,"Author1049_1, Author1049_2",Journal of Medical Virology,2022-12-19,bioRxiv,10.1000/sample.1049,PMC1001049,,2022.0,12.0,85,12,True,57.0,8.0,True
cord-001052,Analysis of lockdown and public health and symptoms and diagnosis in clinical settings,This study examines lockdown with 381 word abstract...,"Author1052_1, Author1052_2",Cell,2019-12-16,Medline,10.1000/sample.1052,PMC1001052,https://example.com/paper_1052,2019.0,12.0,86,13,True,54.0,8.0,True
cord-001053,Analysis of antiviral and coronavirus in clinical settings,This study examines antiviral with 232 word abstract...,"Author1053_1, Author1053_2",Lancet,2019-12-26,Medline,10.1000/sample.1053,PMC1001053,https://example.com/paper_1053,2019.0,12.0,58,8,True,55.0,8.0,True
cord-001054,Analysis of lockdown and transmission and treatment in clinical settings,,"Author1054_1, Author1054_2",New England Journal of Medicine,2020-09-18,bioRxiv,10.1000/sample.1054,PMC1001054,https://example.com/paper_1054,2020.0,9.0,72,10,False,,,True
cord-001055,Analysis of lockdown and transmission and immunity and public health in clinical settings,This study examines lockdown with 440 word abstract...,Author1055_1,Nature Medicine,2021-03-29,PMC,10.1000/sample.1055,PMC1001055,https://example.com/paper_1055,2021.0,3.0,89,13,True,54.0,8.0,True
cord-001057,Analysis of immunity and pandemic and coronavirus and antibody in clinical settings,This study examines immunity with 393 word abstract...,"Author1057_1, Author1057_2",Lancet,2020-11-08,ArXiv,10.1000/sample.1057,PMC1001057,https://example.com/paper_1057,2020.0,11.0,83,12,True,54.0,8.0,True
cord-001059,Analysis of pneumonia and COVID-19 and outbreak and vaccination in clinical settings,This study examines pneumonia with 104 word abstract...,"Author1059_1, Author1059_2",Journal of Virology,2021-05-17,ArXiv,,,https://example.com/paper_1059,2021.0,5.0,84,12,True,55.0,8.0,True
cord-001061,Analysis of therapeutic and immunity and diagnosis and vaccination in clinical settings,This study examines therapeutic with 166 word abstract...,"Author1061_1, Author1061_2",Virology,2019-12-26,ArXiv,10.1000/sample.1061,,https://example.com/paper_1061,2019.0,12.0,87,12,True,57.0,8.0,True
cord-001062,Analysis of outbreak and pandemic and vaccination and pneumonia in clinical settings,This study examines outbreak with 353 word abstract...,"Author1062_1, Author1062_2",Nature,2020-05-02,PMC,,,,2020.0,5.0,84,12,True,54.0,8.0,True
cord-001063,Analysis of public health and pandemic and diagnosis in clinical settings,This study examines public health with 235 word abstract...,"Author1063_1, Author1063_2",Lancet,2021-12-30,medRxiv,10.1000/sample.1063,,https://example.com/paper_1063,2021.0,12.0,73,11,True,59.0,9.0,True
cord-001064,Analysis of pandemic and transmission and diagnosis in clinical settings,This study examines pandemic with 493 word abstract...,"Author1064_1, Author1064_2",Cell,2021-04-08,Medline,10.1000/sample.1064,PMC1001064,https://example.com/paper_1064,2021.0,4.0,72,10,True,54.0,8.0,True
cord-001065,Analysis of SARS-CoV-2 and epidemiology and pneumonia and respiratory in clinical settings,This study examines SARS-CoV-2 with 101 word abstract...,"Author1065_1, Author1065_2",Emerging Infectious Diseases,,Medline,10.1000/sample.1065,PMC1001065,https://example.com/paper_1065,,,90,12,True,56.0,8.0,True
cord-001068,Analysis of symptoms and therapeutic and transmission and diagnosis in clinical settings,,"Author1068_1, Author1068_2",Journal of Medical Virology,2020-07-29,bioRxiv,10.1000/sample.1068,PMC1001068,,2020.0,7.0,88,12,False,,,True
cord-001069,Analysis of therapeutic and COVID-19 and treatment in clinical settings,This study examines therapeutic with 457 word abstract...,"Author1069_1, Author1069_2",Nature,2020-04-11,Medline,10.1000/sample.1069,PMC1001069,https://example.com/paper_1069,2020.0,4.0,71,10,True,57.0,8.0,True
cord-001070,Analysis of transmission and immunity and treatment in clinical settings,This study examines transmission with 387 word abstract...,"Author1070_1, Author1070_2",Nature Medicine,2021-10-29,medRxiv,10.1000/sample.1070,,https://example.com/paper_1070,2021.0,10.0,72,10,True,58.0,8.0,True
cord-001073,Analysis of pandemic and antiviral and vaccination in clinical settings,This study examines pandemic with 388 word abstract...,"Author1073_1, Author1073_2",Clinical Infectious Diseases,2019-12-29,medRxiv,10.1000/sample.1073,PMC1001073,https://example.com/paper_1073,2019.0,12.0,71,10,True,54.0,8.0,True
cord-001074,Analysis of epidemiology and lockdown and coronavirus in clinical settings,This study examines epidemiology with 407 word abstract...,"Author1074_1, Author1074_2",PLoS ONE,2020-09-22,medRxiv,10.1000/sample.1074,PMC1001074,https://example.com/paper_1074,2020.0,9.0,74,10,True,58.0,8.0,True
cord-001076,Analysis of epidemiology and pandemic and immunity and symptoms in clinical settings,This study examines epidemiology with 322 word abstract...,"Author1076_1, Author1076_2",JAMA,2021-09-04,WHO,10.1000/sample.1076,,,2021.0,9.0,84,12,True,58.0,8.0,True
cord-001077,Analysis of therapeutic and respiratory and epidemiology in clinical settings,,"Author1077_1, Author1077_2",BMJ,2020-11-12,bioRxiv,10.1000/sample.1077,PMC1001077,https://example.com/paper_1077,2020.0,11.0,77,10,False,,,True
cord-001078,Analysis of public health and treatment and respiratory in clinical settings,This study examines public health with 108 word abstract...,"Author1078_1, Author1078_2",Science,2021-12-17,WHO,,PMC1001078,https://example.com/paper_1078,2021.0,12.0,76,11,True,59.0,9.0,True
cord-001079,Analysis of pandemic and lockdown in clinical settings,This study examines pandemic with 175 word abstract...,"Author1079_1, Author1079_2",Nature Medicine,2019-12-03,Medline,10.1000/sample.1079,,,2019.0,12.0,54,8,True,54.0,8.0,True
cord-001080,Analysis of lockdown and antiviral in clinical settings,This study examines lockdown with 279 word abstract...,"Author1080_1, Author1080_2",Emerging Infectious Diseases,2020-10-19,WHO,,,https://example.com/paper_1080,2020.0,10.0,55,8,True,54.0,8.0,True
cord-001083,Analysis of vaccination and outbreak and therapeutic and public health in clinical settings,This study examines vaccination with 498 word abstract...,"Author1083_1, Author1083_2",Virology,2021-11-17,PMC,10.1000/sample.1083,PMC1001083,https://example.com/paper_1083,2021.0,11.0,91,13,True,57.0,8.0,True
cord-001084,Analysis of vaccination and public health and pandemic in clinical settings,This study examines vaccination with 361 word abstract...,"Author1084_1, Author1084_2",Clinical Infectious Diseases,2020-01-04,WHO,10.1000/sample.1084,PMC1001084,,2020.0,1.0,75,11,True,57.0,8.0,True
cord-001085,Analysis of treatment and public health and antiviral and COVID-19 in clinical settings,This study examines treatment with 264 word abstract...,"Author1085_1, Author1085_2",BMJ,2021-12-24,ArXiv,,PMC1001085,https://example.com/paper_1085,2021.0,12.0,87,13,True,55.0,8.0,True
cord-001086,Analysis of antiviral and pneumonia and antibody in clinical settings,This study examines antiviral with 485 word abstract...,"Author1086_1, Author1086_2",Science,2021-01-07,PMC,10.1000/sample.1086,PMC1001086,https://example.com/paper_1086,2021.0,1.0,69,10,True,55.0,8.0,True
cord-001087,Analysis of lockdown and public health and clinical in clinical settings,This study examines lockdown with 462 word abstract...,"Author1087_1, Author1087_2",Science Translational Medicine,2021-08-10,WHO,10.1000/sample.1087,PMC1001087,https://example.com/paper_1087,2021.0,8.0,72,11,True,54.0,8.0,True
cord-001089,Analysis of clinical and antiviral and epidemiology and COVID-19 in clinical settings,This study examines clinical with 348 word abstract...,"Author1089_1, Author1089_2",Journal of Virology,2020-09-19,medRxiv,10.1000/sample.1089,PMC1001089,,2020.0,9.0,85,12,True,54.0,8.0,True
cord-001090,Analysis of therapeutic and SARS-CoV-2 and vaccination in clinical settings,,,Virology,2021-10-28,Medline,10.1000/sample.1090,,https://example.com/paper_1090,2021.0,10.0,75,10,False,,,True
cord-001091,Analysis of treatment and outbreak in clinical settings,This study examines treatment with 283 word abstract...,"Author1091_1, Author1091_2",Clinical Infectious Diseases,2021-01-02,Medline,10.1000/sample.1091,PMC1001091,https://example.com/paper_1091,2021.0,1.0,55,8,True,55.0,8.0,True
cord-001092,Analysis of clinical and vaccination and immunity in clinical settings,This study examines clinical with 352 word abstract...,"Author1092_1, Author1092_2",Nature Medicine,2020-04-03,bioRxiv,,PMC1001092,https://example.com/paper_1092,2020.0,4.0,70,10,True,54.0,8.0,True
cord-001093,Analysis of SARS-CoV-2 and vaccination and pneumonia in clinical settings,This study examines SARS-CoV-2 with 425 word abstract...,"Author1093_1, Author1093_2",BMJ,2020-03-20,medRxiv,,,https://example.com/paper_1093,2020.0,3.0,73,10,True,56.0,8.0,True
cord-001094,Analysis of diagnosis and coronavirus in clinical settings,This study examines diagnosis with 436 word abstract...,"Author1094_1, Author1094_2",JAMA,2020-06-12,WHO,10.1000/sample.1094,PMC1001094,https://example.com/paper_1094,2020.0,6.0,58,8,True,55.0,8.0,True
cord-001095,Analysis of pandemic and vaccination and clinical and respiratory in clinical settings,This study examines pandemic with 282 word abstract...,"Author1095_1, Author1095_2",Clinical Infectious Diseases,2021-10-16,medRxiv,,PMC1001095,https://example.com/paper_1095,2021.0,10.0,86,12,True,54.0,8.0,True
cord-001096,Analysis of COVID-19 and treatment and public health in clinical settings,This study examines COVID-19 with 478 word abstract...,"Author1096_1, Author1096_2",,2020-12-08,ArXiv,10.1000/sample.1096,PMC1001096,https://example.com/paper_1096,2020.0,12.0,73,11,True,54.0,8.0,False
cord-001099,Analysis of clinical and symptoms and pneumonia in clinical settings,This study examines clinical with 444 word abstract...,Author1099_1,PLoS ONE,2020-02-28,PMC,10.1000/sample.1099,PMC1001099,https://example.com/paper_1099,2020.0,2.0,68,10,True,54.0,8.0,True
cord-001100,Analysis of SARS-CoV-2 and pneumonia and lockdown and symptoms in clinical settings,This study examines SARS-CoV-2 with 287 word abstract...,"Author1100_1, Author1100_2",Nature,2020-12-19,PMC,10.1000/sample.1100,PMC1001100,https://example.com/paper_1100,2020.0,12.0,83,12,True,56.0,8.0,True
cord-001101,Analysis of coronavirus and transmission and symptoms and treatment in clinical settings,This study examines coronavirus with 172 word abstract...,"Author1101_1, Author1101_2",Virology,2021-11-13,Medline,10.1000/sample.1101,PMC1001101,,2021.0,11.0,88,12,True,57.0,8.0,True
cord-001102,Analysis of outbreak and SARS-CoV-2 and transmission and lockdown in clinical settings,This study examines outbreak with 325 word abstract...,Author1102_1,New England Journal of Medicine,2022-08-27,Medline,,,https://example.com/paper_1102,2022.0,8.0,86,12,True,54.0,8.0,True
cord-001103,Analysis of pneumonia and therapeutic and antiviral in clinical settings,This study examines pneumonia with 117 word abstract...,"Author1103_1, Author1103_2",Nature,2021-10-15,WHO,10.1000/sample.1103,PMC1001103,https://example.com/paper_1103,2021.0,10.0,72,10,True,55.0,8.0,True
cord-001104,Analysis of COVID-19 and clinical and pandemic in clinical settings,,"Author1104_1, Author1104_2",Nature Medicine,2020-04-02,PMC,10.1000/sample.1104,,https://example.com/paper_1104,2020.0,4.0,67,10,False,,,True
cord-001105,Analysis of immunity and lockdown in clinical settings,This study examines immunity with 495 word abstract...,Author1105_1,,2022-05-29,bioRxiv,10.1000/sample.1105,PMC1001105,,2022.0,5.0,54,8,True,54.0,8.0,False
cord-001106,Analysis of coronavirus and symptoms and transmission in clinical settings,This study examines coronavirus with 400 word abstract...,"Author1106_1, Author1106_2",BMJ,2021-05-25,Medline,10.1000/sample.1106,,https://example.com/paper_1106,2021.0,5.0,74,10,True,57.0,8.0,True
cord-001107,Analysis of pneumonia and antiviral and immunity and COVID-19 in clinical settings,This study examines pneumonia with 146 word abstract...,"Author1107_1, Author1107_2",Clinical Infectious Diseases,2020-04-22,medRxiv,10.1000/sample.1107,PMC1001107,https://example.com/paper_1107,2020.0,4.0,82,12,True,55.0,8.0,True
cord-001108,Analysis of pneumonia and outbreak and clinical and diagnosis in clinical settings,This study examines pneumonia with 477 word abstract...,"Author1108_1, Author1108_2",Virology,2021-10-27,Medline,10.1000/sample.1108,,https://example.com/paper_1108,2021.0,10.0,82,12,True,55.0,8.0,True
cord-001109,Analysis of vaccination and symptoms and antiviral and COVID-19 in clinical settings,,"Author1109_1, Author1109_2",Clinical Infectious Diseases,2020-04-30,PMC,10.1000/sample.1109,,,2020.0,4.0,84,12,False,,,True
cord-001110,Analysis of lockdown and therapeutic and coronavirus and antibody in clinical settings,This study examines lockdown with 218 word abstract...,"Author1110_1, Author1110_2",Journal of Virology,2021-02-13,ArXiv,10.1000/sample.1110,PMC1001110,,2021.0,2.0,86,12,True,54.0,8.0,True
cord-001111,Analysis of pandemic and SARS-CoV-2 and public health in clinical settings,This study examines pandemic with 130 word abstract...,"Author1111_1, Author1111_2",Virology,2019-12-22,ArXiv,10.1000/sample.1111,,,2019.0,12.0,74,11,True,54.0,8.0,True
cord-001112,Analysis of clinical and symptoms and antibody and pandemic in clinical settings,This study examines clinical with 384 word abstract...,"Author1112_1, Author1112_2",Virology,2021-09-28,bioRxiv,10.1000/sample.1112,PMC1001112,,2021.0,9.0,80,12,True,54.0,8.0,True
cord-001115,Analysis of coronavirus and diagnosis in clinical settings,This study examines coronavirus with 340 word abstract...,"Author1115_1, Author1115_2",Clinical Infectious Diseases,2020-10-11,bioRxiv,10.1000/sample.1115,PMC1001115,,2020.0,10.0,58,8,True,57.0,8.0,True
cord-001116,Analysis of vaccination and SARS-CoV-2 and outbreak in clinical settings,This study examines vaccination with 317 word abstract...,"Author1116_1, Author1116_2",New England Journal of Medicine,2020-01-16,bioRxiv,10.1000/sample.1116,PMC1001116,,2020.0,1.0,72,10,True,57.0,8.0,True
cord-001117,Analysis of therapeutic and epidemiology and SARS-CoV-2 in clinical settings,This study examines therapeutic with 147 word abstract...,Author1117_1,Journal of Medical Virology,2021-07-25,WHO,,PMC1001117,,2021.0,7.0,76,10,True,57.0,8.0,True
cord-001119,Analysis of symptoms and therapeutic and vaccination and diagnosis in clinical settings,This study examines symptoms with 111 word abstract...,"Author1119_1, Author1119_2",Science Translational Medicine,2020-08-19,PMC,10.1000/sample.1119,PMC1001119,https://example.com/paper_1119,2020.0,8.0,87,12,True,54.0,8.0,True
cord-001120,Analysis of therapeutic and coronavirus and immunity in clinical settings,This study examines therapeutic with 426 word abstract...,"Author1120_1, Author1120_2",Virology,2020-06-28,Medline,,,https://example.com/paper_1120,2020.0,6.0,73,10,True,57.0,8.0,True
cord-001123,Analysis of coronavirus and diagnosis and public health and pneumonia in clinical settings,,"Author1123_1, Author1123_2",,2020-09-11,PMC,10.1000/sample.1123,PMC1001123,https://example.com/paper_1123,2020.0,9.0,90,13,False,,,False
cord-001124,Analysis of coronavirus and outbreak and immunity in clinical settings,This study examines coronavirus with 317 word abstract...,Author1124_1,Lancet,2019-12-01,WHO,,PMC1001124,https://example.com/paper_1124,2019.0,12.0,70,10,True,57.0,8.0,True
cord-001125,Analysis of diagnosis and epidemiology and transmission and respiratory in clinical settings,This study examines diagnosis with 219 word abstract...,"Author1125_1, Author1125_2",Nature,2020-02-21,medRxiv,10.1000/sample.1125,PMC1001125,https://example.com/paper_1125,2020.0,2.0,92,12,True,55.0,8.0,True
cord-001126,Analysis of vaccination and treatment and respiratory and COVID-19 in clinical settings,This study examines vaccination with 435 word abstract...,"Author1126_1, Author1126_2",Journal of Virology,2019-12-26,WHO,10.1000/sample.1126,PMC1001126,,2019.0,12.0,87,12,True,57.0,8.0,True
cord-001127,Analysis of coronavirus and COVID-19 and transmission in clinical settings,This study examines coronavirus with 232 word abstract...,"Author1127_1, Author1127_2",Journal of Medical Virology,2021-11-20,medRxiv,10.1000/sample.1127,PMC1001127,https://example.com/paper_1127,2021.0,11.0,74,10,True,57.0,8.0,True
cord-001128,Analysis of pneumonia and public health and symptoms and immunity in clinical settings,This study examines pneumonia with 283 word abstract...,"Author1128_1, Author1128_2",BMJ,2020-03-20,PMC,10.1000/sample.1128,PMC1001128,https://example.com/paper_1128,2020.0,3.0,86,13,True,55.0,8.0,True
cord-001129,Analysis of antiviral and pandemic and immunity in clinical settings,This study examines antiviral with 145 word abstract...,Author1129_1,Science,,ArXiv,,PMC1001129,https://example.com/paper_1129,,,68,10,True,55.0,8.0,True
cord-001130,Analysis of transmission and treatment and respiratory and coronavirus in clinical settings,This study examines transmission with 405 word abstract...,"Author1130_1, Author1130_2",Journal of Medical Virology,2020-10-14,Medline,,PMC1001130,,2020.0,10.0,91,12,True,58.0,8.0,True
cord-001131,Analysis of lockdown and pandemic and clinical in clinical settings,This study examines lockdown with 443 word abstract...,"Author1131_1, Author1131_2",Virology,2020-02-05,medRxiv,10.1000/sample.1131,,https://example.com/paper_1131,2020.0,2.0,67,10,True,54.0,8.0,True
cord-001132,Analysis of coronavirus and transmission and antibody and therapeutic in clinical settings,This study examines coronavirus with 134 word abstract...,"Author1132_1, Author1132_2",Lancet,2019-12-13,WHO,10.1000/sample.1132,,https://example.com/paper_1132,2019.0,12.0,90,12,True,57.0,8.0,True
cord-001135,Analysis of therapeutic and outbreak in clinical settings,This study examines therapeutic with 354 word abstract...,,Cell,2019-12-12,PMC,10.1000/sample.1135,PMC1001135,https://example.com/paper_1135,2019.0,12.0,57,8,True,57.0,8.0,True
cord-001136,Analysis of coronavirus and immunity in clinical settings,This study examines coronavirus with 203 word abstract...,"Author1136_1, Author1136_2",Science,2022-07-09,WHO,10.1000/sample.1136,,https://example.com/paper_1136,2022.0,7.0,57,8,True,57.0,8.0,True
cord-001137,Analysis of vaccination and therapeutic and diagnosis and COVID-19 in clinical settings,This study examines vaccination with 106 word abstract...,"Author1137_1, Author1137_2",Clinical Infectious Diseases,2019-12-14,WHO,10.1000/sample.1137,PMC1001137,https://example.com/paper_1137,2019.0,12.0,87,12,True,57.0,8.0,True
cord-001138,Analysis of coronavirus and antibody and COVID-19 and public health in clinical settings,This study examines coronavirus with 399 word abstract...,"Author1138_1, Author1138_2",Emerging Infectious Diseases,2021-07-27,PMC,10.1000/sample.1138,,,2021.0,7.0,88,13,True,57.0,8.0,True
cord-001139,Analysis of antiviral and outbreak and pandemic in clinical settings,This study examines antiviral with 252 word abstract...,Author1139_1,PLoS ONE,2021-11-03,bioRxiv,10.1000/sample.1139,,https://example.com/paper_1139,2021.0,11.0,68,10,True,55.0,8.0,True
cord-001142,Analysis of symptoms and transmission in clinical settings,This study examines symptoms with 168 word abstract...,Author1142_1,BMJ,2021-07-31,ArXiv,10.1000/sample.1142,,https://example.com/paper_1142,2021.0,7.0,58,8,True,54.0,8.0,True
cord-001143,Analysis of symptoms and clinical and coronavirus in clinical settings,This study examines symptoms with 181 word abstract...,"Author1143_1, Author1143_2",Journal of Medical Virology,2021-04-13,Medline,,PMC1001143,https://example.com/paper_1143,2021.0,4.0,70,10,True,54.0,8.0,True
cord-001145,Analysis of treatment and pandemic and symptoms and antiviral in clinical settings,This study examines treatment with 263 word abstract...,"Author1145_1, Author1145_2",Nature,2020-08-05,PMC,10.1000/sample.1145,PMC1001145,https://example.com/paper_1145,2020.0,8.0,82,12,True,55.0,8.0,True
cord-001146,Analysis of coronavirus and SARS-CoV-2 in clinical settings,This study examines coronavirus with 204 word abstract...,"Author1146_1, Author1146_2",Journal of Virology,2020-08-20,Medline,10.1000/sample.1146,PMC1001146,https://example.com/paper_1146,2020.0,8.0,59,8,True,57.0,8.0,True
cord-001147,Analysis of outbreak and SARS-CoV-2 and epidemiology in clinical settings,This study examines outbreak with 196 word abstract...,"Author1147_1, Author1147_2",BMJ,2020-11-12,WHO,10.1000/sample.1147,PMC1001147,,2020.0,11.0,73,10,True,54.0,8.0,True
cord-001149,Analysis of transmission and immunity and pandemic and treatment in clinical settings,This study examines transmission with 277 word abstract...,"Author1149_1, Author1149_2",Emerging Infectious Diseases,2021-11-01,WHO,10.1000/sample.1149,PMC1001149,https://example.com/paper_1149,2021.0,11.0,85,12,True,58.0,8.0,True
cord-001150,Analysis of lockdown and public health and pneumonia and immunity in clinical settings,This study examines lockdown with 166 word abstract...,"Author1150_1, Author1150_2",Cell,,bioRxiv,10.1000/sample.1150,,https://example.com/paper_1150,,,86,13,True,54.0,8.0,True
cord-001152,Analysis of symptoms and respiratory in clinical settings,This study examines symptoms with 304 word abstract...,"Author1152_1, Author1152_2",Nature Medicine,2021-01-31,bioRxiv,10.1000/sample.1152,PMC1001152,https://example.com/paper_1152,2021.0,1.0,57,8,True,54.0,8.0,True
cord-001153,Analysis of vaccination and respiratory in clinical settings,This study examines vaccination with 132 word abstract...,"Author1153_1, Author1153_2",Cell,2020-09-30,WHO,10.1000/sample.1153,,https://example.com/paper_1153,2020.0,9.0,60,8,True,57.0,8.0,True
cord-001154,Analysis of immunity and treatment and COVID-19 and diagnosis in clinical settings,This study examines immunity with 219 word abstract...,Author1154_1,Cell,2020-07-01,ArXiv,10.1000/sample.1154,PMC1001154,,2020.0,7.0,82,12,True,54.0,8.0,True
cord-001155,Analysis of transmission and epidemiology and immunity in clinical settings,This study examines transmission with 253 word abstract...,"Author1155_1, Author1155_2",BMJ,2021-04-21,PMC,10.1000/sample.1155,PMC1001155,https://example.com/paper_1155,2021.0,4.0,75,10,True,58.0,8.0,True
cord-001157,Analysis of transmission and respiratory in clinical settings,This study examines transmission with 459 word abstract...,"Author1157_1, Author1157_2",Clinical Infectious Diseases,2020-08-21,medRxiv,10.1000/sample.1157,,https://example.com/paper_1157,2020.0,8.0,61,8,True,58.0,8.0,True
cord-001158,Analysis of coronavirus and treatment and clinical in clinical settings,This study examines coronavirus with 425 word abstract...,"Author1158_1, Author1158_2",New England Journal of Medicine,2021-02-27,WHO,10.1000/sample.1158,,https://example.com/paper_1158,2021.0,2.0,71,10,True,57.0,8.0,True
cord-001160,Analysis of epidemiology and transmission and clinical and pneumonia in clinical settings,This study examines epidemiology with 288 word abstract...,"Author1160_1, Author1160_2",Science Translational Medicine,2020-03-29,ArXiv,10.1000/sample.1160,PMC1001160,,2020.0,3.0,89,12,True,58.0,8.0,True
cord-001161,Analysis of immunity and lockdown and clinical in clinical settings,This study examines immunity with 488 word abstract...,"Author1161_1, Author1161_2",,2020-07-24,Medline,10.1000/sample.1161,,https://example.com/paper_1161,2020.0,7.0,67,10,True,54.0,8.0,False
cord-001162,Analysis of antibody and transmission and epidemiology in clinical settings,This study examines antibody with 118 word abstract...,"Author1162_1, Author1162_2",Clinical Infectious Diseases,2020-06-15,PMC,10.1000/sample.1162,PMC1001162,,2020.0,6.0,75,10,True,54.0,8.0,True
cord-001163,Analysis of SARS-CoV-2 and COVID-19 and outbreak in clinical settings,This study examines SARS-CoV-2 with 313 word abstract...,"Author1163_1, Author1163_2",New England Journal of Medicine,2020-09-22,ArXiv,10.1000/sample.1163,PMC1001163,https://example.com/paper_1163,2020.0,9.0,69,10,True,56.0,8.0,True
cord-001164,Analysis of antibody and diagnosis and SARS-CoV-2 in clinical settings,This study examines antibody with 458 word abstract...,"Author1164_1, Author1164_2",Lancet,2020-04-09,Medline,10.1000/sample.1164,,https://example.com/paper_1164,2020.0,4.0,70,10,True,54.0,8.0,True
cord-001165,Analysis of clinical and pneumonia in clinical settings,This study examines clinical with 235 word abstract...,Author1165_1,PLoS ONE,2019-12-22,WHO,10.1000/sample.1165,,https://example.com/paper_1165,2019.0,12.0,55,8,True,54.0,8.0,True
cord-001169,Analysis of treatment and SARS-CoV-2 and pandemic and antiviral in clinical settings,This study examines treatment with 354 word abstract...,"Author1169_1, Author1169_2",New England Journal of Medicine,2022-06-24,medRxiv,10.1000/sample.1169,PMC1001169,,2022.0,6.0,84,12,True,55.0,8.0,True
cord-001170,Analysis of outbreak and therapeutic and clinical in clinical settings,This study examines outbreak with 158 word abstract...,"Author1170_1, Author1170_2",Lancet,2021-09-02,PMC,10.1000/sample.1170,PMC1001170,https://example.com/paper_1170,2021.0,9.0,70,10,True,54.0,8.0,True
cord-001171,Analysis of antiviral and immunity and SARS-CoV-2 in clinical settings,This study examines antiviral with 489 word abstract...,"Author1171_1, Author1171_2",Science,2020-06-02,bioRxiv,10.1000/sample.1171,PMC1001171,https://example.com/paper_1171,2020.0,6.0,70,10,True,55.0,8.0,True
cord-001172,Analysis of antibody and epidemiology in clinical settings,This study examines antibody with 390 word abstract...,"Author1172_1, Author1172_2",New England Journal of Medicine,2020-01-28,Medline,,PMC1001172,https://example.com/paper_1172,2020.0,1.0,58,8,True,54.0,8.0,True
cord-001173,Analysis of COVID-19 and transmission and therapeutic in clinical settings,This study examines COVID-19 with 306 word abstract...,"Author1173_1, Author1173_2",Science,2020-12-16,medRxiv,10.1000/sample.1173,PMC1001173,https://example.com/paper_1173,2020.0,12.0,74,10,True,54.0,8.0,True
cord-001178,Analysis of respiratory and pandemic and epidemiology and SARS-CoV-2 in clinical settings,This study examines respiratory with 233 word abstract...,"Author1178_1, Author1178_2",Nature Medicine,2020-10-24,bioRxiv,10.1000/sample.1178,,,2020.0,10.0,89,12,True,57.0,8.0,True
cord-001179,Analysis of public health and antiviral and antibody and treatment in clinical settings,This study examines public health with 462 word abstract...,"Author1179_1, Author1179_2",Virology,2020-11-09,WHO,10.1000/sample.1179,PMC1001179,,2020.0,11.0,87,13,True,59.0,9.0,True
cord-001180,Analysis of vaccination and public health and COVID-19 in clinical settings,This study examines vaccination with 222 word abstract...,"Author1180_1, Author1180_2",,2021-12-27,PMC,10.1000/sample.1180,,https://example.com/paper_1180,2021.0,12.0,75,11,True,57.0,8.0,False
cord-001181,Analysis of pandemic and COVID-19 and pneumonia in clinical settings,This study examines pandemic with 368 word abstract...,"Author1181_1, Author1181_2",PLoS ONE,2019-12-14,medRxiv,10.1000/sample.1181,,,2019.0,12.0,68,10,True,54.0,8.0,True
cord-001183,Analysis of therapeutic and public health in clinical settings,This study examines therapeutic with 368 word abstract...,"Author1183_1, Author1183_2",Nature,2022-05-29,Medline,10.1000/sample.1183,PMC1001183,https://example.com/paper_1183,2022.0,5.0,62,9,True,57.0,8.0,True
cord-001184,Analysis of treatment and diagnosis and epidemiology in clinical settings,This study examines treatment with 137 word abstract...,"Author1184_1, Author1184_2",New England Journal of Medicine,2020-05-13,Medline,10.1000/sample.1184,PMC1001184,https://example.com/paper_1184,2020.0,5.0,73,10,True,55.0,8.0,True
cord-001185,Analysis of treatment and diagnosis and symptoms in clinical settings,This study examines treatment with 351 word abstract...,"Author1185_1, Author1185_2",Journal of Virology,2020-08-16,PMC,10.1000/sample.1185,PMC1001185,,2020.0,8.0,69,10,True,55.0,8.0,True
cord-001186,Analysis of SARS-CoV-2 and vaccination and transmission and clinical in clinical settings,This study examines SARS-CoV-2 with 352 word abstract...,,Clinical Infectious Diseases,2020-09-02,ArXiv,10.1000/sample.1186,PMC1001186,https://example.com/paper_1186,2020.0,9.0,89,12,True,56.0,8.0,True
cord-001187,Analysis of immunity and SARS-CoV-2 in clinical settings,This study examines immunity with 376 word abstract...,"Author1187_1, Author1187_2",Science Translational Medicine,2019-12-21,WHO,10.1000/sample.1187,PMC1001187,https://example.com/paper_1187,2019.0,12.0,56,8,True,54.0,8.0,True
cord-001188,Analysis of clinical and diagnosis and epidemiology in clinical settings,This study examines clinical with 477 word abstract...,"Author1188_1, Author1188_2",Clinical Infectious Diseases,2022-09-11,medRxiv,10.1000/sample.1188,PMC1001188,https://example.com/paper_1188,2022.0,9.0,72,10,True,54.0,8.0,True
cord-001189,Analysis of therapeutic and outbreak and antibody and SARS-CoV-2 in clinical settings,This study examines therapeutic with 473 word abstract...,"Author1189_1, Author1189_2",Journal of Virology,2021-12-04,Medline,,PMC1001189,https://example.com/paper_1189,2021.0,12.0,85,12,True,57.0,8.0,True
cord-001190,Analysis of outbreak and public health and immunity and antibody in clinical settings,This study examines outbreak with 363 word abstract...,"Author1190_1, Author1190_2",Emerging Infectious Diseases,2020-09-25,Medline,10.1000/sample.1190,PMC1001190,https://example.com/paper_1190,2020.0,9.0,85,13,True,54.0,8.0,True
cord-001191,Analysis of coronavirus and pandemic and symptoms and respiratory in clinical settings,This study examines coronavirus with 367 word abstract...,"Author1191_1, Author1191_2",New England Journal of Medicine,2020-06-07,medRxiv,,PMC1001191,https://example.com/paper_1191,2020.0,6.0,86,12,True,57.0,8.0,True
cord-001192,Analysis of treatment and pneumonia in clinical settings,This study examines treatment with 249 word abstract...,Author1192_1,Clinical Infectious Diseases,2019-12-14,bioRxiv,10.1000/sample.1192,PMC1001192,,2019.0,12.0,56,8,True,55.0,8.0,True
cord-001193,Analysis of therapeutic and treatment in clinical settings,This study examines therapeutic with 445 word abstract...,"Author1193_1, Author1193_2",New England Journal of Medicine,2022-03-24,Medline,10.1000/sample.1193,,https://example.com/paper_1193,2022.0,3.0,58,8,True,57.0,8.0,True
cord-001196,Analysis of symptoms and clinical and pneumonia and coronavirus in clinical settings,This study examines symptoms with 110 word abstract...,"Author1196_1, Author1196_2",Journal of Medical Virology,2020-07-29,bioRxiv,10.1000/sample.1196,PMC1001196,,2020.0,7.0,84,12,True,54.0,8.0,True
cord-001197,Analysis of epidemiology and diagnosis and coronavirus and pandemic in clinical settings,This study examines epidemiology with 471 word abstract...,"Author1197_1, Author1197_2",Virology,2021-11-11,Medline,10.1000/sample.1197,,https://example.com/paper_1197,2021.0,11.0,88,12,True,58.0,8.0,True
cord-001198,Analysis of coronavirus and public health and lockdown in clinical settings,This study examines coronavirus with 487 word abstract...,"Author1198_1, Author1198_2",Science Translational Medicine,2022-11-16,Medline,10.1000/sample.1198,PMC1001198,https://example.com/paper_1198,2022.0,11.0,75,11,True,57.0,8.0,True
cord-001199,Analysis of SARS-CoV-2 and immunity and coronavirus and public health in clinical settings,This study examines SARS-CoV-2 with 366 word abstract...,"Author1199_1, Author1199_2",Virology,2021-07-02,ArXiv,10.1000/sample.1199,,https://example.com/paper_1199,2021.0,7.0,90,13,True,56.0,8.0,True
cord-001200,Analysis of outbreak and clinical in clinical settings,This study examines outbreak with 289 word abstract...,"Author1200_1, Author1200_2",BMJ,2020-12-11,Medline,10.1000/sample.1200,,https://example.com/paper_1200,2020.0,12.0,54,8,True,54.0,8.0,True
cord-001201,Analysis of respiratory and outbreak and antibody and public health in clinical settings,This study examines respiratory with 402 word abstract...,"Author1201_1, Author1201_2",Science Translational Medicine,2021-01-18,Medline,10.1000/sample.1201,,https://example.com/paper_1201,2021.0,1.0,88,13,True,57.0,8.0,True
cord-001203,Analysis of immunity and antiviral and antibody in clinical settings,This study examines immunity with 333 word abstract...,"Author1203_1, Author1203_2",JAMA,2020-08-06,medRxiv,10.1000/sample.1203,,,2020.0,8.0,68,10,True,54.0,8.0,True
cord-001204,Analysis of treatment and vaccination in clinical settings,This study examines treatment with 381 word abstract...,Author1204_1,BMJ,2020-02-19,medRxiv,10.1000/sample.1204,PMC1001204,,2020.0,2.0,58,8,True,55.0,8.0,True
cord-001205,Analysis of vaccination and pandemic and outbreak and SARS-CoV-2 in clinical settings,This study examines vaccination with 273 word abstract...,"Author1205_1, Author1205_2",BMJ,2022-10-29,medRxiv,10.1000/sample.1205,,https://example.com/paper_1205,2022.0,10.0,85,12,True,57.0,8.0,True
cord-001206,Analysis of lockdown and pneumonia in clinical settings,This study examines lockdown with 341 word abstract...,"Author1206_1, Author1206_2",Nature Medicine,,PMC,10.1000/sample.1206,PMC1001206,,,,55,8,True,54.0,8.0,True
cord-001207,Analysis of clinical and symptoms and lockdown in clinical settings,This study examines clinical with 496 word abstract...,"Author1207_1, Author1207_2",,2021-01-28,PMC,10.1000/sample.1207,PMC1001207,https://example.com/paper_1207,2021.0,1.0,67,10,True,54.0,8.0,False
cord-001208,Analysis of immunity and symptoms in clinical settings,This study examines immunity with 447 word abstract...,"Author1208_1, Author1208_2",Cell,2019-12-30,WHO,10.1000/sample.1208,,https://example.com/paper_1208,2019.0,12.0,54,8,True,54.0,8.0,True
cord-001209,Analysis of outbreak and diagnosis and coronavirus and SARS-CoV-2 in clinical settings,This study examines outbreak with 125 word abstract...,"Author1209_1, Author1209_2",New England Journal of Medicine,2021-05-09,medRxiv,10.1000/sample.1209,PMC1001209,https://example.com/paper_1209,2021.0,5.0,86,12,True,54.0,8.0,True
cord-001211,Analysis of public health and transmission and antiviral and SARS-CoV-2 in clinical settings,This study examines public health with 310 word abstract...,"Author1211_1, Author1211_2",JAMA,2020-08-28,WHO,10.1000/sample.1211,PMC1001211,https://example.com/paper_1211,2020.0,8.0,92,13,True,59.0,9.0,True
cord-001213,Analysis of vaccination and pneumonia and COVID-19 and SARS-CoV-2 in clinical settings,This study examines vaccination with 287 word abstract...,"Author1213_1, Author1213_2",Nature Medicine,2020-07-21,WHO,10.1000/sample.1213,PMC1001213,https://example.com/paper_1213,2020.0,7.0,86,12,True,57.0,8.0,True
cord-001214,Analysis of pneumonia and COVID-19 and therapeutic and SARS-CoV-2 in clinical settings,This study examines pneumonia with 225 word abstract...,"Author1214_1, Author1214_2",Journal of Virology,2021-11-01,PMC,,,https://example.com/paper_1214,2021.0,11.0,86,12,True,55.0,8.0,True
cord-001215,Analysis of pneumonia and SARS-CoV-2 and therapeutic in clinical settings,This study examines pneumonia with 461 word abstract...,,Virology,2020-05-15,ArXiv,10.1000/sample.1215,PMC1001215,https://example.com/paper_1215,2020.0,5.0,73,10,True,55.0,8.0,True
cord-001216,Analysis of COVID-19 and diagnosis and immunity in clinical settings,This study examines COVID-19 with 322 word abstract...,"Author1216_1, Author1216_2",,2021-12-24,Medline,10.1000/sample.1216,,,2021.0,12.0,68,10,True,54.0,8.0,False
cord-001217,Analysis of diagnosis and vaccination and coronavirus and symptoms in clinical settings,This study examines diagnosis with 188 word abstract...,Author1217_1,,2022-04-03,Medline,10.1000/sample.1217,,https://example.com/paper_1217,2022.0,4.0,87,12,True,55.0,8.0,False
cord-001220,Analysis of public health and transmission and epidemiology and treatment in clinical settings,This study examines public health with 252 word abstract...,"Author1220_1, Author1220_2",Cell,,bioRxiv,10.1000/sample.1220,,https://example.com/paper_1220,,,94,13,True,59.0,9.0,True
cord-001223,Analysis of epidemiology and coronavirus and clinical in clinical settings,This study examines epidemiology with 319 word abstract...,Author1223_1,Journal of Virology,2021-08-26,Medline,10.1000/sample.1223,PMC1001223,,2021.0,8.0,74,10,True,58.0,8.0,True
cord-001225,Analysis of coronavirus and antibody in clinical settings,This study examines coronavirus with 262 word abstract...,"Author1225_1, Author1225_2",Emerging Infectious Diseases,2020-08-20,PMC,10.1000/sample.1225,PMC1001225,https://example.com/paper_1225,2020.0,8.0,57,8,True,57.0,8.0,True
cord-001226,Analysis of COVID-19 and treatment and symptoms in clinical settings,This study examines COVID-19 with 167 word abstract...,"Author1226_1, Author1226_2",,2021-06-25,PMC,10.1000/sample.1226,,https://example.com/paper_1226,2021.0,6.0,68,10,True,54.0,8.0,False
cord-001227,Analysis of treatment and transmission in clinical settings,This study examines treatment with 102 word abstract...,"Author1227_1, Author1227_2",Clinical Infectious Diseases,2019-12-20,PMC,10.1000/sample.1227,PMC1001227,,2019.0,12.0,59,8,True,55.0,8.0,True
cord-001228,Analysis of immunity and antiviral and coronavirus and clinical in clinical settings,This study examines immunity with 339 word abstract...,"Author1228_1, Author1228_2",Lancet,2020-11-03,Medline,10.1000/sample.1228,,https://example.com/paper_1228,2020.0,11.0,84,12,True,54.0,8.0,True
cord-001229,Analysis of vaccination and transmission and treatment in clinical settings,This study examines vaccination with 427 word abstract...,"Author1229_1, Author1229_2",Journal of Virology,2019-12-18,ArXiv,10.1000/sample.1229,,https://example.com/paper_1229,2019.0,12.0,75,10,True,57.0,8.0,True
cord-001230,Analysis of COVID-19 and clinical and pneumonia and vaccination in clinical settings,,"Author1230_1, Author1230_2",Cell,2021-12-04,medRxiv,10.1000/sample.1230,PMC1001230,,2021.0,12.0,84,12,False,,,True
cord-001231,Analysis of public health and diagnosis and respiratory and SARS-CoV-2 in clinical settings,This study examines public health with 234 word abstract...,"Author1231_1, Author1231_2",Science,2021-08-10,bioRxiv,10.1000/sample.1231,,,2021.0,8.0,91,13,True,59.0,9.0,True
cord-001232,Analysis of lockdown and antiviral and SARS-CoV-2 in clinical settings,This study examines lockdown with 226 word abstract...,"Author1232_1, Author1232_2",,2021-10-24,ArXiv,10.1000/sample.1232,,https://example.com/paper_1232,2021.0,10.0,70,10,True,54.0,8.0,False
cord-001236,Analysis of diagnosis and clinical and antiviral and therapeutic in clinical settings,This study examines diagnosis with 234 word abstract...,"Author1236_1, Author1236_2",JAMA,2020-11-12,PMC,10.1000/sample.1236,PMC1001236,https://example.com/paper_1236,2020.0,11.0,85,12,True,55.0,8.0,True
cord-001238,Analysis of treatment and transmission and pneumonia in clinical settings,This study examines treatment with 372 word abstract...,"Author1238_1, Author1238_2",BMJ,2022-07-10,medRxiv,10.1000/sample.1238,PMC1001238,https://example.com/paper_1238,2022.0,7.0,73,10,True,55.0,8.0,True
cord-001239,Analysis of SARS-CoV-2 and pneumonia and respiratory and transmission in clinical settings,,"Author1239_1, Author1239_2",Virology,2020-01-31,bioRxiv,10.1000/sample.1239,,,2020.0,1.0,90,12,False,,,True
cord-001241,Analysis of therapeutic and clinical and symptoms in clinical settings,This study examines therapeutic with 182 word abstract...,"Author1241_1, Author1241_2",Cell,2021-07-12,medRxiv,10.1000/sample.1241,PMC1001241,https://example.com/paper_1241,2021.0,7.0,70,10,True,57.0,8.0,True
cord-001242,Analysis of coronavirus and transmission and vaccination in clinical settings,This study examines coronavirus with 135 word abstract...,Author1242_1,,2020-04-05,Medline,10.1000/sample.1242,PMC1001242,https://example.com/paper_1242,2020.0,4.0,77,10,True,57.0,8.0,False
cord-001243,Analysis of antibody and COVID-19 and transmission in clinical settings,This study examines antibody with 329 word abstract...,Author1243_1,Science,2020-09-10,ArXiv,10.1000/sample.1243,PMC1001243,https://example.com/paper_1243,2020.0,9.0,71,10,True,54.0,8.0,True
cord-001244,Analysis of therapeutic and vaccination and pneumonia and coronavirus in clinical settings,This study examines therapeutic with 190 word abstract...,Author1244_1,Emerging Infectious Diseases,2020-01-27,ArXiv,10.1000/sample.1244,PMC1001244,,2020.0,1.0,90,12,True,57.0,8.0,True
cord-001245,Analysis of lockdown and immunity and transmission in clinical settings,This study examines lockdown with 349 word abstract...,"Author1245_1, Author1245_2",Nature,2020-08-29,PMC,10.1000/sample.1245,PMC1001245,https://example.com/paper_1245,2020.0,8.0,71,10,True,54.0,8.0,True
cord-001246,Analysis of symptoms and clinical and vaccination and pneumonia in clinical settings,This study examines symptoms with 328 word abstract...,Author1246_1,Science,2020-09-14,medRxiv,10.1000/sample.1246,PMC1001246,,2020.0,9.0,84,12,True,54.0,8.0,True
cord-001247,Analysis of COVID-19 and clinical and pneumonia and SARS-CoV-2 in clinical settings,This study examines COVID-19 with 233 word abstract...,"Author1247_1, Author1247_2",Science,2020-03-11,bioRxiv,10.1000/sample.1247,PMC1001247,https://example.com/paper_1247,2020.0,3.0,83,12,True,54.0,8.0,True
cord-001248,Analysis of respiratory and coronavirus in clinical settings,This study examines respiratory with 110 word abstract...,"Author1248_1, Author1248_2",Science,2019-12-31,WHO,,PMC1001248,,2019.0,12.0,60,8,True,57.0,8.0,True
cord-001249,Analysis of respiratory and epidemiology and transmission and SARS-CoV-2 in clinical settings,This study examines respiratory with 194 word abstract...,,Virology,2020-08-03,medRxiv,,PMC1001249,https://example.com/paper_1249,2020.0,8.0,93,12,True,57.0,8.0,True
cord-001250,Analysis of coronavirus and diagnosis and outbreak in clinical settings,,"Author1250_1, Author1250_2",Journal of Virology,2021-04-09,PMC,10.1000/sample.1250,PMC1001250,,2021.0,4.0,71,10,False,,,True
cord-001251,Analysis of pneumonia and pandemic and SARS-CoV-2 in clinical settings,This study examines pneumonia with 425 word abstract...,,Virology,2021-12-21,WHO,,PMC1001251,https://example.com/paper_1251,2021.0,12.0,70,10,True,55.0,8.0,True
cord-001252,Analysis of clinical and therapeutic and lockdown in clinical settings,This study examines clinical with 112 word abstract...,Author1252_1,Science Translational Medicine,2021-02-27,ArXiv,10.1000/sample.1252,,,2021.0,2.0,70,10,True,54.0,8.0,True
cord-001253,Analysis of transmission and diagnosis and epidemiology and COVID-19 in clinical settings,This study examines transmission with 123 word abstract...,"Author1253_1, Author1253_2",Journal of Virology,2020-03-08,PMC,10.1000/sample.1253,,https://example.com/paper_1253,2020.0,3.0,89,12,True,58.0,8.0,True
cord-001254,Analysis of symptoms and immunity and coronavirus and SARS-CoV-2 in clinical settings,This study examines symptoms with 164 word abstract...,"Author1254_1, Author1254_2",Journal of Virology,2021-03-25,Medline,10.1000/sample.1254,PMC1001254,https://example.com/paper_1254,2021.0,3.0,85,12,True,54.0,8.0,True
cord-001255,Analysis of public health and antiviral and diagnosis and epidemiology in clinical settings,This study examines public health with 175 word abstract...,"Author1255_1, Author1255_2",PLoS ONE,2020-04-06,ArXiv,10.1000/sample.1255,PMC1001255,https://example.com/paper_1255,2020.0,4.0,91,13,True,59.0,9.0,True
cord-001257,Analysis of antiviral and coronavirus and immunity and pandemic in clinical settings,This study examines antiviral with 162 word abstract...,"Author1257_1, Author1257_2",Science Translational Medicine,2020-11-23,bioRxiv,10.1000/sample.1257,PMC1001257,https://example.com/paper_1257,2020.0,11.0,84,12,True,55.0,8.0,True
cord-001258,Analysis of treatment and public health and immunity and pneumonia in clinical settings,This study examines treatment with 441 word abstract...,"Author1258_1, Author1258_2",Virology,2021-04-12,PMC,10.1000/sample.1258,,https://example.com/paper_1258,2021.0,4.0,87,13,True,55.0,8.0,True
cord-001259,Analysis of treatment and respiratory and outbreak and immunity in clinical settings,This study examines treatment with 291 word abstract...,"Author1259_1, Author1259_2",,2020-03-02,bioRxiv,10.1000/sample.1259,,,2020.0,3.0,84,12,True,55.0,8.0,False
cord-001261,Analysis of antibody and clinical and transmission and SARS-CoV-2 in clinical settings,This study examines antibody with 138 word abstract...,"Author1261_1, Author1261_2",Science Translational Medicine,2019-12-21,bioRxiv,,PMC1001261,,2019.0,12.0,86,12,True,54.0,8.0,True
cord-001262,Analysis of antibody and therapeutic and transmission in clinical settings,This study examines antibody with 252 word abstract...,"Author1262_1, Author1262_2",,2021-09-14,WHO,10.1000/sample.1262,PMC1001262,https://example.com/paper_1262,2021.0,9.0,74,10,True,54.0,8.0,False
cord-001263,Analysis of antibody and public health and antiviral in clinical settings,This study examines antibody with 427 word abstract...,"Author1263_1, Author1263_2",Virology,2022-08-04,PMC,10.1000/sample.1263,,https://example.com/paper_1263,2022.0,8.0,73,11,True,54.0,8.0,True
cord-001265,Analysis of outbreak and transmission and epidemiology and COVID-19 in clinical settings,This study examines outbreak with 430 word abstract...,"Author1265_1, Author1265_2",Journal of Medical Virology,2022-08-27,ArXiv,10.1000/sample.1265,PMC1001265,https://example.com/paper_1265,2022.0,8.0,88,12,True,54.0,8.0,True
cord-001266,Analysis of treatment and antiviral and respiratory in clinical settings,This study examines treatment with 219 word abstract...,"Author1266_1, Author1266_2",PLoS ONE,2019-12-08,Medline,10.1000/sample.1266,,https://example.com/paper_1266,2019.0,12.0,72,10,True,55.0,8.0,True
cord-001267,Analysis of treatment and public health in clinical settings,This study examines treatment with 188 word abstract...,"Author1267_1, Author1267_2",Cell,2021-07-05,PMC,10.1000/sample.1267,PMC1001267,https://example.com/paper_1267,2021.0,7.0,60,9,True,55.0,8.0,True
cord-001268,Analysis of diagnosis and epidemiology and immunity in clinical settings,This study examines diagnosis with 411 word abstract...,"Author1268_1, Author1268_2",Journal of Medical Virology,2020-10-05,PMC,10.1000/sample.1268,PMC1001268,https://example.com/paper_1268,2020.0,10.0,72,10,True,55.0,8.0,True
cord-001269,Analysis of clinical and antibody in clinical settings,This study examines clinical with 196 word abstract...,"Author1269_1, Author1269_2",Science,2020-03-12,Medline,10.1000/sample.1269,PMC1001269,https://example.com/paper_1269,2020.0,3.0,54,8,True,54.0,8.0,True
cord-001271,Analysis of epidemiology and outbreak in clinical settings,This study examines epidemiology with 495 word abstract...,"Author1271_1, Author1271_2",Cell,2020-08-02,WHO,10.1000/sample.1271,PMC1001271,,2020.0,8.0,58,8,True,58.0,8.0,True
cord-001273,Analysis of pneumonia and vaccination and public health in clinical settings,This study examines pneumonia with 204 word abstract...,"Author1273_1, Author1273_2",,2020-06-05,ArXiv,10.1000/sample.1273,PMC1001273,https://example.com/paper_1273,2020.0,6.0,76,11,True,55.0,8.0,False
cord-001276,Analysis of COVID-19 and antibody and pandemic in clinical settings,This study examines COVID-19 with 296 word abstract...,"Author1276_1, Author1276_2",Science Translational Medicine,2019-12-22,medRxiv,10.1000/sample.1276,PMC1001276,https://example.com/paper_1276,2019.0,12.0,67,10,True,54.0,8.0,True
cord-001277,Analysis of antibody and therapeutic and treatment and coronavirus in clinical settings,This study examines antibody with 219 word abstract...,"Author1277_1, Author1277_2",Science,2020-06-26,ArXiv,10.1000/sample.1277,,https://example.com/paper_1277,2020.0,6.0,87,12,True,54.0,8.0,True
cord-001278,Analysis of antiviral and outbreak and respiratory and epidemiology in clinical settings,This study examines antiviral with 245 word abstract...,"Author1278_1, Author1278_2",Nature,2020-11-09,bioRxiv,10.1000/sample.1278,,https://example.com/paper_1278,2020.0,11.0,88,12,True,55.0,8.0,True
cord-001281,Analysis of pneumonia and antiviral and coronavirus in clinical settings,This study examines pneumonia with 368 word abstract...,"Author1281_1, Author1281_2",,2020-12-05,PMC,10.1000/sample.1281,PMC1001281,https://example.com/paper_1281,2020.0,12.0,72,10,True,55.0,8.0,False
cord-001283,Analysis of outbreak and symptoms and diagnosis in clinical settings,,"Author1283_1, Author1283_2",PLoS ONE,2020-08-20,medRxiv,10.1000/sample.1283,,https://example.com/paper_1283,2020.0,8.0,68,10,False,,,True
cord-001284,Analysis of immunity and outbreak and transmission in clinical settings,This study examines immunity with 498 word abstract...,,PLoS ONE,2021-02-28,Medline,10.1000/sample.1284,,https://example.com/paper_1284,2021.0,2.0,71,10,True,54.0,8.0,True
cord-001285,Analysis of immunity and lockdown and therapeutic in clinical settings,This study examines immunity with 301 word abstract...,"Author1285_1, Author1285_2",Clinical Infectious Diseases,2021-08-28,bioRxiv,10.1000/sample.1285,PMC1001285,https://example.com/paper_1285,2021.0,8.0,70,10,True,54.0,8.0,True
cord-001286,Analysis of lockdown and diagnosis in clinical settings,This study examines lockdown with 364 word abstract...,"Author1286_1, Author1286_2",Nature,2021-12-25,bioRxiv,10.1000/sample.1286,,,2021.0,12.0,55,8,True,54.0,8.0,True
cord-001287,Analysis of vaccination and public health and antibody and clinical in clinical settings,This study examines vaccination with 101 word abstract...,,Journal of Virology,2021-02-20,bioRxiv,10.1000/sample.1287,PMC1001287,https://example.com/paper_1287,2021.0,2.0,88,13,True,57.0,8.0,True
cord-001289,Analysis of pandemic and coronavirus and diagnosis in clinical settings,This study examines pandemic with 111 word abstract...,"Author1289_1, Author1289_2",BMJ,2021-10-06,ArXiv,10.1000/sample.1289,,https://example.com/paper_1289,2021.0,10.0,71,10,True,54.0,8.0,True
cord-001290,Analysis of pandemic and antiviral and symptoms in clinical settings,This study examines pandemic with 117 word abstract...,Author1290_1,Virology,2019-12-03,PMC,10.1000/sample.1290,,https://example.com/paper_1290,2019.0,12.0,68,10,True,54.0,8.0,True
cord-001291,Analysis of clinical and therapeutic in clinical settings,,Author1291_1,Nature,2021-02-11,bioRxiv,10.1000/sample.1291,PMC1001291,https://example.com/paper_1291,2021.0,2.0,57,8,False,,,True
cord-001292,Analysis of coronavirus and outbreak and SARS-CoV-2 and clinical in clinical settings,This study examines coronavirus with 442 word abstract...,"Author1292_1, Author1292_2",Science Translational Medicine,2020-11-11,Medline,10.1000/sample.1292,PMC1001292,https://example.com/paper_1292,2020.0,11.0,85,12,True,57.0,8.0,True
cord-001294,Analysis of COVID-19 and treatment and pneumonia in clinical settings,This study examines COVID-19 with 397 word abstract...,"Author1294_1, Author1294_2",Cell,2020-05-20,WHO,10.1000/sample.1294,,,2020.0,5.0,69,10,True,54.0,8.0,True
cord-001295,Analysis of transmission and COVID-19 and coronavirus in clinical settings,This study examines transmission with 287 word abstract...,"Author1295_1, Author1295_2",Journal of Medical Virology,2021-05-10,Medline,10.1000/sample.1295,PMC1001295,,2021.0,5.0,74,10,True,58.0,8.0,True
cord-001296,Analysis of public health and antibody and SARS-CoV-2 and clinical in clinical settings,This study examines public health with 143 word abstract...,"Author1296_1, Author1296_2",,2021-05-16,PMC,10.1000/sample.1296,PMC1001296,https://example.com/paper_1296,2021.0,5.0,87,13,True,59.0,9.0,False
cord-001297,Analysis of transmission and SARS-CoV-2 and pandemic in clinical settings,This study examines transmission with 346 word abstract...,"Author1297_1, Author1297_2",Lancet,2022-02-27,WHO,10.1000/sample.1297,,https://example.com/paper_1297,2022.0,2.0,73,10,True,58.0,8.0,True
cord-001298,Analysis of treatment and coronavirus and epidemiology and COVID-19 in clinical settings,This study examines treatment with 235 word abstract...,"Author1298_1, Author1298_2",Lancet,2021-11-10,ArXiv,,PMC1001298,https://example.com/paper_1298,2021.0,11.0,88,12,True,55.0,8.0,True
cord-001299,Analysis of transmission and antibody in clinical settings,This study examines transmission with 199 word abstract...,"Author1299_1, Author1299_2",BMJ,2020-04-05,medRxiv,10.1000/sample.1299,PMC1001299,,2020.0,4.0,58,8,True,58.0,8.0,True
cord-001300,Analysis of treatment and transmission and diagnosis in clinical settings,This study examines treatment with 107 word abstract...,"Author1300_1, Author1300_2",Journal of Medical Virology,2020-01-25,Medline,10.1000/sample.1300,,https://example.com/paper_1300,2020.0,1.0,73,10,True,55.0,8.0,True
cord-001301,Analysis of vaccination and symptoms in clinical settings,,"Author1301_1, Author1301_2",Nature Medicine,2021-01-11,bioRxiv,10.1000/sample.1301,PMC1001301,https://example.com/paper_1301,2021.0,1.0,57,8,False,,,True
cord-001302,Analysis of therapeutic and public health and outbreak in clinical settings,This study examines therapeutic with 372 word abstract...,"Author1302_1, Author1302_2",Virology,2020-07-18,Medline,10.1000/sample.1302,,,2020.0,7.0,75,11,True,57.0,8.0,True
cord-001305,Analysis of pandemic and respiratory and diagnosis in clinical settings,This study examines pandemic with 377 word abstract...,"Author1305_1, Author1305_2",Emerging Infectious Diseases,2020-02-15,bioRxiv,10.1000/sample.1305,PMC1001305,https://example.com/paper_1305,2020.0,2.0,71,10,True,54.0,8.0,True
cord-001307,Analysis of epidemiology and public health in clinical settings,This study examines epidemiology with 178 word abstract...,,Lancet,2020-09-28,Medline,,,https://example.com/paper_1307,2020.0,9.0,63,9,True,58.0,8.0,True
cord-001309,Analysis of antiviral and SARS-CoV-2 and pandemic in clinical settings,This study examines antiviral with 261 word abstract...,"Author1309_1, Author1309_2",Science Translational Medicine,2020-08-09,WHO,10.1000/sample.1309,PMC1001309,https://example.com/paper_1309,2020.0,8.0,70,10,True,55.0,8.0,True
cord-001311,Analysis of transmission and antibody and SARS-CoV-2 and public health in clinical settings,This study examines transmission with 307 word abstract...,"Author1311_1, Author1311_2",Journal of Medical Virology,2020-01-27,bioRxiv,10.1000/sample.1311,PMC1001311,https://example.com/paper_1311,2020.0,1.0,91,13,True,58.0,8.0,True
cord-001312,Analysis of coronavirus and treatment and clinical and respiratory in clinical settings,This study examines coronavirus with 341 word abstract...,"Author1312_1, Author1312_2",,2021-09-21,Medline,10.1000/sample.1312,,,2021.0,9.0,87,12,True,57.0,8.0,False
cord-001313,Analysis of treatment and outbreak and coronavirus in clinical settings,This study examines treatment with 471 word abstract...,"Author1313_1, Author1313_2",JAMA,2020-10-20,Medline,10.1000/sample.1313,PMC1001313,https://example.com/paper_1313,2020.0,10.0,71,10,True,55.0,8.0,True
cord-001314,Analysis of antiviral and SARS-CoV-2 and therapeutic in clinical settings,This study examines antiviral with 499 word abstract...,"Author1314_1, Author1314_2",New England Journal of Medicine,2020-04-05,medRxiv,10.1000/sample.1314,PMC1001314,,2020.0,4.0,73,10,True,55.0,8.0,True
cord-001315,Analysis of outbreak and symptoms and immunity and treatment in clinical settings,This study examines outbreak with 204 word abstract...,"Author1315_1, Author1315_2",Cell,2020-11-19,bioRxiv,,PMC1001315,https://example.com/paper_1315,2020.0,11.0,81,12,True,54.0,8.0,True
cord-001316,Analysis of therapeutic and respiratory in clinical settings,This study examines therapeutic with 198 word abstract...,"Author1316_1, Author1316_2",Science,2020-04-09,PMC,10.1000/sample.1316,PMC1001316,https://example.com/paper_1316,2020.0,4.0,60,8,True,57.0,8.0,True
cord-001319,Analysis of respiratory and transmission and diagnosis and coronavirus in clinical settings,,Author1319_1,Journal of Virology,2021-01-06,ArXiv,,,https://example.com/paper_1319,2021.0,1.0,91,12,False,,,True
cord-001320,Analysis of vaccination and transmission and respiratory and clinical in clinical settings,This study examines vaccination with 392 word abstract...,,BMJ,2020-09-28,PMC,10.1000/sample.1320,,https://example.com/paper_1320,2020.0,9.0,90,12,True,57.0,8.0,True
cord-001321,Analysis of pneumonia and antibody and respiratory in clinical settings,This study examines pneumonia with 130 word abstract...,"Author1321_1, Author1321_2",Nature Medicine,2020-11-02,PMC,10.1000/sample.1321,,,2020.0,11.0,71,10,True,55.0,8.0,True
cord-001322,Analysis of therapeutic and epidemiology and immunity and pandemic in clinical settings,This study examines therapeutic with 186 word abstract...,Author1322_1,Science Translational Medicine,2020-01-01,medRxiv,,PMC1001322,,2020.0,1.0,87,12,True,57.0,8.0,True
cord-001323,Analysis of transmission and vaccination and therapeutic in clinical settings,This study examines transmission with 231 word abstract...,Author1323_1,Science Translational Medicine,2019-12-13,WHO,10.1000/sample.1323,PMC1001323,https://example.com/paper_1323,2019.0,12.0,77,10,True,58.0,8.0,True
cord-001324,Analysis of COVID-19 and symptoms and respiratory and clinical in clinical settings,This study examines COVID-19 with 146 word abstract...,"Author1324_1, Author1324_2",PLoS ONE,2020-01-08,ArXiv,10.1000/sample.1324,,https://example.com/paper_1324,2020.0,1.0,83,12,True,54.0,8.0,True
cord-001325,Analysis of COVID-19 and coronavirus and SARS-CoV-2 in clinical settings,This study examines COVID-19 with 420 word abstract...,"Author1325_1, Author1325_2",Science Translational Medicine,2022-07-27,Medline,10.1000/sample.1325,,https://example.com/paper_1325,2022.0,7.0,72,10,True,54.0,8.0,True
cord-001326,Analysis of treatment and respiratory and transmission in clinical settings,This study examines treatment with 439 word abstract...,"Author1326_1, Author1326_2",PLoS ONE,2020-09-22,WHO,,PMC1001326,https://example.com/paper_1326,2020.0,9.0,75,10,True,55.0,8.0,True
cord-001327,Analysis of immunity and vaccination and COVID-19 and coronavirus in clinical settings,This study examines immunity with 491 word abstract...,"Author1327_1, Author1327_2",Nature,2021-05-11,bioRxiv,10.1000/sample.1327,PMC1001327,,2021.0,5.0,86,12,True,54.0,8.0,True
cord-001328,Analysis of clinical and public health and antiviral and therapeutic in clinical settings,This study examines clinical with 341 word abstract...,"Author1328_1, Author1328_2",,,medRxiv,10.1000/sample.1328,PMC1001328,https://example.com/paper_1328,,,89,13,True,54.0,8.0,False
cord-001329,Analysis of vaccination and epidemiology and antiviral and therapeutic in clinical settings,This study examines vaccination with 416 word abstract...,"Author1329_1, Author1329_2",Journal of Medical Virology,2020-12-01,PMC,10.1000/sample.1329,,https://example.com/paper_1329,2020.0,12.0,91,12,True,57.0,8.0,True
cord-001332,Analysis of pandemic and respiratory and clinical and antiviral in clinical settings,This study examines pandemic with 178 word abstract...,"Author1332_1, Author1332_2",JAMA,2020-03-16,medRxiv,10.1000/sample.1332,PMC1001332,https://example.com/paper_1332,2020.0,3.0,84,12,True,54.0,8.0,True
cord-001333,Analysis of COVID-19 and SARS-CoV-2 and respiratory and outbreak in clinical settings,This study examines COVID-19 with 200 word abstract...,"Author1333_1, Author1333_2",Journal of Virology,2020-05-24,PMC,,,https://example.com/paper_1333,2020.0,5.0,85,12,True,54.0,8.0,True
cord-001334,Analysis of respiratory and SARS-CoV-2 and antiviral in clinical settings,,"Author1334_1, Author1334_2",Nature,2021-12-03,ArXiv,10.1000/sample.1334,,https://example.com/paper_1334,2021.0,12.0,73,10,False,,,True
cord-001335,Analysis of SARS-CoV-2 and clinical and antiviral and lockdown in clinical settings,This study examines SARS-CoV-2 with 455 word abstract...,"Author1335_1, Author1335_2",BMJ,2020-07-16,ArXiv,10.1000/sample.1335,,https://example.com/paper_1335,2020.0,7.0,83,12,True,56.0,8.0,True
cord-001338,Analysis of transmission and antibody and symptoms in clinical settings,This study examines transmission with 192 word abstract...,"Author1338_1, Author1338_2",PLoS ONE,2020-12-17,WHO,10.1000/sample.1338,,,2020.0,12.0,71,10,True,58.0,8.0,True
cord-001339,Analysis of treatment and lockdown and transmission and outbreak in clinical settings,This study examines treatment with 129 word abstract...,"Author1339_1, Author1339_2",Emerging Infectious Diseases,2020-07-13,ArXiv,10.1000/sample.1339,PMC1001339,https://example.com/paper_1339,2020.0,7.0,85,12,True,55.0,8.0,True
cord-001341,Analysis of public health and clinical and pandemic and symptoms in clinical settings,This study examines public health with 347 word abstract...,"Author1341_1, Author1341_2",Lancet,2019-12-15,Medline,10.1000/sample.1341,PMC1001341,https://example.com/paper_1341,2019.0,12.0,85,13,True,59.0,9.0,True
cord-001342,Analysis of treatment and respiratory in clinical settings,This study examines treatment with 336 word abstract...,"Author1342_1, Author1342_2",Journal of Medical Virology,2021-04-18,medRxiv,10.1000/sample.1342,,https://example.com/paper_1342,2021.0,4.0,58,8,True,55.0,8.0,True
cord-001345,Analysis of vaccination and antiviral and lockdown in clinical settings,This study examines vaccination with 378 word abstract...,"Author1345_1, Author1345_2",Science,2019-12-14,ArXiv,10.1000/sample.1345,PMC1001345,https://example.com/paper_1345,2019.0,12.0,71,10,True,57.0,8.0,True
cord-001346,Analysis of immunity and lockdown and vaccination in clinical settings,This study examines immunity with 341 word abstract...,"Author1346_1, Author1346_2",Science Translational Medicine,2020-10-21,bioRxiv,10.1000/sample.1346,PMC1001346,https://example.com/paper_1346,2020.0,10.0,70,10,True,54.0,8.0,True
cord-001347,Analysis of respiratory and symptoms and public health and COVID-19 in clinical settings,This study examines respiratory with 330 word abstract...,"Author1347_1, Author1347_2",Lancet,2021-04-14,Medline,10.1000/sample.1347,PMC1001347,https://example.com/paper_1347,2021.0,4.0,88,13,True,57.0,8.0,True
cord-001348,Analysis of clinical and respiratory and COVID-19 and epidemiology in clinical settings,This study examines clinical with 332 word abstract...,"Author1348_1, Author1348_2",,2021-07-04,bioRxiv,10.1000/sample.1348,,https://example.com/paper_1348,2021.0,7.0,87,12,True,54.0,8.0,False
cord-001349,Analysis of pneumonia and symptoms and outbreak and antibody in clinical settings,This study examines pneumonia with 478 word abstract...,"Author1349_1, Author1349_2",,2020-01-08,Medline,10.1000/sample.1349,PMC1001349,https://example.com/paper_1349,2020.0,1.0,81,12,True,55.0,8.0,False
cord-001351,Analysis of antibody and public health and clinical in clinical settings,This study examines antibody with 253 word abstract...,"Author1351_1, Author1351_2",,2020-03-29,bioRxiv,10.1000/sample.1351,PMC1001351,https://example.com/paper_1351,2020.0,3.0,72,11,True,54.0,8.0,False
cord-001352,Analysis of antibody and COVID-19 and pandemic in clinical settings,This study examines antibody with 346 word abstract...,"Author1352_1, Author1352_2",JAMA,2019-12-04,bioRxiv,10.1000/sample.1352,PMC1001352,https://example.com/paper_1352,2019.0,12.0,67,10,True,54.0,8.0,True
cord-001353,Analysis of COVID-19 and outbreak in clinical settings,This study examines COVID-19 with 134 word abstract...,Author1353_1,Clinical Infectious Diseases,2021-06-24,bioRxiv,10.1000/sample.1353,PMC1001353,,2021.0,6.0,54,8,True,54.0,8.0,True
cord-001355,Analysis of pandemic and public health and clinical in clinical settings,This study examines pandemic with 168 word abstract...,"Author1355_1, Author1355_2",,2021-06-05,WHO,10.1000/sample.1355,,https://example.com/paper_1355,2021.0,6.0,72,11,True,54.0,8.0,False
cord-001357,Analysis of lockdown and coronavirus and vaccination and clinical in clinical settings,This study examines lockdown with 207 word abstract...,"Author1357_1, Author1357_2",Science,2020-08-16,bioRxiv,,PMC1001357,,2020.0,8.0,86,12,True,54.0,8.0,True
cord-001358,Analysis of clinical and antiviral and outbreak and antibody in clinical settings,This study examines clinical with 284 word abstract...,"Author1358_1, Author1358_2",Lancet,2021-11-10,ArXiv,10.1000/sample.1358,PMC1001358,,2021.0,11.0,81,12,True,54.0,8.0,True
cord-001359,Analysis of therapeutic and immunity and coronavirus in clinical settings,This study examines therapeutic with 236 word abstract...,Author1359_1,New England Journal of Medicine,2019-12-12,bioRxiv,10.1000/sample.1359,,,2019.0,12.0,73,10,True,57.0,8.0,True
cord-001360,Analysis of immunity and transmission and antibody in clinical settings,,"Author1360_1, Author1360_2",Emerging Infectious Diseases,2021-11-30,Medline,10.1000/sample.1360,PMC1001360,,2021.0,11.0,71,10,False,,,True
cord-001361,Analysis of pneumonia and diagnosis and respiratory and coronavirus in clinical settings,This study examines pneumonia with 357 word abstract...,"Author1361_1, Author1361_2",Nature Medicine,2020-10-06,WHO,10.1000/sample.1361,PMC1001361,,2020.0,10.0,88,12,True,55.0,8.0,True
cord-001365,Analysis of treatment and public health and transmission and COVID-19 in clinical settings,This study examines treatment with 117 word abstract...,"Author1365_1, Author1365_2",Journal of Medical Virology,2020-09-20,WHO,,PMC1001365,https://example.com/paper_1365,2020.0,9.0,90,13,True,55.0,8.0,True
cord-001367,Analysis of lockdown and treatment and pneumonia and respiratory in clinical settings,This study examines lockdown with 467 word abstract...,"Author1367_1, Author1367_2",JAMA,2021-12-02,PMC,10.1000/sample.1367,PMC1001367,https://example.com/paper_1367,2021.0,12.0,85,12,True,54.0,8.0,True
cord-001368,Analysis of diagnosis and pandemic in clinical settings,,Author1368_1,Clinical Infectious Diseases,2020-07-12,bioRxiv,10.1000/sample.1368,PMC1001368,https://example.com/paper_1368,2020.0,7.0,55,8,False,,,True
cord-001371,Analysis of immunity and therapeutic and pandemic and public health in clinical settings,This study examines immunity with 491 word abstract...,"Author1371_1, Author1371_2",Science Translational Medicine,2019-12-14,medRxiv,10.1000/sample.1371,PMC1001371,https://example.com/paper_1371,2019.0,12.0,88,13,True,54.0,8.0,True
cord-001374,Analysis of public health and immunity and outbreak and pandemic in clinical settings,This study examines public health with 222 word abstract...,"Author1374_1, Author1374_2",Journal of Medical Virology,2020-04-26,WHO,10.1000/sample.1374,PMC1001374,https://example.com/paper_1374,2020.0,4.0,85,13,True,59.0,9.0,True
cord-001377,Analysis of clinical and SARS-CoV-2 and diagnosis and pneumonia in clinical settings,This study examines clinical with 178 word abstract...,"Author1377_1, Author1377_2",Clinical Infectious Diseases,2021-06-24,PMC,10.1000/sample.1377,PMC1001377,https://example.com/paper_1377,2021.0,6.0,84,12,True,54.0,8.0,True
cord-001378,Analysis of SARS-CoV-2 and antibody and treatment and pneumonia in clinical settings,This study examines SARS-CoV-2 with 486 word abstract...,Author1378_1,JAMA,2020-11-15,ArXiv,10.1000/sample.1378,PMC1001378,https://example.com/paper_1378,2020.0,11.0,84,12,True,56.0,8.0,True
cord-001380,Analysis of respiratory and public health and antibody in clinical settings,,Author1380_1,Nature,2021-03-14,WHO,,PMC1001380,https://example.com/paper_1380,2021.0,3.0,75,11,False,,,True
cord-001381,Analysis of immunity and vaccination and clinical in clinical settings,This study examines immunity with 182 word abstract...,,Lancet,2021-08-13,medRxiv,10.1000/sample.1381,PMC1001381,https://example.com/paper_1381,2021.0,8.0,70,10,True,54.0,8.0,True
cord-001383,Analysis of epidemiology and treatment in clinical settings,This study examines epidemiology with 190 word abstract...,"Author1383_1, Author1383_2",Cell,2020-07-13,PMC,10.1000/sample.1383,PMC1001383,,2020.0,7.0,59,8,True,58.0,8.0,True
cord-001384,Analysis of symptoms and antiviral and clinical and outbreak in clinical settings,This study examines symptoms with 241 word abstract...,"Author1384_1, Author1384_2",Lancet,2020-09-23,ArXiv,10.1000/sample.1384,,https://example.com/paper_1384,2020.0,9.0,81,12,True,54.0,8.0,True
cord-001385,Analysis of vaccination and public health and antiviral in clinical settings,This study examines vaccination with 112 word abstract...,"Author1385_1, Author1385_2",New England Journal of Medicine,2021-01-25,Medline,10.1000/sample.1385,PMC1001385,https://example.com/paper_1385,2021.0,1.0,76,11,True,57.0,8.0,True
cord-001387,Analysis of lockdown and antiviral and clinical and COVID-19 in clinical settings,This study examines lockdown with 359 word abstract...,"Author1387_1, Author1387_2",Science,2020-03-16,Medline,10.1000/sample.1387,PMC1001387,https://example.com/paper_1387,2020.0,3.0,81,12,True,54.0,8.0,True
cord-001388,Analysis of transmission and coronavirus and therapeutic and outbreak in clinical settings,This study examines transmission with 326 word abstract...,"Author1388_1, Author1388_2",,2020-06-29,bioRxiv,10.1000/sample.1388,PMC1001388,https://example.com/paper_1388,2020.0,6.0,90,12,True,58.0,8.0,False
cord-001390,Analysis of lockdown and antiviral and transmission in clinical settings,This study examines lockdown with 116 word abstract...,"Author1390_1, Author1390_2",Lancet,,ArXiv,,PMC1001390,,,,72,10,True,54.0,8.0,True
cord-001391,Analysis of diagnosis and immunity in clinical settings,This study examines diagnosis with 149 word abstract...,"Author1391_1, Author1391_2",JAMA,2020-07-07,Medline,10.1000/sample.1391,PMC1001391,,2020.0,7.0,55,8,True,55.0,8.0,True
cord-001392,Analysis of pandemic and public health in clinical settings,This study examines pandemic with 412 word abstract...,"Author1392_1, Author1392_2",Lancet,2021-07-18,PMC,10.1000/sample.1392,PMC1001392,,2021.0,7.0,59,9,True,54.0,8.0,True
cord-001393,Analysis of clinical and lockdown and pneumonia and COVID-19 in clinical settings,This study examines clinical with 113 word abstract...,"Author1393_1, Author1393_2",Lancet,2021-12-21,Medline,10.1000/sample.1393,PMC1001393,,2021.0,12.0,81,12,True,54.0,8.0,True
cord-001396,Analysis of clinical and respiratory in clinical settings,This study examines clinical with 285 word abstract...,"Author1396_1, Author1396_2",Virology,2020-09-04,bioRxiv,10.1000/sample.1396,PMC1001396,https://example.com/paper_1396,2020.0,9.0,57,8,True,54.0,8.0,True
cord-001399,Analysis of SARS-CoV-2 and coronavirus and symptoms in clinical settings,This study examines SARS-CoV-2 with 143 word abstract...,Author1399_1,,2020-08-13,medRxiv,10.1000/sample.1399,PMC1001399,https://example.com/paper_1399,2020.0,8.0,72,10,True,56.0,8.0,False
cord-001400,Analysis of COVID-19 and antiviral in clinical settings,This study examines COVID-19 with 344 word abstract...,"Author1400_1, Author1400_2",Journal of Medical Virology,2020-07-14,Medline,10.1000/sample.1400,PMC1001400,https://example.com/paper_1400,2020.0,7.0,55,8,True,54.0,8.0,True
cord-001401,Analysis of immunity and antibody and outbreak in clinical settings,This study examines immunity with 306 word abstract...,"Author1401_1, Author1401_2",Lancet,2020-02-22,ArXiv,10.1000/sample.1401,PMC1001401,,2020.0,2.0,67,10,True,54.0,8.0,True
cord-001403,Analysis of antiviral and respiratory and COVID-19 in clinical settings,This study examines antiviral with 388 word abstract...,Author1403_1,Science Translational Medicine,2020-10-28,medRxiv,10.1000/sample.1403,PMC1001403,https://example.com/paper_1403,2020.0,10.0,71,10,True,55.0,8.0,True
cord-001404,Analysis of respiratory and coronavirus and epidemiology and antibody in clinical settings,This study examines respiratory with 372 word abstract...,Author1404_1,Cell,2020-03-17,Medline,10.1000/sample.1404,,https://example.com/paper_1404,2020.0,3.0,90,12,True,57.0,8.0,True
cord-001405,Analysis of symptoms and clinical and transmission and SARS-CoV-2 in clinical settings,This study examines symptoms with 466 word abstract...,"Author1405_1, Author1405_2",Virology,2020-02-24,medRxiv,10.1000/sample.1405,PMC1001405,,2020.0,2.0,86,12,True,54.0,8.0,True
cord-001407,Analysis of lockdown and respiratory and vaccination in clinical settings,This study examines lockdown with 128 word abstract...,"Author1407_1, Author1407_2",Science,,bioRxiv,10.1000/sample.1407,PMC1001407,https://example.com/paper_1407,,,73,10,True,54.0,8.0,True
cord-001408,Analysis of respiratory and diagnosis and epidemiology and coronavirus in clinical settings,This study examines respiratory with 464 word abstract...,"Author1408_1, Author1408_2",Virology,2019-12-08,PMC,10.1000/sample.1408,PMC1001408,https://example.com/paper_1408,2019.0,12.0,91,12,True,57.0,8.0,True
cord-001411,Analysis of vaccination and diagnosis and SARS-CoV-2 and public health in clinical settings,,"Author1411_1, Author1411_2",New England Journal of Medicine,2021-03-03,WHO,10.1000/sample.1411,PMC1001411,https://example.com/paper_1411,2021.0,3.0,91,13,False,,,True
cord-001412,Analysis of public health and therapeutic and antiviral and symptoms in clinical settings,This study examines public health with 422 word abstract...,"Author1412_1, Author1412_2",Nature,2019-12-13,ArXiv,10.1000/sample.1412,PMC1001412,https://example.com/paper_1412,2019.0,12.0,89,13,True,59.0,9.0,True
cord-001413,Analysis of lockdown and diagnosis and immunity and outbreak in clinical settings,This study examines lockdown with 409 word abstract...,Author1413_1,JAMA,2020-07-12,ArXiv,10.1000/sample.1413,PMC1001413,https://example.com/paper_1413,2020.0,7.0,81,12,True,54.0,8.0,True
cord-001414,Analysis of therapeutic and immunity and outbreak and respiratory in clinical settings,This study examines therapeutic with 146 word abstract...,"Author1414_1, Author1414_2",Cell,2019-12-30,WHO,10.1000/sample.1414,,https://example.com/paper_1414,2019.0,12.0,86,12,True,57.0,8.0,True
cord-001415,Analysis of vaccination and transmission and diagnosis in clinical settings,This study examines vaccination with 117 word abstract...,"Author1415_1, Author1415_2",Clinical Infectious Diseases,2020-10-19,ArXiv,10.1000/sample.1415,PMC1001415,https://example.com/paper_1415,2020.0,10.0,75,10,True,57.0,8.0,True
cord-001417,Analysis of COVID-19 and transmission and respiratory and treatment in clinical settings,This study examines COVID-19 with 327 word abstract...,"Author1417_1, Author1417_2",,2021-10-25,medRxiv,10.1000/sample.1417,PMC1001417,https://example.com/paper_1417,2021.0,10.0,88,12,True,54.0,8.0,False
cord-001419,Analysis of symptoms and antibody and antiviral and vaccination in clinical settings,This study examines symptoms with 127 word abstract...,"Author1419_1, Author1419_2",Virology,2020-03-31,PMC,10.1000/sample.1419,PMC1001419,https://example.com/paper_1419,2020.0,3.0,84,12,True,54.0,8.0,True
cord-001420,Analysis of antibody and antiviral and epidemiology in clinical settings,This study examines antibody with 195 word abstract...,"Author1420_1, Author1420_2",Cell,2021-07-16,Medline,10.1000/sample.1420,PMC1001420,https://example.com/paper_1420,2021.0,7.0,72,10,True,54.0,8.0,True
cord-001421,Analysis of SARS-CoV-2 and transmission and clinical and treatment in clinical settings,This study examines SARS-CoV-2 with 281 word abstract...,"Author1421_1, Author1421_2",,2021-08-28,medRxiv,10.1000/sample.1421,PMC1001421,https://example.com/paper_1421,2021.0,8.0,87,12,True,56.0,8.0,False
cord-001422,Analysis of SARS-CoV-2 and symptoms in clinical settings,This study examines SARS-CoV-2 with 203 word abstract...,"Author1422_1, Author1422_2",Nature,2021-04-29,ArXiv,10.1000/sample.1422,,https://example.com/paper_1422,2021.0,4.0,56,8,True,56.0,8.0,True
cord-001423,Analysis of public health and pneumonia and immunity in clinical settings,This study examines public health with 108 word abstract...,"Author1423_1, Author1423_2",Science Translational Medicine,2021-11-30,Medline,10.1000/sample.1423,,https://example.com/paper_1423,2021.0,11.0,73,11,True,59.0,9.0,True
cord-001424,Analysis of antibody and vaccination and treatment in clinical settings,This study examines antibody with 208 word abstract...,"Author1424_1, Author1424_2",Emerging Infectious Diseases,2020-06-28,PMC,10.1000/sample.1424,PMC1001424,https://example.com/paper_1424,2020.0,6.0,71,10,True,54.0,8.0,True
cord-001425,Analysis of pneumonia and antiviral and public health in clinical settings,This study examines pneumonia with 212 word abstract...,"Author1425_1, Author1425_2",Virology,2020-12-27,bioRxiv,10.1000/sample.1425,,https://example.com/paper_1425,2020.0,12.0,74,11,True,55.0,8.0,True
cord-001426,Analysis of antibody and immunity and clinical in clinical settings,This study examines antibody with 118 word abstract...,Author1426_1,,2021-07-01,bioRxiv,10.1000/sample.1426,PMC1001426,https://example.com/paper_1426,2021.0,7.0,67,10,True,54.0,8.0,False
cord-001427,Analysis of public health and coronavirus and epidemiology and pneumonia in clinical settings,This study examines public health with 441 word abstract...,"Author1427_1, Author1427_2",Emerging Infectious Diseases,2020-03-19,bioRxiv,10.1000/sample.1427,PMC1001427,https://example.com/paper_1427,2020.0,3.0,93,13,True,59.0,9.0,True
cord-001428,Analysis of lockdown and respiratory and COVID-19 and pneumonia in clinical settings,This study examines lockdown with 127 word abstract...,"Author1428_1, Author1428_2",Virology,2019-12-10,ArXiv,,PMC1001428,https://example.com/paper_1428,2019.0,12.0,84,12,True,54.0,8.0,True
cord-001429,Analysis of therapeutic and transmission and pandemic in clinical settings,This study examines therapeutic with 410 word abstract...,"Author1429_1, Author1429_2",Clinical Infectious Diseases,2021-11-21,medRxiv,10.1000/sample.1429,PMC1001429,https://example.com/paper_1429,2021.0,11.0,74,10,True,57.0,8.0,True
cord-001430,Analysis of transmission and SARS-CoV-2 and therapeutic and treatment in clinical settings,This study examines transmission with 229 word abstract...,"Author1430_1, Author1430_2",,2020-06-08,WHO,10.1000/sample.1430,PMC1001430,,2020.0,6.0,90,12,True,58.0,8.0,False
cord-001431,Analysis of vaccination and respiratory and clinical and antibody in clinical settings,,"Author1431_1, Author1431_2",Emerging Infectious Diseases,2021-12-29,WHO,10.1000/sample.1431,PMC1001431,https://example.com/paper_1431,2021.0,12.0,86,12,False,,,True
cord-001432,Analysis of outbreak and epidemiology and COVID-19 in clinical settings,This study examines outbreak with 439 word abstract...,"Author1432_1, Author1432_2",New England Journal of Medicine,2020-06-02,WHO,10.1000/sample.1432,PMC1001432,https://example.com/paper_1432,2020.0,6.0,71,10,True,54.0,8.0,True
cord-001433,Analysis of diagnosis and therapeutic and COVID-19 in clinical settings,,"Author1433_1, Author1433_2",Lancet,2021-12-16,medRxiv,10.1000/sample.1433,PMC1001433,https://example.com/paper_1433,2021.0,12.0,71,10,False,,,True
cord-001434,Analysis of SARS-CoV-2 and transmission and treatment in clinical settings,This study examines SARS-CoV-2 with 365 word abstract...,Author1434_1,JAMA,2022-05-20,Medline,10.1000/sample.1434,PMC1001434,https://example.com/paper_1434,2022.0,5.0,74,10,True,56.0,8.0,True
cord-001436,Analysis of transmission and therapeutic and respiratory in clinical settings,This study examines transmission with 420 word abstract...,"Author1436_1, Author1436_2",Cell,2021-11-28,WHO,10.1000/sample.1436,PMC1001436,https://example.com/paper_1436,2021.0,11.0,77,10,True,58.0,8.0,True
cord-001437,Analysis of immunity and vaccination in clinical settings,This study examines immunity with 167 word abstract...,"Author1437_1, Author1437_2",Nature,2021-09-22,WHO,10.1000/sample.1437,PMC1001437,,2021.0,9.0,57,8,True,54.0,8.0,True
cord-001439,Analysis of coronavirus and vaccination and epidemiology in clinical settings,This study examines coronavirus with 440 word abstract...,"Author1439_1, Author1439_2",,2020-05-15,medRxiv,10.1000/sample.1439,PMC1001439,https://example.com/paper_1439,2020.0,5.0,77,10,True,57.0,8.0,False
cord-001441,Analysis of diagnosis and therapeutic and clinical in clinical settings,This study examines diagnosis with 115 word abstract...,"Author1441_1, Author1441_2",Lancet,2020-01-07,ArXiv,10.1000/sample.1441,PMC1001441,https://example.com/paper_1441,2020.0,1.0,71,10,True,55.0,8.0,True
cord-001442,Analysis of diagnosis and treatment and antibody and epidemiology in clinical settings,This study examines diagnosis with 436 word abstract...,Author1442_1,Science,2020-08-21,WHO,10.1000/sample.1442,PMC1001442,https://example.com/paper_1442,2020.0,8.0,86,12,True,55.0,8.0,True
cord-001443,Analysis of respiratory and pandemic in clinical settings,This study examines respiratory with 104 word abstract...,"Author1443_1, Author1443_2",New England Journal of Medicine,2021-11-20,ArXiv,,PMC1001443,,2021.0,11.0,57,8,True,57.0,8.0,True
cord-001445,Analysis of antibody and symptoms and epidemiology in clinical settings,This study examines antibody with 391 word abstract...,Author1445_1,Clinical Infectious Diseases,2021-02-07,ArXiv,10.1000/sample.1445,PMC1001445,https://example.com/paper_1445,2021.0,2.0,71,10,True,54.0,8.0,True
cord-001446,Analysis of pneumonia and lockdown and antiviral in clinical settings,This study examines pneumonia with 167 word abstract...,"Author1446_1, Author1446_2",New England Journal of Medicine,2022-07-22,bioRxiv,10.1000/sample.1446,PMC1001446,https://example.com/paper_1446,2022.0,7.0,69,10,True,55.0,8.0,True
cord-001447,Analysis of transmission and public health and vaccination and SARS-CoV-2 in clinical settings,This study examines transmission with 235 word abstract...,"Author1447_1, Author1447_2",,2021-12-12,ArXiv,10.1000/sample.1447,,https://example.com/paper_1447,2021.0,12.0,94,13,True,58.0,8.0,False
cord-001448,Analysis of COVID-19 and respiratory and epidemiology in clinical settings,This study examines COVID-19 with 212 word abstract...,"Author1448_1, Author1448_2",New England Journal of Medicine,2020-09-22,PMC,10.1000/sample.1448,PMC1001448,https://example.com/paper_1448,2020.0,9.0,74,10,True,54.0,8.0,True
cord-001449,Analysis of lockdown and epidemiology and pneumonia and pandemic in clinical settings,This study examines lockdown with 283 word abstract...,"Author1449_1, Author1449_2",Journal of Medical Virology,2020-03-07,Medline,10.1000/sample.1449,PMC1001449,https://example.com/paper_1449,2020.0,3.0,85,12,True,54.0,8.0,True
cord-001450,Analysis of pandemic and therapeutic and public health and clinical in clinical settings,This study examines pandemic with 491 word abstract...,"Author1450_1, Author1450_2",Lancet,2021-02-19,medRxiv,10.1000/sample.1450,PMC1001450,https://example.com/paper_1450,2021.0,2.0,88,13,True,54.0,8.0,True
cord-001451,Analysis of public health and pandemic and SARS-CoV-2 in clinical settings,This study examines public health with 248 word abstract...,"Author1451_1, Author1451_2",Cell,2019-12-14,ArXiv,10.1000/sample.1451,,https://example.com/paper_1451,2019.0,12.0,74,11,True,59.0,9.0,True
cord-001452,Analysis of outbreak and public health and COVID-19 in clinical settings,This study examines outbreak with 269 word abstract...,"Author1452_1, Author1452_2",Science,2022-02-19,ArXiv,10.1000/sample.1452,PMC1001452,https://example.com/paper_1452,2022.0,2.0,72,11,True,54.0,8.0,True
cord-001453,Analysis of coronavirus and transmission and therapeutic and symptoms in clinical settings,This study examines coronavirus with 215 word abstract...,Author1453_1,JAMA,2020-01-28,medRxiv,10.1000/sample.1453,PMC1001453,,2020.0,1.0,90,12,True,57.0,8.0,True
cord-001454,Analysis of coronavirus and immunity and outbreak and therapeutic in clinical settings,This study examines coronavirus with 381 word abstract...,Author1454_1,Science Translational Medicine,2020-11-04,bioRxiv,10.1000/sample.1454,,https://example.com/paper_1454,2020.0,11.0,86,12,True,57.0,8.0,True
cord-001455,Analysis of transmission and antibody and clinical and coronavirus in clinical settings,This study examines transmission with 499 word abstract...,"Author1455_1, Author1455_2",,2022-04-10,ArXiv,10.1000/sample.1455,PMC1001455,https://example.com/paper_1455,2022.0,4.0,87,12,True,58.0,8.0,False
cord-001457,Analysis of symptoms and pneumonia and pandemic and coronavirus in clinical settings,This study examines symptoms with 384 word abstract...,"Author1457_1, Author1457_2",Cell,,WHO,10.1000/sample.1457,PMC1001457,https://example.com/paper_1457,,,84,12,True,54.0,8.0,True
cord-001458,Analysis of therapeutic and immunity and antibody in clinical settings,This study examines therapeutic with 335 word abstract...,Author1458_1,Emerging Infectious Diseases,2019-12-21,bioRxiv,10.1000/sample.1458,,https://example.com/paper_1458,2019.0,12.0,70,10,True,57.0,8.0,True
cord-001460,Analysis of antibody and respiratory and epidemiology in clinical settings,This study examines antibody with 177 word abstract...,"Author1460_1, Author1460_2",Virology,2020-10-30,PMC,10.1000/sample.1460,PMC1001460,,2020.0,10.0,74,10,True,54.0,8.0,True
cord-001461,Analysis of pandemic and public health and epidemiology in clinical settings,This study examines pandemic with 387 word abstract...,"Author1461_1, Author1461_2",Virology,2020-12-01,WHO,10.1000/sample.1461,PMC1001461,https://example.com/paper_1461,2020.0,12.0,76,11,True,54.0,8.0,True
cord-001462,Analysis of treatment and lockdown and respiratory in clinical settings,This study examines treatment with 251 word abstract...,"Author1462_1, Author1462_2",Nature Medicine,,WHO,10.1000/sample.1462,,https://example.com/paper_1462,,,71,10,True,55.0,8.0,True
cord-001465,Analysis of pneumonia and respiratory and pandemic in clinical settings,This study examines pneumonia with 374 word abstract...,Author1465_1,Science,2021-09-11,WHO,10.1000/sample.1465,PMC1001465,https://example.com/paper_1465,2021.0,9.0,71,10,True,55.0,8.0,True
cord-001468,Analysis of respiratory and vaccination and antibody in clinical settings,This study examines respiratory with 375 word abstract...,"Author1468_1, Author1468_2",BMJ,2020-01-30,WHO,10.1000/sample.1468,,https://example.com/paper_1468,2020.0,1.0,73,10,True,57.0,8.0,True
cord-001469,Analysis of immunity and pneumonia in clinical settings,This study examines immunity with 373 word abstract...,"Author1469_1, Author1469_2",PLoS ONE,,WHO,10.1000/sample.1469,PMC1001469,https://example.com/paper_1469,,,55,8,True,54.0,8.0,True
cord-001471,Analysis of pandemic and public health and SARS-CoV-2 in clinical settings,This study examines pandemic with 422 word abstract...,"Author1471_1, Author1471_2",Emerging Infectious Diseases,2022-07-13,medRxiv,10.1000/sample.1471,,https://example.com/paper_1471,2022.0,7.0,74,11,True,54.0,8.0,True
cord-001472,Analysis of antibody and respiratory and antiviral in clinical settings,This study examines antibody with 402 word abstract...,"Author1472_1, Author1472_2",BMJ,2020-12-05,WHO,10.1000/sample.1472,,https://example.com/paper_1472,2020.0,12.0,71,10,True,54.0,8.0,True
cord-001473,Analysis of respiratory and pandemic and therapeutic in clinical settings,This study examines respiratory with 289 word abstract...,"Author1473_1, Author1473_2",Journal of Medical Virology,2020-06-26,Medline,10.1000/sample.1473,PMC1001473,https://example.com/paper_1473,2020.0,6.0,73,10,True,57.0,8.0,True
cord-001474,Analysis of SARS-CoV-2 and lockdown and vaccination and pandemic in clinical settings,This study examines SARS-CoV-2 with 285 word abstract...,"Author1474_1, Author1474_2",Science,2021-12-27,bioRxiv,10.1000/sample.1474,PMC1001474,https://example.com/paper_1474,2021.0,12.0,85,12,True,56.0,8.0,True
cord-001475,Analysis of SARS-CoV-2 and diagnosis in clinical settings,This study examines SARS-CoV-2 with 253 word abstract...,"Author1475_1, Author1475_2",Science,2022-08-26,Medline,10.1000/sample.1475,,,2022.0,8.0,57,8,True,56.0,8.0,True
cord-001476,Analysis of COVID-19 and outbreak and treatment in clinical settings,This study examines COVID-19 with 293 word abstract...,"Author1476_1, Author1476_2",Clinical Infectious Diseases,2019-12-25,Medline,10.1000/sample.1476,PMC1001476,https://example.com/paper_1476,2019.0,12.0,68,10,True,54.0,8.0,True
cord-001478,Analysis of respiratory and transmission in clinical settings,This study examines respiratory with 328 word abstract...,"Author1478_1, Author1478_2",Science Translational Medicine,2020-05-07,Medline,10.1000/sample.1478,PMC1001478,https://example.com/paper_1478,2020.0,5.0,61,8,True,57.0,8.0,True
cord-001479,Analysis of clinical and therapeutic and treatment in clinical settings,This study examines clinical with 120 word abstract...,"Author1479_1, Author1479_2",,2021-03-20,Medline,10.1000/sample.1479,PMC1001479,https://example.com/paper_1479,2021.0,3.0,71,10,True,54.0,8.0,False
cord-001480,Analysis of lockdown and public health and pneumonia and respiratory in clinical settings,This study examines lockdown with 441 word abstract...,"Author1480_1, Author1480_2",New England Journal of Medicine,2021-11-19,medRxiv,10.1000/sample.1480,PMC1001480,https://example.com/paper_1480,2021.0,11.0,89,13,True,54.0,8.0,True
cord-001481,Analysis of transmission and outbreak in clinical settings,This study examines transmission with 242 word abstract...,"Author1481_1, Author1481_2",Nature Medicine,2021-10-06,medRxiv,10.1000/sample.1481,PMC1001481,https://example.com/paper_1481,2021.0,10.0,58,8,True,58.0,8.0,True
cord-001482,Analysis of COVID-19 and immunity and outbreak in clinical settings,This study examines COVID-19 with 259 word abstract...,"Author1482_1, Author1482_2",Nature,2021-10-13,WHO,10.1000/sample.1482,PMC1001482,https://example.com/paper_1482,2021.0,10.0,67,10,True,54.0,8.0,True
cord-001483,Analysis of antibody and respiratory and treatment and symptoms in clinical settings,This study examines antibody with 335 word abstract...,"Author1483_1, Author1483_2",Lancet,2020-07-12,medRxiv,10.1000/sample.1483,PMC1001483,https://example.com/paper_1483,2020.0,7.0,84,12,True,54.0,8.0,True
cord-001484,Analysis of treatment and antibody and immunity in clinical settings,This study examines treatment with 356 word abstract...,Author1484_1,,2021-03-15,medRxiv,,,https://example.com/paper_1484,2021.0,3.0,68,10,True,55.0,8.0,False
cord-001485,Analysis of lockdown and antibody and symptoms and diagnosis in clinical settings,This study examines lockdown with 469 word abstract...,"Author1485_1, Author1485_2",Clinical Infectious Diseases,2022-11-01,medRxiv,10.1000/sample.1485,,,2022.0,11.0,81,12,True,54.0,8.0,True
cord-001487,Analysis of respiratory and outbreak and public health in clinical settings,This study examines respiratory with 162 word abstract...,"Author1487_1, Author1487_2",Nature,2021-05-13,Medline,10.1000/sample.1487,,https://example.com/paper_1487,2021.0,5.0,75,11,True,57.0,8.0,True
cord-001488,Analysis of SARS-CoV-2 and public health and antiviral in clinical settings,This study examines SARS-CoV-2 with 336 word abstract...,Author1488_1,Virology,2022-06-20,WHO,10.1000/sample.1488,,https://example.com/paper_1488,2022.0,6.0,75,11,True,56.0,8.0,True
cord-001489,Analysis of treatment and diagnosis and antibody in clinical settings,,"Author1489_1, Author1489_2",PLoS ONE,2020-10-24,medRxiv,10.1000/sample.1489,PMC1001489,https://example.com/paper_1489,2020.0,10.0,69,10,False,,,True
cord-001490,Analysis of therapeutic and antiviral in clinical settings,This study examines therapeutic with 408 word abstract...,,Nature,2020-08-02,ArXiv,10.1000/sample.1490,PMC1001490,,2020.0,8.0,58,8,True,57.0,8.0,True
cord-001491,Analysis of epidemiology and treatment and immunity in clinical settings,This study examines epidemiology with 499 word abstract...,"Author1491_1, Author1491_2",Emerging Infectious Diseases,2021-09-05,Medline,10.1000/sample.1491,PMC1001491,https://example.com/paper_1491,2021.0,9.0,72,10,True,58.0,8.0,True
cord-001492,Analysis of epidemiology and treatment and symptoms in clinical settings,This study examines epidemiology with 396 word abstract...,Author1492_1,PLoS ONE,2020-05-23,PMC,10.1000/sample.1492,,,2020.0,5.0,72,10,True,58.0,8.0,True
cord-001493,Analysis of public health and clinical and lockdown and diagnosis in clinical settings,This study examines public health with 436 word abstract...,"Author1493_1, Author1493_2",Lancet,2020-04-29,WHO,,PMC1001493,https://example.com/paper_1493,2020.0,4.0,86,13,True,59.0,9.0,True
cord-001494,Analysis of symptoms and epidemiology and therapeutic in clinical settings,This study examines symptoms with 353 word abstract...,"Author1494_1, Author1494_2",PLoS ONE,2021-07-26,Medline,10.1000/sample.1494,,https://example.com/paper_1494,2021.0,7.0,74,10,True,54.0,8.0,True
cord-001496,Analysis of transmission and treatment and immunity in clinical settings,This study examines transmission with 392 word abstract...,"Author1496_1, Author1496_2",Emerging Infectious Diseases,2021-11-24,ArXiv,10.1000/sample.1496,PMC1001496,https://example.com/paper_1496,2021.0,11.0,72,10,True,58.0,8.0,True
cord-001498,Analysis of lockdown and clinical and pandemic in clinical settings,This study examines lockdown with 120 word abstract...,"Author1498_1, Author1498_2",,2020-06-19,medRxiv,10.1000/sample.1498,PMC1001498,https://example.com/paper_1498,2020.0,6.0,67,10,True,54.0,8.0,False
cord-001499,Analysis of COVID-19 and outbreak and respiratory in clinical settings,This study examines COVID-19 with 101 word abstract...,"Author1499_1, Author1499_2",Clinical Infectious Diseases,2021-12-14,WHO,10.1000/sample.1499,PMC1001499,https://example.com/paper_1499,2021.0,12.0,70,10,True,54.0,8.0,True
cord-001500,Analysis of antibody and COVID-19 and symptoms in clinical settings,This study examines antibody with 289 word abstract...,"Author1500_1, Author1500_2",PLoS ONE,,ArXiv,10.1000/sample.1500,PMC1001500,https://example.com/paper_1500,,,67,10,True,54.0,8.0,True
cord-001502,Analysis of pandemic and antiviral and pneumonia in clinical settings,This study examines pandemic with 147 word abstract...,"Author1502_1, Author1502_2",Nature,2020-07-26,bioRxiv,10.1000/sample.1502,PMC1001502,https://example.com/paper_1502,2020.0,7.0,69,10,True,54.0,8.0,True
cord-001503,Analysis of treatment and outbreak and vaccination and symptoms in clinical settings,This study examines treatment with 485 word abstract...,"Author1503_1, Author1503_2",JAMA,2021-03-01,WHO,10.1000/sample.1503,PMC1001503,,2021.0,3.0,84,12,True,55.0,8.0,True
cord-001504,Analysis of coronavirus and vaccination and therapeutic and immunity in clinical settings,This study examines coronavirus with 188 word abstract...,"Author1504_1, Author1504_2",Journal of Medical Virology,2020-03-21,ArXiv,10.1000/sample.1504,PMC1001504,https://example.com/paper_1504,2020.0,3.0,89,12,True,57.0,8.0,True
cord-001505,Analysis of lockdown and transmission in clinical settings,,"Author1505_1, Author1505_2",Science Translational Medicine,2021-12-26,Medline,10.1000/sample.1505,,https://example.com/paper_1505,2021.0,12.0,58,8,False,,,True
cord-001509,Analysis of antiviral and therapeutic and pneumonia in clinical settings,This study examines antiviral with 381 word abstract...,"Author1509_1, Author1509_2",Clinical Infectious Diseases,2020-02-22,ArXiv,10.1000/sample.1509,PMC1001509,,2020.0,2.0,72,10,True,55.0,8.0,True
cord-001511,Analysis of coronavirus and treatment and pandemic and pneumonia in clinical settings,This study examines coronavirus with 129 word abstract...,"Author1511_1, Author1511_2",Lancet,2020-04-05,medRxiv,10.1000/sample.1511,PMC1001511,https://example.com/paper_1511,2020.0,4.0,85,12,True,57.0,8.0,True
cord-001514,Analysis of SARS-CoV-2 and transmission and vaccination in clinical settings,This study examines SARS-CoV-2 with 399 word abstract...,"Author1514_1, Author1514_2",Lancet,2019-12-28,PMC,10.1000/sample.1514,PMC1001514,https://example.com/paper_1514,2019.0,12.0,76,10,True,56.0,8.0,True
cord-001515,Analysis of epidemiology and therapeutic in clinical settings,This study examines epidemiology with 224 word abstract...,"Author1515_1, Author1515_2",Clinical Infectious Diseases,2022-02-08,bioRxiv,10.1000/sample.1515,PMC1001515,https://example.com/paper_1515,2022.0,2.0,61,8,True,58.0,8.0,True
cord-001516,Analysis of lockdown and clinical and therapeutic and treatment in clinical settings,This study examines lockdown with 295 word abstract...,"Author1516_1, Author1516_2",Journal of Medical Virology,2021-07-26,Medline,10.1000/sample.1516,,,2021.0,7.0,84,12,True,54.0,8.0,True
cord-001517,Analysis of pneumonia and public health and vaccination and SARS-CoV-2 in clinical settings,This study examines pneumonia with 316 word abstract...,"Author1517_1, Author1517_2",,2019-12-15,WHO,,PMC1001517,https://example.com/paper_1517,2019.0,12.0,91,13,True,55.0,8.0,False
cord-001518,Analysis of treatment and transmission and vaccination in clinical settings,This study examines treatment with 492 word abstract...,"Author1518_1, Author1518_2",Nature,2020-02-21,ArXiv,10.1000/sample.1518,,https://example.com/paper_1518,2020.0,2.0,75,10,True,55.0,8.0,True
cord-001519,Analysis of transmission and diagnosis and coronavirus and antibody in clinical settings,This study examines transmission with 320 word abstract...,"Author1519_1, Author1519_2",New England Journal of Medicine,2020-09-16,WHO,10.1000/sample.1519,PMC1001519,https://example.com/paper_1519,2020.0,9.0,88,12,True,58.0,8.0,True
cord-001520,Analysis of outbreak and epidemiology and transmission in clinical settings,This study examines outbreak with 182 word abstract...,"Author1520_1, Author1520_2",,2020-10-27,medRxiv,10.1000/sample.1520,PMC1001520,,2020.0,10.0,75,10,True,54.0,8.0,False
cord-001521,Analysis of pandemic and treatment and lockdown and epidemiology in clinical settings,This study examines pandemic with 393 word abstract...,Author1521_1,Nature Medicine,2020-10-22,ArXiv,10.1000/sample.1521,PMC1001521,,2020.0,10.0,85,12,True,54.0,8.0,True
cord-001522,Analysis of epidemiology and COVID-19 and lockdown and antibody in clinical settings,This study examines epidemiology with 162 word abstract...,"Author1522_1, Author1522_2",Nature,2019-12-18,ArXiv,10.1000/sample.1522,PMC1001522,https://example.com/paper_1522,2019.0,12.0,84,12,True,58.0,8.0,True
cord-001523,Analysis of respiratory and COVID-19 in clinical settings,This study examines respiratory with 266 word abstract...,"Author1523_1, Author1523_2",Emerging Infectious Diseases,2021-12-04,Medline,10.1000/sample.1523,PMC1001523,https://example.com/paper_1523,2021.0,12.0,57,8,True,57.0,8.0,True
cord-001526,Analysis of outbreak and epidemiology and antiviral and pneumonia in clinical settings,This study examines outbreak with 208 word abstract...,"Author1526_1, Author1526_2",Journal of Medical Virology,2019-12-17,WHO,10.1000/sample.1526,PMC1001526,,2019.0,12.0,86,12,True,54.0,8.0,True
cord-001527,Analysis of public health and therapeutic and outbreak and pandemic in clinical settings,This study examines public health with 160 word abstract...,Author1527_1,New England Journal of Medicine,2021-11-20,medRxiv,,PMC1001527,https://example.com/paper_1527,2021.0,11.0,88,13,True,59.0,9.0,True
cord-001528,Analysis of clinical and epidemiology and diagnosis in clinical settings,This study examines clinical with 257 word abstract...,Author1528_1,Journal of Medical Virology,2021-12-11,Medline,10.1000/sample.1528,PMC1001528,https://example.com/paper_1528,2021.0,12.0,72,10,True,54.0,8.0,True
cord-001529,Analysis of transmission and immunity in clinical settings,This study examines transmission with 452 word abstract...,"Author1529_1, Author1529_2",,2020-10-31,WHO,10.1000/sample.1529,PMC1001529,,2020.0,10.0,58,8,True,58.0,8.0,False
cord-001530,Analysis of symptoms and clinical and COVID-19 in clinical settings,,"Author1530_1, Author1530_2",Emerging Infectious Diseases,2021-10-04,Medline,10.1000/sample.1530,PMC1001530,,2021.0,10.0,67,10,False,,,True
cord-001531,Analysis of therapeutic and treatment and coronavirus in clinical settings,This study examines therapeutic with 421 word abstract...,"Author1531_1, Author1531_2",Lancet,2020-07-02,WHO,,,https://example.com/paper_1531,2020.0,7.0,74,10,True,57.0,8.0,True
cord-001532,Analysis of immunity and pneumonia and clinical in clinical settings,This study examines immunity with 163 word abstract...,"Author1532_1, Author1532_2",Cell,2021-10-19,PMC,10.1000/sample.1532,PMC1001532,https://example.com/paper_1532,2021.0,10.0,68,10,True,54.0,8.0,True
cord-001533,Analysis of antiviral and diagnosis and coronavirus and pneumonia in clinical settings,This study examines antiviral with 284 word abstract...,"Author1533_1, Author1533_2",JAMA,2022-08-15,Medline,10.1000/sample.1533,PMC1001533,https://example.com/paper_1533,2022.0,8.0,86,12,True,55.0,8.0,True
cord-001535,Analysis of pneumonia and public health and vaccination in clinical settings,This study examines pneumonia with 126 word abstract...,Author1535_1,PLoS ONE,2021-08-07,Medline,10.1000/sample.1535,,,2021.0,8.0,76,11,True,55.0,8.0,True
cord-001536,Analysis of epidemiology and symptoms in clinical settings,This study examines epidemiology with 170 word abstract...,"Author1536_1, Author1536_2",Journal of Virology,2021-01-28,WHO,10.1000/sample.1536,PMC1001536,https://example.com/paper_1536,2021.0,1.0,58,8,True,58.0,8.0,True
cord-001537,Analysis of outbreak and therapeutic and symptoms and immunity in clinical settings,,"Author1537_1, Author1537_2",Clinical Infectious Diseases,2021-09-30,PMC,10.1000/sample.1537,,https://example.com/paper_1537,2021.0,9.0,83,12,False,,,True
cord-001540,Analysis of COVID-19 and coronavirus and therapeutic in clinical settings,This study examines COVID-19 with 341 word abstract...,"Author1540_1, Author1540_2",Clinical Infectious Diseases,2021-01-06,bioRxiv,10.1000/sample.1540,PMC1001540,https://example.com/paper_1540,2021.0,1.0,73,10,True,54.0,8.0,True
cord-001542,Analysis of antiviral and clinical and treatment and antibody in clinical settings,This study examines antiviral with 326 word abstract...,Author1542_1,BMJ,2020-04-18,PMC,,PMC1001542,https://example.com/paper_1542,2020.0,4.0,82,12,True,55.0,8.0,True
cord-001545,Analysis of coronavirus and treatment and pandemic in clinical settings,This study examines coronavirus with 310 word abstract...,"Author1545_1, Author1545_2",Journal of Medical Virology,2020-08-02,Medline,10.1000/sample.1545,,https://example.com/paper_1545,2020.0,8.0,71,10,True,57.0,8.0,True
cord-001546,Analysis of clinical and pandemic and epidemiology in clinical settings,This study examines clinical with 402 word abstract...,"Author1546_1, Author1546_2",Science Translational Medicine,2020-04-21,medRxiv,10.1000/sample.1546,PMC1001546,https://example.com/paper_1546,2020.0,4.0,71,10,True,54.0,8.0,True
cord-001547,Analysis of COVID-19 and outbreak and immunity in clinical settings,This study examines COVID-19 with 457 word abstract...,"Author1547_1, Author1547_2",Cell,2020-09-02,bioRxiv,,PMC1001547,https://example.com/paper_1547,2020.0,9.0,67,10,True,54.0,8.0,True
cord-001551,Analysis of antibody and therapeutic and symptoms and public health in clinical settings,This study examines antibody with 466 word abstract...,"Author1551_1, Author1551_2",Virology,2022-05-05,bioRxiv,10.1000/sample.1551,PMC1001551,https://example.com/paper_1551,2022.0,5.0,88,13,True,54.0,8.0,True
cord-001553,Analysis of outbreak and epidemiology and coronavirus and vaccination in clinical settings,This study examines outbreak with 328 word abstract...,Author1553_1,Nature Medicine,2022-06-01,Medline,10.1000/sample.1553,PMC1001553,https://example.com/paper_1553,2022.0,6.0,90,12,True,54.0,8.0,True
cord-001554,Analysis of outbreak and symptoms in clinical settings,This study examines outbreak with 444 word abstract...,Author1554_1,BMJ,2020-07-20,medRxiv,10.1000/sample.1554,PMC1001554,https://example.com/paper_1554,2020.0,7.0,54,8,True,54.0,8.0,True
cord-001555,Analysis of epidemiology and symptoms and pneumonia in clinical settings,This study examines epidemiology with 118 word abstract...,"Author1555_1, Author1555_2",Virology,2020-08-16,PMC,10.1000/sample.1555,PMC1001555,https://example.com/paper_1555,2020.0,8.0,72,10,True,58.0,8.0,True
cord-001557,Analysis of pandemic and outbreak and COVID-19 and SARS-CoV-2 in clinical settings,This study examines pandemic with 405 word abstract...,"Author1557_1, Author1557_2",Nature Medicine,2021-12-15,medRxiv,10.1000/sample.1557,PMC1001557,https://example.com/paper_1557,2021.0,12.0,82,12,True,54.0,8.0,True
cord-001560,Analysis of outbreak and public health and treatment and antibody in clinical settings,This study examines outbreak with 368 word abstract...,"Author1560_1, Author1560_2",Journal of Virology,2020-07-08,PMC,10.1000/sample.1560,,https://example.com/paper_1560,2020.0,7.0,86,13,True,54.0,8.0,True
cord-001561,Analysis of pneumonia and symptoms and transmission and vaccination in clinical settings,This study examines pneumonia with 214 word abstract...,"Author1561_1, Author1561_2",BMJ,,bioRxiv,10.1000/sample.1561,PMC1001561,https://example.com/paper_1561,,,88,12,True,55.0,8.0,True
cord-001562,Analysis of vaccination and antibody and epidemiology and SARS-CoV-2 in clinical settings,This study examines vaccination with 190 word abstract...,"Author1562_1, Author1562_2",,2021-12-13,ArXiv,10.1000/sample.1562,PMC1001562,https://example.com/paper_1562,2021.0,12.0,89,12,True,57.0,8.0,False
cord-001563,Analysis of antiviral and epidemiology in clinical settings,This study examines antiviral with 478 word abstract...,"Author1563_1, Author1563_2",Lancet,2020-02-20,Medline,10.1000/sample.1563,,https://example.com/paper_1563,2020.0,2.0,59,8,True,55.0,8.0,True
cord-001567,Analysis of diagnosis and antibody and lockdown in clinical settings,This study examines diagnosis with 272 word abstract...,"Author1567_1, Author1567_2",Cell,2020-02-10,PMC,10.1000/sample.1567,PMC1001567,https://example.com/paper_1567,2020.0,2.0,68,10,True,55.0,8.0,True
cord-001568,Analysis of outbreak and coronavirus in clinical settings,This study examines outbreak with 110 word abstract...,"Author1568_1, Author1568_2",,2021-03-11,medRxiv,10.1000/sample.1568,PMC1001568,https://example.com/paper_1568,2021.0,3.0,57,8,True,54.0,8.0,False
cord-001569,Analysis of antiviral and epidemiology and antibody in clinical settings,This study examines antiviral with 140 word abstract...,"Author1569_1, Author1569_2",Nature,2021-05-23,PMC,10.1000/sample.1569,PMC1001569,https://example.com/paper_1569,2021.0,5.0,72,10,True,55.0,8.0,True
cord-001570,Analysis of coronavirus and diagnosis and COVID-19 and pneumonia in clinical settings,This study examines coronavirus with 437 word abstract...,"Author1570_1, Author1570_2",PLoS ONE,2022-02-26,Medline,10.1000/sample.1570,PMC1001570,,2022.0,2.0,85,12,True,57.0,8.0,True
cord-001571,Analysis of SARS-CoV-2 and lockdown and respiratory in clinical settings,This study examines SARS-CoV-2 with 298 word abstract...,"Author1571_1, Author1571_2",Journal of Medical Virology,2020-12-30,Medline,10.1000/sample.1571,PMC1001571,https://example.com/paper_1571,2020.0,12.0,72,10,True,56.0,8.0,True
cord-001573,Analysis of immunity and pandemic and antibody and symptoms in clinical settings,This study examines immunity with 277 word abstract...,"Author1573_1, Author1573_2",Journal of Medical Virology,2021-01-06,medRxiv,10.1000/sample.1573,PMC1001573,https://example.com/paper_1573,2021.0,1.0,80,12,True,54.0,8.0,True
cord-001574,Analysis of epidemiology and lockdown and vaccination and immunity in clinical settings,This study examines epidemiology with 476 word abstract...,"Author1574_1, Author1574_2",JAMA,2021-11-07,PMC,10.1000/sample.1574,,https://example.com/paper_1574,2021.0,11.0,87,12,True,58.0,8.0,True
cord-001575,Analysis of respiratory and pneumonia and lockdown in clinical settings,This study examines respiratory with 110 word abstract...,,Journal of Virology,2021-12-27,ArXiv,,PMC1001575,https://example.com/paper_1575,2021.0,12.0,71,10,True,57.0,8.0,True
cord-001576,Analysis of clinical and pandemic and epidemiology and pneumonia in clinical settings,This study examines clinical with 301 word abstract...,,Journal of Medical Virology,2019-12-24,ArXiv,10.1000/sample.1576,PMC1001576,,2019.0,12.0,85,12,True,54.0,8.0,True
cord-001580,Analysis of antibody and outbreak and pandemic and antiviral in clinical settings,This study examines antibody with 119 word abstract...,"Author1580_1, Author1580_2",Journal of Medical Virology,2020-07-16,ArXiv,10.1000/sample.1580,,https://example.com/paper_1580,2020.0,7.0,81,12,True,54.0,8.0,True
cord-001581,Analysis of transmission and pneumonia and immunity in clinical settings,This study examines transmission with 398 word abstract...,"Author1581_1, Author1581_2",Virology,2021-01-12,WHO,,,https://example.com/paper_1581,2021.0,1.0,72,10,True,58.0,8.0,True
cord-001583,Analysis of SARS-CoV-2 and symptoms and diagnosis and antibody in clinical settings,This study examines SARS-CoV-2 with 331 word abstract...,"Author1583_1, Author1583_2",Virology,2021-03-08,WHO,10.1000/sample.1583,PMC1001583,https://example.com/paper_1583,2021.0,3.0,83,12,True,56.0,8.0,True
cord-001584,Analysis of outbreak and immunity and antiviral in clinical settings,This study examines outbreak with 282 word abstract...,"Author1584_1, Author1584_2",JAMA,2019-12-03,bioRxiv,10.1000/sample.1584,,,2019.0,12.0,68,10,True,54.0,8.0,True
cord-001586,Analysis of lockdown and epidemiology in clinical settings,This study examines lockdown with 320 word abstract...,"Author1586_1, Author1586_2",New England Journal of Medicine,2020-01-06,ArXiv,10.1000/sample.1586,PMC1001586,https://example.com/paper_1586,2020.0,1.0,58,8,True,54.0,8.0,True
cord-001587,Analysis of epidemiology and pandemic and antibody in clinical settings,This study examines epidemiology with 163 word abstract...,"Author1587_1, Author1587_2",Virology,2020-11-19,WHO,10.1000/sample.1587,,https://example.com/paper_1587,2020.0,11.0,71,10,True,58.0,8.0,True
cord-001589,Analysis of antibody and pandemic in clinical settings,This study examines antibody with 191 word abstract...,"Author1589_1, Author1589_2",Science Translational Medicine,2020-11-05,WHO,10.1000/sample.1589,PMC1001589,https://example.com/paper_1589,2020.0,11.0,54,8,True,54.0,8.0,True
cord-001590,Analysis of outbreak and therapeutic and antiviral and clinical in clinical settings,This study examines outbreak with 266 word abstract...,"Author1590_1, Author1590_2",Clinical Infectious Diseases,2019-12-15,bioRxiv,10.1000/sample.1590,PMC1001590,,2019.0,12.0,84,12,True,54.0,8.0,True
cord-001593,Analysis of diagnosis and COVID-19 and antibody and respiratory in clinical settings,This study examines diagnosis with 410 word abstract...,"Author1593_1, Author1593_2",Journal of Medical Virology,2021-06-04,WHO,10.1000/sample.1593,PMC1001593,https://example.com/paper_1593,2021.0,6.0,84,12,True,55.0,8.0,True
cord-001594,Analysis of antiviral and antibody and transmission and pandemic in clinical settings,This study examines antiviral with 276 word abstract...,"Author1594_1, Author1594_2",Cell,2022-04-17,PMC,10.1000/sample.1594,PMC1001594,,2022.0,4.0,85,12,True,55.0,8.0,True
cord-001595,Analysis of symptoms and pandemic and treatment and pneumonia in clinical settings,This study examines symptoms with 468 word abstract...,"Author1595_1, Author1595_2",Science Translational Medicine,2022-02-15,ArXiv,10.1000/sample.1595,PMC1001595,https://example.com/paper_1595,2022.0,2.0,82,12,True,54.0,8.0,True
cord-001596,Analysis of antibody and outbreak and vaccination and COVID-19 in clinical settings,This study examines antibody with 121 word abstract...,Author1596_1,Journal of Medical Virology,2022-10-16,Medline,10.1000/sample.1596,PMC1001596,,2022.0,10.0,83,12,True,54.0,8.0,True
cord-001597,Analysis of therapeutic and coronavirus and treatment in clinical settings,This study examines therapeutic with 345 word abstract...,Author1597_1,Cell,2021-01-22,ArXiv,10.1000/sample.1597,PMC1001597,https://example.com/paper_1597,2021.0,1.0,74,10,True,57.0,8.0,True
cord-001599,Analysis of vaccination and outbreak and coronavirus in clinical settings,This study examines vaccination with 255 word abstract...,"Author1599_1, Author1599_2",Journal of Medical Virology,2022-03-04,WHO,10.1000/sample.1599,PMC1001599,https://example.com/paper_1599,2022.0,3.0,73,10,True,57.0,8.0,True
cord-001600,Analysis of pneumonia and COVID-19 and treatment in clinical settings,,"Author1600_1, Author1600_2",,2019-12-01,medRxiv,10.1000/sample.1600,PMC1001600,https://example.com/paper_1600,2019.0,12.0,69,10,False,,,False
cord-001601,Analysis of immunity and SARS-CoV-2 and pneumonia in clinical settings,This study examines immunity with 404 word abstract...,"Author1601_1, Author1601_2",Journal of Medical Virology,2020-08-04,medRxiv,10.1000/sample.1601,,,2020.0,8.0,70,10,True,54.0,8.0,True
cord-001603,Analysis of clinical and antibody and SARS-CoV-2 and immunity in clinical settings,,"Author1603_1, Author1603_2",Lancet,2021-06-22,medRxiv,10.1000/sample.1603,,https://example.com/paper_1603,2021.0,6.0,82,12,False,,,True
cord-001604,Analysis of antibody and coronavirus and COVID-19 and lockdown in clinical settings,This study examines antibody with 180 word abstract...,"Author1604_1, Author1604_2",Journal of Medical Virology,2020-04-29,WHO,,PMC1001604,,2020.0,4.0,83,12,True,54.0,8.0,True
cord-001606,Analysis of transmission and antibody and diagnosis and clinical in clinical settings,This study examines transmission with 186 word abstract...,"Author1606_1, Author1606_2",,2020-02-27,bioRxiv,,PMC1001606,https://example.com/paper_1606,2020.0,2.0,85,12,True,58.0,8.0,False
cord-001607,Analysis of vaccination and clinical and transmission in clinical settings,This study examines vaccination with 490 word abstract...,"Author1607_1, Author1607_2",Cell,2021-04-25,bioRxiv,10.1000/sample.1607,,https://example.com/paper_1607,2021.0,4.0,74,10,True,57.0,8.0,True
cord-001608,Analysis of immunity and pneumonia and lockdown in clinical settings,This study examines immunity with 131 word abstract...,"Author1608_1, Author1608_2",Virology,2021-11-24,bioRxiv,10.1000/sample.1608,PMC1001608,https://example.com/paper_1608,2021.0,11.0,68,10,True,54.0,8.0,True
cord-001609,Analysis of immunity and clinical and COVID-19 and antibody in clinical settings,This study examines immunity with 240 word abstract...,"Author1609_1, Author1609_2",,2021-03-14,PMC,10.1000/sample.1609,PMC1001609,https://example.com/paper_1609,2021.0,3.0,80,12,True,54.0,8.0,False
cord-001613,Analysis of SARS-CoV-2 and pneumonia and public health and symptoms in clinical settings,This study examines SARS-CoV-2 with 427 word abstract...,"Author1613_1, Author1613_2",Virology,2021-05-07,medRxiv,10.1000/sample.1613,,https://example.com/paper_1613,2021.0,5.0,88,13,True,56.0,8.0,True
cord-001615,Analysis of therapeutic and epidemiology and antiviral in clinical settings,This study examines therapeutic with 183 word abstract...,"Author1615_1, Author1615_2",Nature Medicine,2020-05-26,ArXiv,10.1000/sample.1615,PMC1001615,https://example.com/paper_1615,2020.0,5.0,75,10,True,57.0,8.0,True
cord-001616,Analysis of treatment and antiviral and COVID-19 and epidemiology in clinical settings,This study examines treatment with 495 word abstract...,"Author1616_1, Author1616_2",,2020-06-01,PMC,10.1000/sample.1616,,https://example.com/paper_1616,2020.0,6.0,86,12,True,55.0,8.0,False
cord-001617,Analysis of public health and vaccination and diagnosis and outbreak in clinical settings,This study examines public health with 192 word abstract...,"Author1617_1, Author1617_2",,2021-10-24,ArXiv,10.1000/sample.1617,PMC1001617,https://example.com/paper_1617,2021.0,10.0,89,13,True,59.0,9.0,False
cord-001619,Analysis of symptoms and outbreak and therapeutic and COVID-19 in clinical settings,This study examines symptoms with 291 word abstract...,"Author1619_1, Author1619_2",,2021-02-13,Medline,10.1000/sample.1619,,https://example.com/paper_1619,2021.0,2.0,83,12,True,54.0,8.0,False
cord-001620,Analysis of symptoms and epidemiology in clinical settings,This study examines symptoms with 132 word abstract...,"Author1620_1, Author1620_2",PLoS ONE,2019-12-19,medRxiv,10.1000/sample.1620,PMC1001620,https://example.com/paper_1620,2019.0,12.0,58,8,True,54.0,8.0,True
cord-001624,Analysis of antibody and COVID-19 and diagnosis in clinical settings,This study examines antibody with 415 word abstract...,"Author1624_1, Author1624_2",Nature Medicine,2021-10-22,WHO,10.1000/sample.1624,PMC1001624,https://example.com/paper_1624,2021.0,10.0,68,10,True,54.0,8.0,True
cord-001627,Analysis of public health and SARS-CoV-2 and respiratory and antibody in clinical settings,This study examines public health with 228 word abstract...,"Author1627_1, Author1627_2",BMJ,2021-08-21,bioRxiv,10.1000/sample.1627,PMC1001627,https://example.com/paper_1627,2021.0,8.0,90,13,True,59.0,9.0,True
cord-001628,Analysis of transmission and diagnosis and epidemiology in clinical settings,This study examines transmission with 216 word abstract...,"Author1628_1, Author1628_2",Virology,2021-11-04,Medline,10.1000/sample.1628,PMC1001628,https://example.com/paper_1628,2021.0,11.0,76,10,True,58.0,8.0,True
cord-001629,Analysis of public health and therapeutic and antibody and diagnosis in clinical settings,This study examines public health with 412 word abstract...,Author1629_1,JAMA,2021-09-18,Medline,10.1000/sample.1629,PMC1001629,https://example.com/paper_1629,2021.0,9.0,89,13,True,59.0,9.0,True
cord-001630,Analysis of antiviral and diagnosis and symptoms in clinical settings,This study examines antiviral with 341 word abstract...,"Author1630_1, Author1630_2",PLoS ONE,2021-09-13,PMC,10.1000/sample.1630,PMC1001630,https://example.com/paper_1630,2021.0,9.0,69,10,True,55.0,8.0,True
cord-001632,Analysis of pneumonia and immunity in clinical settings,This study examines pneumonia with 382 word abstract...,Author1632_1,Emerging Infectious Diseases,2021-03-10,PMC,10.1000/sample.1632,PMC1001632,https://example.com/paper_1632,2021.0,3.0,55,8,True,55.0,8.0,True
cord-001633,Analysis of COVID-19 and SARS-CoV-2 and transmission and respiratory in clinical settings,This study examines COVID-19 with 116 word abstract...,"Author1633_1, Author1633_2",Emerging Infectious Diseases,2021-09-09,ArXiv,10.1000/sample.1633,PMC1001633,https://example.com/paper_1633,2021.0,9.0,89,12,True,54.0,8.0,True
cord-001636,Analysis of symptoms and transmission and epidemiology and coronavirus in clinical settings,This study examines symptoms with 387 word abstract...,"Author1636_1, Author1636_2",Clinical Infectious Diseases,2020-09-19,medRxiv,10.1000/sample.1636,PMC1001636,https://example.com/paper_1636,2020.0,9.0,91,12,True,54.0,8.0,True
cord-001637,Analysis of coronavirus and respiratory and symptoms and vaccination in clinical settings,This study examines coronavirus with 278 word abstract...,Author1637_1,Lancet,2022-09-04,bioRxiv,10.1000/sample.1637,,https://example.com/paper_1637,2022.0,9.0,89,12,True,57.0,8.0,True
cord-001640,Analysis of coronavirus and pandemic in clinical settings,This study examines coronavirus with 456 word abstract...,Author1640_1,Nature Medicine,2021-10-14,bioRxiv,10.1000/sample.1640,PMC1001640,https://example.com/paper_1640,2021.0,10.0,57,8,True,57.0,8.0,True
cord-001641,Analysis of antiviral and clinical and antibody and treatment in clinical settings,,"Author1641_1, Author1641_2",PLoS ONE,2020-01-02,Medline,10.1000/sample.1641,,,2020.0,1.0,82,12,False,,,True
cord-001644,Analysis of therapeutic and epidemiology and immunity and transmission in clinical settings,This study examines therapeutic with 233 word abstract...,Author1644_1,Nature Medicine,2020-06-11,WHO,10.1000/sample.1644,,https://example.com/paper_1644,2020.0,6.0,91,12,True,57.0,8.0,True
cord-001645,Analysis of immunity and diagnosis and COVID-19 in clinical settings,This study examines immunity with 142 word abstract...,"Author1645_1, Author1645_2",Lancet,2020-11-30,PMC,10.1000/sample.1645,,https://example.com/paper_1645,2020.0,11.0,68,10,True,54.0,8.0,True
cord-001647,Analysis of clinical and antibody and pneumonia and outbreak in clinical settings,This study examines clinical with 364 word abstract...,"Author1647_1, Author1647_2",Virology,2020-04-04,medRxiv,10.1000/sample.1647,PMC1001647,https://example.com/paper_1647,2020.0,4.0,81,12,True,54.0,8.0,True
cord-001649,Analysis of antiviral and coronavirus and transmission in clinical settings,This study examines antiviral with 364 word abstract...,"Author1649_1, Author1649_2",New England Journal of Medicine,2020-11-21,medRxiv,10.1000/sample.1649,PMC1001649,https://example.com/paper_1649,2020.0,11.0,75,10,True,55.0,8.0,True
cord-001651,Analysis of COVID-19 and clinical and transmission in clinical settings,This study examines COVID-19 with 109 word abstract...,"Author1651_1, Author1651_2",Emerging Infectious Diseases,2021-11-09,bioRxiv,10.1000/sample.1651,,https://example.com/paper_1651,2021.0,11.0,71,10,True,54.0,8.0,True
cord-001652,Analysis of clinical and epidemiology and coronavirus in clinical settings,This study examines clinical with 339 word abstract...,"Author1652_1, Author1652_2",Clinical Infectious Diseases,2021-10-17,Medline,,PMC1001652,https://example.com/paper_1652,2021.0,10.0,74,10,True,54.0,8.0,True
cord-001653,Analysis of immunity and diagnosis and pneumonia and antiviral in clinical settings,This study examines immunity with 212 word abstract...,"Author1653_1, Author1653_2",Journal of Medical Virology,2020-06-16,WHO,10.1000/sample.1653,PMC1001653,https://example.com/paper_1653,2020.0,6.0,83,12,True,54.0,8.0,True
cord-001654,Analysis of epidemiology and antiviral and therapeutic and diagnosis in clinical settings,This study examines epidemiology with 361 word abstract...,,Journal of Medical Virology,2022-10-31,Medline,10.1000/sample.1654,PMC1001654,https://example.com/paper_1654,2022.0,10.0,89,12,True,58.0,8.0,True
cord-001656,Analysis of therapeutic and respiratory and transmission and coronavirus in clinical settings,This study examines therapeutic with 182 word abstract...,"Author1656_1, Author1656_2",Cell,2020-04-02,PMC,,PMC1001656,https://example.com/paper_1656,2020.0,4.0,93,12,True,57.0,8.0,True
cord-001657,Analysis of epidemiology and lockdown and treatment in clinical settings,This study examines epidemiology with 377 word abstract...,"Author1657_1, Author1657_2",JAMA,2022-08-30,Medline,10.1000/sample.1657,PMC1001657,https://example.com/paper_1657,2022.0,8.0,72,10,True,58.0,8.0,True
cord-001658,Analysis of lockdown and transmission and vaccination and SARS-CoV-2 in clinical settings,This study examines lockdown with 243 word abstract...,"Author1658_1, Author1658_2",Journal of Virology,2022-10-20,medRxiv,10.1000/sample.1658,PMC1001658,https://example.com/paper_1658,2022.0,10.0,89,12,True,54.0,8.0,True
cord-001659,Analysis of vaccination and immunity and SARS-CoV-2 and epidemiology in clinical settings,This study examines vaccination with 202 word abstract...,"Author1659_1, Author1659_2",Virology,2020-07-02,WHO,10.1000/sample.1659,PMC1001659,,2020.0,7.0,89,12,True,57.0,8.0,True
cord-001660,Analysis of respiratory and vaccination and pandemic and transmission in clinical settings,This study examines respiratory with 484 word abstract...,"Author1660_1, Author1660_2",Virology,2021-04-29,WHO,10.1000/sample.1660,PMC1001660,https://example.com/paper_1660,2021.0,4.0,90,12,True,57.0,8.0,True
cord-001661,Analysis of vaccination and respiratory and epidemiology and antiviral in clinical settings,This study examines vaccination with 175 word abstract...,"Author1661_1, Author1661_2",BMJ,2020-01-26,Medline,10.1000/sample.1661,PMC1001661,https://example.com/paper_1661,2020.0,1.0,91,12,True,57.0,8.0,True
cord-001662,Analysis of pandemic and treatment and transmission in clinical settings,This study examines pandemic with 464 word abstract...,"Author1662_1, Author1662_2",,,PMC,10.1000/sample.1662,,,,,72,10,True,54.0,8.0,False
cord-001664,Analysis of coronavirus and epidemiology and antibody in clinical settings,This study examines coronavirus with 481 word abstract...,Author1664_1,Cell,2021-09-19,bioRxiv,,,https://example.com/paper_1664,2021.0,9.0,74,10,True,57.0,8.0,True
cord-001665,Analysis of COVID-19 and transmission and antiviral and pandemic in clinical settings,This study examines COVID-19 with 220 word abstract...,"Author1665_1, Author1665_2",,2022-08-01,PMC,10.1000/sample.1665,,https://example.com/paper_1665,2022.0,8.0,85,12,True,54.0,8.0,False
cord-001667,Analysis of pneumonia and antiviral and lockdown in clinical settings,This study examines pneumonia with 427 word abstract...,"Author1667_1, Author1667_2",Science,2021-10-20,WHO,10.1000/sample.1667,,https://example.com/paper_1667,2021.0,10.0,69,10,True,55.0,8.0,True
cord-001668,Analysis of public health and pneumonia and antiviral and COVID-19 in clinical settings,This study examines public health with 145 word abstract...,,,2020-05-06,ArXiv,10.1000/sample.1668,PMC1001668,https://example.com/paper_1668,2020.0,5.0,87,13,True,59.0,9.0,False
cord-001670,Analysis of lockdown and therapeutic and pandemic and immunity in clinical settings,This study examines lockdown with 427 word abstract...,"Author1670_1, Author1670_2",PLoS ONE,2021-10-29,WHO,10.1000/sample.1670,PMC1001670,,2021.0,10.0,83,12,True,54.0,8.0,True
cord-001671,Analysis of pandemic and SARS-CoV-2 and immunity in clinical settings,This study examines pandemic with 287 word abstract...,"Author1671_1, Author1671_2",Journal of Medical Virology,2020-02-12,Medline,10.1000/sample.1671,PMC1001671,https://example.com/paper_1671,2020.0,2.0,69,10,True,54.0,8.0,True
cord-001672,Analysis of antiviral and immunity and pandemic and therapeutic in clinical settings,This study examines antiviral with 361 word abstract...,"Author1672_1, Author1672_2",PLoS ONE,2020-02-12,bioRxiv,10.1000/sample.1672,PMC1001672,,2020.0,2.0,84,12,True,55.0,8.0,True
cord-001674,Analysis of antiviral and pneumonia and COVID-19 in clinical settings,This study examines antiviral with 210 word abstract...,"Author1674_1, Author1674_2",Emerging Infectious Diseases,2021-01-23,medRxiv,,PMC1001674,https://example.com/paper_1674,2021.0,1.0,69,10,True,55.0,8.0,True
cord-001675,Analysis of therapeutic and epidemiology in clinical settings,This study examines therapeutic with 153 word abstract...,"Author1675_1, Author1675_2",Science Translational Medicine,2020-11-20,WHO,10.1000/sample.1675,PMC1001675,https://example.com/paper_1675,2020.0,11.0,61,8,True,57.0,8.0,True
cord-001677,Analysis of antibody and antiviral and vaccination and COVID-19 in clinical settings,This study examines antibody with 194 word abstract...,"Author1677_1, Author1677_2",Virology,2020-08-15,medRxiv,10.1000/sample.1677,,https://example.com/paper_1677,2020.0,8.0,84,12,True,54.0,8.0,True
cord-001679,Analysis of symptoms and respiratory and clinical in clinical settings,This study examines symptoms with 454 word abstract...,"Author1679_1, Author1679_2",Science,2019-12-28,medRxiv,10.1000/sample.1679,,https://example.com/paper_1679,2019.0,12.0,70,10,True,54.0,8.0,True
cord-001680,Analysis of coronavirus and COVID-19 and outbreak in clinical settings,This study examines coronavirus with 216 word abstract...,"Author1680_1, Author1680_2",Clinical Infectious Diseases,2020-09-01,PMC,10.1000/sample.1680,PMC1001680,https://example.com/paper_1680,2020.0,9.0,70,10,True,57.0,8.0,True
cord-001682,Analysis of pneumonia and diagnosis and lockdown and public health in clinical settings,This study examines pneumonia with 206 word abstract...,"Author1682_1, Author1682_2",Science Translational Medicine,2022-11-13,PMC,10.1000/sample.1682,PMC1001682,https://example.com/paper_1682,2022.0,11.0,87,13,True,55.0,8.0,True
cord-001684,Analysis of outbreak and clinical and antibody in clinical settings,This study examines outbreak with 473 word abstract...,"Author1684_1, Author1684_2",Cell,,Medline,10.1000/sample.1684,PMC1001684,,,,67,10,True,54.0,8.0,True
cord-001685,Analysis of coronavirus and lockdown and outbreak in clinical settings,This study examines coronavirus with 341 word abstract...,"Author1685_1, Author1685_2",Science Translational Medicine,2021-07-03,bioRxiv,10.1000/sample.1685,PMC1001685,https://example.com/paper_1685,2021.0,7.0,70,10,True,57.0,8.0,True
cord-001688,Analysis of immunity and therapeutic and transmission in clinical settings,This study examines immunity with 189 word abstract...,"Author1688_1, Author1688_2",Clinical Infectious Diseases,2021-01-28,Medline,10.1000/sample.1688,,https://example.com/paper_1688,2021.0,1.0,74,10,True,54.0,8.0,True
cord-001690,Analysis of respiratory and transmission and outbreak in clinical settings,This study examines respiratory with 262 word abstract...,"Author1690_1, Author1690_2",Clinical Infectious Diseases,2022-07-12,Medline,10.1000/sample.1690,PMC1001690,,2022.0,7.0,74,10,True,57.0,8.0,True
cord-001691,Analysis of antibody and coronavirus and transmission in clinical settings,This study examines antibody with 488 word abstract...,Author1691_1,PLoS ONE,2020-06-04,bioRxiv,10.1000/sample.1691,PMC1001691,https://example.com/paper_1691,2020.0,6.0,74,10,True,54.0,8.0,True
cord-001692,Analysis of diagnosis and treatment and respiratory in clinical settings,This study examines diagnosis with 336 word abstract...,"Author1692_1, Author1692_2",,2020-10-05,ArXiv,10.1000/sample.1692,,https://example.com/paper_1692,2020.0,10.0,72,10,True,55.0,8.0,False
cord-001693,Analysis of epidemiology and antiviral and transmission in clinical settings,This study examines epidemiology with 341 word abstract...,"Author1693_1, Author1693_2",Nature,2021-12-18,medRxiv,10.1000/sample.1693,PMC1001693,https://example.com/paper_1693,2021.0,12.0,76,10,True,58.0,8.0,True
cord-001694,Analysis of clinical and public health and diagnosis and lockdown in clinical settings,This study examines clinical with 298 word abstract...,Author1694_1,Virology,2020-07-04,ArXiv,10.1000/sample.1694,,https://example.com/paper_1694,2020.0,7.0,86,13,True,54.0,8.0,True
cord-001695,Analysis of COVID-19 and symptoms and lockdown and SARS-CoV-2 in clinical settings,This study examines COVID-19 with 297 word abstract...,"Author1695_1, Author1695_2",,2020-02-02,WHO,10.1000/sample.1695,,https://example.com/paper_1695,2020.0,2.0,82,12,True,54.0,8.0,False
cord-001697,Analysis of diagnosis and public health and clinical and treatment in clinical settings,This study examines diagnosis with 486 word abstract...,"Author1697_1, Author1697_2",Lancet,2020-03-11,Medline,10.1000/sample.1697,PMC1001697,https://example.com/paper_1697,2020.0,3.0,87,13,True,55.0,8.0,True
cord-001698,Analysis of coronavirus and SARS-CoV-2 and clinical in clinical settings,This study examines coronavirus with 320 word abstract...,"Author1698_1, Author1698_2",PLoS ONE,2022-10-16,ArXiv,10.1000/sample.1698,,https://example.com/paper_1698,2022.0,10.0,72,10,True,57.0,8.0,True
cord-001699,Analysis of pneumonia and therapeutic and vaccination and public health in clinical settings,This study examines pneumonia with 383 word abstract...,"Author1699_1, Author1699_2",Science,2020-12-15,bioRxiv,10.1000/sample.1699,PMC1001699,https://example.com/paper_1699,2020.0,12.0,92,13,True,55.0,8.0,True
cord-001700,Analysis of clinical and public health and antiviral in clinical settings,This study examines clinical with 335 word abstract...,"Author1700_1, Author1700_2",,2020-06-01,WHO,10.1000/sample.1700,PMC1001700,,2020.0,6.0,73,11,True,54.0,8.0,False
cord-001703,Analysis of coronavirus and respiratory and immunity in clinical settings,This study examines coronavirus with 459 word abstract...,"Author1703_1, Author1703_2",Cell,2020-06-19,WHO,10.1000/sample.1703,PMC1001703,,2020.0,6.0,73,10,True,57.0,8.0,True
cord-001705,Analysis of respiratory and public health and epidemiology and diagnosis in clinical settings,This study examines respiratory with 318 word abstract...,"Author1705_1, Author1705_2",Cell,2021-09-12,bioRxiv,10.1000/sample.1705,,https://example.com/paper_1705,2021.0,9.0,93,13,True,57.0,8.0,True
cord-001706,Analysis of epidemiology and pandemic and public health and outbreak in clinical settings,This study examines epidemiology with 123 word abstract...,"Author1706_1, Author1706_2",Nature,2020-01-22,WHO,10.1000/sample.1706,PMC1001706,https://example.com/paper_1706,2020.0,1.0,89,13,True,58.0,8.0,True
cord-001707,Analysis of symptoms and antiviral and antibody in clinical settings,This study examines symptoms with 174 word abstract...,"Author1707_1, Author1707_2",,2020-05-26,PMC,10.1000/sample.1707,PMC1001707,https://example.com/paper_1707,2020.0,5.0,68,10,True,54.0,8.0,False
cord-001711,Analysis of immunity and therapeutic and treatment in clinical settings,This study examines immunity with 445 word abstract...,Author1711_1,Science Translational Medicine,2022-04-01,medRxiv,10.1000/sample.1711,,https://example.com/paper_1711,2022.0,4.0,71,10,True,54.0,8.0,True
cord-001713,Analysis of COVID-19 and antiviral and treatment and vaccination in clinical settings,This study examines COVID-19 with 276 word abstract...,"Author1713_1, Author1713_2",Journal of Virology,2021-01-25,PMC,10.1000/sample.1713,PMC1001713,https://example.com/paper_1713,2021.0,1.0,85,12,True,54.0,8.0,True
cord-001714,Analysis of antiviral and respiratory and vaccination in clinical settings,This study examines antiviral with 198 word abstract...,"Author1714_1, Author1714_2",JAMA,2021-11-13,WHO,10.1000/sample.1714,PMC1001714,,2021.0,11.0,74,10,True,55.0,8.0,True
cord-001715,Analysis of diagnosis and COVID-19 in clinical settings,This study examines diagnosis with 469 word abstract...,"Author1715_1, Author1715_2",,2021-11-16,medRxiv,10.1000/sample.1715,PMC1001715,,2021.0,11.0,55,8,True,55.0,8.0,False
cord-001717,Analysis of lockdown and antibody and public health and pneumonia in clinical settings,This study examines lockdown with 497 word abstract...,"Author1717_1, Author1717_2",PLoS ONE,2019-12-21,ArXiv,10.1000/sample.1717,PMC1001717,https://example.com/paper_1717,2019.0,12.0,86,13,True,54.0,8.0,True
cord-001718,Analysis of antibody and vaccination in clinical settings,This study examines antibody with 300 word abstract...,"Author1718_1, Author1718_2",New England Journal of Medicine,2020-10-23,PMC,10.1000/sample.1718,,https://example.com/paper_1718,2020.0,10.0,57,8,True,54.0,8.0,True
cord-001719,Analysis of pneumonia and therapeutic and clinical and symptoms in clinical settings,,"Author1719_1, Author1719_2",Lancet,2020-05-07,bioRxiv,10.1000/sample.1719,,https://example.com/paper_1719,2020.0,5.0,84,12,False,,,True
cord-001720,Analysis of therapeutic and COVID-19 and public health and antibody in clinical settings,This study examines therapeutic with 109 word abstract...,"Author1720_1, Author1720_2",Virology,2021-10-02,PMC,10.1000/sample.1720,,https://example.com/paper_1720,2021.0,10.0,88,13,True,57.0,8.0,True
cord-001721,Analysis of coronavirus and clinical and pandemic in clinical settings,This study examines coronavirus with 146 word abstract...,Author1721_1,Nature Medicine,2020-06-02,medRxiv,10.1000/sample.1721,PMC1001721,https://example.com/paper_1721,2020.0,6.0,70,10,True,57.0,8.0,True
cord-001723,Analysis of lockdown and symptoms in clinical settings,This study examines lockdown with 294 word abstract...,"Author1723_1, Author1723_2",Nature,2021-03-16,medRxiv,10.1000/sample.1723,PMC1001723,,2021.0,3.0,54,8,True,54.0,8.0,True
cord-001724,Analysis of treatment and public health and vaccination and SARS-CoV-2 in clinical settings,This study examines treatment with 280 word abstract...,Author1724_1,New England Journal of Medicine,2022-06-29,ArXiv,10.1000/sample.1724,PMC1001724,https://example.com/paper_1724,2022.0,6.0,91,13,True,55.0,8.0,True
cord-001725,Analysis of symptoms and antibody and antiviral and COVID-19 in clinical settings,This study examines symptoms with 363 word abstract...,"Author1725_1, Author1725_2",Nature Medicine,2020-09-11,bioRxiv,,PMC1001725,https://example.com/paper_1725,2020.0,9.0,81,12,True,54.0,8.0,True
cord-001726,Analysis of SARS-CoV-2 and respiratory and immunity and coronavirus in clinical settings,This study examines SARS-CoV-2 with 489 word abstract...,"Author1726_1, Author1726_2",New England Journal of Medicine,2019-12-19,WHO,10.1000/sample.1726,,,2019.0,12.0,88,12,True,56.0,8.0,True
cord-001727,Analysis of coronavirus and COVID-19 and pneumonia in clinical settings,This study examines coronavirus with 176 word abstract...,"Author1727_1, Author1727_2",Nature Medicine,2021-03-27,medRxiv,10.1000/sample.1727,PMC1001727,https://example.com/paper_1727,2021.0,3.0,71,10,True,57.0,8.0,True
cord-001728,Analysis of antiviral and transmission and symptoms in clinical settings,This study examines antiviral with 200 word abstract...,"Author1728_1, Author1728_2",PLoS ONE,2021-09-12,WHO,10.1000/sample.1728,PMC1001728,https://example.com/paper_1728,2021.0,9.0,72,10,True,55.0,8.0,True
cord-001729,Analysis of immunity and coronavirus and lockdown and diagnosis in clinical settings,This study examines immunity with 457 word abstract...,Author1729_1,Journal of Medical Virology,2020-07-20,bioRxiv,10.1000/sample.1729,PMC1001729,,2020.0,7.0,84,12,True,54.0,8.0,True
cord-001730,Analysis of treatment and SARS-CoV-2 and coronavirus in clinical settings,This study examines treatment with 238 word abstract...,"Author1730_1, Author1730_2",Emerging Infectious Diseases,2020-12-22,medRxiv,10.1000/sample.1730,PMC1001730,https://example.com/paper_1730,2020.0,12.0,73,10,True,55.0,8.0,True
cord-001731,Analysis of lockdown and outbreak in clinical settings,This study examines lockdown with 215 word abstract...,"Author1731_1, Author1731_2",PLoS ONE,2020-03-23,ArXiv,10.1000/sample.1731,,https://example.com/paper_1731,2020.0,3.0,54,8,True,54.0,8.0,True
cord-001732,Analysis of epidemiology and SARS-CoV-2 in clinical settings,This study examines epidemiology with 102 word abstract...,"Author1732_1, Author1732_2",Nature,2021-07-12,medRxiv,10.1000/sample.1732,PMC1001732,,2021.0,7.0,60,8,True,58.0,8.0,True
cord-001733,Analysis of treatment and outbreak and antibody and lockdown in clinical settings,This study examines treatment with 144 word abstract...,"Author1733_1, Author1733_2",PLoS ONE,2022-09-29,ArXiv,10.1000/sample.1733,PMC1001733,,2022.0,9.0,81,12,True,55.0,8.0,True
cord-001735,Analysis of antiviral and SARS-CoV-2 and transmission in clinical settings,This study examines antiviral with 448 word abstract...,"Author1735_1, Author1735_2",,2020-02-08,PMC,10.1000/sample.1735,PMC1001735,https://example.com/paper_1735,2020.0,2.0,74,10,True,55.0,8.0,False
cord-001736,Analysis of antibody and public health and epidemiology and immunity in clinical settings,This study examines antibody with 389 word abstract...,"Author1736_1, Author1736_2",PLoS ONE,2020-01-11,medRxiv,10.1000/sample.1736,PMC1001736,https://example.com/paper_1736,2020.0,1.0,89,13,True,54.0,8.0,True
cord-001739,Analysis of treatment and public health and vaccination and epidemiology in clinical settings,This study examines treatment with 457 word abstract...,"Author1739_1, Author1739_2",New England Journal of Medicine,2020-04-18,medRxiv,10.1000/sample.1739,PMC1001739,https://example.com/paper_1739,2020.0,4.0,93,13,True,55.0,8.0,True
cord-001740,Analysis of COVID-19 and coronavirus and pandemic and immunity in clinical settings,This study examines COVID-19 with 489 word abstract...,"Author1740_1, Author1740_2",Nature,2020-09-03,PMC,10.1000/sample.1740,,https://example.com/paper_1740,2020.0,9.0,83,12,True,54.0,8.0,True
cord-001741,Analysis of vaccination and pneumonia and respiratory and coronavirus in clinical settings,This study examines vaccination with 354 word abstract...,"Author1741_1, Author1741_2",Journal of Virology,2020-04-27,WHO,10.1000/sample.1741,PMC1001741,https://example.com/paper_1741,2020.0,4.0,90,12,True,57.0,8.0,True
cord-001744,Analysis of transmission and clinical and outbreak in clinical settings,This study examines transmission with 362 word abstract...,Author1744_1,,2020-05-09,Medline,10.1000/sample.1744,,https://example.com/paper_1744,2020.0,5.0,71,10,True,58.0,8.0,False
cord-001745,Analysis of treatment and diagnosis and respiratory in clinical settings,This study examines treatment with 171 word abstract...,"Author1745_1, Author1745_2",Journal of Virology,2021-01-23,WHO,10.1000/sample.1745,PMC1001745,https://example.com/paper_1745,2021.0,1.0,72,10,True,55.0,8.0,True
cord-001746,Analysis of antiviral and SARS-CoV-2 in clinical settings,This study examines antiviral with 491 word abstract...,Author1746_1,Journal of Virology,2021-06-01,Medline,10.1000/sample.1746,,https://example.com/paper_1746,2021.0,6.0,57,8,True,55.0,8.0,True
cord-001747,Analysis of symptoms and respiratory and outbreak in clinical settings,This study examines symptoms with 446 word abstract...,"Author1747_1, Author1747_2",Nature,2020-12-03,medRxiv,,,https://example.com/paper_1747,2020.0,12.0,70,10,True,54.0,8.0,True
cord-001748,Analysis of coronavirus and respiratory and public health and COVID-19 in clinical settings,This study examines coronavirus with 478 word abstract...,"Author1748_1, Author1748_2",JAMA,2020-03-28,ArXiv,10.1000/sample.1748,PMC1001748,https://example.com/paper_1748,2020.0,3.0,91,13,True,57.0,8.0,True
cord-001749,Analysis of COVID-19 and antibody and pandemic and SARS-CoV-2 in clinical settings,This study examines COVID-19 with 332 word abstract...,"Author1749_1, Author1749_2",Journal of Medical Virology,2022-07-30,ArXiv,10.1000/sample.1749,PMC1001749,https://example.com/paper_1749,2022.0,7.0,82,12,True,54.0,8.0,True
cord-001750,Analysis of coronavirus and lockdown and pneumonia in clinical settings,This study examines coronavirus with 451 word abstract...,"Author1750_1, Author1750_2",Virology,2022-10-19,bioRxiv,10.1000/sample.1750,PMC1001750,,2022.0,10.0,71,10,True,57.0,8.0,True
cord-001752,Analysis of pandemic and lockdown and immunity and public health in clinical settings,This study examines pandemic with 132 word abstract...,"Author1752_1, Author1752_2",Journal of Medical Virology,2019-12-11,ArXiv,10.1000/sample.1752,PMC1001752,https://example.com/paper_1752,2019.0,12.0,85,13,True,54.0,8.0,True
cord-001753,Analysis of vaccination and public health and treatment and SARS-CoV-2 in clinical settings,This study examines vaccination with 465 word abstract...,"Author1753_1, Author1753_2",PLoS ONE,2020-03-26,PMC,10.1000/sample.1753,PMC1001753,https://example.com/paper_1753,2020.0,3.0,91,13,True,57.0,8.0,True
cord-001754,Analysis of pandemic and antibody and coronavirus in clinical settings,This study examines pandemic with 105 word abstract...,"Author1754_1, Author1754_2",Journal of Medical Virology,2019-12-01,PMC,10.1000/sample.1754,PMC1001754,https://example.com/paper_1754,2019.0,12.0,70,10,True,54.0,8.0,True
cord-001755,Analysis of SARS-CoV-2 and antibody and symptoms and immunity in clinical settings,This study examines SARS-CoV-2 with 299 word abstract...,Author1755_1,Lancet,2019-12-17,medRxiv,10.1000/sample.1755,,https://example.com/paper_1755,2019.0,12.0,82,12,True,56.0,8.0,True
cord-001756,Analysis of vaccination and diagnosis and lockdown in clinical settings,This study examines vaccination with 272 word abstract...,"Author1756_1, Author1756_2",Journal of Virology,2020-10-22,bioRxiv,10.1000/sample.1756,PMC1001756,https://example.com/paper_1756,2020.0,10.0,71,10,True,57.0,8.0,True
cord-001757,Analysis of coronavirus and COVID-19 and therapeutic in clinical settings,This study examines coronavirus with 351 word abstract...,"Author1757_1, Author1757_2",Clinical Infectious Diseases,2022-06-11,PMC,10.1000/sample.1757,,https://example.com/paper_1757,2022.0,6.0,73,10,True,57.0,8.0,True
cord-001760,Analysis of symptoms and clinical and therapeutic in clinical settings,This study examines symptoms with 208 word abstract...,"Author1760_1, Author1760_2",New England Journal of Medicine,2020-04-25,Medline,10.1000/sample.1760,PMC1001760,https://example.com/paper_1760,2020.0,4.0,70,10,True,54.0,8.0,True
cord-001762,Analysis of diagnosis and epidemiology and transmission in clinical settings,This study examines diagnosis with 254 word abstract...,"Author1762_1, Author1762_2",Science Translational Medicine,2020-03-07,bioRxiv,,PMC1001762,https://example.com/paper_1762,2020.0,3.0,76,10,True,55.0,8.0,True
cord-001763,Analysis of immunity and COVID-19 and antibody in clinical settings,,"Author1763_1, Author1763_2",BMJ,2021-12-22,medRxiv,10.1000/sample.1763,PMC1001763,,2021.0,12.0,67,10,False,,,True
cord-001767,Analysis of diagnosis and antiviral and symptoms and pandemic in clinical settings,This study examines diagnosis with 392 word abstract...,"Author1767_1, Author1767_2",Science Translational Medicine,2022-08-24,medRxiv,10.1000/sample.1767,PMC1001767,https://example.com/paper_1767,2022.0,8.0,82,12,True,55.0,8.0,True
cord-001768,Analysis of lockdown and pneumonia and symptoms in clinical settings,This study examines lockdown with 201 word abstract...,Author1768_1,New England Journal of Medicine,2021-10-26,bioRxiv,10.1000/sample.1768,,,2021.0,10.0,68,10,True,54.0,8.0,True
cord-001769,Analysis of lockdown and transmission and coronavirus and diagnosis in clinical settings,This study examines lockdown with 268 word abstract...,"Author1769_1, Author1769_2",,2020-12-20,bioRxiv,,PMC1001769,https://example.com/paper_1769,2020.0,12.0,88,12,True,54.0,8.0,False
cord-001771,Analysis of COVID-19 and pneumonia in clinical settings,This study examines COVID-19 with 411 word abstract...,"Author1771_1, Author1771_2",Science Translational Medicine,2021-09-05,bioRxiv,10.1000/sample.1771,PMC1001771,https://example.com/paper_1771,2021.0,9.0,55,8,True,54.0,8.0,True
cord-001773,Analysis of immunity and therapeutic and coronavirus in clinical settings,This study examines immunity with 338 word abstract...,"Author1773_1, Author1773_2",Journal of Medical Virology,,medRxiv,10.1000/sample.1773,PMC1001773,,,,73,10,True,54.0,8.0,True
cord-001774,Analysis of public health and clinical and COVID-19 in clinical settings,This study examines public health with 178 word abstract...,"Author1774_1, Author1774_2",BMJ,2020-05-11,PMC,10.1000/sample.1774,PMC1001774,https://example.com/paper_1774,2020.0,5.0,72,11,True,59.0,9.0,True
cord-001775,Analysis of vaccination and treatment and clinical and antiviral in clinical settings,This study examines vaccination with 198 word abstract...,,Science Translational Medicine,2022-03-18,PMC,10.1000/sample.1775,PMC1001775,,2022.0,3.0,85,12,True,57.0,8.0,True
cord-001776,Analysis of respiratory and outbreak and clinical in clinical settings,This study examines respiratory with 353 word abstract...,"Author1776_1, Author1776_2",Journal of Medical Virology,2022-12-04,WHO,10.1000/sample.1776,,https://example.com/paper_1776,2022.0,12.0,70,10,True,57.0,8.0,True
cord-001777,Analysis of transmission and COVID-19 and symptoms in clinical settings,This study examines transmission with 359 word abstract...,"Author1777_1, Author1777_2",Nature,2020-02-23,Medline,10.1000/sample.1777,,,2020.0,2.0,71,10,True,58.0,8.0,True
cord-001778,Analysis of transmission and respiratory and vaccination in clinical settings,,"Author1778_1, Author1778_2",PLoS ONE,2020-02-22,PMC,10.1000/sample.1778,PMC1001778,,2020.0,2.0,77,10,False,,,True
cord-001779,Analysis of SARS-CoV-2 and antiviral and symptoms in clinical settings,This study examines SARS-CoV-2 with 466 word abstract...,"Author1779_1, Author1779_2",Virology,2019-12-12,ArXiv,10.1000/sample.1779,,https://example.com/paper_1779,2019.0,12.0,70,10,True,56.0,8.0,True
cord-001780,Analysis of COVID-19 and antibody and symptoms in clinical settings,This study examines COVID-19 with 204 word abstract...,"Author1780_1, Author1780_2",Clinical Infectious Diseases,2021-12-26,ArXiv,10.1000/sample.1780,,https://example.com/paper_1780,2021.0,12.0,67,10,True,54.0,8.0,True
cord-001781,Analysis of lockdown and clinical and antibody and pneumonia in clinical settings,This study examines lockdown with 223 word abstract...,Author1781_1,Nature,2020-04-15,ArXiv,10.1000/sample.1781,PMC1001781,https://example.com/paper_1781,2020.0,4.0,81,12,True,54.0,8.0,True
cord-001782,Analysis of immunity and lockdown and respiratory and COVID-19 in clinical settings,This study examines immunity with 492 word abstract...,"Author1782_1, Author1782_2",Science,2020-09-30,PMC,10.1000/sample.1782,PMC1001782,https://example.com/paper_1782,2020.0,9.0,83,12,True,54.0,8.0,True
cord-001783,Analysis of immunity and antiviral and public health in clinical settings,This study examines immunity with 143 word abstract...,"Author1783_1, Author1783_2",Science Translational Medicine,2021-01-06,bioRxiv,10.1000/sample.1783,,https://example.com/paper_1783,2021.0,1.0,73,11,True,54.0,8.0,True
cord-001784,Analysis of diagnosis and antiviral and vaccination in clinical settings,This study examines diagnosis with 350 word abstract...,"Author1784_1, Author1784_2",Science,2020-03-30,medRxiv,10.1000/sample.1784,,https://example.com/paper_1784,2020.0,3.0,72,10,True,55.0,8.0,True
cord-001785,Analysis of treatment and lockdown and public health in clinical settings,This study examines treatment with 237 word abstract...,"Author1785_1, Author1785_2",Nature,2019-12-15,PMC,10.1000/sample.1785,,https://example.com/paper_1785,2019.0,12.0,73,11,True,55.0,8.0,True
cord-001787,Analysis of pneumonia and symptoms and COVID-19 and vaccination in clinical settings,This study examines pneumonia with 174 word abstract...,"Author1787_1, Author1787_2",Science,2021-09-11,PMC,10.1000/sample.1787,PMC1001787,https://example.com/paper_1787,2021.0,9.0,84,12,True,55.0,8.0,True
cord-001788,Analysis of COVID-19 and pandemic and transmission and lockdown in clinical settings,This study examines COVID-19 with 341 word abstract...,"Author1788_1, Author1788_2",Clinical Infectious Diseases,2021-09-16,WHO,10.1000/sample.1788,PMC1001788,https://example.com/paper_1788,2021.0,9.0,84,12,True,54.0,8.0,True
cord-001789,Analysis of diagnosis and treatment and epidemiology and antiviral in clinical settings,This study examines diagnosis with 462 word abstract...,"Author1789_1, Author1789_2",Nature Medicine,,WHO,10.1000/sample.1789,PMC1001789,https://example.com/paper_1789,,,87,12,True,55.0,8.0,True
cord-001790,Analysis of respiratory and antiviral and immunity and clinical in clinical settings,This study examines respiratory with 112 word abstract...,"Author1790_1, Author1790_2",PLoS ONE,2021-10-17,medRxiv,10.1000/sample.1790,PMC1001790,https://example.com/paper_1790,2021.0,10.0,84,12,True,57.0,8.0,True
cord-001791,Analysis of therapeutic and respiratory and transmission in clinical settings,This study examines therapeutic with 120 word abstract...,"Author1791_1, Author1791_2",Science,2021-04-04,PMC,10.1000/sample.1791,PMC1001791,https://example.com/paper_1791,2021.0,4.0,77,10,True,57.0,8.0,True
cord-001793,Analysis of transmission and outbreak and immunity and epidemiology in clinical settings,This study examines transmission with 333 word abstract...,"Author1793_1, Author1793_2",Lancet,,ArXiv,,,https://example.com/paper_1793,,,88,12,True,58.0,8.0,True
cord-001794,Analysis of pneumonia and clinical and symptoms and SARS-CoV-2 in clinical settings,,"Author1794_1, Author1794_2",Science,2021-10-02,medRxiv,10.1000/sample.1794,,https://example.com/paper_1794,2021.0,10.0,83,12,False,,,True
cord-001795,Analysis of outbreak and pandemic and respiratory in clinical settings,This study examines outbreak with 274 word abstract...,"Author1795_1, Author1795_2",Cell,2020-12-08,WHO,10.1000/sample.1795,,https://example.com/paper_1795,2020.0,12.0,70,10,True,54.0,8.0,True
cord-001796,Analysis of SARS-CoV-2 and vaccination and epidemiology and pneumonia in clinical settings,This study examines SARS-CoV-2 with 414 word abstract...,"Author1796_1, Author1796_2",Nature Medicine,2020-06-19,medRxiv,10.1000/sample.1796,PMC1001796,https://example.com/paper_1796,2020.0,6.0,90,12,True,56.0,8.0,True
cord-001799,Analysis of immunity and coronavirus and treatment and epidemiology in clinical settings,This study examines immunity with 310 word abstract...,"Author1799_1, Author1799_2",Clinical Infectious Diseases,2022-06-17,Medline,10.1000/sample.1799,,https://example.com/paper_1799,2022.0,6.0,88,12,True,54.0,8.0,True
cord-001800,Analysis of treatment and public health and pneumonia in clinical settings,This study examines treatment with 267 word abstract...,"Author1800_1, Author1800_2",Science,2021-12-26,Medline,,PMC1001800,https://example.com/paper_1800,2021.0,12.0,74,11,True,55.0,8.0,True
cord-001804,Analysis of coronavirus and symptoms and vaccination and epidemiology in clinical settings,This study examines coronavirus with 173 word abstract...,"Author1804_1, Author1804_2",Cell,,ArXiv,10.1000/sample.1804,,https://example.com/paper_1804,,,90,12,True,57.0,8.0,True
cord-001805,Analysis of clinical and pandemic in clinical settings,This study examines clinical with 281 word abstract...,"Author1805_1, Author1805_2",,2020-06-10,PMC,10.1000/sample.1805,PMC1001805,https://example.com/paper_1805,2020.0,6.0,54,8,True,54.0,8.0,False
cord-001806,Analysis of clinical and epidemiology and treatment in clinical settings,This study examines clinical with 222 word abstract...,"Author1806_1, Author1806_2",JAMA,2020-01-07,WHO,10.1000/sample.1806,PMC1001806,https://example.com/paper_1806,2020.0,1.0,72,10,True,54.0,8.0,True
cord-001807,Analysis of pneumonia and outbreak and SARS-CoV-2 in clinical settings,This study examines pneumonia with 422 word abstract...,"Author1807_1, Author1807_2",BMJ,2020-03-28,PMC,10.1000/sample.1807,PMC1001807,https://example.com/paper_1807,2020.0,3.0,70,10,True,55.0,8.0,True
cord-001808,Analysis of immunity and SARS-CoV-2 and pneumonia and antibody in clinical settings,This study examines immunity with 344 word abstract...,"Author1808_1, Author1808_2",Science Translational Medicine,2022-08-30,Medline,10.1000/sample.1808,,https://example.com/paper_1808,2022.0,8.0,83,12,True,54.0,8.0,True
cord-001811,Analysis of immunity and pneumonia and treatment in clinical settings,This study examines immunity with 126 word abstract...,"Author1811_1, Author1811_2",Science Translational Medicine,2020-05-05,Medline,10.1000/sample.1811,PMC1001811,https://example.com/paper_1811,2020.0,5.0,69,10,True,54.0,8.0,True
cord-001814,Analysis of SARS-CoV-2 and pneumonia and diagnosis in clinical settings,This study examines SARS-CoV-2 with 222 word abstract...,"Author1814_1, Author1814_2",,2019-12-06,medRxiv,10.1000/sample.1814,PMC1001814,https://example.com/paper_1814,2019.0,12.0,71,10,True,56.0,8.0,False
cord-001816,Analysis of treatment and COVID-19 in clinical settings,This study examines treatment with 321 word abstract...,"Author1816_1, Author1816_2",Science Translational Medicine,2020-03-12,Medline,10.1000/sample.1816,PMC1001816,https://example.com/paper_1816,2020.0,3.0,55,8,True,55.0,8.0,True
cord-001817,Analysis of epidemiology and coronavirus and symptoms in clinical settings,,"Author1817_1, Author1817_2",Virology,2019-12-07,WHO,10.1000/sample.1817,PMC1001817,https://example.com/paper_1817,2019.0,12.0,74,10,False,,,True
cord-001818,Analysis of SARS-CoV-2 and pandemic in clinical settings,This study examines SARS-CoV-2 with 426 word abstract...,"Author1818_1, Author1818_2",Science Translational Medicine,2021-12-03,ArXiv,10.1000/sample.1818,PMC1001818,https://example.com/paper_1818,2021.0,12.0,56,8,True,56.0,8.0,True
cord-001820,Analysis of respiratory and vaccination in clinical settings,This study examines respiratory with 252 word abstract...,"Author1820_1, Author1820_2",Science Translational Medicine,2021-05-03,ArXiv,10.1000/sample.1820,,https://example.com/paper_1820,2021.0,5.0,60,8,True,57.0,8.0,True
cord-001822,Analysis of public health and immunity and therapeutic and diagnosis in clinical settings,This study examines public health with 231 word abstract...,"Author1822_1, Author1822_2",PLoS ONE,2020-02-03,ArXiv,10.1000/sample.1822,PMC1001822,https://example.com/paper_1822,2020.0,2.0,89,13,True,59.0,9.0,True
cord-001823,Analysis of diagnosis and coronavirus and respiratory in clinical settings,This study examines diagnosis with 258 word abstract...,"Author1823_1, Author1823_2",JAMA,2021-11-17,WHO,10.1000/sample.1823,PMC1001823,https://example.com/paper_1823,2021.0,11.0,74,10,True,55.0,8.0,True
cord-001825,Analysis of public health and respiratory and COVID-19 and therapeutic in clinical settings,This study examines public health with 257 word abstract...,"Author1825_1, Author1825_2",New England Journal of Medicine,2020-07-18,Medline,10.1000/sample.1825,,https://example.com/paper_1825,2020.0,7.0,91,13,True,59.0,9.0,True
cord-001826,Analysis of pandemic and antibody and diagnosis and clinical in clinical settings,,"Author1826_1, Author1826_2",JAMA,2021-10-05,bioRxiv,10.1000/sample.1826,,https://example.com/paper_1826,2021.0,10.0,81,12,False,,,True
cord-001827,Analysis of pandemic and immunity and outbreak and coronavirus in clinical settings,This study examines pandemic with 200 word abstract...,"Author1827_1, Author1827_2",,2021-10-13,PMC,10.1000/sample.1827,PMC1001827,,2021.0,10.0,83,12,True,54.0,8.0,False
cord-001828,Analysis of coronavirus and vaccination and respiratory and pandemic in clinical settings,This study examines coronavirus with 378 word abstract...,Author1828_1,Journal of Medical Virology,2021-02-24,medRxiv,10.1000/sample.1828,PMC1001828,https://example.com/paper_1828,2021.0,2.0,89,12,True,57.0,8.0,True
cord-001831,Analysis of immunity and respiratory and transmission and lockdown in clinical settings,This study examines immunity with 194 word abstract...,"Author1831_1, Author1831_2",Lancet,2019-12-07,medRxiv,10.1000/sample.1831,PMC1001831,https://example.com/paper_1831,2019.0,12.0,87,12,True,54.0,8.0,True
cord-001833,Analysis of transmission and symptoms and antiviral and vaccination in clinical settings,This study examines transmission with 307 word abstract...,Author1833_1,BMJ,2021-04-27,ArXiv,10.1000/sample.1833,,https://example.com/paper_1833,2021.0,4.0,88,12,True,58.0,8.0,True
cord-001834,Analysis of pneumonia and therapeutic and clinical and pandemic in clinical settings,This study examines pneumonia with 137 word abstract...,"Author1834_1, Author1834_2",Clinical Infectious Diseases,2021-04-02,Medline,10.1000/sample.1834,PMC1001834,https://example.com/paper_1834,2021.0,4.0,84,12,True,55.0,8.0,True
cord-001835,Analysis of coronavirus and respiratory and pandemic and public health in clinical settings,This study examines coronavirus with 419 word abstract...,"Author1835_1, Author1835_2",Emerging Infectious Diseases,2019-12-24,bioRxiv,10.1000/sample.1835,PMC1001835,https://example.com/paper_1835,2019.0,12.0,91,13,True,57.0,8.0,True
cord-001837,Analysis of public health and epidemiology and treatment in clinical settings,,"Author1837_1, Author1837_2",Cell,2021-01-15,WHO,10.1000/sample.1837,,https://example.com/paper_1837,2021.0,1.0,77,11,False,,,True
cord-001838,Analysis of outbreak and pandemic and clinical in clinical settings,This study examines outbreak with 336 word abstract...,"Author1838_1, Author1838_2",Journal of Virology,2020-01-10,PMC,10.1000/sample.1838,PMC1001838,https://example.com/paper_1838,2020.0,1.0,67,10,True,54.0,8.0,True
cord-001840,Analysis of antiviral and immunity and coronavirus in clinical settings,This study examines antiviral with 228 word abstract...,"Author1840_1, Author1840_2",PLoS ONE,2021-07-01,PMC,,,,2021.0,7.0,71,10,True,55.0,8.0,True
cord-001842,Analysis of antibody and immunity and SARS-CoV-2 in clinical settings,This study examines antibody with 221 word abstract...,"Author1842_1, Author1842_2",Journal of Virology,2020-09-13,medRxiv,10.1000/sample.1842,,https://example.com/paper_1842,2020.0,9.0,69,10,True,54.0,8.0,True
cord-001844,Analysis of transmission and therapeutic and vaccination in clinical settings,This study examines transmission with 238 word abstract...,"Author1844_1, Author1844_2",Nature,2021-03-06,bioRxiv,,,https://example.com/paper_1844,2021.0,3.0,77,10,True,58.0,8.0,True
cord-001845,Analysis of pneumonia and epidemiology and clinical in clinical settings,This study examines pneumonia with 279 word abstract...,"Author1845_1, Author1845_2",PLoS ONE,2021-07-08,ArXiv,10.1000/sample.1845,PMC1001845,,2021.0,7.0,72,10,True,55.0,8.0,True
cord-001847,Analysis of COVID-19 and respiratory and antibody in clinical settings,This study examines COVID-19 with 459 word abstract...,Author1847_1,Nature,2021-09-05,ArXiv,10.1000/sample.1847,PMC1001847,,2021.0,9.0,70,10,True,54.0,8.0,True
cord-001848,Analysis of coronavirus and respiratory and transmission and antibody in clinical settings,,Author1848_1,Lancet,2021-05-17,WHO,10.1000/sample.1848,PMC1001848,https://example.com/paper_1848,2021.0,5.0,90,12,False,,,True
cord-001849,Analysis of pneumonia and public health in clinical settings,This study examines pneumonia with 206 word abstract...,Author1849_1,Journal of Virology,2020-09-06,PMC,10.1000/sample.1849,PMC1001849,,2020.0,9.0,60,9,True,55.0,8.0,True
cord-001850,Analysis of therapeutic and outbreak and coronavirus in clinical settings,This study examines therapeutic with 214 word abstract...,,Lancet,2020-08-17,medRxiv,10.1000/sample.1850,,,2020.0,8.0,73,10,True,57.0,8.0,True
cord-001853,Analysis of COVID-19 and pandemic and diagnosis and outbreak in clinical settings,,"Author1853_1, Author1853_2",PLoS ONE,2020-07-26,Medline,10.1000/sample.1853,PMC1001853,https://example.com/paper_1853,2020.0,7.0,81,12,False,,,True
cord-001854,Analysis of COVID-19 and pneumonia and pandemic and coronavirus in clinical settings,This study examines COVID-19 with 145 word abstract...,"Author1854_1, Author1854_2",BMJ,2020-10-19,ArXiv,10.1000/sample.1854,PMC1001854,https://example.com/paper_1854,2020.0,10.0,84,12,True,54.0,8.0,True
cord-001855,Analysis of diagnosis and SARS-CoV-2 in clinical settings,This study examines diagnosis with 405 word abstract...,"Author1855_1, Author1855_2",,2020-09-14,WHO,10.1000/sample.1855,PMC1001855,https://example.com/paper_1855,2020.0,9.0,57,8,True,55.0,8.0,False
cord-001857,Analysis of outbreak and pneumonia and COVID-19 and respiratory in clinical settings,This study examines outbreak with 114 word abstract...,"Author1857_1, Author1857_2",PLoS ONE,2020-05-26,Medline,10.1000/sample.1857,,https://example.com/paper_1857,2020.0,5.0,84,12,True,54.0,8.0,True
cord-001859,Analysis of COVID-19 and vaccination and clinical in clinical settings,This study examines COVID-19 with 169 word abstract...,"Author1859_1, Author1859_2",Virology,2020-11-01,ArXiv,10.1000/sample.1859,PMC1001859,https://example.com/paper_1859,2020.0,11.0,70,10,True,54.0,8.0,True
cord-001860,Analysis of pandemic and respiratory and immunity in clinical settings,This study examines pandemic with 472 word abstract...,Author1860_1,Journal of Medical Virology,2020-09-06,PMC,,PMC1001860,https://example.com/paper_1860,2020.0,9.0,70,10,True,54.0,8.0,True
cord-001863,Analysis of COVID-19 and outbreak and pneumonia and symptoms in clinical settings,This study examines COVID-19 with 456 word abstract...,"Author1863_1, Author1863_2",Science,2022-02-17,bioRxiv,,PMC1001863,,2022.0,2.0,81,12,True,54.0,8.0,True
cord-001864,Analysis of antibody and pneumonia and epidemiology and clinical in clinical settings,This study examines antibody with 470 word abstract...,"Author1864_1, Author1864_2",Lancet,2021-12-28,PMC,10.1000/sample.1864,PMC1001864,https://example.com/paper_1864,2021.0,12.0,85,12,True,54.0,8.0,True
cord-001865,Analysis of immunity and epidemiology and SARS-CoV-2 in clinical settings,This study examines immunity with 110 word abstract...,"Author1865_1, Author1865_2",Nature Medicine,2020-08-25,WHO,10.1000/sample.1865,PMC1001865,https://example.com/paper_1865,2020.0,8.0,73,10,True,54.0,8.0,True
cord-001866,Analysis of outbreak and vaccination and pandemic and epidemiology in clinical settings,This study examines outbreak with 364 word abstract...,"Author1866_1, Author1866_2",Lancet,2021-10-27,bioRxiv,10.1000/sample.1866,,https://example.com/paper_1866,2021.0,10.0,87,12,True,54.0,8.0,True
cord-001867,Analysis of outbreak and transmission and diagnosis and public health in clinical settings,This study examines outbreak with 274 word abstract...,"Author1867_1, Author1867_2",Science,2021-04-15,ArXiv,10.1000/sample.1867,,https://example.com/paper_1867,2021.0,4.0,90,13,True,54.0,8.0,True
cord-001868,Analysis of public health and outbreak and clinical in clinical settings,This study examines public health with 202 word abstract...,"Author1868_1, Author1868_2",Emerging Infectious Diseases,2021-10-18,WHO,10.1000/sample.1868,PMC1001868,https://example.com/paper_1868,2021.0,10.0,72,11,True,59.0,9.0,True
cord-001869,Analysis of vaccination and immunity and therapeutic and diagnosis in clinical settings,This study examines vaccination with 354 word abstract...,"Author1869_1, Author1869_2",BMJ,2020-12-15,ArXiv,10.1000/sample.1869,PMC1001869,https://example.com/paper_1869,2020.0,12.0,87,12,True,57.0,8.0,True
cord-001870,Analysis of epidemiology and pneumonia and transmission in clinical settings,This study examines epidemiology with 123 word abstract...,"Author1870_1, Author1870_2",Clinical Infectious Diseases,2021-10-13,ArXiv,,PMC1001870,https://example.com/paper_1870,2021.0,10.0,76,10,True,58.0,8.0,True
cord-001871,Analysis of outbreak and therapeutic in clinical settings,This study examines outbreak with 215 word abstract...,"Author1871_1, Author1871_2",,2021-12-17,bioRxiv,10.1000/sample.1871,PMC1001871,https://example.com/paper_1871,2021.0,12.0,57,8,True,54.0,8.0,False
cord-001872,Analysis of coronavirus and COVID-19 and SARS-CoV-2 in clinical settings,This study examines coronavirus with 382 word abstract...,"Author1872_1, Author1872_2",,2021-05-10,ArXiv,10.1000/sample.1872,PMC1001872,https://example.com/paper_1872,2021.0,5.0,72,10,True,57.0,8.0,False
cord-001873,Analysis of antibody and clinical and outbreak and immunity in clinical settings,This study examines antibody with 352 word abstract...,Author1873_1,,2020-06-07,ArXiv,,,https://example.com/paper_1873,2020.0,6.0,80,12,True,54.0,8.0,False
cord-001874,Analysis of outbreak and pneumonia in clinical settings,This study examines outbreak with 198 word abstract...,"Author1874_1, Author1874_2",,2021-09-27,PMC,,PMC1001874,https://example.com/paper_1874,2021.0,9.0,55,8,True,54.0,8.0,False
cord-001875,Analysis of pandemic and respiratory and COVID-19 and public health in clinical settings,This study examines pandemic with 400 word abstract...,"Author1875_1, Author1875_2",Lancet,2019-12-04,bioRxiv,10.1000/sample.1875,PMC1001875,https://example.com/paper_1875,2019.0,12.0,88,13,True,54.0,8.0,True
cord-001876,Analysis of antibody and public health and SARS-CoV-2 in clinical settings,This study examines antibody with 330 word abstract...,Author1876_1,Nature,2021-12-06,Medline,10.1000/sample.1876,PMC1001876,https://example.com/paper_1876,2021.0,12.0,74,11,True,54.0,8.0,True
cord-001878,Analysis of therapeutic and symptoms and antiviral and respiratory in clinical settings,This study examines therapeutic with 191 word abstract...,"Author1878_1, Author1878_2",BMJ,2021-11-06,Medline,10.1000/sample.1878,PMC1001878,https://example.com/paper_1878,2021.0,11.0,87,12,True,57.0,8.0,True
cord-001879,Analysis of COVID-19 and antibody and clinical and diagnosis in clinical settings,This study examines COVID-19 with 459 word abstract...,Author1879_1,BMJ,2020-09-27,ArXiv,10.1000/sample.1879,PMC1001879,https://example.com/paper_1879,2020.0,9.0,81,12,True,54.0,8.0,True
cord-001880,Analysis of coronavirus and respiratory and outbreak in clinical settings,This study examines coronavirus with 356 word abstract...,"Author1880_1, Author1880_2",BMJ,2019-12-07,bioRxiv,,PMC1001880,https://example.com/paper_1880,2019.0,12.0,73,10,True,57.0,8.0,True
cord-001882,Analysis of clinical and antiviral and antibody in clinical settings,This study examines clinical with 317 word abstract...,"Author1882_1, Author1882_2",Lancet,2019-12-07,bioRxiv,10.1000/sample.1882,PMC1001882,https://example.com/paper_1882,2019.0,12.0,68,10,True,54.0,8.0,True
cord-001883,Analysis of SARS-CoV-2 and diagnosis and treatment and symptoms in clinical settings,This study examines SARS-CoV-2 with 436 word abstract...,"Author1883_1, Author1883_2",Emerging Infectious Diseases,2019-12-23,PMC,10.1000/sample.1883,PMC1001883,https://example.com/paper_1883,2019.0,12.0,84,12,True,56.0,8.0,True
cord-001884,Analysis of SARS-CoV-2 and clinical and treatment and lockdown in clinical settings,This study examines SARS-CoV-2 with 437 word abstract...,"Author1884_1, Author1884_2",JAMA,2020-06-03,PMC,10.1000/sample.1884,PMC1001884,https://example.com/paper_1884,2020.0,6.0,83,12,True,56.0,8.0,True
cord-001886,Analysis of epidemiology and pneumonia and transmission and antibody in clinical settings,This study examines epidemiology with 414 word abstract...,"Author1886_1, Author1886_2",PLoS ONE,2021-05-04,bioRxiv,10.1000/sample.1886,PMC1001886,https://example.com/paper_1886,2021.0,5.0,89,12,True,58.0,8.0,True
cord-001887,Analysis of antiviral and pneumonia in clinical settings,This study examines antiviral with 217 word abstract...,"Author1887_1, Author1887_2",Clinical Infectious Diseases,2021-02-01,PMC,10.1000/sample.1887,PMC1001887,https://example.com/paper_1887,2021.0,2.0,56,8,True,55.0,8.0,True
cord-001890,Analysis of outbreak and antibody and coronavirus and COVID-19 in clinical settings,This study examines outbreak with 404 word abstract...,"Author1890_1, Author1890_2",,2021-01-17,bioRxiv,10.1000/sample.1890,PMC1001890,https://example.com/paper_1890,2021.0,1.0,83,12,True,54.0,8.0,False
cord-001893,Analysis of immunity and transmission and epidemiology and COVID-19 in clinical settings,This study examines immunity with 427 word abstract...,Author1893_1,Nature,2020-11-23,bioRxiv,10.1000/sample.1893,PMC1001893,https://example.com/paper_1893,2020.0,11.0,88,12,True,54.0,8.0,True
cord-001894,Analysis of coronavirus and epidemiology in clinical settings,This study examines coronavirus with 489 word abstract...,Author1894_1,Science,2020-08-28,bioRxiv,10.1000/sample.1894,PMC1001894,https://example.com/paper_1894,2020.0,8.0,61,8,True,57.0,8.0,True
cord-001895,Analysis of epidemiology and diagnosis and COVID-19 in clinical settings,This study examines epidemiology with 163 word abstract...,"Author1895_1, Author1895_2",Nature Medicine,,WHO,10.1000/sample.1895,PMC1001895,https://example.com/paper_1895,,,72,10,True,58.0,8.0,True
cord-001897,Analysis of diagnosis and pneumonia and immunity in clinical settings,This study examines diagnosis with 239 word abstract...,"Author1897_1, Author1897_2",Science Translational Medicine,2021-06-19,ArXiv,10.1000/sample.1897,,https://example.com/paper_1897,2021.0,6.0,69,10,True,55.0,8.0,True
cord-001899,Analysis of pneumonia and epidemiology and antiviral and symptoms in clinical settings,This study examines pneumonia with 267 word abstract...,"Author1899_1, Author1899_2",JAMA,2020-09-08,medRxiv,10.1000/sample.1899,PMC1001899,https://example.com/paper_1899,2020.0,9.0,86,12,True,55.0,8.0,True
cord-001900,Analysis of respiratory and epidemiology and immunity and public health in clinical settings,,"Author1900_1, Author1900_2",Journal of Virology,2019-12-27,WHO,10.1000/sample.1900,PMC1001900,https://example.com/paper_1900,2019.0,12.0,92,13,False,,,True
cord-001903,Analysis of coronavirus and pandemic and clinical in clinical settings,This study examines coronavirus with 213 word abstract...,"Author1903_1, Author1903_2",Cell,,PMC,10.1000/sample.1903,PMC1001903,https://example.com/paper_1903,,,70,10,True,57.0,8.0,True
cord-001904,Analysis of transmission and outbreak and symptoms and respiratory in clinical settings,This study examines transmission with 315 word abstract...,"Author1904_1, Author1904_2",,2020-03-31,bioRxiv,10.1000/sample.1904,PMC1001904,,2020.0,3.0,87,12,True,58.0,8.0,False
cord-001905,Analysis of SARS-CoV-2 and antibody and treatment and vaccination in clinical settings,This study examines SARS-CoV-2 with 446 word abstract...,"Author1905_1, Author1905_2",,2020-12-26,ArXiv,,PMC1001905,https://example.com/paper_1905,2020.0,12.0,86,12,True,56.0,8.0,False
cord-001906,Analysis of antibody and pandemic and therapeutic in clinical settings,This study examines antibody with 348 word abstract...,"Author1906_1, Author1906_2",,,bioRxiv,10.1000/sample.1906,PMC1001906,https://example.com/paper_1906,,,70,10,True,54.0,8.0,False
cord-001907,Analysis of epidemiology and pandemic and coronavirus and vaccination in clinical settings,This study examines epidemiology with 229 word abstract...,"Author1907_1, Author1907_2",New England Journal of Medicine,2020-01-15,medRxiv,10.1000/sample.1907,,https://example.com/paper_1907,2020.0,1.0,90,12,True,58.0,8.0,True
cord-001908,Analysis of outbreak and pandemic in clinical settings,This study examines outbreak with 387 word abstract...,"Author1908_1, Author1908_2",Virology,2021-11-03,WHO,10.1000/sample.1908,,https://example.com/paper_1908,2021.0,11.0,54,8,True,54.0,8.0,True
cord-001909,Analysis of respiratory and antibody and outbreak in clinical settings,This study examines respiratory with 207 word abstract...,"Author1909_1, Author1909_2",Lancet,2020-05-20,Medline,10.1000/sample.1909,,https://example.com/paper_1909,2020.0,5.0,70,10,True,57.0,8.0,True
cord-001910,Analysis of SARS-CoV-2 and pneumonia and symptoms in clinical settings,This study examines SARS-CoV-2 with 201 word abstract...,Author1910_1,New England Journal of Medicine,2021-08-19,bioRxiv,,,https://example.com/paper_1910,2021.0,8.0,70,10,True,56.0,8.0,True
cord-001911,Analysis of pneumonia and vaccination and transmission and symptoms in clinical settings,This study examines pneumonia with 450 word abstract...,"Author1911_1, Author1911_2",Lancet,2019-12-05,medRxiv,10.1000/sample.1911,,https://example.com/paper_1911,2019.0,12.0,88,12,True,55.0,8.0,True
cord-001912,Analysis of epidemiology and clinical and diagnosis in clinical settings,This study examines epidemiology with 328 word abstract...,"Author1912_1, Author1912_2",Emerging Infectious Diseases,2021-07-29,bioRxiv,10.1000/sample.1912,PMC1001912,https://example.com/paper_1912,2021.0,7.0,72,10,True,58.0,8.0,True
cord-001913,Analysis of SARS-CoV-2 and pneumonia and COVID-19 and clinical in clinical settings,This study examines SARS-CoV-2 with 274 word abstract...,"Author1913_1, Author1913_2",Lancet,2020-06-04,ArXiv,10.1000/sample.1913,PMC1001913,https://example.com/paper_1913,2020.0,6.0,83,12,True,56.0,8.0,True
cord-001914,Analysis of transmission and clinical and symptoms and public health in clinical settings,This study examines transmission with 406 word abstract...,"Author1914_1, Author1914_2",Virology,2020-01-14,Medline,10.1000/sample.1914,PMC1001914,https://example.com/paper_1914,2020.0,1.0,89,13,True,58.0,8.0,True
cord-001916,Analysis of vaccination and epidemiology and antibody and lockdown in clinical settings,This study examines vaccination with 195 word abstract...,"Author1916_1, Author1916_2",Journal of Virology,2022-06-04,WHO,10.1000/sample.1916,PMC1001916,https://example.com/paper_1916,2022.0,6.0,87,12,True,57.0,8.0,True
cord-001918,Analysis of antiviral and transmission and lockdown and pandemic in clinical settings,This study examines antiviral with 167 word abstract...,"Author1918_1, Author1918_2",Journal of Virology,2021-08-21,medRxiv,10.1000/sample.1918,PMC1001918,,2021.0,8.0,85,12,True,55.0,8.0,True
cord-001919,Analysis of pneumonia and antibody and COVID-19 and public health in clinical settings,This study examines pneumonia with 176 word abstract...,"Author1919_1, Author1919_2",BMJ,2020-11-30,ArXiv,10.1000/sample.1919,PMC1001919,,2020.0,11.0,86,13,True,55.0,8.0,True
cord-001921,Analysis of epidemiology and clinical and outbreak in clinical settings,This study examines epidemiology with 353 word abstract...,Author1921_1,Science,2020-03-10,medRxiv,10.1000/sample.1921,,https://example.com/paper_1921,2020.0,3.0,71,10,True,58.0,8.0,True
cord-001922,Analysis of treatment and pneumonia and pandemic and respiratory in clinical settings,This study examines treatment with 241 word abstract...,"Author1922_1, Author1922_2",Science,2020-07-09,PMC,10.1000/sample.1922,,https://example.com/paper_1922,2020.0,7.0,85,12,True,55.0,8.0,True
cord-001923,Analysis of respiratory and transmission and immunity in clinical settings,This study examines respiratory with 497 word abstract...,"Author1923_1, Author1923_2",Journal of Medical Virology,2022-09-22,WHO,10.1000/sample.1923,,https://example.com/paper_1923,2022.0,9.0,74,10,True,57.0,8.0,True
cord-001925,Analysis of public health and symptoms and coronavirus in clinical settings,This study examines public health with 234 word abstract...,"Author1925_1, Author1925_2",Clinical Infectious Diseases,2019-12-01,Medline,10.1000/sample.1925,,https://example.com/paper_1925,2019.0,12.0,75,11,True,59.0,9.0,True
cord-001927,Analysis of COVID-19 and respiratory and diagnosis in clinical settings,This study examines COVID-19 with 298 word abstract...,Author1927_1,Nature Medicine,2020-04-18,WHO,10.1000/sample.1927,,,2020.0,4.0,71,10,True,54.0,8.0,True
cord-001929,Analysis of lockdown and vaccination and clinical and epidemiology in clinical settings,This study examines lockdown with 126 word abstract...,"Author1929_1, Author1929_2",JAMA,2021-11-25,ArXiv,10.1000/sample.1929,,https://example.com/paper_1929,2021.0,11.0,87,12,True,54.0,8.0,True
cord-001931,Analysis of antibody and epidemiology and immunity and diagnosis in clinical settings,This study examines antibody with 454 word abstract...,"Author1931_1, Author1931_2",Nature,2020-01-25,bioRxiv,10.1000/sample.1931,PMC1001931,https://example.com/paper_1931,2020.0,1.0,85,12,True,54.0,8.0,True
cord-001932,Analysis of antiviral and clinical and pneumonia and diagnosis in clinical settings,This study examines antiviral with 456 word abstract...,"Author1932_1, Author1932_2",Science Translational Medicine,2020-08-01,bioRxiv,10.1000/sample.1932,PMC1001932,https://example.com/paper_1932,2020.0,8.0,83,12,True,55.0,8.0,True
cord-001933,Analysis of treatment and lockdown and immunity and clinical in clinical settings,This study examines treatment with 488 word abstract...,"Author1933_1, Author1933_2",Science Translational Medicine,2020-10-20,WHO,10.1000/sample.1933,PMC1001933,https://example.com/paper_1933,2020.0,10.0,81,12,True,55.0,8.0,True
cord-001934,Analysis of outbreak and transmission and COVID-19 in clinical settings,This study examines outbreak with 335 word abstract...,"Author1934_1, Author1934_2",Journal of Virology,2020-10-02,bioRxiv,10.1000/sample.1934,,https://example.com/paper_1934,2020.0,10.0,71,10,True,54.0,8.0,True
cord-001935,Analysis of respiratory and transmission and coronavirus and epidemiology in clinical settings,This study examines respiratory with 382 word abstract...,"Author1935_1, Author1935_2",,2020-11-17,PMC,10.1000/sample.1935,PMC1001935,,2020.0,11.0,94,12,True,57.0,8.0,False
cord-001936,Analysis of antibody and epidemiology and lockdown and vaccination in clinical settings,This study examines antibody with 411 word abstract...,"Author1936_1, Author1936_2",Science Translational Medicine,2021-02-24,Medline,10.1000/sample.1936,,https://example.com/paper_1936,2021.0,2.0,87,12,True,54.0,8.0,True
cord-001937,Analysis of COVID-19 and lockdown in clinical settings,This study examines COVID-19 with 205 word abstract...,"Author1937_1, Author1937_2",Emerging Infectious Diseases,2020-11-16,medRxiv,10.1000/sample.1937,PMC1001937,https://example.com/paper_1937,2020.0,11.0,54,8,True,54.0,8.0,True
cord-001938,Analysis of coronavirus and antiviral and vaccination in clinical settings,,"Author1938_1, Author1938_2",Nature Medicine,2021-05-19,WHO,,PMC1001938,https://example.com/paper_1938,2021.0,5.0,74,10,False,,,True
cord-001940,Analysis of transmission and therapeutic and epidemiology and public health in clinical settings,This study examines transmission with 197 word abstract...,"Author1940_1, Author1940_2",Journal of Medical Virology,2020-01-02,bioRxiv,10.1000/sample.1940,PMC1001940,https://example.com/paper_1940,2020.0,1.0,96,13,True,58.0,8.0,True
cord-001941,Analysis of antiviral and epidemiology and outbreak and pandemic in clinical settings,,"Author1941_1, Author1941_2",JAMA,2021-10-18,Medline,10.1000/sample.1941,,,2021.0,10.0,85,12,False,,,True
cord-001942,Analysis of clinical and lockdown and treatment in clinical settings,This study examines clinical with 365 word abstract...,"Author1942_1, Author1942_2",Nature,2019-12-07,medRxiv,10.1000/sample.1942,PMC1001942,https://example.com/paper_1942,2019.0,12.0,68,10,True,54.0,8.0,True
cord-001944,Analysis of antiviral and epidemiology and pneumonia and clinical in clinical settings,This study examines antiviral with 481 word abstract...,"Author1944_1, Author1944_2",Cell,2021-11-13,medRxiv,10.1000/sample.1944,PMC1001944,https://example.com/paper_1944,2021.0,11.0,86,12,True,55.0,8.0,True
cord-001945,Analysis of transmission and symptoms and diagnosis and antibody in clinical settings,This study examines transmission with 168 word abstract...,"Author1945_1, Author1945_2",Nature Medicine,2020-08-23,PMC,10.1000/sample.1945,PMC1001945,https://example.com/paper_1945,2020.0,8.0,85,12,True,58.0,8.0,True
cord-001946,Analysis of treatment and immunity and transmission in clinical settings,This study examines treatment with 185 word abstract...,"Author1946_1, Author1946_2",BMJ,2021-11-16,bioRxiv,10.1000/sample.1946,PMC1001946,https://example.com/paper_1946,2021.0,11.0,72,10,True,55.0,8.0,True
cord-001947,Analysis of antiviral and COVID-19 and SARS-CoV-2 and public health in clinical settings,This study examines antiviral with 246 word abstract...,"Author1947_1, Author1947_2",JAMA,2020-04-08,Medline,10.1000/sample.1947,PMC1001947,https://example.com/paper_1947,2020.0,4.0,88,13,True,55.0,8.0,True
cord-001950,Analysis of immunity and treatment in clinical settings,This study examines immunity with 153 word abstract...,"Author1950_1, Author1950_2",JAMA,2019-12-13,PMC,10.1000/sample.1950,,https://example.com/paper_1950,2019.0,12.0,55,8,True,54.0,8.0,True
cord-001952,Analysis of diagnosis and respiratory and antibody in clinical settings,This study examines diagnosis with 334 word abstract...,Author1952_1,Nature,2021-08-31,medRxiv,10.1000/sample.1952,,https://example.com/paper_1952,2021.0,8.0,71,10,True,55.0,8.0,True
cord-001954,Analysis of antiviral and diagnosis and pneumonia and therapeutic in clinical settings,This study examines antiviral with 315 word abstract...,"Author1954_1, Author1954_2",Clinical Infectious Diseases,2021-04-10,bioRxiv,10.1000/sample.1954,,https://example.com/paper_1954,2021.0,4.0,86,12,True,55.0,8.0,True
cord-001959,Analysis of treatment and diagnosis and vaccination in clinical settings,This study examines treatment with 459 word abstract...,Author1959_1,Journal of Virology,2019-12-04,WHO,10.1000/sample.1959,PMC1001959,https://example.com/paper_1959,2019.0,12.0,72,10,True,55.0,8.0,True
cord-001960,Analysis of epidemiology and respiratory and COVID-19 in clinical settings,This study examines epidemiology with 256 word abstract...,Author1960_1,Science,2019-12-31,WHO,10.1000/sample.1960,PMC1001960,https://example.com/paper_1960,2019.0,12.0,74,10,True,58.0,8.0,True
cord-001961,Analysis of therapeutic and outbreak and immunity and public health in clinical settings,This study examines therapeutic with 228 word abstract...,"Author1961_1, Author1961_2",Cell,2021-09-04,Medline,10.1000/sample.1961,PMC1001961,,2021.0,9.0,88,13,True,57.0,8.0,True
cord-001962,Analysis of COVID-19 and diagnosis and SARS-CoV-2 in clinical settings,This study examines COVID-19 with 306 word abstract...,"Author1962_1, Author1962_2",,2020-03-22,WHO,10.1000/sample.1962,PMC1001962,https://example.com/paper_1962,2020.0,3.0,70,10,True,54.0,8.0,False
cord-001964,Analysis of pneumonia and SARS-CoV-2 and diagnosis and symptoms in clinical settings,This study examines pneumonia with 293 word abstract...,"Author1964_1, Author1964_2",PLoS ONE,2021-09-17,bioRxiv,10.1000/sample.1964,PMC1001964,https://example.com/paper_1964,2021.0,9.0,84,12,True,55.0,8.0,True
cord-001965,Analysis of diagnosis and pneumonia in clinical settings,This study examines diagnosis with 147 word abstract...,"Author1965_1, Author1965_2",Clinical Infectious Diseases,2020-12-22,WHO,10.1000/sample.1965,PMC1001965,https://example.com/paper_1965,2020.0,12.0,56,8,True,55.0,8.0,True
cord-001966,Analysis of SARS-CoV-2 and therapeutic and pneumonia and symptoms in clinical settings,This study examines SARS-CoV-2 with 496 word abstract...,"Author1966_1, Author1966_2",New England Journal of Medicine,2020-05-08,WHO,10.1000/sample.1966,,https://example.com/paper_1966,2020.0,5.0,86,12,True,56.0,8.0,True
cord-001967,Analysis of immunity and epidemiology and outbreak in clinical settings,This study examines immunity with 476 word abstract...,"Author1967_1, Author1967_2",Cell,2021-01-21,medRxiv,10.1000/sample.1967,PMC1001967,https://example.com/paper_1967,2021.0,1.0,71,10,True,54.0,8.0,True
cord-001968,Analysis of antiviral and diagnosis and public health and pneumonia in clinical settings,This study examines antiviral with 496 word abstract...,"Author1968_1, Author1968_2",Science,,bioRxiv,10.1000/sample.1968,,https://example.com/paper_1968,,,88,13,True,55.0,8.0,True
cord-001969,Analysis of COVID-19 and coronavirus and vaccination in clinical settings,This study examines COVID-19 with 260 word abstract...,"Author1969_1, Author1969_2",Science Translational Medicine,2020-07-14,ArXiv,10.1000/sample.1969,PMC1001969,https://example.com/paper_1969,2020.0,7.0,73,10,True,54.0,8.0,True
cord-001970,Analysis of lockdown and treatment and antiviral in clinical settings,This study examines lockdown with 401 word abstract...,"Author1970_1, Author1970_2",Nature Medicine,,Medline,10.1000/sample.1970,,https://example.com/paper_1970,,,69,10,True,54.0,8.0,True
cord-001971,Analysis of clinical and respiratory and pandemic and public health in clinical settings,This study examines clinical with 298 word abstract...,"Author1971_1, Author1971_2",Emerging Infectious Diseases,2021-06-03,PMC,10.1000/sample.1971,PMC1001971,https://example.com/paper_1971,2021.0,6.0,88,13,True,54.0,8.0,True
cord-001972,Analysis of antiviral and immunity and treatment and pandemic in clinical settings,This study examines antiviral with 178 word abstract...,"Author1972_1, Author1972_2",Science,2020-03-23,bioRxiv,,PMC1001972,,2020.0,3.0,82,12,True,55.0,8.0,True
cord-001975,Analysis of respiratory and outbreak and antiviral in clinical settings,This study examines respiratory with 395 word abstract...,"Author1975_1, Author1975_2",PLoS ONE,2022-06-22,WHO,10.1000/sample.1975,PMC1001975,,2022.0,6.0,71,10,True,57.0,8.0,True
cord-001976,Analysis of therapeutic and COVID-19 and immunity and lockdown in clinical settings,This study examines therapeutic with 253 word abstract...,"Author1976_1, Author1976_2",Virology,2020-05-29,PMC,10.1000/sample.1976,,https://example.com/paper_1976,2020.0,5.0,83,12,True,57.0,8.0,True
cord-001977,Analysis of antibody and transmission in clinical settings,,"Author1977_1, Author1977_2",JAMA,2021-06-22,PMC,10.1000/sample.1977,PMC1001977,https://example.com/paper_1977,2021.0,6.0,58,8,False,,,True
cord-001979,Analysis of pneumonia and COVID-19 in clinical settings,This study examines pneumonia with 280 word abstract...,"Author1979_1, Author1979_2",Virology,2020-12-05,medRxiv,10.1000/sample.1979,,https://example.com/paper_1979,2020.0,12.0,55,8,True,55.0,8.0,True
cord-001980,Analysis of antibody and transmission and SARS-CoV-2 in clinical settings,This study examines antibody with 102 word abstract...,"Author1980_1, Author1980_2",BMJ,2020-03-17,PMC,10.1000/sample.1980,PMC1001980,https://example.com/paper_1980,2020.0,3.0,73,10,True,54.0,8.0,True
cord-001981,Analysis of respiratory and epidemiology and coronavirus in clinical settings,This study examines respiratory with 169 word abstract...,"Author1981_1, Author1981_2",,2021-04-27,bioRxiv,10.1000/sample.1981,PMC1001981,,2021.0,4.0,77,10,True,57.0,8.0,False
cord-001983,Analysis of coronavirus and symptoms in clinical settings,This study examines coronavirus with 262 word abstract...,"Author1983_1, Author1983_2",,2022-02-19,ArXiv,10.1000/sample.1983,PMC1001983,https://example.com/paper_1983,2022.0,2.0,57,8,True,57.0,8.0,False
cord-001984,Analysis of transmission and antiviral and clinical in clinical settings,This study examines transmission with 133 word abstract...,"Author1984_1, Author1984_2",Science Translational Medicine,2019-12-04,WHO,10.1000/sample.1984,,https://example.com/paper_1984,2019.0,12.0,72,10,True,58.0,8.0,True
cord-001989,Analysis of SARS-CoV-2 and epidemiology and COVID-19 in clinical settings,This study examines SARS-CoV-2 with 465 word abstract...,Author1989_1,Clinical Infectious Diseases,2020-11-19,Medline,10.1000/sample.1989,PMC1001989,https://example.com/paper_1989,2020.0,11.0,73,10,True,56.0,8.0,True
cord-001991,Analysis of epidemiology and outbreak and pneumonia and lockdown in clinical settings,This study examines epidemiology with 149 word abstract...,"Author1991_1, Author1991_2",,2020-09-01,bioRxiv,10.1000/sample.1991,PMC1001991,https://example.com/paper_1991,2020.0,9.0,85,12,True,58.0,8.0,False
cord-001992,Analysis of antibody and therapeutic and transmission and public health in clinical settings,This study examines antibody with 234 word abstract...,"Author1992_1, Author1992_2",Journal of Medical Virology,2020-06-09,medRxiv,10.1000/sample.1992,PMC1001992,https://example.com/paper_1992,2020.0,6.0,92,13,True,54.0,8.0,True
cord-001993,Analysis of antibody and antiviral and respiratory and immunity in clinical settings,This study examines antibody with 477 word abstract...,"Author1993_1, Author1993_2",JAMA,2019-12-13,PMC,10.1000/sample.1993,PMC1001993,,2019.0,12.0,84,12,True,54.0,8.0,True
cord-001994,Analysis of coronavirus and vaccination and symptoms and transmission in clinical settings,This study examines coronavirus with 279 word abstract...,"Author1994_1, Author1994_2",Clinical Infectious Diseases,2020-01-03,medRxiv,10.1000/sample.1994,,https://example.com/paper_1994,2020.0,1.0,90,12,True,57.0,8.0,True
cord-001995,Analysis of lockdown and antibody and SARS-CoV-2 in clinical settings,This study examines lockdown with 244 word abstract...,Author1995_1,JAMA,2021-11-12,PMC,10.1000/sample.1995,PMC1001995,,2021.0,11.0,69,10,True,54.0,8.0,True
cord-001996,Analysis of pandemic and respiratory and symptoms and treatment in clinical settings,This study examines pandemic with 218 word abstract...,"Author1996_1, Author1996_2",Science,2020-01-20,ArXiv,10.1000/sample.1996,,https://example.com/paper_1996,2020.0,1.0,84,12,True,54.0,8.0,True
cord-001997,Analysis of diagnosis and treatment and coronavirus and transmission in clinical settings,This study examines diagnosis with 434 word abstract...,"Author1997_1, Author1997_2",Journal of Medical Virology,2020-08-05,PMC,10.1000/sample.1997,,https://example.com/paper_1997,2020.0,8.0,89,12,True,55.0,8.0,True
cord-001998,Analysis of antiviral and COVID-19 and pneumonia and antibody in clinical settings,This study examines antiviral with 392 word abstract...,"Author1998_1, Author1998_2",Cell,2020-12-18,ArXiv,10.1000/sample.1998,,https://example.com/paper_1998,2020.0,12.0,82,12,True,55.0,8.0,True
cord-002000,Analysis of immunity and epidemiology and therapeutic and SARS-CoV-2 in clinical settings,This study examines immunity with 404 word abstract...,"Author2000_1, Author2000_2",Journal of Virology,2021-09-29,bioRxiv,10.1000/sample.2000,,https://example.com/paper_2000,2021.0,9.0,89,12,True,54.0,8.0,True
cord-002002,Analysis of SARS-CoV-2 and coronavirus in clinical settings,This study examines SARS-CoV-2 with 405 word abstract...,"Author2002_1, Author2002_2",Journal of Medical Virology,2021-04-12,WHO,10.1000/sample.2002,PMC1002002,,2021.0,4.0,59,8,True,56.0,8.0,True
cord-002010,Analysis of COVID-19 and epidemiology and diagnosis in clinical settings,This study examines COVID-19 with 405 word abstract...,"Author2010_1, Author2010_2",PLoS ONE,2021-03-21,WHO,10.1000/sample.2010,PMC1002010,,2021.0,3.0,72,10,True,54.0,8.0,True
cord-002012,Analysis of clinical and public health and diagnosis in clinical settings,This study examines clinical with 314 word abstract...,"Author2012_1, Author2012_2",Science Translational Medicine,2020-03-20,bioRxiv,10.1000/sample.2012,PMC1002012,https://example.com/paper_2012,2020.0,3.0,73,11,True,54.0,8.0,True
cord-002013,Analysis of public health and antiviral and pandemic in clinical settings,This study examines public health with 303 word abstract...,Author2013_1,Cell,2020-04-23,Medline,10.1000/sample.2013,PMC1002013,,2020.0,4.0,73,11,True,59.0,9.0,True
cord-002014,Analysis of treatment and vaccination and coronavirus in clinical settings,This study examines treatment with 181 word abstract...,"Author2014_1, Author2014_2",JAMA,2020-10-18,medRxiv,10.1000/sample.2014,PMC1002014,https://example.com/paper_2014,2020.0,10.0,74,10,True,55.0,8.0,True
cord-002015,Analysis of COVID-19 and antiviral and symptoms and respiratory in clinical settings,This study examines COVID-19 with 225 word abstract...,"Author2015_1, Author2015_2",New England Journal of Medicine,2021-12-11,Medline,10.1000/sample.2015,PMC1002015,,2021.0,12.0,84,12,True,54.0,8.0,True
cord-002016,Analysis of SARS-CoV-2 and vaccination and transmission and pneumonia in clinical settings,This study examines SARS-CoV-2 with 328 word abstract...,"Author2016_1, Author2016_2",Journal of Medical Virology,2021-04-26,PMC,10.1000/sample.2016,,https://example.com/paper_2016,2021.0,4.0,90,12,True,56.0,8.0,True
cord-002017,Analysis of outbreak and symptoms and coronavirus in clinical settings,This study examines outbreak with 445 word abstract...,"Author2017_1, Author2017_2",Journal of Virology,2021-06-30,Medline,10.1000/sample.2017,PMC1002017,https://example.com/paper_2017,2021.0,6.0,70,10,True,54.0,8.0,True
cord-002020,Analysis of outbreak and COVID-19 and antiviral in clinical settings,This study examines outbreak with 411 word abstract...,,,2021-04-27,Medline,10.1000/sample.2020,,https://example.com/paper_2020,2021.0,4.0,68,10,True,54.0,8.0,False
cord-002022,Analysis of therapeutic and pandemic in clinical settings,This study examines therapeutic with 481 word abstract...,"Author2022_1, Author2022_2",JAMA,2022-04-19,bioRxiv,10.1000/sample.2022,,https://example.com/paper_2022,2022.0,4.0,57,8,True,57.0,8.0,True
cord-002025,Analysis of respiratory and coronavirus and public health in clinical settings,This study examines respiratory with 332 word abstract...,"Author2025_1, Author2025_2",BMJ,2020-02-27,ArXiv,10.1000/sample.2025,,https://example.com/paper_2025,2020.0,2.0,78,11,True,57.0,8.0,True
cord-002027,Analysis of diagnosis and coronavirus and pandemic and antibody in clinical settings,This study examines diagnosis with 337 word abstract...,"Author2027_1, Author2027_2",Nature Medicine,2020-11-05,bioRxiv,10.1000/sample.2027,PMC1002027,https://example.com/paper_2027,2020.0,11.0,84,12,True,55.0,8.0,True
cord-002029,Analysis of pneumonia and antibody and outbreak and diagnosis in clinical settings,This study examines pneumonia with 347 word abstract...,"Author2029_1, Author2029_2",Nature,2019-12-21,bioRxiv,,PMC1002029,,2019.0,12.0,82,12,True,55.0,8.0,True
cord-002030,Analysis of therapeutic and pneumonia and lockdown in clinical settings,This study examines therapeutic with 473 word abstract...,"Author2030_1, Author2030_2",,2021-12-19,bioRxiv,10.1000/sample.2030,,https://example.com/paper_2030,2021.0,12.0,71,10,True,57.0,8.0,False
cord-002031,Analysis of symptoms and pneumonia and pandemic in clinical settings,This study examines symptoms with 284 word abstract...,"Author2031_1, Author2031_2",Journal of Virology,2021-03-08,medRxiv,10.1000/sample.2031,PMC1002031,https://example.com/paper_2031,2021.0,3.0,68,10,True,54.0,8.0,True
cord-002032,Analysis of clinical and immunity and COVID-19 and transmission in clinical settings,This study examines clinical with 441 word abstract...,"Author2032_1, Author2032_2",Nature Medicine,2021-02-16,PMC,10.1000/sample.2032,PMC1002032,https://example.com/paper_2032,2021.0,2.0,84,12,True,54.0,8.0,True
cord-002033,Analysis of symptoms and treatment and COVID-19 in clinical settings,,"Author2033_1, Author2033_2",Emerging Infectious Diseases,2021-05-19,ArXiv,10.1000/sample.2033,PMC1002033,https://example.com/paper_2033,2021.0,5.0,68,10,False,,,True
cord-002036,Analysis of therapeutic and clinical and coronavirus and vaccination in clinical settings,This study examines therapeutic with 100 word abstract...,"Author2036_1, Author2036_2",JAMA,2020-10-14,PMC,10.1000/sample.2036,PMC1002036,,2020.0,10.0,89,12,True,57.0,8.0,True
cord-002037,Analysis of pneumonia and treatment and outbreak in clinical settings,This study examines pneumonia with 314 word abstract...,,Journal of Virology,2020-05-14,medRxiv,,PMC1002037,https://example.com/paper_2037,2020.0,5.0,69,10,True,55.0,8.0,True
cord-002038,Analysis of COVID-19 and lockdown and antiviral in clinical settings,This study examines COVID-19 with 447 word abstract...,"Author2038_1, Author2038_2",BMJ,2020-05-22,PMC,10.1000/sample.2038,PMC1002038,,2020.0,5.0,68,10,True,54.0,8.0,True
cord-002039,Analysis of public health and antiviral and COVID-19 in clinical settings,This study examines public health with 315 word abstract...,"Author2039_1, Author2039_2",Nature,2021-06-11,bioRxiv,10.1000/sample.2039,PMC1002039,,2021.0,6.0,73,11,True,59.0,9.0,True
cord-002040,Analysis of antibody and COVID-19 and lockdown in clinical settings,This study examines antibody with 122 word abstract...,"Author2040_1, Author2040_2",BMJ,2021-07-01,ArXiv,10.1000/sample.2040,,,2021.0,7.0,67,10,True,54.0,8.0,True
cord-002042,Analysis of therapeutic and pandemic and respiratory in clinical settings,This study examines therapeutic with 173 word abstract...,"Author2042_1, Author2042_2",Journal of Virology,2019-12-16,PMC,10.1000/sample.2042,,https://example.com/paper_2042,2019.0,12.0,73,10,True,57.0,8.0,True
cord-002043,Analysis of immunity and pneumonia and COVID-19 and symptoms in clinical settings,This study examines immunity with 454 word abstract...,"Author2043_1, Author2043_2",Journal of Medical Virology,2020-02-23,Medline,10.1000/sample.2043,,https://example.com/paper_2043,2020.0,2.0,81,12,True,54.0,8.0,True
cord-002045,Analysis of symptoms and treatment in clinical settings,This study examines symptoms with 147 word abstract...,"Author2045_1, Author2045_2",Science,2022-07-02,bioRxiv,10.1000/sample.2045,PMC1002045,https://example.com/paper_2045,2022.0,7.0,55,8,True,54.0,8.0,True
cord-002046,Analysis of diagnosis and respiratory and clinical and pandemic in clinical settings,This study examines diagnosis with 459 word abstract...,"Author2046_1, Author2046_2",,2021-02-02,PMC,10.1000/sample.2046,PMC1002046,https://example.com/paper_2046,2021.0,2.0,84,12,True,55.0,8.0,False
cord-002047,Analysis of public health and clinical and transmission in clinical settings,This study examines public health with 248 word abstract...,"Author2047_1, Author2047_2",Journal of Virology,2019-12-20,ArXiv,10.1000/sample.2047,PMC1002047,https://example.com/paper_2047,2019.0,12.0,76,11,True,59.0,9.0,True
cord-002048,Analysis of outbreak and antibody and epidemiology and symptoms in clinical settings,,"Author2048_1, Author2048_2",Journal of Virology,2020-08-10,Medline,10.1000/sample.2048,PMC1002048,https://example.com/paper_2048,2020.0,8.0,84,12,False,,,True
cord-002049,Analysis of transmission and immunity and SARS-CoV-2 in clinical settings,This study examines transmission with 413 word abstract...,"Author2049_1, Author2049_2",JAMA,,medRxiv,10.1000/sample.2049,PMC1002049,https://example.com/paper_2049,,,73,10,True,58.0,8.0,True
cord-002050,Analysis of diagnosis and pneumonia and pandemic and vaccination in clinical settings,This study examines diagnosis with 214 word abstract...,"Author2050_1, Author2050_2",JAMA,2020-01-14,ArXiv,10.1000/sample.2050,PMC1002050,https://example.com/paper_2050,2020.0,1.0,85,12,True,55.0,8.0,True
cord-002051,Analysis of clinical and symptoms and immunity in clinical settings,This study examines clinical with 333 word abstract...,"Author2051_1, Author2051_2",PLoS ONE,2021-10-19,medRxiv,10.1000/sample.2051,,https://example.com/paper_2051,2021.0,10.0,67,10,True,54.0,8.0,True
cord-002055,Analysis of antiviral and epidemiology and coronavirus and public health in clinical settings,This study examines antiviral with 495 word abstract...,"Author2055_1, Author2055_2",Science,,WHO,10.1000/sample.2055,PMC1002055,https://example.com/paper_2055,,,93,13,True,55.0,8.0,True
cord-002056,Analysis of treatment and vaccination and symptoms in clinical settings,This study examines treatment with 205 word abstract...,Author2056_1,Nature,2020-06-09,PMC,10.1000/sample.2056,,https://example.com/paper_2056,2020.0,6.0,71,10,True,55.0,8.0,True
cord-002057,Analysis of pneumonia and coronavirus and epidemiology and immunity in clinical settings,This study examines pneumonia with 291 word abstract...,"Author2057_1, Author2057_2",JAMA,2020-02-21,PMC,10.1000/sample.2057,,https://example.com/paper_2057,2020.0,2.0,88,12,True,55.0,8.0,True
cord-002058,Analysis of clinical and immunity and SARS-CoV-2 in clinical settings,This study examines clinical with 488 word abstract...,Author2058_1,JAMA,2021-07-06,PMC,10.1000/sample.2058,PMC1002058,,2021.0,7.0,69,10,True,54.0,8.0,True
cord-002059,Analysis of outbreak and coronavirus and treatment and transmission in clinical settings,This study examines outbreak with 468 word abstract...,"Author2059_1, Author2059_2",Nature Medicine,2020-06-02,bioRxiv,10.1000/sample.2059,PMC1002059,https://example.com/paper_2059,2020.0,6.0,88,12,True,54.0,8.0,True
cord-002061,Analysis of COVID-19 and SARS-CoV-2 and public health in clinical settings,This study examines COVID-19 with 345 word abstract...,"Author2061_1, Author2061_2",Clinical Infectious Diseases,2022-12-17,bioRxiv,10.1000/sample.2061,PMC1002061,https://example.com/paper_2061,2022.0,12.0,74,11,True,54.0,8.0,True
cord-002062,Analysis of public health and clinical and therapeutic and transmission in clinical settings,This study examines public health with 226 word abstract...,"Author2062_1, Author2062_2",Clinical Infectious Diseases,2022-09-11,bioRxiv,10.1000/sample.2062,PMC1002062,https://example.com/paper_2062,2022.0,9.0,92,13,True,59.0,9.0,True
cord-002065,Analysis of outbreak and COVID-19 and pandemic in clinical settings,This study examines outbreak with 483 word abstract...,"Author2065_1, Author2065_2",Nature Medicine,2021-03-13,PMC,10.1000/sample.2065,PMC1002065,https://example.com/paper_2065,2021.0,3.0,67,10,True,54.0,8.0,True
cord-002066,Analysis of outbreak and therapeutic and COVID-19 and diagnosis in clinical settings,This study examines outbreak with 336 word abstract...,"Author2066_1, Author2066_2",Science Translational Medicine,2020-05-16,bioRxiv,10.1000/sample.2066,PMC1002066,https://example.com/paper_2066,2020.0,5.0,84,12,True,54.0,8.0,True
cord-002067,Analysis of coronavirus and antiviral and pneumonia in clinical settings,This study examines coronavirus with 455 word abstract...,"Author2067_1, Author2067_2",Cell,2022-04-05,Medline,10.1000/sample.2067,PMC1002067,https://example.com/paper_2067,2022.0,4.0,72,10,True,57.0,8.0,True
cord-002068,Analysis of antibody and SARS-CoV-2 and immunity in clinical settings,This study examines antibody with 257 word abstract...,"Author2068_1, Author2068_2",Nature,2020-10-01,bioRxiv,10.1000/sample.2068,PMC1002068,https://example.com/paper_2068,2020.0,10.0,69,10,True,54.0,8.0,True
cord-002069,Analysis of treatment and transmission and clinical in clinical settings,This study examines treatment with 388 word abstract...,"Author2069_1, Author2069_2",PLoS ONE,2021-10-13,PMC,10.1000/sample.2069,PMC1002069,https://example.com/paper_2069,2021.0,10.0,72,10,True,55.0,8.0,True
cord-002070,Analysis of respiratory and public health and antiviral in clinical settings,This study examines respiratory with 309 word abstract...,"Author2070_1, Author2070_2",,2022-05-18,WHO,10.1000/sample.2070,PMC1002070,https://example.com/paper_2070,2022.0,5.0,76,11,True,57.0,8.0,False
cord-002071,Analysis of immunity and epidemiology and antibody and COVID-19 in clinical settings,This study examines immunity with 331 word abstract...,"Author2071_1, Author2071_2",,2021-10-29,ArXiv,10.1000/sample.2071,PMC1002071,https://example.com/paper_2071,2021.0,10.0,84,12,True,54.0,8.0,False
cord-002072,Analysis of symptoms and epidemiology and respiratory in clinical settings,This study examines symptoms with 351 word abstract...,"Author2072_1, Author2072_2",JAMA,2021-08-12,medRxiv,10.1000/sample.2072,PMC1002072,,2021.0,8.0,74,10,True,54.0,8.0,True
cord-002073,Analysis of pneumonia and transmission in clinical settings,This study examines pneumonia with 288 word abstract...,"Author2073_1, Author2073_2",Journal of Virology,2020-03-06,medRxiv,,,,2020.0,3.0,59,8,True,55.0,8.0,True
cord-002074,Analysis of antibody and outbreak and therapeutic in clinical settings,This study examines antibody with 462 word abstract...,Author2074_1,JAMA,2019-12-01,bioRxiv,10.1000/sample.2074,PMC1002074,https://example.com/paper_2074,2019.0,12.0,70,10,True,54.0,8.0,True
cord-002075,Analysis of lockdown and outbreak and pneumonia in clinical settings,This study examines lockdown with 325 word abstract...,"Author2075_1, Author2075_2",,,Medline,10.1000/sample.2075,,https://example.com/paper_2075,,,68,10,True,54.0,8.0,False
cord-002076,Analysis of coronavirus and antiviral and epidemiology and symptoms in clinical settings,This study examines coronavirus with 270 word abstract...,"Author2076_1, Author2076_2",Science,2021-01-31,medRxiv,10.1000/sample.2076,,https://example.com/paper_2076,2021.0,1.0,88,12,True,57.0,8.0,True
cord-002077,Analysis of immunity and pneumonia and SARS-CoV-2 in clinical settings,This study examines immunity with 111 word abstract...,"Author2077_1, Author2077_2",Journal of Medical Virology,2020-07-24,Medline,10.1000/sample.2077,PMC1002077,,2020.0,7.0,70,10,True,54.0,8.0,True
cord-002080,Analysis of lockdown and COVID-19 and clinical in clinical settings,This study examines lockdown with 159 word abstract...,"Author2080_1, Author2080_2",Cell,2021-11-23,PMC,10.1000/sample.2080,PMC1002080,,2021.0,11.0,67,10,True,54.0,8.0,True
cord-002081,Analysis of coronavirus and COVID-19 and treatment and pandemic in clinical settings,This study examines coronavirus with 300 word abstract...,"Author2081_1, Author2081_2",PLoS ONE,2019-12-18,medRxiv,,PMC1002081,https://example.com/paper_2081,2019.0,12.0,84,12,True,57.0,8.0,True
cord-002082,Analysis of vaccination and antibody and diagnosis in clinical settings,,"Author2082_1, Author2082_2",,2021-12-26,PMC,,,https://example.com/paper_2082,2021.0,12.0,71,10,False,,,False
cord-002085,Analysis of respiratory and antiviral and symptoms in clinical settings,This study examines respiratory with 412 word abstract...,"Author2085_1, Author2085_2",Science Translational Medicine,2020-04-22,ArXiv,10.1000/sample.2085,PMC1002085,https://example.com/paper_2085,2020.0,4.0,71,10,True,57.0,8.0,True
cord-002086,Analysis of therapeutic and coronavirus and diagnosis in clinical settings,This study examines therapeutic with 149 word abstract...,"Author2086_1, Author2086_2",Clinical Infectious Diseases,2021-11-11,bioRxiv,10.1000/sample.2086,PMC1002086,https://example.com/paper_2086,2021.0,11.0,74,10,True,57.0,8.0,True
cord-002087,Analysis of epidemiology and pandemic and diagnosis in clinical settings,This study examines epidemiology with 261 word abstract...,"Author2087_1, Author2087_2",Journal of Virology,2020-04-09,Medline,10.1000/sample.2087,PMC1002087,https://example.com/paper_2087,2020.0,4.0,72,10,True,58.0,8.0,True
cord-002089,Analysis of symptoms and antibody and SARS-CoV-2 and antiviral in clinical settings,This study examines symptoms with 284 word abstract...,"Author2089_1, Author2089_2",Science,2020-03-06,WHO,10.1000/sample.2089,PMC1002089,https://example.com/paper_2089,2020.0,3.0,83,12,True,54.0,8.0,True
cord-002090,Analysis of antiviral and clinical and epidemiology and outbreak in clinical settings,This study examines antiviral with 234 word abstract...,"Author2090_1, Author2090_2",Journal of Medical Virology,2020-02-08,medRxiv,,PMC1002090,https://example.com/paper_2090,2020.0,2.0,85,12,True,55.0,8.0,True
cord-002091,Analysis of lockdown and immunity and vaccination in clinical settings,This study examines lockdown with 350 word abstract...,"Author2091_1, Author2091_2",Clinical Infectious Diseases,2021-03-22,ArXiv,10.1000/sample.2091,,,2021.0,3.0,70,10,True,54.0,8.0,True
cord-002093,Analysis of respiratory and immunity and diagnosis in clinical settings,This study examines respiratory with 240 word abstract...,"Author2093_1, Author2093_2",Journal of Virology,2021-05-12,PMC,10.1000/sample.2093,PMC1002093,,2021.0,5.0,71,10,True,57.0,8.0,True
cord-002094,Analysis of vaccination and clinical and COVID-19 and public health in clinical settings,This study examines vaccination with 147 word abstract...,Author2094_1,Nature,2020-11-13,Medline,10.1000/sample.2094,,https://example.com/paper_2094,2020.0,11.0,88,13,True,57.0,8.0,True
cord-002095,Analysis of immunity and coronavirus and clinical and pneumonia in clinical settings,This study examines immunity with 136 word abstract...,"Author2095_1, Author2095_2",JAMA,2020-09-04,bioRxiv,10.1000/sample.2095,PMC1002095,https://example.com/paper_2095,2020.0,9.0,84,12,True,54.0,8.0,True
cord-002097,Analysis of SARS-CoV-2 and immunity and clinical in clinical settings,This study examines SARS-CoV-2 with 113 word abstract...,"Author2097_1, Author2097_2",Emerging Infectious Diseases,2020-10-01,bioRxiv,10.1000/sample.2097,PMC1002097,https://example.com/paper_2097,2020.0,10.0,69,10,True,56.0,8.0,True
cord-002098,Analysis of vaccination and clinical and treatment and coronavirus in clinical settings,This study examines vaccination with 368 word abstract...,Author2098_1,Nature,2020-10-08,medRxiv,10.1000/sample.2098,PMC1002098,,2020.0,10.0,87,12,True,57.0,8.0,True
cord-002099,Analysis of SARS-CoV-2 and coronavirus and pneumonia in clinical settings,This study examines SARS-CoV-2 with 246 word abstract...,Author2099_1,Journal of Medical Virology,2021-07-17,bioRxiv,10.1000/sample.2099,PMC1002099,,2021.0,7.0,73,10,True,56.0,8.0,True
cord-002102,Analysis of epidemiology and respiratory and clinical in clinical settings,This study examines epidemiology with 166 word abstract...,"Author2102_1, Author2102_2",Nature,2021-06-03,Medline,10.1000/sample.2102,PMC1002102,https://example.com/paper_2102,2021.0,6.0,74,10,True,58.0,8.0,True
cord-002103,Analysis of coronavirus and diagnosis and epidemiology in clinical settings,This study examines coronavirus with 171 word abstract...,"Author2103_1, Author2103_2",Science Translational Medicine,2020-05-11,medRxiv,10.1000/sample.2103,PMC1002103,https://example.com/paper_2103,2020.0,5.0,75,10,True,57.0,8.0,True
cord-002106,Analysis of coronavirus and respiratory and public health and vaccination in clinical settings,This study examines coronavirus with 466 word abstract...,"Author2106_1, Author2106_2",Virology,2021-03-19,PMC,10.1000/sample.2106,,https://example.com/paper_2106,2021.0,3.0,94,13,True,57.0,8.0,True
cord-002108,Analysis of epidemiology and SARS-CoV-2 and immunity in clinical settings,This study examines epidemiology with 237 word abstract...,"Author2108_1, Author2108_2",Lancet,,bioRxiv,10.1000/sample.2108,,https://example.com/paper_2108,,,73,10,True,58.0,8.0,True
cord-002110,Analysis of antibody and respiratory and therapeutic in clinical settings,This study examines antibody with 499 word abstract...,"Author2110_1, Author2110_2",Emerging Infectious Diseases,,WHO,10.1000/sample.2110,PMC1002110,https://example.com/paper_2110,,,73,10,True,54.0,8.0,True
cord-002111,Analysis of outbreak and SARS-CoV-2 and epidemiology and antiviral in clinical settings,This study examines outbreak with 170 word abstract...,"Author2111_1, Author2111_2",New England Journal of Medicine,2021-08-10,bioRxiv,10.1000/sample.2111,PMC1002111,https://example.com/paper_2111,2021.0,8.0,87,12,True,54.0,8.0,True
cord-002113,Analysis of coronavirus and antibody and public health and immunity in clinical settings,This study examines coronavirus with 184 word abstract...,"Author2113_1, Author2113_2",Clinical Infectious Diseases,2020-07-22,Medline,10.1000/sample.2113,,,2020.0,7.0,88,13,True,57.0,8.0,True
cord-002114,Analysis of therapeutic and COVID-19 and SARS-CoV-2 in clinical settings,This study examines therapeutic with 255 word abstract...,"Author2114_1, Author2114_2",Clinical Infectious Diseases,2020-09-13,ArXiv,10.1000/sample.2114,PMC1002114,https://example.com/paper_2114,2020.0,9.0,72,10,True,57.0,8.0,True
cord-002115,Analysis of SARS-CoV-2 and treatment and public health and epidemiology in clinical settings,This study examines SARS-CoV-2 with 244 word abstract...,"Author2115_1, Author2115_2",Cell,2020-01-18,medRxiv,10.1000/sample.2115,PMC1002115,https://example.com/paper_2115,2020.0,1.0,92,13,True,56.0,8.0,True
cord-002116,Analysis of antibody and treatment and clinical in clinical settings,This study examines antibody with 252 word abstract...,"Author2116_1, Author2116_2",Science Translational Medicine,2020-08-04,Medline,10.1000/sample.2116,,https://example.com/paper_2116,2020.0,8.0,68,10,True,54.0,8.0,True
cord-002117,Analysis of antibody and COVID-19 and vaccination in clinical settings,,"Author2117_1, Author2117_2",,2019-12-07,Medline,10.1000/sample.2117,PMC1002117,,2019.0,12.0,70,10,False,,,False
cord-002118,Analysis of therapeutic and SARS-CoV-2 in clinical settings,This study examines therapeutic with 128 word abstract...,"Author2118_1, Author2118_2",Journal of Virology,2021-10-29,PMC,10.1000/sample.2118,PMC1002118,https://example.com/paper_2118,2021.0,10.0,59,8,True,57.0,8.0,True
cord-002120,Analysis of coronavirus and clinical and pandemic and transmission in clinical settings,This study examines coronavirus with 196 word abstract...,"Author2120_1, Author2120_2",Nature,2021-04-19,medRxiv,10.1000/sample.2120,PMC1002120,https://example.com/paper_2120,2021.0,4.0,87,12,True,57.0,8.0,True
cord-002124,Analysis of transmission and pneumonia and therapeutic and pandemic in clinical settings,This study examines transmission with 112 word abstract...,"Author2124_1, Author2124_2",Clinical Infectious Diseases,2021-01-03,Medline,10.1000/sample.2124,PMC1002124,https://example.com/paper_2124,2021.0,1.0,88,12,True,58.0,8.0,True
cord-002125,Analysis of SARS-CoV-2 and coronavirus and diagnosis and respiratory in clinical settings,This study examines SARS-CoV-2 with 123 word abstract...,"Author2125_1, Author2125_2",BMJ,2020-12-11,WHO,10.1000/sample.2125,,https://example.com/paper_2125,2020.0,12.0,89,12,True,56.0,8.0,True
cord-002126,Analysis of epidemiology and transmission in clinical settings,This study examines epidemiology with 458 word abstract...,"Author2126_1, Author2126_2",Journal of Virology,2022-12-28,bioRxiv,10.1000/sample.2126,PMC1002126,https://example.com/paper_2126,2022.0,12.0,62,8,True,58.0,8.0,True
cord-002127,Analysis of outbreak and immunity in clinical settings,This study examines outbreak with 170 word abstract...,"Author2127_1, Author2127_2",Science Translational Medicine,2020-03-16,medRxiv,10.1000/sample.2127,PMC1002127,https://example.com/paper_2127,2020.0,3.0,54,8,True,54.0,8.0,True
cord-002128,Analysis of clinical and pneumonia and epidemiology in clinical settings,This study examines clinical with 159 word abstract...,"Author2128_1, Author2128_2",BMJ,2020-05-28,bioRxiv,10.1000/sample.2128,PMC1002128,https://example.com/paper_2128,2020.0,5.0,72,10,True,54.0,8.0,True
cord-002131,Analysis of clinical and vaccination in clinical settings,This study examines clinical with 157 word abstract...,"Author2131_1, Author2131_2",Science Translational Medicine,2020-04-01,ArXiv,10.1000/sample.2131,PMC1002131,https://example.com/paper_2131,2020.0,4.0,57,8,True,54.0,8.0,True
cord-002132,Analysis of immunity and coronavirus and respiratory in clinical settings,This study examines immunity with 453 word abstract...,"Author2132_1, Author2132_2",Science,2021-08-08,ArXiv,10.1000/sample.2132,,https://example.com/paper_2132,2021.0,8.0,73,10,True,54.0,8.0,True
cord-002134,Analysis of antiviral and symptoms in clinical settings,This study examines antiviral with 171 word abstract...,"Author2134_1, Author2134_2",Lancet,2020-12-21,Medline,,PMC1002134,https://example.com/paper_2134,2020.0,12.0,55,8,True,55.0,8.0,True
cord-002136,Analysis of COVID-19 and pandemic and epidemiology and public health in clinical settings,This study examines COVID-19 with 493 word abstract...,Author2136_1,Emerging Infectious Diseases,2020-08-20,medRxiv,10.1000/sample.2136,PMC1002136,https://example.com/paper_2136,2020.0,8.0,89,13,True,54.0,8.0,True
cord-002137,Analysis of antiviral and vaccination and clinical in clinical settings,This study examines antiviral with 453 word abstract...,"Author2137_1, Author2137_2",,2021-11-19,medRxiv,10.1000/sample.2137,PMC1002137,,2021.0,11.0,71,10,True,55.0,8.0,False
cord-002139,Analysis of therapeutic and transmission and public health and antibody in clinical settings,,"Author2139_1, Author2139_2",PLoS ONE,2020-01-22,PMC,10.1000/sample.2139,PMC1002139,,2020.0,1.0,92,13,False,,,True
cord-002140,Analysis of therapeutic and clinical and COVID-19 and antibody in clinical settings,This study examines therapeutic with 239 word abstract...,"Author2140_1, Author2140_2",Clinical Infectious Diseases,2020-12-02,bioRxiv,10.1000/sample.2140,,,2020.0,12.0,83,12,True,57.0,8.0,True
cord-002142,Analysis of SARS-CoV-2 and immunity and epidemiology in clinical settings,This study examines SARS-CoV-2 with 390 word abstract...,"Author2142_1, Author2142_2",Lancet,2019-12-05,bioRxiv,10.1000/sample.2142,PMC1002142,,2019.0,12.0,73,10,True,56.0,8.0,True
cord-002143,Analysis of pneumonia and pandemic and diagnosis in clinical settings,This study examines pneumonia with 342 word abstract...,"Author2143_1, Author2143_2",Nature,2021-10-09,medRxiv,,,https://example.com/paper_2143,2021.0,10.0,69,10,True,55.0,8.0,True
cord-002144,Analysis of SARS-CoV-2 and coronavirus and immunity and transmission in clinical settings,This study examines SARS-CoV-2 with 136 word abstract...,"Author2144_1, Author2144_2",Science Translational Medicine,2020-04-14,ArXiv,10.1000/sample.2144,PMC1002144,https://example.com/paper_2144,2020.0,4.0,89,12,True,56.0,8.0,True
cord-002145,Analysis of epidemiology and outbreak and transmission and vaccination in clinical settings,This study examines epidemiology with 423 word abstract...,"Author2145_1, Author2145_2",PLoS ONE,2021-11-25,Medline,10.1000/sample.2145,,https://example.com/paper_2145,2021.0,11.0,91,12,True,58.0,8.0,True
cord-002146,Analysis of treatment and immunity and coronavirus in clinical settings,This study examines treatment with 277 word abstract...,"Author2146_1, Author2146_2",Science Translational Medicine,2020-07-23,Medline,10.1000/sample.2146,,https://example.com/paper_2146,2020.0,7.0,71,10,True,55.0,8.0,True
cord-002148,Analysis of COVID-19 and clinical and coronavirus in clinical settings,This study examines COVID-19 with 288 word abstract...,Author2148_1,Journal of Virology,2020-04-11,PMC,10.1000/sample.2148,,https://example.com/paper_2148,2020.0,4.0,70,10,True,54.0,8.0,True
cord-002149,Analysis of transmission and SARS-CoV-2 and coronavirus and clinical in clinical settings,This study examines transmission with 143 word abstract...,"Author2149_1, Author2149_2",Virology,2020-04-21,medRxiv,10.1000/sample.2149,PMC1002149,https://example.com/paper_2149,2020.0,4.0,89,12,True,58.0,8.0,True
cord-002150,Analysis of transmission and coronavirus and diagnosis and pandemic in clinical settings,This study examines transmission with 210 word abstract...,"Author2150_1, Author2150_2",Virology,2019-12-25,bioRxiv,10.1000/sample.2150,PMC1002150,https://example.com/paper_2150,2019.0,12.0,88,12,True,58.0,8.0,True
cord-002153,Analysis of diagnosis and coronavirus and lockdown and clinical in clinical settings,This study examines diagnosis with 187 word abstract...,Author2153_1,Science,2020-12-03,WHO,10.1000/sample.2153,PMC1002153,https://example.com/paper_2153,2020.0,12.0,84,12,True,55.0,8.0,True
cord-002154,Analysis of SARS-CoV-2 and lockdown and public health in clinical settings,This study examines SARS-CoV-2 with 225 word abstract...,"Author2154_1, Author2154_2",Science,2021-06-04,medRxiv,10.1000/sample.2154,,https://example.com/paper_2154,2021.0,6.0,74,11,True,56.0,8.0,True
cord-002155,Analysis of pandemic and respiratory and COVID-19 and pneumonia in clinical settings,This study examines pandemic with 266 word abstract...,"Author2155_1, Author2155_2",BMJ,2020-12-12,bioRxiv,,,https://example.com/paper_2155,2020.0,12.0,84,12,True,54.0,8.0,True
cord-002156,Analysis of respiratory and symptoms and pneumonia and SARS-CoV-2 in clinical settings,This study examines respiratory with 362 word abstract...,"Author2156_1, Author2156_2",,2020-12-22,WHO,10.1000/sample.2156,PMC1002156,https://example.com/paper_2156,2020.0,12.0,86,12,True,57.0,8.0,False
cord-002157,Analysis of antiviral and lockdown and respiratory and clinical in clinical settings,This study examines antiviral with 268 word abstract...,Author2157_1,PLoS ONE,2021-11-29,WHO,10.1000/sample.2157,,https://example.com/paper_2157,2021.0,11.0,84,12,True,55.0,8.0,True
cord-002160,Analysis of therapeutic and pandemic and SARS-CoV-2 in clinical settings,This study examines therapeutic with 360 word abstract...,"Author2160_1, Author2160_2",Nature Medicine,2020-11-15,ArXiv,10.1000/sample.2160,,https://example.com/paper_2160,2020.0,11.0,72,10,True,57.0,8.0,True
cord-002161,Analysis of vaccination and diagnosis and transmission and symptoms in clinical settings,This study examines vaccination with 407 word abstract...,,Emerging Infectious Diseases,2020-06-18,ArXiv,10.1000/sample.2161,PMC1002161,https://example.com/paper_2161,2020.0,6.0,88,12,True,57.0,8.0,True
cord-002164,Analysis of antibody and therapeutic and coronavirus and immunity in clinical settings,This study examines antibody with 388 word abstract...,Author2164_1,Nature Medicine,2020-08-03,Medline,10.1000/sample.2164,PMC1002164,,2020.0,8.0,86,12,True,54.0,8.0,True
cord-002167,Analysis of diagnosis and public health and immunity in clinical settings,This study examines diagnosis with 426 word abstract...,"Author2167_1, Author2167_2",BMJ,2020-09-30,ArXiv,10.1000/sample.2167,PMC1002167,,2020.0,9.0,73,11,True,55.0,8.0,True
cord-002170,Analysis of lockdown and COVID-19 and coronavirus and respiratory in clinical settings,This study examines lockdown with 483 word abstract...,"Author2170_1, Author2170_2",Nature Medicine,2020-06-26,Medline,10.1000/sample.2170,PMC1002170,https://example.com/paper_2170,2020.0,6.0,86,12,True,54.0,8.0,True
cord-002171,Analysis of therapeutic and clinical and COVID-19 in clinical settings,This study examines therapeutic with 301 word abstract...,"Author2171_1, Author2171_2",New England Journal of Medicine,2021-05-05,PMC,10.1000/sample.2171,,https://example.com/paper_2171,2021.0,5.0,70,10,True,57.0,8.0,True
cord-002172,Analysis of pneumonia and pandemic and public health and outbreak in clinical settings,This study examines pneumonia with 193 word abstract...,"Author2172_1, Author2172_2",Nature,2020-06-12,WHO,10.1000/sample.2172,PMC1002172,,2020.0,6.0,86,13,True,55.0,8.0,True
cord-002173,Analysis of pneumonia and treatment in clinical settings,This study examines pneumonia with 224 word abstract...,"Author2173_1, Author2173_2",Science,2021-06-15,WHO,,PMC1002173,,2021.0,6.0,56,8,True,55.0,8.0,True
cord-002175,Analysis of vaccination and pneumonia and SARS-CoV-2 and epidemiology in clinical settings,This study examines vaccination with 321 word abstract...,"Author2175_1, Author2175_2",Virology,2021-09-11,ArXiv,10.1000/sample.2175,PMC1002175,https://example.com/paper_2175,2021.0,9.0,90,12,True,57.0,8.0,True
cord-002176,Analysis of public health and clinical and immunity and therapeutic in clinical settings,This study examines public health with 374 word abstract...,"Author2176_1, Author2176_2",,2021-09-13,WHO,10.1000/sample.2176,PMC1002176,,2021.0,9.0,88,13,True,59.0,9.0,False
cord-002177,Analysis of epidemiology and COVID-19 and antiviral in clinical settings,,"Author2177_1, Author2177_2",,2019-12-13,PMC,10.1000/sample.2177,PMC1002177,https://example.com/paper_2177,2019.0,12.0,72,10,False,,,False
cord-002179,Analysis of COVID-19 and treatment and lockdown and clinical in clinical settings,This study examines COVID-19 with 495 word abstract...,"Author2179_1, Author2179_2",Science Translational Medicine,2021-03-14,medRxiv,10.1000/sample.2179,PMC1002179,https://example.com/paper_2179,2021.0,3.0,81,12,True,54.0,8.0,True
cord-002180,Analysis of immunity and symptoms and COVID-19 and public health in clinical settings,This study examines immunity with 118 word abstract...,"Author2180_1, Author2180_2",Lancet,2020-01-19,medRxiv,10.1000/sample.2180,PMC1002180,https://example.com/paper_2180,2020.0,1.0,85,13,True,54.0,8.0,True
cord-002182,Analysis of lockdown and vaccination and pneumonia in clinical settings,This study examines lockdown with 202 word abstract...,"Author2182_1, Author2182_2",Cell,2021-06-13,bioRxiv,10.1000/sample.2182,PMC1002182,https://example.com/paper_2182,2021.0,6.0,71,10,True,54.0,8.0,True
cord-002184,Analysis of SARS-CoV-2 and lockdown and therapeutic and antiviral in clinical settings,This study examines SARS-CoV-2 with 304 word abstract...,"Author2184_1, Author2184_2",Virology,2021-08-08,bioRxiv,10.1000/sample.2184,PMC1002184,https://example.com/paper_2184,2021.0,8.0,86,12,True,56.0,8.0,True
cord-002185,Analysis of pandemic and clinical in clinical settings,This study examines pandemic with 158 word abstract...,"Author2185_1, Author2185_2",,2020-09-28,Medline,10.1000/sample.2185,,https://example.com/paper_2185,2020.0,9.0,54,8,True,54.0,8.0,False
cord-002186,Analysis of transmission and antiviral and coronavirus in clinical settings,This study examines transmission with 261 word abstract...,Author2186_1,Emerging Infectious Diseases,2020-02-01,bioRxiv,10.1000/sample.2186,PMC1002186,https://example.com/paper_2186,2020.0,2.0,75,10,True,58.0,8.0,True
cord-002189,Analysis of symptoms and clinical and coronavirus and lockdown in clinical settings,This study examines symptoms with 362 word abstract...,"Author2189_1, Author2189_2",,2021-04-19,PMC,10.1000/sample.2189,PMC1002189,https://example.com/paper_2189,2021.0,4.0,83,12,True,54.0,8.0,False
cord-002190,Analysis of public health and epidemiology and antiviral in clinical settings,This study examines public health with 281 word abstract...,"Author2190_1, Author2190_2",Nature Medicine,2021-04-18,medRxiv,10.1000/sample.2190,,https://example.com/paper_2190,2021.0,4.0,77,11,True,59.0,9.0,True
cord-002192,Analysis of transmission and lockdown and clinical in clinical settings,This study examines transmission with 346 word abstract...,"Author2192_1, Author2192_2",,2022-01-03,PMC,10.1000/sample.2192,PMC1002192,https://example.com/paper_2192,2022.0,1.0,71,10,True,58.0,8.0,False
cord-002193,Analysis of lockdown and transmission and respiratory in clinical settings,This study examines lockdown with 368 word abstract...,"Author2193_1, Author2193_2",Emerging Infectious Diseases,2020-12-27,WHO,10.1000/sample.2193,,https://example.com/paper_2193,2020.0,12.0,74,10,True,54.0,8.0,True
cord-002194,Analysis of antiviral and outbreak and respiratory in clinical settings,This study examines antiviral with 149 word abstract...,"Author2194_1, Author2194_2",PLoS ONE,2021-04-11,ArXiv,10.1000/sample.2194,PMC1002194,https://example.com/paper_2194,2021.0,4.0,71,10,True,55.0,8.0,True
cord-002197,Analysis of pneumonia and public health and antibody and treatment in clinical settings,This study examines pneumonia with 442 word abstract...,Author2197_1,,2021-02-28,bioRxiv,10.1000/sample.2197,PMC1002197,,2021.0,2.0,87,13,True,55.0,8.0,False
cord-002198,Analysis of symptoms and COVID-19 and vaccination and respiratory in clinical settings,This study examines symptoms with 136 word abstract...,"Author2198_1, Author2198_2",Nature,2020-10-04,WHO,10.1000/sample.2198,PMC1002198,https://example.com/paper_2198,2020.0,10.0,86,12,True,54.0,8.0,True
cord-002199,Analysis of clinical and pandemic and public health in clinical settings,This study examines clinical with 326 word abstract...,Author2199_1,Nature,2021-09-16,Medline,10.1000/sample.2199,PMC1002199,,2021.0,9.0,72,11,True,54.0,8.0,True
cord-002200,Analysis of treatment and transmission and therapeutic and COVID-19 in clinical settings,This study examines treatment with 220 word abstract...,"Author2200_1, Author2200_2",Emerging Infectious Diseases,2020-04-09,PMC,10.1000/sample.2200,,,2020.0,4.0,88,12,True,55.0,8.0,True
cord-002202,Analysis of COVID-19 and pneumonia and outbreak and symptoms in clinical settings,This study examines COVID-19 with 137 word abstract...,"Author2202_1, Author2202_2",Science,2019-12-08,Medline,10.1000/sample.2202,PMC1002202,,2019.0,12.0,81,12,True,54.0,8.0,True
cord-002203,Analysis of pneumonia and COVID-19 and diagnosis in clinical settings,This study examines pneumonia with 357 word abstract...,"Author2203_1, Author2203_2",BMJ,2021-02-27,WHO,10.1000/sample.2203,,https://example.com/paper_2203,2021.0,2.0,69,10,True,55.0,8.0,True
cord-002204,Analysis of public health and outbreak and COVID-19 and symptoms in clinical settings,This study examines public health with 347 word abstract...,"Author2204_1, Author2204_2",Cell,2019-12-09,ArXiv,10.1000/sample.2204,,https://example.com/paper_2204,2019.0,12.0,85,13,True,59.0,9.0,True
cord-002205,Analysis of coronavirus and vaccination and diagnosis and SARS-CoV-2 in clinical settings,This study examines coronavirus with 124 word abstract...,"Author2205_1, Author2205_2",Clinical Infectious Diseases,2022-10-16,Medline,10.1000/sample.2205,,https://example.com/paper_2205,2022.0,10.0,89,12,True,57.0,8.0,True
cord-002206,Analysis of diagnosis and pneumonia and pandemic in clinical settings,This study examines diagnosis with 369 word abstract...,"Author2206_1, Author2206_2",New England Journal of Medicine,2020-10-13,bioRxiv,10.1000/sample.2206,PMC1002206,https://example.com/paper_2206,2020.0,10.0,69,10,True,55.0,8.0,True
cord-002209,Analysis of antibody and lockdown and pandemic in clinical settings,This study examines antibody with 376 word abstract...,"Author2209_1, Author2209_2",Nature Medicine,2019-12-13,ArXiv,10.1000/sample.2209,,https://example.com/paper_2209,2019.0,12.0,67,10,True,54.0,8.0,True
cord-002211,Analysis of pneumonia and antibody and public health in clinical settings,This study examines pneumonia with 116 word abstract...,"Author2211_1, Author2211_2",New England Journal of Medicine,2021-12-21,ArXiv,10.1000/sample.2211,PMC1002211,,2021.0,12.0,73,11,True,55.0,8.0,True
cord-002213,Analysis of transmission and treatment and antiviral and COVID-19 in clinical settings,This study examines transmission with 226 word abstract...,"Author2213_1, Author2213_2",PLoS ONE,2021-11-20,medRxiv,10.1000/sample.2213,PMC1002213,https://example.com/paper_2213,2021.0,11.0,86,12,True,58.0,8.0,True
cord-002214,Analysis of vaccination and pandemic in clinical settings,This study examines vaccination with 168 word abstract...,"Author2214_1, Author2214_2",Virology,2020-03-21,bioRxiv,10.1000/sample.2214,PMC1002214,https://example.com/paper_2214,2020.0,3.0,57,8,True,57.0,8.0,True
cord-002215,Analysis of respiratory and outbreak in clinical settings,,"Author2215_1, Author2215_2",New England Journal of Medicine,2020-10-19,medRxiv,10.1000/sample.2215,PMC1002215,https://example.com/paper_2215,2020.0,10.0,57,8,False,,,True
cord-002216,Analysis of transmission and symptoms and outbreak in clinical settings,This study examines transmission with 406 word abstract...,"Author2216_1, Author2216_2",Nature,2021-01-11,Medline,10.1000/sample.2216,,https://example.com/paper_2216,2021.0,1.0,71,10,True,58.0,8.0,True
cord-002219,Analysis of diagnosis and vaccination and pandemic in clinical settings,This study examines diagnosis with 132 word abstract...,"Author2219_1, Author2219_2",Journal of Virology,2020-07-11,PMC,10.1000/sample.2219,,https://example.com/paper_2219,2020.0,7.0,71,10,True,55.0,8.0,True
cord-002220,Analysis of SARS-CoV-2 and vaccination and antibody and transmission in clinical settings,This study examines SARS-CoV-2 with 109 word abstract...,"Author2220_1, Author2220_2",PLoS ONE,2021-06-09,bioRxiv,10.1000/sample.2220,PMC1002220,https://example.com/paper_2220,2021.0,6.0,89,12,True,56.0,8.0,True
cord-002221,Analysis of SARS-CoV-2 and vaccination and treatment in clinical settings,,"Author2221_1, Author2221_2",PLoS ONE,2020-05-17,medRxiv,10.1000/sample.2221,PMC1002221,https://example.com/paper_2221,2020.0,5.0,73,10,False,,,True
cord-002222,Analysis of diagnosis and antiviral and outbreak in clinical settings,This study examines diagnosis with 443 word abstract...,Author2222_1,BMJ,2021-12-02,bioRxiv,10.1000/sample.2222,,https://example.com/paper_2222,2021.0,12.0,69,10,True,55.0,8.0,True
cord-002223,Analysis of transmission and immunity and treatment and vaccination in clinical settings,This study examines transmission with 492 word abstract...,"Author2223_1, Author2223_2",PLoS ONE,2020-05-13,WHO,10.1000/sample.2223,PMC1002223,https://example.com/paper_2223,2020.0,5.0,88,12,True,58.0,8.0,True
cord-002224,Analysis of transmission and clinical and vaccination in clinical settings,This study examines transmission with 169 word abstract...,"Author2224_1, Author2224_2",Science,2021-10-25,bioRxiv,10.1000/sample.2224,PMC1002224,https://example.com/paper_2224,2021.0,10.0,74,10,True,58.0,8.0,True
cord-002227,Analysis of transmission and diagnosis and coronavirus and respiratory in clinical settings,This study examines transmission with 430 word abstract...,"Author2227_1, Author2227_2",Emerging Infectious Diseases,2020-08-20,medRxiv,,PMC1002227,https://example.com/paper_2227,2020.0,8.0,91,12,True,58.0,8.0,True
cord-002228,Analysis of therapeutic and antiviral and pneumonia and symptoms in clinical settings,,"Author2228_1, Author2228_2",Journal of Medical Virology,2020-02-12,Medline,,PMC1002228,https://example.com/paper_2228,2020.0,2.0,85,12,False,,,True
cord-002229,Analysis of antiviral and clinical and coronavirus in clinical settings,This study examines antiviral with 382 word abstract...,"Author2229_1, Author2229_2",Science Translational Medicine,2020-08-18,WHO,,PMC1002229,https://example.com/paper_2229,2020.0,8.0,71,10,True,55.0,8.0,True
cord-002232,Analysis of antiviral and pneumonia and symptoms and immunity in clinical settings,This study examines antiviral with 378 word abstract...,"Author2232_1, Author2232_2",,2020-08-06,PMC,10.1000/sample.2232,PMC1002232,,2020.0,8.0,82,12,True,55.0,8.0,False
cord-002233,Analysis of epidemiology and outbreak and clinical and immunity in clinical settings,This study examines epidemiology with 266 word abstract...,"Author2233_1, Author2233_2",PLoS ONE,2020-08-23,WHO,,PMC1002233,https://example.com/paper_2233,2020.0,8.0,84,12,True,58.0,8.0,True
cord-002235,Analysis of treatment and vaccination and coronavirus and COVID-19 in clinical settings,,"Author2235_1, Author2235_2",Science,2020-03-21,bioRxiv,10.1000/sample.2235,PMC1002235,https://example.com/paper_2235,2020.0,3.0,87,12,False,,,True
cord-002237,Analysis of pandemic and transmission and symptoms and public health in clinical settings,This study examines pandemic with 104 word abstract...,"Author2237_1, Author2237_2",BMJ,2020-11-27,WHO,10.1000/sample.2237,,https://example.com/paper_2237,2020.0,11.0,89,13,True,54.0,8.0,True
cord-002239,Analysis of pneumonia and treatment and transmission and respiratory in clinical settings,This study examines pneumonia with 468 word abstract...,"Author2239_1, Author2239_2",Journal of Medical Virology,2021-10-01,ArXiv,10.1000/sample.2239,,https://example.com/paper_2239,2021.0,10.0,89,12,True,55.0,8.0,True
cord-002240,Analysis of pandemic and treatment and pneumonia and immunity in clinical settings,This study examines pandemic with 400 word abstract...,"Author2240_1, Author2240_2",Emerging Infectious Diseases,2020-05-22,ArXiv,10.1000/sample.2240,PMC1002240,https://example.com/paper_2240,2020.0,5.0,82,12,True,54.0,8.0,True
cord-002241,Analysis of respiratory and pneumonia and epidemiology and COVID-19 in clinical settings,This study examines respiratory with 487 word abstract...,"Author2241_1, Author2241_2",BMJ,2020-10-20,Medline,10.1000/sample.2241,PMC1002241,https://example.com/paper_2241,2020.0,10.0,88,12,True,57.0,8.0,True
cord-002243,Analysis of outbreak and coronavirus and public health and clinical in clinical settings,This study examines outbreak with 415 word abstract...,"Author2243_1, Author2243_2",Science Translational Medicine,,bioRxiv,,PMC1002243,,,,88,13,True,54.0,8.0,True
cord-002244,Analysis of SARS-CoV-2 and pandemic and treatment in clinical settings,This study examines SARS-CoV-2 with 372 word abstract...,"Author2244_1, Author2244_2",Journal of Medical Virology,2021-12-27,PMC,10.1000/sample.2244,PMC1002244,https://example.com/paper_2244,2021.0,12.0,70,10,True,56.0,8.0,True
cord-002245,Analysis of SARS-CoV-2 and diagnosis and clinical and respiratory in clinical settings,This study examines SARS-CoV-2 with 292 word abstract...,"Author2245_1, Author2245_2",Virology,2020-09-07,ArXiv,10.1000/sample.2245,PMC1002245,https://example.com/paper_2245,2020.0,9.0,86,12,True,56.0,8.0,True
cord-002246,Analysis of immunity and therapeutic and coronavirus and treatment in clinical settings,This study examines immunity with 225 word abstract...,"Author2246_1, Author2246_2",Science,2020-04-05,WHO,10.1000/sample.2246,PMC1002246,,2020.0,4.0,87,12,True,54.0,8.0,True
cord-002247,Analysis of outbreak and antibody and transmission in clinical settings,This study examines outbreak with 121 word abstract...,"Author2247_1, Author2247_2",New England Journal of Medicine,2020-11-14,Medline,10.1000/sample.2247,PMC1002247,https://example.com/paper_2247,2020.0,11.0,71,10,True,54.0,8.0,True
cord-002249,Analysis of pandemic and lockdown and COVID-19 in clinical settings,This study examines pandemic with 195 word abstract...,"Author2249_1, Author2249_2",Nature,2020-12-09,WHO,10.1000/sample.2249,,,2020.0,12.0,67,10,True,54.0,8.0,True
cord-002250,Analysis of SARS-CoV-2 and therapeutic and public health in clinical settings,This study examines SARS-CoV-2 with 384 word abstract...,"Author2250_1, Author2250_2",Cell,2019-12-31,Medline,10.1000/sample.2250,PMC1002250,https://example.com/paper_2250,2019.0,12.0,77,11,True,56.0,8.0,True
cord-002252,Analysis of epidemiology and antiviral and coronavirus in clinical settings,This study examines epidemiology with 420 word abstract...,"Author2252_1, Author2252_2",Clinical Infectious Diseases,2020-08-05,ArXiv,,PMC1002252,https://example.com/paper_2252,2020.0,8.0,75,10,True,58.0,8.0,True
cord-002253,Analysis of epidemiology and public health and treatment in clinical settings,This study examines epidemiology with 459 word abstract...,"Author2253_1, Author2253_2",Science Translational Medicine,2020-09-28,ArXiv,10.1000/sample.2253,PMC1002253,https://example.com/paper_2253,2020.0,9.0,77,11,True,58.0,8.0,True
cord-002254,Analysis of respiratory and antibody and pandemic and COVID-19 in clinical settings,This study examines respiratory with 225 word abstract...,,BMJ,2021-06-04,bioRxiv,10.1000/sample.2254,PMC1002254,https://example.com/paper_2254,2021.0,6.0,83,12,True,57.0,8.0,True
cord-002255,Analysis of diagnosis and treatment and pneumonia in clinical settings,This study examines diagnosis with 331 word abstract...,"Author2255_1, Author2255_2",Journal of Virology,2021-01-09,medRxiv,10.1000/sample.2255,PMC1002255,https://example.com/paper_2255,2021.0,1.0,70,10,True,55.0,8.0,True
cord-002258,Analysis of lockdown and vaccination and symptoms in clinical settings,This study examines lockdown with 370 word abstract...,Author2258_1,,2020-02-09,bioRxiv,10.1000/sample.2258,PMC1002258,,2020.0,2.0,70,10,True,54.0,8.0,False
cord-002259,Analysis of respiratory and immunity and vaccination in clinical settings,This study examines respiratory with 307 word abstract...,"Author2259_1, Author2259_2",Journal of Virology,,Medline,10.1000/sample.2259,PMC1002259,,,,73,10,True,57.0,8.0,True
cord-002261,Analysis of lockdown and transmission and SARS-CoV-2 and antibody in clinical settings,This study examines lockdown with 140 word abstract...,"Author2261_1, Author2261_2",BMJ,2021-01-10,bioRxiv,,PMC1002261,https://example.com/paper_2261,2021.0,1.0,86,12,True,54.0,8.0,True
cord-002262,Analysis of immunity and vaccination and clinical and therapeutic in clinical settings,This study examines immunity with 129 word abstract...,Author2262_1,,2019-12-07,ArXiv,10.1000/sample.2262,PMC1002262,https://example.com/paper_2262,2019.0,12.0,86,12,True,54.0,8.0,False
cord-002264,Analysis of vaccination and transmission and coronavirus in clinical settings,This study examines vaccination with 483 word abstract...,,PLoS ONE,,PMC,10.1000/sample.2264,PMC1002264,https://example.com/paper_2264,,,77,10,True,57.0,8.0,True
cord-002265,Analysis of symptoms and public health and therapeutic and coronavirus in clinical settings,This study examines symptoms with 410 word abstract...,"Author2265_1, Author2265_2",Journal of Medical Virology,2019-12-05,PMC,10.1000/sample.2265,PMC1002265,https://example.com/paper_2265,2019.0,12.0,91,13,True,54.0,8.0,True
cord-002266,Analysis of vaccination and coronavirus and public health and diagnosis in clinical settings,This study examines vaccination with 490 word abstract...,"Author2266_1, Author2266_2",,2021-09-25,bioRxiv,,PMC1002266,https://example.com/paper_2266,2021.0,9.0,92,13,True,57.0,8.0,False
cord-002267,Analysis of diagnosis and antibody and vaccination and respiratory in clinical settings,This study examines diagnosis with 152 word abstract...,"Author2267_1, Author2267_2",Lancet,2020-04-12,ArXiv,10.1000/sample.2267,PMC1002267,https://example.com/paper_2267,2020.0,4.0,87,12,True,55.0,8.0,True
cord-002268,Analysis of clinical and therapeutic and coronavirus and treatment in clinical settings,This study examines clinical with 194 word abstract...,"Author2268_1, Author2268_2",Nature Medicine,2020-11-13,bioRxiv,10.1000/sample.2268,PMC1002268,https://example.com/paper_2268,2020.0,11.0,87,12,True,54.0,8.0,True
cord-002269,Analysis of treatment and pneumonia and epidemiology and outbreak in clinical settings,This study examines treatment with 351 word abstract...,Author2269_1,Lancet,2020-07-31,PMC,10.1000/sample.2269,PMC1002269,https://example.com/paper_2269,2020.0,7.0,86,12,True,55.0,8.0,True
cord-002270,Analysis of public health and immunity and outbreak in clinical settings,This study examines public health with 362 word abstract...,"Author2270_1, Author2270_2",PLoS ONE,2020-07-26,bioRxiv,10.1000/sample.2270,,https://example.com/paper_2270,2020.0,7.0,72,11,True,59.0,9.0,True
cord-002272,Analysis of lockdown and vaccination and immunity and transmission in clinical settings,This study examines lockdown with 306 word abstract...,"Author2272_1, Author2272_2",Science Translational Medicine,2021-01-06,bioRxiv,10.1000/sample.2272,PMC1002272,https://example.com/paper_2272,2021.0,1.0,87,12,True,54.0,8.0,True
cord-002274,Analysis of outbreak and antiviral and public health in clinical settings,This study examines outbreak with 451 word abstract...,Author2274_1,Nature Medicine,2020-08-15,Medline,10.1000/sample.2274,PMC1002274,https://example.com/paper_2274,2020.0,8.0,73,11,True,54.0,8.0,True
cord-002275,Analysis of outbreak and antiviral and diagnosis in clinical settings,This study examines outbreak with 260 word abstract...,"Author2275_1, Author2275_2",Lancet,2019-12-30,bioRxiv,10.1000/sample.2275,PMC1002275,https://example.com/paper_2275,2019.0,12.0,69,10,True,54.0,8.0,True
cord-002276,Analysis of immunity and lockdown and epidemiology in clinical settings,This study examines immunity with 463 word abstract...,"Author2276_1, Author2276_2",Science,2021-03-14,bioRxiv,10.1000/sample.2276,PMC1002276,https://example.com/paper_2276,2021.0,3.0,71,10,True,54.0,8.0,True
cord-002277,Analysis of coronavirus and treatment in clinical settings,This study examines coronavirus with 283 word abstract...,"Author2277_1, Author2277_2",Virology,2020-10-31,medRxiv,10.1000/sample.2277,PMC1002277,https://example.com/paper_2277,2020.0,10.0,58,8,True,57.0,8.0,True
cord-002279,Analysis of transmission and lockdown and SARS-CoV-2 in clinical settings,This study examines transmission with 122 word abstract...,Author2279_1,,2021-07-07,bioRxiv,10.1000/sample.2279,PMC1002279,https://example.com/paper_2279,2021.0,7.0,73,10,True,58.0,8.0,False
cord-002280,Analysis of respiratory and therapeutic and symptoms and pneumonia in clinical settings,This study examines respiratory with 320 word abstract...,"Author2280_1, Author2280_2",Nature,2020-11-21,medRxiv,10.1000/sample.2280,,https://example.com/paper_2280,2020.0,11.0,87,12,True,57.0,8.0,True
cord-002281,Analysis of pneumonia and treatment and SARS-CoV-2 and public health in clinical settings,This study examines pneumonia with 250 word abstract...,"Author2281_1, Author2281_2",New England Journal of Medicine,2020-04-23,WHO,10.1000/sample.2281,PMC1002281,https://example.com/paper_2281,2020.0,4.0,89,13,True,55.0,8.0,True
cord-002282,Analysis of diagnosis and antibody in clinical settings,This study examines diagnosis with 353 word abstract...,Author2282_1,PLoS ONE,2020-04-14,bioRxiv,10.1000/sample.2282,PMC1002282,,2020.0,4.0,55,8,True,55.0,8.0,True
cord-002287,Analysis of diagnosis and pandemic and treatment and vaccination in clinical settings,This study examines diagnosis with 283 word abstract...,"Author2287_1, Author2287_2",Nature,2019-12-25,WHO,10.1000/sample.2287,,https://example.com/paper_2287,2019.0,12.0,85,12,True,55.0,8.0,True
cord-002289,Analysis of clinical and immunity and public health and transmission in clinical settings,This study examines clinical with 226 word abstract...,,Journal of Virology,2020-12-12,PMC,10.1000/sample.2289,PMC1002289,https://example.com/paper_2289,2020.0,12.0,89,13,True,54.0,8.0,True
cord-002291,Analysis of vaccination and epidemiology and therapeutic and pneumonia in clinical settings,This study examines vaccination with 302 word abstract...,"Author2291_1, Author2291_2",Emerging Infectious Diseases,2021-07-20,bioRxiv,10.1000/sample.2291,,,2021.0,7.0,91,12,True,57.0,8.0,True
cord-002292,Analysis of respiratory and epidemiology and immunity and clinical in clinical settings,This study examines respiratory with 446 word abstract...,"Author2292_1, Author2292_2",New England Journal of Medicine,,PMC,10.1000/sample.2292,PMC1002292,https://example.com/paper_2292,,,87,12,True,57.0,8.0,True
cord-002295,Analysis of symptoms and pneumonia and therapeutic in clinical settings,This study examines symptoms with 250 word abstract...,Author2295_1,Science Translational Medicine,2022-11-22,bioRxiv,10.1000/sample.2295,PMC1002295,https://example.com/paper_2295,2022.0,11.0,71,10,True,54.0,8.0,True
cord-002297,Analysis of coronavirus and pandemic and public health and vaccination in clinical settings,This study examines coronavirus with 175 word abstract...,"Author2297_1, Author2297_2",Emerging Infectious Diseases,2020-07-04,medRxiv,10.1000/sample.2297,PMC1002297,,2020.0,7.0,91,13,True,57.0,8.0,True
cord-002300,Analysis of SARS-CoV-2 and outbreak in clinical settings,This study examines SARS-CoV-2 with 269 word abstract...,"Author2300_1, Author2300_2",BMJ,2020-10-01,WHO,10.1000/sample.2300,PMC1002300,https://example.com/paper_2300,2020.0,10.0,56,8,True,56.0,8.0,True
cord-002301,Analysis of therapeutic and vaccination and pandemic and public health in clinical settings,This study examines therapeutic with 416 word abstract...,"Author2301_1, Author2301_2",,2021-05-02,ArXiv,10.1000/sample.2301,,https://example.com/paper_2301,2021.0,5.0,91,13,True,57.0,8.0,False
cord-002302,Analysis of SARS-CoV-2 and pneumonia and public health and transmission in clinical settings,This study examines SARS-CoV-2 with 211 word abstract...,"Author2302_1, Author2302_2",,2022-07-26,medRxiv,,PMC1002302,https://example.com/paper_2302,2022.0,7.0,92,13,True,56.0,8.0,False
cord-002303,Analysis of epidemiology and antiviral and vaccination in clinical settings,This study examines epidemiology with 226 word abstract...,"Author2303_1, Author2303_2",Science,2020-04-12,ArXiv,10.1000/sample.2303,PMC1002303,https://example.com/paper_2303,2020.0,4.0,75,10,True,58.0,8.0,True
cord-002305,Analysis of public health and pneumonia and epidemiology in clinical settings,This study examines public health with 184 word abstract...,"Author2305_1, Author2305_2",Emerging Infectious Diseases,2021-02-19,Medline,10.1000/sample.2305,,https://example.com/paper_2305,2021.0,2.0,77,11,True,59.0,9.0,True
cord-002306,Analysis of COVID-19 and pneumonia and clinical in clinical settings,This study examines COVID-19 with 327 word abstract...,"Author2306_1, Author2306_2",Journal of Virology,2020-08-05,Medline,10.1000/sample.2306,PMC1002306,https://example.com/paper_2306,2020.0,8.0,68,10,True,54.0,8.0,True
cord-002307,Analysis of antiviral and public health and symptoms and COVID-19 in clinical settings,This study examines antiviral with 274 word abstract...,"Author2307_1, Author2307_2",Clinical Infectious Diseases,2021-11-11,WHO,10.1000/sample.2307,PMC1002307,,2021.0,11.0,86,13,True,55.0,8.0,True
cord-002308,Analysis of antibody and treatment in clinical settings,This study examines antibody with 293 word abstract...,"Author2308_1, Author2308_2",Science Translational Medicine,2021-03-07,ArXiv,,PMC1002308,https://example.com/paper_2308,2021.0,3.0,55,8,True,54.0,8.0,True
cord-002310,Analysis of immunity and clinical in clinical settings,This study examines immunity with 104 word abstract...,"Author2310_1, Author2310_2",Science Translational Medicine,2019-12-22,medRxiv,10.1000/sample.2310,PMC1002310,https://example.com/paper_2310,2019.0,12.0,54,8,True,54.0,8.0,True
cord-002311,Analysis of respiratory and immunity and public health in clinical settings,This study examines respiratory with 135 word abstract...,"Author2311_1, Author2311_2",Virology,2020-05-01,bioRxiv,10.1000/sample.2311,PMC1002311,https://example.com/paper_2311,2020.0,5.0,75,11,True,57.0,8.0,True
cord-002312,Analysis of pandemic and COVID-19 and antibody in clinical settings,This study examines pandemic with 267 word abstract...,"Author2312_1, Author2312_2",Clinical Infectious Diseases,2022-07-06,Medline,10.1000/sample.2312,,,2022.0,7.0,67,10,True,54.0,8.0,True
cord-002313,Analysis of lockdown and outbreak and therapeutic in clinical settings,This study examines lockdown with 138 word abstract...,"Author2313_1, Author2313_2",Lancet,2021-12-18,ArXiv,10.1000/sample.2313,PMC1002313,https://example.com/paper_2313,2021.0,12.0,70,10,True,54.0,8.0,True
cord-002314,Analysis of transmission and vaccination in clinical settings,This study examines transmission with 291 word abstract...,Author2314_1,Cell,2021-05-28,medRxiv,10.1000/sample.2314,,https://example.com/paper_2314,2021.0,5.0,61,8,True,58.0,8.0,True
cord-002318,Analysis of epidemiology and COVID-19 and pneumonia in clinical settings,This study examines epidemiology with 205 word abstract...,"Author2318_1, Author2318_2",JAMA,2019-12-10,bioRxiv,,,https://example.com/paper_2318,2019.0,12.0,72,10,True,58.0,8.0,True
cord-002319,Analysis of public health and transmission and therapeutic and vaccination in clinical settings,This study examines public health with 456 word abstract...,"Author2319_1, Author2319_2",New England Journal of Medicine,2021-06-09,medRxiv,10.1000/sample.2319,PMC1002319,https://example.com/paper_2319,2021.0,6.0,95,13,True,59.0,9.0,True
cord-002320,Analysis of public health and outbreak and lockdown in clinical settings,This study examines public health with 147 word abstract...,"Author2320_1, Author2320_2",Emerging Infectious Diseases,2021-03-07,bioRxiv,10.1000/sample.2320,PMC1002320,https://example.com/paper_2320,2021.0,3.0,72,11,True,59.0,9.0,True
cord-002321,Analysis of pneumonia and lockdown and epidemiology and pandemic in clinical settings,This study examines pneumonia with 399 word abstract...,"Author2321_1, Author2321_2",Journal of Medical Virology,2020-12-12,bioRxiv,10.1000/sample.2321,,https://example.com/paper_2321,2020.0,12.0,85,12,True,55.0,8.0,True
cord-002322,Analysis of pneumonia and diagnosis and symptoms in clinical settings,This study examines pneumonia with 486 word abstract...,"Author2322_1, Author2322_2",Science,2020-12-03,bioRxiv,,,https://example.com/paper_2322,2020.0,12.0,69,10,True,55.0,8.0,True
cord-002323,Analysis of pneumonia and epidemiology and symptoms in clinical settings,This study examines pneumonia with 251 word abstract...,"Author2323_1, Author2323_2",Science,2021-08-23,Medline,10.1000/sample.2323,PMC1002323,https://example.com/paper_2323,2021.0,8.0,72,10,True,55.0,8.0,True
cord-002325,Analysis of immunity and therapeutic and symptoms and antibody in clinical settings,This study examines immunity with 134 word abstract...,"Author2325_1, Author2325_2",Lancet,2020-10-15,PMC,10.1000/sample.2325,PMC1002325,https://example.com/paper_2325,2020.0,10.0,83,12,True,54.0,8.0,True
cord-002326,Analysis of symptoms and clinical and pneumonia and lockdown in clinical settings,This study examines symptoms with 359 word abstract...,"Author2326_1, Author2326_2",Nature,2020-05-01,PMC,10.1000/sample.2326,PMC1002326,https://example.com/paper_2326,2020.0,5.0,81,12,True,54.0,8.0,True
cord-002328,Analysis of lockdown and clinical in clinical settings,This study examines lockdown with 218 word abstract...,"Author2328_1, Author2328_2",Journal of Medical Virology,,WHO,10.1000/sample.2328,PMC1002328,https://example.com/paper_2328,,,54,8,True,54.0,8.0,True
cord-002329,Analysis of clinical and treatment and transmission and SARS-CoV-2 in clinical settings,This study examines clinical with 133 word abstract...,"Author2329_1, Author2329_2",Nature Medicine,2021-03-15,ArXiv,10.1000/sample.2329,PMC1002329,https://example.com/paper_2329,2021.0,3.0,87,12,True,54.0,8.0,True
cord-002331,Analysis of lockdown and antibody and diagnosis in clinical settings,This study examines lockdown with 359 word abstract...,"Author2331_1, Author2331_2",Clinical Infectious Diseases,2020-04-25,PMC,10.1000/sample.2331,PMC1002331,https://example.com/paper_2331,2020.0,4.0,68,10,True,54.0,8.0,True
cord-002334,Analysis of pandemic and lockdown and epidemiology and immunity in clinical settings,This study examines pandemic with 354 word abstract...,"Author2334_1, Author2334_2",Science,2021-08-02,medRxiv,10.1000/sample.2334,PMC1002334,https://example.com/paper_2334,2021.0,8.0,84,12,True,54.0,8.0,True
cord-002335,Analysis of immunity and diagnosis and pandemic and outbreak in clinical settings,This study examines immunity with 353 word abstract...,"Author2335_1, Author2335_2",PLoS ONE,2022-10-07,ArXiv,10.1000/sample.2335,,,2022.0,10.0,81,12,True,54.0,8.0,True
cord-002336,Analysis of SARS-CoV-2 and coronavirus and antibody and antiviral in clinical settings,This study examines SARS-CoV-2 with 375 word abstract...,"Author2336_1, Author2336_2",Journal of Medical Virology,2020-05-08,PMC,10.1000/sample.2336,PMC1002336,https://example.com/paper_2336,2020.0,5.0,86,12,True,56.0,8.0,True
cord-002337,Analysis of COVID-19 and coronavirus and clinical in clinical settings,This study examines COVID-19 with 415 word abstract...,"Author2337_1, Author2337_2",Journal of Virology,2020-11-13,WHO,10.1000/sample.2337,PMC1002337,https://example.com/paper_2337,2020.0,11.0,70,10,True,54.0,8.0,True
cord-002338,Analysis of coronavirus and epidemiology and symptoms in clinical settings,This study examines coronavirus with 224 word abstract...,"Author2338_1, Author2338_2",BMJ,2021-01-31,PMC,10.1000/sample.2338,PMC1002338,https://example.com/paper_2338,2021.0,1.0,74,10,True,57.0,8.0,True
cord-002339,Analysis of diagnosis and outbreak and symptoms in clinical settings,This study examines diagnosis with 417 word abstract...,"Author2339_1, Author2339_2",New England Journal of Medicine,2020-03-09,WHO,10.1000/sample.2339,PMC1002339,https://example.com/paper_2339,2020.0,3.0,68,10,True,55.0,8.0,True
cord-002341,Analysis of therapeutic and COVID-19 and pneumonia and epidemiology in clinical settings,This study examines therapeutic with 447 word abstract...,,JAMA,2021-08-19,bioRxiv,10.1000/sample.2341,,https://example.com/paper_2341,2021.0,8.0,88,12,True,57.0,8.0,True
cord-002342,Analysis of epidemiology and COVID-19 in clinical settings,This study examines epidemiology with 353 word abstract...,"Author2342_1, Author2342_2",Nature Medicine,2020-10-12,PMC,10.1000/sample.2342,,https://example.com/paper_2342,2020.0,10.0,58,8,True,58.0,8.0,True
cord-002345,Analysis of lockdown and vaccination and antiviral in clinical settings,This study examines lockdown with 451 word abstract...,"Author2345_1, Author2345_2",Virology,2021-03-26,medRxiv,10.1000/sample.2345,PMC1002345,https://example.com/paper_2345,2021.0,3.0,71,10,True,54.0,8.0,True
cord-002346,Analysis of antibody and vaccination and pneumonia in clinical settings,This study examines antibody with 338 word abstract...,"Author2346_1, Author2346_2",BMJ,2021-04-01,WHO,10.1000/sample.2346,,https://example.com/paper_2346,2021.0,4.0,71,10,True,54.0,8.0,True
cord-002348,Analysis of therapeutic and antiviral and lockdown in clinical settings,This study examines therapeutic with 461 word abstract...,,Science Translational Medicine,2020-06-12,ArXiv,10.1000/sample.2348,PMC1002348,https://example.com/paper_2348,2020.0,6.0,71,10,True,57.0,8.0,True
cord-002350,Analysis of pandemic and pneumonia in clinical settings,This study examines pandemic with 267 word abstract...,"Author2350_1, Author2350_2",Nature Medicine,2022-09-17,medRxiv,10.1000/sample.2350,PMC1002350,https://example.com/paper_2350,2022.0,9.0,55,8,True,54.0,8.0,True
cord-002353,Analysis of coronavirus and respiratory in clinical settings,This study examines coronavirus with 161 word abstract...,Author2353_1,BMJ,2020-01-26,medRxiv,10.1000/sample.2353,PMC1002353,https://example.com/paper_2353,2020.0,1.0,60,8,True,57.0,8.0,True
cord-002354,Analysis of clinical and antibody and coronavirus in clinical settings,This study examines clinical with 146 word abstract...,"Author2354_1, Author2354_2",Clinical Infectious Diseases,2020-11-02,Medline,10.1000/sample.2354,PMC1002354,https://example.com/paper_2354,2020.0,11.0,70,10,True,54.0,8.0,True
cord-002355,Analysis of therapeutic and lockdown and clinical in clinical settings,This study examines therapeutic with 404 word abstract...,"Author2355_1, Author2355_2",PLoS ONE,2022-02-27,bioRxiv,10.1000/sample.2355,PMC1002355,,2022.0,2.0,70,10,True,57.0,8.0,True
cord-002357,Analysis of pandemic and epidemiology and vaccination in clinical settings,This study examines pandemic with 287 word abstract...,"Author2357_1, Author2357_2",,2020-02-16,medRxiv,10.1000/sample.2357,,,2020.0,2.0,74,10,True,54.0,8.0,False
cord-002359,Analysis of therapeutic and symptoms and COVID-19 in clinical settings,This study examines therapeutic with 159 word abstract...,"Author2359_1, Author2359_2",New England Journal of Medicine,2020-05-11,WHO,10.1000/sample.2359,PMC1002359,https://example.com/paper_2359,2020.0,5.0,70,10,True,57.0,8.0,True
cord-002360,Analysis of clinical and respiratory and lockdown and diagnosis in clinical settings,This study examines clinical with 151 word abstract...,"Author2360_1, Author2360_2",Cell,2020-12-15,medRxiv,,PMC1002360,https://example.com/paper_2360,2020.0,12.0,84,12,True,54.0,8.0,True
cord-002362,Analysis of pandemic and antiviral and coronavirus and COVID-19 in clinical settings,This study examines pandemic with 324 word abstract...,"Author2362_1, Author2362_2",PLoS ONE,2020-04-25,medRxiv,10.1000/sample.2362,,https://example.com/paper_2362,2020.0,4.0,84,12,True,54.0,8.0,True
cord-002364,Analysis of vaccination and outbreak and antibody in clinical settings,This study examines vaccination with 457 word abstract...,"Author2364_1, Author2364_2",,2021-09-29,bioRxiv,10.1000/sample.2364,,https://example.com/paper_2364,2021.0,9.0,70,10,True,57.0,8.0,False
cord-002365,Analysis of antiviral and pandemic and outbreak in clinical settings,This study examines antiviral with 492 word abstract...,"Author2365_1, Author2365_2",Emerging Infectious Diseases,2020-05-29,PMC,10.1000/sample.2365,,https://example.com/paper_2365,2020.0,5.0,68,10,True,55.0,8.0,True
cord-002370,Analysis of pandemic and coronavirus and therapeutic and public health in clinical settings,This study examines pandemic with 495 word abstract...,"Author2370_1, Author2370_2",Virology,2020-10-24,Medline,10.1000/sample.2370,PMC1002370,https://example.com/paper_2370,2020.0,10.0,91,13,True,54.0,8.0,True
cord-002371,Analysis of diagnosis and outbreak and vaccination and antibody in clinical settings,This study examines diagnosis with 475 word abstract...,"Author2371_1, Author2371_2",Emerging Infectious Diseases,2020-12-14,ArXiv,10.1000/sample.2371,PMC1002371,https://example.com/paper_2371,2020.0,12.0,84,12,True,55.0,8.0,True
cord-002372,Analysis of therapeutic and immunity and vaccination in clinical settings,This study examines therapeutic with 146 word abstract...,"Author2372_1, Author2372_2",Emerging Infectious Diseases,2022-09-19,medRxiv,,,https://example.com/paper_2372,2022.0,9.0,73,10,True,57.0,8.0,True
cord-002373,Analysis of respiratory and coronavirus and pneumonia and transmission in clinical settings,This study examines respiratory with 412 word abstract...,"Author2373_1, Author2373_2",Nature,2020-11-19,bioRxiv,,PMC1002373,https://example.com/paper_2373,2020.0,11.0,91,12,True,57.0,8.0,True
cord-002375,Analysis of diagnosis and vaccination and clinical in clinical settings,This study examines diagnosis with 265 word abstract...,"Author2375_1, Author2375_2",BMJ,2021-01-08,WHO,10.1000/sample.2375,,https://example.com/paper_2375,2021.0,1.0,71,10,True,55.0,8.0,True
cord-002378,Analysis of epidemiology and transmission and diagnosis and public health in clinical settings,This study examines epidemiology with 289 word abstract...,"Author2378_1, Author2378_2",Journal of Medical Virology,2022-01-04,ArXiv,10.1000/sample.2378,PMC1002378,https://example.com/paper_2378,2022.0,1.0,94,13,True,58.0,8.0,True
cord-002380,Analysis of treatment and coronavirus and lockdown in clinical settings,,Author2380_1,Science Translational Medicine,2021-09-02,Medline,10.1000/sample.2380,PMC1002380,https://example.com/paper_2380,2021.0,9.0,71,10,False,,,True
cord-002381,Analysis of public health and clinical and antibody and diagnosis in clinical settings,This study examines public health with 156 word abstract...,"Author2381_1, Author2381_2",Journal of Virology,2020-05-20,ArXiv,10.1000/sample.2381,,,2020.0,5.0,86,13,True,59.0,9.0,True
cord-002383,Analysis of epidemiology and respiratory and pandemic in clinical settings,This study examines epidemiology with 411 word abstract...,Author2383_1,Journal of Medical Virology,2022-08-27,medRxiv,10.1000/sample.2383,PMC1002383,https://example.com/paper_2383,2022.0,8.0,74,10,True,58.0,8.0,True
cord-002384,Analysis of immunity and coronavirus and pneumonia in clinical settings,This study examines immunity with 470 word abstract...,Author2384_1,Clinical Infectious Diseases,2020-02-04,WHO,10.1000/sample.2384,,https://example.com/paper_2384,2020.0,2.0,71,10,True,54.0,8.0,True
cord-002386,Analysis of immunity and epidemiology and antibody and SARS-CoV-2 in clinical settings,This study examines immunity with 487 word abstract...,Author2386_1,Lancet,2020-12-20,medRxiv,10.1000/sample.2386,,,2020.0,12.0,86,12,True,54.0,8.0,True
cord-002387,Analysis of vaccination and pandemic and public health and lockdown in clinical settings,This study examines vaccination with 162 word abstract...,"Author2387_1, Author2387_2",Journal of Medical Virology,2020-09-26,bioRxiv,10.1000/sample.2387,PMC1002387,,2020.0,9.0,88,13,True,57.0,8.0,True
cord-002389,Analysis of public health and outbreak and antibody and COVID-19 in clinical settings,This study examines public health with 281 word abstract...,"Author2389_1, Author2389_2",Virology,2019-12-16,ArXiv,10.1000/sample.2389,PMC1002389,https://example.com/paper_2389,2019.0,12.0,85,13,True,59.0,9.0,True
cord-002390,Analysis of coronavirus and lockdown and respiratory in clinical settings,This study examines coronavirus with 316 word abstract...,"Author2390_1, Author2390_2",Virology,2021-06-10,PMC,10.1000/sample.2390,,https://example.com/paper_2390,2021.0,6.0,73,10,True,57.0,8.0,True
cord-002393,Analysis of respiratory and outbreak and clinical and transmission in clinical settings,This study examines respiratory with 195 word abstract...,"Author2393_1, Author2393_2",PLoS ONE,,bioRxiv,10.1000/sample.2393,,,,,87,12,True,57.0,8.0,True
cord-002395,Analysis of vaccination and pandemic and lockdown and respiratory in clinical settings,This study examines vaccination with 449 word abstract...,"Author2395_1, Author2395_2",Clinical Infectious Diseases,2021-06-28,medRxiv,10.1000/sample.2395,,,2021.0,6.0,86,12,True,57.0,8.0,True
cord-002397,Analysis of outbreak and respiratory and antiviral and therapeutic in clinical settings,This study examines outbreak with 285 word abstract...,"Author2397_1, Author2397_2",Journal of Virology,2020-09-30,bioRxiv,10.1000/sample.2397,PMC1002397,,2020.0,9.0,87,12,True,54.0,8.0,True
cord-002399,Analysis of symptoms and COVID-19 and pandemic in clinical settings,This study examines symptoms with 244 word abstract...,Author2399_1,Emerging Infectious Diseases,2021-07-21,Medline,10.1000/sample.2399,PMC1002399,https://example.com/paper_2399,2021.0,7.0,67,10,True,54.0,8.0,True
cord-002401,Analysis of outbreak and transmission and coronavirus in clinical settings,This study examines outbreak with 222 word abstract...,"Author2401_1, Author2401_2",Science,2022-01-18,PMC,10.1000/sample.2401,PMC1002401,https://example.com/paper_2401,2022.0,1.0,74,10,True,54.0,8.0,True
cord-002402,Analysis of public health and clinical in clinical settings,This study examines public health with 226 word abstract...,"Author2402_1, Author2402_2",Clinical Infectious Diseases,2020-03-20,bioRxiv,10.1000/sample.2402,PMC1002402,https://example.com/paper_2402,2020.0,3.0,59,9,True,59.0,9.0,True
cord-002403,Analysis of therapeutic and SARS-CoV-2 and public health and vaccination in clinical settings,This study examines therapeutic with 368 word abstract...,"Author2403_1, Author2403_2",New England Journal of Medicine,2021-05-28,ArXiv,10.1000/sample.2403,PMC1002403,https://example.com/paper_2403,2021.0,5.0,93,13,True,57.0,8.0,True
cord-002404,Analysis of COVID-19 and immunity and SARS-CoV-2 and outbreak in clinical settings,This study examines COVID-19 with 116 word abstract...,"Author2404_1, Author2404_2",Nature,,PMC,10.1000/sample.2404,,https://example.com/paper_2404,,,82,12,True,54.0,8.0,True
cord-002405,Analysis of epidemiology and antiviral and pandemic and vaccination in clinical settings,This study examines epidemiology with 240 word abstract...,"Author2405_1, Author2405_2",Clinical Infectious Diseases,2022-03-05,Medline,10.1000/sample.2405,PMC1002405,https://example.com/paper_2405,2022.0,3.0,88,12,True,58.0,8.0,True
cord-002406,Analysis of symptoms and clinical and epidemiology in clinical settings,This study examines symptoms with 408 word abstract...,"Author2406_1, Author2406_2",Lancet,2022-03-20,PMC,,,https://example.com/paper_2406,2022.0,3.0,71,10,True,54.0,8.0,True
cord-002407,Analysis of pneumonia and outbreak and epidemiology in clinical settings,This study examines pneumonia with 377 word abstract...,"Author2407_1, Author2407_2",Science,2020-01-09,Medline,10.1000/sample.2407,PMC1002407,https://example.com/paper_2407,2020.0,1.0,72,10,True,55.0,8.0,True
cord-002408,Analysis of public health and vaccination and symptoms and pandemic in clinical settings,This study examines public health with 228 word abstract...,"Author2408_1, Author2408_2",JAMA,2021-06-18,ArXiv,10.1000/sample.2408,,,2021.0,6.0,88,13,True,59.0,9.0,True
cord-002409,Analysis of coronavirus and pneumonia and transmission and clinical in clinical settings,This study examines coronavirus with 428 word abstract...,"Author2409_1, Author2409_2",Nature,2021-04-25,medRxiv,10.1000/sample.2409,PMC1002409,https://example.com/paper_2409,2021.0,4.0,88,12,True,57.0,8.0,True
cord-002410,Analysis of diagnosis and treatment and antiviral in clinical settings,This study examines diagnosis with 152 word abstract...,"Author2410_1, Author2410_2",Science Translational Medicine,2019-12-17,ArXiv,10.1000/sample.2410,PMC1002410,https://example.com/paper_2410,2019.0,12.0,70,10,True,55.0,8.0,True
cord-002411,Analysis of epidemiology and pandemic and symptoms in clinical settings,This study examines epidemiology with 409 word abstract...,"Author2411_1, Author2411_2",Lancet,2020-11-23,ArXiv,10.1000/sample.2411,,https://example.com/paper_2411,2020.0,11.0,71,10,True,58.0,8.0,True
cord-002412,Analysis of immunity and outbreak and epidemiology and antiviral in clinical settings,,"Author2412_1, Author2412_2",BMJ,2020-01-30,medRxiv,10.1000/sample.2412,PMC1002412,https://example.com/paper_2412,2020.0,1.0,85,12,False,,,True
cord-002413,Analysis of treatment and immunity and pneumonia in clinical settings,,"Author2413_1, Author2413_2",Journal of Medical Virology,,WHO,10.1000/sample.2413,PMC1002413,,,,69,10,False,,,True
cord-002415,Analysis of lockdown and antibody and COVID-19 in clinical settings,This study examines lockdown with 394 word abstract...,"Author2415_1, Author2415_2",Lancet,2020-07-17,bioRxiv,10.1000/sample.2415,PMC1002415,https://example.com/paper_2415,2020.0,7.0,67,10,True,54.0,8.0,True
cord-002416,Analysis of diagnosis and pneumonia and treatment in clinical settings,This study examines diagnosis with 487 word abstract...,"Author2416_1, Author2416_2",Journal of Medical Virology,2020-07-08,WHO,10.1000/sample.2416,,,2020.0,7.0,70,10,True,55.0,8.0,True
cord-002419,Analysis of symptoms and vaccination and pneumonia and transmission in clinical settings,This study examines symptoms with 213 word abstract...,"Author2419_1, Author2419_2",Cell,2020-09-17,Medline,,PMC1002419,https://example.com/paper_2419,2020.0,9.0,88,12,True,54.0,8.0,True
cord-002420,Analysis of respiratory and pneumonia and symptoms in clinical settings,This study examines respiratory with 349 word abstract...,"Author2420_1, Author2420_2",BMJ,,bioRxiv,10.1000/sample.2420,,https://example.com/paper_2420,,,71,10,True,57.0,8.0,True
cord-002421,Analysis of public health and vaccination and immunity in clinical settings,This study examines public health with 328 word abstract...,"Author2421_1, Author2421_2",Journal of Virology,2020-10-06,bioRxiv,10.1000/sample.2421,PMC1002421,https://example.com/paper_2421,2020.0,10.0,75,11,True,59.0,9.0,True
cord-002422,Analysis of vaccination and pneumonia and immunity in clinical settings,This study examines vaccination with 399 word abstract...,"Author2422_1, Author2422_2",BMJ,2019-12-08,Medline,10.1000/sample.2422,PMC1002422,https://example.com/paper_2422,2019.0,12.0,71,10,True,57.0,8.0,True
cord-002423,Analysis of clinical and SARS-CoV-2 and symptoms in clinical settings,This study examines clinical with 192 word abstract...,"Author2423_1, Author2423_2",Nature,2021-09-05,bioRxiv,10.1000/sample.2423,PMC1002423,,2021.0,9.0,69,10,True,54.0,8.0,True
cord-002424,Analysis of lockdown and transmission and epidemiology and therapeutic in clinical settings,This study examines lockdown with 262 word abstract...,"Author2424_1, Author2424_2",Science Translational Medicine,2021-12-11,WHO,10.1000/sample.2424,,https://example.com/paper_2424,2021.0,12.0,91,12,True,54.0,8.0,True
cord-002425,Analysis of clinical and antiviral and therapeutic in clinical settings,This study examines clinical with 338 word abstract...,Author2425_1,BMJ,2020-08-03,bioRxiv,10.1000/sample.2425,PMC1002425,https://example.com/paper_2425,2020.0,8.0,71,10,True,54.0,8.0,True
cord-002426,Analysis of COVID-19 and lockdown and epidemiology in clinical settings,This study examines COVID-19 with 361 word abstract...,"Author2426_1, Author2426_2",Lancet,2022-03-09,bioRxiv,10.1000/sample.2426,PMC1002426,https://example.com/paper_2426,2022.0,3.0,71,10,True,54.0,8.0,True
cord-002428,Analysis of pneumonia and transmission and antiviral and diagnosis in clinical settings,This study examines pneumonia with 207 word abstract...,"Author2428_1, Author2428_2",Journal of Virology,2020-09-06,WHO,10.1000/sample.2428,PMC1002428,https://example.com/paper_2428,2020.0,9.0,87,12,True,55.0,8.0,True
cord-002429,Analysis of lockdown and antiviral and symptoms in clinical settings,This study examines lockdown with 387 word abstract...,Author2429_1,Journal of Medical Virology,2021-05-07,Medline,10.1000/sample.2429,PMC1002429,https://example.com/paper_2429,2021.0,5.0,68,10,True,54.0,8.0,True
cord-002430,Analysis of transmission and public health and immunity in clinical settings,This study examines transmission with 459 word abstract...,"Author2430_1, Author2430_2",Nature Medicine,2020-02-09,bioRxiv,10.1000/sample.2430,PMC1002430,https://example.com/paper_2430,2020.0,2.0,76,11,True,58.0,8.0,True
cord-002434,Analysis of diagnosis and transmission and public health and COVID-19 in clinical settings,This study examines diagnosis with 479 word abstract...,"Author2434_1, Author2434_2",Science,2021-07-11,PMC,,PMC1002434,https://example.com/paper_2434,2021.0,7.0,90,13,True,55.0,8.0,True
cord-002435,Analysis of diagnosis and immunity and pandemic in clinical settings,This study examines diagnosis with 349 word abstract...,"Author2435_1, Author2435_2",Cell,2020-05-02,WHO,10.1000/sample.2435,PMC1002435,https://example.com/paper_2435,2020.0,5.0,68,10,True,55.0,8.0,True
cord-002437,Analysis of symptoms and treatment and respiratory and public health in clinical settings,This study examines symptoms with 267 word abstract...,Author2437_1,Nature,2022-01-22,bioRxiv,,PMC1002437,https://example.com/paper_2437,2022.0,1.0,89,13,True,54.0,8.0,True
cord-002440,Analysis of antiviral and pandemic and coronavirus in clinical settings,This study examines antiviral with 489 word abstract...,"Author2440_1, Author2440_2",Journal of Medical Virology,2020-06-17,Medline,10.1000/sample.2440,PMC1002440,https://example.com/paper_2440,2020.0,6.0,71,10,True,55.0,8.0,True
cord-002441,Analysis of clinical and pneumonia and diagnosis and SARS-CoV-2 in clinical settings,This study examines clinical with 304 word abstract...,Author2441_1,Science Translational Medicine,2020-07-19,ArXiv,10.1000/sample.2441,PMC1002441,https://example.com/paper_2441,2020.0,7.0,84,12,True,54.0,8.0,True
cord-002442,Analysis of outbreak and symptoms and lockdown in clinical settings,This study examines outbreak with 355 word abstract...,"Author2442_1, Author2442_2",Virology,2022-10-02,Medline,10.1000/sample.2442,,https://example.com/paper_2442,2022.0,10.0,67,10,True,54.0,8.0,True
cord-002444,Analysis of treatment and antibody and respiratory in clinical settings,This study examines treatment with 410 word abstract...,"Author2444_1, Author2444_2",New England Journal of Medicine,2020-05-21,medRxiv,10.1000/sample.2444,PMC1002444,,2020.0,5.0,71,10,True,55.0,8.0,True
cord-002445,Analysis of pandemic and therapeutic and lockdown in clinical settings,This study examines pandemic with 243 word abstract...,,JAMA,2021-12-01,ArXiv,10.1000/sample.2445,,https://example.com/paper_2445,2021.0,12.0,70,10,True,54.0,8.0,True
cord-002447,Analysis of treatment and SARS-CoV-2 and pneumonia and public health in clinical settings,This study examines treatment with 268 word abstract...,"Author2447_1, Author2447_2",Nature Medicine,2020-08-31,PMC,10.1000/sample.2447,,https://example.com/paper_2447,2020.0,8.0,89,13,True,55.0,8.0,True
cord-002449,Analysis of transmission and diagnosis and public health and clinical in clinical settings,This study examines transmission with 358 word abstract...,Author2449_1,Virology,,ArXiv,10.1000/sample.2449,PMC1002449,https://example.com/paper_2449,,,90,13,True,58.0,8.0,True
cord-002451,Analysis of pneumonia and lockdown and immunity in clinical settings,This study examines pneumonia with 364 word abstract...,"Author2451_1, Author2451_2",Nature,2021-05-02,bioRxiv,10.1000/sample.2451,PMC1002451,,2021.0,5.0,68,10,True,55.0,8.0,True
cord-002453,Analysis of symptoms and public health and outbreak in clinical settings,This study examines symptoms with 321 word abstract...,Author2453_1,Cell,2019-12-01,Medline,10.1000/sample.2453,PMC1002453,https://example.com/paper_2453,2019.0,12.0,72,11,True,54.0,8.0,True
cord-002455,Analysis of antiviral and diagnosis and respiratory in clinical settings,This study examines antiviral with 163 word abstract...,"Author2455_1, Author2455_2",PLoS ONE,2021-02-12,PMC,10.1000/sample.2455,PMC1002455,,2021.0,2.0,72,10,True,55.0,8.0,True
cord-002456,Analysis of antiviral and coronavirus and lockdown and public health in clinical settings,This study examines antiviral with 464 word abstract...,Author2456_1,,2021-01-05,bioRxiv,10.1000/sample.2456,PMC1002456,https://example.com/paper_2456,2021.0,1.0,89,13,True,55.0,8.0,False
cord-002458,Analysis of respiratory and therapeutic and coronavirus in clinical settings,This study examines respiratory with 385 word abstract...,Author2458_1,BMJ,2021-05-09,WHO,10.1000/sample.2458,PMC1002458,https://example.com/paper_2458,2021.0,5.0,76,10,True,57.0,8.0,True
cord-002459,Analysis of respiratory and treatment and vaccination and antiviral in clinical settings,This study examines respiratory with 119 word abstract...,Author2459_1,Cell,2022-02-10,medRxiv,10.1000/sample.2459,PMC1002459,https://example.com/paper_2459,2022.0,2.0,88,12,True,57.0,8.0,True
cord-002460,Analysis of pandemic and therapeutic and public health and treatment in clinical settings,This study examines pandemic with 486 word abstract...,"Author2460_1, Author2460_2",Journal of Virology,2020-12-30,medRxiv,10.1000/sample.2460,PMC1002460,https://example.com/paper_2460,2020.0,12.0,89,13,True,54.0,8.0,True
cord-002462,Analysis of diagnosis and antibody and antiviral and clinical in clinical settings,This study examines diagnosis with 174 word abstract...,"Author2462_1, Author2462_2",Nature,2020-04-01,Medline,10.1000/sample.2462,PMC1002462,https://example.com/paper_2462,2020.0,4.0,82,12,True,55.0,8.0,True
cord-002463,Analysis of symptoms and vaccination in clinical settings,This study examines symptoms with 250 word abstract...,"Author2463_1, Author2463_2",PLoS ONE,2020-02-27,ArXiv,,PMC1002463,https://example.com/paper_2463,2020.0,2.0,57,8,True,54.0,8.0,True
cord-002464,Analysis of pneumonia and antiviral and coronavirus and transmission in clinical settings,This study examines pneumonia with 326 word abstract...,"Author2464_1, Author2464_2",Nature,2021-07-04,medRxiv,10.1000/sample.2464,PMC1002464,https://example.com/paper_2464,2021.0,7.0,89,12,True,55.0,8.0,True
cord-002465,Analysis of immunity and respiratory and SARS-CoV-2 and outbreak in clinical settings,This study examines immunity with 445 word abstract...,"Author2465_1, Author2465_2",Nature,2019-12-05,WHO,10.1000/sample.2465,PMC1002465,https://example.com/paper_2465,2019.0,12.0,85,12,True,54.0,8.0,True
cord-002466,Analysis of respiratory and clinical and COVID-19 and pandemic in clinical settings,This study examines respiratory with 334 word abstract...,"Author2466_1, Author2466_2",BMJ,2020-02-19,Medline,10.1000/sample.2466,,https://example.com/paper_2466,2020.0,2.0,83,12,True,57.0,8.0,True
cord-002467,Analysis of COVID-19 and pandemic and vaccination in clinical settings,This study examines COVID-19 with 456 word abstract...,"Author2467_1, Author2467_2",Lancet,2021-03-22,ArXiv,10.1000/sample.2467,,https://example.com/paper_2467,2021.0,3.0,70,10,True,54.0,8.0,True
cord-002468,Analysis of antiviral and outbreak and diagnosis in clinical settings,This study examines antiviral with 300 word abstract...,"Author2468_1, Author2468_2",,2020-08-27,WHO,10.1000/sample.2468,PMC1002468,https://example.com/paper_2468,2020.0,8.0,69,10,True,55.0,8.0,False
cord-002469,Analysis of lockdown and transmission and pneumonia and antiviral in clinical settings,This study examines lockdown with 296 word abstract...,"Author2469_1, Author2469_2",PLoS ONE,2020-09-13,bioRxiv,10.1000/sample.2469,PMC1002469,,2020.0,9.0,86,12,True,54.0,8.0,True
cord-002470,Analysis of epidemiology and lockdown in clinical settings,This study examines epidemiology with 467 word abstract...,"Author2470_1, Author2470_2",Science,2020-12-21,bioRxiv,10.1000/sample.2470,PMC1002470,https://example.com/paper_2470,2020.0,12.0,58,8,True,58.0,8.0,True
cord-002471,Analysis of coronavirus and clinical in clinical settings,This study examines coronavirus with 167 word abstract...,"Author2471_1, Author2471_2",Clinical Infectious Diseases,2019-12-02,PMC,10.1000/sample.2471,PMC1002471,https://example.com/paper_2471,2019.0,12.0,57,8,True,57.0,8.0,True
cord-002473,Analysis of diagnosis and coronavirus and transmission in clinical settings,This study examines diagnosis with 312 word abstract...,"Author2473_1, Author2473_2",Nature Medicine,2021-01-26,Medline,10.1000/sample.2473,,https://example.com/paper_2473,2021.0,1.0,75,10,True,55.0,8.0,True
cord-002474,Analysis of pneumonia and symptoms and vaccination and immunity in clinical settings,This study examines pneumonia with 445 word abstract...,"Author2474_1, Author2474_2",Nature,2021-05-26,Medline,10.1000/sample.2474,,https://example.com/paper_2474,2021.0,5.0,84,12,True,55.0,8.0,True
cord-002475,Analysis of immunity and antibody and lockdown and vaccination in clinical settings,This study examines immunity with 431 word abstract...,"Author2475_1, Author2475_2",,2021-06-30,WHO,10.1000/sample.2475,PMC1002475,https://example.com/paper_2475,2021.0,6.0,83,12,True,54.0,8.0,False
cord-002476,Analysis of lockdown and public health and antibody in clinical settings,This study examines lockdown with 442 word abstract...,"Author2476_1, Author2476_2",New England Journal of Medicine,2020-02-04,ArXiv,,PMC1002476,,2020.0,2.0,72,11,True,54.0,8.0,True
cord-002478,Analysis of respiratory and lockdown and antiviral in clinical settings,This study examines respiratory with 450 word abstract...,"Author2478_1, Author2478_2",Journal of Medical Virology,2021-05-25,Medline,10.1000/sample.2478,PMC1002478,https://example.com/paper_2478,2021.0,5.0,71,10,True,57.0,8.0,True
cord-002480,Analysis of COVID-19 and transmission and epidemiology and diagnosis in clinical settings,This study examines COVID-19 with 218 word abstract...,"Author2480_1, Author2480_2",Journal of Medical Virology,2020-03-06,Medline,,,https://example.com/paper_2480,2020.0,3.0,89,12,True,54.0,8.0,True
cord-002481,Analysis of symptoms and outbreak and diagnosis in clinical settings,This study examines symptoms with 327 word abstract...,"Author2481_1, Author2481_2",Emerging Infectious Diseases,2021-10-19,WHO,10.1000/sample.2481,PMC1002481,https://example.com/paper_2481,2021.0,10.0,68,10,True,54.0,8.0,True
cord-002482,Analysis of vaccination and therapeutic and pneumonia in clinical settings,This study examines vaccination with 366 word abstract...,Author2482_1,New England Journal of Medicine,2021-01-13,PMC,10.1000/sample.2482,PMC1002482,https://example.com/paper_2482,2021.0,1.0,74,10,True,57.0,8.0,True
cord-002484,Analysis of vaccination and public health and treatment in clinical settings,This study examines vaccination with 462 word abstract...,"Author2484_1, Author2484_2",New England Journal of Medicine,,PMC,10.1000/sample.2484,PMC1002484,https://example.com/paper_2484,,,76,11,True,57.0,8.0,True
cord-002485,Analysis of immunity and treatment and antibody in clinical settings,This study examines immunity with 223 word abstract...,"Author2485_1, Author2485_2",Clinical Infectious Diseases,2020-12-17,ArXiv,10.1000/sample.2485,PMC1002485,https://example.com/paper_2485,2020.0,12.0,68,10,True,54.0,8.0,True
cord-002487,Analysis of public health and treatment and respiratory and antibody in clinical settings,This study examines public health with 403 word abstract...,Author2487_1,Nature,2020-12-12,medRxiv,10.1000/sample.2487,PMC1002487,https://example.com/paper_2487,2020.0,12.0,89,13,True,59.0,9.0,True
cord-002488,Analysis of outbreak and antibody and treatment in clinical settings,This study examines outbreak with 367 word abstract...,"Author2488_1, Author2488_2",Clinical Infectious Diseases,2021-03-15,WHO,,PMC1002488,https://example.com/paper_2488,2021.0,3.0,68,10,True,54.0,8.0,True
cord-002490,Analysis of clinical and transmission and epidemiology in clinical settings,This study examines clinical with 419 word abstract...,"Author2490_1, Author2490_2",Lancet,2019-12-20,Medline,10.1000/sample.2490,PMC1002490,https://example.com/paper_2490,2019.0,12.0,75,10,True,54.0,8.0,True
cord-002492,Analysis of antiviral and outbreak and symptoms in clinical settings,This study examines antiviral with 434 word abstract...,"Author2492_1, Author2492_2",Science,2020-08-10,WHO,10.1000/sample.2492,PMC1002492,https://example.com/paper_2492,2020.0,8.0,68,10,True,55.0,8.0,True
cord-002494,Analysis of SARS-CoV-2 and therapeutic and immunity in clinical settings,This study examines SARS-CoV-2 with 393 word abstract...,,,2020-09-24,ArXiv,10.1000/sample.2494,PMC1002494,https://example.com/paper_2494,2020.0,9.0,72,10,True,56.0,8.0,False
cord-002495,Analysis of pandemic and therapeutic and treatment in clinical settings,This study examines pandemic with 134 word abstract...,"Author2495_1, Author2495_2",Emerging Infectious Diseases,,PMC,,PMC1002495,https://example.com/paper_2495,,,71,10,True,54.0,8.0,True
cord-002498,Analysis of immunity and transmission and SARS-CoV-2 and coronavirus in clinical settings,This study examines immunity with 428 word abstract...,Author2498_1,PLoS ONE,2020-03-23,Medline,10.1000/sample.2498,PMC1002498,https://example.com/paper_2498,2020.0,3.0,89,12,True,54.0,8.0,True
cord-002499,Analysis of SARS-CoV-2 and therapeutic and public health and transmission in clinical settings,This study examines SARS-CoV-2 with 282 word abstract...,"Author2499_1, Author2499_2",Nature Medicine,2020-04-20,WHO,10.1000/sample.2499,,,2020.0,4.0,94,13,True,56.0,8.0,True
cord-002500,Analysis of pneumonia and treatment and COVID-19 in clinical settings,This study examines pneumonia with 244 word abstract...,"Author2500_1, Author2500_2",Virology,2021-04-11,WHO,10.1000/sample.2500,PMC1002500,https://example.com/paper_2500,2021.0,4.0,69,10,True,55.0,8.0,True
cord-002502,Analysis of therapeutic and immunity and respiratory in clinical settings,This study examines therapeutic with 309 word abstract...,"Author2502_1, Author2502_2",New England Journal of Medicine,2021-01-06,PMC,,PMC1002502,https://example.com/paper_2502,2021.0,1.0,73,10,True,57.0,8.0,True
cord-002503,Analysis of COVID-19 and epidemiology and antiviral in clinical settings,This study examines COVID-19 with 471 word abstract...,"Author2503_1, Author2503_2",Nature Medicine,2020-05-31,bioRxiv,,PMC1002503,https://example.com/paper_2503,2020.0,5.0,72,10,True,54.0,8.0,True
cord-002504,Analysis of clinical and outbreak and diagnosis and antibody in clinical settings,This study examines clinical with 336 word abstract...,"Author2504_1, Author2504_2",Lancet,2022-04-22,Medline,10.1000/sample.2504,PMC1002504,https://example.com/paper_2504,2022.0,4.0,81,12,True,54.0,8.0,True
cord-002505,Analysis of immunity and therapeutic and lockdown in clinical settings,This study examines immunity with 161 word abstract...,"Author2505_1, Author2505_2",Science Translational Medicine,2020-08-25,PMC,10.1000/sample.2505,PMC1002505,https://example.com/paper_2505,2020.0,8.0,70,10,True,54.0,8.0,True
cord-002507,Analysis of pandemic and transmission and outbreak and SARS-CoV-2 in clinical settings,This study examines pandemic with 105 word abstract...,"Author2507_1, Author2507_2",Cell,2021-10-10,PMC,10.1000/sample.2507,PMC1002507,https://example.com/paper_2507,2021.0,10.0,86,12,True,54.0,8.0,True
cord-002508,Analysis of outbreak and pneumonia and COVID-19 and vaccination in clinical settings,This study examines outbreak with 407 word abstract...,"Author2508_1, Author2508_2",,2020-04-17,ArXiv,10.1000/sample.2508,PMC1002508,https://example.com/paper_2508,2020.0,4.0,84,12,True,54.0,8.0,False
cord-002512,Analysis of SARS-CoV-2 and antiviral and epidemiology and symptoms in clinical settings,This study examines SARS-CoV-2 with 366 word abstract...,"Author2512_1, Author2512_2",Lancet,2021-11-14,WHO,,,https://example.com/paper_2512,2021.0,11.0,87,12,True,56.0,8.0,True
cord-002514,Analysis of antibody and clinical and public health and outbreak in clinical settings,,"Author2514_1, Author2514_2",,2021-05-08,medRxiv,10.1000/sample.2514,PMC1002514,https://example.com/paper_2514,2021.0,5.0,85,13,False,,,False
cord-002515,Analysis of treatment and coronavirus and COVID-19 in clinical settings,This study examines treatment with 456 word abstract...,"Author2515_1, Author2515_2",Science Translational Medicine,2022-08-07,PMC,10.1000/sample.2515,PMC1002515,https://example.com/paper_2515,2022.0,8.0,71,10,True,55.0,8.0,True
cord-002516,Analysis of antibody and symptoms and antiviral in clinical settings,This study examines antibody with 412 word abstract...,,Clinical Infectious Diseases,2020-09-27,medRxiv,10.1000/sample.2516,PMC1002516,https://example.com/paper_2516,2020.0,9.0,68,10,True,54.0,8.0,True
cord-002517,Analysis of treatment and antibody and coronavirus and respiratory in clinical settings,,"Author2517_1, Author2517_2",Journal of Medical Virology,2021-02-13,PMC,10.1000/sample.2517,,https://example.com/paper_2517,2021.0,2.0,87,12,False,,,True
cord-002518,Analysis of outbreak and immunity and SARS-CoV-2 and COVID-19 in clinical settings,This study examines outbreak with 253 word abstract...,"Author2518_1, Author2518_2",PLoS ONE,2020-01-20,ArXiv,10.1000/sample.2518,PMC1002518,https://example.com/paper_2518,2020.0,1.0,82,12,True,54.0,8.0,True
cord-002519,Analysis of COVID-19 and immunity and epidemiology in clinical settings,This study examines COVID-19 with 261 word abstract...,Author2519_1,PLoS ONE,2020-07-08,PMC,10.1000/sample.2519,PMC1002519,https://example.com/paper_2519,2020.0,7.0,71,10,True,54.0,8.0,True
cord-002521,Analysis of treatment and coronavirus and vaccination and pandemic in clinical settings,This study examines treatment with 133 word abstract...,Author2521_1,Nature,2021-05-19,medRxiv,10.1000/sample.2521,PMC1002521,https://example.com/paper_2521,2021.0,5.0,87,12,True,55.0,8.0,True
cord-002522,Analysis of clinical and vaccination and public health in clinical settings,This study examines clinical with 390 word abstract...,"Author2522_1, Author2522_2",Nature,2019-12-15,bioRxiv,10.1000/sample.2522,PMC1002522,https://example.com/paper_2522,2019.0,12.0,75,11,True,54.0,8.0,True
cord-002524,Analysis of pandemic and COVID-19 and pneumonia and epidemiology in clinical settings,This study examines pandemic with 235 word abstract...,"Author2524_1, Author2524_2",Clinical Infectious Diseases,2020-03-05,WHO,10.1000/sample.2524,,https://example.com/paper_2524,2020.0,3.0,85,12,True,54.0,8.0,True
cord-002526,Analysis of pneumonia and public health and symptoms in clinical settings,This study examines pneumonia with 465 word abstract...,"Author2526_1, Author2526_2",Science Translational Medicine,2020-01-20,ArXiv,10.1000/sample.2526,,https://example.com/paper_2526,2020.0,1.0,73,11,True,55.0,8.0,True
cord-002527,Analysis of symptoms and antibody and clinical in clinical settings,This study examines symptoms with 428 word abstract...,"Author2527_1, Author2527_2",Cell,2021-01-16,ArXiv,10.1000/sample.2527,PMC1002527,,2021.0,1.0,67,10,True,54.0,8.0,True
cord-002528,Analysis of pandemic and vaccination in clinical settings,This study examines pandemic with 336 word abstract...,Author2528_1,Clinical Infectious Diseases,2021-07-21,PMC,10.1000/sample.2528,PMC1002528,https://example.com/paper_2528,2021.0,7.0,57,8,True,54.0,8.0,True
cord-002533,Analysis of antiviral and epidemiology and transmission and antibody in clinical settings,This study examines antiviral with 136 word abstract...,"Author2533_1, Author2533_2",Science Translational Medicine,2022-09-30,Medline,10.1000/sample.2533,PMC1002533,,2022.0,9.0,89,12,True,55.0,8.0,True
cord-002536,Analysis of respiratory and pneumonia and treatment in clinical settings,This study examines respiratory with 271 word abstract...,"Author2536_1, Author2536_2",,,bioRxiv,10.1000/sample.2536,,https://example.com/paper_2536,,,72,10,True,57.0,8.0,False
cord-002537,Analysis of coronavirus and outbreak and epidemiology in clinical settings,This study examines coronavirus with 335 word abstract...,"Author2537_1, Author2537_2",Emerging Infectious Diseases,2020-07-12,ArXiv,10.1000/sample.2537,PMC1002537,https://example.com/paper_2537,2020.0,7.0,74,10,True,57.0,8.0,True
cord-002538,Analysis of vaccination and outbreak and lockdown in clinical settings,This study examines vaccination with 363 word abstract...,"Author2538_1, Author2538_2",PLoS ONE,2020-12-20,PMC,10.1000/sample.2538,PMC1002538,https://example.com/paper_2538,2020.0,12.0,70,10,True,57.0,8.0,True
cord-002539,Analysis of transmission and therapeutic and lockdown and immunity in clinical settings,This study examines transmission with 167 word abstract...,"Author2539_1, Author2539_2",New England Journal of Medicine,2020-12-26,medRxiv,10.1000/sample.2539,PMC1002539,,2020.0,12.0,87,12,True,58.0,8.0,True
cord-002540,Analysis of therapeutic and antiviral and outbreak and pandemic in clinical settings,This study examines therapeutic with 474 word abstract...,"Author2540_1, Author2540_2",,2021-05-02,bioRxiv,10.1000/sample.2540,PMC1002540,https://example.com/paper_2540,2021.0,5.0,84,12,True,57.0,8.0,False
cord-002542,Analysis of pneumonia and respiratory and therapeutic and coronavirus in clinical settings,This study examines pneumonia with 141 word abstract...,"Author2542_1, Author2542_2",BMJ,2020-04-25,Medline,10.1000/sample.2542,,https://example.com/paper_2542,2020.0,4.0,90,12,True,55.0,8.0,True
cord-002544,Analysis of clinical and SARS-CoV-2 and antiviral in clinical settings,This study examines clinical with 123 word abstract...,"Author2544_1, Author2544_2",BMJ,2020-05-15,PMC,10.1000/sample.2544,PMC1002544,https://example.com/paper_2544,2020.0,5.0,70,10,True,54.0,8.0,True
cord-002546,Analysis of coronavirus and COVID-19 and treatment and immunity in clinical settings,This study examines coronavirus with 180 word abstract...,"Author2546_1, Author2546_2",Nature Medicine,2020-05-02,ArXiv,10.1000/sample.2546,PMC1002546,https://example.com/paper_2546,2020.0,5.0,84,12,True,57.0,8.0,True
cord-002547,Analysis of transmission and respiratory and clinical in clinical settings,This study examines transmission with 111 word abstract...,"Author2547_1, Author2547_2",Nature,2019-12-25,PMC,10.1000/sample.2547,PMC1002547,https://example.com/paper_2547,2019.0,12.0,74,10,True,58.0,8.0,True
cord-002552,Analysis of diagnosis and outbreak and antibody in clinical settings,This study examines diagnosis with 418 word abstract...,Author2552_1,,2021-08-07,bioRxiv,10.1000/sample.2552,,https://example.com/paper_2552,2021.0,8.0,68,10,True,55.0,8.0,False
cord-002553,Analysis of COVID-19 and immunity and antiviral and coronavirus in clinical settings,This study examines COVID-19 with 313 word abstract...,Author2553_1,BMJ,2020-12-14,bioRxiv,10.1000/sample.2553,PMC1002553,,2020.0,12.0,84,12,True,54.0,8.0,True
cord-002554,Analysis of symptoms and diagnosis and transmission in clinical settings,,"Author2554_1, Author2554_2",BMJ,2020-07-12,WHO,10.1000/sample.2554,PMC1002554,,2020.0,7.0,72,10,False,,,True
cord-002555,Analysis of respiratory and transmission and pneumonia in clinical settings,This study examines respiratory with 216 word abstract...,"Author2555_1, Author2555_2",Emerging Infectious Diseases,2019-12-18,PMC,10.1000/sample.2555,PMC1002555,,2019.0,12.0,75,10,True,57.0,8.0,True
cord-002556,Analysis of pneumonia and pandemic and immunity in clinical settings,This study examines pneumonia with 175 word abstract...,"Author2556_1, Author2556_2",,2021-08-30,Medline,10.1000/sample.2556,PMC1002556,https://example.com/paper_2556,2021.0,8.0,68,10,True,55.0,8.0,False
cord-002559,Analysis of COVID-19 and antiviral and epidemiology in clinical settings,This study examines COVID-19 with 115 word abstract...,"Author2559_1, Author2559_2",,2021-01-15,WHO,10.1000/sample.2559,PMC1002559,https://example.com/paper_2559,2021.0,1.0,72,10,True,54.0,8.0,False
cord-002560,Analysis of public health and respiratory and therapeutic in clinical settings,This study examines public health with 116 word abstract...,Author2560_1,Science Translational Medicine,2022-06-28,Medline,10.1000/sample.2560,PMC1002560,https://example.com/paper_2560,2022.0,6.0,78,11,True,59.0,9.0,True
cord-002561,Analysis of COVID-19 and public health and coronavirus and SARS-CoV-2 in clinical settings,This study examines COVID-19 with 162 word abstract...,"Author2561_1, Author2561_2",Nature Medicine,2020-12-10,medRxiv,10.1000/sample.2561,,https://example.com/paper_2561,2020.0,12.0,90,13,True,54.0,8.0,True
cord-002565,Analysis of antiviral and antibody and therapeutic in clinical settings,This study examines antiviral with 449 word abstract...,"Author2565_1, Author2565_2",Nature Medicine,2020-09-23,medRxiv,10.1000/sample.2565,PMC1002565,https://example.com/paper_2565,2020.0,9.0,71,10,True,55.0,8.0,True
cord-002567,Analysis of SARS-CoV-2 and transmission and symptoms and outbreak in clinical settings,,"Author2567_1, Author2567_2",Clinical Infectious Diseases,2020-07-22,bioRxiv,10.1000/sample.2567,PMC1002567,https://example.com/paper_2567,2020.0,7.0,86,12,False,,,True
cord-002568,Analysis of symptoms and diagnosis and clinical and vaccination in clinical settings,This study examines symptoms with 193 word abstract...,"Author2568_1, Author2568_2",Cell,2021-01-27,WHO,10.1000/sample.2568,PMC1002568,https://example.com/paper_2568,2021.0,1.0,84,12,True,54.0,8.0,True
cord-002569,Analysis of antibody and pneumonia and symptoms and immunity in clinical settings,This study examines antibody with 338 word abstract...,"Author2569_1, Author2569_2",Emerging Infectious Diseases,2020-01-18,Medline,10.1000/sample.2569,,https://example.com/paper_2569,2020.0,1.0,81,12,True,54.0,8.0,True
cord-002572,Analysis of public health and clinical and vaccination in clinical settings,This study examines public health with 252 word abstract...,Author2572_1,Science,2021-07-16,PMC,,PMC1002572,https://example.com/paper_2572,2021.0,7.0,75,11,True,59.0,9.0,True
cord-002573,Analysis of COVID-19 and vaccination and lockdown and pneumonia in clinical settings,This study examines COVID-19 with 424 word abstract...,"Author2573_1, Author2573_2",,2021-02-10,WHO,10.1000/sample.2573,PMC1002573,https://example.com/paper_2573,2021.0,2.0,84,12,True,54.0,8.0,False
cord-002574,Analysis of antibody and treatment and COVID-19 and lockdown in clinical settings,This study examines antibody with 483 word abstract...,"Author2574_1, Author2574_2",Science,2021-03-22,bioRxiv,,PMC1002574,https://example.com/paper_2574,2021.0,3.0,81,12,True,54.0,8.0,True
cord-002575,Analysis of vaccination and pandemic and symptoms and antiviral in clinical settings,This study examines vaccination with 159 word abstract...,"Author2575_1, Author2575_2",Journal of Virology,2021-04-22,Medline,10.1000/sample.2575,PMC1002575,https://example.com/paper_2575,2021.0,4.0,84,12,True,57.0,8.0,True
cord-002576,Analysis of coronavirus and therapeutic and lockdown and outbreak in clinical settings,This study examines coronavirus with 178 word abstract...,Author2576_1,Journal of Medical Virology,2020-01-04,WHO,10.1000/sample.2576,PMC1002576,https://example.com/paper_2576,2020.0,1.0,86,12,True,57.0,8.0,True
cord-002577,Analysis of lockdown and coronavirus and outbreak and clinical in clinical settings,This study examines lockdown with 317 word abstract...,"Author2577_1, Author2577_2",Nature Medicine,2020-07-11,Medline,10.1000/sample.2577,PMC1002577,https://example.com/paper_2577,2020.0,7.0,83,12,True,54.0,8.0,True
cord-002578,Analysis of pandemic and coronavirus and immunity in clinical settings,This study examines pandemic with 234 word abstract...,"Author2578_1, Author2578_2",JAMA,2020-04-15,medRxiv,10.1000/sample.2578,PMC1002578,https://example.com/paper_2578,2020.0,4.0,70,10,True,54.0,8.0,True
cord-002580,Analysis of diagnosis and clinical and SARS-CoV-2 in clinical settings,,"Author2580_1, Author2580_2",Science,2021-12-24,bioRxiv,,PMC1002580,,2021.0,12.0,70,10,False,,,True
cord-002581,Analysis of diagnosis and pneumonia and outbreak in clinical settings,This study examines diagnosis with 497 word abstract...,"Author2581_1, Author2581_2",Science,2020-05-20,ArXiv,10.1000/sample.2581,PMC1002581,https://example.com/paper_2581,2020.0,5.0,69,10,True,55.0,8.0,True
cord-002582,Analysis of antiviral and SARS-CoV-2 and antibody in clinical settings,This study examines antiviral with 200 word abstract...,"Author2582_1, Author2582_2",Nature,2021-05-08,medRxiv,10.1000/sample.2582,PMC1002582,https://example.com/paper_2582,2021.0,5.0,70,10,True,55.0,8.0,True
cord-002584,Analysis of therapeutic and lockdown and diagnosis in clinical settings,This study examines therapeutic with 243 word abstract...,"Author2584_1, Author2584_2",Nature,2021-01-30,ArXiv,10.1000/sample.2584,PMC1002584,https://example.com/paper_2584,2021.0,1.0,71,10,True,57.0,8.0,True
cord-002585,Analysis of antiviral and respiratory and COVID-19 and therapeutic in clinical settings,This study examines antiviral with 126 word abstract...,"Author2585_1, Author2585_2",Journal of Medical Virology,2021-09-27,PMC,10.1000/sample.2585,PMC1002585,https://example.com/paper_2585,2021.0,9.0,87,12,True,55.0,8.0,True
cord-002586,Analysis of lockdown and public health and treatment in clinical settings,This study examines lockdown with 383 word abstract...,"Author2586_1, Author2586_2",Cell,,WHO,10.1000/sample.2586,PMC1002586,,,,73,11,True,54.0,8.0,True
cord-002588,Analysis of vaccination and diagnosis and antiviral in clinical settings,,"Author2588_1, Author2588_2",Journal of Virology,2022-08-23,bioRxiv,10.1000/sample.2588,,https://example.com/paper_2588,2022.0,8.0,72,10,False,,,True
cord-002589,Analysis of pneumonia and public health and COVID-19 in clinical settings,This study examines pneumonia with 122 word abstract...,"Author2589_1, Author2589_2",New England Journal of Medicine,2021-08-13,medRxiv,10.1000/sample.2589,PMC1002589,https://example.com/paper_2589,2021.0,8.0,73,11,True,55.0,8.0,True
cord-002591,Analysis of symptoms and SARS-CoV-2 and epidemiology and clinical in clinical settings,,"Author2591_1, Author2591_2",PLoS ONE,2020-06-05,WHO,10.1000/sample.2591,PMC1002591,https://example.com/paper_2591,2020.0,6.0,86,12,False,,,True
cord-002592,Analysis of public health and therapeutic and coronavirus and epidemiology in clinical settings,This study examines public health with 144 word abstract...,"Author2592_1, Author2592_2",Emerging Infectious Diseases,2020-08-19,ArXiv,10.1000/sample.2592,PMC1002592,,2020.0,8.0,95,13,True,59.0,9.0,True
cord-002593,Analysis of treatment and clinical and symptoms and public health in clinical settings,This study examines treatment with 310 word abstract...,Author2593_1,,2019-12-01,PMC,10.1000/sample.2593,PMC1002593,https://example.com/paper_2593,2019.0,12.0,86,13,True,55.0,8.0,False
cord-002595,Analysis of clinical and epidemiology and immunity in clinical settings,This study examines clinical with 442 word abstract...,"Author2595_1, Author2595_2",New England Journal of Medicine,2020-08-27,Medline,10.1000/sample.2595,PMC1002595,https://example.com/paper_2595,2020.0,8.0,71,10,True,54.0,8.0,True
cord-002597,Analysis of COVID-19 and respiratory in clinical settings,This study examines COVID-19 with 494 word abstract...,"Author2597_1, Author2597_2",Nature,2020-04-24,ArXiv,10.1000/sample.2597,,https://example.com/paper_2597,2020.0,4.0,57,8,True,54.0,8.0,True
cord-002599,Analysis of clinical and antibody and epidemiology and pandemic in clinical settings,This study examines clinical with 241 word abstract...,"Author2599_1, Author2599_2",Science,2022-06-30,WHO,10.1000/sample.2599,PMC1002599,,2022.0,6.0,84,12,True,54.0,8.0,True
cord-002601,Analysis of transmission and immunity and antibody and outbreak in clinical settings,This study examines transmission with 317 word abstract...,"Author2601_1, Author2601_2",Science Translational Medicine,2020-02-16,PMC,10.1000/sample.2601,PMC1002601,https://example.com/paper_2601,2020.0,2.0,84,12,True,58.0,8.0,True
cord-002605,Analysis of lockdown and clinical and public health in clinical settings,This study examines lockdown with 470 word abstract...,"Author2605_1, Author2605_2",,2021-04-12,ArXiv,10.1000/sample.2605,,https://example.com/paper_2605,2021.0,4.0,72,11,True,54.0,8.0,False
cord-002606,Analysis of diagnosis and COVID-19 and immunity and SARS-CoV-2 in clinical settings,This study examines diagnosis with 118 word abstract...,"Author2606_1, Author2606_2",BMJ,2020-09-25,bioRxiv,10.1000/sample.2606,,https://example.com/paper_2606,2020.0,9.0,83,12,True,55.0,8.0,True
cord-002608,Analysis of epidemiology and pneumonia and respiratory and COVID-19 in clinical settings,This study examines epidemiology with 163 word abstract...,"Author2608_1, Author2608_2",Science Translational Medicine,2022-05-28,PMC,10.1000/sample.2608,PMC1002608,,2022.0,5.0,88,12,True,58.0,8.0,True
cord-002609,Analysis of epidemiology and treatment and COVID-19 in clinical settings,This study examines epidemiology with 465 word abstract...,"Author2609_1, Author2609_2",Science Translational Medicine,2020-06-09,WHO,10.1000/sample.2609,,https://example.com/paper_2609,2020.0,6.0,72,10,True,58.0,8.0,True
cord-002610,Analysis of SARS-CoV-2 and pandemic and epidemiology in clinical settings,This study examines SARS-CoV-2 with 484 word abstract...,"Author2610_1, Author2610_2",Cell,2021-02-07,WHO,10.1000/sample.2610,,https://example.com/paper_2610,2021.0,2.0,73,10,True,56.0,8.0,True
cord-002611,Analysis of diagnosis and antiviral and respiratory in clinical settings,This study examines diagnosis with 270 word abstract...,"Author2611_1, Author2611_2",Virology,,PMC,10.1000/sample.2611,PMC1002611,https://example.com/paper_2611,,,72,10,True,55.0,8.0,True
cord-002613,Analysis of transmission and outbreak and symptoms in clinical settings,This study examines transmission with 400 word abstract...,Author2613_1,Clinical Infectious Diseases,2021-06-10,WHO,10.1000/sample.2613,PMC1002613,https://example.com/paper_2613,2021.0,6.0,71,10,True,58.0,8.0,True
cord-002614,Analysis of lockdown and SARS-CoV-2 and antibody and coronavirus in clinical settings,This study examines lockdown with 254 word abstract...,"Author2614_1, Author2614_2",BMJ,2021-02-28,ArXiv,10.1000/sample.2614,PMC1002614,https://example.com/paper_2614,2021.0,2.0,85,12,True,54.0,8.0,True
cord-002615,Analysis of epidemiology and vaccination and outbreak in clinical settings,This study examines epidemiology with 239 word abstract...,"Author2615_1, Author2615_2",Emerging Infectious Diseases,,bioRxiv,10.1000/sample.2615,PMC1002615,,,,74,10,True,58.0,8.0,True
cord-002616,Analysis of clinical and outbreak in clinical settings,This study examines clinical with 449 word abstract...,"Author2616_1, Author2616_2",PLoS ONE,2020-06-28,WHO,10.1000/sample.2616,PMC1002616,,2020.0,6.0,54,8,True,54.0,8.0,True
cord-002617,Analysis of pneumonia and pandemic and lockdown and diagnosis in clinical settings,This study examines pneumonia with 354 word abstract...,"Author2617_1, Author2617_2",New England Journal of Medicine,2020-10-07,PMC,10.1000/sample.2617,PMC1002617,https://example.com/paper_2617,2020.0,10.0,82,12,True,55.0,8.0,True
cord-002618,Analysis of transmission and public health and pandemic and treatment in clinical settings,This study examines transmission with 280 word abstract...,"Author2618_1, Author2618_2",Nature Medicine,2020-10-09,PMC,,PMC1002618,https://example.com/paper_2618,2020.0,10.0,90,13,True,58.0,8.0,True
cord-002619,Analysis of treatment and outbreak and lockdown in clinical settings,This study examines treatment with 256 word abstract...,Author2619_1,Emerging Infectious Diseases,2020-11-07,ArXiv,10.1000/sample.2619,PMC1002619,https://example.com/paper_2619,2020.0,11.0,68,10,True,55.0,8.0,True
cord-002623,Analysis of transmission and treatment and outbreak in clinical settings,This study examines transmission with 424 word abstract...,"Author2623_1, Author2623_2",New England Journal of Medicine,2020-06-04,WHO,10.1000/sample.2623,PMC1002623,https://example.com/paper_2623,2020.0,6.0,72,10,True,58.0,8.0,True
cord-002626,Analysis of transmission and antiviral and lockdown and diagnosis in clinical settings,This study examines transmission with 208 word abstract...,"Author2626_1, Author2626_2",Nature,2021-06-03,PMC,10.1000/sample.2626,PMC1002626,https://example.com/paper_2626,2021.0,6.0,86,12,True,58.0,8.0,True
cord-002627,Analysis of pneumonia and coronavirus and pandemic in clinical settings,This study examines pneumonia with 341 word abstract...,"Author2627_1, Author2627_2",Journal of Medical Virology,2020-03-03,bioRxiv,10.1000/sample.2627,PMC1002627,https://example.com/paper_2627,2020.0,3.0,71,10,True,55.0,8.0,True
cord-002628,Analysis of clinical and pneumonia and pandemic in clinical settings,This study examines clinical with 292 word abstract...,"Author2628_1, Author2628_2",,2020-11-01,Medline,,PMC1002628,https://example.com/paper_2628,2020.0,11.0,68,10,True,54.0,8.0,False
cord-002630,Analysis of coronavirus and immunity and pandemic in clinical settings,This study examines coronavirus with 235 word abstract...,"Author2630_1, Author2630_2",Lancet,2020-10-21,WHO,10.1000/sample.2630,,https://example.com/paper_2630,2020.0,10.0,70,10,True,57.0,8.0,True
cord-002632,Analysis of symptoms and vaccination and coronavirus in clinical settings,,"Author2632_1, Author2632_2",Science,2020-12-01,ArXiv,10.1000/sample.2632,PMC1002632,,2020.0,12.0,73,10,False,,,True
cord-002633,Analysis of lockdown and clinical and epidemiology and symptoms in clinical settings,This study examines lockdown with 406 word abstract...,"Author2633_1, Author2633_2",Emerging Infectious Diseases,2021-01-20,Medline,,PMC1002633,https://example.com/paper_2633,2021.0,1.0,84,12,True,54.0,8.0,True
cord-002635,Analysis of antiviral and coronavirus and public health and treatment in clinical settings,This study examines antiviral with 304 word abstract...,"Author2635_1, Author2635_2",BMJ,2021-02-04,medRxiv,10.1000/sample.2635,PMC1002635,https://example.com/paper_2635,2021.0,2.0,90,13,True,55.0,8.0,True
cord-002636,Analysis of immunity and outbreak and pneumonia and clinical in clinical settings,,"Author2636_1, Author2636_2",Emerging Infectious Diseases,2021-01-01,medRxiv,10.1000/sample.2636,PMC1002636,https://example.com/paper_2636,2021.0,1.0,81,12,False,,,True
cord-002637,Analysis of lockdown and immunity and pneumonia in clinical settings,This study examines lockdown with 416 word abstract...,Author2637_1,PLoS ONE,2021-09-09,bioRxiv,10.1000/sample.2637,PMC1002637,,2021.0,9.0,68,10,True,54.0,8.0,True
cord-002638,Analysis of diagnosis and transmission and antiviral and pandemic in clinical settings,This study examines diagnosis with 169 word abstract...,,JAMA,2020-08-01,Medline,,PMC1002638,https://example.com/paper_2638,2020.0,8.0,86,12,True,55.0,8.0,True
cord-002640,Analysis of lockdown and pneumonia and immunity in clinical settings,This study examines lockdown with 452 word abstract...,"Author2640_1, Author2640_2",Clinical Infectious Diseases,2022-11-16,Medline,10.1000/sample.2640,,https://example.com/paper_2640,2022.0,11.0,68,10,True,54.0,8.0,True
cord-002642,Analysis of transmission and outbreak and epidemiology and pneumonia in clinical settings,This study examines transmission with 427 word abstract...,"Author2642_1, Author2642_2",Nature,2019-12-13,Medline,10.1000/sample.2642,PMC1002642,https://example.com/paper_2642,2019.0,12.0,89,12,True,58.0,8.0,True
cord-002643,Analysis of SARS-CoV-2 and antibody and epidemiology and pandemic in clinical settings,This study examines SARS-CoV-2 with 300 word abstract...,"Author2643_1, Author2643_2",Journal of Medical Virology,2020-05-16,Medline,10.1000/sample.2643,PMC1002643,https://example.com/paper_2643,2020.0,5.0,86,12,True,56.0,8.0,True
cord-002644,Analysis of COVID-19 and clinical in clinical settings,,"Author2644_1, Author2644_2",Clinical Infectious Diseases,2020-12-26,WHO,10.1000/sample.2644,PMC1002644,https://example.com/paper_2644,2020.0,12.0,54,8,False,,,True
cord-002646,Analysis of vaccination and pandemic and COVID-19 and lockdown in clinical settings,This study examines vaccination with 223 word abstract...,"Author2646_1, Author2646_2",Journal of Virology,2021-12-10,PMC,10.1000/sample.2646,PMC1002646,,2021.0,12.0,83,12,True,57.0,8.0,True
cord-002647,Analysis of vaccination and diagnosis and coronavirus in clinical settings,This study examines vaccination with 261 word abstract...,"Author2647_1, Author2647_2",BMJ,2020-01-29,bioRxiv,10.1000/sample.2647,PMC1002647,https://example.com/paper_2647,2020.0,1.0,74,10,True,57.0,8.0,True
cord-002648,Analysis of treatment and outbreak and clinical and pneumonia in clinical settings,This study examines treatment with 310 word abstract...,"Author2648_1, Author2648_2",Cell,2020-11-15,Medline,,PMC1002648,,2020.0,11.0,82,12,True,55.0,8.0,True
cord-002652,Analysis of epidemiology and immunity and antiviral and coronavirus in clinical settings,This study examines epidemiology with 470 word abstract...,"Author2652_1, Author2652_2",BMJ,2021-12-21,ArXiv,10.1000/sample.2652,PMC1002652,https://example.com/paper_2652,2021.0,12.0,88,12,True,58.0,8.0,True
cord-002654,Analysis of vaccination and lockdown and diagnosis and symptoms in clinical settings,This study examines vaccination with 232 word abstract...,Author2654_1,PLoS ONE,2020-01-08,Medline,10.1000/sample.2654,,https://example.com/paper_2654,2020.0,1.0,84,12,True,57.0,8.0,True
cord-002656,Analysis of immunity and symptoms and vaccination in clinical settings,This study examines immunity with 435 word abstract...,Author2656_1,Virology,2020-06-12,medRxiv,10.1000/sample.2656,PMC1002656,https://example.com/paper_2656,2020.0,6.0,70,10,True,54.0,8.0,True
cord-002657,Analysis of lockdown and immunity and pandemic and diagnosis in clinical settings,This study examines lockdown with 380 word abstract...,"Author2657_1, Author2657_2",Science Translational Medicine,2020-07-15,WHO,10.1000/sample.2657,,,2020.0,7.0,81,12,True,54.0,8.0,True
cord-002659,Analysis of symptoms and pneumonia and therapeutic and lockdown in clinical settings,This study examines symptoms with 421 word abstract...,"Author2659_1, Author2659_2",BMJ,2020-09-24,ArXiv,,PMC1002659,https://example.com/paper_2659,2020.0,9.0,84,12,True,54.0,8.0,True
cord-002660,Analysis of SARS-CoV-2 and respiratory and pneumonia and antiviral in clinical settings,This study examines SARS-CoV-2 with 487 word abstract...,"Author2660_1, Author2660_2",Lancet,2020-12-23,PMC,10.1000/sample.2660,PMC1002660,https://example.com/paper_2660,2020.0,12.0,87,12,True,56.0,8.0,True
cord-002662,Analysis of pneumonia and diagnosis and outbreak and antiviral in clinical settings,This study examines pneumonia with 473 word abstract...,"Author2662_1, Author2662_2",New England Journal of Medicine,2021-11-16,ArXiv,10.1000/sample.2662,PMC1002662,https://example.com/paper_2662,2021.0,11.0,83,12,True,55.0,8.0,True
cord-002663,Analysis of clinical and SARS-CoV-2 and vaccination and COVID-19 in clinical settings,This study examines clinical with 246 word abstract...,"Author2663_1, Author2663_2",PLoS ONE,2021-06-21,ArXiv,10.1000/sample.2663,PMC1002663,https://example.com/paper_2663,2021.0,6.0,85,12,True,54.0,8.0,True
cord-002664,Analysis of antiviral and vaccination and SARS-CoV-2 in clinical settings,,Author2664_1,Science,2020-01-25,ArXiv,,,https://example.com/paper_2664,2020.0,1.0,73,10,False,,,True
cord-002665,Analysis of therapeutic and coronavirus and clinical in clinical settings,This study examines therapeutic with 455 word abstract...,"Author2665_1, Author2665_2",Nature Medicine,2021-11-13,WHO,10.1000/sample.2665,,https://example.com/paper_2665,2021.0,11.0,73,10,True,57.0,8.0,True
cord-002666,Analysis of immunity and transmission and antibody and clinical in clinical settings,This study examines immunity with 277 word abstract...,"Author2666_1, Author2666_2",Nature Medicine,2022-04-27,WHO,10.1000/sample.2666,,https://example.com/paper_2666,2022.0,4.0,84,12,True,54.0,8.0,True
cord-002668,Analysis of antiviral and pneumonia and clinical and immunity in clinical settings,This study examines antiviral with 150 word abstract...,"Author2668_1, Author2668_2",,2020-09-25,bioRxiv,10.1000/sample.2668,,https://example.com/paper_2668,2020.0,9.0,82,12,True,55.0,8.0,False
cord-002669,Analysis of pandemic and treatment and coronavirus and COVID-19 in clinical settings,This study examines pandemic with 301 word abstract...,"Author2669_1, Author2669_2",Science,2021-01-11,medRxiv,10.1000/sample.2669,PMC1002669,https://example.com/paper_2669,2021.0,1.0,84,12,True,54.0,8.0,True
cord-002670,Analysis of lockdown and vaccination and pandemic in clinical settings,This study examines lockdown with 360 word abstract...,"Author2670_1, Author2670_2",Science,2021-05-19,Medline,10.1000/sample.2670,PMC1002670,https://example.com/paper_2670,2021.0,5.0,70,10,True,54.0,8.0,True
cord-002674,Analysis of pandemic and antibody and vaccination in clinical settings,This study examines pandemic with 299 word abstract...,"Author2674_1, Author2674_2",Clinical Infectious Diseases,2020-10-18,Medline,10.1000/sample.2674,,https://example.com/paper_2674,2020.0,10.0,70,10,True,54.0,8.0,True
cord-002675,Analysis of treatment and immunity and public health in clinical settings,This study examines treatment with 402 word abstract...,"Author2675_1, Author2675_2",BMJ,2021-05-13,PMC,,PMC1002675,,2021.0,5.0,73,11,True,55.0,8.0,True
cord-002676,Analysis of coronavirus and pneumonia and treatment in clinical settings,This study examines coronavirus with 469 word abstract...,"Author2676_1, Author2676_2",JAMA,2020-09-10,PMC,,,https://example.com/paper_2676,2020.0,9.0,72,10,True,57.0,8.0,True
cord-002677,Analysis of epidemiology and vaccination and treatment and public health in clinical settings,This study examines epidemiology with 398 word abstract...,Author2677_1,New England Journal of Medicine,2020-07-11,Medline,10.1000/sample.2677,PMC1002677,https://example.com/paper_2677,2020.0,7.0,93,13,True,58.0,8.0,True
cord-002678,Analysis of coronavirus and symptoms and treatment and pandemic in clinical settings,This study examines coronavirus with 334 word abstract...,"Author2678_1, Author2678_2",BMJ,2020-05-25,PMC,10.1000/sample.2678,PMC1002678,https://example.com/paper_2678,2020.0,5.0,84,12,True,57.0,8.0,True
cord-002683,Analysis of antiviral and antibody and pneumonia in clinical settings,This study examines antiviral with 407 word abstract...,"Author2683_1, Author2683_2",Lancet,2020-03-06,bioRxiv,10.1000/sample.2683,PMC1002683,https://example.com/paper_2683,2020.0,3.0,69,10,True,55.0,8.0,True
cord-002684,Analysis of pneumonia and therapeutic and epidemiology in clinical settings,This study examines pneumonia with 488 word abstract...,"Author2684_1, Author2684_2",Science,2021-03-08,bioRxiv,10.1000/sample.2684,PMC1002684,,2021.0,3.0,75,10,True,55.0,8.0,True
cord-002685,Analysis of COVID-19 and transmission and treatment in clinical settings,This study examines COVID-19 with 475 word abstract...,"Author2685_1, Author2685_2",JAMA,2020-04-04,medRxiv,10.1000/sample.2685,PMC1002685,https://example.com/paper_2685,2020.0,4.0,72,10,True,54.0,8.0,True
cord-002686,Analysis of epidemiology and therapeutic and pneumonia and SARS-CoV-2 in clinical settings,This study examines epidemiology with 431 word abstract...,"Author2686_1, Author2686_2",Nature,2021-10-08,Medline,10.1000/sample.2686,PMC1002686,https://example.com/paper_2686,2021.0,10.0,90,12,True,58.0,8.0,True
cord-002687,Analysis of pneumonia and antiviral and coronavirus and diagnosis in clinical settings,This study examines pneumonia with 139 word abstract...,"Author2687_1, Author2687_2",New England Journal of Medicine,2020-02-23,Medline,,PMC1002687,https://example.com/paper_2687,2020.0,2.0,86,12,True,55.0,8.0,True
cord-002689,Analysis of immunity and vaccination and public health in clinical settings,This study examines immunity with 334 word abstract...,Author2689_1,Nature,2021-07-24,bioRxiv,10.1000/sample.2689,PMC1002689,,2021.0,7.0,75,11,True,54.0,8.0,True
cord-002690,Analysis of SARS-CoV-2 and coronavirus and symptoms and immunity in clinical settings,This study examines SARS-CoV-2 with 318 word abstract...,"Author2690_1, Author2690_2",Science Translational Medicine,2020-04-25,medRxiv,10.1000/sample.2690,PMC1002690,https://example.com/paper_2690,2020.0,4.0,85,12,True,56.0,8.0,True
cord-002691,Analysis of pneumonia and outbreak and clinical in clinical settings,This study examines pneumonia with 140 word abstract...,"Author2691_1, Author2691_2",New England Journal of Medicine,2021-04-18,PMC,10.1000/sample.2691,,https://example.com/paper_2691,2021.0,4.0,68,10,True,55.0,8.0,True
cord-002693,Analysis of therapeutic and symptoms and public health and antibody in clinical settings,This study examines therapeutic with 146 word abstract...,"Author2693_1, Author2693_2",Nature,2020-08-27,medRxiv,10.1000/sample.2693,PMC1002693,https://example.com/paper_2693,2020.0,8.0,88,13,True,57.0,8.0,True
cord-002694,Analysis of public health and transmission and pneumonia and symptoms in clinical settings,This study examines public health with 455 word abstract...,"Author2694_1, Author2694_2",Nature Medicine,2020-01-12,ArXiv,,PMC1002694,https://example.com/paper_2694,2020.0,1.0,90,13,True,59.0,9.0,True
cord-002696,Analysis of antibody and pandemic and clinical and SARS-CoV-2 in clinical settings,This study examines antibody with 201 word abstract...,"Author2696_1, Author2696_2",Nature Medicine,2020-05-14,WHO,10.1000/sample.2696,PMC1002696,https://example.com/paper_2696,2020.0,5.0,82,12,True,54.0,8.0,True
cord-002697,Analysis of outbreak and lockdown and clinical and vaccination in clinical settings,This study examines outbreak with 405 word abstract...,"Author2697_1, Author2697_2",Virology,,WHO,10.1000/sample.2697,,https://example.com/paper_2697,,,83,12,True,54.0,8.0,True
cord-002701,Analysis of therapeutic and clinical and vaccination and transmission in clinical settings,This study examines therapeutic with 315 word abstract...,"Author2701_1, Author2701_2",,2020-09-15,medRxiv,,PMC1002701,https://example.com/paper_2701,2020.0,9.0,90,12,True,57.0,8.0,False
cord-002702,Analysis of pneumonia and immunity and transmission and SARS-CoV-2 in clinical settings,This study examines pneumonia with 417 word abstract...,"Author2702_1, Author2702_2",,2021-10-23,bioRxiv,10.1000/sample.2702,PMC1002702,,2021.0,10.0,87,12,True,55.0,8.0,False
cord-002704,Analysis of clinical and treatment and respiratory and outbreak in clinical settings,This study examines clinical with 297 word abstract...,"Author2704_1, Author2704_2",Cell,2020-04-25,medRxiv,10.1000/sample.2704,PMC1002704,https://example.com/paper_2704,2020.0,4.0,84,12,True,54.0,8.0,True
cord-002706,Analysis of outbreak and antibody in clinical settings,This study examines outbreak with 406 word abstract...,Author2706_1,Science Translational Medicine,2019-12-13,bioRxiv,10.1000/sample.2706,PMC1002706,https://example.com/paper_2706,2019.0,12.0,54,8,True,54.0,8.0,True
cord-002708,Analysis of respiratory and coronavirus and lockdown in clinical settings,This study examines respiratory with 161 word abstract...,"Author2708_1, Author2708_2",Science,2020-07-15,ArXiv,10.1000/sample.2708,PMC1002708,https://example.com/paper_2708,2020.0,7.0,73,10,True,57.0,8.0,True
cord-002709,Analysis of pandemic and transmission and therapeutic in clinical settings,This study examines pandemic with 275 word abstract...,"Author2709_1, Author2709_2",Emerging Infectious Diseases,2020-07-09,PMC,10.1000/sample.2709,,,2020.0,7.0,74,10,True,54.0,8.0,True
cord-002710,Analysis of lockdown and transmission and vaccination and outbreak in clinical settings,,"Author2710_1, Author2710_2",Clinical Infectious Diseases,2020-02-18,medRxiv,10.1000/sample.2710,PMC1002710,https://example.com/paper_2710,2020.0,2.0,87,12,False,,,True
cord-002711,Analysis of therapeutic and treatment and immunity in clinical settings,This study examines therapeutic with 459 word abstract...,"Author2711_1, Author2711_2",JAMA,2020-10-11,medRxiv,10.1000/sample.2711,PMC1002711,https://example.com/paper_2711,2020.0,10.0,71,10,True,57.0,8.0,True
cord-002712,Analysis of outbreak and coronavirus and epidemiology and vaccination in clinical settings,This study examines outbreak with 260 word abstract...,"Author2712_1, Author2712_2",Emerging Infectious Diseases,2022-07-19,WHO,10.1000/sample.2712,PMC1002712,https://example.com/paper_2712,2022.0,7.0,90,12,True,54.0,8.0,True
cord-002714,Analysis of clinical and antiviral and immunity in clinical settings,This study examines clinical with 155 word abstract...,"Author2714_1, Author2714_2",PLoS ONE,2019-12-25,bioRxiv,10.1000/sample.2714,PMC1002714,https://example.com/paper_2714,2019.0,12.0,68,10,True,54.0,8.0,True
cord-002717,Analysis of pneumonia and treatment and pandemic and coronavirus in clinical settings,This study examines pneumonia with 431 word abstract...,Author2717_1,Cell,2022-04-27,bioRxiv,10.1000/sample.2717,PMC1002717,https://example.com/paper_2717,2022.0,4.0,85,12,True,55.0,8.0,True
cord-002718,Analysis of lockdown and SARS-CoV-2 and pandemic and vaccination in clinical settings,This study examines lockdown with 249 word abstract...,"Author2718_1, Author2718_2",BMJ,2020-04-20,PMC,10.1000/sample.2718,PMC1002718,https://example.com/paper_2718,2020.0,4.0,85,12,True,54.0,8.0,True
cord-002719,Analysis of vaccination and transmission in clinical settings,This study examines vaccination with 134 word abstract...,"Author2719_1, Author2719_2",Nature,2021-11-05,PMC,10.1000/sample.2719,,https://example.com/paper_2719,2021.0,11.0,61,8,True,57.0,8.0,True
cord-002720,Analysis of antiviral and respiratory and immunity in clinical settings,This study examines antiviral with 116 word abstract...,"Author2720_1, Author2720_2",Clinical Infectious Diseases,2021-08-11,WHO,10.1000/sample.2720,,https://example.com/paper_2720,2021.0,8.0,71,10,True,55.0,8.0,True
cord-002721,Analysis of public health and vaccination and diagnosis in clinical settings,This study examines public health with 140 word abstract...,"Author2721_1, Author2721_2",Science,2020-01-28,medRxiv,10.1000/sample.2721,PMC1002721,https://example.com/paper_2721,2020.0,1.0,76,11,True,59.0,9.0,True
cord-002722,Analysis of coronavirus and clinical and respiratory in clinical settings,This study examines coronavirus with 225 word abstract...,"Author2722_1, Author2722_2",New England Journal of Medicine,2020-01-11,medRxiv,10.1000/sample.2722,,https://example.com/paper_2722,2020.0,1.0,73,10,True,57.0,8.0,True
cord-002723,Analysis of vaccination and antibody and lockdown in clinical settings,This study examines vaccination with 220 word abstract...,"Author2723_1, Author2723_2",New England Journal of Medicine,2020-03-09,ArXiv,10.1000/sample.2723,,https://example.com/paper_2723,2020.0,3.0,70,10,True,57.0,8.0,True
cord-002724,Analysis of symptoms and respiratory and diagnosis and SARS-CoV-2 in clinical settings,This study examines symptoms with 150 word abstract...,"Author2724_1, Author2724_2",BMJ,2020-04-11,bioRxiv,10.1000/sample.2724,PMC1002724,https://example.com/paper_2724,2020.0,4.0,86,12,True,54.0,8.0,True
cord-002726,Analysis of pandemic and transmission and antiviral and symptoms in clinical settings,This study examines pandemic with 334 word abstract...,"Author2726_1, Author2726_2",Science Translational Medicine,2020-09-10,PMC,10.1000/sample.2726,PMC1002726,https://example.com/paper_2726,2020.0,9.0,85,12,True,54.0,8.0,True
cord-002727,Analysis of outbreak and lockdown in clinical settings,This study examines outbreak with 306 word abstract...,Author2727_1,Science,2021-09-26,ArXiv,10.1000/sample.2727,PMC1002727,https://example.com/paper_2727,2021.0,9.0,54,8,True,54.0,8.0,True
cord-002728,Analysis of antiviral and treatment and COVID-19 and lockdown in clinical settings,This study examines antiviral with 471 word abstract...,"Author2728_1, Author2728_2",Science Translational Medicine,2021-08-01,medRxiv,10.1000/sample.2728,,https://example.com/paper_2728,2021.0,8.0,82,12,True,55.0,8.0,True
cord-002729,Analysis of therapeutic and antiviral and immunity and coronavirus in clinical settings,This study examines therapeutic with 194 word abstract...,,Clinical Infectious Diseases,2021-02-20,bioRxiv,10.1000/sample.2729,,https://example.com/paper_2729,2021.0,2.0,87,12,True,57.0,8.0,True
cord-002730,Analysis of symptoms and outbreak in clinical settings,This study examines symptoms with 373 word abstract...,Author2730_1,JAMA,2019-12-01,Medline,10.1000/sample.2730,,https://example.com/paper_2730,2019.0,12.0,54,8,True,54.0,8.0,True
cord-002731,Analysis of epidemiology and antiviral and outbreak and symptoms in clinical settings,This study examines epidemiology with 214 word abstract...,"Author2731_1, Author2731_2",,2021-03-20,Medline,10.1000/sample.2731,PMC1002731,https://example.com/paper_2731,2021.0,3.0,85,12,True,58.0,8.0,False
cord-002735,Analysis of outbreak and epidemiology and antiviral and COVID-19 in clinical settings,This study examines outbreak with 357 word abstract...,Author2735_1,Journal of Medical Virology,2019-12-28,PMC,10.1000/sample.2735,PMC1002735,https://example.com/paper_2735,2019.0,12.0,85,12,True,54.0,8.0,True
cord-002739,Analysis of immunity and therapeutic and symptoms in clinical settings,This study examines immunity with 395 word abstract...,Author2739_1,Journal of Virology,2020-05-08,ArXiv,10.1000/sample.2739,,,2020.0,5.0,70,10,True,54.0,8.0,True
cord-002740,Analysis of clinical and vaccination and antiviral in clinical settings,This study examines clinical with 167 word abstract...,"Author2740_1, Author2740_2",Journal of Medical Virology,2021-07-01,WHO,10.1000/sample.2740,,https://example.com/paper_2740,2021.0,7.0,71,10,True,54.0,8.0,True
cord-002741,Analysis of lockdown and diagnosis and COVID-19 in clinical settings,This study examines lockdown with 424 word abstract...,"Author2741_1, Author2741_2",Emerging Infectious Diseases,2022-09-09,medRxiv,10.1000/sample.2741,PMC1002741,https://example.com/paper_2741,2022.0,9.0,68,10,True,54.0,8.0,True
cord-002742,Analysis of vaccination and pandemic and immunity in clinical settings,This study examines vaccination with 158 word abstract...,"Author2742_1, Author2742_2",Cell,2020-04-27,medRxiv,10.1000/sample.2742,,https://example.com/paper_2742,2020.0,4.0,70,10,True,57.0,8.0,True
cord-002743,Analysis of diagnosis and public health and therapeutic and pneumonia in clinical settings,This study examines diagnosis with 476 word abstract...,"Author2743_1, Author2743_2",PLoS ONE,2019-12-07,WHO,10.1000/sample.2743,PMC1002743,https://example.com/paper_2743,2019.0,12.0,90,13,True,55.0,8.0,True
cord-002744,Analysis of clinical and public health and vaccination and COVID-19 in clinical settings,This study examines clinical with 131 word abstract...,"Author2744_1, Author2744_2",New England Journal of Medicine,2021-12-18,WHO,10.1000/sample.2744,,https://example.com/paper_2744,2021.0,12.0,88,13,True,54.0,8.0,True
cord-002745,Analysis of therapeutic and pneumonia and immunity in clinical settings,This study examines therapeutic with 347 word abstract...,"Author2745_1, Author2745_2",BMJ,2020-03-13,medRxiv,10.1000/sample.2745,,https://example.com/paper_2745,2020.0,3.0,71,10,True,57.0,8.0,True
cord-002747,Analysis of symptoms and treatment and respiratory in clinical settings,This study examines symptoms with 210 word abstract...,"Author2747_1, Author2747_2",,2021-05-30,Medline,,,https://example.com/paper_2747,2021.0,5.0,71,10,True,54.0,8.0,False
cord-002749,Analysis of SARS-CoV-2 and immunity and antiviral and COVID-19 in clinical settings,This study examines SARS-CoV-2 with 422 word abstract...,"Author2749_1, Author2749_2",PLoS ONE,2021-06-09,Medline,,PMC1002749,https://example.com/paper_2749,2021.0,6.0,83,12,True,56.0,8.0,True
cord-002750,Analysis of SARS-CoV-2 and pandemic and outbreak in clinical settings,This study examines SARS-CoV-2 with 106 word abstract...,"Author2750_1, Author2750_2",PLoS ONE,2021-09-19,medRxiv,,PMC1002750,https://example.com/paper_2750,2021.0,9.0,69,10,True,56.0,8.0,True
cord-002751,Analysis of epidemiology and public health and therapeutic in clinical settings,This study examines epidemiology with 261 word abstract...,"Author2751_1, Author2751_2",Virology,2020-02-11,WHO,10.1000/sample.2751,PMC1002751,,2020.0,2.0,79,11,True,58.0,8.0,True
cord-002752,Analysis of public health and SARS-CoV-2 and treatment and symptoms in clinical settings,This study examines public health with 223 word abstract...,"Author2752_1, Author2752_2",PLoS ONE,2020-07-25,WHO,10.1000/sample.2752,PMC1002752,https://example.com/paper_2752,2020.0,7.0,88,13,True,59.0,9.0,True
cord-002753,Analysis of SARS-CoV-2 and public health and diagnosis and outbreak in clinical settings,This study examines SARS-CoV-2 with 246 word abstract...,"Author2753_1, Author2753_2",Lancet,2021-10-22,ArXiv,,PMC1002753,https://example.com/paper_2753,2021.0,10.0,88,13,True,56.0,8.0,True
cord-002754,Analysis of antibody and immunity and pneumonia and COVID-19 in clinical settings,This study examines antibody with 319 word abstract...,"Author2754_1, Author2754_2",Science,2020-05-11,WHO,10.1000/sample.2754,PMC1002754,https://example.com/paper_2754,2020.0,5.0,81,12,True,54.0,8.0,True
cord-002755,Analysis of transmission and coronavirus and pandemic and immunity in clinical settings,This study examines transmission with 470 word abstract...,"Author2755_1, Author2755_2",Journal of Virology,2021-04-24,medRxiv,,,https://example.com/paper_2755,2021.0,4.0,87,12,True,58.0,8.0,True
cord-002756,Analysis of respiratory and outbreak and transmission in clinical settings,,"Author2756_1, Author2756_2",Virology,2020-08-02,WHO,10.1000/sample.2756,PMC1002756,,2020.0,8.0,74,10,False,,,True
cord-002761,Analysis of immunity and respiratory and pandemic and transmission in clinical settings,This study examines immunity with 261 word abstract...,"Author2761_1, Author2761_2",Virology,2022-11-28,bioRxiv,10.1000/sample.2761,,https://example.com/paper_2761,2022.0,11.0,87,12,True,54.0,8.0,True
cord-002762,Analysis of symptoms and therapeutic and transmission and pandemic in clinical settings,This study examines symptoms with 415 word abstract...,"Author2762_1, Author2762_2",Nature,2022-01-03,WHO,10.1000/sample.2762,PMC1002762,,2022.0,1.0,87,12,True,54.0,8.0,True
cord-002763,Analysis of lockdown and respiratory in clinical settings,This study examines lockdown with 237 word abstract...,"Author2763_1, Author2763_2",Cell,2022-09-27,ArXiv,10.1000/sample.2763,PMC1002763,https://example.com/paper_2763,2022.0,9.0,57,8,True,54.0,8.0,True
cord-002765,Analysis of public health and vaccination and antiviral in clinical settings,This study examines public health with 190 word abstract...,"Author2765_1, Author2765_2",Clinical Infectious Diseases,2021-10-10,bioRxiv,10.1000/sample.2765,PMC1002765,https://example.com/paper_2765,2021.0,10.0,76,11,True,59.0,9.0,True
cord-002767,Analysis of lockdown and antibody and symptoms and epidemiology in clinical settings,This study examines lockdown with 272 word abstract...,"Author2767_1, Author2767_2",JAMA,2021-08-23,PMC,10.1000/sample.2767,PMC1002767,,2021.0,8.0,84,12,True,54.0,8.0,True
cord-002770,Analysis of clinical and therapeutic and diagnosis and antibody in clinical settings,This study examines clinical with 435 word abstract...,Author2770_1,Clinical Infectious Diseases,2020-03-09,bioRxiv,,PMC1002770,https://example.com/paper_2770,2020.0,3.0,84,12,True,54.0,8.0,True
cord-002771,Analysis of pandemic and coronavirus and lockdown and clinical in clinical settings,This study examines pandemic with 186 word abstract...,"Author2771_1, Author2771_2",Lancet,2022-01-23,bioRxiv,10.1000/sample.2771,PMC1002771,https://example.com/paper_2771,2022.0,1.0,83,12,True,54.0,8.0,True
cord-002772,Analysis of symptoms and respiratory and treatment and antiviral in clinical settings,This study examines symptoms with 385 word abstract...,"Author2772_1, Author2772_2",Cell,2019-12-08,medRxiv,10.1000/sample.2772,PMC1002772,https://example.com/paper_2772,2019.0,12.0,85,12,True,54.0,8.0,True
cord-002773,Analysis of immunity and public health and pneumonia and SARS-CoV-2 in clinical settings,This study examines immunity with 144 word abstract...,"Author2773_1, Author2773_2",Journal of Virology,2020-08-10,ArXiv,10.1000/sample.2773,PMC1002773,https://example.com/paper_2773,2020.0,8.0,88,13,True,54.0,8.0,True
cord-002774,Analysis of transmission and immunity and coronavirus and treatment in clinical settings,This study examines transmission with 277 word abstract...,Author2774_1,Emerging Infectious Diseases,2021-03-13,ArXiv,10.1000/sample.2774,PMC1002774,https://example.com/paper_2774,2021.0,3.0,88,12,True,58.0,8.0,True
cord-002777,Analysis of clinical and pneumonia and respiratory and diagnosis in clinical settings,This study examines clinical with 470 word abstract...,"Author2777_1, Author2777_2",Virology,2020-07-02,WHO,10.1000/sample.2777,PMC1002777,https://example.com/paper_2777,2020.0,7.0,85,12,True,54.0,8.0,True
cord-002781,Analysis of immunity and antibody and vaccination and antiviral in clinical settings,This study examines immunity with 395 word abstract...,"Author2781_1, Author2781_2",New England Journal of Medicine,2021-06-19,ArXiv,10.1000/sample.2781,PMC1002781,https://example.com/paper_2781,2021.0,6.0,84,12,True,54.0,8.0,True
cord-002782,Analysis of immunity and transmission and treatment and antibody in clinical settings,This study examines immunity with 176 word abstract...,"Author2782_1, Author2782_2",,2019-12-16,WHO,10.1000/sample.2782,PMC1002782,https://example.com/paper_2782,2019.0,12.0,85,12,True,54.0,8.0,False
cord-002784,Analysis of respiratory and SARS-CoV-2 and pandemic and coronavirus in clinical settings,This study examines respiratory with 494 word abstract...,"Author2784_1, Author2784_2",PLoS ONE,2021-08-18,bioRxiv,10.1000/sample.2784,PMC1002784,https://example.com/paper_2784,2021.0,8.0,88,12,True,57.0,8.0,True
cord-002785,Analysis of COVID-19 and pandemic and outbreak in clinical settings,This study examines COVID-19 with 186 word abstract...,"Author2785_1, Author2785_2",JAMA,2020-05-17,bioRxiv,10.1000/sample.2785,PMC1002785,https://example.com/paper_2785,2020.0,5.0,67,10,True,54.0,8.0,True
cord-002786,Analysis of immunity and vaccination and pandemic in clinical settings,This study examines immunity with 328 word abstract...,"Author2786_1, Author2786_2",Clinical Infectious Diseases,,Medline,10.1000/sample.2786,PMC1002786,https://example.com/paper_2786,,,70,10,True,54.0,8.0,True
cord-002787,Analysis of therapeutic and lockdown and pneumonia in clinical settings,This study examines therapeutic with 342 word abstract...,Author2787_1,PLoS ONE,2020-09-02,WHO,10.1000/sample.2787,PMC1002787,,2020.0,9.0,71,10,True,57.0,8.0,True
cord-002788,Analysis of SARS-CoV-2 and coronavirus and antiviral in clinical settings,,"Author2788_1, Author2788_2",Cell,2021-04-13,PMC,10.1000/sample.2788,PMC1002788,https://example.com/paper_2788,2021.0,4.0,73,10,False,,,True
cord-002789,Analysis of vaccination and therapeutic in clinical settings,This study examines vaccination with 350 word abstract...,"Author2789_1, Author2789_2",Nature Medicine,2021-05-27,Medline,10.1000/sample.2789,PMC1002789,https://example.com/paper_2789,2021.0,5.0,60,8,True,57.0,8.0,True
cord-002790,Analysis of SARS-CoV-2 and public health and respiratory and symptoms in clinical settings,,"Author2790_1, Author2790_2",Cell,2021-03-22,ArXiv,10.1000/sample.2790,PMC1002790,https://example.com/paper_2790,2021.0,3.0,90,13,False,,,True
cord-002792,Analysis of pneumonia and pandemic and lockdown in clinical settings,This study examines pneumonia with 417 word abstract...,"Author2792_1, Author2792_2",Clinical Infectious Diseases,2021-01-27,bioRxiv,10.1000/sample.2792,PMC1002792,https://example.com/paper_2792,2021.0,1.0,68,10,True,55.0,8.0,True
cord-002793,Analysis of pneumonia and vaccination and pandemic and coronavirus in clinical settings,This study examines pneumonia with 142 word abstract...,,Clinical Infectious Diseases,2021-03-03,ArXiv,10.1000/sample.2793,PMC1002793,https://example.com/paper_2793,2021.0,3.0,87,12,True,55.0,8.0,True
cord-002794,Analysis of therapeutic and public health and vaccination in clinical settings,This study examines therapeutic with 306 word abstract...,"Author2794_1, Author2794_2",Science Translational Medicine,2021-12-26,medRxiv,10.1000/sample.2794,PMC1002794,https://example.com/paper_2794,2021.0,12.0,78,11,True,57.0,8.0,True
cord-002795,Analysis of respiratory and pandemic and epidemiology in clinical settings,This study examines respiratory with 225 word abstract...,"Author2795_1, Author2795_2",Journal of Virology,2020-01-29,ArXiv,,PMC1002795,,2020.0,1.0,74,10,True,57.0,8.0,True
cord-002797,Analysis of COVID-19 and transmission and SARS-CoV-2 in clinical settings,This study examines COVID-19 with 448 word abstract...,"Author2797_1, Author2797_2",Emerging Infectious Diseases,2020-05-12,Medline,,,,2020.0,5.0,73,10,True,54.0,8.0,True
cord-002799,Analysis of treatment and antiviral and immunity in clinical settings,This study examines treatment with 455 word abstract...,"Author2799_1, Author2799_2",Virology,2020-02-19,bioRxiv,10.1000/sample.2799,PMC1002799,,2020.0,2.0,69,10,True,55.0,8.0,True
cord-002800,Analysis of treatment and therapeutic and respiratory in clinical settings,This study examines treatment with 387 word abstract...,Author2800_1,BMJ,2020-07-23,Medline,10.1000/sample.2800,PMC1002800,https://example.com/paper_2800,2020.0,7.0,74,10,True,55.0,8.0,True
cord-002801,Analysis of immunity and epidemiology in clinical settings,This study examines immunity with 334 word abstract...,Author2801_1,New England Journal of Medicine,2020-03-18,Medline,10.1000/sample.2801,PMC1002801,https://example.com/paper_2801,2020.0,3.0,58,8,True,54.0,8.0,True
cord-002803,Analysis of immunity and public health and symptoms in clinical settings,This study examines immunity with 484 word abstract...,"Author2803_1, Author2803_2",PLoS ONE,,bioRxiv,,,https://example.com/paper_2803,,,72,11,True,54.0,8.0,True
cord-002804,Analysis of therapeutic and pandemic and respiratory and immunity in clinical settings,This study examines therapeutic with 395 word abstract...,Author2804_1,Journal of Virology,2020-03-26,bioRxiv,10.1000/sample.2804,PMC1002804,https://example.com/paper_2804,2020.0,3.0,86,12,True,57.0,8.0,True
cord-002805,Analysis of clinical and COVID-19 and therapeutic and lockdown in clinical settings,This study examines clinical with 405 word abstract...,"Author2805_1, Author2805_2",PLoS ONE,2019-12-13,WHO,10.1000/sample.2805,,https://example.com/paper_2805,2019.0,12.0,83,12,True,54.0,8.0,True
cord-002806,Analysis of diagnosis and coronavirus and symptoms and epidemiology in clinical settings,This study examines diagnosis with 325 word abstract...,"Author2806_1, Author2806_2",Science Translational Medicine,2020-11-18,medRxiv,10.1000/sample.2806,,https://example.com/paper_2806,2020.0,11.0,88,12,True,55.0,8.0,True
cord-002807,Analysis of immunity and epidemiology and lockdown and respiratory in clinical settings,This study examines immunity with 220 word abstract...,"Author2807_1, Author2807_2",Emerging Infectious Diseases,2021-10-22,ArXiv,,PMC1002807,https://example.com/paper_2807,2021.0,10.0,87,12,True,54.0,8.0,True
cord-002809,Analysis of SARS-CoV-2 and diagnosis and pneumonia and antibody in clinical settings,This study examines SARS-CoV-2 with 311 word abstract...,Author2809_1,Science,2021-07-13,medRxiv,10.1000/sample.2809,PMC1002809,https://example.com/paper_2809,2021.0,7.0,84,12,True,56.0,8.0,True
cord-002811,Analysis of public health and respiratory and outbreak and diagnosis in clinical settings,This study examines public health with 342 word abstract...,"Author2811_1, Author2811_2",Virology,2021-03-03,WHO,10.1000/sample.2811,PMC1002811,https://example.com/paper_2811,2021.0,3.0,89,13,True,59.0,9.0,True
cord-002812,Analysis of COVID-19 and transmission and epidemiology and vaccination in clinical settings,This study examines COVID-19 with 256 word abstract...,Author2812_1,Lancet,2021-07-22,ArXiv,10.1000/sample.2812,PMC1002812,https://example.com/paper_2812,2021.0,7.0,91,12,True,54.0,8.0,True
cord-002813,Analysis of pandemic and coronavirus and epidemiology and treatment in clinical settings,This study examines pandemic with 489 word abstract...,"Author2813_1, Author2813_2",Journal of Virology,2021-02-16,Medline,10.1000/sample.2813,PMC1002813,https://example.com/paper_2813,2021.0,2.0,88,12,True,54.0,8.0,True
cord-002814,Analysis of antiviral and transmission and coronavirus in clinical settings,This study examines antiviral with 480 word abstract...,"Author2814_1, Author2814_2",Science,2021-04-20,Medline,10.1000/sample.2814,,https://example.com/paper_2814,2021.0,4.0,75,10,True,55.0,8.0,True
cord-002815,Analysis of epidemiology and antibody and SARS-CoV-2 in clinical settings,This study examines epidemiology with 275 word abstract...,"Author2815_1, Author2815_2",PLoS ONE,2021-12-26,WHO,,,https://example.com/paper_2815,2021.0,12.0,73,10,True,58.0,8.0,True
cord-002817,Analysis of epidemiology and lockdown and therapeutic and clinical in clinical settings,This study examines epidemiology with 491 word abstract...,Author2817_1,Journal of Medical Virology,2020-11-09,bioRxiv,10.1000/sample.2817,PMC1002817,https://example.com/paper_2817,2020.0,11.0,87,12,True,58.0,8.0,True
cord-002821,Analysis of diagnosis and pandemic and immunity in clinical settings,This study examines diagnosis with 252 word abstract...,Author2821_1,BMJ,2020-11-21,WHO,10.1000/sample.2821,PMC1002821,https://example.com/paper_2821,2020.0,11.0,68,10,True,55.0,8.0,True
cord-002822,Analysis of symptoms and treatment and pandemic in clinical settings,This study examines symptoms with 228 word abstract...,Author2822_1,Nature,2021-06-09,bioRxiv,10.1000/sample.2822,PMC1002822,https://example.com/paper_2822,2021.0,6.0,68,10,True,54.0,8.0,True
cord-002823,Analysis of coronavirus and public health and respiratory in clinical settings,This study examines coronavirus with 480 word abstract...,"Author2823_1, Author2823_2",New England Journal of Medicine,2022-01-01,medRxiv,10.1000/sample.2823,PMC1002823,https://example.com/paper_2823,2022.0,1.0,78,11,True,57.0,8.0,True
cord-002825,Analysis of clinical and symptoms and SARS-CoV-2 in clinical settings,This study examines clinical with 112 word abstract...,,Nature Medicine,2020-11-10,WHO,10.1000/sample.2825,PMC1002825,https://example.com/paper_2825,2020.0,11.0,69,10,True,54.0,8.0,True
cord-002826,Analysis of antiviral and respiratory and epidemiology in clinical settings,This study examines antiviral with 246 word abstract...,"Author2826_1, Author2826_2",New England Journal of Medicine,2019-12-23,Medline,10.1000/sample.2826,,https://example.com/paper_2826,2019.0,12.0,75,10,True,55.0,8.0,True
cord-002827,Analysis of symptoms and transmission and therapeutic in clinical settings,,"Author2827_1, Author2827_2",New England Journal of Medicine,2019-12-28,bioRxiv,10.1000/sample.2827,,https://example.com/paper_2827,2019.0,12.0,74,10,False,,,True
cord-002829,Analysis of COVID-19 and vaccination and epidemiology in clinical settings,This study examines COVID-19 with 338 word abstract...,"Author2829_1, Author2829_2",New England Journal of Medicine,2022-02-05,Medline,10.1000/sample.2829,PMC1002829,https://example.com/paper_2829,2022.0,2.0,74,10,True,54.0,8.0,True
cord-002830,Analysis of pandemic and antibody and therapeutic and clinical in clinical settings,This study examines pandemic with 272 word abstract...,Author2830_1,Cell,2021-12-26,ArXiv,10.1000/sample.2830,,,2021.0,12.0,83,12,True,54.0,8.0,True
cord-002831,Analysis of epidemiology and transmission and immunity and SARS-CoV-2 in clinical settings,This study examines epidemiology with 289 word abstract...,"Author2831_1, Author2831_2",Clinical Infectious Diseases,2020-06-14,medRxiv,10.1000/sample.2831,PMC1002831,https://example.com/paper_2831,2020.0,6.0,90,12,True,58.0,8.0,True
cord-002836,Analysis of public health and diagnosis and epidemiology in clinical settings,This study examines public health with 457 word abstract...,"Author2836_1, Author2836_2",New England Journal of Medicine,2021-01-05,Medline,10.1000/sample.2836,,,2021.0,1.0,77,11,True,59.0,9.0,True
cord-002838,Analysis of symptoms and therapeutic and diagnosis in clinical settings,This study examines symptoms with 280 word abstract...,"Author2838_1, Author2838_2",,2020-04-04,PMC,,,https://example.com/paper_2838,2020.0,4.0,71,10,True,54.0,8.0,False
cord-002839,Analysis of symptoms and transmission and public health and respiratory in clinical settings,This study examines symptoms with 484 word abstract...,Author2839_1,Clinical Infectious Diseases,2022-03-20,medRxiv,10.1000/sample.2839,,https://example.com/paper_2839,2022.0,3.0,92,13,True,54.0,8.0,True
cord-002842,Analysis of therapeutic and antiviral and coronavirus and immunity in clinical settings,This study examines therapeutic with 269 word abstract...,"Author2842_1, Author2842_2",Journal of Medical Virology,2019-12-09,bioRxiv,10.1000/sample.2842,PMC1002842,https://example.com/paper_2842,2019.0,12.0,87,12,True,57.0,8.0,True
cord-002844,Analysis of respiratory and COVID-19 and antibody in clinical settings,This study examines respiratory with 224 word abstract...,"Author2844_1, Author2844_2",PLoS ONE,2020-11-29,ArXiv,,,https://example.com/paper_2844,2020.0,11.0,70,10,True,57.0,8.0,True
cord-002847,Analysis of COVID-19 and pneumonia and coronavirus in clinical settings,This study examines COVID-19 with 433 word abstract...,"Author2847_1, Author2847_2",Lancet,2021-07-02,bioRxiv,10.1000/sample.2847,PMC1002847,https://example.com/paper_2847,2021.0,7.0,71,10,True,54.0,8.0,True
cord-002849,Analysis of immunity and COVID-19 and vaccination in clinical settings,,"Author2849_1, Author2849_2",Journal of Virology,2020-01-12,ArXiv,10.1000/sample.2849,PMC1002849,https://example.com/paper_2849,2020.0,1.0,70,10,False,,,True
cord-002850,Analysis of immunity and pandemic and epidemiology and public health in clinical settings,This study examines immunity with 444 word abstract...,"Author2850_1, Author2850_2",Cell,2021-04-28,WHO,10.1000/sample.2850,,https://example.com/paper_2850,2021.0,4.0,89,13,True,54.0,8.0,True
cord-002851,Analysis of vaccination and coronavirus and treatment in clinical settings,,"Author2851_1, Author2851_2",Science Translational Medicine,2020-05-10,Medline,10.1000/sample.2851,PMC1002851,https://example.com/paper_2851,2020.0,5.0,74,10,False,,,True
cord-002853,Analysis of outbreak and vaccination and lockdown in clinical settings,This study examines outbreak with 468 word abstract...,"Author2853_1, Author2853_2",JAMA,2021-10-22,WHO,,,https://example.com/paper_2853,2021.0,10.0,70,10,True,54.0,8.0,True
cord-002854,Analysis of vaccination and transmission and SARS-CoV-2 and clinical in clinical settings,This study examines vaccination with 481 word abstract...,"Author2854_1, Author2854_2",Cell,2020-12-04,WHO,10.1000/sample.2854,PMC1002854,,2020.0,12.0,89,12,True,57.0,8.0,True
cord-002855,Analysis of antibody and symptoms and immunity and diagnosis in clinical settings,This study examines antibody with 140 word abstract...,"Author2855_1, Author2855_2",Clinical Infectious Diseases,2021-05-25,ArXiv,10.1000/sample.2855,PMC1002855,https://example.com/paper_2855,2021.0,5.0,81,12,True,54.0,8.0,True
cord-002856,Analysis of vaccination and outbreak and respiratory in clinical settings,This study examines vaccination with 241 word abstract...,Author2856_1,Journal of Virology,2021-07-14,bioRxiv,10.1000/sample.2856,PMC1002856,https://example.com/paper_2856,2021.0,7.0,73,10,True,57.0,8.0,True
cord-002858,Analysis of antibody and transmission and pandemic and pneumonia in clinical settings,This study examines antibody with 254 word abstract...,"Author2858_1, Author2858_2",Journal of Virology,2020-04-24,ArXiv,10.1000/sample.2858,PMC1002858,https://example.com/paper_2858,2020.0,4.0,85,12,True,54.0,8.0,True
cord-002859,Analysis of pandemic and diagnosis and treatment in clinical settings,This study examines pandemic with 326 word abstract...,"Author2859_1, Author2859_2",Clinical Infectious Diseases,2021-07-29,ArXiv,10.1000/sample.2859,PMC1002859,,2021.0,7.0,69,10,True,54.0,8.0,True
cord-002862,Analysis of public health and transmission and SARS-CoV-2 and antibody in clinical settings,This study examines public health with 380 word abstract...,"Author2862_1, Author2862_2",BMJ,2019-12-19,Medline,10.1000/sample.2862,PMC1002862,,2019.0,12.0,91,13,True,59.0,9.0,True
cord-002864,Analysis of antiviral and outbreak and epidemiology in clinical settings,This study examines antiviral with 274 word abstract...,"Author2864_1, Author2864_2",Virology,2020-12-24,medRxiv,10.1000/sample.2864,PMC1002864,https://example.com/paper_2864,2020.0,12.0,72,10,True,55.0,8.0,True
cord-002865,Analysis of SARS-CoV-2 and clinical and respiratory and epidemiology in clinical settings,This study examines SARS-CoV-2 with 471 word abstract...,"Author2865_1, Author2865_2",Journal of Medical Virology,2020-09-26,ArXiv,10.1000/sample.2865,,,2020.0,9.0,89,12,True,56.0,8.0,True
cord-002867,Analysis of pneumonia and outbreak and diagnosis in clinical settings,This study examines pneumonia with 184 word abstract...,"Author2867_1, Author2867_2",Journal of Virology,2020-05-23,Medline,10.1000/sample.2867,PMC1002867,https://example.com/paper_2867,2020.0,5.0,69,10,True,55.0,8.0,True
cord-002868,Analysis of lockdown and antiviral and vaccination in clinical settings,This study examines lockdown with 358 word abstract...,"Author2868_1, Author2868_2",BMJ,2020-08-22,medRxiv,10.1000/sample.2868,PMC1002868,https://example.com/paper_2868,2020.0,8.0,71,10,True,54.0,8.0,True
cord-002869,Analysis of lockdown and SARS-CoV-2 and transmission in clinical settings,This study examines lockdown with 173 word abstract...,"Author2869_1, Author2869_2",Nature Medicine,2021-03-26,medRxiv,10.1000/sample.2869,PMC1002869,https://example.com/paper_2869,2021.0,3.0,73,10,True,54.0,8.0,True
cord-002870,Analysis of treatment and clinical and transmission in clinical settings,This study examines treatment with 153 word abstract...,Author2870_1,Nature Medicine,2020-10-04,WHO,,PMC1002870,https://example.com/paper_2870,2020.0,10.0,72,10,True,55.0,8.0,True
cord-002873,Analysis of public health and symptoms and pandemic and antibody in clinical settings,This study examines public health with 227 word abstract...,"Author2873_1, Author2873_2",JAMA,2020-05-02,medRxiv,,PMC1002873,https://example.com/paper_2873,2020.0,5.0,85,13,True,59.0,9.0,True
cord-002875,Analysis of vaccination and respiratory and antiviral and treatment in clinical settings,This study examines vaccination with 473 word abstract...,"Author2875_1, Author2875_2",,2020-12-07,PMC,10.1000/sample.2875,,,2020.0,12.0,88,12,True,57.0,8.0,False
cord-002876,Analysis of lockdown and therapeutic and pneumonia in clinical settings,This study examines lockdown with 113 word abstract...,Author2876_1,Science,2022-07-24,WHO,10.1000/sample.2876,PMC1002876,https://example.com/paper_2876,2022.0,7.0,71,10,True,54.0,8.0,True
cord-002878,Analysis of SARS-CoV-2 and transmission and respiratory in clinical settings,This study examines SARS-CoV-2 with 385 word abstract...,"Author2878_1, Author2878_2",New England Journal of Medicine,2020-08-03,bioRxiv,10.1000/sample.2878,PMC1002878,https://example.com/paper_2878,2020.0,8.0,76,10,True,56.0,8.0,True
cord-002879,Analysis of lockdown and SARS-CoV-2 and pandemic and antibody in clinical settings,This study examines lockdown with 120 word abstract...,Author2879_1,Science Translational Medicine,2021-03-06,ArXiv,,,https://example.com/paper_2879,2021.0,3.0,82,12,True,54.0,8.0,True
cord-002881,Analysis of treatment and pandemic and antibody and symptoms in clinical settings,This study examines treatment with 106 word abstract...,"Author2881_1, Author2881_2",Cell,2021-10-15,WHO,,,https://example.com/paper_2881,2021.0,10.0,81,12,True,55.0,8.0,True
cord-002882,Analysis of respiratory and diagnosis and lockdown in clinical settings,This study examines respiratory with 425 word abstract...,"Author2882_1, Author2882_2",PLoS ONE,2020-11-13,ArXiv,10.1000/sample.2882,PMC1002882,,2020.0,11.0,71,10,True,57.0,8.0,True
cord-002883,Analysis of coronavirus and outbreak and diagnosis and symptoms in clinical settings,This study examines coronavirus with 267 word abstract...,"Author2883_1, Author2883_2",Journal of Virology,2020-10-28,Medline,10.1000/sample.2883,PMC1002883,https://example.com/paper_2883,2020.0,10.0,84,12,True,57.0,8.0,True
cord-002885,Analysis of immunity and coronavirus and lockdown in clinical settings,This study examines immunity with 177 word abstract...,"Author2885_1, Author2885_2",PLoS ONE,2021-10-21,bioRxiv,10.1000/sample.2885,PMC1002885,https://example.com/paper_2885,2021.0,10.0,70,10,True,54.0,8.0,True
cord-002888,Analysis of immunity and respiratory and COVID-19 and pandemic in clinical settings,,Author2888_1,JAMA,2021-10-17,bioRxiv,10.1000/sample.2888,PMC1002888,https://example.com/paper_2888,2021.0,10.0,83,12,False,,,True
cord-002893,Analysis of SARS-CoV-2 and public health and lockdown and COVID-19 in clinical settings,This study examines SARS-CoV-2 with 409 word abstract...,"Author2893_1, Author2893_2",Virology,,Medline,,,https://example.com/paper_2893,,,87,13,True,56.0,8.0,True
cord-002894,Analysis of clinical and public health and symptoms and antiviral in clinical settings,This study examines clinical with 285 word abstract...,Author2894_1,Clinical Infectious Diseases,2020-06-07,WHO,10.1000/sample.2894,PMC1002894,https://example.com/paper_2894,2020.0,6.0,86,13,True,54.0,8.0,True
cord-002895,Analysis of symptoms and SARS-CoV-2 and clinical and COVID-19 in clinical settings,This study examines symptoms with 378 word abstract...,"Author2895_1, Author2895_2",Clinical Infectious Diseases,2020-12-01,PMC,10.1000/sample.2895,PMC1002895,https://example.com/paper_2895,2020.0,12.0,82,12,True,54.0,8.0,True
cord-002896,Analysis of pneumonia and diagnosis and SARS-CoV-2 in clinical settings,This study examines pneumonia with 362 word abstract...,"Author2896_1, Author2896_2",Journal of Medical Virology,2020-12-09,PMC,10.1000/sample.2896,,https://example.com/paper_2896,2020.0,12.0,71,10,True,55.0,8.0,True
cord-002897,Analysis of epidemiology and outbreak and symptoms in clinical settings,,"Author2897_1, Author2897_2",Lancet,2021-05-22,ArXiv,10.1000/sample.2897,PMC1002897,https://example.com/paper_2897,2021.0,5.0,71,10,False,,,True
cord-002899,Analysis of epidemiology and therapeutic and public health in clinical settings,This study examines epidemiology with 454 word abstract...,"Author2899_1, Author2899_2",Journal of Virology,2020-07-12,bioRxiv,10.1000/sample.2899,PMC1002899,https://example.com/paper_2899,2020.0,7.0,79,11,True,58.0,8.0,True
cord-002901,Analysis of immunity and vaccination and therapeutic and transmission in clinical settings,This study examines immunity with 159 word abstract...,"Author2901_1, Author2901_2",Nature Medicine,2020-10-11,medRxiv,10.1000/sample.2901,PMC1002901,https://example.com/paper_2901,2020.0,10.0,90,12,True,54.0,8.0,True
cord-002902,Analysis of diagnosis and epidemiology and respiratory in clinical settings,This study examines diagnosis with 364 word abstract...,"Author2902_1, Author2902_2",New England Journal of Medicine,2021-07-19,Medline,10.1000/sample.2902,PMC1002902,https://example.com/paper_2902,2021.0,7.0,75,10,True,55.0,8.0,True
cord-002903,Analysis of clinical and respiratory and diagnosis and treatment in clinical settings,This study examines clinical with 134 word abstract...,Author2903_1,Journal of Virology,2020-08-13,WHO,10.1000/sample.2903,PMC1002903,https://example.com/paper_2903,2020.0,8.0,85,12,True,54.0,8.0,True
cord-002904,Analysis of transmission and pandemic and diagnosis and outbreak in clinical settings,This study examines transmission with 168 word abstract...,Author2904_1,Science Translational Medicine,2020-07-26,PMC,10.1000/sample.2904,,,2020.0,7.0,85,12,True,58.0,8.0,True
cord-002906,Analysis of therapeutic and symptoms in clinical settings,This study examines therapeutic with 204 word abstract...,"Author2906_1, Author2906_2",Journal of Virology,2022-09-25,bioRxiv,10.1000/sample.2906,PMC1002906,https://example.com/paper_2906,2022.0,9.0,57,8,True,57.0,8.0,True
cord-002910,Analysis of clinical and coronavirus and immunity in clinical settings,This study examines clinical with 186 word abstract...,"Author2910_1, Author2910_2",Clinical Infectious Diseases,2021-10-02,medRxiv,10.1000/sample.2910,PMC1002910,https://example.com/paper_2910,2021.0,10.0,70,10,True,54.0,8.0,True
cord-002911,Analysis of lockdown and public health and treatment and vaccination in clinical settings,This study examines lockdown with 245 word abstract...,Author2911_1,JAMA,2021-07-22,PMC,10.1000/sample.2911,,https://example.com/paper_2911,2021.0,7.0,89,13,True,54.0,8.0,True
cord-002912,Analysis of epidemiology and respiratory and pneumonia and treatment in clinical settings,This study examines epidemiology with 438 word abstract...,"Author2912_1, Author2912_2",Nature,2022-08-02,PMC,10.1000/sample.2912,,https://example.com/paper_2912,2022.0,8.0,89,12,True,58.0,8.0,True
cord-002914,Analysis of transmission and SARS-CoV-2 and respiratory in clinical settings,This study examines transmission with 387 word abstract...,"Author2914_1, Author2914_2",Science,2020-07-28,PMC,10.1000/sample.2914,PMC1002914,https://example.com/paper_2914,2020.0,7.0,76,10,True,58.0,8.0,True
cord-002916,Analysis of clinical and therapeutic and pandemic and COVID-19 in clinical settings,This study examines clinical with 447 word abstract...,Author2916_1,PLoS ONE,2021-11-11,ArXiv,10.1000/sample.2916,,https://example.com/paper_2916,2021.0,11.0,83,12,True,54.0,8.0,True
cord-002917,Analysis of transmission and vaccination and coronavirus and COVID-19 in clinical settings,This study examines transmission with 320 word abstract...,"Author2917_1, Author2917_2",Journal of Medical Virology,2020-07-26,ArXiv,10.1000/sample.2917,,https://example.com/paper_2917,2020.0,7.0,90,12,True,58.0,8.0,True
cord-002918,Analysis of coronavirus and antibody and pandemic in clinical settings,This study examines coronavirus with 116 word abstract...,"Author2918_1, Author2918_2",,2021-04-10,PMC,10.1000/sample.2918,,https://example.com/paper_2918,2021.0,4.0,70,10,True,57.0,8.0,False
cord-002919,Analysis of coronavirus and immunity and pneumonia in clinical settings,This study examines coronavirus with 121 word abstract...,"Author2919_1, Author2919_2",Journal of Medical Virology,2021-12-27,WHO,10.1000/sample.2919,,https://example.com/paper_2919,2021.0,12.0,71,10,True,57.0,8.0,True
cord-002920,Analysis of public health and epidemiology and clinical and outbreak in clinical settings,This study examines public health with 289 word abstract...,"Author2920_1, Author2920_2",Journal of Medical Virology,2021-09-20,Medline,10.1000/sample.2920,,,2021.0,9.0,89,13,True,59.0,9.0,True
cord-002921,Analysis of pandemic and immunity and pneumonia and transmission in clinical settings,This study examines pandemic with 205 word abstract...,"Author2921_1, Author2921_2",,2020-03-17,Medline,10.1000/sample.2921,,,2020.0,3.0,85,12,True,54.0,8.0,False
cord-002923,Analysis of public health and COVID-19 and outbreak in clinical settings,This study examines public health with 418 word abstract...,"Author2923_1, Author2923_2",BMJ,,ArXiv,10.1000/sample.2923,,https://example.com/paper_2923,,,72,11,True,59.0,9.0,True
cord-002925,Analysis of outbreak and therapeutic and transmission and pandemic in clinical settings,This study examines outbreak with 110 word abstract...,Author2925_1,,2021-06-13,WHO,10.1000/sample.2925,,https://example.com/paper_2925,2021.0,6.0,87,12,True,54.0,8.0,False
cord-002926,Analysis of SARS-CoV-2 and immunity and outbreak and symptoms in clinical settings,This study examines SARS-CoV-2 with 314 word abstract...,"Author2926_1, Author2926_2",Nature,2020-07-03,bioRxiv,10.1000/sample.2926,PMC1002926,https://example.com/paper_2926,2020.0,7.0,82,12,True,56.0,8.0,True
cord-002927,Analysis of antiviral and diagnosis and treatment and lockdown in clinical settings,This study examines antiviral with 494 word abstract...,"Author2927_1, Author2927_2",Journal of Medical Virology,2021-02-16,PMC,10.1000/sample.2927,PMC1002927,https://example.com/paper_2927,2021.0,2.0,83,12,True,55.0,8.0,True
cord-002929,Analysis of transmission and symptoms and therapeutic and coronavirus in clinical settings,This study examines transmission with 186 word abstract...,"Author2929_1, Author2929_2",Science,2020-08-28,bioRxiv,10.1000/sample.2929,,https://example.com/paper_2929,2020.0,8.0,90,12,True,58.0,8.0,True
cord-002931,Analysis of diagnosis and pandemic and epidemiology and treatment in clinical settings,This study examines diagnosis with 416 word abstract...,"Author2931_1, Author2931_2",Journal of Virology,2020-08-21,PMC,10.1000/sample.2931,PMC1002931,,2020.0,8.0,86,12,True,55.0,8.0,True
cord-002932,Analysis of antiviral and SARS-CoV-2 and treatment and therapeutic in clinical settings,This study examines antiviral with 441 word abstract...,"Author2932_1, Author2932_2",Nature,2022-12-10,Medline,,PMC1002932,https://example.com/paper_2932,2022.0,12.0,87,12,True,55.0,8.0,True
cord-002936,Analysis of public health and outbreak and antiviral and pneumonia in clinical settings,This study examines public health with 317 word abstract...,"Author2936_1, Author2936_2",Nature Medicine,2019-12-08,medRxiv,10.1000/sample.2936,,,2019.0,12.0,87,13,True,59.0,9.0,True
cord-002937,Analysis of clinical and coronavirus and epidemiology and public health in clinical settings,This study examines clinical with 313 word abstract...,"Author2937_1, Author2937_2",PLoS ONE,2020-12-27,bioRxiv,10.1000/sample.2937,PMC1002937,https://example.com/paper_2937,2020.0,12.0,92,13,True,54.0,8.0,True
cord-002938,Analysis of diagnosis and vaccination and treatment and COVID-19 in clinical settings,This study examines diagnosis with 204 word abstract...,Author2938_1,Cell,2020-07-04,ArXiv,10.1000/sample.2938,PMC1002938,https://example.com/paper_2938,2020.0,7.0,85,12,True,55.0,8.0,True
cord-002939,Analysis of outbreak and pandemic and diagnosis and antibody in clinical settings,This study examines outbreak with 246 word abstract...,"Author2939_1, Author2939_2",Emerging Infectious Diseases,2021-03-18,Medline,10.1000/sample.2939,PMC1002939,https://example.com/paper_2939,2021.0,3.0,81,12,True,54.0,8.0,True
cord-002940,Analysis of respiratory and symptoms and therapeutic and antibody in clinical settings,This study examines respiratory with 484 word abstract...,"Author2940_1, Author2940_2",Emerging Infectious Diseases,2020-02-08,PMC,10.1000/sample.2940,PMC1002940,https://example.com/paper_2940,2020.0,2.0,86,12,True,57.0,8.0,True
cord-002942,Analysis of diagnosis and respiratory and symptoms in clinical settings,This study examines diagnosis with 137 word abstract...,,Emerging Infectious Diseases,2020-04-07,medRxiv,10.1000/sample.2942,PMC1002942,,2020.0,4.0,71,10,True,55.0,8.0,True
cord-002943,Analysis of vaccination and clinical and immunity and public health in clinical settings,This study examines vaccination with 250 word abstract...,"Author2943_1, Author2943_2",PLoS ONE,2021-04-09,WHO,10.1000/sample.2943,PMC1002943,https://example.com/paper_2943,2021.0,4.0,88,13,True,57.0,8.0,True
cord-002945,Analysis of antibody and lockdown and transmission and clinical in clinical settings,This study examines antibody with 297 word abstract...,"Author2945_1, Author2945_2",Cell,2021-06-10,medRxiv,10.1000/sample.2945,PMC1002945,https://example.com/paper_2945,2021.0,6.0,84,12,True,54.0,8.0,True
cord-002946,Analysis of public health and SARS-CoV-2 and COVID-19 and antibody in clinical settings,This study examines public health with 249 word abstract...,"Author2946_1, Author2946_2",Journal of Virology,2021-01-28,ArXiv,10.1000/sample.2946,PMC1002946,https://example.com/paper_2946,2021.0,1.0,87,13,True,59.0,9.0,True
cord-002947,Analysis of COVID-19 and therapeutic and immunity and symptoms in clinical settings,This study examines COVID-19 with 343 word abstract...,"Author2947_1, Author2947_2",New England Journal of Medicine,2020-11-02,medRxiv,,PMC1002947,https://example.com/paper_2947,2020.0,11.0,83,12,True,54.0,8.0,True
cord-002948,Analysis of pneumonia and vaccination and symptoms in clinical settings,,"Author2948_1, Author2948_2",Science,2020-08-15,bioRxiv,10.1000/sample.2948,,,2020.0,8.0,71,10,False,,,True
cord-002951,Analysis of SARS-CoV-2 and antibody and antiviral and pneumonia in clinical settings,This study examines SARS-CoV-2 with 429 word abstract...,"Author2951_1, Author2951_2",Nature,2021-04-20,PMC,10.1000/sample.2951,PMC1002951,https://example.com/paper_2951,2021.0,4.0,84,12,True,56.0,8.0,True
cord-002952,Analysis of clinical and lockdown and antiviral in clinical settings,This study examines clinical with 237 word abstract...,"Author2952_1, Author2952_2",Journal of Virology,2020-06-11,medRxiv,10.1000/sample.2952,PMC1002952,,2020.0,6.0,68,10,True,54.0,8.0,True
cord-002953,Analysis of epidemiology and outbreak and transmission in clinical settings,This study examines epidemiology with 112 word abstract...,Author2953_1,Science,2019-12-30,Medline,10.1000/sample.2953,,,2019.0,12.0,75,10,True,58.0,8.0,True
cord-002956,Analysis of treatment and clinical and coronavirus and COVID-19 in clinical settings,This study examines treatment with 489 word abstract...,Author2956_1,Nature Medicine,2021-06-26,Medline,10.1000/sample.2956,PMC1002956,https://example.com/paper_2956,2021.0,6.0,84,12,True,55.0,8.0,True
cord-002957,Analysis of vaccination and pneumonia and coronavirus and treatment in clinical settings,This study examines vaccination with 475 word abstract...,"Author2957_1, Author2957_2",BMJ,2019-12-14,ArXiv,10.1000/sample.2957,PMC1002957,,2019.0,12.0,88,12,True,57.0,8.0,True
cord-002958,Analysis of transmission and antibody and pneumonia and immunity in clinical settings,This study examines transmission with 385 word abstract...,"Author2958_1, Author2958_2",PLoS ONE,2022-12-31,medRxiv,,,,2022.0,12.0,85,12,True,58.0,8.0,True
cord-002959,Analysis of lockdown and therapeutic and COVID-19 in clinical settings,This study examines lockdown with 186 word abstract...,"Author2959_1, Author2959_2",Science Translational Medicine,2019-12-07,medRxiv,10.1000/sample.2959,PMC1002959,https://example.com/paper_2959,2019.0,12.0,70,10,True,54.0,8.0,True
cord-002961,Analysis of COVID-19 and lockdown and pneumonia and respiratory in clinical settings,This study examines COVID-19 with 155 word abstract...,Author2961_1,Lancet,2019-12-09,Medline,10.1000/sample.2961,PMC1002961,https://example.com/paper_2961,2019.0,12.0,84,12,True,54.0,8.0,True
cord-002962,Analysis of treatment and SARS-CoV-2 and pandemic and antibody in clinical settings,This study examines treatment with 382 word abstract...,"Author2962_1, Author2962_2",Cell,2021-02-09,ArXiv,10.1000/sample.2962,PMC1002962,https://example.com/paper_2962,2021.0,2.0,83,12,True,55.0,8.0,True
cord-002964,Analysis of pneumonia and public health and coronavirus and epidemiology in clinical settings,,"Author2964_1, Author2964_2",Nature Medicine,2021-10-01,Medline,10.1000/sample.2964,,https://example.com/paper_2964,2021.0,10.0,93,13,False,,,True
cord-002965,Analysis of respiratory and treatment and immunity and coronavirus in clinical settings,This study examines respiratory with 299 word abstract...,Author2965_1,Nature,2020-02-09,PMC,10.1000/sample.2965,PMC1002965,https://example.com/paper_2965,2020.0,2.0,87,12,True,57.0,8.0,True
cord-002966,Analysis of vaccination and lockdown and clinical in clinical settings,This study examines vaccination with 416 word abstract...,"Author2966_1, Author2966_2",Clinical Infectious Diseases,2021-08-28,ArXiv,10.1000/sample.2966,PMC1002966,https://example.com/paper_2966,2021.0,8.0,70,10,True,57.0,8.0,True
cord-002967,Analysis of coronavirus and immunity and transmission in clinical settings,This study examines coronavirus with 296 word abstract...,"Author2967_1, Author2967_2",PLoS ONE,2020-02-18,medRxiv,10.1000/sample.2967,,https://example.com/paper_2967,2020.0,2.0,74,10,True,57.0,8.0,True
cord-002968,Analysis of transmission and treatment and public health and respiratory in clinical settings,This study examines transmission with 170 word abstract...,"Author2968_1, Author2968_2",JAMA,2019-12-04,PMC,10.1000/sample.2968,PMC1002968,https://example.com/paper_2968,2019.0,12.0,93,13,True,58.0,8.0,True
cord-002969,Analysis of pneumonia and vaccination and transmission in clinical settings,This study examines pneumonia with 173 word abstract...,"Author2969_1, Author2969_2",Cell,2021-07-10,ArXiv,10.1000/sample.2969,PMC1002969,https://example.com/paper_2969,2021.0,7.0,75,10,True,55.0,8.0,True
cord-002972,Analysis of coronavirus and epidemiology and respiratory and immunity in clinical settings,This study examines coronavirus with 336 word abstract...,Author2972_1,Lancet,2019-12-07,Medline,10.1000/sample.2972,PMC1002972,https://example.com/paper_2972,2019.0,12.0,90,12,True,57.0,8.0,True
cord-002973,Analysis of diagnosis and public health in clinical settings,This study examines diagnosis with 266 word abstract...,"Author2973_1, Author2973_2",Science,2020-08-12,PMC,10.1000/sample.2973,PMC1002973,https://example.com/paper_2973,2020.0,8.0,60,9,True,55.0,8.0,True
cord-002974,Analysis of coronavirus and immunity and antiviral and transmission in clinical settings,This study examines coronavirus with 475 word abstract...,Author2974_1,BMJ,2019-12-02,bioRxiv,10.1000/sample.2974,PMC1002974,https://example.com/paper_2974,2019.0,12.0,88,12,True,57.0,8.0,True
cord-002975,Analysis of respiratory and public health and outbreak and coronavirus in clinical settings,This study examines respiratory with 392 word abstract...,"Author2975_1, Author2975_2",Clinical Infectious Diseases,2020-04-13,medRxiv,10.1000/sample.2975,,https://example.com/paper_2975,2020.0,4.0,91,13,True,57.0,8.0,True
cord-002976,Analysis of public health and respiratory and antiviral in clinical settings,This study examines public health with 449 word abstract...,"Author2976_1, Author2976_2",Emerging Infectious Diseases,2020-09-09,WHO,10.1000/sample.2976,PMC1002976,https://example.com/paper_2976,2020.0,9.0,76,11,True,59.0,9.0,True
cord-002977,Analysis of pneumonia and SARS-CoV-2 and immunity and transmission in clinical settings,This study examines pneumonia with 281 word abstract...,"Author2977_1, Author2977_2",Science Translational Medicine,2020-01-22,ArXiv,10.1000/sample.2977,PMC1002977,https://example.com/paper_2977,2020.0,1.0,87,12,True,55.0,8.0,True
cord-002978,Analysis of clinical and COVID-19 and outbreak in clinical settings,This study examines clinical with 417 word abstract...,"Author2978_1, Author2978_2",,,medRxiv,,PMC1002978,,,,67,10,True,54.0,8.0,False
cord-002979,Analysis of clinical and transmission and public health and SARS-CoV-2 in clinical settings,This study examines clinical with 440 word abstract...,"Author2979_1, Author2979_2",Journal of Virology,2021-11-09,Medline,10.1000/sample.2979,PMC1002979,https://example.com/paper_2979,2021.0,11.0,91,13,True,54.0,8.0,True
cord-002980,Analysis of therapeutic and transmission and vaccination in clinical settings,This study examines therapeutic with 138 word abstract...,"Author2980_1, Author2980_2",Cell,,WHO,10.1000/sample.2980,PMC1002980,https://example.com/paper_2980,,,77,10,True,57.0,8.0,True
cord-002982,Analysis of diagnosis and antiviral and clinical in clinical settings,This study examines diagnosis with 425 word abstract...,"Author2982_1, Author2982_2",PLoS ONE,,ArXiv,10.1000/sample.2982,PMC1002982,https://example.com/paper_2982,,,69,10,True,55.0,8.0,True
cord-002983,Analysis of respiratory and public health and diagnosis and clinical in clinical settings,This study examines respiratory with 106 word abstract...,Author2983_1,,2020-08-22,ArXiv,10.1000/sample.2983,,https://example.com/paper_2983,2020.0,8.0,89,13,True,57.0,8.0,False
cord-002985,Analysis of transmission and symptoms and vaccination and lockdown in clinical settings,This study examines transmission with 333 word abstract...,"Author2985_1, Author2985_2",New England Journal of Medicine,2021-12-12,WHO,10.1000/sample.2985,PMC1002985,https://example.com/paper_2985,2021.0,12.0,87,12,True,58.0,8.0,True
cord-002986,Analysis of pandemic and symptoms and outbreak and treatment in clinical settings,This study examines pandemic with 189 word abstract...,"Author2986_1, Author2986_2",Journal of Virology,2020-07-10,medRxiv,10.1000/sample.2986,,,2020.0,7.0,81,12,True,54.0,8.0,True
cord-002988,Analysis of pandemic and antibody and antiviral and vaccination in clinical settings,This study examines pandemic with 222 word abstract...,"Author2988_1, Author2988_2",Lancet,2019-12-20,medRxiv,,,https://example.com/paper_2988,2019.0,12.0,84,12,True,54.0,8.0,True
cord-002989,Analysis of antibody and treatment and coronavirus in clinical settings,This study examines antibody with 444 word abstract...,"Author2989_1, Author2989_2",JAMA,2019-12-03,medRxiv,10.1000/sample.2989,,https://example.com/paper_2989,2019.0,12.0,71,10,True,54.0,8.0,True
cord-002990,Analysis of transmission and vaccination and coronavirus and public health in clinical settings,This study examines transmission with 160 word abstract...,"Author2990_1, Author2990_2",Science,,bioRxiv,10.1000/sample.2990,,,,,95,13,True,58.0,8.0,True
cord-002991,Analysis of transmission and therapeutic and outbreak in clinical settings,This study examines transmission with 365 word abstract...,"Author2991_1, Author2991_2",Nature Medicine,2021-04-07,bioRxiv,10.1000/sample.2991,PMC1002991,https://example.com/paper_2991,2021.0,4.0,74,10,True,58.0,8.0,True
cord-002994,Analysis of outbreak and SARS-CoV-2 and lockdown in clinical settings,This study examines outbreak with 141 word abstract...,"Author2994_1, Author2994_2",Journal of Virology,2021-06-30,medRxiv,10.1000/sample.2994,PMC1002994,https://example.com/paper_2994,2021.0,6.0,69,10,True,54.0,8.0,True
cord-002995,Analysis of lockdown and antiviral and outbreak and respiratory in clinical settings,This study examines lockdown with 209 word abstract...,Author2995_1,New England Journal of Medicine,2020-12-08,WHO,10.1000/sample.2995,,https://example.com/paper_2995,2020.0,12.0,84,12,True,54.0,8.0,True
cord-002996,Analysis of clinical and antibody and COVID-19 in clinical settings,This study examines clinical with 413 word abstract...,"Author2996_1, Author2996_2",Clinical Infectious Diseases,2020-09-25,Medline,10.1000/sample.2996,PMC1002996,https://example.com/paper_2996,2020.0,9.0,67,10,True,54.0,8.0,True
cord-002999,Analysis of clinical and treatment and SARS-CoV-2 and pneumonia in clinical settings,This study examines clinical with 400 word abstract...,"Author2999_1, Author2999_2",Virology,2020-04-19,bioRxiv,10.1000/sample.2999,PMC1002999,https://example.com/paper_2999,2020.0,4.0,84,12,True,54.0,8.0,True
cord-003000,Analysis of transmission and vaccination and pandemic in clinical settings,This study examines transmission with 212 word abstract...,"Author3000_1, Author3000_2",Science Translational Medicine,2021-07-19,Medline,10.1000/sample.3000,,https://example.com/paper_3000,2021.0,7.0,74,10,True,58.0,8.0,True
cord-003003,Analysis of pneumonia and public health and clinical and vaccination in clinical settings,This study examines pneumonia with 312 word abstract...,"Author3003_1, Author3003_2",New England Journal of Medicine,2019-12-17,ArXiv,10.1000/sample.3003,,https://example.com/paper_3003,2019.0,12.0,89,13,True,55.0,8.0,True
cord-003004,Analysis of antibody and vaccination and antiviral in clinical settings,This study examines antibody with 242 word abstract...,"Author3004_1, Author3004_2",Science Translational Medicine,2020-03-20,Medline,10.1000/sample.3004,PMC1003004,https://example.com/paper_3004,2020.0,3.0,71,10,True,54.0,8.0,True
cord-003006,Analysis of transmission and lockdown and respiratory in clinical settings,This study examines transmission with 435 word abstract...,"Author3006_1, Author3006_2",Cell,2020-07-08,PMC,,PMC1003006,,2020.0,7.0,74,10,True,58.0,8.0,True
cord-003010,Analysis of treatment and COVID-19 and pandemic and SARS-CoV-2 in clinical settings,This study examines treatment with 269 word abstract...,"Author3010_1, Author3010_2",PLoS ONE,2021-09-03,bioRxiv,10.1000/sample.3010,PMC1003010,https://example.com/paper_3010,2021.0,9.0,83,12,True,55.0,8.0,True
cord-003011,Analysis of vaccination and coronavirus and epidemiology in clinical settings,This study examines vaccination with 477 word abstract...,Author3011_1,,2020-06-22,PMC,,PMC1003011,https://example.com/paper_3011,2020.0,6.0,77,10,True,57.0,8.0,False
cord-003015,Analysis of pandemic and epidemiology and coronavirus in clinical settings,This study examines pandemic with 113 word abstract...,"Author3015_1, Author3015_2",BMJ,2021-05-10,PMC,10.1000/sample.3015,PMC1003015,https://example.com/paper_3015,2021.0,5.0,74,10,True,54.0,8.0,True
cord-003016,Analysis of symptoms and COVID-19 and lockdown in clinical settings,This study examines symptoms with 333 word abstract...,"Author3016_1, Author3016_2",,2021-07-21,bioRxiv,10.1000/sample.3016,PMC1003016,https://example.com/paper_3016,2021.0,7.0,67,10,True,54.0,8.0,False
cord-003020,Analysis of pandemic and respiratory and diagnosis and SARS-CoV-2 in clinical settings,This study examines pandemic with 285 word abstract...,"Author3020_1, Author3020_2",Virology,2021-08-10,PMC,10.1000/sample.3020,PMC1003020,https://example.com/paper_3020,2021.0,8.0,86,12,True,54.0,8.0,True
cord-003021,Analysis of clinical and antibody and lockdown in clinical settings,This study examines clinical with 149 word abstract...,"Author3021_1, Author3021_2",Emerging Infectious Diseases,2020-10-04,bioRxiv,10.1000/sample.3021,PMC1003021,https://example.com/paper_3021,2020.0,10.0,67,10,True,54.0,8.0,True
cord-003022,Analysis of vaccination and pneumonia and antibody and public health in clinical settings,This study examines vaccination with 147 word abstract...,"Author3022_1, Author3022_2",Science Translational Medicine,2020-08-18,ArXiv,10.1000/sample.3022,PMC1003022,https://example.com/paper_3022,2020.0,8.0,89,13,True,57.0,8.0,True
cord-003023,Analysis of symptoms and treatment and diagnosis in clinical settings,This study examines symptoms with 373 word abstract...,"Author3023_1, Author3023_2",BMJ,,PMC,10.1000/sample.3023,,,,,69,10,True,54.0,8.0,True
cord-003025,Analysis of symptoms and therapeutic in clinical settings,This study examines symptoms with 268 word abstract...,"Author3025_1, Author3025_2",Cell,2020-07-26,Medline,10.1000/sample.3025,PMC1003025,https://example.com/paper_3025,2020.0,7.0,57,8,True,54.0,8.0,True
cord-003028,Analysis of SARS-CoV-2 and antibody in clinical settings,This study examines SARS-CoV-2 with 361 word abstract...,"Author3028_1, Author3028_2",BMJ,2020-11-19,Medline,10.1000/sample.3028,,https://example.com/paper_3028,2020.0,11.0,56,8,True,56.0,8.0,True
cord-003029,Analysis of symptoms and SARS-CoV-2 and antiviral and antibody in clinical settings,This study examines symptoms with 357 word abstract...,"Author3029_1, Author3029_2",Science,2020-07-31,bioRxiv,10.1000/sample.3029,PMC1003029,https://example.com/paper_3029,2020.0,7.0,83,12,True,54.0,8.0,True
cord-003030,Analysis of SARS-CoV-2 and respiratory and outbreak in clinical settings,This study examines SARS-CoV-2 with 165 word abstract...,"Author3030_1, Author3030_2",Science,2020-04-14,bioRxiv,10.1000/sample.3030,PMC1003030,https://example.com/paper_3030,2020.0,4.0,72,10,True,56.0,8.0,True
cord-003031,Analysis of SARS-CoV-2 and epidemiology in clinical settings,This study examines SARS-CoV-2 with 496 word abstract...,"Author3031_1, Author3031_2",Clinical Infectious Diseases,2022-01-07,PMC,10.1000/sample.3031,,https://example.com/paper_3031,2022.0,1.0,60,8,True,56.0,8.0,True
cord-003034,Analysis of SARS-CoV-2 and clinical and therapeutic and pneumonia in clinical settings,This study examines SARS-CoV-2 with 104 word abstract...,Author3034_1,Journal of Virology,2020-07-18,PMC,10.1000/sample.3034,PMC1003034,,2020.0,7.0,86,12,True,56.0,8.0,True
cord-003036,Analysis of public health and respiratory and treatment in clinical settings,This study examines public health with 159 word abstract...,Author3036_1,PLoS ONE,2021-04-20,bioRxiv,10.1000/sample.3036,PMC1003036,https://example.com/paper_3036,2021.0,4.0,76,11,True,59.0,9.0,True
cord-003037,Analysis of antibody and antiviral and public health in clinical settings,This study examines antibody with 141 word abstract...,"Author3037_1, Author3037_2",JAMA,2020-07-22,WHO,10.1000/sample.3037,,,2020.0,7.0,73,11,True,54.0,8.0,True
cord-003038,Analysis of transmission and diagnosis and outbreak and vaccination in clinical settings,This study examines transmission with 236 word abstract...,"Author3038_1, Author3038_2",Nature Medicine,2020-07-20,PMC,10.1000/sample.3038,,https://example.com/paper_3038,2020.0,7.0,88,12,True,58.0,8.0,True
cord-003040,Analysis of vaccination and SARS-CoV-2 and transmission in clinical settings,This study examines vaccination with 139 word abstract...,"Author3040_1, Author3040_2",Science,2022-08-06,ArXiv,10.1000/sample.3040,PMC1003040,https://example.com/paper_3040,2022.0,8.0,76,10,True,57.0,8.0,True
cord-003041,Analysis of vaccination and treatment and outbreak in clinical settings,This study examines vaccination with 321 word abstract...,"Author3041_1, Author3041_2",Nature Medicine,2019-12-02,bioRxiv,10.1000/sample.3041,PMC1003041,https://example.com/paper_3041,2019.0,12.0,71,10,True,57.0,8.0,True
cord-003045,Analysis of COVID-19 and pandemic and symptoms in clinical settings,This study examines COVID-19 with 250 word abstract...,"Author3045_1, Author3045_2",Nature,2020-03-27,Medline,,,https://example.com/paper_3045,2020.0,3.0,67,10,True,54.0,8.0,True
cord-003047,Analysis of symptoms and outbreak and antiviral in clinical settings,This study examines symptoms with 202 word abstract...,"Author3047_1, Author3047_2",Lancet,,WHO,10.1000/sample.3047,PMC1003047,https://example.com/paper_3047,,,68,10,True,54.0,8.0,True
cord-003048,Analysis of lockdown and coronavirus and respiratory in clinical settings,This study examines lockdown with 127 word abstract...,"Author3048_1, Author3048_2",Clinical Infectious Diseases,2019-12-23,medRxiv,,PMC1003048,https://example.com/paper_3048,2019.0,12.0,73,10,True,54.0,8.0,True
cord-003049,Analysis of pneumonia and antiviral and vaccination and public health in clinical settings,This study examines pneumonia with 220 word abstract...,"Author3049_1, Author3049_2",Emerging Infectious Diseases,2020-04-27,ArXiv,10.1000/sample.3049,PMC1003049,https://example.com/paper_3049,2020.0,4.0,90,13,True,55.0,8.0,True
cord-003050,Analysis of SARS-CoV-2 and clinical and symptoms and outbreak in clinical settings,This study examines SARS-CoV-2 with 179 word abstract...,Author3050_1,JAMA,2020-10-21,medRxiv,10.1000/sample.3050,PMC1003050,https://example.com/paper_3050,2020.0,10.0,82,12,True,56.0,8.0,True
cord-003051,Analysis of antiviral and SARS-CoV-2 and clinical in clinical settings,This study examines antiviral with 307 word abstract...,"Author3051_1, Author3051_2",Nature,2020-08-11,Medline,10.1000/sample.3051,PMC1003051,https://example.com/paper_3051,2020.0,8.0,70,10,True,55.0,8.0,True
cord-003053,Analysis of epidemiology and immunity in clinical settings,This study examines epidemiology with 292 word abstract...,"Author3053_1, Author3053_2",Science,2021-04-11,Medline,10.1000/sample.3053,PMC1003053,https://example.com/paper_3053,2021.0,4.0,58,8,True,58.0,8.0,True
cord-003054,Analysis of lockdown and coronavirus in clinical settings,This study examines lockdown with 277 word abstract...,"Author3054_1, Author3054_2",Journal of Virology,2020-05-07,PMC,10.1000/sample.3054,,https://example.com/paper_3054,2020.0,5.0,57,8,True,54.0,8.0,True
cord-003056,Analysis of antibody and SARS-CoV-2 and therapeutic in clinical settings,This study examines antibody with 249 word abstract...,"Author3056_1, Author3056_2",,2020-08-20,ArXiv,10.1000/sample.3056,PMC1003056,https://example.com/paper_3056,2020.0,8.0,72,10,True,54.0,8.0,False
cord-003057,Analysis of COVID-19 and SARS-CoV-2 and pneumonia in clinical settings,This study examines COVID-19 with 285 word abstract...,Author3057_1,Lancet,2020-07-24,Medline,10.1000/sample.3057,,https://example.com/paper_3057,2020.0,7.0,70,10,True,54.0,8.0,True
cord-003058,Analysis of pandemic and immunity and COVID-19 and antibody in clinical settings,This study examines pandemic with 295 word abstract...,"Author3058_1, Author3058_2",Science Translational Medicine,2020-08-01,WHO,10.1000/sample.3058,PMC1003058,https://example.com/paper_3058,2020.0,8.0,80,12,True,54.0,8.0,True
cord-003059,Analysis of immunity and clinical and respiratory and lockdown in clinical settings,This study examines immunity with 265 word abstract...,"Author3059_1, Author3059_2",Journal of Virology,2021-07-16,Medline,10.1000/sample.3059,PMC1003059,https://example.com/paper_3059,2021.0,7.0,83,12,True,54.0,8.0,True
cord-003060,Analysis of treatment and clinical and epidemiology and antibody in clinical settings,This study examines treatment with 218 word abstract...,"Author3060_1, Author3060_2",BMJ,2020-12-02,Medline,10.1000/sample.3060,PMC1003060,https://example.com/paper_3060,2020.0,12.0,85,12,True,55.0,8.0,True
cord-003062,Analysis of symptoms and treatment and lockdown in clinical settings,This study examines symptoms with 166 word abstract...,"Author3062_1, Author3062_2",JAMA,2019-12-13,medRxiv,10.1000/sample.3062,PMC1003062,,2019.0,12.0,68,10,True,54.0,8.0,True
cord-003064,Analysis of lockdown and vaccination and epidemiology in clinical settings,This study examines lockdown with 133 word abstract...,"Author3064_1, Author3064_2",BMJ,2020-03-12,medRxiv,10.1000/sample.3064,PMC1003064,https://example.com/paper_3064,2020.0,3.0,74,10,True,54.0,8.0,True
cord-003067,Analysis of pneumonia and symptoms in clinical settings,This study examines pneumonia with 404 word abstract...,"Author3067_1, Author3067_2",Lancet,2020-09-22,WHO,10.1000/sample.3067,,,2020.0,9.0,55,8,True,55.0,8.0,True
cord-003068,Analysis of vaccination and public health and lockdown and transmission in clinical settings,This study examines vaccination with 428 word abstract...,"Author3068_1, Author3068_2",Virology,2021-08-02,ArXiv,10.1000/sample.3068,PMC1003068,https://example.com/paper_3068,2021.0,8.0,92,13,True,57.0,8.0,True
cord-003069,Analysis of treatment and clinical and coronavirus and antibody in clinical settings,This study examines treatment with 493 word abstract...,"Author3069_1, Author3069_2",Virology,2020-06-13,medRxiv,10.1000/sample.3069,PMC1003069,https://example.com/paper_3069,2020.0,6.0,84,12,True,55.0,8.0,True
cord-003070,Analysis of immunity and epidemiology and clinical and vaccination in clinical settings,This study examines immunity with 326 word abstract...,"Author3070_1, Author3070_2",Science,2021-03-17,bioRxiv,10.1000/sample.3070,PMC1003070,https://example.com/paper_3070,2021.0,3.0,87,12,True,54.0,8.0,True
cord-003073,Analysis of pneumonia and transmission and immunity and lockdown in clinical settings,This study examines pneumonia with 318 word abstract...,"Author3073_1, Author3073_2",Nature Medicine,2021-01-30,ArXiv,10.1000/sample.3073,PMC1003073,https://example.com/paper_3073,2021.0,1.0,85,12,True,55.0,8.0,True
cord-003074,Analysis of SARS-CoV-2 and immunity and therapeutic and epidemiology in clinical settings,This study examines SARS-CoV-2 with 202 word abstract...,"Author3074_1, Author3074_2",Virology,2021-10-06,ArXiv,10.1000/sample.3074,PMC1003074,,2021.0,10.0,89,12,True,56.0,8.0,True
cord-003075,Analysis of public health and treatment and clinical in clinical settings,This study examines public health with 377 word abstract...,"Author3075_1, Author3075_2",Science,2021-06-10,PMC,10.1000/sample.3075,,,2021.0,6.0,73,11,True,59.0,9.0,True
cord-003076,Analysis of lockdown and pandemic and vaccination in clinical settings,This study examines lockdown with 150 word abstract...,Author3076_1,,2021-05-15,PMC,,,https://example.com/paper_3076,2021.0,5.0,70,10,True,54.0,8.0,False
cord-003080,Analysis of public health and immunity and antiviral and COVID-19 in clinical settings,This study examines public health with 335 word abstract...,"Author3080_1, Author3080_2",Virology,2020-09-04,Medline,10.1000/sample.3080,PMC1003080,https://example.com/paper_3080,2020.0,9.0,86,13,True,59.0,9.0,True
cord-003081,Analysis of therapeutic and diagnosis and pneumonia and public health in clinical settings,This study examines therapeutic with 141 word abstract...,"Author3081_1, Author3081_2",JAMA,2020-07-08,PMC,,,https://example.com/paper_3081,2020.0,7.0,90,13,True,57.0,8.0,True
cord-003083,Analysis of respiratory and therapeutic and treatment in clinical settings,This study examines respiratory with 354 word abstract...,Author3083_1,Virology,2020-11-05,PMC,10.1000/sample.3083,PMC1003083,https://example.com/paper_3083,2020.0,11.0,74,10,True,57.0,8.0,True
cord-003084,Analysis of antibody and public health and transmission in clinical settings,This study examines antibody with 384 word abstract...,"Author3084_1, Author3084_2",Nature,2021-07-26,WHO,10.1000/sample.3084,PMC1003084,https://example.com/paper_3084,2021.0,7.0,76,11,True,54.0,8.0,True
cord-003087,Analysis of diagnosis and immunity and coronavirus in clinical settings,This study examines diagnosis with 293 word abstract...,"Author3087_1, Author3087_2",BMJ,2020-03-25,PMC,10.1000/sample.3087,PMC1003087,https://example.com/paper_3087,2020.0,3.0,71,10,True,55.0,8.0,True
cord-003089,Analysis of pandemic and immunity and antiviral and lockdown in clinical settings,This study examines pandemic with 228 word abstract...,"Author3089_1, Author3089_2",Journal of Medical Virology,,medRxiv,10.1000/sample.3089,PMC1003089,,,,81,12,True,54.0,8.0,True
cord-003091,Analysis of treatment and epidemiology and antibody in clinical settings,This study examines treatment with 354 word abstract...,"Author3091_1, Author3091_2",PLoS ONE,2020-04-21,ArXiv,10.1000/sample.3091,,https://example.com/paper_3091,2020.0,4.0,72,10,True,55.0,8.0,True
cord-003093,Analysis of public health and antiviral and vaccination and SARS-CoV-2 in clinical settings,This study examines public health with 492 word abstract...,"Author3093_1, Author3093_2",,2019-12-22,Medline,10.1000/sample.3093,PMC1003093,https://example.com/paper_3093,2019.0,12.0,91,13,True,59.0,9.0,False
cord-003094,Analysis of symptoms and antibody and diagnosis and pneumonia in clinical settings,This study examines symptoms with 308 word abstract...,"Author3094_1, Author3094_2",Science Translational Medicine,2020-09-28,bioRxiv,10.1000/sample.3094,PMC1003094,https://example.com/paper_3094,2020.0,9.0,82,12,True,54.0,8.0,True
cord-003097,Analysis of pneumonia and diagnosis and clinical and therapeutic in clinical settings,This study examines pneumonia with 288 word abstract...,,Journal of Virology,2021-02-15,medRxiv,,PMC1003097,,2021.0,2.0,85,12,True,55.0,8.0,True
cord-003098,Analysis of antibody and immunity and outbreak in clinical settings,This study examines antibody with 346 word abstract...,"Author3098_1, Author3098_2",Science Translational Medicine,2020-07-14,medRxiv,10.1000/sample.3098,,https://example.com/paper_3098,2020.0,7.0,67,10,True,54.0,8.0,True
cord-003099,Analysis of therapeutic and antibody and SARS-CoV-2 and coronavirus in clinical settings,This study examines therapeutic with 243 word abstract...,"Author3099_1, Author3099_2",Emerging Infectious Diseases,2021-07-09,ArXiv,10.1000/sample.3099,PMC1003099,https://example.com/paper_3099,2021.0,7.0,88,12,True,57.0,8.0,True
cord-003100,Analysis of pneumonia and coronavirus and symptoms and respiratory in clinical settings,This study examines pneumonia with 397 word abstract...,"Author3100_1, Author3100_2",BMJ,2020-01-11,ArXiv,10.1000/sample.3100,PMC1003100,https://example.com/paper_3100,2020.0,1.0,87,12,True,55.0,8.0,True
cord-003101,Analysis of outbreak and coronavirus and pandemic and respiratory in clinical settings,This study examines outbreak with 180 word abstract...,"Author3101_1, Author3101_2",Nature,2020-10-14,WHO,10.1000/sample.3101,PMC1003101,https://example.com/paper_3101,2020.0,10.0,86,12,True,54.0,8.0,True
cord-003103,Analysis of antiviral and lockdown and antibody in clinical settings,This study examines antiviral with 470 word abstract...,"Author3103_1, Author3103_2",Science Translational Medicine,2022-11-06,medRxiv,10.1000/sample.3103,PMC1003103,https://example.com/paper_3103,2022.0,11.0,68,10,True,55.0,8.0,True
cord-003105,Analysis of treatment and transmission and respiratory in clinical settings,This study examines treatment with 379 word abstract...,"Author3105_1, Author3105_2",Journal of Virology,2020-01-23,WHO,10.1000/sample.3105,PMC1003105,https://example.com/paper_3105,2020.0,1.0,75,10,True,55.0,8.0,True
cord-003106,Analysis of respiratory and therapeutic and immunity and antibody in clinical settings,This study examines respiratory with 382 word abstract...,"Author3106_1, Author3106_2",PLoS ONE,2020-02-14,Medline,10.1000/sample.3106,PMC1003106,https://example.com/paper_3106,2020.0,2.0,86,12,True,57.0,8.0,True
cord-003107,Analysis of antiviral and epidemiology and therapeutic in clinical settings,This study examines antiviral with 139 word abstract...,"Author3107_1, Author3107_2",Nature,2020-08-18,bioRxiv,10.1000/sample.3107,,,2020.0,8.0,75,10,True,55.0,8.0,True
cord-003109,Analysis of treatment and lockdown and symptoms and antibody in clinical settings,This study examines treatment with 255 word abstract...,"Author3109_1, Author3109_2",Emerging Infectious Diseases,2020-11-28,ArXiv,10.1000/sample.3109,PMC1003109,https://example.com/paper_3109,2020.0,11.0,81,12,True,55.0,8.0,True
cord-003110,Analysis of lockdown and COVID-19 and immunity and diagnosis in clinical settings,This study examines lockdown with 397 word abstract...,"Author3110_1, Author3110_2",Journal of Medical Virology,2019-12-18,bioRxiv,10.1000/sample.3110,PMC1003110,https://example.com/paper_3110,2019.0,12.0,81,12,True,54.0,8.0,True
cord-003112,Analysis of antiviral and respiratory and pandemic in clinical settings,This study examines antiviral with 148 word abstract...,Author3112_1,Cell,2020-07-24,bioRxiv,10.1000/sample.3112,PMC1003112,https://example.com/paper_3112,2020.0,7.0,71,10,True,55.0,8.0,True
cord-003113,Analysis of public health and coronavirus and pneumonia and immunity in clinical settings,This study examines public health with 475 word abstract...,"Author3113_1, Author3113_2",Cell,2020-04-21,PMC,10.1000/sample.3113,,,2020.0,4.0,89,13,True,59.0,9.0,True
cord-003114,Analysis of epidemiology and SARS-CoV-2 and pandemic and antiviral in clinical settings,This study examines epidemiology with 420 word abstract...,"Author3114_1, Author3114_2",Science Translational Medicine,2021-06-22,Medline,10.1000/sample.3114,PMC1003114,https://example.com/paper_3114,2021.0,6.0,87,12,True,58.0,8.0,True
cord-003115,Analysis of SARS-CoV-2 and COVID-19 and epidemiology and pandemic in clinical settings,This study examines SARS-CoV-2 with 155 word abstract...,"Author3115_1, Author3115_2",,2021-01-16,medRxiv,10.1000/sample.3115,PMC1003115,https://example.com/paper_3115,2021.0,1.0,86,12,True,56.0,8.0,False
cord-003117,Analysis of therapeutic and diagnosis and immunity and SARS-CoV-2 in clinical settings,This study examines therapeutic with 276 word abstract...,Author3117_1,Science Translational Medicine,2019-12-19,Medline,10.1000/sample.3117,,https://example.com/paper_3117,2019.0,12.0,86,12,True,57.0,8.0,True
cord-003118,Analysis of outbreak and symptoms and clinical in clinical settings,This study examines outbreak with 424 word abstract...,"Author3118_1, Author3118_2",,2022-11-02,ArXiv,10.1000/sample.3118,,https://example.com/paper_3118,2022.0,11.0,67,10,True,54.0,8.0,False
cord-003120,Analysis of transmission and COVID-19 and SARS-CoV-2 in clinical settings,This study examines transmission with 488 word abstract...,Author3120_1,Science,2021-01-11,bioRxiv,10.1000/sample.3120,PMC1003120,https://example.com/paper_3120,2021.0,1.0,73,10,True,58.0,8.0,True
cord-003122,Analysis of lockdown and respiratory and pandemic and therapeutic in clinical settings,This study examines lockdown with 257 word abstract...,Author3122_1,Science,2020-08-07,PMC,10.1000/sample.3122,PMC1003122,https://example.com/paper_3122,2020.0,8.0,86,12,True,54.0,8.0,True
cord-003123,Analysis of antibody and pneumonia and COVID-19 in clinical settings,This study examines antibody with 264 word abstract...,"Author3123_1, Author3123_2",Emerging Infectious Diseases,2020-12-19,medRxiv,10.1000/sample.3123,,https://example.com/paper_3123,2020.0,12.0,68,10,True,54.0,8.0,True
cord-003124,Analysis of pandemic and symptoms and COVID-19 and coronavirus in clinical settings,This study examines pandemic with 311 word abstract...,"Author3124_1, Author3124_2",Science,2020-09-21,medRxiv,10.1000/sample.3124,PMC1003124,https://example.com/paper_3124,2020.0,9.0,83,12,True,54.0,8.0,True
cord-003125,Analysis of therapeutic and epidemiology and antiviral and pandemic in clinical settings,This study examines therapeutic with 259 word abstract...,Author3125_1,New England Journal of Medicine,2020-03-14,ArXiv,10.1000/sample.3125,PMC1003125,https://example.com/paper_3125,2020.0,3.0,88,12,True,57.0,8.0,True
cord-003126,Analysis of therapeutic and antiviral and pandemic in clinical settings,This study examines therapeutic with 141 word abstract...,"Author3126_1, Author3126_2",,2020-10-21,Medline,10.1000/sample.3126,PMC1003126,,2020.0,10.0,71,10,True,57.0,8.0,False
cord-003127,Analysis of public health and symptoms and immunity in clinical settings,This study examines public health with 304 word abstract...,"Author3127_1, Author3127_2",Emerging Infectious Diseases,2021-12-20,WHO,10.1000/sample.3127,PMC1003127,https://example.com/paper_3127,2021.0,12.0,72,11,True,59.0,9.0,True
cord-003128,Analysis of respiratory and antiviral and epidemiology and lockdown in clinical settings,This study examines respiratory with 158 word abstract...,"Author3128_1, Author3128_2",BMJ,2021-09-03,Medline,,PMC1003128,https://example.com/paper_3128,2021.0,9.0,88,12,True,57.0,8.0,True
cord-003129,Analysis of therapeutic and public health and clinical and pandemic in clinical settings,This study examines therapeutic with 384 word abstract...,"Author3129_1, Author3129_2",,2022-09-09,bioRxiv,10.1000/sample.3129,,,2022.0,9.0,88,13,True,57.0,8.0,False
cord-003132,Analysis of pandemic and clinical and public health and respiratory in clinical settings,This study examines pandemic with 421 word abstract...,"Author3132_1, Author3132_2",Journal of Virology,2020-11-25,WHO,10.1000/sample.3132,PMC1003132,https://example.com/paper_3132,2020.0,11.0,88,13,True,54.0,8.0,True
cord-003135,Analysis of coronavirus and treatment and immunity and vaccination in clinical settings,This study examines coronavirus with 143 word abstract...,"Author3135_1, Author3135_2",Lancet,2020-01-12,WHO,10.1000/sample.3135,PMC1003135,https://example.com/paper_3135,2020.0,1.0,87,12,True,57.0,8.0,True
cord-003138,Analysis of antiviral and clinical and antibody and respiratory in clinical settings,This study examines antiviral with 412 word abstract...,"Author3138_1, Author3138_2",Nature Medicine,2020-06-26,bioRxiv,,PMC1003138,https://example.com/paper_3138,2020.0,6.0,84,12,True,55.0,8.0,True
cord-003139,Analysis of respiratory and immunity and symptoms in clinical settings,This study examines respiratory with 458 word abstract...,Author3139_1,Lancet,2020-02-02,WHO,10.1000/sample.3139,PMC1003139,https://example.com/paper_3139,2020.0,2.0,70,10,True,57.0,8.0,True
cord-003140,Analysis of antiviral and outbreak and SARS-CoV-2 in clinical settings,This study examines antiviral with 464 word abstract...,"Author3140_1, Author3140_2",Emerging Infectious Diseases,2020-03-09,bioRxiv,10.1000/sample.3140,PMC1003140,,2020.0,3.0,70,10,True,55.0,8.0,True
cord-003141,Analysis of pneumonia and vaccination and transmission and respiratory in clinical settings,This study examines pneumonia with 320 word abstract...,"Author3141_1, Author3141_2",BMJ,2021-02-17,Medline,10.1000/sample.3141,PMC1003141,https://example.com/paper_3141,2021.0,2.0,91,12,True,55.0,8.0,True
cord-003142,Analysis of pandemic and antibody and diagnosis in clinical settings,This study examines pandemic with 118 word abstract...,"Author3142_1, Author3142_2",Science,2021-03-27,WHO,10.1000/sample.3142,PMC1003142,https://example.com/paper_3142,2021.0,3.0,68,10,True,54.0,8.0,True
cord-003143,Analysis of epidemiology and treatment and public health in clinical settings,This study examines epidemiology with 289 word abstract...,"Author3143_1, Author3143_2",,2021-03-28,ArXiv,10.1000/sample.3143,PMC1003143,https://example.com/paper_3143,2021.0,3.0,77,11,True,58.0,8.0,False
cord-003144,Analysis of transmission and public health and clinical in clinical settings,,"Author3144_1, Author3144_2",Journal of Virology,2022-09-09,bioRxiv,10.1000/sample.3144,PMC1003144,https://example.com/paper_3144,2022.0,9.0,76,11,False,,,True
cord-003145,Analysis of pneumonia and lockdown and transmission in clinical settings,This study examines pneumonia with 166 word abstract...,"Author3145_1, Author3145_2",PLoS ONE,2020-06-17,WHO,10.1000/sample.3145,PMC1003145,https://example.com/paper_3145,2020.0,6.0,72,10,True,55.0,8.0,True
cord-003146,Analysis of transmission and diagnosis and outbreak and epidemiology in clinical settings,This study examines transmission with 220 word abstract...,"Author3146_1, Author3146_2",Journal of Virology,2021-07-04,ArXiv,10.1000/sample.3146,PMC1003146,,2021.0,7.0,89,12,True,58.0,8.0,True
cord-003149,Analysis of epidemiology and coronavirus and therapeutic in clinical settings,This study examines epidemiology with 217 word abstract...,"Author3149_1, Author3149_2",Science Translational Medicine,2021-06-02,WHO,10.1000/sample.3149,PMC1003149,,2021.0,6.0,77,10,True,58.0,8.0,True
cord-003150,Analysis of epidemiology and symptoms and transmission and antibody in clinical settings,This study examines epidemiology with 383 word abstract...,Author3150_1,PLoS ONE,2021-09-30,medRxiv,,PMC1003150,https://example.com/paper_3150,2021.0,9.0,88,12,True,58.0,8.0,True
cord-003151,Analysis of vaccination and coronavirus and pneumonia and antiviral in clinical settings,This study examines vaccination with 364 word abstract...,"Author3151_1, Author3151_2",Science,2021-10-22,bioRxiv,10.1000/sample.3151,,https://example.com/paper_3151,2021.0,10.0,88,12,True,57.0,8.0,True
cord-003152,Analysis of antiviral and SARS-CoV-2 and immunity in clinical settings,This study examines antiviral with 321 word abstract...,Author3152_1,Cell,2020-01-06,ArXiv,10.1000/sample.3152,,,2020.0,1.0,70,10,True,55.0,8.0,True
cord-003153,Analysis of coronavirus and pandemic and COVID-19 and respiratory in clinical settings,This study examines coronavirus with 476 word abstract...,"Author3153_1, Author3153_2",BMJ,2021-11-15,WHO,10.1000/sample.3153,PMC1003153,https://example.com/paper_3153,2021.0,11.0,86,12,True,57.0,8.0,True
cord-003154,Analysis of pandemic and treatment in clinical settings,This study examines pandemic with 278 word abstract...,Author3154_1,Science,2020-09-19,ArXiv,10.1000/sample.3154,PMC1003154,https://example.com/paper_3154,2020.0,9.0,55,8,True,54.0,8.0,True
cord-003156,Analysis of antiviral and vaccination and treatment in clinical settings,This study examines antiviral with 206 word abstract...,"Author3156_1, Author3156_2",Journal of Medical Virology,2021-01-20,PMC,10.1000/sample.3156,PMC1003156,https://example.com/paper_3156,2021.0,1.0,72,10,True,55.0,8.0,True
cord-003158,Analysis of respiratory and SARS-CoV-2 and vaccination and public health in clinical settings,This study examines respiratory with 426 word abstract...,"Author3158_1, Author3158_2",Science Translational Medicine,2020-08-28,WHO,10.1000/sample.3158,PMC1003158,https://example.com/paper_3158,2020.0,8.0,93,13,True,57.0,8.0,True
cord-003159,Analysis of coronavirus and pneumonia and therapeutic in clinical settings,This study examines coronavirus with 147 word abstract...,"Author3159_1, Author3159_2",,2020-12-16,Medline,10.1000/sample.3159,PMC1003159,https://example.com/paper_3159,2020.0,12.0,74,10,True,57.0,8.0,False
cord-003162,Analysis of coronavirus and vaccination and COVID-19 and symptoms in clinical settings,,Author3162_1,Emerging Infectious Diseases,2020-06-12,ArXiv,10.1000/sample.3162,,https://example.com/paper_3162,2020.0,6.0,86,12,False,,,True
cord-003165,Analysis of treatment and outbreak and clinical in clinical settings,This study examines treatment with 287 word abstract...,"Author3165_1, Author3165_2",Emerging Infectious Diseases,2020-12-26,bioRxiv,10.1000/sample.3165,PMC1003165,https://example.com/paper_3165,2020.0,12.0,68,10,True,55.0,8.0,True
cord-003166,Analysis of therapeutic and respiratory and pandemic and vaccination in clinical settings,This study examines therapeutic with 460 word abstract...,"Author3166_1, Author3166_2",Cell,2021-05-30,WHO,10.1000/sample.3166,PMC1003166,,2021.0,5.0,89,12,True,57.0,8.0,True
cord-003170,Analysis of public health and therapeutic and epidemiology and pneumonia in clinical settings,This study examines public health with 189 word abstract...,Author3170_1,Cell,2021-04-27,WHO,10.1000/sample.3170,PMC1003170,https://example.com/paper_3170,2021.0,4.0,93,13,True,59.0,9.0,True
cord-003171,Analysis of vaccination and lockdown and public health in clinical settings,This study examines vaccination with 191 word abstract...,"Author3171_1, Author3171_2",Emerging Infectious Diseases,2021-06-24,PMC,10.1000/sample.3171,PMC1003171,https://example.com/paper_3171,2021.0,6.0,75,11,True,57.0,8.0,True
cord-003172,Analysis of vaccination and respiratory and epidemiology in clinical settings,This study examines vaccination with 288 word abstract...,"Author3172_1, Author3172_2",JAMA,2020-11-30,Medline,10.1000/sample.3172,,https://example.com/paper_3172,2020.0,11.0,77,10,True,57.0,8.0,True
cord-003174,Analysis of treatment and SARS-CoV-2 in clinical settings,This study examines treatment with 304 word abstract...,"Author3174_1, Author3174_2",Journal of Virology,2021-06-23,Medline,10.1000/sample.3174,PMC1003174,https://example.com/paper_3174,2021.0,6.0,57,8,True,55.0,8.0,True
cord-003175,Analysis of outbreak and public health and pandemic and vaccination in clinical settings,This study examines outbreak with 497 word abstract...,"Author3175_1, Author3175_2",Journal of Virology,2021-08-07,WHO,,PMC1003175,https://example.com/paper_3175,2021.0,8.0,88,13,True,54.0,8.0,True
cord-003176,Analysis of antibody and outbreak and antiviral in clinical settings,This study examines antibody with 193 word abstract...,"Author3176_1, Author3176_2",Science,2020-01-02,PMC,,PMC1003176,https://example.com/paper_3176,2020.0,1.0,68,10,True,54.0,8.0,True
cord-003179,Analysis of respiratory and clinical in clinical settings,This study examines respiratory with 125 word abstract...,"Author3179_1, Author3179_2",PLoS ONE,2020-12-29,PMC,10.1000/sample.3179,,https://example.com/paper_3179,2020.0,12.0,57,8,True,57.0,8.0,True
cord-003180,Analysis of COVID-19 and symptoms and pneumonia in clinical settings,This study examines COVID-19 with 497 word abstract...,"Author3180_1, Author3180_2",BMJ,2020-12-26,ArXiv,10.1000/sample.3180,PMC1003180,https://example.com/paper_3180,2020.0,12.0,68,10,True,54.0,8.0,True
cord-003181,Analysis of immunity and clinical and treatment and respiratory in clinical settings,,"Author3181_1, Author3181_2",BMJ,2020-09-21,ArXiv,10.1000/sample.3181,PMC1003181,,2020.0,9.0,84,12,False,,,True
cord-003183,Analysis of antiviral and COVID-19 and immunity in clinical settings,This study examines antiviral with 427 word abstract...,"Author3183_1, Author3183_2",Cell,2021-12-05,medRxiv,10.1000/sample.3183,PMC1003183,https://example.com/paper_3183,2021.0,12.0,68,10,True,55.0,8.0,True
cord-003186,Analysis of vaccination and SARS-CoV-2 and public health in clinical settings,This study examines vaccination with 165 word abstract...,"Author3186_1, Author3186_2",Journal of Medical Virology,2021-10-15,ArXiv,10.1000/sample.3186,PMC1003186,https://example.com/paper_3186,2021.0,10.0,77,11,True,57.0,8.0,True
cord-003187,Analysis of antibody and vaccination and symptoms and clinical in clinical settings,This study examines antibody with 223 word abstract...,"Author3187_1, Author3187_2",,2021-09-24,WHO,10.1000/sample.3187,PMC1003187,https://example.com/paper_3187,2021.0,9.0,83,12,True,54.0,8.0,False
cord-003188,Analysis of treatment and immunity and antiviral and diagnosis in clinical settings,This study examines treatment with 245 word abstract...,"Author3188_1, Author3188_2",Virology,2021-07-12,medRxiv,10.1000/sample.3188,,https://example.com/paper_3188,2021.0,7.0,83,12,True,55.0,8.0,True
cord-003189,Analysis of pneumonia and treatment and SARS-CoV-2 in clinical settings,This study examines pneumonia with 423 word abstract...,"Author3189_1, Author3189_2",Emerging Infectious Diseases,,medRxiv,10.1000/sample.3189,PMC1003189,https://example.com/paper_3189,,,71,10,True,55.0,8.0,True
cord-003191,Analysis of diagnosis and outbreak and clinical in clinical settings,This study examines diagnosis with 495 word abstract...,"Author3191_1, Author3191_2",Nature Medicine,2021-06-25,medRxiv,10.1000/sample.3191,,https://example.com/paper_3191,2021.0,6.0,68,10,True,55.0,8.0,True
cord-003193,Analysis of symptoms and therapeutic and pneumonia in clinical settings,This study examines symptoms with 163 word abstract...,"Author3193_1, Author3193_2",New England Journal of Medicine,2020-03-27,medRxiv,10.1000/sample.3193,PMC1003193,https://example.com/paper_3193,2020.0,3.0,71,10,True,54.0,8.0,True
cord-003194,Analysis of outbreak and coronavirus and vaccination in clinical settings,This study examines outbreak with 107 word abstract...,"Author3194_1, Author3194_2",Lancet,,bioRxiv,10.1000/sample.3194,,,,,73,10,True,54.0,8.0,True
cord-003197,Analysis of outbreak and antibody and public health and lockdown in clinical settings,This study examines outbreak with 214 word abstract...,"Author3197_1, Author3197_2",BMJ,2020-12-07,bioRxiv,10.1000/sample.3197,,https://example.com/paper_3197,2020.0,12.0,85,13,True,54.0,8.0,True
cord-003199,Analysis of SARS-CoV-2 and diagnosis and clinical in clinical settings,This study examines SARS-CoV-2 with 369 word abstract...,"Author3199_1, Author3199_2",Nature,2020-04-24,ArXiv,10.1000/sample.3199,PMC1003199,,2020.0,4.0,70,10,True,56.0,8.0,True
cord-003200,Analysis of therapeutic and pneumonia and antibody in clinical settings,This study examines therapeutic with 423 word abstract...,"Author3200_1, Author3200_2",New England Journal of Medicine,2020-01-22,PMC,,PMC1003200,https://example.com/paper_3200,2020.0,1.0,71,10,True,57.0,8.0,True
cord-003201,Analysis of respiratory and COVID-19 and outbreak and SARS-CoV-2 in clinical settings,This study examines respiratory with 485 word abstract...,,Emerging Infectious Diseases,2021-03-26,Medline,10.1000/sample.3201,PMC1003201,https://example.com/paper_3201,2021.0,3.0,85,12,True,57.0,8.0,True
cord-003202,Analysis of SARS-CoV-2 and public health and coronavirus in clinical settings,This study examines SARS-CoV-2 with 196 word abstract...,"Author3202_1, Author3202_2",JAMA,2022-03-05,medRxiv,10.1000/sample.3202,PMC1003202,https://example.com/paper_3202,2022.0,3.0,77,11,True,56.0,8.0,True
cord-003203,Analysis of coronavirus and diagnosis and transmission and immunity in clinical settings,This study examines coronavirus with 300 word abstract...,"Author3203_1, Author3203_2",Nature Medicine,2022-05-28,ArXiv,10.1000/sample.3203,,,2022.0,5.0,88,12,True,57.0,8.0,True
cord-003204,Analysis of lockdown and pandemic and epidemiology in clinical settings,This study examines lockdown with 445 word abstract...,"Author3204_1, Author3204_2",BMJ,2021-04-26,PMC,10.1000/sample.3204,,,2021.0,4.0,71,10,True,54.0,8.0,True
cord-003205,Analysis of symptoms and coronavirus and clinical and antiviral in clinical settings,This study examines symptoms with 112 word abstract...,Author3205_1,Journal of Medical Virology,2020-12-28,ArXiv,10.1000/sample.3205,PMC1003205,https://example.com/paper_3205,2020.0,12.0,84,12,True,54.0,8.0,True
cord-003206,Analysis of diagnosis and epidemiology and antiviral in clinical settings,This study examines diagnosis with 381 word abstract...,"Author3206_1, Author3206_2",Clinical Infectious Diseases,2021-11-01,ArXiv,10.1000/sample.3206,PMC1003206,https://example.com/paper_3206,2021.0,11.0,73,10,True,55.0,8.0,True
cord-003207,Analysis of SARS-CoV-2 and pneumonia and COVID-19 in clinical settings,This study examines SARS-CoV-2 with 113 word abstract...,"Author3207_1, Author3207_2",Nature,2021-08-23,WHO,,PMC1003207,https://example.com/paper_3207,2021.0,8.0,70,10,True,56.0,8.0,True
cord-003209,Analysis of antibody and pandemic and therapeutic and lockdown in clinical settings,This study examines antibody with 167 word abstract...,"Author3209_1, Author3209_2",Virology,2020-05-09,ArXiv,10.1000/sample.3209,,https://example.com/paper_3209,2020.0,5.0,83,12,True,54.0,8.0,True
cord-003212,Analysis of COVID-19 and lockdown and pandemic and immunity in clinical settings,This study examines COVID-19 with 301 word abstract...,"Author3212_1, Author3212_2",BMJ,2019-12-15,ArXiv,10.1000/sample.3212,,https://example.com/paper_3212,2019.0,12.0,80,12,True,54.0,8.0,True
cord-003215,Analysis of vaccination and respiratory and antiviral and pneumonia in clinical settings,,"Author3215_1, Author3215_2",Science Translational Medicine,,ArXiv,10.1000/sample.3215,PMC1003215,https://example.com/paper_3215,,,88,12,False,,,True
cord-003216,Analysis of antiviral and epidemiology and transmission and immunity in clinical settings,This study examines antiviral with 221 word abstract...,"Author3216_1, Author3216_2",Science Translational Medicine,2019-12-16,bioRxiv,10.1000/sample.3216,PMC1003216,,2019.0,12.0,89,12,True,55.0,8.0,True
cord-003217,Analysis of respiratory and SARS-CoV-2 and pandemic in clinical settings,This study examines respiratory with 453 word abstract...,"Author3217_1, Author3217_2",Virology,2021-09-15,ArXiv,10.1000/sample.3217,PMC1003217,https://example.com/paper_3217,2021.0,9.0,72,10,True,57.0,8.0,True
cord-003218,Analysis of coronavirus and COVID-19 and public health and symptoms in clinical settings,This study examines coronavirus with 450 word abstract...,"Author3218_1, Author3218_2",New England Journal of Medicine,,Medline,10.1000/sample.3218,PMC1003218,https://example.com/paper_3218,,,88,13,True,57.0,8.0,True
cord-003220,Analysis of SARS-CoV-2 and respiratory and diagnosis in clinical settings,This study examines SARS-CoV-2 with 448 word abstract...,"Author3220_1, Author3220_2",JAMA,2022-10-20,WHO,10.1000/sample.3220,PMC1003220,https://example.com/paper_3220,2022.0,10.0,73,10,True,56.0,8.0,True
cord-003221,Analysis of transmission and antibody and diagnosis and symptoms in clinical settings,This study examines transmission with 195 word abstract...,"Author3221_1, Author3221_2",Lancet,2020-07-31,WHO,10.1000/sample.3221,PMC1003221,https://example.com/paper_3221,2020.0,7.0,85,12,True,58.0,8.0,True
cord-003222,Analysis of respiratory and immunity and antiviral and SARS-CoV-2 in clinical settings,This study examines respiratory with 299 word abstract...,"Author3222_1, Author3222_2",New England Journal of Medicine,2021-09-06,WHO,10.1000/sample.3222,PMC1003222,https://example.com/paper_3222,2021.0,9.0,86,12,True,57.0,8.0,True
cord-003223,Analysis of lockdown and transmission and therapeutic and SARS-CoV-2 in clinical settings,This study examines lockdown with 242 word abstract...,"Author3223_1, Author3223_2",Lancet,2022-10-13,PMC,10.1000/sample.3223,PMC1003223,https://example.com/paper_3223,2022.0,10.0,89,12,True,54.0,8.0,True
cord-003225,Analysis of lockdown and therapeutic and diagnosis and epidemiology in clinical settings,This study examines lockdown with 371 word abstract...,"Author3225_1, Author3225_2",New England Journal of Medicine,2020-06-03,WHO,10.1000/sample.3225,PMC1003225,https://example.com/paper_3225,2020.0,6.0,88,12,True,54.0,8.0,True
cord-003226,Analysis of antibody and public health and pandemic and coronavirus in clinical settings,This study examines antibody with 352 word abstract...,"Author3226_1, Author3226_2",,2021-10-23,ArXiv,10.1000/sample.3226,PMC1003226,https://example.com/paper_3226,2021.0,10.0,88,13,True,54.0,8.0,False
cord-003227,Analysis of diagnosis and vaccination and antibody and antiviral in clinical settings,This study examines diagnosis with 255 word abstract...,"Author3227_1, Author3227_2",Emerging Infectious Diseases,2020-11-08,medRxiv,10.1000/sample.3227,PMC1003227,https://example.com/paper_3227,2020.0,11.0,85,12,True,55.0,8.0,True
cord-003228,Analysis of coronavirus and antibody and epidemiology and COVID-19 in clinical settings,This study examines coronavirus with 376 word abstract...,"Author3228_1, Author3228_2",Nature,2020-01-10,WHO,10.1000/sample.3228,PMC1003228,,2020.0,1.0,87,12,True,57.0,8.0,True
cord-003229,Analysis of pneumonia and vaccination and treatment in clinical settings,This study examines pneumonia with 366 word abstract...,Author3229_1,Lancet,2020-01-28,medRxiv,10.1000/sample.3229,PMC1003229,https://example.com/paper_3229,2020.0,1.0,72,10,True,55.0,8.0,True
cord-003230,Analysis of COVID-19 and coronavirus and pandemic in clinical settings,This study examines COVID-19 with 197 word abstract...,"Author3230_1, Author3230_2",PLoS ONE,2019-12-24,medRxiv,10.1000/sample.3230,PMC1003230,https://example.com/paper_3230,2019.0,12.0,70,10,True,54.0,8.0,True
cord-003231,Analysis of epidemiology and respiratory and SARS-CoV-2 in clinical settings,,Author3231_1,,2020-01-08,ArXiv,10.1000/sample.3231,,https://example.com/paper_3231,2020.0,1.0,76,10,False,,,False
cord-003232,Analysis of antibody and COVID-19 and pneumonia in clinical settings,This study examines antibody with 315 word abstract...,Author3232_1,Clinical Infectious Diseases,2021-04-03,bioRxiv,10.1000/sample.3232,PMC1003232,,2021.0,4.0,68,10,True,54.0,8.0,True
cord-003235,Analysis of treatment and transmission and diagnosis and epidemiology in clinical settings,This study examines treatment with 222 word abstract...,"Author3235_1, Author3235_2",Nature Medicine,2020-04-26,bioRxiv,10.1000/sample.3235,PMC1003235,https://example.com/paper_3235,2020.0,4.0,90,12,True,55.0,8.0,True
cord-003237,Analysis of transmission and symptoms and public health and clinical in clinical settings,This study examines transmission with 349 word abstract...,"Author3237_1, Author3237_2",Virology,2020-09-15,bioRxiv,10.1000/sample.3237,PMC1003237,,2020.0,9.0,89,13,True,58.0,8.0,True
cord-003239,Analysis of clinical and diagnosis and outbreak and therapeutic in clinical settings,This study examines clinical with 348 word abstract...,"Author3239_1, Author3239_2",Nature Medicine,2020-08-23,Medline,10.1000/sample.3239,PMC1003239,,2020.0,8.0,84,12,True,54.0,8.0,True
cord-003240,Analysis of treatment and public health and diagnosis in clinical settings,This study examines treatment with 349 word abstract...,"Author3240_1, Author3240_2",Journal of Medical Virology,2021-11-12,ArXiv,10.1000/sample.3240,PMC1003240,https://example.com/paper_3240,2021.0,11.0,74,11,True,55.0,8.0,True
cord-003241,Analysis of lockdown and diagnosis and therapeutic in clinical settings,This study examines lockdown with 358 word abstract...,Author3241_1,Clinical Infectious Diseases,2021-02-18,ArXiv,10.1000/sample.3241,,,2021.0,2.0,71,10,True,54.0,8.0,True
cord-003250,Analysis of symptoms and lockdown and COVID-19 and therapeutic in clinical settings,This study examines symptoms with 155 word abstract...,"Author3250_1, Author3250_2",PLoS ONE,2022-12-19,Medline,10.1000/sample.3250,PMC1003250,,2022.0,12.0,83,12,True,54.0,8.0,True
cord-003252,Analysis of immunity and epidemiology and antiviral in clinical settings,This study examines immunity with 488 word abstract...,"Author3252_1, Author3252_2",PLoS ONE,2022-05-30,medRxiv,10.1000/sample.3252,,https://example.com/paper_3252,2022.0,5.0,72,10,True,54.0,8.0,True
cord-003255,Analysis of clinical and vaccination and immunity and antiviral in clinical settings,This study examines clinical with 341 word abstract...,"Author3255_1, Author3255_2",Emerging Infectious Diseases,2021-08-27,WHO,10.1000/sample.3255,PMC1003255,https://example.com/paper_3255,2021.0,8.0,84,12,True,54.0,8.0,True
cord-003256,Analysis of transmission and COVID-19 and clinical and SARS-CoV-2 in clinical settings,This study examines transmission with 171 word abstract...,"Author3256_1, Author3256_2",JAMA,2020-10-21,PMC,10.1000/sample.3256,,https://example.com/paper_3256,2020.0,10.0,86,12,True,58.0,8.0,True
cord-003257,Analysis of antibody and pneumonia and respiratory and public health in clinical settings,This study examines antibody with 214 word abstract...,"Author3257_1, Author3257_2",Virology,2021-10-18,WHO,10.1000/sample.3257,PMC1003257,https://example.com/paper_3257,2021.0,10.0,89,13,True,54.0,8.0,True
cord-003258,Analysis of clinical and antiviral and transmission and antibody in clinical settings,This study examines clinical with 278 word abstract...,"Author3258_1, Author3258_2",,2021-11-14,ArXiv,10.1000/sample.3258,,https://example.com/paper_3258,2021.0,11.0,85,12,True,54.0,8.0,False
cord-003259,Analysis of antibody and diagnosis and immunity and antiviral in clinical settings,This study examines antibody with 271 word abstract...,"Author3259_1, Author3259_2",Lancet,2021-04-08,ArXiv,10.1000/sample.3259,PMC1003259,,2021.0,4.0,82,12,True,54.0,8.0,True
cord-003261,Analysis of pneumonia and antiviral and antibody and treatment in clinical settings,This study examines pneumonia with 154 word abstract...,"Author3261_1, Author3261_2",Cell,,WHO,10.1000/sample.3261,,https://example.com/paper_3261,,,83,12,True,55.0,8.0,True
cord-003262,Analysis of diagnosis and vaccination and antiviral in clinical settings,This study examines diagnosis with 456 word abstract...,"Author3262_1, Author3262_2",BMJ,2020-04-02,WHO,10.1000/sample.3262,PMC1003262,https://example.com/paper_3262,2020.0,4.0,72,10,True,55.0,8.0,True
cord-003264,Analysis of COVID-19 and lockdown and pneumonia in clinical settings,This study examines COVID-19 with 424 word abstract...,"Author3264_1, Author3264_2",Lancet,2021-10-19,medRxiv,10.1000/sample.3264,PMC1003264,https://example.com/paper_3264,2021.0,10.0,68,10,True,54.0,8.0,True
cord-003265,Analysis of SARS-CoV-2 and epidemiology and vaccination and public health in clinical settings,This study examines SARS-CoV-2 with 181 word abstract...,"Author3265_1, Author3265_2",Science,2020-03-12,bioRxiv,10.1000/sample.3265,PMC1003265,https://example.com/paper_3265,2020.0,3.0,94,13,True,56.0,8.0,True
cord-003268,Analysis of pneumonia and lockdown and clinical in clinical settings,This study examines pneumonia with 305 word abstract...,"Author3268_1, Author3268_2",Clinical Infectious Diseases,2020-12-19,WHO,10.1000/sample.3268,PMC1003268,https://example.com/paper_3268,2020.0,12.0,68,10,True,55.0,8.0,True
cord-003269,Analysis of treatment and pandemic and coronavirus and clinical in clinical settings,This study examines treatment with 289 word abstract...,Author3269_1,Nature,2021-09-27,WHO,10.1000/sample.3269,PMC1003269,https://example.com/paper_3269,2021.0,9.0,84,12,True,55.0,8.0,True
cord-003270,Analysis of pandemic and lockdown and outbreak and transmission in clinical settings,This study examines pandemic with 264 word abstract...,"Author3270_1, Author3270_2",Lancet,2021-05-21,bioRxiv,10.1000/sample.3270,PMC1003270,https://example.com/paper_3270,2021.0,5.0,84,12,True,54.0,8.0,True
cord-003271,Analysis of transmission and antiviral and outbreak and antibody in clinical settings,This study examines transmission with 261 word abstract...,,Nature Medicine,2021-06-04,PMC,,,https://example.com/paper_3271,2021.0,6.0,85,12,True,58.0,8.0,True
cord-003272,Analysis of lockdown and SARS-CoV-2 and therapeutic and symptoms in clinical settings,This study examines lockdown with 280 word abstract...,"Author3272_1, Author3272_2",Nature Medicine,2021-02-14,WHO,10.1000/sample.3272,PMC1003272,https://example.com/paper_3272,2021.0,2.0,85,12,True,54.0,8.0,True
cord-003273,Analysis of symptoms and public health and diagnosis and COVID-19 in clinical settings,This study examines symptoms with 194 word abstract...,"Author3273_1, Author3273_2",JAMA,2020-11-08,ArXiv,10.1000/sample.3273,PMC1003273,https://example.com/paper_3273,2020.0,11.0,86,13,True,54.0,8.0,True
cord-003274,Analysis of outbreak and transmission and lockdown in clinical settings,This study examines outbreak with 388 word abstract...,"Author3274_1, Author3274_2",PLoS ONE,2021-05-12,WHO,10.1000/sample.3274,,,2021.0,5.0,71,10,True,54.0,8.0,True
cord-003275,Analysis of antiviral and COVID-19 and clinical and pneumonia in clinical settings,This study examines antiviral with 181 word abstract...,Author3275_1,New England Journal of Medicine,2019-12-04,bioRxiv,10.1000/sample.3275,PMC1003275,https://example.com/paper_3275,2019.0,12.0,82,12,True,55.0,8.0,True
cord-003276,Analysis of epidemiology and transmission and SARS-CoV-2 and coronavirus in clinical settings,This study examines epidemiology with 421 word abstract...,"Author3276_1, Author3276_2",Virology,2021-05-20,medRxiv,10.1000/sample.3276,PMC1003276,,2021.0,5.0,93,12,True,58.0,8.0,True
cord-003277,Analysis of public health and epidemiology and antibody and diagnosis in clinical settings,This study examines public health with 460 word abstract...,"Author3277_1, Author3277_2",,2019-12-18,ArXiv,10.1000/sample.3277,PMC1003277,https://example.com/paper_3277,2019.0,12.0,90,13,True,59.0,9.0,False
cord-003278,Analysis of vaccination and public health and diagnosis in clinical settings,This study examines vaccination with 115 word abstract...,"Author3278_1, Author3278_2",JAMA,2020-02-02,Medline,10.1000/sample.3278,,https://example.com/paper_3278,2020.0,2.0,76,11,True,57.0,8.0,True
cord-003280,Analysis of antiviral and antibody and diagnosis and symptoms in clinical settings,This study examines antiviral with 219 word abstract...,"Author3280_1, Author3280_2",Nature Medicine,2020-11-22,bioRxiv,10.1000/sample.3280,PMC1003280,https://example.com/paper_3280,2020.0,11.0,82,12,True,55.0,8.0,True
cord-003281,Analysis of transmission and antiviral and outbreak and immunity in clinical settings,This study examines transmission with 386 word abstract...,"Author3281_1, Author3281_2",JAMA,2020-07-17,bioRxiv,10.1000/sample.3281,,https://example.com/paper_3281,2020.0,7.0,85,12,True,58.0,8.0,True
cord-003284,Analysis of therapeutic and transmission in clinical settings,This study examines therapeutic with 252 word abstract...,"Author3284_1, Author3284_2",Cell,2020-03-03,bioRxiv,10.1000/sample.3284,PMC1003284,https://example.com/paper_3284,2020.0,3.0,61,8,True,57.0,8.0,True
cord-003285,Analysis of immunity and pneumonia and pandemic in clinical settings,This study examines immunity with 230 word abstract...,"Author3285_1, Author3285_2",,2020-07-25,bioRxiv,10.1000/sample.3285,PMC1003285,https://example.com/paper_3285,2020.0,7.0,68,10,True,54.0,8.0,False
cord-003286,Analysis of antibody and antiviral and outbreak in clinical settings,This study examines antibody with 184 word abstract...,"Author3286_1, Author3286_2",Journal of Medical Virology,2020-10-25,PMC,,PMC1003286,https://example.com/paper_3286,2020.0,10.0,68,10,True,54.0,8.0,True
cord-003287,Analysis of treatment and public health and transmission and respiratory in clinical settings,This study examines treatment with 332 word abstract...,"Author3287_1, Author3287_2",Nature,2019-12-20,Medline,10.1000/sample.3287,PMC1003287,https://example.com/paper_3287,2019.0,12.0,93,13,True,55.0,8.0,True
cord-003290,Analysis of antiviral and coronavirus and respiratory and vaccination in clinical settings,This study examines antiviral with 314 word abstract...,"Author3290_1, Author3290_2",Virology,,ArXiv,10.1000/sample.3290,PMC1003290,https://example.com/paper_3290,,,90,12,True,55.0,8.0,True
cord-003291,Analysis of vaccination and immunity in clinical settings,This study examines vaccination with 196 word abstract...,"Author3291_1, Author3291_2",Science Translational Medicine,2021-07-05,bioRxiv,10.1000/sample.3291,PMC1003291,,2021.0,7.0,57,8,True,57.0,8.0,True
cord-003292,Analysis of symptoms and epidemiology and SARS-CoV-2 in clinical settings,This study examines symptoms with 351 word abstract...,"Author3292_1, Author3292_2",,2020-03-07,ArXiv,,,https://example.com/paper_3292,2020.0,3.0,73,10,True,54.0,8.0,False
cord-003293,Analysis of diagnosis and antiviral and treatment in clinical settings,This study examines diagnosis with 366 word abstract...,"Author3293_1, Author3293_2",Lancet,2020-10-19,Medline,10.1000/sample.3293,,https://example.com/paper_3293,2020.0,10.0,70,10,True,55.0,8.0,True
cord-003294,Analysis of symptoms and antiviral and treatment in clinical settings,This study examines symptoms with 222 word abstract...,Author3294_1,Cell,2020-01-20,WHO,10.1000/sample.3294,PMC1003294,https://example.com/paper_3294,2020.0,1.0,69,10,True,54.0,8.0,True
cord-003295,Analysis of treatment and antibody and diagnosis and pneumonia in clinical settings,This study examines treatment with 334 word abstract...,"Author3295_1, Author3295_2",Emerging Infectious Diseases,2020-04-22,WHO,10.1000/sample.3295,PMC1003295,https://example.com/paper_3295,2020.0,4.0,83,12,True,55.0,8.0,True
cord-003297,Analysis of coronavirus and COVID-19 and lockdown in clinical settings,This study examines coronavirus with 225 word abstract...,"Author3297_1, Author3297_2",Journal of Virology,2020-03-07,bioRxiv,,PMC1003297,,2020.0,3.0,70,10,True,57.0,8.0,True
cord-003300,Analysis of symptoms and lockdown and COVID-19 and clinical in clinical settings,This study examines symptoms with 179 word abstract...,"Author3300_1, Author3300_2",Science Translational Medicine,2019-12-10,WHO,10.1000/sample.3300,PMC1003300,https://example.com/paper_3300,2019.0,12.0,80,12,True,54.0,8.0,True
cord-003301,Analysis of transmission and pandemic and COVID-19 and public health in clinical settings,This study examines transmission with 360 word abstract...,"Author3301_1, Author3301_2",Journal of Medical Virology,2021-02-18,ArXiv,10.1000/sample.3301,PMC1003301,https://example.com/paper_3301,2021.0,2.0,89,13,True,58.0,8.0,True
cord-003302,Analysis of symptoms and vaccination and respiratory and epidemiology in clinical settings,This study examines symptoms with 121 word abstract...,"Author3302_1, Author3302_2",Emerging Infectious Diseases,2022-04-01,ArXiv,,PMC1003302,https://example.com/paper_3302,2022.0,4.0,90,12,True,54.0,8.0,True
cord-003303,Analysis of respiratory and clinical and transmission in clinical settings,This study examines respiratory with 374 word abstract...,"Author3303_1, Author3303_2",,2021-10-30,PMC,10.1000/sample.3303,PMC1003303,https://example.com/paper_3303,2021.0,10.0,74,10,True,57.0,8.0,False
cord-003306,Analysis of pandemic and immunity and pneumonia and lockdown in clinical settings,This study examines pandemic with 466 word abstract...,Author3306_1,Nature,2021-08-26,WHO,10.1000/sample.3306,,,2021.0,8.0,81,12,True,54.0,8.0,True
cord-003307,Analysis of transmission and vaccination and respiratory in clinical settings,This study examines transmission with 401 word abstract...,"Author3307_1, Author3307_2",Emerging Infectious Diseases,2019-12-04,PMC,10.1000/sample.3307,PMC1003307,https://example.com/paper_3307,2019.0,12.0,77,10,True,58.0,8.0,True
cord-003309,Analysis of outbreak and diagnosis and treatment in clinical settings,This study examines outbreak with 151 word abstract...,"Author3309_1, Author3309_2",PLoS ONE,2020-11-09,Medline,10.1000/sample.3309,,https://example.com/paper_3309,2020.0,11.0,69,10,True,54.0,8.0,True
cord-003310,Analysis of lockdown and clinical and epidemiology and antiviral in clinical settings,This study examines lockdown with 326 word abstract...,"Author3310_1, Author3310_2",Science,2020-11-05,WHO,10.1000/sample.3310,PMC1003310,https://example.com/paper_3310,2020.0,11.0,85,12,True,54.0,8.0,True
cord-003311,Analysis of outbreak and diagnosis in clinical settings,This study examines outbreak with 275 word abstract...,"Author3311_1, Author3311_2",BMJ,2021-07-12,ArXiv,10.1000/sample.3311,,,2021.0,7.0,55,8,True,54.0,8.0,True
cord-003312,Analysis of public health and epidemiology and respiratory in clinical settings,,"Author3312_1, Author3312_2",,2020-09-23,PMC,10.1000/sample.3312,PMC1003312,https://example.com/paper_3312,2020.0,9.0,79,11,False,,,False
cord-003315,Analysis of lockdown and antiviral and epidemiology and public health in clinical settings,This study examines lockdown with 254 word abstract...,Author3315_1,Journal of Virology,2022-07-28,ArXiv,10.1000/sample.3315,PMC1003315,https://example.com/paper_3315,2022.0,7.0,90,13,True,54.0,8.0,True
cord-003316,Analysis of vaccination and public health in clinical settings,This study examines vaccination with 325 word abstract...,"Author3316_1, Author3316_2",Emerging Infectious Diseases,2022-01-25,bioRxiv,10.1000/sample.3316,PMC1003316,https://example.com/paper_3316,2022.0,1.0,62,9,True,57.0,8.0,True
cord-003318,Analysis of epidemiology and public health and treatment and COVID-19 in clinical settings,This study examines epidemiology with 382 word abstract...,"Author3318_1, Author3318_2",,2022-02-20,PMC,10.1000/sample.3318,PMC1003318,,2022.0,2.0,90,13,True,58.0,8.0,False
cord-003319,Analysis of symptoms and epidemiology and transmission and respiratory in clinical settings,,"Author3319_1, Author3319_2",Lancet,2022-02-11,ArXiv,10.1000/sample.3319,PMC1003319,https://example.com/paper_3319,2022.0,2.0,91,12,False,,,True
cord-003324,Analysis of epidemiology and therapeutic and coronavirus in clinical settings,This study examines epidemiology with 288 word abstract...,"Author3324_1, Author3324_2",BMJ,2021-02-22,Medline,10.1000/sample.3324,PMC1003324,https://example.com/paper_3324,2021.0,2.0,77,10,True,58.0,8.0,True
cord-003325,Analysis of respiratory and therapeutic and antibody and vaccination in clinical settings,This study examines respiratory with 308 word abstract...,"Author3325_1, Author3325_2",,2022-10-09,ArXiv,10.1000/sample.3325,,,2022.0,10.0,89,12,True,57.0,8.0,False
cord-003326,Analysis of coronavirus and vaccination and therapeutic and lockdown in clinical settings,This study examines coronavirus with 391 word abstract...,"Author3326_1, Author3326_2",Nature Medicine,2020-07-26,WHO,10.1000/sample.3326,,https://example.com/paper_3326,2020.0,7.0,89,12,True,57.0,8.0,True
cord-003327,Analysis of COVID-19 and transmission and clinical in clinical settings,This study examines COVID-19 with 426 word abstract...,"Author3327_1, Author3327_2",Cell,2021-05-31,medRxiv,10.1000/sample.3327,,https://example.com/paper_3327,2021.0,5.0,71,10,True,54.0,8.0,True
cord-003332,Analysis of SARS-CoV-2 and symptoms and epidemiology in clinical settings,This study examines SARS-CoV-2 with 136 word abstract...,"Author3332_1, Author3332_2",Journal of Medical Virology,2020-05-19,bioRxiv,10.1000/sample.3332,PMC1003332,https://example.com/paper_3332,2020.0,5.0,73,10,True,56.0,8.0,True
cord-003333,Analysis of respiratory and antiviral and public health in clinical settings,This study examines respiratory with 212 word abstract...,"Author3333_1, Author3333_2",Virology,2020-06-20,Medline,10.1000/sample.3333,PMC1003333,,2020.0,6.0,76,11,True,57.0,8.0,True
cord-003334,Analysis of antibody and symptoms and clinical and therapeutic in clinical settings,This study examines antibody with 326 word abstract...,"Author3334_1, Author3334_2",,2021-03-28,bioRxiv,10.1000/sample.3334,PMC1003334,,2021.0,3.0,83,12,True,54.0,8.0,False
cord-003335,Analysis of respiratory and transmission and symptoms and immunity in clinical settings,This study examines respiratory with 246 word abstract...,"Author3335_1, Author3335_2",BMJ,2019-12-11,ArXiv,10.1000/sample.3335,PMC1003335,https://example.com/paper_3335,2019.0,12.0,87,12,True,57.0,8.0,True
cord-003338,Analysis of lockdown and antiviral and therapeutic in clinical settings,This study examines lockdown with 191 word abstract...,"Author3338_1, Author3338_2",Clinical Infectious Diseases,2021-04-24,PMC,10.1000/sample.3338,PMC1003338,https://example.com/paper_3338,2021.0,4.0,71,10,True,54.0,8.0,True
cord-003339,Analysis of vaccination and immunity and lockdown in clinical settings,This study examines vaccination with 286 word abstract...,"Author3339_1, Author3339_2",,2022-07-07,Medline,10.1000/sample.3339,PMC1003339,https://example.com/paper_3339,2022.0,7.0,70,10,True,57.0,8.0,False
cord-003340,Analysis of diagnosis and outbreak and coronavirus in clinical settings,This study examines diagnosis with 328 word abstract...,"Author3340_1, Author3340_2",Journal of Virology,2019-12-24,ArXiv,10.1000/sample.3340,PMC1003340,,2019.0,12.0,71,10,True,55.0,8.0,True
cord-003343,Analysis of symptoms and clinical and immunity and lockdown in clinical settings,This study examines symptoms with 117 word abstract...,"Author3343_1, Author3343_2",Science,2020-12-13,medRxiv,10.1000/sample.3343,,https://example.com/paper_3343,2020.0,12.0,80,12,True,54.0,8.0,True
cord-003344,Analysis of therapeutic and outbreak and vaccination and treatment in clinical settings,This study examines therapeutic with 107 word abstract...,"Author3344_1, Author3344_2",Journal of Medical Virology,2020-05-07,PMC,10.1000/sample.3344,PMC1003344,https://example.com/paper_3344,2020.0,5.0,87,12,True,57.0,8.0,True
cord-003345,Analysis of transmission and respiratory and pneumonia and immunity in clinical settings,This study examines transmission with 115 word abstract...,"Author3345_1, Author3345_2",PLoS ONE,,WHO,10.1000/sample.3345,PMC1003345,https://example.com/paper_3345,,,88,12,True,58.0,8.0,True
cord-003346,Analysis of therapeutic and respiratory and immunity in clinical settings,This study examines therapeutic with 252 word abstract...,"Author3346_1, Author3346_2",Science Translational Medicine,2021-08-30,bioRxiv,10.1000/sample.3346,PMC1003346,https://example.com/paper_3346,2021.0,8.0,73,10,True,57.0,8.0,True
cord-003351,Analysis of clinical and pandemic and outbreak in clinical settings,This study examines clinical with 309 word abstract...,"Author3351_1, Author3351_2",Cell,2019-12-27,medRxiv,10.1000/sample.3351,,,2019.0,12.0,67,10,True,54.0,8.0,True
cord-003354,Analysis of antibody and epidemiology and coronavirus and pneumonia in clinical settings,,"Author3354_1, Author3354_2",Lancet,2020-02-21,ArXiv,10.1000/sample.3354,PMC1003354,https://example.com/paper_3354,2020.0,2.0,88,12,False,,,True
cord-003355,Analysis of clinical and immunity and antibody in clinical settings,This study examines clinical with 334 word abstract...,"Author3355_1, Author3355_2",Emerging Infectious Diseases,2019-12-14,WHO,10.1000/sample.3355,,https://example.com/paper_3355,2019.0,12.0,67,10,True,54.0,8.0,True
cord-003356,Analysis of antibody and outbreak and symptoms and treatment in clinical settings,This study examines antibody with 285 word abstract...,Author3356_1,Virology,2021-02-05,bioRxiv,10.1000/sample.3356,,https://example.com/paper_3356,2021.0,2.0,81,12,True,54.0,8.0,True
cord-003357,Analysis of pneumonia and diagnosis and lockdown in clinical settings,This study examines pneumonia with 130 word abstract...,"Author3357_1, Author3357_2",Science,2022-03-19,medRxiv,10.1000/sample.3357,PMC1003357,https://example.com/paper_3357,2022.0,3.0,69,10,True,55.0,8.0,True
cord-003358,Analysis of pneumonia and SARS-CoV-2 and transmission and immunity in clinical settings,This study examines pneumonia with 251 word abstract...,"Author3358_1, Author3358_2",New England Journal of Medicine,2021-03-25,bioRxiv,10.1000/sample.3358,PMC1003358,,2021.0,3.0,87,12,True,55.0,8.0,True
cord-003359,Analysis of symptoms and outbreak and SARS-CoV-2 in clinical settings,This study examines symptoms with 485 word abstract...,Author3359_1,Science Translational Medicine,2020-06-22,bioRxiv,10.1000/sample.3359,PMC1003359,https://example.com/paper_3359,2020.0,6.0,69,10,True,54.0,8.0,True
cord-003361,Analysis of therapeutic and clinical and pneumonia and immunity in clinical settings,This study examines therapeutic with 111 word abstract...,"Author3361_1, Author3361_2",,2021-11-09,ArXiv,10.1000/sample.3361,PMC1003361,https://example.com/paper_3361,2021.0,11.0,84,12,True,57.0,8.0,False
cord-003362,Analysis of coronavirus and outbreak and public health and pandemic in clinical settings,This study examines coronavirus with 451 word abstract...,Author3362_1,PLoS ONE,2020-04-25,PMC,10.1000/sample.3362,PMC1003362,https://example.com/paper_3362,2020.0,4.0,88,13,True,57.0,8.0,True
cord-003363,Analysis of diagnosis and treatment and immunity in clinical settings,This study examines diagnosis with 377 word abstract...,"Author3363_1, Author3363_2",Journal of Virology,2021-05-26,PMC,10.1000/sample.3363,PMC1003363,https://example.com/paper_3363,2021.0,5.0,69,10,True,55.0,8.0,True
cord-003364,Analysis of epidemiology and public health and vaccination and antiviral in clinical settings,This study examines epidemiology with 168 word abstract...,"Author3364_1, Author3364_2",Science,2020-07-07,medRxiv,10.1000/sample.3364,,https://example.com/paper_3364,2020.0,7.0,93,13,True,58.0,8.0,True
cord-003366,Analysis of therapeutic and antiviral and vaccination in clinical settings,This study examines therapeutic with 454 word abstract...,"Author3366_1, Author3366_2",Journal of Medical Virology,2019-12-20,ArXiv,10.1000/sample.3366,PMC1003366,https://example.com/paper_3366,2019.0,12.0,74,10,True,57.0,8.0,True
cord-003367,Analysis of transmission and lockdown and public health and outbreak in clinical settings,This study examines transmission with 237 word abstract...,"Author3367_1, Author3367_2",Nature,2020-05-09,Medline,,PMC1003367,https://example.com/paper_3367,2020.0,5.0,89,13,True,58.0,8.0,True
cord-003369,Analysis of outbreak and epidemiology and vaccination and antibody in clinical settings,,"Author3369_1, Author3369_2",New England Journal of Medicine,2020-03-09,bioRxiv,10.1000/sample.3369,PMC1003369,https://example.com/paper_3369,2020.0,3.0,87,12,False,,,True
cord-003372,Analysis of transmission and epidemiology and antibody in clinical settings,This study examines transmission with 270 word abstract...,"Author3372_1, Author3372_2",PLoS ONE,,WHO,10.1000/sample.3372,,https://example.com/paper_3372,,,75,10,True,58.0,8.0,True
cord-003374,Analysis of symptoms and antiviral and lockdown in clinical settings,This study examines symptoms with 111 word abstract...,"Author3374_1, Author3374_2",,2021-03-14,ArXiv,10.1000/sample.3374,,,2021.0,3.0,68,10,True,54.0,8.0,False
cord-003375,Analysis of antibody and treatment and vaccination in clinical settings,This study examines antibody with 204 word abstract...,"Author3375_1, Author3375_2",Clinical Infectious Diseases,2021-02-03,medRxiv,10.1000/sample.3375,PMC1003375,https://example.com/paper_3375,2021.0,2.0,71,10,True,54.0,8.0,True
cord-003376,Analysis of clinical and diagnosis and therapeutic and respiratory in clinical settings,This study examines clinical with 312 word abstract...,"Author3376_1, Author3376_2",JAMA,2022-10-25,WHO,10.1000/sample.3376,PMC1003376,https://example.com/paper_3376,2022.0,10.0,87,12,True,54.0,8.0,True
cord-003378,Analysis of antiviral and symptoms and public health in clinical settings,This study examines antiviral with 290 word abstract...,"Author3378_1, Author3378_2",Nature Medicine,2021-05-30,PMC,10.1000/sample.3378,PMC1003378,https://example.com/paper_3378,2021.0,5.0,73,11,True,55.0,8.0,True
cord-003380,Analysis of treatment and antibody and coronavirus and immunity in clinical settings,This study examines treatment with 303 word abstract...,"Author3380_1, Author3380_2",Emerging Infectious Diseases,2020-11-28,ArXiv,10.1000/sample.3380,PMC1003380,https://example.com/paper_3380,2020.0,11.0,84,12,True,55.0,8.0,True
cord-003381,Analysis of pandemic and COVID-19 and antiviral and public health in clinical settings,,"Author3381_1, Author3381_2",,2021-05-02,PMC,10.1000/sample.3381,PMC1003381,https://example.com/paper_3381,2021.0,5.0,86,13,False,,,False
cord-003382,Analysis of antiviral and coronavirus and vaccination in clinical settings,This study examines antiviral with 361 word abstract...,"Author3382_1, Author3382_2",Nature,2020-06-21,PMC,,PMC1003382,https://example.com/paper_3382,2020.0,6.0,74,10,True,55.0,8.0,True
cord-003383,Analysis of lockdown and therapeutic and treatment and pneumonia in clinical settings,This study examines lockdown with 164 word abstract...,"Author3383_1, Author3383_2",Journal of Medical Virology,2020-10-08,PMC,10.1000/sample.3383,,,2020.0,10.0,85,12,True,54.0,8.0,True
cord-003384,Analysis of symptoms and pandemic and diagnosis and immunity in clinical settings,This study examines symptoms with 305 word abstract...,"Author3384_1, Author3384_2",Cell,2019-12-01,bioRxiv,,PMC1003384,,2019.0,12.0,81,12,True,54.0,8.0,True
cord-003385,Analysis of COVID-19 and respiratory and outbreak in clinical settings,This study examines COVID-19 with 377 word abstract...,"Author3385_1, Author3385_2",,2021-10-10,PMC,10.1000/sample.3385,PMC1003385,https://example.com/paper_3385,2021.0,10.0,70,10,True,54.0,8.0,False
cord-003387,Analysis of coronavirus and antiviral and transmission in clinical settings,This study examines coronavirus with 366 word abstract...,"Author3387_1, Author3387_2",New England Journal of Medicine,2020-02-03,WHO,10.1000/sample.3387,PMC1003387,https://example.com/paper_3387,2020.0,2.0,75,10,True,57.0,8.0,True
cord-003389,Analysis of pneumonia and respiratory and epidemiology in clinical settings,This study examines pneumonia with 135 word abstract...,"Author3389_1, Author3389_2",Clinical Infectious Diseases,2022-11-10,medRxiv,10.1000/sample.3389,PMC1003389,https://example.com/paper_3389,2022.0,11.0,75,10,True,55.0,8.0,True
cord-003390,Analysis of treatment and SARS-CoV-2 and lockdown in clinical settings,,"Author3390_1, Author3390_2",Journal of Medical Virology,2020-09-20,ArXiv,10.1000/sample.3390,PMC1003390,,2020.0,9.0,70,10,False,,,True
cord-003391,Analysis of antibody and lockdown and symptoms in clinical settings,This study examines antibody with 407 word abstract...,"Author3391_1, Author3391_2",BMJ,2021-02-08,Medline,10.1000/sample.3391,PMC1003391,https://example.com/paper_3391,2021.0,2.0,67,10,True,54.0,8.0,True
cord-003394,Analysis of transmission and pneumonia and respiratory in clinical settings,This study examines transmission with 497 word abstract...,Author3394_1,Journal of Medical Virology,2020-01-06,WHO,10.1000/sample.3394,PMC1003394,https://example.com/paper_3394,2020.0,1.0,75,10,True,58.0,8.0,True
cord-003396,Analysis of symptoms and transmission and antiviral and epidemiology in clinical settings,This study examines symptoms with 414 word abstract...,Author3396_1,PLoS ONE,2021-06-15,WHO,10.1000/sample.3396,,,2021.0,6.0,89,12,True,54.0,8.0,True
cord-003397,Analysis of epidemiology and SARS-CoV-2 and clinical and COVID-19 in clinical settings,This study examines epidemiology with 284 word abstract...,"Author3397_1, Author3397_2",,2020-02-07,PMC,10.1000/sample.3397,PMC1003397,,2020.0,2.0,86,12,True,58.0,8.0,False
cord-003398,Analysis of treatment and coronavirus and outbreak in clinical settings,This study examines treatment with 486 word abstract...,"Author3398_1, Author3398_2",Cell,2020-04-07,PMC,10.1000/sample.3398,PMC1003398,https://example.com/paper_3398,2020.0,4.0,71,10,True,55.0,8.0,True
cord-003400,Analysis of diagnosis and lockdown and treatment in clinical settings,This study examines diagnosis with 480 word abstract...,"Author3400_1, Author3400_2",Nature,2020-10-07,WHO,10.1000/sample.3400,PMC1003400,,2020.0,10.0,69,10,True,55.0,8.0,True
cord-003403,Analysis of respiratory and COVID-19 and clinical in clinical settings,This study examines respiratory with 282 word abstract...,"Author3403_1, Author3403_2",Science,2020-06-21,PMC,10.1000/sample.3403,PMC1003403,https://example.com/paper_3403,2020.0,6.0,70,10,True,57.0,8.0,True
cord-003406,Analysis of diagnosis and respiratory and lockdown in clinical settings,This study examines diagnosis with 255 word abstract...,"Author3406_1, Author3406_2",Science,2020-01-13,Medline,10.1000/sample.3406,PMC1003406,https://example.com/paper_3406,2020.0,1.0,71,10,True,55.0,8.0,True
cord-003408,Analysis of COVID-19 and transmission and pneumonia and epidemiology in clinical settings,This study examines COVID-19 with 318 word abstract...,"Author3408_1, Author3408_2",Virology,2019-12-18,PMC,10.1000/sample.3408,PMC1003408,https://example.com/paper_3408,2019.0,12.0,89,12,True,54.0,8.0,True
cord-003410,Analysis of transmission and therapeutic and pandemic in clinical settings,This study examines transmission with 318 word abstract...,"Author3410_1, Author3410_2",Lancet,2019-12-03,bioRxiv,10.1000/sample.3410,,https://example.com/paper_3410,2019.0,12.0,74,10,True,58.0,8.0,True
cord-003411,Analysis of pandemic and public health and therapeutic and antiviral in clinical settings,This study examines pandemic with 496 word abstract...,"Author3411_1, Author3411_2",Clinical Infectious Diseases,2020-07-28,PMC,,,https://example.com/paper_3411,2020.0,7.0,89,13,True,54.0,8.0,True
cord-003415,Analysis of treatment and symptoms and pandemic and SARS-CoV-2 in clinical settings,This study examines treatment with 474 word abstract...,"Author3415_1, Author3415_2",Cell,2020-07-03,medRxiv,10.1000/sample.3415,PMC1003415,,2020.0,7.0,83,12,True,55.0,8.0,True
cord-003418,Analysis of SARS-CoV-2 and respiratory and treatment and antibody in clinical settings,This study examines SARS-CoV-2 with 282 word abstract...,"Author3418_1, Author3418_2",New England Journal of Medicine,2021-09-24,medRxiv,10.1000/sample.3418,PMC1003418,,2021.0,9.0,86,12,True,56.0,8.0,True
cord-003420,Analysis of outbreak and respiratory and symptoms in clinical settings,This study examines outbreak with 315 word abstract...,"Author3420_1, Author3420_2",PLoS ONE,2020-07-19,WHO,10.1000/sample.3420,PMC1003420,https://example.com/paper_3420,2020.0,7.0,70,10,True,54.0,8.0,True
cord-003421,Analysis of vaccination and clinical and immunity in clinical settings,This study examines vaccination with 100 word abstract...,"Author3421_1, Author3421_2",Emerging Infectious Diseases,2020-08-14,bioRxiv,,PMC1003421,,2020.0,8.0,70,10,True,57.0,8.0,True
cord-003424,Analysis of vaccination and antiviral and transmission in clinical settings,This study examines vaccination with 257 word abstract...,"Author3424_1, Author3424_2",PLoS ONE,2020-05-02,medRxiv,10.1000/sample.3424,PMC1003424,https://example.com/paper_3424,2020.0,5.0,75,10,True,57.0,8.0,True
cord-003425,Analysis of antibody and symptoms and diagnosis in clinical settings,This study examines antibody with 454 word abstract...,"Author3425_1, Author3425_2",Cell,2020-05-09,bioRxiv,10.1000/sample.3425,,https://example.com/paper_3425,2020.0,5.0,68,10,True,54.0,8.0,True
cord-003426,Analysis of vaccination and public health and lockdown in clinical settings,This study examines vaccination with 456 word abstract...,"Author3426_1, Author3426_2",Nature Medicine,2020-05-09,medRxiv,10.1000/sample.3426,PMC1003426,https://example.com/paper_3426,2020.0,5.0,75,11,True,57.0,8.0,True
cord-003427,Analysis of diagnosis and COVID-19 and symptoms and epidemiology in clinical settings,This study examines diagnosis with 461 word abstract...,"Author3427_1, Author3427_2",Nature,2022-11-10,Medline,10.1000/sample.3427,,,2022.0,11.0,85,12,True,55.0,8.0,True
cord-003428,Analysis of COVID-19 and immunity and symptoms in clinical settings,This study examines COVID-19 with 148 word abstract...,Author3428_1,Lancet,2021-04-12,medRxiv,10.1000/sample.3428,,https://example.com/paper_3428,2021.0,4.0,67,10,True,54.0,8.0,True
cord-003429,Analysis of SARS-CoV-2 and lockdown in clinical settings,This study examines SARS-CoV-2 with 378 word abstract...,"Author3429_1, Author3429_2",JAMA,2021-10-24,bioRxiv,10.1000/sample.3429,,https://example.com/paper_3429,2021.0,10.0,56,8,True,56.0,8.0,True
cord-003431,Analysis of pandemic and immunity and lockdown and antibody in clinical settings,This study examines pandemic with 409 word abstract...,"Author3431_1, Author3431_2",Nature Medicine,2019-12-09,PMC,,PMC1003431,https://example.com/paper_3431,2019.0,12.0,80,12,True,54.0,8.0,True
cord-003432,Analysis of antiviral and diagnosis and symptoms and transmission in clinical settings,This study examines antiviral with 150 word abstract...,"Author3432_1, Author3432_2",Journal of Virology,2021-03-12,PMC,10.1000/sample.3432,,https://example.com/paper_3432,2021.0,3.0,86,12,True,55.0,8.0,True
cord-003435,Analysis of antibody and respiratory and coronavirus in clinical settings,This study examines antibody with 300 word abstract...,"Author3435_1, Author3435_2",Virology,2020-08-05,PMC,10.1000/sample.3435,,https://example.com/paper_3435,2020.0,8.0,73,10,True,54.0,8.0,True
cord-003436,Analysis of symptoms and diagnosis and treatment and epidemiology in clinical settings,This study examines symptoms with 499 word abstract...,"Author3436_1, Author3436_2",JAMA,2021-11-05,PMC,10.1000/sample.3436,PMC1003436,https://example.com/paper_3436,2021.0,11.0,86,12,True,54.0,8.0,True
cord-003437,Analysis of vaccination and transmission and clinical and antibody in clinical settings,This study examines vaccination with 122 word abstract...,Author3437_1,PLoS ONE,2020-01-18,bioRxiv,10.1000/sample.3437,PMC1003437,https://example.com/paper_3437,2020.0,1.0,87,12,True,57.0,8.0,True
cord-003439,Analysis of respiratory and outbreak and therapeutic and public health in clinical settings,This study examines respiratory with 264 word abstract...,"Author3439_1, Author3439_2",,2021-11-06,bioRxiv,10.1000/sample.3439,PMC1003439,,2021.0,11.0,91,13,True,57.0,8.0,False
cord-003441,Analysis of public health and antibody and outbreak in clinical settings,This study examines public health with 237 word abstract...,"Author3441_1, Author3441_2",,2020-11-12,WHO,,PMC1003441,https://example.com/paper_3441,2020.0,11.0,72,11,True,59.0,9.0,False
cord-003442,Analysis of treatment and transmission and epidemiology and antibody in clinical settings,This study examines treatment with 372 word abstract...,"Author3442_1, Author3442_2",Science,2021-01-27,PMC,10.1000/sample.3442,PMC1003442,,2021.0,1.0,89,12,True,55.0,8.0,True
cord-003443,Analysis of immunity and outbreak and antiviral and COVID-19 in clinical settings,This study examines immunity with 115 word abstract...,"Author3443_1, Author3443_2",Virology,2019-12-29,PMC,10.1000/sample.3443,,https://example.com/paper_3443,2019.0,12.0,81,12,True,54.0,8.0,True
cord-003446,Analysis of antiviral and treatment and symptoms in clinical settings,This study examines antiviral with 303 word abstract...,"Author3446_1, Author3446_2",Clinical Infectious Diseases,2020-05-17,Medline,10.1000/sample.3446,PMC1003446,,2020.0,5.0,69,10,True,55.0,8.0,True
cord-003447,Analysis of vaccination and antiviral and pandemic and pneumonia in clinical settings,,"Author3447_1, Author3447_2",Science,2022-06-27,medRxiv,10.1000/sample.3447,PMC1003447,https://example.com/paper_3447,2022.0,6.0,85,12,False,,,True
cord-003448,Analysis of lockdown and pneumonia and antiviral in clinical settings,This study examines lockdown with 354 word abstract...,"Author3448_1, Author3448_2",New England Journal of Medicine,2021-11-21,PMC,10.1000/sample.3448,PMC1003448,https://example.com/paper_3448,2021.0,11.0,69,10,True,54.0,8.0,True
cord-003449,Analysis of coronavirus and symptoms and antibody in clinical settings,This study examines coronavirus with 266 word abstract...,"Author3449_1, Author3449_2",,2022-01-26,PMC,10.1000/sample.3449,PMC1003449,https://example.com/paper_3449,2022.0,1.0,70,10,True,57.0,8.0,False
cord-003450,Analysis of symptoms and diagnosis and COVID-19 in clinical settings,This study examines symptoms with 124 word abstract...,"Author3450_1, Author3450_2",Lancet,2021-05-02,bioRxiv,10.1000/sample.3450,PMC1003450,https://example.com/paper_3450,2021.0,5.0,68,10,True,54.0,8.0,True
cord-003453,Analysis of transmission and antiviral and antibody and respiratory in clinical settings,This study examines transmission with 123 word abstract...,"Author3453_1, Author3453_2",,2020-07-10,PMC,10.1000/sample.3453,PMC1003453,https://example.com/paper_3453,2020.0,7.0,88,12,True,58.0,8.0,False
cord-003454,Analysis of diagnosis and transmission and symptoms and therapeutic in clinical settings,This study examines diagnosis with 152 word abstract...,"Author3454_1, Author3454_2",Science,2019-12-07,WHO,10.1000/sample.3454,PMC1003454,https://example.com/paper_3454,2019.0,12.0,88,12,True,55.0,8.0,True
cord-003455,Analysis of coronavirus and therapeutic and pandemic and outbreak in clinical settings,This study examines coronavirus with 407 word abstract...,"Author3455_1, Author3455_2",,2020-04-15,medRxiv,10.1000/sample.3455,,,2020.0,4.0,86,12,True,57.0,8.0,False
cord-003456,Analysis of transmission and coronavirus and pandemic and public health in clinical settings,,"Author3456_1, Author3456_2",,2019-12-29,ArXiv,10.1000/sample.3456,PMC1003456,,2019.0,12.0,92,13,False,,,False
cord-003457,Analysis of pneumonia and symptoms and SARS-CoV-2 and transmission in clinical settings,This study examines pneumonia with 140 word abstract...,"Author3457_1, Author3457_2",Nature Medicine,2021-10-24,Medline,10.1000/sample.3457,,https://example.com/paper_3457,2021.0,10.0,87,12,True,55.0,8.0,True
cord-003458,Analysis of antiviral and vaccination and symptoms and pneumonia in clinical settings,This study examines antiviral with 261 word abstract...,"Author3458_1, Author3458_2",Virology,2021-11-28,ArXiv,10.1000/sample.3458,PMC1003458,https://example.com/paper_3458,2021.0,11.0,85,12,True,55.0,8.0,True
cord-003460,Analysis of outbreak and coronavirus and respiratory and diagnosis in clinical settings,This study examines outbreak with 216 word abstract...,"Author3460_1, Author3460_2",Virology,2020-12-04,WHO,10.1000/sample.3460,PMC1003460,https://example.com/paper_3460,2020.0,12.0,87,12,True,54.0,8.0,True
cord-003463,Analysis of SARS-CoV-2 and coronavirus and transmission in clinical settings,This study examines SARS-CoV-2 with 122 word abstract...,"Author3463_1, Author3463_2",Virology,2021-03-14,PMC,10.1000/sample.3463,PMC1003463,https://example.com/paper_3463,2021.0,3.0,76,10,True,56.0,8.0,True
cord-003465,Analysis of pandemic and therapeutic and clinical in clinical settings,This study examines pandemic with 272 word abstract...,Author3465_1,Journal of Medical Virology,,WHO,10.1000/sample.3465,PMC1003465,https://example.com/paper_3465,,,70,10,True,54.0,8.0,True
cord-003467,Analysis of clinical and pandemic and COVID-19 in clinical settings,This study examines clinical with 438 word abstract...,"Author3467_1, Author3467_2",Nature Medicine,2021-04-08,Medline,10.1000/sample.3467,PMC1003467,,2021.0,4.0,67,10,True,54.0,8.0,True
cord-003468,Analysis of antibody and immunity and outbreak and coronavirus in clinical settings,This study examines antibody with 287 word abstract...,"Author3468_1, Author3468_2",JAMA,2021-07-18,ArXiv,10.1000/sample.3468,PMC1003468,https://example.com/paper_3468,2021.0,7.0,83,12,True,54.0,8.0,True
cord-003469,Analysis of treatment and clinical and coronavirus and diagnosis in clinical settings,,"Author3469_1, Author3469_2",Emerging Infectious Diseases,2020-11-10,medRxiv,10.1000/sample.3469,PMC1003469,https://example.com/paper_3469,2020.0,11.0,85,12,False,,,True
cord-003470,Analysis of antiviral and SARS-CoV-2 and lockdown in clinical settings,This study examines antiviral with 120 word abstract...,"Author3470_1, Author3470_2",,2020-11-03,PMC,10.1000/sample.3470,PMC1003470,https://example.com/paper_3470,2020.0,11.0,70,10,True,55.0,8.0,False
cord-003472,Analysis of therapeutic and symptoms and public health in clinical settings,This study examines therapeutic with 260 word abstract...,"Author3472_1, Author3472_2",PLoS ONE,2020-10-17,Medline,10.1000/sample.3472,PMC1003472,https://example.com/paper_3472,2020.0,10.0,75,11,True,57.0,8.0,True
cord-003473,Analysis of antiviral and epidemiology and transmission in clinical settings,This study examines antiviral with 469 word abstract...,Author3473_1,Cell,2021-06-03,medRxiv,,,,2021.0,6.0,76,10,True,55.0,8.0,True
cord-003474,Analysis of outbreak and pneumonia and epidemiology in clinical settings,This study examines outbreak with 223 word abstract...,"Author3474_1, Author3474_2",Lancet,2020-11-14,bioRxiv,10.1000/sample.3474,,https://example.com/paper_3474,2020.0,11.0,72,10,True,54.0,8.0,True
cord-003476,Analysis of vaccination and COVID-19 and diagnosis in clinical settings,This study examines vaccination with 378 word abstract...,"Author3476_1, Author3476_2",New England Journal of Medicine,2021-08-19,PMC,10.1000/sample.3476,PMC1003476,https://example.com/paper_3476,2021.0,8.0,71,10,True,57.0,8.0,True
cord-003477,Analysis of transmission and vaccination and treatment and clinical in clinical settings,This study examines transmission with 126 word abstract...,"Author3477_1, Author3477_2",BMJ,2020-11-10,medRxiv,10.1000/sample.3477,PMC1003477,https://example.com/paper_3477,2020.0,11.0,88,12,True,58.0,8.0,True
cord-003478,Analysis of outbreak and lockdown and COVID-19 and coronavirus in clinical settings,This study examines outbreak with 131 word abstract...,"Author3478_1, Author3478_2",,2021-05-23,ArXiv,,PMC1003478,,2021.0,5.0,83,12,True,54.0,8.0,False
cord-003479,Analysis of respiratory and clinical and pandemic and immunity in clinical settings,This study examines respiratory with 384 word abstract...,"Author3479_1, Author3479_2",Journal of Virology,2020-01-09,ArXiv,,PMC1003479,https://example.com/paper_3479,2020.0,1.0,83,12,True,57.0,8.0,True
cord-003482,Analysis of treatment and transmission and vaccination and immunity in clinical settings,This study examines treatment with 346 word abstract...,"Author3482_1, Author3482_2",Virology,2021-07-14,PMC,10.1000/sample.3482,PMC1003482,https://example.com/paper_3482,2021.0,7.0,88,12,True,55.0,8.0,True
cord-003484,Analysis of pandemic and antiviral and SARS-CoV-2 in clinical settings,This study examines pandemic with 399 word abstract...,"Author3484_1, Author3484_2",Lancet,2021-08-11,Medline,10.1000/sample.3484,PMC1003484,,2021.0,8.0,70,10,True,54.0,8.0,True
cord-003485,Analysis of symptoms and public health and vaccination in clinical settings,This study examines symptoms with 426 word abstract...,"Author3485_1, Author3485_2",Virology,2020-12-03,Medline,10.1000/sample.3485,PMC1003485,https://example.com/paper_3485,2020.0,12.0,75,11,True,54.0,8.0,True
cord-003486,Analysis of coronavirus and vaccination and lockdown and pneumonia in clinical settings,This study examines coronavirus with 260 word abstract...,"Author3486_1, Author3486_2",Journal of Medical Virology,2020-01-29,medRxiv,10.1000/sample.3486,PMC1003486,https://example.com/paper_3486,2020.0,1.0,87,12,True,57.0,8.0,True
cord-003487,Analysis of immunity and antiviral in clinical settings,This study examines immunity with 273 word abstract...,"Author3487_1, Author3487_2",New England Journal of Medicine,2021-01-02,medRxiv,10.1000/sample.3487,PMC1003487,https://example.com/paper_3487,2021.0,1.0,55,8,True,54.0,8.0,True
cord-003488,Analysis of antibody and clinical and treatment in clinical settings,This study examines antibody with 407 word abstract...,"Author3488_1, Author3488_2",PLoS ONE,2022-06-08,PMC,10.1000/sample.3488,PMC1003488,,2022.0,6.0,68,10,True,54.0,8.0,True
cord-003490,Analysis of antiviral and symptoms and diagnosis in clinical settings,This study examines antiviral with 128 word abstract...,Author3490_1,New England Journal of Medicine,2020-04-16,WHO,10.1000/sample.3490,PMC1003490,https://example.com/paper_3490,2020.0,4.0,69,10,True,55.0,8.0,True
cord-003491,Analysis of transmission and COVID-19 and lockdown in clinical settings,This study examines transmission with 208 word abstract...,"Author3491_1, Author3491_2",Lancet,2021-01-14,medRxiv,10.1000/sample.3491,PMC1003491,https://example.com/paper_3491,2021.0,1.0,71,10,True,58.0,8.0,True
cord-003492,Analysis of antiviral and clinical and respiratory and symptoms in clinical settings,This study examines antiviral with 458 word abstract...,"Author3492_1, Author3492_2",Science Translational Medicine,2019-12-17,bioRxiv,10.1000/sample.3492,,https://example.com/paper_3492,2019.0,12.0,84,12,True,55.0,8.0,True
cord-003493,Analysis of therapeutic and SARS-CoV-2 and lockdown and epidemiology in clinical settings,This study examines therapeutic with 384 word abstract...,"Author3493_1, Author3493_2",Emerging Infectious Diseases,2019-12-27,bioRxiv,10.1000/sample.3493,,,2019.0,12.0,89,12,True,57.0,8.0,True
cord-003495,Analysis of transmission and therapeutic and COVID-19 in clinical settings,This study examines transmission with 212 word abstract...,"Author3495_1, Author3495_2",Nature,2019-12-04,Medline,10.1000/sample.3495,PMC1003495,https://example.com/paper_3495,2019.0,12.0,74,10,True,58.0,8.0,True
cord-003496,Analysis of antiviral and respiratory and COVID-19 and lockdown in clinical settings,This study examines antiviral with 383 word abstract...,"Author3496_1, Author3496_2",BMJ,2021-07-04,bioRxiv,10.1000/sample.3496,PMC1003496,https://example.com/paper_3496,2021.0,7.0,84,12,True,55.0,8.0,True
cord-003497,Analysis of vaccination and antiviral and coronavirus in clinical settings,This study examines vaccination with 253 word abstract...,Author3497_1,Clinical Infectious Diseases,2021-11-14,Medline,10.1000/sample.3497,PMC1003497,,2021.0,11.0,74,10,True,57.0,8.0,True
cord-003499,Analysis of immunity and diagnosis and epidemiology in clinical settings,This study examines immunity with 475 word abstract...,"Author3499_1, Author3499_2",Lancet,2021-04-05,Medline,10.1000/sample.3499,PMC1003499,https://example.com/paper_3499,2021.0,4.0,72,10,True,54.0,8.0,True
cord-003502,Analysis of outbreak and clinical and therapeutic and epidemiology in clinical settings,This study examines outbreak with 302 word abstract...,"Author3502_1, Author3502_2",Virology,2020-07-14,PMC,,PMC1003502,https://example.com/paper_3502,2020.0,7.0,87,12,True,54.0,8.0,True
cord-003503,Analysis of SARS-CoV-2 and treatment and transmission and antibody in clinical settings,This study examines SARS-CoV-2 with 421 word abstract...,Author3503_1,Virology,2019-12-12,Medline,10.1000/sample.3503,PMC1003503,https://example.com/paper_3503,2019.0,12.0,87,12,True,56.0,8.0,True
cord-003504,Analysis of lockdown and transmission and symptoms and clinical in clinical settings,This study examines lockdown with 109 word abstract...,"Author3504_1, Author3504_2",,2021-12-31,PMC,10.1000/sample.3504,PMC1003504,https://example.com/paper_3504,2021.0,12.0,84,12,True,54.0,8.0,False
cord-003505,Analysis of outbreak and transmission and therapeutic and COVID-19 in clinical settings,This study examines outbreak with 485 word abstract...,"Author3505_1, Author3505_2",Lancet,2020-07-19,medRxiv,10.1000/sample.3505,PMC1003505,https://example.com/paper_3505,2020.0,7.0,87,12,True,54.0,8.0,True
cord-003508,Analysis of antibody and treatment and outbreak in clinical settings,This study examines antibody with 442 word abstract...,"Author3508_1, Author3508_2",Nature,2021-08-02,PMC,10.1000/sample.3508,,https://example.com/paper_3508,2021.0,8.0,68,10,True,54.0,8.0,True
cord-003510,Analysis of lockdown and pneumonia and treatment and coronavirus in clinical settings,This study examines lockdown with 184 word abstract...,Author3510_1,Journal of Medical Virology,2020-02-01,medRxiv,,PMC1003510,https://example.com/paper_3510,2020.0,2.0,85,12,True,54.0,8.0,True
cord-003511,Analysis of antibody and diagnosis and outbreak in clinical settings,This study examines antibody with 222 word abstract...,"Author3511_1, Author3511_2",Journal of Virology,2019-12-14,Medline,10.1000/sample.3511,PMC1003511,https://example.com/paper_3511,2019.0,12.0,68,10,True,54.0,8.0,True
cord-003512,Analysis of pneumonia and therapeutic and public health and COVID-19 in clinical settings,This study examines pneumonia with 299 word abstract...,"Author3512_1, Author3512_2",Lancet,2020-11-21,bioRxiv,10.1000/sample.3512,PMC1003512,https://example.com/paper_3512,2020.0,11.0,89,13,True,55.0,8.0,True
cord-003515,Analysis of pandemic and pneumonia and public health in clinical settings,This study examines pandemic with 466 word abstract...,"Author3515_1, Author3515_2",,2019-12-12,medRxiv,,PMC1003515,https://example.com/paper_3515,2019.0,12.0,73,11,True,54.0,8.0,False
cord-003516,Analysis of epidemiology and pandemic and treatment and pneumonia in clinical settings,This study examines epidemiology with 371 word abstract...,"Author3516_1, Author3516_2",New England Journal of Medicine,2020-08-01,PMC,10.1000/sample.3516,PMC1003516,,2020.0,8.0,86,12,True,58.0,8.0,True
cord-003517,Analysis of respiratory and SARS-CoV-2 and vaccination and transmission in clinical settings,This study examines respiratory with 311 word abstract...,"Author3517_1, Author3517_2",JAMA,2020-04-08,Medline,10.1000/sample.3517,PMC1003517,https://example.com/paper_3517,2020.0,4.0,92,12,True,57.0,8.0,True
cord-003518,Analysis of treatment and coronavirus and diagnosis in clinical settings,This study examines treatment with 491 word abstract...,"Author3518_1, Author3518_2",Nature Medicine,2021-01-27,ArXiv,10.1000/sample.3518,PMC1003518,https://example.com/paper_3518,2021.0,1.0,72,10,True,55.0,8.0,True
cord-003519,Analysis of therapeutic and coronavirus and COVID-19 and treatment in clinical settings,This study examines therapeutic with 224 word abstract...,"Author3519_1, Author3519_2",Emerging Infectious Diseases,2021-01-18,Medline,10.1000/sample.3519,,https://example.com/paper_3519,2021.0,1.0,87,12,True,57.0,8.0,True
cord-003520,Analysis of antiviral and public health and antibody and treatment in clinical settings,This study examines antiviral with 378 word abstract...,"Author3520_1, Author3520_2",BMJ,2020-11-27,PMC,10.1000/sample.3520,,https://example.com/paper_3520,2020.0,11.0,87,13,True,55.0,8.0,True
cord-003521,Analysis of outbreak and public health and transmission and immunity in clinical settings,,"Author3521_1, Author3521_2",Journal of Virology,2021-03-21,ArXiv,,PMC1003521,https://example.com/paper_3521,2021.0,3.0,89,13,False,,,True
cord-003522,Analysis of transmission and outbreak and treatment and diagnosis in clinical settings,This study examines transmission with 218 word abstract...,"Author3522_1, Author3522_2",,2021-05-23,medRxiv,,,https://example.com/paper_3522,2021.0,5.0,86,12,True,58.0,8.0,False
cord-003523,Analysis of vaccination and clinical and pneumonia in clinical settings,This study examines vaccination with 486 word abstract...,Author3523_1,Science Translational Medicine,2020-05-15,Medline,10.1000/sample.3523,PMC1003523,https://example.com/paper_3523,2020.0,5.0,71,10,True,57.0,8.0,True
cord-003524,Analysis of vaccination and symptoms and treatment and antiviral in clinical settings,This study examines vaccination with 142 word abstract...,Author3524_1,Clinical Infectious Diseases,2020-02-16,bioRxiv,,PMC1003524,,2020.0,2.0,85,12,True,57.0,8.0,True
cord-003525,Analysis of SARS-CoV-2 and public health and respiratory in clinical settings,This study examines SARS-CoV-2 with 231 word abstract...,"Author3525_1, Author3525_2",PLoS ONE,2021-11-09,WHO,10.1000/sample.3525,PMC1003525,https://example.com/paper_3525,2021.0,11.0,77,11,True,56.0,8.0,True
cord-003526,Analysis of pandemic and clinical and therapeutic and vaccination in clinical settings,This study examines pandemic with 448 word abstract...,"Author3526_1, Author3526_2",Nature Medicine,2019-12-25,medRxiv,10.1000/sample.3526,PMC1003526,https://example.com/paper_3526,2019.0,12.0,86,12,True,54.0,8.0,True
cord-003528,Analysis of transmission and antibody and epidemiology and treatment in clinical settings,This study examines transmission with 340 word abstract...,"Author3528_1, Author3528_2",Nature Medicine,2020-05-04,medRxiv,10.1000/sample.3528,PMC1003528,https://example.com/paper_3528,2020.0,5.0,89,12,True,58.0,8.0,True
cord-003530,Analysis of therapeutic and vaccination and pandemic and epidemiology in clinical settings,This study examines therapeutic with 114 word abstract...,"Author3530_1, Author3530_2",,2021-06-08,PMC,10.1000/sample.3530,,https://example.com/paper_3530,2021.0,6.0,90,12,True,57.0,8.0,False
cord-003531,Analysis of SARS-CoV-2 and coronavirus and symptoms and COVID-19 in clinical settings,This study examines SARS-CoV-2 with 456 word abstract...,"Author3531_1, Author3531_2",Journal of Medical Virology,2022-10-16,Medline,,,https://example.com/paper_3531,2022.0,10.0,85,12,True,56.0,8.0,True
cord-003532,Analysis of pandemic and coronavirus and pneumonia and COVID-19 in clinical settings,This study examines pandemic with 195 word abstract...,"Author3532_1, Author3532_2",Journal of Medical Virology,2021-12-20,WHO,10.1000/sample.3532,PMC1003532,,2021.0,12.0,84,12,True,54.0,8.0,True
cord-003533,Analysis of SARS-CoV-2 and epidemiology and vaccination in clinical settings,This study examines SARS-CoV-2 with 352 word abstract...,"Author3533_1, Author3533_2",Science Translational Medicine,2020-11-01,ArXiv,10.1000/sample.3533,,https://example.com/paper_3533,2020.0,11.0,76,10,True,56.0,8.0,True
cord-003534,Analysis of SARS-CoV-2 and epidemiology and diagnosis and antibody in clinical settings,,"Author3534_1, Author3534_2",PLoS ONE,2020-08-02,WHO,10.1000/sample.3534,,,2020.0,8.0,87,12,False,,,True
cord-003535,Analysis of epidemiology and SARS-CoV-2 and transmission and COVID-19 in clinical settings,This study examines epidemiology with 199 word abstract...,"Author3535_1, Author3535_2",Nature Medicine,2020-10-21,PMC,10.1000/sample.3535,,https://example.com/paper_3535,2020.0,10.0,90,12,True,58.0,8.0,True
cord-003540,Analysis of respiratory and public health and antibody and pandemic in clinical settings,This study examines respiratory with 439 word abstract...,"Author3540_1, Author3540_2",Lancet,2021-10-06,Medline,10.1000/sample.3540,,https://example.com/paper_3540,2021.0,10.0,88,13,True,57.0,8.0,True
cord-003541,Analysis of outbreak and COVID-19 and pneumonia in clinical settings,This study examines outbreak with 372 word abstract...,"Author3541_1, Author3541_2",Journal of Virology,2019-12-10,bioRxiv,10.1000/sample.3541,PMC1003541,https://example.com/paper_3541,2019.0,12.0,68,10,True,54.0,8.0,True
cord-003543,Analysis of lockdown and COVID-19 and epidemiology in clinical settings,This study examines lockdown with 367 word abstract...,"Author3543_1, Author3543_2",,2021-05-20,medRxiv,10.1000/sample.3543,PMC1003543,https://example.com/paper_3543,2021.0,5.0,71,10,True,54.0,8.0,False
cord-003545,Analysis of COVID-19 and clinical and vaccination and antiviral in clinical settings,This study examines COVID-19 with 460 word abstract...,"Author3545_1, Author3545_2",,2020-06-15,Medline,10.1000/sample.3545,PMC1003545,https://example.com/paper_3545,2020.0,6.0,84,12,True,54.0,8.0,False
cord-003546,Analysis of transmission and clinical and antibody and antiviral in clinical settings,This study examines transmission with 191 word abstract...,"Author3546_1, Author3546_2",PLoS ONE,2020-09-23,ArXiv,10.1000/sample.3546,PMC1003546,https://example.com/paper_3546,2020.0,9.0,85,12,True,58.0,8.0,True
cord-003547,Analysis of pandemic and clinical and symptoms and public health in clinical settings,This study examines pandemic with 375 word abstract...,"Author3547_1, Author3547_2",Nature,,PMC,10.1000/sample.3547,PMC1003547,,,,85,13,True,54.0,8.0,True
cord-003548,Analysis of respiratory and treatment and coronavirus in clinical settings,This study examines respiratory with 254 word abstract...,"Author3548_1, Author3548_2",Journal of Medical Virology,2021-05-23,bioRxiv,10.1000/sample.3548,PMC1003548,,2021.0,5.0,74,10,True,57.0,8.0,True
cord-003549,Analysis of vaccination and immunity and treatment in clinical settings,This study examines vaccination with 316 word abstract...,Author3549_1,Journal of Virology,2019-12-16,ArXiv,10.1000/sample.3549,PMC1003549,,2019.0,12.0,71,10,True,57.0,8.0,True
cord-003551,Analysis of outbreak and treatment and symptoms in clinical settings,This study examines outbreak with 133 word abstract...,"Author3551_1, Author3551_2",New England Journal of Medicine,2020-02-24,medRxiv,10.1000/sample.3551,PMC1003551,https://example.com/paper_3551,2020.0,2.0,68,10,True,54.0,8.0,True
cord-003552,Analysis of epidemiology and immunity and SARS-CoV-2 in clinical settings,This study examines epidemiology with 178 word abstract...,"Author3552_1, Author3552_2",Clinical Infectious Diseases,2020-07-04,medRxiv,10.1000/sample.3552,,,2020.0,7.0,73,10,True,58.0,8.0,True
cord-003553,Analysis of vaccination and pneumonia and antibody and therapeutic in clinical settings,This study examines vaccination with 239 word abstract...,Author3553_1,Science,2020-04-17,medRxiv,10.1000/sample.3553,,https://example.com/paper_3553,2020.0,4.0,87,12,True,57.0,8.0,True
cord-003554,Analysis of antiviral and outbreak in clinical settings,,"Author3554_1, Author3554_2",,2019-12-05,Medline,10.1000/sample.3554,,https://example.com/paper_3554,2019.0,12.0,55,8,False,,,False
cord-003556,Analysis of diagnosis and antiviral and pneumonia and immunity in clinical settings,This study examines diagnosis with 151 word abstract...,"Author3556_1, Author3556_2",Virology,2021-04-25,Medline,10.1000/sample.3556,PMC1003556,https://example.com/paper_3556,2021.0,4.0,83,12,True,55.0,8.0,True
cord-003558,Analysis of treatment and lockdown and clinical in clinical settings,This study examines treatment with 127 word abstract...,"Author3558_1, Author3558_2",Clinical Infectious Diseases,2021-05-06,WHO,10.1000/sample.3558,PMC1003558,,2021.0,5.0,68,10,True,55.0,8.0,True
cord-003560,Analysis of antiviral and outbreak and respiratory and pneumonia in clinical settings,This study examines antiviral with 429 word abstract...,"Author3560_1, Author3560_2",Nature Medicine,2022-11-05,ArXiv,10.1000/sample.3560,PMC1003560,https://example.com/paper_3560,2022.0,11.0,85,12,True,55.0,8.0,True
cord-003561,Analysis of epidemiology and clinical and public health in clinical settings,,"Author3561_1, Author3561_2",Journal of Medical Virology,2021-08-11,medRxiv,10.1000/sample.3561,PMC1003561,https://example.com/paper_3561,2021.0,8.0,76,11,False,,,True
cord-003562,Analysis of respiratory and therapeutic and immunity and antiviral in clinical settings,This study examines respiratory with 400 word abstract...,"Author3562_1, Author3562_2",,2021-11-24,medRxiv,10.1000/sample.3562,PMC1003562,,2021.0,11.0,87,12,True,57.0,8.0,False
cord-003563,Analysis of treatment and clinical and SARS-CoV-2 and vaccination in clinical settings,This study examines treatment with 342 word abstract...,"Author3563_1, Author3563_2",BMJ,2022-12-28,ArXiv,10.1000/sample.3563,PMC1003563,https://example.com/paper_3563,2022.0,12.0,86,12,True,55.0,8.0,True
cord-003566,Analysis of clinical and epidemiology and COVID-19 and pandemic in clinical settings,This study examines clinical with 226 word abstract...,"Author3566_1, Author3566_2",New England Journal of Medicine,2021-08-29,PMC,10.1000/sample.3566,PMC1003566,https://example.com/paper_3566,2021.0,8.0,84,12,True,54.0,8.0,True
cord-003568,Analysis of treatment and clinical and immunity and vaccination in clinical settings,This study examines treatment with 227 word abstract...,"Author3568_1, Author3568_2",,2020-10-08,PMC,10.1000/sample.3568,PMC1003568,https://example.com/paper_3568,2020.0,10.0,84,12,True,55.0,8.0,False
cord-003571,Analysis of epidemiology and antibody and pneumonia and coronavirus in clinical settings,This study examines epidemiology with 431 word abstract...,"Author3571_1, Author3571_2",Science Translational Medicine,2020-11-06,WHO,10.1000/sample.3571,PMC1003571,https://example.com/paper_3571,2020.0,11.0,88,12,True,58.0,8.0,True
cord-003572,Analysis of lockdown and transmission and diagnosis in clinical settings,This study examines lockdown with 342 word abstract...,"Author3572_1, Author3572_2",Science Translational Medicine,2021-03-06,Medline,10.1000/sample.3572,PMC1003572,https://example.com/paper_3572,2021.0,3.0,72,10,True,54.0,8.0,True
cord-003577,Analysis of pneumonia and coronavirus and immunity and epidemiology in clinical settings,This study examines pneumonia with 323 word abstract...,"Author3577_1, Author3577_2",Science,2020-11-09,medRxiv,10.1000/sample.3577,,https://example.com/paper_3577,2020.0,11.0,88,12,True,55.0,8.0,True
cord-003578,Analysis of SARS-CoV-2 and transmission and epidemiology in clinical settings,This study examines SARS-CoV-2 with 385 word abstract...,"Author3578_1, Author3578_2",,2021-09-19,ArXiv,10.1000/sample.3578,PMC1003578,https://example.com/paper_3578,2021.0,9.0,77,10,True,56.0,8.0,False
cord-003579,Analysis of vaccination and immunity and epidemiology in clinical settings,This study examines vaccination with 309 word abstract...,"Author3579_1, Author3579_2",Nature Medicine,,bioRxiv,10.1000/sample.3579,PMC1003579,https://example.com/paper_3579,,,74,10,True,57.0,8.0,True
cord-003580,Analysis of pneumonia and immunity and diagnosis in clinical settings,,"Author3580_1, Author3580_2",New England Journal of Medicine,2020-07-02,bioRxiv,10.1000/sample.3580,,,2020.0,7.0,69,10,False,,,True
cord-003581,Analysis of respiratory and therapeutic and pneumonia and pandemic in clinical settings,This study examines respiratory with 122 word abstract...,"Author3581_1, Author3581_2",Nature,2020-09-01,Medline,10.1000/sample.3581,PMC1003581,https://example.com/paper_3581,2020.0,9.0,87,12,True,57.0,8.0,True
cord-003582,Analysis of vaccination and epidemiology and public health in clinical settings,This study examines vaccination with 284 word abstract...,"Author3582_1, Author3582_2",Nature,2020-05-25,medRxiv,,,https://example.com/paper_3582,2020.0,5.0,79,11,True,57.0,8.0,True
cord-003583,Analysis of pandemic and SARS-CoV-2 and antibody and symptoms in clinical settings,This study examines pandemic with 403 word abstract...,"Author3583_1, Author3583_2",Science,2022-12-12,bioRxiv,10.1000/sample.3583,PMC1003583,https://example.com/paper_3583,2022.0,12.0,82,12,True,54.0,8.0,True
cord-003588,Analysis of epidemiology and antiviral and public health in clinical settings,This study examines epidemiology with 187 word abstract...,"Author3588_1, Author3588_2",Journal of Medical Virology,2021-04-17,bioRxiv,10.1000/sample.3588,PMC1003588,https://example.com/paper_3588,2021.0,4.0,77,11,True,58.0,8.0,True
cord-003589,Analysis of epidemiology and symptoms and coronavirus and treatment in clinical settings,This study examines epidemiology with 196 word abstract...,"Author3589_1, Author3589_2",Nature,2020-11-29,bioRxiv,10.1000/sample.3589,PMC1003589,,2020.0,11.0,88,12,True,58.0,8.0,True
cord-003590,Analysis of pneumonia and SARS-CoV-2 in clinical settings,This study examines pneumonia with 271 word abstract...,"Author3590_1, Author3590_2",Cell,2021-05-17,medRxiv,10.1000/sample.3590,,https://example.com/paper_3590,2021.0,5.0,57,8,True,55.0,8.0,True
cord-003592,Analysis of diagnosis and antibody and treatment and public health in clinical settings,This study examines diagnosis with 173 word abstract...,"Author3592_1, Author3592_2",Virology,2021-06-11,PMC,10.1000/sample.3592,PMC1003592,https://example.com/paper_3592,2021.0,6.0,87,13,True,55.0,8.0,True
cord-003593,Analysis of respiratory and COVID-19 and antibody and public health in clinical settings,,"Author3593_1, Author3593_2",Lancet,2020-08-27,bioRxiv,10.1000/sample.3593,PMC1003593,https://example.com/paper_3593,2020.0,8.0,88,13,False,,,True
cord-003596,Analysis of antibody and therapeutic and treatment and outbreak in clinical settings,This study examines antibody with 141 word abstract...,"Author3596_1, Author3596_2",,,WHO,10.1000/sample.3596,PMC1003596,https://example.com/paper_3596,,,84,12,True,54.0,8.0,False
cord-003598,Analysis of diagnosis and transmission and antibody and SARS-CoV-2 in clinical settings,This study examines diagnosis with 484 word abstract...,"Author3598_1, Author3598_2",Science Translational Medicine,2021-03-29,bioRxiv,10.1000/sample.3598,PMC1003598,https://example.com/paper_3598,2021.0,3.0,87,12,True,55.0,8.0,True
cord-003599,Analysis of therapeutic and lockdown and outbreak and immunity in clinical settings,This study examines therapeutic with 314 word abstract...,"Author3599_1, Author3599_2",Journal of Medical Virology,2021-04-22,ArXiv,10.1000/sample.3599,,,2021.0,4.0,83,12,True,57.0,8.0,True
cord-003600,Analysis of antibody and outbreak and treatment in clinical settings,This study examines antibody with 393 word abstract...,,,2021-08-14,ArXiv,,,https://example.com/paper_3600,2021.0,8.0,68,10,True,54.0,8.0,False
cord-003603,Analysis of immunity and SARS-CoV-2 and clinical in clinical settings,This study examines immunity with 321 word abstract...,"Author3603_1, Author3603_2",Science,2020-03-12,medRxiv,10.1000/sample.3603,PMC1003603,,2020.0,3.0,69,10,True,54.0,8.0,True
cord-003604,Analysis of immunity and antibody and pandemic in clinical settings,This study examines immunity with 305 word abstract...,Author3604_1,,2020-08-27,WHO,10.1000/sample.3604,PMC1003604,https://example.com/paper_3604,2020.0,8.0,67,10,True,54.0,8.0,False
cord-003605,Analysis of coronavirus and epidemiology and symptoms and treatment in clinical settings,This study examines coronavirus with 333 word abstract...,"Author3605_1, Author3605_2",JAMA,2019-12-03,medRxiv,10.1000/sample.3605,PMC1003605,https://example.com/paper_3605,2019.0,12.0,88,12,True,57.0,8.0,True
cord-003607,Analysis of SARS-CoV-2 and antiviral and treatment and immunity in clinical settings,This study examines SARS-CoV-2 with 353 word abstract...,"Author3607_1, Author3607_2",JAMA,2020-11-09,ArXiv,10.1000/sample.3607,PMC1003607,https://example.com/paper_3607,2020.0,11.0,84,12,True,56.0,8.0,True
cord-003610,Analysis of lockdown and coronavirus and SARS-CoV-2 in clinical settings,This study examines lockdown with 274 word abstract...,"Author3610_1, Author3610_2",Clinical Infectious Diseases,2020-03-14,PMC,10.1000/sample.3610,,,2020.0,3.0,72,10,True,54.0,8.0,True
cord-003611,Analysis of immunity and COVID-19 and outbreak and transmission in clinical settings,This study examines immunity with 446 word abstract...,"Author3611_1, Author3611_2",Science,2021-09-27,PMC,10.1000/sample.3611,PMC1003611,https://example.com/paper_3611,2021.0,9.0,84,12,True,54.0,8.0,True
cord-003615,Analysis of public health and treatment and pandemic in clinical settings,This study examines public health with 145 word abstract...,"Author3615_1, Author3615_2",Virology,2021-02-20,medRxiv,10.1000/sample.3615,,https://example.com/paper_3615,2021.0,2.0,73,11,True,59.0,9.0,True
cord-003616,Analysis of therapeutic and outbreak and public health in clinical settings,This study examines therapeutic with 215 word abstract...,"Author3616_1, Author3616_2",Journal of Medical Virology,2020-03-13,ArXiv,10.1000/sample.3616,,https://example.com/paper_3616,2020.0,3.0,75,11,True,57.0,8.0,True
cord-003618,Analysis of immunity and diagnosis and symptoms and clinical in clinical settings,This study examines immunity with 469 word abstract...,Author3618_1,Nature Medicine,2021-08-30,bioRxiv,10.1000/sample.3618,PMC1003618,,2021.0,8.0,81,12,True,54.0,8.0,True
cord-003620,Analysis of transmission and COVID-19 and antiviral and symptoms in clinical settings,This study examines transmission with 352 word abstract...,"Author3620_1, Author3620_2",New England Journal of Medicine,2020-11-08,Medline,,PMC1003620,https://example.com/paper_3620,2020.0,11.0,85,12,True,58.0,8.0,True
cord-003621,Analysis of epidemiology and SARS-CoV-2 and public health and symptoms in clinical settings,This study examines epidemiology with 178 word abstract...,"Author3621_1, Author3621_2",Lancet,2021-09-14,bioRxiv,10.1000/sample.3621,PMC1003621,https://example.com/paper_3621,2021.0,9.0,91,13,True,58.0,8.0,True
cord-003622,Analysis of diagnosis and therapeutic and antibody in clinical settings,This study examines diagnosis with 397 word abstract...,"Author3622_1, Author3622_2",Clinical Infectious Diseases,2019-12-10,ArXiv,10.1000/sample.3622,PMC1003622,https://example.com/paper_3622,2019.0,12.0,71,10,True,55.0,8.0,True
cord-003623,Analysis of antiviral and COVID-19 and diagnosis and lockdown in clinical settings,This study examines antiviral with 445 word abstract...,Author3623_1,Journal of Virology,2020-07-23,bioRxiv,,,https://example.com/paper_3623,2020.0,7.0,82,12,True,55.0,8.0,True
cord-003624,Analysis of clinical and SARS-CoV-2 and treatment in clinical settings,This study examines clinical with 493 word abstract...,"Author3624_1, Author3624_2",Lancet,2021-06-12,ArXiv,10.1000/sample.3624,PMC1003624,https://example.com/paper_3624,2021.0,6.0,70,10,True,54.0,8.0,True
cord-003625,Analysis of transmission and therapeutic and antiviral and coronavirus in clinical settings,,"Author3625_1, Author3625_2",Emerging Infectious Diseases,2020-01-27,medRxiv,10.1000/sample.3625,PMC1003625,https://example.com/paper_3625,2020.0,1.0,91,12,False,,,True
cord-003627,Analysis of antiviral and COVID-19 and pandemic and pneumonia in clinical settings,This study examines antiviral with 440 word abstract...,"Author3627_1, Author3627_2",Journal of Medical Virology,2021-12-31,bioRxiv,,PMC1003627,,2021.0,12.0,82,12,True,55.0,8.0,True
cord-003628,Analysis of treatment and public health and antiviral and lockdown in clinical settings,This study examines treatment with 185 word abstract...,"Author3628_1, Author3628_2",Cell,2021-11-04,Medline,10.1000/sample.3628,PMC1003628,https://example.com/paper_3628,2021.0,11.0,87,13,True,55.0,8.0,True
cord-003630,Analysis of clinical and treatment and respiratory and immunity in clinical settings,This study examines clinical with 391 word abstract...,"Author3630_1, Author3630_2",PLoS ONE,2020-12-17,ArXiv,10.1000/sample.3630,,https://example.com/paper_3630,2020.0,12.0,84,12,True,54.0,8.0,True
cord-003632,Analysis of antibody and pandemic and public health and COVID-19 in clinical settings,This study examines antibody with 235 word abstract...,"Author3632_1, Author3632_2",,2021-06-10,PMC,,PMC1003632,https://example.com/paper_3632,2021.0,6.0,85,13,True,54.0,8.0,False
cord-003633,Analysis of therapeutic and diagnosis and pneumonia in clinical settings,This study examines therapeutic with 346 word abstract...,Author3633_1,Journal of Medical Virology,2020-05-24,medRxiv,10.1000/sample.3633,,https://example.com/paper_3633,2020.0,5.0,72,10,True,57.0,8.0,True
cord-003634,Analysis of symptoms and lockdown and treatment and pneumonia in clinical settings,This study examines symptoms with 479 word abstract...,"Author3634_1, Author3634_2",PLoS ONE,2020-10-07,WHO,10.1000/sample.3634,PMC1003634,https://example.com/paper_3634,2020.0,10.0,82,12,True,54.0,8.0,True
cord-003635,Analysis of antibody and coronavirus and treatment in clinical settings,This study examines antibody with 394 word abstract...,"Author3635_1, Author3635_2",Clinical Infectious Diseases,2021-08-05,ArXiv,10.1000/sample.3635,PMC1003635,https://example.com/paper_3635,2021.0,8.0,71,10,True,54.0,8.0,True
cord-003638,Analysis of respiratory and coronavirus and epidemiology and clinical in clinical settings,This study examines respiratory with 482 word abstract...,Author3638_1,JAMA,2019-12-20,PMC,10.1000/sample.3638,PMC1003638,https://example.com/paper_3638,2019.0,12.0,90,12,True,57.0,8.0,True
cord-003639,Analysis of symptoms and lockdown and public health and SARS-CoV-2 in clinical settings,This study examines symptoms with 429 word abstract...,"Author3639_1, Author3639_2",Lancet,2019-12-11,Medline,10.1000/sample.3639,PMC1003639,,2019.0,12.0,87,13,True,54.0,8.0,True
cord-003641,Analysis of vaccination and immunity and antibody in clinical settings,This study examines vaccination with 129 word abstract...,"Author3641_1, Author3641_2",BMJ,2020-08-16,medRxiv,10.1000/sample.3641,PMC1003641,https://example.com/paper_3641,2020.0,8.0,70,10,True,57.0,8.0,True
cord-003642,Analysis of COVID-19 and SARS-CoV-2 and transmission and lockdown in clinical settings,This study examines COVID-19 with 127 word abstract...,"Author3642_1, Author3642_2",,2021-05-11,PMC,10.1000/sample.3642,PMC1003642,,2021.0,5.0,86,12,True,54.0,8.0,False
cord-003646,Analysis of public health and lockdown and outbreak in clinical settings,This study examines public health with 297 word abstract...,"Author3646_1, Author3646_2",JAMA,2020-04-07,WHO,10.1000/sample.3646,PMC1003646,https://example.com/paper_3646,2020.0,4.0,72,11,True,59.0,9.0,True
cord-003649,Analysis of immunity and pandemic and respiratory in clinical settings,This study examines immunity with 433 word abstract...,"Author3649_1, Author3649_2",Lancet,2021-09-13,Medline,10.1000/sample.3649,PMC1003649,https://example.com/paper_3649,2021.0,9.0,70,10,True,54.0,8.0,True
cord-003650,Analysis of symptoms and respiratory and coronavirus in clinical settings,This study examines symptoms with 439 word abstract...,"Author3650_1, Author3650_2",PLoS ONE,2020-08-03,medRxiv,10.1000/sample.3650,PMC1003650,https://example.com/paper_3650,2020.0,8.0,73,10,True,54.0,8.0,True
cord-003652,Analysis of therapeutic and COVID-19 and antibody and public health in clinical settings,This study examines therapeutic with 333 word abstract...,Author3652_1,BMJ,2021-08-25,ArXiv,,PMC1003652,,2021.0,8.0,88,13,True,57.0,8.0,True
cord-003653,Analysis of epidemiology and pandemic and antiviral and outbreak in clinical settings,This study examines epidemiology with 296 word abstract...,"Author3653_1, Author3653_2",Virology,2019-12-09,PMC,,PMC1003653,https://example.com/paper_3653,2019.0,12.0,85,12,True,58.0,8.0,True
cord-003655,Analysis of outbreak and lockdown and therapeutic and respiratory in clinical settings,This study examines outbreak with 478 word abstract...,"Author3655_1, Author3655_2",Journal of Virology,2020-05-31,bioRxiv,10.1000/sample.3655,,https://example.com/paper_3655,2020.0,5.0,86,12,True,54.0,8.0,True
cord-003656,Analysis of epidemiology and pandemic and SARS-CoV-2 and vaccination in clinical settings,This study examines epidemiology with 307 word abstract...,"Author3656_1, Author3656_2",Journal of Virology,2020-10-06,bioRxiv,10.1000/sample.3656,,https://example.com/paper_3656,2020.0,10.0,89,12,True,58.0,8.0,True
cord-003657,Analysis of treatment and epidemiology and COVID-19 and antibody in clinical settings,This study examines treatment with 215 word abstract...,"Author3657_1, Author3657_2",New England Journal of Medicine,2020-02-02,WHO,10.1000/sample.3657,,https://example.com/paper_3657,2020.0,2.0,85,12,True,55.0,8.0,True
cord-003658,Analysis of outbreak and immunity and transmission and lockdown in clinical settings,This study examines outbreak with 129 word abstract...,"Author3658_1, Author3658_2",Lancet,,PMC,10.1000/sample.3658,PMC1003658,,,,84,12,True,54.0,8.0,True
cord-003659,Analysis of lockdown and vaccination and diagnosis and public health in clinical settings,This study examines lockdown with 487 word abstract...,"Author3659_1, Author3659_2",,2020-06-15,bioRxiv,10.1000/sample.3659,PMC1003659,https://example.com/paper_3659,2020.0,6.0,89,13,True,54.0,8.0,False
cord-003661,Analysis of public health and SARS-CoV-2 and treatment and pneumonia in clinical settings,This study examines public health with 151 word abstract...,Author3661_1,Nature,2022-02-05,PMC,10.1000/sample.3661,PMC1003661,https://example.com/paper_3661,2022.0,2.0,89,13,True,59.0,9.0,True
cord-003662,Analysis of treatment and clinical and antibody in clinical settings,This study examines treatment with 440 word abstract...,"Author3662_1, Author3662_2",,,PMC,10.1000/sample.3662,,https://example.com/paper_3662,,,68,10,True,55.0,8.0,False
cord-003664,Analysis of antibody and pneumonia and public health and respiratory in clinical settings,This study examines antibody with 215 word abstract...,"Author3664_1, Author3664_2",Cell,2022-07-15,bioRxiv,10.1000/sample.3664,,https://example.com/paper_3664,2022.0,7.0,89,13,True,54.0,8.0,True
cord-003665,Analysis of public health and vaccination and symptoms in clinical settings,This study examines public health with 125 word abstract...,"Author3665_1, Author3665_2",Nature,2019-12-02,bioRxiv,10.1000/sample.3665,,,2019.0,12.0,75,11,True,59.0,9.0,True
cord-003666,Analysis of public health and antibody and therapeutic and lockdown in clinical settings,This study examines public health with 492 word abstract...,"Author3666_1, Author3666_2",JAMA,2022-08-19,PMC,10.1000/sample.3666,PMC1003666,https://example.com/paper_3666,2022.0,8.0,88,13,True,59.0,9.0,True
cord-003667,Analysis of epidemiology and therapeutic and pneumonia in clinical settings,This study examines epidemiology with 246 word abstract...,"Author3667_1, Author3667_2",Virology,2021-03-14,bioRxiv,10.1000/sample.3667,PMC1003667,https://example.com/paper_3667,2021.0,3.0,75,10,True,58.0,8.0,True
cord-003669,Analysis of antiviral and epidemiology and COVID-19 and clinical in clinical settings,This study examines antiviral with 445 word abstract...,"Author3669_1, Author3669_2",Clinical Infectious Diseases,2021-06-09,ArXiv,10.1000/sample.3669,,,2021.0,6.0,85,12,True,55.0,8.0,True
cord-003670,Analysis of diagnosis and SARS-CoV-2 and lockdown in clinical settings,This study examines diagnosis with 264 word abstract...,"Author3670_1, Author3670_2",Science,2020-09-09,PMC,10.1000/sample.3670,,,2020.0,9.0,70,10,True,55.0,8.0,True
cord-003672,Analysis of outbreak and antibody and immunity and treatment in clinical settings,This study examines outbreak with 245 word abstract...,"Author3672_1, Author3672_2",Journal of Medical Virology,2021-11-18,ArXiv,,PMC1003672,,2021.0,11.0,81,12,True,54.0,8.0,True
cord-003673,Analysis of antibody and symptoms and outbreak in clinical settings,This study examines antibody with 373 word abstract...,"Author3673_1, Author3673_2",Journal of Medical Virology,2020-01-30,bioRxiv,10.1000/sample.3673,,https://example.com/paper_3673,2020.0,1.0,67,10,True,54.0,8.0,True
cord-003675,Analysis of antibody and public health and pneumonia in clinical settings,This study examines antibody with 343 word abstract...,"Author3675_1, Author3675_2",,2021-09-04,bioRxiv,10.1000/sample.3675,PMC1003675,,2021.0,9.0,73,11,True,54.0,8.0,False
cord-003676,Analysis of antiviral and transmission and therapeutic in clinical settings,This study examines antiviral with 108 word abstract...,Author3676_1,Emerging Infectious Diseases,2019-12-08,Medline,10.1000/sample.3676,,https://example.com/paper_3676,2019.0,12.0,75,10,True,55.0,8.0,True
cord-003677,Analysis of clinical and respiratory and SARS-CoV-2 and lockdown in clinical settings,This study examines clinical with 291 word abstract...,Author3677_1,Journal of Medical Virology,,Medline,,,,,,85,12,True,54.0,8.0,True
cord-003678,Analysis of epidemiology and vaccination and coronavirus in clinical settings,This study examines epidemiology with 252 word abstract...,"Author3678_1, Author3678_2",,2020-05-07,PMC,10.1000/sample.3678,PMC1003678,https://example.com/paper_3678,2020.0,5.0,77,10,True,58.0,8.0,False
cord-003679,Analysis of coronavirus and clinical and vaccination in clinical settings,This study examines coronavirus with 436 word abstract...,"Author3679_1, Author3679_2",,2019-12-26,medRxiv,10.1000/sample.3679,PMC1003679,,2019.0,12.0,73,10,True,57.0,8.0,False
cord-003680,Analysis of public health and antiviral and lockdown and immunity in clinical settings,This study examines public health with 494 word abstract...,"Author3680_1, Author3680_2",Journal of Medical Virology,2021-01-10,Medline,10.1000/sample.3680,PMC1003680,https://example.com/paper_3680,2021.0,1.0,86,13,True,59.0,9.0,True
cord-003682,Analysis of pandemic and lockdown and symptoms and diagnosis in clinical settings,This study examines pandemic with 144 word abstract...,"Author3682_1, Author3682_2",Clinical Infectious Diseases,2021-03-01,PMC,10.1000/sample.3682,PMC1003682,https://example.com/paper_3682,2021.0,3.0,81,12,True,54.0,8.0,True
cord-003683,Analysis of SARS-CoV-2 and symptoms and transmission in clinical settings,This study examines SARS-CoV-2 with 304 word abstract...,"Author3683_1, Author3683_2",Journal of Medical Virology,2021-10-16,PMC,10.1000/sample.3683,PMC1003683,,2021.0,10.0,73,10,True,56.0,8.0,True
cord-003686,Analysis of epidemiology and pneumonia and antibody and pandemic in clinical settings,This study examines epidemiology with 472 word abstract...,"Author3686_1, Author3686_2",Virology,,bioRxiv,10.1000/sample.3686,PMC1003686,,,,85,12,True,58.0,8.0,True
cord-003688,Analysis of immunity and treatment and coronavirus in clinical settings,,"Author3688_1, Author3688_2",Nature Medicine,2019-12-20,WHO,,,https://example.com/paper_3688,2019.0,12.0,71,10,False,,,True
cord-003690,Analysis of transmission and public health and pneumonia and SARS-CoV-2 in clinical settings,This study examines transmission with 341 word abstract...,"Author3690_1, Author3690_2",Lancet,2021-09-18,PMC,10.1000/sample.3690,PMC1003690,https://example.com/paper_3690,2021.0,9.0,92,13,True,58.0,8.0,True
cord-003691,Analysis of antibody and diagnosis and transmission and COVID-19 in clinical settings,This study examines antibody with 125 word abstract...,"Author3691_1, Author3691_2",Science Translational Medicine,2020-07-09,PMC,10.1000/sample.3691,,https://example.com/paper_3691,2020.0,7.0,85,12,True,54.0,8.0,True
cord-003693,Analysis of coronavirus and antiviral and diagnosis and antibody in clinical settings,This study examines coronavirus with 340 word abstract...,"Author3693_1, Author3693_2",Cell,2020-04-30,ArXiv,10.1000/sample.3693,PMC1003693,https://example.com/paper_3693,2020.0,4.0,85,12,True,57.0,8.0,True
cord-003694,Analysis of symptoms and pandemic and outbreak in clinical settings,This study examines symptoms with 351 word abstract...,"Author3694_1, Author3694_2",BMJ,2022-02-10,bioRxiv,10.1000/sample.3694,PMC1003694,https://example.com/paper_3694,2022.0,2.0,67,10,True,54.0,8.0,True
cord-003695,Analysis of coronavirus and transmission and treatment and immunity in clinical settings,This study examines coronavirus with 185 word abstract...,"Author3695_1, Author3695_2",JAMA,2019-12-14,Medline,10.1000/sample.3695,,https://example.com/paper_3695,2019.0,12.0,88,12,True,57.0,8.0,True
cord-003698,Analysis of SARS-CoV-2 and treatment and immunity in clinical settings,This study examines SARS-CoV-2 with 461 word abstract...,"Author3698_1, Author3698_2",Journal of Virology,2021-09-27,PMC,10.1000/sample.3698,PMC1003698,https://example.com/paper_3698,2021.0,9.0,70,10,True,56.0,8.0,True
cord-003699,Analysis of diagnosis and coronavirus and epidemiology in clinical settings,This study examines diagnosis with 126 word abstract...,"Author3699_1, Author3699_2",Science,,ArXiv,10.1000/sample.3699,,https://example.com/paper_3699,,,75,10,True,55.0,8.0,True
cord-003703,Analysis of coronavirus and treatment and pneumonia and epidemiology in clinical settings,This study examines coronavirus with 112 word abstract...,"Author3703_1, Author3703_2",Journal of Virology,2019-12-18,bioRxiv,10.1000/sample.3703,PMC1003703,https://example.com/paper_3703,2019.0,12.0,89,12,True,57.0,8.0,True
cord-003704,Analysis of pandemic and outbreak and symptoms and COVID-19 in clinical settings,This study examines pandemic with 312 word abstract...,"Author3704_1, Author3704_2",BMJ,2021-02-04,PMC,10.1000/sample.3704,PMC1003704,https://example.com/paper_3704,2021.0,2.0,80,12,True,54.0,8.0,True
cord-003705,Analysis of SARS-CoV-2 and transmission and antibody and lockdown in clinical settings,This study examines SARS-CoV-2 with 453 word abstract...,"Author3705_1, Author3705_2",Virology,2021-03-01,Medline,10.1000/sample.3705,PMC1003705,https://example.com/paper_3705,2021.0,3.0,86,12,True,56.0,8.0,True
cord-003709,Analysis of vaccination and respiratory and immunity in clinical settings,This study examines vaccination with 158 word abstract...,Author3709_1,Nature,2021-11-06,WHO,10.1000/sample.3709,PMC1003709,https://example.com/paper_3709,2021.0,11.0,73,10,True,57.0,8.0,True
cord-003710,Analysis of symptoms and SARS-CoV-2 and pneumonia in clinical settings,This study examines symptoms with 323 word abstract...,"Author3710_1, Author3710_2",Virology,2020-08-22,bioRxiv,,,https://example.com/paper_3710,2020.0,8.0,70,10,True,54.0,8.0,True
cord-003711,Analysis of pneumonia and lockdown and therapeutic in clinical settings,This study examines pneumonia with 346 word abstract...,"Author3711_1, Author3711_2",Nature Medicine,2022-04-22,ArXiv,10.1000/sample.3711,,https://example.com/paper_3711,2022.0,4.0,71,10,True,55.0,8.0,True
cord-003716,Analysis of COVID-19 and SARS-CoV-2 and immunity and antibody in clinical settings,This study examines COVID-19 with 260 word abstract...,Author3716_1,Science,2021-11-01,medRxiv,10.1000/sample.3716,PMC1003716,https://example.com/paper_3716,2021.0,11.0,82,12,True,54.0,8.0,True
cord-003717,Analysis of transmission and diagnosis and treatment in clinical settings,This study examines transmission with 204 word abstract...,"Author3717_1, Author3717_2",JAMA,2021-03-08,bioRxiv,10.1000/sample.3717,,,2021.0,3.0,73,10,True,58.0,8.0,True
cord-003718,Analysis of vaccination and pandemic and outbreak in clinical settings,This study examines vaccination with 352 word abstract...,"Author3718_1, Author3718_2",Clinical Infectious Diseases,2020-04-27,Medline,10.1000/sample.3718,,https://example.com/paper_3718,2020.0,4.0,70,10,True,57.0,8.0,True
cord-003720,Analysis of pandemic and antibody and transmission and respiratory in clinical settings,This study examines pandemic with 444 word abstract...,"Author3720_1, Author3720_2",BMJ,2021-06-01,Medline,10.1000/sample.3720,,,2021.0,6.0,87,12,True,54.0,8.0,True
cord-003722,Analysis of immunity and vaccination and symptoms and therapeutic in clinical settings,This study examines immunity with 326 word abstract...,"Author3722_1, Author3722_2",Lancet,2020-12-12,medRxiv,10.1000/sample.3722,PMC1003722,,2020.0,12.0,86,12,True,54.0,8.0,True
cord-003723,Analysis of outbreak and coronavirus and SARS-CoV-2 in clinical settings,This study examines outbreak with 312 word abstract...,,JAMA,2021-01-30,medRxiv,10.1000/sample.3723,,,2021.0,1.0,72,10,True,54.0,8.0,True
cord-003724,Analysis of public health and COVID-19 and antibody in clinical settings,This study examines public health with 294 word abstract...,"Author3724_1, Author3724_2",PLoS ONE,2021-12-21,medRxiv,10.1000/sample.3724,PMC1003724,https://example.com/paper_3724,2021.0,12.0,72,11,True,59.0,9.0,True
cord-003728,Analysis of epidemiology and pneumonia and public health in clinical settings,This study examines epidemiology with 396 word abstract...,"Author3728_1, Author3728_2",Science Translational Medicine,2021-02-02,medRxiv,10.1000/sample.3728,PMC1003728,,2021.0,2.0,77,11,True,58.0,8.0,True
cord-003730,Analysis of treatment and antiviral and SARS-CoV-2 and outbreak in clinical settings,This study examines treatment with 475 word abstract...,"Author3730_1, Author3730_2",Journal of Medical Virology,2021-11-20,ArXiv,10.1000/sample.3730,PMC1003730,https://example.com/paper_3730,2021.0,11.0,84,12,True,55.0,8.0,True
cord-003731,Analysis of pneumonia and COVID-19 and pandemic and antibody in clinical settings,This study examines pneumonia with 213 word abstract...,"Author3731_1, Author3731_2",Cell,2020-12-08,bioRxiv,,PMC1003731,https://example.com/paper_3731,2020.0,12.0,81,12,True,55.0,8.0,True
cord-003732,Analysis of pandemic and public health and diagnosis and transmission in clinical settings,This study examines pandemic with 328 word abstract...,"Author3732_1, Author3732_2",Emerging Infectious Diseases,2021-02-02,WHO,10.1000/sample.3732,PMC1003732,https://example.com/paper_3732,2021.0,2.0,90,13,True,54.0,8.0,True
cord-003733,Analysis of COVID-19 and public health and vaccination and therapeutic in clinical settings,This study examines COVID-19 with 180 word abstract...,"Author3733_1, Author3733_2",Journal of Medical Virology,2020-11-25,ArXiv,10.1000/sample.3733,,,2020.0,11.0,91,13,True,54.0,8.0,True
cord-003734,Analysis of respiratory and vaccination and immunity in clinical settings,This study examines respiratory with 167 word abstract...,"Author3734_1, Author3734_2",Science,2020-04-05,PMC,10.1000/sample.3734,PMC1003734,https://example.com/paper_3734,2020.0,4.0,73,10,True,57.0,8.0,True
cord-003735,Analysis of symptoms and coronavirus and lockdown in clinical settings,This study examines symptoms with 264 word abstract...,Author3735_1,BMJ,,medRxiv,10.1000/sample.3735,PMC1003735,https://example.com/paper_3735,,,70,10,True,54.0,8.0,True
cord-003737,Analysis of pneumonia and treatment and clinical in clinical settings,This study examines pneumonia with 131 word abstract...,Author3737_1,Nature,2021-10-21,Medline,10.1000/sample.3737,PMC1003737,,2021.0,10.0,69,10,True,55.0,8.0,True
cord-003739,Analysis of outbreak and pandemic and immunity and pneumonia in clinical settings,This study examines outbreak with 268 word abstract...,"Author3739_1, Author3739_2",,2021-07-14,Medline,10.1000/sample.3739,PMC1003739,,2021.0,7.0,81,12,True,54.0,8.0,False
cord-003740,Analysis of lockdown and clinical and therapeutic in clinical settings,This study examines lockdown with 115 word abstract...,"Author3740_1, Author3740_2",Virology,2021-07-26,PMC,10.1000/sample.3740,PMC1003740,,2021.0,7.0,70,10,True,54.0,8.0,True
cord-003741,Analysis of antiviral and SARS-CoV-2 and epidemiology in clinical settings,This study examines antiviral with 425 word abstract...,"Author3741_1, Author3741_2",,2021-08-18,PMC,10.1000/sample.3741,PMC1003741,https://example.com/paper_3741,2021.0,8.0,74,10,True,55.0,8.0,False
cord-003743,Analysis of diagnosis and coronavirus and vaccination in clinical settings,This study examines diagnosis with 406 word abstract...,"Author3743_1, Author3743_2",,2020-11-01,PMC,10.1000/sample.3743,PMC1003743,https://example.com/paper_3743,2020.0,11.0,74,10,True,55.0,8.0,False
cord-003745,Analysis of epidemiology and symptoms and coronavirus in clinical settings,This study examines epidemiology with 133 word abstract...,"Author3745_1, Author3745_2",PLoS ONE,2021-06-15,PMC,10.1000/sample.3745,PMC1003745,https://example.com/paper_3745,2021.0,6.0,74,10,True,58.0,8.0,True
cord-003746,Analysis of outbreak and antiviral and pneumonia in clinical settings,This study examines outbreak with 254 word abstract...,"Author3746_1, Author3746_2",Journal of Virology,2021-12-29,Medline,10.1000/sample.3746,PMC1003746,https://example.com/paper_3746,2021.0,12.0,69,10,True,54.0,8.0,True
cord-003747,Analysis of vaccination and outbreak and therapeutic in clinical settings,This study examines vaccination with 494 word abstract...,"Author3747_1, Author3747_2",New England Journal of Medicine,2020-10-17,Medline,10.1000/sample.3747,PMC1003747,,2020.0,10.0,73,10,True,57.0,8.0,True
cord-003748,Analysis of outbreak and public health and epidemiology and treatment in clinical settings,This study examines outbreak with 276 word abstract...,"Author3748_1, Author3748_2",Clinical Infectious Diseases,2019-12-13,WHO,,,https://example.com/paper_3748,2019.0,12.0,90,13,True,54.0,8.0,True
cord-003750,Analysis of public health and antiviral and pandemic and respiratory in clinical settings,This study examines public health with 151 word abstract...,"Author3750_1, Author3750_2",Cell,2020-06-23,medRxiv,10.1000/sample.3750,,https://example.com/paper_3750,2020.0,6.0,89,13,True,59.0,9.0,True
cord-003752,Analysis of clinical and antiviral and SARS-CoV-2 and vaccination in clinical settings,This study examines clinical with 445 word abstract...,"Author3752_1, Author3752_2",Virology,2021-11-17,Medline,10.1000/sample.3752,,https://example.com/paper_3752,2021.0,11.0,86,12,True,54.0,8.0,True
cord-003753,Analysis of symptoms and pandemic and therapeutic and immunity in clinical settings,This study examines symptoms with 269 word abstract...,"Author3753_1, Author3753_2",New England Journal of Medicine,,ArXiv,10.1000/sample.3753,PMC1003753,https://example.com/paper_3753,,,83,12,True,54.0,8.0,True
cord-003754,Analysis of public health and outbreak and therapeutic in clinical settings,,"Author3754_1, Author3754_2",Journal of Medical Virology,2019-12-05,PMC,10.1000/sample.3754,,https://example.com/paper_3754,2019.0,12.0,75,11,False,,,True
cord-003755,Analysis of treatment and symptoms and pandemic and public health in clinical settings,This study examines treatment with 161 word abstract...,"Author3755_1, Author3755_2",Nature,2020-12-20,Medline,10.1000/sample.3755,PMC1003755,https://example.com/paper_3755,2020.0,12.0,86,13,True,55.0,8.0,True
cord-003757,Analysis of epidemiology and treatment and antiviral and vaccination in clinical settings,This study examines epidemiology with 456 word abstract...,"Author3757_1, Author3757_2",New England Journal of Medicine,2019-12-14,WHO,10.1000/sample.3757,PMC1003757,https://example.com/paper_3757,2019.0,12.0,89,12,True,58.0,8.0,True
cord-003759,Analysis of symptoms and therapeutic and antiviral and COVID-19 in clinical settings,This study examines symptoms with 244 word abstract...,Author3759_1,Science,2020-10-15,Medline,10.1000/sample.3759,,https://example.com/paper_3759,2020.0,10.0,84,12,True,54.0,8.0,True
cord-003760,Analysis of therapeutic and SARS-CoV-2 and epidemiology and vaccination in clinical settings,,"Author3760_1, Author3760_2",Nature Medicine,2020-08-25,Medline,10.1000/sample.3760,PMC1003760,https://example.com/paper_3760,2020.0,8.0,92,12,False,,,True
cord-003761,Analysis of respiratory and symptoms and clinical in clinical settings,This study examines respiratory with 305 word abstract...,Author3761_1,Science,2020-03-12,bioRxiv,10.1000/sample.3761,PMC1003761,https://example.com/paper_3761,2020.0,3.0,70,10,True,57.0,8.0,True
cord-003763,Analysis of respiratory and public health and transmission and antiviral in clinical settings,This study examines respiratory with 122 word abstract...,"Author3763_1, Author3763_2",Lancet,2020-07-01,ArXiv,,PMC1003763,https://example.com/paper_3763,2020.0,7.0,93,13,True,57.0,8.0,True
cord-003764,Analysis of clinical and pandemic and treatment and antibody in clinical settings,This study examines clinical with 255 word abstract...,"Author3764_1, Author3764_2",Clinical Infectious Diseases,2021-09-12,medRxiv,,,,2021.0,9.0,81,12,True,54.0,8.0,True
cord-003765,Analysis of SARS-CoV-2 and pandemic and immunity in clinical settings,This study examines SARS-CoV-2 with 276 word abstract...,"Author3765_1, Author3765_2",BMJ,2021-06-06,medRxiv,10.1000/sample.3765,PMC1003765,,2021.0,6.0,69,10,True,56.0,8.0,True
cord-003766,Analysis of treatment and clinical and coronavirus and vaccination in clinical settings,This study examines treatment with 428 word abstract...,"Author3766_1, Author3766_2",Journal of Virology,2021-08-06,medRxiv,10.1000/sample.3766,PMC1003766,https://example.com/paper_3766,2021.0,8.0,87,12,True,55.0,8.0,True
cord-003771,Analysis of immunity and transmission and SARS-CoV-2 in clinical settings,This study examines immunity with 392 word abstract...,"Author3771_1, Author3771_2",,2020-07-15,ArXiv,10.1000/sample.3771,,https://example.com/paper_3771,2020.0,7.0,73,10,True,54.0,8.0,False
cord-003772,Analysis of respiratory and diagnosis and symptoms and vaccination in clinical settings,This study examines respiratory with 227 word abstract...,"Author3772_1, Author3772_2",Nature,2020-10-25,WHO,10.1000/sample.3772,PMC1003772,https://example.com/paper_3772,2020.0,10.0,87,12,True,57.0,8.0,True
cord-003773,Analysis of vaccination and antibody and lockdown and clinical in clinical settings,This study examines vaccination with 493 word abstract...,"Author3773_1, Author3773_2",Clinical Infectious Diseases,,ArXiv,,,,,,83,12,True,57.0,8.0,True
cord-003775,Analysis of vaccination and diagnosis and SARS-CoV-2 in clinical settings,This study examines vaccination with 348 word abstract...,"Author3775_1, Author3775_2",Journal of Medical Virology,2021-04-08,PMC,10.1000/sample.3775,,https://example.com/paper_3775,2021.0,4.0,73,10,True,57.0,8.0,True
cord-003776,Analysis of symptoms and outbreak and public health and antibody in clinical settings,This study examines symptoms with 402 word abstract...,"Author3776_1, Author3776_2",New England Journal of Medicine,2021-07-25,WHO,10.1000/sample.3776,PMC1003776,https://example.com/paper_3776,2021.0,7.0,85,13,True,54.0,8.0,True
cord-003777,Analysis of symptoms and clinical and diagnosis and respiratory in clinical settings,This study examines symptoms with 421 word abstract...,"Author3777_1, Author3777_2",Journal of Medical Virology,2021-02-20,medRxiv,10.1000/sample.3777,PMC1003777,,2021.0,2.0,84,12,True,54.0,8.0,True
cord-003778,Analysis of clinical and immunity and pneumonia and transmission in clinical settings,This study examines clinical with 110 word abstract...,"Author3778_1, Author3778_2",Nature,2021-10-01,ArXiv,10.1000/sample.3778,PMC1003778,https://example.com/paper_3778,2021.0,10.0,85,12,True,54.0,8.0,True
cord-003781,Analysis of pneumonia and respiratory and outbreak in clinical settings,This study examines pneumonia with 361 word abstract...,Author3781_1,Nature,2020-08-19,medRxiv,10.1000/sample.3781,,https://example.com/paper_3781,2020.0,8.0,71,10,True,55.0,8.0,True
cord-003782,Analysis of symptoms and diagnosis and therapeutic and immunity in clinical settings,This study examines symptoms with 323 word abstract...,"Author3782_1, Author3782_2",,2020-02-29,medRxiv,10.1000/sample.3782,PMC1003782,https://example.com/paper_3782,2020.0,2.0,84,12,True,54.0,8.0,False
cord-003787,Analysis of SARS-CoV-2 and antiviral and respiratory and pneumonia in clinical settings,This study examines SARS-CoV-2 with 270 word abstract...,"Author3787_1, Author3787_2",Cell,2020-12-25,medRxiv,10.1000/sample.3787,PMC1003787,https://example.com/paper_3787,2020.0,12.0,87,12,True,56.0,8.0,True
cord-003788,Analysis of pandemic and SARS-CoV-2 and diagnosis and respiratory in clinical settings,This study examines pandemic with 205 word abstract...,Author3788_1,JAMA,2020-10-09,bioRxiv,,,https://example.com/paper_3788,2020.0,10.0,86,12,True,54.0,8.0,True
cord-003791,Analysis of public health and outbreak and respiratory and lockdown in clinical settings,This study examines public health with 253 word abstract...,"Author3791_1, Author3791_2",Clinical Infectious Diseases,2020-02-22,Medline,,PMC1003791,https://example.com/paper_3791,2020.0,2.0,88,13,True,59.0,9.0,True
cord-003792,Analysis of SARS-CoV-2 and public health and diagnosis in clinical settings,This study examines SARS-CoV-2 with 445 word abstract...,"Author3792_1, Author3792_2",,2020-02-18,PMC,10.1000/sample.3792,PMC1003792,https://example.com/paper_3792,2020.0,2.0,75,11,True,56.0,8.0,False
cord-003793,Analysis of antiviral and symptoms and treatment in clinical settings,This study examines antiviral with 221 word abstract...,"Author3793_1, Author3793_2",Virology,2020-10-14,Medline,10.1000/sample.3793,PMC1003793,https://example.com/paper_3793,2020.0,10.0,69,10,True,55.0,8.0,True
cord-003795,Analysis of epidemiology and vaccination and diagnosis and SARS-CoV-2 in clinical settings,This study examines epidemiology with 416 word abstract...,"Author3795_1, Author3795_2",Virology,2020-08-19,medRxiv,10.1000/sample.3795,PMC1003795,https://example.com/paper_3795,2020.0,8.0,90,12,True,58.0,8.0,True
cord-003796,Analysis of pneumonia and antiviral and immunity and treatment in clinical settings,This study examines pneumonia with 259 word abstract...,"Author3796_1, Author3796_2",,2020-12-19,ArXiv,10.1000/sample.3796,PMC1003796,https://example.com/paper_3796,2020.0,12.0,83,12,True,55.0,8.0,False
cord-003797,Analysis of pandemic and outbreak and clinical in clinical settings,This study examines pandemic with 183 word abstract...,"Author3797_1, Author3797_2",PLoS ONE,2020-10-04,WHO,10.1000/sample.3797,PMC1003797,https://example.com/paper_3797,2020.0,10.0,67,10,True,54.0,8.0,True
cord-003798,Analysis of clinical and symptoms and coronavirus in clinical settings,This study examines clinical with 308 word abstract...,"Author3798_1, Author3798_2",,2021-01-07,bioRxiv,,PMC1003798,,2021.0,1.0,70,10,True,54.0,8.0,False
cord-003799,Analysis of vaccination and respiratory and public health and clinical in clinical settings,This study examines vaccination with 301 word abstract...,"Author3799_1, Author3799_2",Clinical Infectious Diseases,2021-11-29,PMC,,PMC1003799,https://example.com/paper_3799,2021.0,11.0,91,13,True,57.0,8.0,True
cord-003801,Analysis of pandemic and therapeutic and antibody in clinical settings,This study examines pandemic with 242 word abstract...,"Author3801_1, Author3801_2",Journal of Virology,2022-12-02,PMC,10.1000/sample.3801,PMC1003801,https://example.com/paper_3801,2022.0,12.0,70,10,True,54.0,8.0,True
cord-003802,Analysis of SARS-CoV-2 and treatment and antiviral in clinical settings,This study examines SARS-CoV-2 with 195 word abstract...,"Author3802_1, Author3802_2",Nature Medicine,2020-12-27,WHO,10.1000/sample.3802,PMC1003802,https://example.com/paper_3802,2020.0,12.0,71,10,True,56.0,8.0,True
cord-003803,Analysis of treatment and pandemic and antiviral in clinical settings,This study examines treatment with 227 word abstract...,"Author3803_1, Author3803_2",Nature Medicine,2021-07-13,WHO,10.1000/sample.3803,,,2021.0,7.0,69,10,True,55.0,8.0,True
cord-003804,Analysis of symptoms and immunity and coronavirus in clinical settings,This study examines symptoms with 311 word abstract...,"Author3804_1, Author3804_2",Journal of Virology,2020-07-23,WHO,10.1000/sample.3804,PMC1003804,,2020.0,7.0,70,10,True,54.0,8.0,True
cord-003806,Analysis of diagnosis and epidemiology in clinical settings,This study examines diagnosis with 161 word abstract...,"Author3806_1, Author3806_2",,2020-06-17,ArXiv,10.1000/sample.3806,PMC1003806,https://example.com/paper_3806,2020.0,6.0,59,8,True,55.0,8.0,False
cord-003807,Analysis of respiratory and SARS-CoV-2 and therapeutic and transmission in clinical settings,This study examines respiratory with 113 word abstract...,"Author3807_1, Author3807_2",Journal of Virology,2020-01-03,Medline,,,https://example.com/paper_3807,2020.0,1.0,92,12,True,57.0,8.0,True
cord-003809,Analysis of pneumonia and pandemic and respiratory in clinical settings,This study examines pneumonia with 277 word abstract...,Author3809_1,Nature,2020-11-10,ArXiv,10.1000/sample.3809,PMC1003809,https://example.com/paper_3809,2020.0,11.0,71,10,True,55.0,8.0,True
cord-003810,Analysis of transmission and immunity and SARS-CoV-2 and therapeutic in clinical settings,This study examines transmission with 244 word abstract...,"Author3810_1, Author3810_2",Emerging Infectious Diseases,2019-12-01,WHO,10.1000/sample.3810,PMC1003810,https://example.com/paper_3810,2019.0,12.0,89,12,True,58.0,8.0,True
cord-003813,Analysis of antiviral and immunity and therapeutic in clinical settings,This study examines antiviral with 202 word abstract...,"Author3813_1, Author3813_2",Science Translational Medicine,2019-12-29,PMC,10.1000/sample.3813,,https://example.com/paper_3813,2019.0,12.0,71,10,True,55.0,8.0,True
cord-003814,Analysis of epidemiology and antiviral and diagnosis and treatment in clinical settings,This study examines epidemiology with 294 word abstract...,,Journal of Medical Virology,2019-12-18,PMC,10.1000/sample.3814,PMC1003814,https://example.com/paper_3814,2019.0,12.0,87,12,True,58.0,8.0,True
cord-003817,Analysis of respiratory and COVID-19 and therapeutic and pandemic in clinical settings,This study examines respiratory with 132 word abstract...,"Author3817_1, Author3817_2",Virology,2021-09-30,ArXiv,,,https://example.com/paper_3817,2021.0,9.0,86,12,True,57.0,8.0,True
cord-003818,Analysis of SARS-CoV-2 and transmission and symptoms in clinical settings,This study examines SARS-CoV-2 with 229 word abstract...,"Author3818_1, Author3818_2",Virology,2021-08-15,bioRxiv,10.1000/sample.3818,PMC1003818,https://example.com/paper_3818,2021.0,8.0,73,10,True,56.0,8.0,True
cord-003819,Analysis of immunity and coronavirus and vaccination and lockdown in clinical settings,This study examines immunity with 243 word abstract...,"Author3819_1, Author3819_2",New England Journal of Medicine,2020-01-15,medRxiv,10.1000/sample.3819,,https://example.com/paper_3819,2020.0,1.0,86,12,True,54.0,8.0,True
cord-003820,Analysis of pneumonia and clinical and therapeutic in clinical settings,This study examines pneumonia with 478 word abstract...,"Author3820_1, Author3820_2",PLoS ONE,,bioRxiv,10.1000/sample.3820,PMC1003820,https://example.com/paper_3820,,,71,10,True,55.0,8.0,True
cord-003823,Analysis of coronavirus and SARS-CoV-2 and COVID-19 in clinical settings,This study examines coronavirus with 357 word abstract...,"Author3823_1, Author3823_2",Science,2019-12-14,bioRxiv,10.1000/sample.3823,PMC1003823,https://example.com/paper_3823,2019.0,12.0,72,10,True,57.0,8.0,True
cord-003825,Analysis of outbreak and antiviral and clinical in clinical settings,This study examines outbreak with 109 word abstract...,"Author3825_1, Author3825_2",Cell,2019-12-08,bioRxiv,10.1000/sample.3825,PMC1003825,,2019.0,12.0,68,10,True,54.0,8.0,True
cord-003827,Analysis of pandemic and antibody and respiratory in clinical settings,This study examines pandemic with 222 word abstract...,"Author3827_1, Author3827_2",Nature Medicine,2021-10-08,WHO,10.1000/sample.3827,PMC1003827,https://example.com/paper_3827,2021.0,10.0,70,10,True,54.0,8.0,True
cord-003828,Analysis of clinical and coronavirus and vaccination and public health in clinical settings,This study examines clinical with 325 word abstract...,"Author3828_1, Author3828_2",Clinical Infectious Diseases,2021-11-05,ArXiv,10.1000/sample.3828,PMC1003828,https://example.com/paper_3828,2021.0,11.0,91,13,True,54.0,8.0,True
cord-003830,Analysis of pneumonia and vaccination and immunity in clinical settings,This study examines pneumonia with 167 word abstract...,,Nature Medicine,2021-12-14,medRxiv,10.1000/sample.3830,PMC1003830,,2021.0,12.0,71,10,True,55.0,8.0,True
cord-003832,Analysis of public health and therapeutic and pandemic and treatment in clinical settings,This study examines public health with 453 word abstract...,"Author3832_1, Author3832_2",Science,2021-09-29,bioRxiv,10.1000/sample.3832,PMC1003832,,2021.0,9.0,89,13,True,59.0,9.0,True
cord-003834,Analysis of SARS-CoV-2 and lockdown and respiratory and symptoms in clinical settings,This study examines SARS-CoV-2 with 149 word abstract...,"Author3834_1, Author3834_2",Virology,2021-03-01,bioRxiv,10.1000/sample.3834,PMC1003834,https://example.com/paper_3834,2021.0,3.0,85,12,True,56.0,8.0,True
cord-003836,Analysis of vaccination and antibody and symptoms in clinical settings,This study examines vaccination with 446 word abstract...,"Author3836_1, Author3836_2",Journal of Virology,2021-07-27,WHO,10.1000/sample.3836,PMC1003836,https://example.com/paper_3836,2021.0,7.0,70,10,True,57.0,8.0,True
cord-003837,Analysis of clinical and symptoms and outbreak in clinical settings,This study examines clinical with 375 word abstract...,"Author3837_1, Author3837_2",Science Translational Medicine,,Medline,10.1000/sample.3837,PMC1003837,,,,67,10,True,54.0,8.0,True
cord-003841,Analysis of therapeutic and outbreak and immunity and symptoms in clinical settings,This study examines therapeutic with 278 word abstract...,"Author3841_1, Author3841_2",New England Journal of Medicine,2019-12-20,Medline,10.1000/sample.3841,PMC1003841,https://example.com/paper_3841,2019.0,12.0,83,12,True,57.0,8.0,True
cord-003842,Analysis of respiratory and immunity and lockdown in clinical settings,This study examines respiratory with 284 word abstract...,"Author3842_1, Author3842_2",Emerging Infectious Diseases,,medRxiv,10.1000/sample.3842,PMC1003842,https://example.com/paper_3842,,,70,10,True,57.0,8.0,True
cord-003843,Analysis of antiviral and SARS-CoV-2 and transmission and vaccination in clinical settings,This study examines antiviral with 213 word abstract...,Author3843_1,,2019-12-08,ArXiv,10.1000/sample.3843,,https://example.com/paper_3843,2019.0,12.0,90,12,True,55.0,8.0,False
cord-003846,Analysis of coronavirus and therapeutic and clinical in clinical settings,This study examines coronavirus with 234 word abstract...,"Author3846_1, Author3846_2",PLoS ONE,2020-12-05,WHO,10.1000/sample.3846,PMC1003846,,2020.0,12.0,73,10,True,57.0,8.0,True
cord-003847,Analysis of therapeutic and epidemiology and COVID-19 and treatment in clinical settings,This study examines therapeutic with 323 word abstract...,"Author3847_1, Author3847_2",New England Journal of Medicine,2021-10-15,PMC,10.1000/sample.3847,PMC1003847,https://example.com/paper_3847,2021.0,10.0,88,12,True,57.0,8.0,True
cord-003849,Analysis of antibody and therapeutic and symptoms in clinical settings,This study examines antibody with 479 word abstract...,Author3849_1,Lancet,2021-06-08,bioRxiv,10.1000/sample.3849,PMC1003849,https://example.com/paper_3849,2021.0,6.0,70,10,True,54.0,8.0,True
cord-003851,Analysis of pandemic and SARS-CoV-2 and antibody in clinical settings,This study examines pandemic with 308 word abstract...,,Cell,2021-11-12,Medline,10.1000/sample.3851,,https://example.com/paper_3851,2021.0,11.0,69,10,True,54.0,8.0,True
cord-003852,Analysis of immunity and respiratory and public health and epidemiology in clinical settings,This study examines immunity with 249 word abstract...,"Author3852_1, Author3852_2",PLoS ONE,2020-09-22,Medline,10.1000/sample.3852,PMC1003852,https://example.com/paper_3852,2020.0,9.0,92,13,True,54.0,8.0,True
cord-003853,Analysis of SARS-CoV-2 and vaccination and transmission in clinical settings,This study examines SARS-CoV-2 with 296 word abstract...,"Author3853_1, Author3853_2",JAMA,2019-12-12,ArXiv,10.1000/sample.3853,,,2019.0,12.0,76,10,True,56.0,8.0,True
cord-003854,Analysis of public health and COVID-19 and immunity and respiratory in clinical settings,This study examines public health with 173 word abstract...,"Author3854_1, Author3854_2",Emerging Infectious Diseases,2020-10-03,bioRxiv,10.1000/sample.3854,PMC1003854,https://example.com/paper_3854,2020.0,10.0,88,13,True,59.0,9.0,True
cord-003855,Analysis of transmission and treatment and COVID-19 and antiviral in clinical settings,This study examines transmission with 168 word abstract...,Author3855_1,Journal of Medical Virology,2020-04-17,Medline,10.1000/sample.3855,,,2020.0,4.0,86,12,True,58.0,8.0,True
cord-003856,Analysis of pandemic and COVID-19 and epidemiology and SARS-CoV-2 in clinical settings,This study examines pandemic with 175 word abstract...,"Author3856_1, Author3856_2",Science Translational Medicine,2020-01-02,PMC,10.1000/sample.3856,PMC1003856,https://example.com/paper_3856,2020.0,1.0,86,12,True,54.0,8.0,True
cord-003858,Analysis of COVID-19 and epidemiology and coronavirus in clinical settings,This study examines COVID-19 with 206 word abstract...,"Author3858_1, Author3858_2",PLoS ONE,2020-05-19,PMC,10.1000/sample.3858,PMC1003858,https://example.com/paper_3858,2020.0,5.0,74,10,True,54.0,8.0,True
cord-003859,Analysis of vaccination and clinical and coronavirus and pneumonia in clinical settings,This study examines vaccination with 124 word abstract...,"Author3859_1, Author3859_2",New England Journal of Medicine,2020-11-17,medRxiv,10.1000/sample.3859,PMC1003859,,2020.0,11.0,87,12,True,57.0,8.0,True
cord-003860,Analysis of lockdown and outbreak and diagnosis in clinical settings,This study examines lockdown with 341 word abstract...,"Author3860_1, Author3860_2",Science,2021-10-28,bioRxiv,10.1000/sample.3860,PMC1003860,https://example.com/paper_3860,2021.0,10.0,68,10,True,54.0,8.0,True
cord-003862,Analysis of pandemic and public health and outbreak and antiviral in clinical settings,This study examines pandemic with 189 word abstract...,"Author3862_1, Author3862_2",Emerging Infectious Diseases,2020-12-22,WHO,10.1000/sample.3862,PMC1003862,https://example.com/paper_3862,2020.0,12.0,86,13,True,54.0,8.0,True
cord-003865,Analysis of antibody and COVID-19 and vaccination and pandemic in clinical settings,,"Author3865_1, Author3865_2",Science,2020-04-17,PMC,10.1000/sample.3865,PMC1003865,https://example.com/paper_3865,2020.0,4.0,83,12,False,,,True
cord-003866,Analysis of immunity and pandemic and outbreak in clinical settings,This study examines immunity with 236 word abstract...,Author3866_1,Science Translational Medicine,2021-08-06,ArXiv,10.1000/sample.3866,,https://example.com/paper_3866,2021.0,8.0,67,10,True,54.0,8.0,True
cord-003871,Analysis of diagnosis and antiviral and coronavirus and outbreak in clinical settings,This study examines diagnosis with 421 word abstract...,"Author3871_1, Author3871_2",Lancet,2020-09-19,Medline,10.1000/sample.3871,,,2020.0,9.0,85,12,True,55.0,8.0,True
cord-003872,Analysis of diagnosis and clinical and transmission in clinical settings,This study examines diagnosis with 281 word abstract...,"Author3872_1, Author3872_2",Journal of Medical Virology,2021-03-03,bioRxiv,10.1000/sample.3872,PMC1003872,https://example.com/paper_3872,2021.0,3.0,72,10,True,55.0,8.0,True
cord-003878,Analysis of outbreak and respiratory and treatment in clinical settings,This study examines outbreak with 460 word abstract...,"Author3878_1, Author3878_2",Cell,2021-12-12,ArXiv,10.1000/sample.3878,,,2021.0,12.0,71,10,True,54.0,8.0,True
cord-003879,Analysis of coronavirus and pneumonia and outbreak and vaccination in clinical settings,This study examines coronavirus with 158 word abstract...,"Author3879_1, Author3879_2",Clinical Infectious Diseases,2021-06-10,bioRxiv,10.1000/sample.3879,PMC1003879,,2021.0,6.0,87,12,True,57.0,8.0,True
cord-003881,Analysis of clinical and antiviral and lockdown and treatment in clinical settings,This study examines clinical with 450 word abstract...,"Author3881_1, Author3881_2",Nature Medicine,2022-04-01,WHO,10.1000/sample.3881,PMC1003881,https://example.com/paper_3881,2022.0,4.0,82,12,True,54.0,8.0,True
cord-003882,Analysis of therapeutic and antiviral and pneumonia in clinical settings,This study examines therapeutic with 476 word abstract...,"Author3882_1, Author3882_2",BMJ,2021-11-05,medRxiv,10.1000/sample.3882,PMC1003882,,2021.0,11.0,72,10,True,57.0,8.0,True
cord-003883,Analysis of transmission and pandemic and lockdown and coronavirus in clinical settings,This study examines transmission with 469 word abstract...,"Author3883_1, Author3883_2",Virology,2020-07-13,ArXiv,10.1000/sample.3883,PMC1003883,https://example.com/paper_3883,2020.0,7.0,87,12,True,58.0,8.0,True
cord-003884,Analysis of epidemiology and vaccination and transmission in clinical settings,This study examines epidemiology with 440 word abstract...,"Author3884_1, Author3884_2",PLoS ONE,2020-07-26,Medline,10.1000/sample.3884,PMC1003884,https://example.com/paper_3884,2020.0,7.0,78,10,True,58.0,8.0,True
cord-003885,Analysis of coronavirus and diagnosis and pandemic in clinical settings,This study examines coronavirus with 348 word abstract...,"Author3885_1, Author3885_2",Cell,2022-05-11,Medline,10.1000/sample.3885,PMC1003885,https://example.com/paper_3885,2022.0,5.0,71,10,True,57.0,8.0,True
cord-003886,Analysis of public health and diagnosis and coronavirus in clinical settings,This study examines public health with 244 word abstract...,"Author3886_1, Author3886_2",BMJ,2021-01-11,ArXiv,10.1000/sample.3886,PMC1003886,,2021.0,1.0,76,11,True,59.0,9.0,True
cord-003892,Analysis of antibody and pneumonia and respiratory and symptoms in clinical settings,This study examines antibody with 252 word abstract...,"Author3892_1, Author3892_2",Clinical Infectious Diseases,2020-04-03,PMC,10.1000/sample.3892,,https://example.com/paper_3892,2020.0,4.0,84,12,True,54.0,8.0,True
cord-003893,Analysis of pandemic and respiratory and transmission and vaccination in clinical settings,This study examines pandemic with 491 word abstract...,"Author3893_1, Author3893_2",,2021-03-27,ArXiv,10.1000/sample.3893,PMC1003893,,2021.0,3.0,90,12,True,54.0,8.0,False
cord-003894,Analysis of antiviral and vaccination and transmission and outbreak in clinical settings,This study examines antiviral with 168 word abstract...,Author3894_1,JAMA,2020-04-15,PMC,10.1000/sample.3894,PMC1003894,,2020.0,4.0,88,12,True,55.0,8.0,True
cord-003895,Analysis of vaccination and diagnosis and COVID-19 and pandemic in clinical settings,This study examines vaccination with 456 word abstract...,"Author3895_1, Author3895_2",BMJ,2021-08-31,Medline,10.1000/sample.3895,PMC1003895,https://example.com/paper_3895,2021.0,8.0,84,12,True,57.0,8.0,True
cord-003896,Analysis of vaccination and lockdown and pandemic and antiviral in clinical settings,This study examines vaccination with 187 word abstract...,"Author3896_1, Author3896_2",Cell,2022-03-09,medRxiv,10.1000/sample.3896,PMC1003896,,2022.0,3.0,84,12,True,57.0,8.0,True
cord-003897,Analysis of outbreak and pneumonia and vaccination in clinical settings,This study examines outbreak with 410 word abstract...,Author3897_1,Lancet,2021-02-19,ArXiv,10.1000/sample.3897,PMC1003897,https://example.com/paper_3897,2021.0,2.0,71,10,True,54.0,8.0,True
cord-003899,Analysis of immunity and respiratory and outbreak and treatment in clinical settings,This study examines immunity with 358 word abstract...,"Author3899_1, Author3899_2",New England Journal of Medicine,2019-12-31,PMC,10.1000/sample.3899,PMC1003899,https://example.com/paper_3899,2019.0,12.0,84,12,True,54.0,8.0,True
cord-003901,Analysis of public health and therapeutic and lockdown in clinical settings,This study examines public health with 158 word abstract...,"Author3901_1, Author3901_2",Emerging Infectious Diseases,2020-08-14,PMC,10.1000/sample.3901,PMC1003901,https://example.com/paper_3901,2020.0,8.0,75,11,True,59.0,9.0,True
cord-003902,Analysis of antibody and SARS-CoV-2 and clinical and treatment in clinical settings,This study examines antibody with 143 word abstract...,"Author3902_1, Author3902_2",BMJ,2022-12-31,medRxiv,10.1000/sample.3902,PMC1003902,,2022.0,12.0,83,12,True,54.0,8.0,True
cord-003903,Analysis of pneumonia and antibody and epidemiology and transmission in clinical settings,This study examines pneumonia with 420 word abstract...,Author3903_1,Clinical Infectious Diseases,2021-10-17,PMC,10.1000/sample.3903,PMC1003903,https://example.com/paper_3903,2021.0,10.0,89,12,True,55.0,8.0,True
cord-003904,Analysis of vaccination and epidemiology and lockdown and SARS-CoV-2 in clinical settings,This study examines vaccination with 321 word abstract...,"Author3904_1, Author3904_2",Journal of Virology,2020-01-21,bioRxiv,,,https://example.com/paper_3904,2020.0,1.0,89,12,True,57.0,8.0,True
cord-003906,Analysis of epidemiology and outbreak and respiratory in clinical settings,,"Author3906_1, Author3906_2",Lancet,2020-12-21,PMC,10.1000/sample.3906,PMC1003906,https://example.com/paper_3906,2020.0,12.0,74,10,False,,,True
cord-003907,Analysis of transmission and lockdown and pneumonia in clinical settings,This study examines transmission with 416 word abstract...,"Author3907_1, Author3907_2",,2020-04-13,WHO,10.1000/sample.3907,,https://example.com/paper_3907,2020.0,4.0,72,10,True,58.0,8.0,False
cord-003908,Analysis of epidemiology and pneumonia and respiratory and clinical in clinical settings,This study examines epidemiology with 406 word abstract...,"Author3908_1, Author3908_2",Nature,2020-07-11,WHO,10.1000/sample.3908,,https://example.com/paper_3908,2020.0,7.0,88,12,True,58.0,8.0,True
cord-003909,Analysis of clinical and antiviral and respiratory in clinical settings,This study examines clinical with 177 word abstract...,"Author3909_1, Author3909_2",Journal of Medical Virology,,PMC,10.1000/sample.3909,PMC1003909,https://example.com/paper_3909,,,71,10,True,54.0,8.0,True
cord-003912,Analysis of outbreak and SARS-CoV-2 and respiratory and diagnosis in clinical settings,This study examines outbreak with 199 word abstract...,"Author3912_1, Author3912_2",BMJ,2020-01-22,ArXiv,10.1000/sample.3912,PMC1003912,https://example.com/paper_3912,2020.0,1.0,86,12,True,54.0,8.0,True
cord-003915,Analysis of immunity and treatment and epidemiology in clinical settings,This study examines immunity with 417 word abstract...,"Author3915_1, Author3915_2",Journal of Medical Virology,2020-10-02,WHO,10.1000/sample.3915,,,2020.0,10.0,72,10,True,54.0,8.0,True
cord-003916,Analysis of antiviral and coronavirus and COVID-19 and diagnosis in clinical settings,This study examines antiviral with 476 word abstract...,"Author3916_1, Author3916_2",Cell,2021-12-19,medRxiv,10.1000/sample.3916,,https://example.com/paper_3916,2021.0,12.0,85,12,True,55.0,8.0,True
cord-003917,Analysis of treatment and immunity and therapeutic and public health in clinical settings,This study examines treatment with 321 word abstract...,"Author3917_1, Author3917_2",Emerging Infectious Diseases,2020-02-23,Medline,10.1000/sample.3917,,,2020.0,2.0,89,13,True,55.0,8.0,True
cord-003918,Analysis of clinical and vaccination and lockdown in clinical settings,This study examines clinical with 275 word abstract...,"Author3918_1, Author3918_2",Journal of Medical Virology,2019-12-02,Medline,10.1000/sample.3918,PMC1003918,,2019.0,12.0,70,10,True,54.0,8.0,True
cord-003923,Analysis of immunity and treatment and antiviral in clinical settings,This study examines immunity with 195 word abstract...,,Journal of Medical Virology,2021-04-13,Medline,10.1000/sample.3923,PMC1003923,https://example.com/paper_3923,2021.0,4.0,69,10,True,54.0,8.0,True
cord-003924,Analysis of SARS-CoV-2 and immunity and respiratory and epidemiology in clinical settings,This study examines SARS-CoV-2 with 319 word abstract...,Author3924_1,Emerging Infectious Diseases,2019-12-09,PMC,10.1000/sample.3924,PMC1003924,,2019.0,12.0,89,12,True,56.0,8.0,True
cord-003925,Analysis of pneumonia and diagnosis and outbreak and public health in clinical settings,This study examines pneumonia with 492 word abstract...,"Author3925_1, Author3925_2",JAMA,2021-06-25,WHO,10.1000/sample.3925,,https://example.com/paper_3925,2021.0,6.0,87,13,True,55.0,8.0,True
cord-003926,Analysis of treatment and vaccination and clinical and transmission in clinical settings,This study examines treatment with 287 word abstract...,"Author3926_1, Author3926_2",Nature Medicine,2022-05-09,bioRxiv,,PMC1003926,,2022.0,5.0,88,12,True,55.0,8.0,True
cord-003927,Analysis of vaccination and public health and immunity in clinical settings,This study examines vaccination with 498 word abstract...,"Author3927_1, Author3927_2",Science Translational Medicine,2020-10-06,PMC,10.1000/sample.3927,PMC1003927,https://example.com/paper_3927,2020.0,10.0,75,11,True,57.0,8.0,True
cord-003928,Analysis of clinical and immunity and symptoms in clinical settings,This study examines clinical with 304 word abstract...,"Author3928_1, Author3928_2",Science,2020-01-11,ArXiv,10.1000/sample.3928,PMC1003928,https://example.com/paper_3928,2020.0,1.0,67,10,True,54.0,8.0,True
cord-003930,Analysis of COVID-19 and SARS-CoV-2 and immunity in clinical settings,This study examines COVID-19 with 264 word abstract...,"Author3930_1, Author3930_2",JAMA,2021-11-17,PMC,,PMC1003930,https://example.com/paper_3930,2021.0,11.0,69,10,True,54.0,8.0,True
cord-003931,Analysis of COVID-19 and immunity and antiviral and clinical in clinical settings,This study examines COVID-19 with 242 word abstract...,"Author3931_1, Author3931_2",Lancet,2020-03-21,WHO,10.1000/sample.3931,PMC1003931,https://example.com/paper_3931,2020.0,3.0,81,12,True,54.0,8.0,True
cord-003933,Analysis of therapeutic and immunity and public health in clinical settings,This study examines therapeutic with 346 word abstract...,"Author3933_1, Author3933_2",Science,2020-05-15,WHO,10.1000/sample.3933,PMC1003933,https://example.com/paper_3933,2020.0,5.0,75,11,True,57.0,8.0,True
cord-003934,Analysis of COVID-19 and lockdown and antibody in clinical settings,This study examines COVID-19 with 321 word abstract...,"Author3934_1, Author3934_2",Science,2019-12-20,medRxiv,10.1000/sample.3934,PMC1003934,https://example.com/paper_3934,2019.0,12.0,67,10,True,54.0,8.0,True
cord-003936,Analysis of coronavirus and SARS-CoV-2 and lockdown in clinical settings,This study examines coronavirus with 264 word abstract...,"Author3936_1, Author3936_2",,2020-01-07,bioRxiv,,,https://example.com/paper_3936,2020.0,1.0,72,10,True,57.0,8.0,False
cord-003937,Analysis of respiratory and coronavirus and immunity in clinical settings,This study examines respiratory with 388 word abstract...,"Author3937_1, Author3937_2",Emerging Infectious Diseases,2020-02-03,medRxiv,10.1000/sample.3937,PMC1003937,https://example.com/paper_3937,2020.0,2.0,73,10,True,57.0,8.0,True
cord-003938,Analysis of COVID-19 and antiviral and pandemic and transmission in clinical settings,This study examines COVID-19 with 329 word abstract...,"Author3938_1, Author3938_2",,2021-01-24,WHO,10.1000/sample.3938,PMC1003938,https://example.com/paper_3938,2021.0,1.0,85,12,True,54.0,8.0,False
cord-003939,Analysis of epidemiology and COVID-19 and transmission and SARS-CoV-2 in clinical settings,This study examines epidemiology with 364 word abstract...,"Author3939_1, Author3939_2",Journal of Medical Virology,2020-07-05,ArXiv,10.1000/sample.3939,PMC1003939,https://example.com/paper_3939,2020.0,7.0,90,12,True,58.0,8.0,True
cord-003941,Analysis of outbreak and therapeutic and antiviral in clinical settings,This study examines outbreak with 124 word abstract...,"Author3941_1, Author3941_2",Journal of Medical Virology,2021-09-13,WHO,10.1000/sample.3941,,https://example.com/paper_3941,2021.0,9.0,71,10,True,54.0,8.0,True
cord-003943,Analysis of antibody and coronavirus and clinical in clinical settings,This study examines antibody with 122 word abstract...,"Author3943_1, Author3943_2",Nature,2021-07-04,medRxiv,10.1000/sample.3943,PMC1003943,https://example.com/paper_3943,2021.0,7.0,70,10,True,54.0,8.0,True
cord-003944,Analysis of symptoms and outbreak and immunity and public health in clinical settings,This study examines symptoms with 301 word abstract...,"Author3944_1, Author3944_2",Virology,2020-10-30,medRxiv,10.1000/sample.3944,PMC1003944,https://example.com/paper_3944,2020.0,10.0,85,13,True,54.0,8.0,True
cord-003945,Analysis of antibody and respiratory and SARS-CoV-2 and symptoms in clinical settings,This study examines antibody with 213 word abstract...,"Author3945_1, Author3945_2",BMJ,2020-02-13,WHO,10.1000/sample.3945,,,2020.0,2.0,85,12,True,54.0,8.0,True
cord-003946,Analysis of therapeutic and pneumonia and coronavirus and COVID-19 in clinical settings,,"Author3946_1, Author3946_2",Journal of Virology,2020-07-02,PMC,10.1000/sample.3946,PMC1003946,https://example.com/paper_3946,2020.0,7.0,87,12,False,,,True
cord-003948,Analysis of diagnosis and pandemic and outbreak in clinical settings,This study examines diagnosis with 108 word abstract...,"Author3948_1, Author3948_2",PLoS ONE,2020-12-09,medRxiv,10.1000/sample.3948,PMC1003948,https://example.com/paper_3948,2020.0,12.0,68,10,True,55.0,8.0,True
cord-003949,Analysis of therapeutic and SARS-CoV-2 and symptoms in clinical settings,This study examines therapeutic with 361 word abstract...,"Author3949_1, Author3949_2",Journal of Medical Virology,,PMC,10.1000/sample.3949,PMC1003949,https://example.com/paper_3949,,,72,10,True,57.0,8.0,True
cord-003950,Analysis of immunity and antibody and COVID-19 in clinical settings,This study examines immunity with 126 word abstract...,"Author3950_1, Author3950_2",Journal of Medical Virology,2021-12-02,bioRxiv,10.1000/sample.3950,,https://example.com/paper_3950,2021.0,12.0,67,10,True,54.0,8.0,True
cord-003951,Analysis of transmission and antiviral and lockdown in clinical settings,This study examines transmission with 330 word abstract...,Author3951_1,PLoS ONE,2021-03-22,medRxiv,10.1000/sample.3951,PMC1003951,,2021.0,3.0,72,10,True,58.0,8.0,True
cord-003953,Analysis of immunity and lockdown and clinical and symptoms in clinical settings,This study examines immunity with 317 word abstract...,"Author3953_1, Author3953_2",Emerging Infectious Diseases,2021-05-01,WHO,10.1000/sample.3953,PMC1003953,,2021.0,5.0,80,12,True,54.0,8.0,True
cord-003954,Analysis of pneumonia and COVID-19 and symptoms and lockdown in clinical settings,This study examines pneumonia with 299 word abstract...,Author3954_1,New England Journal of Medicine,2021-11-07,ArXiv,10.1000/sample.3954,PMC1003954,https://example.com/paper_3954,2021.0,11.0,81,12,True,55.0,8.0,True
cord-003956,Analysis of pneumonia and symptoms and outbreak and SARS-CoV-2 in clinical settings,This study examines pneumonia with 372 word abstract...,"Author3956_1, Author3956_2",Science,2021-01-07,WHO,10.1000/sample.3956,PMC1003956,,2021.0,1.0,83,12,True,55.0,8.0,True
cord-003958,Analysis of coronavirus and diagnosis and SARS-CoV-2 and public health in clinical settings,This study examines coronavirus with 245 word abstract...,"Author3958_1, Author3958_2",,2019-12-09,Medline,,,,2019.0,12.0,91,13,True,57.0,8.0,False
cord-003959,Analysis of diagnosis and SARS-CoV-2 and therapeutic and coronavirus in clinical settings,This study examines diagnosis with 283 word abstract...,"Author3959_1, Author3959_2",Emerging Infectious Diseases,2019-12-19,PMC,10.1000/sample.3959,PMC1003959,https://example.com/paper_3959,2019.0,12.0,89,12,True,55.0,8.0,True
cord-003960,Analysis of antibody and COVID-19 in clinical settings,This study examines antibody with 215 word abstract...,"Author3960_1, Author3960_2",Cell,2020-05-16,medRxiv,10.1000/sample.3960,,https://example.com/paper_3960,2020.0,5.0,54,8,True,54.0,8.0,True
cord-003963,Analysis of outbreak and pneumonia and pandemic in clinical settings,This study examines outbreak with 474 word abstract...,"Author3963_1, Author3963_2",Lancet,2021-05-17,WHO,10.1000/sample.3963,PMC1003963,https://example.com/paper_3963,2021.0,5.0,68,10,True,54.0,8.0,True
cord-003967,Analysis of pandemic and SARS-CoV-2 and outbreak in clinical settings,This study examines pandemic with 181 word abstract...,"Author3967_1, Author3967_2",Science Translational Medicine,2019-12-15,Medline,10.1000/sample.3967,,https://example.com/paper_3967,2019.0,12.0,69,10,True,54.0,8.0,True
cord-003969,Analysis of pneumonia and immunity and vaccination and diagnosis in clinical settings,This study examines pneumonia with 398 word abstract...,"Author3969_1, Author3969_2",Science Translational Medicine,2020-06-08,medRxiv,10.1000/sample.3969,PMC1003969,https://example.com/paper_3969,2020.0,6.0,85,12,True,55.0,8.0,True
cord-003970,Analysis of epidemiology and immunity and lockdown in clinical settings,This study examines epidemiology with 488 word abstract...,"Author3970_1, Author3970_2",Science,2022-07-20,bioRxiv,10.1000/sample.3970,PMC1003970,https://example.com/paper_3970,2022.0,7.0,71,10,True,58.0,8.0,True
cord-003971,Analysis of COVID-19 and immunity and lockdown and treatment in clinical settings,This study examines COVID-19 with 168 word abstract...,"Author3971_1, Author3971_2",Lancet,2021-10-13,WHO,10.1000/sample.3971,PMC1003971,https://example.com/paper_3971,2021.0,10.0,81,12,True,54.0,8.0,True
cord-003972,Analysis of immunity and public health and coronavirus and clinical in clinical settings,This study examines immunity with 282 word abstract...,"Author3972_1, Author3972_2",PLoS ONE,2021-06-01,WHO,10.1000/sample.3972,PMC1003972,https://example.com/paper_3972,2021.0,6.0,88,13,True,54.0,8.0,True
cord-003974,Analysis of epidemiology and vaccination and respiratory and clinical in clinical settings,,"Author3974_1, Author3974_2",Emerging Infectious Diseases,2020-09-29,PMC,,,,2020.0,9.0,90,12,False,,,True
cord-003975,Analysis of coronavirus and pandemic and diagnosis and therapeutic in clinical settings,This study examines coronavirus with 137 word abstract...,"Author3975_1, Author3975_2",,2020-09-30,Medline,10.1000/sample.3975,,https://example.com/paper_3975,2020.0,9.0,87,12,True,57.0,8.0,False
cord-003976,Analysis of vaccination and epidemiology and respiratory in clinical settings,This study examines vaccination with 393 word abstract...,"Author3976_1, Author3976_2",Journal of Virology,2021-09-01,WHO,10.1000/sample.3976,PMC1003976,https://example.com/paper_3976,2021.0,9.0,77,10,True,57.0,8.0,True
cord-003977,Analysis of antibody and respiratory and antiviral and treatment in clinical settings,This study examines antibody with 109 word abstract...,"Author3977_1, Author3977_2",Nature Medicine,2020-10-13,medRxiv,10.1000/sample.3977,PMC1003977,https://example.com/paper_3977,2020.0,10.0,85,12,True,54.0,8.0,True
cord-003979,Analysis of respiratory and SARS-CoV-2 and lockdown in clinical settings,This study examines respiratory with 271 word abstract...,"Author3979_1, Author3979_2",New England Journal of Medicine,2020-05-06,ArXiv,10.1000/sample.3979,PMC1003979,https://example.com/paper_3979,2020.0,5.0,72,10,True,57.0,8.0,True
cord-003981,Analysis of public health and treatment and diagnosis in clinical settings,This study examines public health with 251 word abstract...,"Author3981_1, Author3981_2",New England Journal of Medicine,2020-09-21,ArXiv,10.1000/sample.3981,PMC1003981,https://example.com/paper_3981,2020.0,9.0,74,11,True,59.0,9.0,True
cord-003983,Analysis of clinical and COVID-19 and pneumonia and treatment in clinical settings,This study examines clinical with 133 word abstract...,"Author3983_1, Author3983_2",Journal of Medical Virology,2021-05-18,PMC,10.1000/sample.3983,PMC1003983,https://example.com/paper_3983,2021.0,5.0,82,12,True,54.0,8.0,True
cord-003984,Analysis of diagnosis and vaccination and COVID-19 in clinical settings,,"Author3984_1, Author3984_2",,2020-08-13,ArXiv,10.1000/sample.3984,PMC1003984,https://example.com/paper_3984,2020.0,8.0,71,10,False,,,False
cord-003985,Analysis of pandemic and public health and respiratory and antibody in clinical settings,,"Author3985_1, Author3985_2",Virology,2019-12-12,ArXiv,10.1000/sample.3985,PMC1003985,https://example.com/paper_3985,2019.0,12.0,88,13,False,,,True
cord-003986,Analysis of coronavirus and clinical and symptoms in clinical settings,This study examines coronavirus with 236 word abstract...,Author3986_1,Lancet,2020-05-03,WHO,10.1000/sample.3986,PMC1003986,https://example.com/paper_3986,2020.0,5.0,70,10,True,57.0,8.0,True
cord-003988,Analysis of public health and antibody and treatment and antiviral in clinical settings,This study examines public health with 343 word abstract...,"Author3988_1, Author3988_2",Journal of Virology,2021-09-29,Medline,10.1000/sample.3988,PMC1003988,https://example.com/paper_3988,2021.0,9.0,87,13,True,59.0,9.0,True
cord-003991,Analysis of pneumonia and respiratory and antibody in clinical settings,This study examines pneumonia with 240 word abstract...,"Author3991_1, Author3991_2",Virology,2019-12-01,WHO,10.1000/sample.3991,,,2019.0,12.0,71,10,True,55.0,8.0,True
cord-003992,Analysis of lockdown and pandemic and diagnosis in clinical settings,,"Author3992_1, Author3992_2",Nature Medicine,2022-01-12,medRxiv,10.1000/sample.3992,PMC1003992,https://example.com/paper_3992,2022.0,1.0,68,10,False,,,True
cord-003993,Analysis of antiviral and vaccination and outbreak and symptoms in clinical settings,This study examines antiviral with 252 word abstract...,"Author3993_1, Author3993_2",Science Translational Medicine,2020-04-25,WHO,10.1000/sample.3993,,https://example.com/paper_3993,2020.0,4.0,84,12,True,55.0,8.0,True
cord-003994,Analysis of public health and vaccination and antibody and lockdown in clinical settings,This study examines public health with 269 word abstract...,,Journal of Medical Virology,2021-09-03,Medline,10.1000/sample.3994,PMC1003994,https://example.com/paper_3994,2021.0,9.0,88,13,True,59.0,9.0,True
cord-003995,Analysis of treatment and pneumonia and diagnosis and outbreak in clinical settings,This study examines treatment with 139 word abstract...,Author3995_1,Nature Medicine,2021-01-14,medRxiv,10.1000/sample.3995,PMC1003995,https://example.com/paper_3995,2021.0,1.0,83,12,True,55.0,8.0,True
cord-003997,Analysis of vaccination and antiviral and epidemiology and respiratory in clinical settings,This study examines vaccination with 166 word abstract...,"Author3997_1, Author3997_2",Lancet,2022-10-14,Medline,10.1000/sample.3997,PMC1003997,https://example.com/paper_3997,2022.0,10.0,91,12,True,57.0,8.0,True
cord-003999,Analysis of epidemiology and pandemic and antiviral and transmission in clinical settings,This study examines epidemiology with 384 word abstract...,"Author3999_1, Author3999_2",,2021-02-08,medRxiv,10.1000/sample.3999,PMC1003999,,2021.0,2.0,89,12,True,58.0,8.0,False
cord-004000,Analysis of antibody and antiviral and vaccination and coronavirus in clinical settings,This study examines antibody with 173 word abstract...,"Author4000_1, Author4000_2",Virology,2020-11-01,WHO,10.1000/sample.4000,,https://example.com/paper_4000,2020.0,11.0,87,12,True,54.0,8.0,True
cord-004002,Analysis of transmission and symptoms and antiviral and antibody in clinical settings,,"Author4002_1, Author4002_2",New England Journal of Medicine,2020-09-21,Medline,10.1000/sample.4002,PMC1004002,https://example.com/paper_4002,2020.0,9.0,85,12,False,,,True
cord-004006,Analysis of transmission and symptoms and lockdown and COVID-19 in clinical settings,,"Author4006_1, Author4006_2",Emerging Infectious Diseases,,Medline,10.1000/sample.4006,,,,,84,12,False,,,True
cord-004007,Analysis of lockdown and public health in clinical settings,This study examines lockdown with 301 word abstract...,"Author4007_1, Author4007_2",JAMA,2022-11-25,PMC,10.1000/sample.4007,,https://example.com/paper_4007,2022.0,11.0,59,9,True,54.0,8.0,True
cord-004010,Analysis of transmission and COVID-19 and coronavirus and diagnosis in clinical settings,This study examines transmission with 300 word abstract...,"Author4010_1, Author4010_2",Clinical Infectious Diseases,2021-10-28,PMC,10.1000/sample.4010,PMC1004010,https://example.com/paper_4010,2021.0,10.0,88,12,True,58.0,8.0,True
cord-004012,Analysis of pandemic and respiratory and coronavirus in clinical settings,This study examines pandemic with 211 word abstract...,,Virology,2021-06-17,Medline,10.1000/sample.4012,PMC1004012,https://example.com/paper_4012,2021.0,6.0,73,10,True,54.0,8.0,True
cord-004013,Analysis of vaccination and respiratory and epidemiology and lockdown in clinical settings,This study examines vaccination with 255 word abstract...,Author4013_1,Nature Medicine,2020-12-05,medRxiv,10.1000/sample.4013,PMC1004013,https://example.com/paper_4013,2020.0,12.0,90,12,True,57.0,8.0,True
cord-004014,Analysis of epidemiology and vaccination and clinical in clinical settings,This study examines epidemiology with 137 word abstract...,Author4014_1,Journal of Medical Virology,2021-08-19,ArXiv,10.1000/sample.4014,PMC1004014,https://example.com/paper_4014,2021.0,8.0,74,10,True,58.0,8.0,True
cord-004016,Analysis of symptoms and coronavirus and diagnosis in clinical settings,This study examines symptoms with 347 word abstract...,"Author4016_1, Author4016_2",BMJ,2021-01-12,ArXiv,10.1000/sample.4016,,https://example.com/paper_4016,2021.0,1.0,71,10,True,54.0,8.0,True
cord-004018,Analysis of diagnosis and clinical and epidemiology and antibody in clinical settings,This study examines diagnosis with 325 word abstract...,"Author4018_1, Author4018_2",Virology,2022-09-08,PMC,10.1000/sample.4018,PMC1004018,,2022.0,9.0,85,12,True,55.0,8.0,True
cord-004019,Analysis of antibody and diagnosis and lockdown and transmission in clinical settings,This study examines antibody with 406 word abstract...,"Author4019_1, Author4019_2",Journal of Medical Virology,2020-05-26,WHO,,PMC1004019,https://example.com/paper_4019,2020.0,5.0,85,12,True,54.0,8.0,True
cord-004020,Analysis of pneumonia and symptoms and immunity in clinical settings,This study examines pneumonia with 177 word abstract...,"Author4020_1, Author4020_2",,2021-12-23,bioRxiv,10.1000/sample.4020,,https://example.com/paper_4020,2021.0,12.0,68,10,True,55.0,8.0,False
cord-004023,Analysis of COVID-19 and SARS-CoV-2 and antiviral in clinical settings,This study examines COVID-19 with 287 word abstract...,"Author4023_1, Author4023_2",New England Journal of Medicine,2021-08-05,ArXiv,10.1000/sample.4023,PMC1004023,https://example.com/paper_4023,2021.0,8.0,70,10,True,54.0,8.0,True
cord-004025,Analysis of treatment and antiviral and pandemic and COVID-19 in clinical settings,This study examines treatment with 153 word abstract...,"Author4025_1, Author4025_2",Virology,2020-02-18,ArXiv,10.1000/sample.4025,PMC1004025,https://example.com/paper_4025,2020.0,2.0,82,12,True,55.0,8.0,True
cord-004027,Analysis of diagnosis and transmission and SARS-CoV-2 in clinical settings,This study examines diagnosis with 213 word abstract...,"Author4027_1, Author4027_2",Lancet,2019-12-23,Medline,10.1000/sample.4027,PMC1004027,https://example.com/paper_4027,2019.0,12.0,74,10,True,55.0,8.0,True
cord-004028,Analysis of pandemic and SARS-CoV-2 and epidemiology in clinical settings,This study examines pandemic with 167 word abstract...,"Author4028_1, Author4028_2",BMJ,2022-05-03,WHO,10.1000/sample.4028,PMC1004028,https://example.com/paper_4028,2022.0,5.0,73,10,True,54.0,8.0,True
cord-004029,Analysis of COVID-19 and pandemic and vaccination and treatment in clinical settings,This study examines COVID-19 with 239 word abstract...,,Emerging Infectious Diseases,2021-04-30,medRxiv,10.1000/sample.4029,PMC1004029,https://example.com/paper_4029,2021.0,4.0,84,12,True,54.0,8.0,True
cord-004032,Analysis of lockdown and SARS-CoV-2 and pneumonia in clinical settings,This study examines lockdown with 367 word abstract...,"Author4032_1, Author4032_2",Emerging Infectious Diseases,2020-07-10,ArXiv,10.1000/sample.4032,PMC1004032,https://example.com/paper_4032,2020.0,7.0,70,10,True,54.0,8.0,True
cord-004033,Analysis of transmission and treatment and diagnosis in clinical settings,This study examines transmission with 210 word abstract...,"Author4033_1, Author4033_2",JAMA,2020-04-30,medRxiv,10.1000/sample.4033,PMC1004033,https://example.com/paper_4033,2020.0,4.0,73,10,True,58.0,8.0,True
cord-004035,Analysis of outbreak and epidemiology and immunity and vaccination in clinical settings,This study examines outbreak with 166 word abstract...,"Author4035_1, Author4035_2",Cell,2021-03-19,PMC,10.1000/sample.4035,PMC1004035,https://example.com/paper_4035,2021.0,3.0,87,12,True,54.0,8.0,True
cord-004037,Analysis of pandemic and epidemiology and public health in clinical settings,This study examines pandemic with 120 word abstract...,"Author4037_1, Author4037_2",PLoS ONE,2021-03-18,medRxiv,10.1000/sample.4037,,,2021.0,3.0,76,11,True,54.0,8.0,True
cord-004039,Analysis of antiviral and coronavirus and respiratory in clinical settings,This study examines antiviral with 150 word abstract...,"Author4039_1, Author4039_2",New England Journal of Medicine,2021-03-18,bioRxiv,10.1000/sample.4039,PMC1004039,,2021.0,3.0,74,10,True,55.0,8.0,True
cord-004041,Analysis of pneumonia and antibody and lockdown and respiratory in clinical settings,This study examines pneumonia with 324 word abstract...,"Author4041_1, Author4041_2",Emerging Infectious Diseases,2019-12-18,WHO,10.1000/sample.4041,PMC1004041,https://example.com/paper_4041,2019.0,12.0,84,12,True,55.0,8.0,True
cord-004044,Analysis of epidemiology and antiviral and coronavirus and pandemic in clinical settings,This study examines epidemiology with 377 word abstract...,"Author4044_1, Author4044_2",,2020-06-08,Medline,10.1000/sample.4044,PMC1004044,https://example.com/paper_4044,2020.0,6.0,88,12,True,58.0,8.0,False
cord-004047,Analysis of respiratory and immunity and antibody and diagnosis in clinical settings,This study examines respiratory with 253 word abstract...,"Author4047_1, Author4047_2",JAMA,2020-03-15,ArXiv,10.1000/sample.4047,,https://example.com/paper_4047,2020.0,3.0,84,12,True,57.0,8.0,True
cord-004048,Analysis of treatment and vaccination and pneumonia in clinical settings,This study examines treatment with 451 word abstract...,"Author4048_1, Author4048_2",BMJ,2021-10-30,WHO,10.1000/sample.4048,,https://example.com/paper_4048,2021.0,10.0,72,10,True,55.0,8.0,True
cord-004049,Analysis of epidemiology and respiratory and antibody in clinical settings,This study examines epidemiology with 451 word abstract...,"Author4049_1, Author4049_2",Cell,2020-07-01,WHO,10.1000/sample.4049,PMC1004049,,2020.0,7.0,74,10,True,58.0,8.0,True
cord-004052,Analysis of symptoms and immunity and treatment in clinical settings,This study examines symptoms with 320 word abstract...,"Author4052_1, Author4052_2",New England Journal of Medicine,2020-03-11,ArXiv,10.1000/sample.4052,PMC1004052,https://example.com/paper_4052,2020.0,3.0,68,10,True,54.0,8.0,True
cord-004055,Analysis of vaccination and treatment and pandemic in clinical settings,This study examines vaccination with 343 word abstract...,"Author4055_1, Author4055_2",Lancet,2020-11-21,WHO,10.1000/sample.4055,,,2020.0,11.0,71,10,True,57.0,8.0,True
cord-004056,Analysis of treatment and pandemic and immunity in clinical settings,This study examines treatment with 138 word abstract...,Author4056_1,Science,2021-11-05,Medline,10.1000/sample.4056,PMC1004056,https://example.com/paper_4056,2021.0,11.0,68,10,True,55.0,8.0,True
cord-004060,Analysis of public health and therapeutic in clinical settings,This study examines public health with 390 word abstract...,"Author4060_1, Author4060_2",Science,2021-08-31,Medline,10.1000/sample.4060,PMC1004060,https://example.com/paper_4060,2021.0,8.0,62,9,True,59.0,9.0,True
cord-004061,Analysis of transmission and epidemiology and outbreak in clinical settings,This study examines transmission with 482 word abstract...,"Author4061_1, Author4061_2",Journal of Virology,2019-12-23,PMC,10.1000/sample.4061,PMC1004061,https://example.com/paper_4061,2019.0,12.0,75,10,True,58.0,8.0,True
cord-004062,Analysis of treatment and immunity and symptoms and transmission in clinical settings,This study examines treatment with 387 word abstract...,"Author4062_1, Author4062_2",,2021-08-17,PMC,10.1000/sample.4062,PMC1004062,,2021.0,8.0,85,12,True,55.0,8.0,False
cord-004064,Analysis of diagnosis and treatment and lockdown in clinical settings,This study examines diagnosis with 339 word abstract...,"Author4064_1, Author4064_2",PLoS ONE,2020-03-14,medRxiv,10.1000/sample.4064,,https://example.com/paper_4064,2020.0,3.0,69,10,True,55.0,8.0,True
cord-004065,Analysis of public health and treatment and antibody and COVID-19 in clinical settings,This study examines public health with 411 word abstract...,"Author4065_1, Author4065_2",Lancet,2020-09-21,ArXiv,10.1000/sample.4065,PMC1004065,https://example.com/paper_4065,2020.0,9.0,86,13,True,59.0,9.0,True
cord-004067,Analysis of antibody and clinical and pandemic in clinical settings,This study examines antibody with 395 word abstract...,"Author4067_1, Author4067_2",Journal of Virology,2020-12-17,WHO,10.1000/sample.4067,PMC1004067,https://example.com/paper_4067,2020.0,12.0,67,10,True,54.0,8.0,True
cord-004068,Analysis of pneumonia and diagnosis and outbreak and coronavirus in clinical settings,This study examines pneumonia with 194 word abstract...,"Author4068_1, Author4068_2",JAMA,2021-06-04,WHO,10.1000/sample.4068,,https://example.com/paper_4068,2021.0,6.0,85,12,True,55.0,8.0,True
cord-004069,Analysis of SARS-CoV-2 and COVID-19 and antiviral and transmission in clinical settings,This study examines SARS-CoV-2 with 356 word abstract...,"Author4069_1, Author4069_2",PLoS ONE,2020-03-14,Medline,10.1000/sample.4069,,https://example.com/paper_4069,2020.0,3.0,87,12,True,56.0,8.0,True
cord-004070,Analysis of treatment and SARS-CoV-2 and public health in clinical settings,This study examines treatment with 128 word abstract...,"Author4070_1, Author4070_2",Cell,2020-09-10,medRxiv,10.1000/sample.4070,PMC1004070,https://example.com/paper_4070,2020.0,9.0,75,11,True,55.0,8.0,True
cord-004072,Analysis of clinical and transmission and respiratory in clinical settings,This study examines clinical with 465 word abstract...,"Author4072_1, Author4072_2",Nature Medicine,2020-02-04,bioRxiv,10.1000/sample.4072,PMC1004072,,2020.0,2.0,74,10,True,54.0,8.0,True
cord-004075,Analysis of antibody and vaccination and public health in clinical settings,,Author4075_1,,2020-02-03,ArXiv,10.1000/sample.4075,PMC1004075,https://example.com/paper_4075,2020.0,2.0,75,11,False,,,False
cord-004076,Analysis of pandemic and respiratory and public health and antibody in clinical settings,This study examines pandemic with 173 word abstract...,"Author4076_1, Author4076_2",Clinical Infectious Diseases,2019-12-09,WHO,10.1000/sample.4076,,https://example.com/paper_4076,2019.0,12.0,88,13,True,54.0,8.0,True
cord-004077,Analysis of antibody and symptoms and coronavirus in clinical settings,This study examines antibody with 175 word abstract...,Author4077_1,Virology,2021-10-03,Medline,10.1000/sample.4077,,https://example.com/paper_4077,2021.0,10.0,70,10,True,54.0,8.0,True
cord-004079,Analysis of COVID-19 and outbreak and therapeutic in clinical settings,,Author4079_1,Nature Medicine,2020-01-05,PMC,10.1000/sample.4079,,https://example.com/paper_4079,2020.0,1.0,70,10,False,,,True
cord-004080,Analysis of outbreak and respiratory and pandemic and antiviral in clinical settings,This study examines outbreak with 416 word abstract...,"Author4080_1, Author4080_2",Emerging Infectious Diseases,2020-06-29,medRxiv,10.1000/sample.4080,PMC1004080,https://example.com/paper_4080,2020.0,6.0,84,12,True,54.0,8.0,True
cord-004081,Analysis of clinical and epidemiology and vaccination in clinical settings,This study examines clinical with 422 word abstract...,"Author4081_1, Author4081_2",Nature,2020-08-19,WHO,10.1000/sample.4081,PMC1004081,https://example.com/paper_4081,2020.0,8.0,74,10,True,54.0,8.0,True
cord-004082,Analysis of coronavirus and respiratory and symptoms in clinical settings,This study examines coronavirus with 280 word abstract...,"Author4082_1, Author4082_2",JAMA,2021-07-29,WHO,10.1000/sample.4082,PMC1004082,,2021.0,7.0,73,10,True,57.0,8.0,True
cord-004085,Analysis of antiviral and COVID-19 and vaccination and SARS-CoV-2 in clinical settings,This study examines antiviral with 444 word abstract...,"Author4085_1, Author4085_2",Virology,2020-07-11,medRxiv,10.1000/sample.4085,PMC1004085,https://example.com/paper_4085,2020.0,7.0,86,12,True,55.0,8.0,True
cord-004086,Analysis of SARS-CoV-2 and transmission and immunity in clinical settings,This study examines SARS-CoV-2 with 168 word abstract...,"Author4086_1, Author4086_2",Journal of Virology,2021-05-11,PMC,10.1000/sample.4086,,,2021.0,5.0,73,10,True,56.0,8.0,True
cord-004087,Analysis of coronavirus and vaccination and antiviral and antibody in clinical settings,This study examines coronavirus with 376 word abstract...,"Author4087_1, Author4087_2",,2020-02-20,medRxiv,10.1000/sample.4087,PMC1004087,,2020.0,2.0,87,12,True,57.0,8.0,False
cord-004088,Analysis of pneumonia and coronavirus and transmission and antibody in clinical settings,This study examines pneumonia with 197 word abstract...,"Author4088_1, Author4088_2",Emerging Infectious Diseases,2020-12-13,medRxiv,10.1000/sample.4088,,https://example.com/paper_4088,2020.0,12.0,88,12,True,55.0,8.0,True
cord-004090,Analysis of pandemic and lockdown and transmission in clinical settings,This study examines pandemic with 426 word abstract...,"Author4090_1, Author4090_2",JAMA,2020-02-01,Medline,10.1000/sample.4090,PMC1004090,,2020.0,2.0,71,10,True,54.0,8.0,True
cord-004091,Analysis of SARS-CoV-2 and therapeutic and lockdown and diagnosis in clinical settings,,"Author4091_1, Author4091_2",Nature Medicine,2022-10-22,WHO,10.1000/sample.4091,,,2022.0,10.0,86,12,False,,,True
cord-004092,Analysis of public health and pandemic and COVID-19 in clinical settings,This study examines public health with 289 word abstract...,"Author4092_1, Author4092_2",BMJ,2020-05-16,WHO,10.1000/sample.4092,PMC1004092,,2020.0,5.0,72,11,True,59.0,9.0,True
cord-004093,Analysis of antiviral and symptoms and pneumonia in clinical settings,This study examines antiviral with 217 word abstract...,"Author4093_1, Author4093_2",Virology,2020-12-23,PMC,10.1000/sample.4093,,,2020.0,12.0,69,10,True,55.0,8.0,True
cord-004094,Analysis of COVID-19 and antiviral and outbreak and pneumonia in clinical settings,,"Author4094_1, Author4094_2",Lancet,2021-03-03,Medline,10.1000/sample.4094,PMC1004094,,2021.0,3.0,82,12,False,,,True
cord-004095,Analysis of vaccination and transmission and coronavirus and immunity in clinical settings,This study examines vaccination with 319 word abstract...,"Author4095_1, Author4095_2",Nature,2020-07-09,Medline,10.1000/sample.4095,PMC1004095,https://example.com/paper_4095,2020.0,7.0,90,12,True,57.0,8.0,True
cord-004096,Analysis of coronavirus and treatment and SARS-CoV-2 in clinical settings,This study examines coronavirus with 126 word abstract...,"Author4096_1, Author4096_2",Nature Medicine,2022-03-16,medRxiv,10.1000/sample.4096,PMC1004096,https://example.com/paper_4096,2022.0,3.0,73,10,True,57.0,8.0,True
cord-004099,Analysis of vaccination and COVID-19 and immunity in clinical settings,This study examines vaccination with 464 word abstract...,"Author4099_1, Author4099_2",Journal of Medical Virology,2020-08-14,bioRxiv,10.1000/sample.4099,,https://example.com/paper_4099,2020.0,8.0,70,10,True,57.0,8.0,True
cord-004100,Analysis of pandemic and therapeutic and transmission in clinical settings,This study examines pandemic with 281 word abstract...,,Nature Medicine,2020-05-07,bioRxiv,10.1000/sample.4100,PMC1004100,https://example.com/paper_4100,2020.0,5.0,74,10,True,54.0,8.0,True
cord-004102,Analysis of therapeutic and antibody and pandemic in clinical settings,This study examines therapeutic with 230 word abstract...,"Author4102_1, Author4102_2",Nature Medicine,2020-06-02,bioRxiv,10.1000/sample.4102,,https://example.com/paper_4102,2020.0,6.0,70,10,True,57.0,8.0,True
cord-004104,Analysis of lockdown and SARS-CoV-2 and clinical in clinical settings,This study examines lockdown with 121 word abstract...,"Author4104_1, Author4104_2",BMJ,2021-02-09,medRxiv,10.1000/sample.4104,PMC1004104,https://example.com/paper_4104,2021.0,2.0,69,10,True,54.0,8.0,True
cord-004106,Analysis of symptoms and therapeutic and respiratory and treatment in clinical settings,,"Author4106_1, Author4106_2",BMJ,2021-10-26,Medline,10.1000/sample.4106,PMC1004106,https://example.com/paper_4106,2021.0,10.0,87,12,False,,,True
cord-004107,Analysis of COVID-19 and antibody and immunity in clinical settings,This study examines COVID-19 with 402 word abstract...,"Author4107_1, Author4107_2",BMJ,2020-09-25,Medline,10.1000/sample.4107,,https://example.com/paper_4107,2020.0,9.0,67,10,True,54.0,8.0,True
cord-004110,Analysis of diagnosis and pandemic and coronavirus and clinical in clinical settings,This study examines diagnosis with 186 word abstract...,Author4110_1,Virology,2019-12-15,Medline,10.1000/sample.4110,PMC1004110,https://example.com/paper_4110,2019.0,12.0,84,12,True,55.0,8.0,True
cord-004113,Analysis of diagnosis and symptoms and transmission in clinical settings,This study examines diagnosis with 371 word abstract...,Author4113_1,Nature Medicine,2022-09-10,WHO,10.1000/sample.4113,PMC1004113,,2022.0,9.0,72,10,True,55.0,8.0,True
cord-004116,Analysis of transmission and epidemiology and therapeutic in clinical settings,This study examines transmission with 338 word abstract...,"Author4116_1, Author4116_2",BMJ,2020-12-14,bioRxiv,10.1000/sample.4116,PMC1004116,https://example.com/paper_4116,2020.0,12.0,78,10,True,58.0,8.0,True
cord-004120,Analysis of coronavirus and immunity and pneumonia and diagnosis in clinical settings,This study examines coronavirus with 338 word abstract...,"Author4120_1, Author4120_2",Science,2020-03-16,WHO,10.1000/sample.4120,PMC1004120,,2020.0,3.0,85,12,True,57.0,8.0,True
cord-004122,Analysis of antibody and epidemiology and pneumonia in clinical settings,This study examines antibody with 193 word abstract...,"Author4122_1, Author4122_2",Science,2021-07-16,WHO,10.1000/sample.4122,PMC1004122,https://example.com/paper_4122,2021.0,7.0,72,10,True,54.0,8.0,True
cord-004124,Analysis of COVID-19 and vaccination and public health in clinical settings,This study examines COVID-19 with 367 word abstract...,Author4124_1,Emerging Infectious Diseases,2021-03-19,PMC,10.1000/sample.4124,,https://example.com/paper_4124,2021.0,3.0,75,11,True,54.0,8.0,True
cord-004125,Analysis of immunity and symptoms and COVID-19 in clinical settings,This study examines immunity with 296 word abstract...,"Author4125_1, Author4125_2",Cell,2020-08-27,Medline,10.1000/sample.4125,PMC1004125,,2020.0,8.0,67,10,True,54.0,8.0,True
cord-004126,Analysis of antiviral and vaccination and transmission in clinical settings,This study examines antiviral with 427 word abstract...,"Author4126_1, Author4126_2",Nature,2019-12-13,bioRxiv,10.1000/sample.4126,,https://example.com/paper_4126,2019.0,12.0,75,10,True,55.0,8.0,True
cord-004128,Analysis of SARS-CoV-2 and public health and pneumonia in clinical settings,This study examines SARS-CoV-2 with 224 word abstract...,"Author4128_1, Author4128_2",Emerging Infectious Diseases,2021-03-26,PMC,10.1000/sample.4128,PMC1004128,,2021.0,3.0,75,11,True,56.0,8.0,True
cord-004129,Analysis of transmission and treatment and diagnosis and clinical in clinical settings,This study examines transmission with 387 word abstract...,"Author4129_1, Author4129_2",Science,2022-11-06,bioRxiv,10.1000/sample.4129,PMC1004129,https://example.com/paper_4129,2022.0,11.0,86,12,True,58.0,8.0,True
cord-004132,Analysis of lockdown and diagnosis and epidemiology and public health in clinical settings,This study examines lockdown with 250 word abstract...,"Author4132_1, Author4132_2",Journal of Medical Virology,2020-08-01,PMC,10.1000/sample.4132,PMC1004132,,2020.0,8.0,90,13,True,54.0,8.0,True
cord-004133,Analysis of coronavirus and immunity and therapeutic and antiviral in clinical settings,This study examines coronavirus with 394 word abstract...,"Author4133_1, Author4133_2",Science,,medRxiv,10.1000/sample.4133,PMC1004133,,,,87,12,True,57.0,8.0,True
cord-004134,Analysis of diagnosis and therapeutic and pandemic in clinical settings,This study examines diagnosis with 163 word abstract...,"Author4134_1, Author4134_2",New England Journal of Medicine,2020-04-10,medRxiv,10.1000/sample.4134,,https://example.com/paper_4134,2020.0,4.0,71,10,True,55.0,8.0,True
cord-004137,Analysis of transmission and pandemic and symptoms in clinical settings,This study examines transmission with 198 word abstract...,"Author4137_1, Author4137_2",Journal of Virology,2020-04-18,WHO,10.1000/sample.4137,PMC1004137,https://example.com/paper_4137,2020.0,4.0,71,10,True,58.0,8.0,True
cord-004138,Analysis of public health and vaccination and treatment in clinical settings,This study examines public health with 228 word abstract...,Author4138_1,PLoS ONE,2020-08-03,medRxiv,10.1000/sample.4138,PMC1004138,https://example.com/paper_4138,2020.0,8.0,76,11,True,59.0,9.0,True
cord-004140,Analysis of outbreak and antiviral and pandemic and lockdown in clinical settings,This study examines outbreak with 314 word abstract...,Author4140_1,Clinical Infectious Diseases,2021-04-19,ArXiv,10.1000/sample.4140,,,2021.0,4.0,81,12,True,54.0,8.0,True
cord-004141,Analysis of pandemic and antiviral and antibody in clinical settings,This study examines pandemic with 384 word abstract...,"Author4141_1, Author4141_2",Cell,2021-12-12,WHO,10.1000/sample.4141,,,2021.0,12.0,68,10,True,54.0,8.0,True
cord-004142,Analysis of transmission and COVID-19 and public health in clinical settings,This study examines transmission with 393 word abstract...,"Author4142_1, Author4142_2",PLoS ONE,2020-01-20,Medline,10.1000/sample.4142,,https://example.com/paper_4142,2020.0,1.0,76,11,True,58.0,8.0,True
cord-004147,Analysis of antiviral and therapeutic and immunity and public health in clinical settings,This study examines antiviral with 337 word abstract...,"Author4147_1, Author4147_2",PLoS ONE,2020-01-04,medRxiv,10.1000/sample.4147,PMC1004147,https://example.com/paper_4147,2020.0,1.0,89,13,True,55.0,8.0,True
cord-004148,Analysis of pneumonia and public health and transmission in clinical settings,This study examines pneumonia with 312 word abstract...,"Author4148_1, Author4148_2",Virology,2020-10-14,WHO,10.1000/sample.4148,PMC1004148,,2020.0,10.0,77,11,True,55.0,8.0,True
cord-004149,Analysis of therapeutic and pneumonia and treatment in clinical settings,This study examines therapeutic with 237 word abstract...,"Author4149_1, Author4149_2",Clinical Infectious Diseases,2021-11-04,bioRxiv,10.1000/sample.4149,,https://example.com/paper_4149,2021.0,11.0,72,10,True,57.0,8.0,True
cord-004150,Analysis of public health and respiratory and outbreak and pneumonia in clinical settings,This study examines public health with 264 word abstract...,"Author4150_1, Author4150_2",Science Translational Medicine,2022-11-28,medRxiv,,PMC1004150,https://example.com/paper_4150,2022.0,11.0,89,13,True,59.0,9.0,True
cord-004153,Analysis of vaccination and COVID-19 and pandemic in clinical settings,This study examines vaccination with 405 word abstract...,"Author4153_1, Author4153_2",Lancet,2020-09-15,ArXiv,10.1000/sample.4153,,,2020.0,9.0,70,10,True,57.0,8.0,True
cord-004157,Analysis of coronavirus and respiratory and therapeutic and SARS-CoV-2 in clinical settings,This study examines coronavirus with 409 word abstract...,Author4157_1,Nature Medicine,2020-05-12,bioRxiv,10.1000/sample.4157,PMC1004157,https://example.com/paper_4157,2020.0,5.0,91,12,True,57.0,8.0,True
cord-004158,Analysis of symptoms and SARS-CoV-2 and coronavirus in clinical settings,This study examines symptoms with 244 word abstract...,"Author4158_1, Author4158_2",Nature,2020-08-11,medRxiv,10.1000/sample.4158,PMC1004158,https://example.com/paper_4158,2020.0,8.0,72,10,True,54.0,8.0,True
cord-004160,Analysis of pneumonia and therapeutic and vaccination in clinical settings,,Author4160_1,Journal of Medical Virology,2019-12-22,Medline,10.1000/sample.4160,PMC1004160,https://example.com/paper_4160,2019.0,12.0,74,10,False,,,True
cord-004162,Analysis of SARS-CoV-2 and vaccination and lockdown in clinical settings,This study examines SARS-CoV-2 with 340 word abstract...,"Author4162_1, Author4162_2",Virology,2021-08-14,bioRxiv,10.1000/sample.4162,,https://example.com/paper_4162,2021.0,8.0,72,10,True,56.0,8.0,True
cord-004163,Analysis of symptoms and treatment and SARS-CoV-2 and clinical in clinical settings,This study examines symptoms with 493 word abstract...,"Author4163_1, Author4163_2",,2020-01-19,PMC,10.1000/sample.4163,PMC1004163,https://example.com/paper_4163,2020.0,1.0,83,12,True,54.0,8.0,False
cord-004164,Analysis of vaccination and symptoms and respiratory and pneumonia in clinical settings,This study examines vaccination with 192 word abstract...,"Author4164_1, Author4164_2",Emerging Infectious Diseases,2021-08-13,bioRxiv,10.1000/sample.4164,,https://example.com/paper_4164,2021.0,8.0,87,12,True,57.0,8.0,True
cord-004165,Analysis of antibody and lockdown and outbreak and symptoms in clinical settings,This study examines antibody with 116 word abstract...,"Author4165_1, Author4165_2",Cell,2020-01-31,bioRxiv,10.1000/sample.4165,PMC1004165,,2020.0,1.0,80,12,True,54.0,8.0,True
cord-004168,Analysis of public health and pandemic and epidemiology in clinical settings,This study examines public health with 313 word abstract...,"Author4168_1, Author4168_2",Emerging Infectious Diseases,2020-02-24,PMC,10.1000/sample.4168,PMC1004168,https://example.com/paper_4168,2020.0,2.0,76,11,True,59.0,9.0,True
cord-004169,Analysis of clinical and immunity and respiratory in clinical settings,This study examines clinical with 138 word abstract...,"Author4169_1, Author4169_2",Lancet,2020-12-09,medRxiv,10.1000/sample.4169,PMC1004169,https://example.com/paper_4169,2020.0,12.0,70,10,True,54.0,8.0,True
cord-004170,Analysis of clinical and immunity and transmission in clinical settings,This study examines clinical with 231 word abstract...,"Author4170_1, Author4170_2",Nature Medicine,2021-06-25,medRxiv,10.1000/sample.4170,PMC1004170,https://example.com/paper_4170,2021.0,6.0,71,10,True,54.0,8.0,True
cord-004171,Analysis of pneumonia and coronavirus and immunity and symptoms in clinical settings,This study examines pneumonia with 241 word abstract...,"Author4171_1, Author4171_2",,2021-01-11,bioRxiv,10.1000/sample.4171,PMC1004171,https://example.com/paper_4171,2021.0,1.0,84,12,True,55.0,8.0,False
cord-004172,Analysis of treatment and diagnosis and public health and pneumonia in clinical settings,This study examines treatment with 245 word abstract...,"Author4172_1, Author4172_2",New England Journal of Medicine,2021-11-07,medRxiv,10.1000/sample.4172,PMC1004172,,2021.0,11.0,88,13,True,55.0,8.0,True
cord-004173,Analysis of pneumonia and antibody and lockdown in clinical settings,This study examines pneumonia with 418 word abstract...,"Author4173_1, Author4173_2",Journal of Virology,2020-08-12,bioRxiv,,,,2020.0,8.0,68,10,True,55.0,8.0,True
cord-004177,Analysis of epidemiology and vaccination and lockdown in clinical settings,This study examines epidemiology with 498 word abstract...,"Author4177_1, Author4177_2",Lancet,2021-10-15,PMC,10.1000/sample.4177,PMC1004177,https://example.com/paper_4177,2021.0,10.0,74,10,True,58.0,8.0,True
cord-004179,Analysis of pandemic and respiratory and coronavirus and symptoms in clinical settings,This study examines pandemic with 477 word abstract...,"Author4179_1, Author4179_2",New England Journal of Medicine,2020-08-26,bioRxiv,10.1000/sample.4179,PMC1004179,https://example.com/paper_4179,2020.0,8.0,86,12,True,54.0,8.0,True
cord-004180,Analysis of coronavirus and treatment and epidemiology and respiratory in clinical settings,This study examines coronavirus with 421 word abstract...,"Author4180_1, Author4180_2",Science,2019-12-26,bioRxiv,10.1000/sample.4180,PMC1004180,,2019.0,12.0,91,12,True,57.0,8.0,True
cord-004181,Analysis of symptoms and pandemic and coronavirus in clinical settings,This study examines symptoms with 296 word abstract...,"Author4181_1, Author4181_2",New England Journal of Medicine,2019-12-21,PMC,10.1000/sample.4181,PMC1004181,https://example.com/paper_4181,2019.0,12.0,70,10,True,54.0,8.0,True
cord-004184,Analysis of antibody and antiviral and pneumonia in clinical settings,This study examines antibody with 360 word abstract...,"Author4184_1, Author4184_2",,2020-03-09,PMC,10.1000/sample.4184,PMC1004184,https://example.com/paper_4184,2020.0,3.0,69,10,True,54.0,8.0,False
cord-004188,Analysis of coronavirus and lockdown and antibody in clinical settings,,"Author4188_1, Author4188_2",Cell,2020-08-12,bioRxiv,10.1000/sample.4188,PMC1004188,https://example.com/paper_4188,2020.0,8.0,70,10,False,,,True
cord-004191,Analysis of public health and coronavirus and therapeutic in clinical settings,This study examines public health with 313 word abstract...,"Author4191_1, Author4191_2",Virology,2020-02-10,Medline,10.1000/sample.4191,PMC1004191,https://example.com/paper_4191,2020.0,2.0,78,11,True,59.0,9.0,True
cord-004193,Analysis of outbreak and epidemiology and lockdown in clinical settings,This study examines outbreak with 203 word abstract...,"Author4193_1, Author4193_2",Science,2021-07-02,medRxiv,10.1000/sample.4193,PMC1004193,https://example.com/paper_4193,2021.0,7.0,71,10,True,54.0,8.0,True
cord-004196,Analysis of coronavirus and pneumonia and immunity and diagnosis in clinical settings,This study examines coronavirus with 441 word abstract...,,Nature,2021-11-13,PMC,10.1000/sample.4196,PMC1004196,,2021.0,11.0,85,12,True,57.0,8.0,True
cord-004199,Analysis of diagnosis and therapeutic and transmission in clinical settings,This study examines diagnosis with 169 word abstract...,"Author4199_1, Author4199_2",Nature,2020-12-21,bioRxiv,10.1000/sample.4199,,https://example.com/paper_4199,2020.0,12.0,75,10,True,55.0,8.0,True
cord-004201,Analysis of immunity and symptoms and SARS-CoV-2 and COVID-19 in clinical settings,This study examines immunity with 158 word abstract...,"Author4201_1, Author4201_2",Journal of Virology,2022-02-11,medRxiv,,PMC1004201,https://example.com/paper_4201,2022.0,2.0,82,12,True,54.0,8.0,True
cord-004202,Analysis of diagnosis and transmission and lockdown and outbreak in clinical settings,This study examines diagnosis with 447 word abstract...,Author4202_1,Lancet,2020-07-06,Medline,10.1000/sample.4202,,https://example.com/paper_4202,2020.0,7.0,85,12,True,55.0,8.0,True
cord-004207,Analysis of COVID-19 and diagnosis and outbreak and symptoms in clinical settings,This study examines COVID-19 with 223 word abstract...,"Author4207_1, Author4207_2",Virology,2020-04-23,medRxiv,,,,2020.0,4.0,81,12,True,54.0,8.0,True
cord-004209,Analysis of immunity and outbreak and COVID-19 in clinical settings,This study examines immunity with 191 word abstract...,"Author4209_1, Author4209_2",Clinical Infectious Diseases,2021-08-22,Medline,10.1000/sample.4209,PMC1004209,https://example.com/paper_4209,2021.0,8.0,67,10,True,54.0,8.0,True
cord-004211,Analysis of therapeutic and epidemiology and pandemic in clinical settings,This study examines therapeutic with 191 word abstract...,"Author4211_1, Author4211_2",Lancet,2020-12-19,bioRxiv,10.1000/sample.4211,PMC1004211,https://example.com/paper_4211,2020.0,12.0,74,10,True,57.0,8.0,True
cord-004214,Analysis of antiviral and pneumonia and respiratory and antibody in clinical settings,This study examines antiviral with 275 word abstract...,"Author4214_1, Author4214_2",BMJ,2022-08-24,Medline,10.1000/sample.4214,,https://example.com/paper_4214,2022.0,8.0,85,12,True,55.0,8.0,True
cord-004218,Analysis of public health and respiratory and transmission in clinical settings,This study examines public health with 408 word abstract...,"Author4218_1, Author4218_2",,2021-04-29,PMC,,PMC1004218,https://example.com/paper_4218,2021.0,4.0,79,11,True,59.0,9.0,False
cord-004219,Analysis of COVID-19 and outbreak and vaccination in clinical settings,This study examines COVID-19 with 184 word abstract...,"Author4219_1, Author4219_2",,2021-09-07,PMC,10.1000/sample.4219,PMC1004219,,2021.0,9.0,70,10,True,54.0,8.0,False
cord-004220,Analysis of immunity and public health and therapeutic in clinical settings,This study examines immunity with 277 word abstract...,"Author4220_1, Author4220_2",,2020-04-06,bioRxiv,10.1000/sample.4220,,https://example.com/paper_4220,2020.0,4.0,75,11,True,54.0,8.0,False
cord-004222,Analysis of therapeutic and COVID-19 and transmission in clinical settings,This study examines therapeutic with 355 word abstract...,"Author4222_1, Author4222_2",Cell,2021-11-14,medRxiv,10.1000/sample.4222,PMC1004222,https://example.com/paper_4222,2021.0,11.0,74,10,True,57.0,8.0,True
cord-004223,Analysis of pneumonia and outbreak and respiratory in clinical settings,This study examines pneumonia with 404 word abstract...,"Author4223_1, Author4223_2",Journal of Medical Virology,2021-03-01,PMC,10.1000/sample.4223,PMC1004223,https://example.com/paper_4223,2021.0,3.0,71,10,True,55.0,8.0,True
cord-004224,Analysis of antiviral and transmission and vaccination in clinical settings,This study examines antiviral with 107 word abstract...,"Author4224_1, Author4224_2",Nature Medicine,2022-03-05,ArXiv,10.1000/sample.4224,PMC1004224,https://example.com/paper_4224,2022.0,3.0,75,10,True,55.0,8.0,True
cord-004226,Analysis of immunity and symptoms and epidemiology and public health in clinical settings,This study examines immunity with 110 word abstract...,"Author4226_1, Author4226_2",JAMA,2020-03-25,medRxiv,10.1000/sample.4226,PMC1004226,,2020.0,3.0,89,13,True,54.0,8.0,True
cord-004227,Analysis of pneumonia and outbreak and pandemic and clinical in clinical settings,This study examines pneumonia with 241 word abstract...,"Author4227_1, Author4227_2",Nature,2020-07-13,ArXiv,10.1000/sample.4227,,https://example.com/paper_4227,2020.0,7.0,81,12,True,55.0,8.0,True
cord-004228,Analysis of symptoms and pneumonia and immunity in clinical settings,This study examines symptoms with 174 word abstract...,"Author4228_1, Author4228_2",Nature,2021-09-06,bioRxiv,10.1000/sample.4228,PMC1004228,https://example.com/paper_4228,2021.0,9.0,68,10,True,54.0,8.0,True
cord-004229,Analysis of therapeutic and treatment and vaccination in clinical settings,,"Author4229_1, Author4229_2",,2022-10-11,WHO,10.1000/sample.4229,PMC1004229,,2022.0,10.0,74,10,False,,,False
cord-004231,Analysis of antiviral and lockdown and diagnosis and COVID-19 in clinical settings,This study examines antiviral with 189 word abstract...,Author4231_1,JAMA,2020-05-25,PMC,10.1000/sample.4231,PMC1004231,https://example.com/paper_4231,2020.0,5.0,82,12,True,55.0,8.0,True
cord-004232,Analysis of antibody and public health and symptoms and pandemic in clinical settings,This study examines antibody with 186 word abstract...,"Author4232_1, Author4232_2",PLoS ONE,2020-04-02,ArXiv,10.1000/sample.4232,PMC1004232,https://example.com/paper_4232,2020.0,4.0,85,13,True,54.0,8.0,True
cord-004233,Analysis of public health and SARS-CoV-2 and immunity and antibody in clinical settings,This study examines public health with 146 word abstract...,"Author4233_1, Author4233_2",Nature Medicine,2020-08-11,ArXiv,10.1000/sample.4233,PMC1004233,https://example.com/paper_4233,2020.0,8.0,87,13,True,59.0,9.0,True
cord-004235,Analysis of pneumonia and pandemic and antibody in clinical settings,This study examines pneumonia with 258 word abstract...,"Author4235_1, Author4235_2",Nature,2020-01-06,Medline,10.1000/sample.4235,PMC1004235,,2020.0,1.0,68,10,True,55.0,8.0,True
cord-004236,Analysis of SARS-CoV-2 and coronavirus and therapeutic and antibody in clinical settings,This study examines SARS-CoV-2 with 355 word abstract...,"Author4236_1, Author4236_2",Journal of Virology,2022-12-28,medRxiv,10.1000/sample.4236,,https://example.com/paper_4236,2022.0,12.0,88,12,True,56.0,8.0,True
cord-004237,Analysis of symptoms and immunity and vaccination and transmission in clinical settings,This study examines symptoms with 120 word abstract...,"Author4237_1, Author4237_2",Virology,2022-12-07,PMC,10.1000/sample.4237,,https://example.com/paper_4237,2022.0,12.0,87,12,True,54.0,8.0,True
cord-004238,Analysis of treatment and pneumonia and coronavirus and respiratory in clinical settings,This study examines treatment with 438 word abstract...,"Author4238_1, Author4238_2",PLoS ONE,2020-05-14,bioRxiv,10.1000/sample.4238,PMC1004238,https://example.com/paper_4238,2020.0,5.0,88,12,True,55.0,8.0,True
cord-004239,Analysis of epidemiology and COVID-19 and clinical in clinical settings,,"Author4239_1, Author4239_2",Nature Medicine,2020-04-30,PMC,10.1000/sample.4239,PMC1004239,https://example.com/paper_4239,2020.0,4.0,71,10,False,,,True
cord-004240,Analysis of therapeutic and treatment and SARS-CoV-2 in clinical settings,This study examines therapeutic with 424 word abstract...,"Author4240_1, Author4240_2",Science,2021-04-22,medRxiv,10.1000/sample.4240,PMC1004240,https://example.com/paper_4240,2021.0,4.0,73,10,True,57.0,8.0,True
cord-004244,Analysis of outbreak and diagnosis and pandemic in clinical settings,This study examines outbreak with 460 word abstract...,,Nature,2020-11-13,PMC,,PMC1004244,,2020.0,11.0,68,10,True,54.0,8.0,True
cord-004245,Analysis of coronavirus and COVID-19 and transmission and diagnosis in clinical settings,This study examines coronavirus with 160 word abstract...,Author4245_1,Lancet,2021-03-27,WHO,10.1000/sample.4245,PMC1004245,https://example.com/paper_4245,2021.0,3.0,88,12,True,57.0,8.0,True
cord-004246,Analysis of lockdown and symptoms and immunity and coronavirus in clinical settings,This study examines lockdown with 104 word abstract...,"Author4246_1, Author4246_2",Emerging Infectious Diseases,2021-11-17,WHO,10.1000/sample.4246,PMC1004246,https://example.com/paper_4246,2021.0,11.0,83,12,True,54.0,8.0,True
cord-004247,Analysis of therapeutic and coronavirus and SARS-CoV-2 and antiviral in clinical settings,This study examines therapeutic with 257 word abstract...,"Author4247_1, Author4247_2",Science,2020-05-03,bioRxiv,10.1000/sample.4247,PMC1004247,https://example.com/paper_4247,2020.0,5.0,89,12,True,57.0,8.0,True
cord-004248,Analysis of antibody and pneumonia and symptoms and lockdown in clinical settings,This study examines antibody with 234 word abstract...,"Author4248_1, Author4248_2",Clinical Infectious Diseases,2021-07-21,Medline,10.1000/sample.4248,,https://example.com/paper_4248,2021.0,7.0,81,12,True,54.0,8.0,True
cord-004249,Analysis of pneumonia and public health and therapeutic in clinical settings,This study examines pneumonia with 344 word abstract...,"Author4249_1, Author4249_2",PLoS ONE,2019-12-04,bioRxiv,10.1000/sample.4249,PMC1004249,,2019.0,12.0,76,11,True,55.0,8.0,True
cord-004250,Analysis of vaccination and respiratory and immunity and symptoms in clinical settings,,"Author4250_1, Author4250_2",Journal of Virology,2020-11-10,WHO,10.1000/sample.4250,PMC1004250,https://example.com/paper_4250,2020.0,11.0,86,12,False,,,True
cord-004251,Analysis of symptoms and outbreak and pandemic and antibody in clinical settings,This study examines symptoms with 142 word abstract...,Author4251_1,Nature,2020-08-12,Medline,10.1000/sample.4251,,https://example.com/paper_4251,2020.0,8.0,80,12,True,54.0,8.0,True
cord-004253,Analysis of transmission and public health and pandemic and therapeutic in clinical settings,This study examines transmission with 432 word abstract...,Author4253_1,Clinical Infectious Diseases,2020-11-08,PMC,10.1000/sample.4253,PMC1004253,https://example.com/paper_4253,2020.0,11.0,92,13,True,58.0,8.0,True
cord-004256,Analysis of symptoms and antiviral and public health in clinical settings,This study examines symptoms with 290 word abstract...,"Author4256_1, Author4256_2",Emerging Infectious Diseases,2020-02-22,bioRxiv,10.1000/sample.4256,PMC1004256,https://example.com/paper_4256,2020.0,2.0,73,11,True,54.0,8.0,True
cord-004257,Analysis of immunity and COVID-19 and therapeutic in clinical settings,This study examines immunity with 495 word abstract...,"Author4257_1, Author4257_2",Journal of Medical Virology,2020-08-04,PMC,10.1000/sample.4257,,https://example.com/paper_4257,2020.0,8.0,70,10,True,54.0,8.0,True
cord-004258,Analysis of COVID-19 and outbreak and lockdown in clinical settings,This study examines COVID-19 with 136 word abstract...,"Author4258_1, Author4258_2",Journal of Medical Virology,2020-06-03,bioRxiv,10.1000/sample.4258,,https://example.com/paper_4258,2020.0,6.0,67,10,True,54.0,8.0,True
cord-004259,Analysis of epidemiology and antiviral and COVID-19 and lockdown in clinical settings,This study examines epidemiology with 391 word abstract...,"Author4259_1, Author4259_2",JAMA,2020-10-22,medRxiv,10.1000/sample.4259,PMC1004259,https://example.com/paper_4259,2020.0,10.0,85,12,True,58.0,8.0,True
cord-004260,Analysis of treatment and coronavirus and SARS-CoV-2 in clinical settings,This study examines treatment with 407 word abstract...,"Author4260_1, Author4260_2",Science Translational Medicine,2020-06-06,WHO,,PMC1004260,https://example.com/paper_4260,2020.0,6.0,73,10,True,55.0,8.0,True
cord-004261,Analysis of epidemiology and vaccination and symptoms and SARS-CoV-2 in clinical settings,This study examines epidemiology with 488 word abstract...,"Author4261_1, Author4261_2",Science Translational Medicine,2020-03-17,PMC,10.1000/sample.4261,,https://example.com/paper_4261,2020.0,3.0,89,12,True,58.0,8.0,True
cord-004263,Analysis of lockdown and SARS-CoV-2 and public health and transmission in clinical settings,This study examines lockdown with 197 word abstract...,"Author4263_1, Author4263_2",Nature,2020-05-03,Medline,10.1000/sample.4263,PMC1004263,https://example.com/paper_4263,2020.0,5.0,91,13,True,54.0,8.0,True
cord-004265,Analysis of immunity and coronavirus and SARS-CoV-2 in clinical settings,This study examines immunity with 138 word abstract...,"Author4265_1, Author4265_2",,2020-08-09,medRxiv,10.1000/sample.4265,PMC1004265,https://example.com/paper_4265,2020.0,8.0,72,10,True,54.0,8.0,False
cord-004266,Analysis of diagnosis and SARS-CoV-2 and treatment and antibody in clinical settings,This study examines diagnosis with 111 word abstract...,"Author4266_1, Author4266_2",,2022-04-22,medRxiv,10.1000/sample.4266,PMC1004266,,2022.0,4.0,84,12,True,55.0,8.0,False
cord-004268,Analysis of pneumonia and vaccination and coronavirus in clinical settings,This study examines pneumonia with 427 word abstract...,Author4268_1,New England Journal of Medicine,2020-04-17,WHO,10.1000/sample.4268,PMC1004268,https://example.com/paper_4268,2020.0,4.0,74,10,True,55.0,8.0,True
cord-004269,Analysis of therapeutic and pneumonia and epidemiology and transmission in clinical settings,This study examines therapeutic with 492 word abstract...,"Author4269_1, Author4269_2",Journal of Virology,2020-08-14,ArXiv,10.1000/sample.4269,PMC1004269,https://example.com/paper_4269,2020.0,8.0,92,12,True,57.0,8.0,True
cord-004272,Analysis of antibody and coronavirus and outbreak and pneumonia in clinical settings,This study examines antibody with 165 word abstract...,"Author4272_1, Author4272_2",JAMA,2021-03-26,bioRxiv,10.1000/sample.4272,PMC1004272,https://example.com/paper_4272,2021.0,3.0,84,12,True,54.0,8.0,True
cord-004273,Analysis of treatment and immunity and diagnosis and lockdown in clinical settings,This study examines treatment with 126 word abstract...,"Author4273_1, Author4273_2",Cell,2020-08-29,PMC,10.1000/sample.4273,,https://example.com/paper_4273,2020.0,8.0,82,12,True,55.0,8.0,True
cord-004274,Analysis of antibody and coronavirus and clinical and pandemic in clinical settings,This study examines antibody with 411 word abstract...,"Author4274_1, Author4274_2",Journal of Virology,2022-04-16,WHO,10.1000/sample.4274,,https://example.com/paper_4274,2022.0,4.0,83,12,True,54.0,8.0,True
cord-004277,Analysis of COVID-19 and respiratory and immunity in clinical settings,This study examines COVID-19 with 419 word abstract...,"Author4277_1, Author4277_2",Virology,2020-05-01,bioRxiv,10.1000/sample.4277,PMC1004277,https://example.com/paper_4277,2020.0,5.0,70,10,True,54.0,8.0,True
cord-004279,Analysis of vaccination and lockdown and outbreak in clinical settings,This study examines vaccination with 363 word abstract...,"Author4279_1, Author4279_2",,2020-09-26,medRxiv,10.1000/sample.4279,PMC1004279,https://example.com/paper_4279,2020.0,9.0,70,10,True,57.0,8.0,False
cord-004280,Analysis of COVID-19 and SARS-CoV-2 and therapeutic and transmission in clinical settings,This study examines COVID-19 with 473 word abstract...,"Author4280_1, Author4280_2",Clinical Infectious Diseases,2021-03-09,PMC,10.1000/sample.4280,,https://example.com/paper_4280,2021.0,3.0,89,12,True,54.0,8.0,True
cord-004281,Analysis of treatment and coronavirus and diagnosis and vaccination in clinical settings,This study examines treatment with 216 word abstract...,Author4281_1,Journal of Medical Virology,2021-11-10,PMC,10.1000/sample.4281,PMC1004281,https://example.com/paper_4281,2021.0,11.0,88,12,True,55.0,8.0,True
cord-004282,Analysis of clinical and epidemiology and coronavirus and COVID-19 in clinical settings,This study examines clinical with 424 word abstract...,"Author4282_1, Author4282_2",Journal of Virology,2020-04-14,bioRxiv,10.1000/sample.4282,PMC1004282,https://example.com/paper_4282,2020.0,4.0,87,12,True,54.0,8.0,True
cord-004284,Analysis of pneumonia and therapeutic and transmission in clinical settings,This study examines pneumonia with 111 word abstract...,"Author4284_1, Author4284_2",Virology,2022-10-02,WHO,10.1000/sample.4284,PMC1004284,https://example.com/paper_4284,2022.0,10.0,75,10,True,55.0,8.0,True
cord-004285,Analysis of therapeutic and COVID-19 and diagnosis and pneumonia in clinical settings,This study examines therapeutic with 301 word abstract...,"Author4285_1, Author4285_2",Emerging Infectious Diseases,2021-09-10,ArXiv,10.1000/sample.4285,,https://example.com/paper_4285,2021.0,9.0,85,12,True,57.0,8.0,True
cord-004293,Analysis of immunity and epidemiology and transmission in clinical settings,This study examines immunity with 193 word abstract...,,Science Translational Medicine,2020-08-11,medRxiv,10.1000/sample.4293,PMC1004293,https://example.com/paper_4293,2020.0,8.0,75,10,True,54.0,8.0,True
cord-004297,Analysis of vaccination and public health and therapeutic in clinical settings,This study examines vaccination with 360 word abstract...,"Author4297_1, Author4297_2",BMJ,2022-12-16,medRxiv,10.1000/sample.4297,,https://example.com/paper_4297,2022.0,12.0,78,11,True,57.0,8.0,True
cord-004298,Analysis of SARS-CoV-2 and clinical and diagnosis and lockdown in clinical settings,This study examines SARS-CoV-2 with 321 word abstract...,Author4298_1,Journal of Virology,2020-01-09,medRxiv,10.1000/sample.4298,PMC1004298,https://example.com/paper_4298,2020.0,1.0,83,12,True,56.0,8.0,True
cord-004300,Analysis of pneumonia and coronavirus and therapeutic in clinical settings,This study examines pneumonia with 352 word abstract...,"Author4300_1, Author4300_2",Lancet,2019-12-20,WHO,10.1000/sample.4300,,https://example.com/paper_4300,2019.0,12.0,74,10,True,55.0,8.0,True
cord-004301,Analysis of therapeutic and vaccination and immunity in clinical settings,This study examines therapeutic with 154 word abstract...,"Author4301_1, Author4301_2",,2020-03-05,ArXiv,10.1000/sample.4301,PMC1004301,https://example.com/paper_4301,2020.0,3.0,73,10,True,57.0,8.0,False
cord-004302,Analysis of COVID-19 and clinical and therapeutic in clinical settings,This study examines COVID-19 with 270 word abstract...,Author4302_1,,2021-05-19,medRxiv,10.1000/sample.4302,,https://example.com/paper_4302,2021.0,5.0,70,10,True,54.0,8.0,False
cord-004303,Analysis of immunity and diagnosis and transmission in clinical settings,This study examines immunity with 371 word abstract...,"Author4303_1, Author4303_2",PLoS ONE,2020-06-21,Medline,10.1000/sample.4303,PMC1004303,https://example.com/paper_4303,2020.0,6.0,72,10,True,54.0,8.0,True
cord-004304,Analysis of COVID-19 and outbreak and pneumonia and clinical in clinical settings,This study examines COVID-19 with 381 word abstract...,"Author4304_1, Author4304_2",BMJ,2021-03-11,ArXiv,10.1000/sample.4304,PMC1004304,https://example.com/paper_4304,2021.0,3.0,81,12,True,54.0,8.0,True
cord-004305,Analysis of therapeutic and vaccination and antibody and pandemic in clinical settings,This study examines therapeutic with 313 word abstract...,"Author4305_1, Author4305_2",Lancet,2021-07-24,bioRxiv,,PMC1004305,https://example.com/paper_4305,2021.0,7.0,86,12,True,57.0,8.0,True
cord-004307,Analysis of respiratory and diagnosis and vaccination and transmission in clinical settings,This study examines respiratory with 185 word abstract...,"Author4307_1, Author4307_2",Cell,2022-06-22,PMC,10.1000/sample.4307,PMC1004307,https://example.com/paper_4307,2022.0,6.0,91,12,True,57.0,8.0,True
cord-004308,Analysis of coronavirus and COVID-19 and respiratory in clinical settings,This study examines coronavirus with 136 word abstract...,"Author4308_1, Author4308_2",Journal of Medical Virology,2021-04-27,bioRxiv,10.1000/sample.4308,PMC1004308,https://example.com/paper_4308,2021.0,4.0,73,10,True,57.0,8.0,True
cord-004309,Analysis of pneumonia and transmission and diagnosis and treatment in clinical settings,This study examines pneumonia with 334 word abstract...,"Author4309_1, Author4309_2",PLoS ONE,2020-08-20,ArXiv,10.1000/sample.4309,PMC1004309,https://example.com/paper_4309,2020.0,8.0,87,12,True,55.0,8.0,True
cord-004310,Analysis of diagnosis and respiratory and vaccination and SARS-CoV-2 in clinical settings,This study examines diagnosis with 121 word abstract...,"Author4310_1, Author4310_2",New England Journal of Medicine,2020-10-14,medRxiv,10.1000/sample.4310,,https://example.com/paper_4310,2020.0,10.0,89,12,True,55.0,8.0,True
cord-004313,Analysis of antiviral and outbreak and diagnosis and lockdown in clinical settings,This study examines antiviral with 357 word abstract...,Author4313_1,Lancet,2020-07-30,Medline,10.1000/sample.4313,PMC1004313,https://example.com/paper_4313,2020.0,7.0,82,12,True,55.0,8.0,True
cord-004315,Analysis of diagnosis and therapeutic and lockdown and pneumonia in clinical settings,This study examines diagnosis with 237 word abstract...,"Author4315_1, Author4315_2",Lancet,2020-12-22,medRxiv,10.1000/sample.4315,PMC1004315,,2020.0,12.0,85,12,True,55.0,8.0,True
cord-004316,Analysis of symptoms and vaccination and antiviral and COVID-19 in clinical settings,This study examines symptoms with 410 word abstract...,Author4316_1,Science Translational Medicine,2021-03-28,Medline,10.1000/sample.4316,PMC1004316,https://example.com/paper_4316,2021.0,3.0,84,12,True,54.0,8.0,True
cord-004317,Analysis of respiratory and transmission and epidemiology and symptoms in clinical settings,This study examines respiratory with 411 word abstract...,"Author4317_1, Author4317_2",Virology,2021-01-05,ArXiv,,PMC1004317,https://example.com/paper_4317,2021.0,1.0,91,12,True,57.0,8.0,True
cord-004318,Analysis of SARS-CoV-2 and coronavirus and pandemic and lockdown in clinical settings,This study examines SARS-CoV-2 with 369 word abstract...,"Author4318_1, Author4318_2",Lancet,2022-08-16,PMC,,,https://example.com/paper_4318,2022.0,8.0,85,12,True,56.0,8.0,True
cord-004320,Analysis of public health and pneumonia and respiratory and clinical in clinical settings,This study examines public health with 459 word abstract...,"Author4320_1, Author4320_2",JAMA,2021-04-04,bioRxiv,10.1000/sample.4320,PMC1004320,https://example.com/paper_4320,2021.0,4.0,89,13,True,59.0,9.0,True
cord-004321,Analysis of treatment and lockdown and pandemic in clinical settings,This study examines treatment with 143 word abstract...,"Author4321_1, Author4321_2",Science,2020-04-11,medRxiv,,,https://example.com/paper_4321,2020.0,4.0,68,10,True,55.0,8.0,True
cord-004324,Analysis of pandemic and SARS-CoV-2 and clinical in clinical settings,This study examines pandemic with 180 word abstract...,"Author4324_1, Author4324_2",JAMA,2020-03-03,ArXiv,10.1000/sample.4324,PMC1004324,https://example.com/paper_4324,2020.0,3.0,69,10,True,54.0,8.0,True
cord-004325,Analysis of pandemic and lockdown and respiratory and epidemiology in clinical settings,This study examines pandemic with 159 word abstract...,"Author4325_1, Author4325_2",PLoS ONE,2021-07-29,PMC,10.1000/sample.4325,PMC1004325,https://example.com/paper_4325,2021.0,7.0,87,12,True,54.0,8.0,True
cord-004326,Analysis of lockdown and transmission and diagnosis and coronavirus in clinical settings,This study examines lockdown with 405 word abstract...,"Author4326_1, Author4326_2",Nature Medicine,2021-11-27,Medline,10.1000/sample.4326,,,2021.0,11.0,88,12,True,54.0,8.0,True
cord-004327,Analysis of therapeutic and diagnosis and public health and antiviral in clinical settings,This study examines therapeutic with 393 word abstract...,Author4327_1,PLoS ONE,2020-03-11,WHO,10.1000/sample.4327,,https://example.com/paper_4327,2020.0,3.0,90,13,True,57.0,8.0,True
cord-004329,Analysis of epidemiology and pandemic and symptoms and coronavirus in clinical settings,This study examines epidemiology with 320 word abstract...,"Author4329_1, Author4329_2",Science Translational Medicine,2020-07-03,WHO,10.1000/sample.4329,PMC1004329,https://example.com/paper_4329,2020.0,7.0,87,12,True,58.0,8.0,True
cord-004331,Analysis of pneumonia and vaccination and antiviral in clinical settings,This study examines pneumonia with 194 word abstract...,"Author4331_1, Author4331_2",BMJ,2021-06-09,bioRxiv,10.1000/sample.4331,PMC1004331,https://example.com/paper_4331,2021.0,6.0,72,10,True,55.0,8.0,True
cord-004332,Analysis of antiviral and therapeutic and outbreak in clinical settings,This study examines antiviral with 119 word abstract...,"Author4332_1, Author4332_2",Journal of Virology,2022-07-25,medRxiv,10.1000/sample.4332,PMC1004332,https://example.com/paper_4332,2022.0,7.0,71,10,True,55.0,8.0,True
cord-004334,Analysis of epidemiology and antiviral and lockdown in clinical settings,This study examines epidemiology with 160 word abstract...,"Author4334_1, Author4334_2",New England Journal of Medicine,2019-12-07,PMC,10.1000/sample.4334,PMC1004334,https://example.com/paper_4334,2019.0,12.0,72,10,True,58.0,8.0,True
cord-004336,Analysis of COVID-19 and coronavirus and respiratory and therapeutic in clinical settings,This study examines COVID-19 with 301 word abstract...,"Author4336_1, Author4336_2",PLoS ONE,2020-06-16,bioRxiv,,PMC1004336,https://example.com/paper_4336,2020.0,6.0,89,12,True,54.0,8.0,True
cord-004337,Analysis of therapeutic and pneumonia and coronavirus in clinical settings,This study examines therapeutic with 106 word abstract...,"Author4337_1, Author4337_2",Lancet,2021-04-23,PMC,10.1000/sample.4337,PMC1004337,https://example.com/paper_4337,2021.0,4.0,74,10,True,57.0,8.0,True
cord-004339,Analysis of pandemic and symptoms and therapeutic and outbreak in clinical settings,This study examines pandemic with 457 word abstract...,"Author4339_1, Author4339_2",Virology,2020-08-29,ArXiv,10.1000/sample.4339,PMC1004339,https://example.com/paper_4339,2020.0,8.0,83,12,True,54.0,8.0,True
cord-004341,Analysis of antibody and pandemic and coronavirus in clinical settings,This study examines antibody with 180 word abstract...,"Author4341_1, Author4341_2",Science Translational Medicine,2020-03-04,Medline,10.1000/sample.4341,PMC1004341,https://example.com/paper_4341,2020.0,3.0,70,10,True,54.0,8.0,True
cord-004342,Analysis of respiratory and epidemiology and antibody and pneumonia in clinical settings,This study examines respiratory with 191 word abstract...,"Author4342_1, Author4342_2",Emerging Infectious Diseases,2021-02-03,medRxiv,10.1000/sample.4342,PMC1004342,https://example.com/paper_4342,2021.0,2.0,88,12,True,57.0,8.0,True
cord-004346,Analysis of outbreak and respiratory and coronavirus and COVID-19 in clinical settings,This study examines outbreak with 497 word abstract...,"Author4346_1, Author4346_2",New England Journal of Medicine,2021-07-22,medRxiv,10.1000/sample.4346,PMC1004346,https://example.com/paper_4346,2021.0,7.0,86,12,True,54.0,8.0,True
cord-004347,Analysis of clinical and respiratory and transmission and coronavirus in clinical settings,This study examines clinical with 228 word abstract...,"Author4347_1, Author4347_2",JAMA,2020-12-18,bioRxiv,10.1000/sample.4347,,https://example.com/paper_4347,2020.0,12.0,90,12,True,54.0,8.0,True
cord-004348,Analysis of treatment and SARS-CoV-2 and diagnosis and antibody in clinical settings,This study examines treatment with 266 word abstract...,"Author4348_1, Author4348_2",Nature,2019-12-22,ArXiv,10.1000/sample.4348,,https://example.com/paper_4348,2019.0,12.0,84,12,True,55.0,8.0,True
cord-004349,Analysis of respiratory and epidemiology and clinical and pandemic in clinical settings,This study examines respiratory with 255 word abstract...,"Author4349_1, Author4349_2",Virology,2019-12-11,ArXiv,10.1000/sample.4349,PMC1004349,https://example.com/paper_4349,2019.0,12.0,87,12,True,57.0,8.0,True
cord-004350,Analysis of respiratory and clinical and public health and therapeutic in clinical settings,This study examines respiratory with 138 word abstract...,"Author4350_1, Author4350_2",,2021-04-13,ArXiv,10.1000/sample.4350,,,2021.0,4.0,91,13,True,57.0,8.0,False
cord-004351,Analysis of public health and lockdown and treatment in clinical settings,This study examines public health with 421 word abstract...,"Author4351_1, Author4351_2",Journal of Medical Virology,2020-09-01,medRxiv,10.1000/sample.4351,,https://example.com/paper_4351,2020.0,9.0,73,11,True,59.0,9.0,True
cord-004352,Analysis of pandemic and diagnosis and therapeutic and immunity in clinical settings,This study examines pandemic with 144 word abstract...,"Author4352_1, Author4352_2",Science Translational Medicine,2021-12-08,ArXiv,10.1000/sample.4352,,https://example.com/paper_4352,2021.0,12.0,84,12,True,54.0,8.0,True
cord-004354,Analysis of treatment and epidemiology and vaccination in clinical settings,This study examines treatment with 387 word abstract...,"Author4354_1, Author4354_2",Virology,2020-02-12,WHO,10.1000/sample.4354,,https://example.com/paper_4354,2020.0,2.0,75,10,True,55.0,8.0,True
cord-004356,Analysis of transmission and immunity and coronavirus and antibody in clinical settings,This study examines transmission with 371 word abstract...,"Author4356_1, Author4356_2",Emerging Infectious Diseases,2020-06-22,medRxiv,10.1000/sample.4356,,https://example.com/paper_4356,2020.0,6.0,87,12,True,58.0,8.0,True
cord-004357,Analysis of COVID-19 and antiviral and diagnosis and public health in clinical settings,This study examines COVID-19 with 318 word abstract...,"Author4357_1, Author4357_2",Cell,,Medline,10.1000/sample.4357,PMC1004357,,,,87,13,True,54.0,8.0,True
cord-004358,Analysis of outbreak and therapeutic and pandemic and symptoms in clinical settings,This study examines outbreak with 265 word abstract...,"Author4358_1, Author4358_2",New England Journal of Medicine,2020-11-01,WHO,,PMC1004358,,2020.0,11.0,83,12,True,54.0,8.0,True
cord-004359,Analysis of public health and diagnosis and symptoms and antiviral in clinical settings,This study examines public health with 425 word abstract...,"Author4359_1, Author4359_2",PLoS ONE,2021-10-19,PMC,10.1000/sample.4359,PMC1004359,https://example.com/paper_4359,2021.0,10.0,87,13,True,59.0,9.0,True
cord-004360,Analysis of pandemic and lockdown and outbreak and immunity in clinical settings,This study examines pandemic with 263 word abstract...,"Author4360_1, Author4360_2",New England Journal of Medicine,2020-10-01,medRxiv,10.1000/sample.4360,,,2020.0,10.0,80,12,True,54.0,8.0,True
cord-004363,Analysis of diagnosis and treatment and respiratory and epidemiology in clinical settings,This study examines diagnosis with 353 word abstract...,Author4363_1,Clinical Infectious Diseases,2021-07-30,Medline,10.1000/sample.4363,PMC1004363,https://example.com/paper_4363,2021.0,7.0,89,12,True,55.0,8.0,True
cord-004365,Analysis of clinical and coronavirus and diagnosis and COVID-19 in clinical settings,This study examines clinical with 480 word abstract...,"Author4365_1, Author4365_2",Cell,2022-07-12,ArXiv,,PMC1004365,https://example.com/paper_4365,2022.0,7.0,84,12,True,54.0,8.0,True
cord-004366,Analysis of respiratory and diagnosis and coronavirus and COVID-19 in clinical settings,This study examines respiratory with 102 word abstract...,"Author4366_1, Author4366_2",Journal of Virology,2021-10-13,ArXiv,10.1000/sample.4366,,https://example.com/paper_4366,2021.0,10.0,87,12,True,57.0,8.0,True
cord-004367,Analysis of symptoms and pandemic and public health and epidemiology in clinical settings,This study examines symptoms with 243 word abstract...,"Author4367_1, Author4367_2",Cell,2020-07-29,bioRxiv,10.1000/sample.4367,PMC1004367,https://example.com/paper_4367,2020.0,7.0,89,13,True,54.0,8.0,True
cord-004368,Analysis of COVID-19 and lockdown and SARS-CoV-2 in clinical settings,This study examines COVID-19 with 241 word abstract...,"Author4368_1, Author4368_2",,2020-07-25,PMC,10.1000/sample.4368,PMC1004368,https://example.com/paper_4368,2020.0,7.0,69,10,True,54.0,8.0,False
cord-004369,Analysis of pandemic and symptoms and COVID-19 in clinical settings,This study examines pandemic with 350 word abstract...,"Author4369_1, Author4369_2",,2021-12-02,WHO,10.1000/sample.4369,PMC1004369,https://example.com/paper_4369,2021.0,12.0,67,10,True,54.0,8.0,False
cord-004370,Analysis of antibody and antiviral and public health and transmission in clinical settings,This study examines antibody with 302 word abstract...,"Author4370_1, Author4370_2",BMJ,2021-02-21,ArXiv,10.1000/sample.4370,PMC1004370,https://example.com/paper_4370,2021.0,2.0,90,13,True,54.0,8.0,True
cord-004371,Analysis of coronavirus and therapeutic and SARS-CoV-2 in clinical settings,This study examines coronavirus with 385 word abstract...,"Author4371_1, Author4371_2",JAMA,2020-08-10,PMC,10.1000/sample.4371,PMC1004371,https://example.com/paper_4371,2020.0,8.0,75,10,True,57.0,8.0,True
cord-004372,Analysis of coronavirus and lockdown and therapeutic and symptoms in clinical settings,This study examines coronavirus with 442 word abstract...,"Author4372_1, Author4372_2",Emerging Infectious Diseases,2019-12-18,medRxiv,10.1000/sample.4372,PMC1004372,https://example.com/paper_4372,2019.0,12.0,86,12,True,57.0,8.0,True
cord-004373,Analysis of vaccination and COVID-19 and antiviral and pneumonia in clinical settings,This study examines vaccination with 432 word abstract...,"Author4373_1, Author4373_2",Nature,2020-02-28,PMC,,PMC1004373,https://example.com/paper_4373,2020.0,2.0,85,12,True,57.0,8.0,True
cord-004374,Analysis of treatment and SARS-CoV-2 and pandemic in clinical settings,This study examines treatment with 279 word abstract...,"Author4374_1, Author4374_2",Nature,2019-12-11,Medline,10.1000/sample.4374,PMC1004374,https://example.com/paper_4374,2019.0,12.0,70,10,True,55.0,8.0,True
cord-004376,Analysis of epidemiology and pandemic and coronavirus in clinical settings,This study examines epidemiology with 442 word abstract...,"Author4376_1, Author4376_2",PLoS ONE,2020-10-09,bioRxiv,10.1000/sample.4376,PMC1004376,https://example.com/paper_4376,2020.0,10.0,74,10,True,58.0,8.0,True
cord-004377,Analysis of pneumonia and COVID-19 and lockdown and symptoms in clinical settings,This study examines pneumonia with 352 word abstract...,"Author4377_1, Author4377_2",Clinical Infectious Diseases,2019-12-13,WHO,10.1000/sample.4377,PMC1004377,https://example.com/paper_4377,2019.0,12.0,81,12,True,55.0,8.0,True
cord-004378,Analysis of epidemiology and public health and immunity and pneumonia in clinical settings,This study examines epidemiology with 359 word abstract...,"Author4378_1, Author4378_2",Journal of Medical Virology,2020-09-03,bioRxiv,10.1000/sample.4378,PMC1004378,https://example.com/paper_4378,2020.0,9.0,90,13,True,58.0,8.0,True
cord-004379,Analysis of coronavirus and epidemiology and diagnosis in clinical settings,This study examines coronavirus with 471 word abstract...,"Author4379_1, Author4379_2",Lancet,2019-12-30,Medline,10.1000/sample.4379,,https://example.com/paper_4379,2019.0,12.0,75,10,True,57.0,8.0,True
cord-004380,Analysis of respiratory and vaccination and therapeutic and clinical in clinical settings,This study examines respiratory with 323 word abstract...,"Author4380_1, Author4380_2",Clinical Infectious Diseases,2021-07-19,WHO,10.1000/sample.4380,PMC1004380,https://example.com/paper_4380,2021.0,7.0,89,12,True,57.0,8.0,True
cord-004381,Analysis of therapeutic and vaccination and COVID-19 and outbreak in clinical settings,This study examines therapeutic with 166 word abstract...,"Author4381_1, Author4381_2",Journal of Medical Virology,2020-01-30,PMC,10.1000/sample.4381,PMC1004381,https://example.com/paper_4381,2020.0,1.0,86,12,True,57.0,8.0,True
cord-004383,Analysis of epidemiology and coronavirus and transmission and lockdown in clinical settings,This study examines epidemiology with 135 word abstract...,"Author4383_1, Author4383_2",Nature,,bioRxiv,10.1000/sample.4383,PMC1004383,,,,91,12,True,58.0,8.0,True
cord-004384,Analysis of treatment and antiviral and diagnosis in clinical settings,This study examines treatment with 258 word abstract...,"Author4384_1, Author4384_2",Lancet,2021-09-06,bioRxiv,10.1000/sample.4384,PMC1004384,https://example.com/paper_4384,2021.0,9.0,70,10,True,55.0,8.0,True
cord-004385,Analysis of COVID-19 and pandemic and lockdown in clinical settings,This study examines COVID-19 with 159 word abstract...,"Author4385_1, Author4385_2",Clinical Infectious Diseases,,Medline,10.1000/sample.4385,PMC1004385,,,,67,10,True,54.0,8.0,True
cord-004386,Analysis of pneumonia and treatment and coronavirus in clinical settings,This study examines pneumonia with 263 word abstract...,"Author4386_1, Author4386_2",Science Translational Medicine,2020-02-18,bioRxiv,10.1000/sample.4386,PMC1004386,https://example.com/paper_4386,2020.0,2.0,72,10,True,55.0,8.0,True
cord-004387,Analysis of pneumonia and antiviral and COVID-19 in clinical settings,This study examines pneumonia with 288 word abstract...,"Author4387_1, Author4387_2",Journal of Virology,,PMC,10.1000/sample.4387,,https://example.com/paper_4387,,,69,10,True,55.0,8.0,True
cord-004389,Analysis of SARS-CoV-2 and public health and symptoms in clinical settings,This study examines SARS-CoV-2 with 438 word abstract...,"Author4389_1, Author4389_2",Emerging Infectious Diseases,2022-05-01,ArXiv,10.1000/sample.4389,PMC1004389,https://example.com/paper_4389,2022.0,5.0,74,11,True,56.0,8.0,True
cord-004391,Analysis of clinical and antiviral and SARS-CoV-2 in clinical settings,This study examines clinical with 205 word abstract...,"Author4391_1, Author4391_2",Journal of Virology,2021-01-05,bioRxiv,10.1000/sample.4391,,https://example.com/paper_4391,2021.0,1.0,70,10,True,54.0,8.0,True
cord-004392,Analysis of antiviral and symptoms and vaccination and COVID-19 in clinical settings,This study examines antiviral with 469 word abstract...,"Author4392_1, Author4392_2",Journal of Virology,2020-05-20,bioRxiv,10.1000/sample.4392,PMC1004392,https://example.com/paper_4392,2020.0,5.0,84,12,True,55.0,8.0,True
cord-004393,Analysis of transmission and COVID-19 and antibody in clinical settings,This study examines transmission with 290 word abstract...,"Author4393_1, Author4393_2",Cell,2022-08-28,ArXiv,10.1000/sample.4393,PMC1004393,https://example.com/paper_4393,2022.0,8.0,71,10,True,58.0,8.0,True
cord-004394,Analysis of treatment and respiratory and immunity and vaccination in clinical settings,This study examines treatment with 492 word abstract...,"Author4394_1, Author4394_2",New England Journal of Medicine,2020-07-01,medRxiv,10.1000/sample.4394,,https://example.com/paper_4394,2020.0,7.0,87,12,True,55.0,8.0,True
cord-004396,Analysis of outbreak and epidemiology and immunity and COVID-19 in clinical settings,This study examines outbreak with 212 word abstract...,"Author4396_1, Author4396_2",JAMA,2020-08-15,WHO,10.1000/sample.4396,,https://example.com/paper_4396,2020.0,8.0,84,12,True,54.0,8.0,True
cord-004397,Analysis of antiviral and immunity and treatment in clinical settings,This study examines antiviral with 314 word abstract...,"Author4397_1, Author4397_2",Lancet,2020-10-07,ArXiv,10.1000/sample.4397,,https://example.com/paper_4397,2020.0,10.0,69,10,True,55.0,8.0,True
cord-004398,Analysis of therapeutic and COVID-19 and pneumonia in clinical settings,This study examines therapeutic with 186 word abstract...,"Author4398_1, Author4398_2",Journal of Virology,2019-12-13,medRxiv,10.1000/sample.4398,,https://example.com/paper_4398,2019.0,12.0,71,10,True,57.0,8.0,True
cord-004399,Analysis of vaccination and SARS-CoV-2 and coronavirus in clinical settings,This study examines vaccination with 474 word abstract...,"Author4399_1, Author4399_2",Emerging Infectious Diseases,2022-11-13,bioRxiv,10.1000/sample.4399,,https://example.com/paper_4399,2022.0,11.0,75,10,True,57.0,8.0,True
cord-004401,Analysis of symptoms and pneumonia and public health and therapeutic in clinical settings,This study examines symptoms with 429 word abstract...,"Author4401_1, Author4401_2",Nature Medicine,2021-05-19,bioRxiv,10.1000/sample.4401,PMC1004401,https://example.com/paper_4401,2021.0,5.0,89,13,True,54.0,8.0,True
cord-004403,Analysis of immunity and epidemiology and antibody and lockdown in clinical settings,,"Author4403_1, Author4403_2",JAMA,2022-01-18,medRxiv,10.1000/sample.4403,PMC1004403,https://example.com/paper_4403,2022.0,1.0,84,12,False,,,True
cord-004404,Analysis of immunity and public health and antibody and lockdown in clinical settings,This study examines immunity with 316 word abstract...,"Author4404_1, Author4404_2",BMJ,2021-09-09,PMC,10.1000/sample.4404,PMC1004404,https://example.com/paper_4404,2021.0,9.0,85,13,True,54.0,8.0,True
cord-004405,Analysis of outbreak and coronavirus and treatment in clinical settings,This study examines outbreak with 418 word abstract...,"Author4405_1, Author4405_2",PLoS ONE,2020-06-11,medRxiv,10.1000/sample.4405,PMC1004405,https://example.com/paper_4405,2020.0,6.0,71,10,True,54.0,8.0,True
cord-004406,Analysis of treatment and outbreak and epidemiology in clinical settings,This study examines treatment with 362 word abstract...,"Author4406_1, Author4406_2",,2019-12-18,ArXiv,,PMC1004406,https://example.com/paper_4406,2019.0,12.0,72,10,True,55.0,8.0,False
cord-004408,Analysis of antibody and therapeutic and pandemic in clinical settings,This study examines antibody with 319 word abstract...,"Author4408_1, Author4408_2",Nature Medicine,2021-03-02,medRxiv,10.1000/sample.4408,PMC1004408,https://example.com/paper_4408,2021.0,3.0,70,10,True,54.0,8.0,True
cord-004409,Analysis of therapeutic and outbreak and antiviral in clinical settings,This study examines therapeutic with 384 word abstract...,Author4409_1,Emerging Infectious Diseases,2021-07-10,medRxiv,10.1000/sample.4409,PMC1004409,https://example.com/paper_4409,2021.0,7.0,71,10,True,57.0,8.0,True
cord-004410,Analysis of SARS-CoV-2 and coronavirus and treatment in clinical settings,This study examines SARS-CoV-2 with 436 word abstract...,"Author4410_1, Author4410_2",Emerging Infectious Diseases,2022-04-04,medRxiv,10.1000/sample.4410,PMC1004410,https://example.com/paper_4410,2022.0,4.0,73,10,True,56.0,8.0,True
cord-004414,Analysis of therapeutic and immunity and antibody and SARS-CoV-2 in clinical settings,This study examines therapeutic with 403 word abstract...,"Author4414_1, Author4414_2",New England Journal of Medicine,,medRxiv,10.1000/sample.4414,PMC1004414,https://example.com/paper_4414,,,85,12,True,57.0,8.0,True
cord-004417,Analysis of symptoms and transmission and diagnosis and clinical in clinical settings,This study examines symptoms with 404 word abstract...,"Author4417_1, Author4417_2",PLoS ONE,2020-04-11,medRxiv,10.1000/sample.4417,PMC1004417,https://example.com/paper_4417,2020.0,4.0,85,12,True,54.0,8.0,True
cord-004420,Analysis of epidemiology and immunity and public health and coronavirus in clinical settings,This study examines epidemiology with 496 word abstract...,"Author4420_1, Author4420_2",New England Journal of Medicine,,Medline,10.1000/sample.4420,PMC1004420,https://example.com/paper_4420,,,92,13,True,58.0,8.0,True
cord-004423,Analysis of vaccination and antiviral and pandemic and immunity in clinical settings,This study examines vaccination with 150 word abstract...,"Author4423_1, Author4423_2",,2021-12-28,bioRxiv,10.1000/sample.4423,PMC1004423,https://example.com/paper_4423,2021.0,12.0,84,12,True,57.0,8.0,False
cord-004425,Analysis of symptoms and antiviral and outbreak in clinical settings,,Author4425_1,Cell,2020-12-14,bioRxiv,10.1000/sample.4425,PMC1004425,https://example.com/paper_4425,2020.0,12.0,68,10,False,,,True
cord-004427,Analysis of antiviral and vaccination and therapeutic in clinical settings,This study examines antiviral with 132 word abstract...,,JAMA,2020-02-23,Medline,10.1000/sample.4427,,,2020.0,2.0,74,10,True,55.0,8.0,True
cord-004428,Analysis of antibody and epidemiology and clinical in clinical settings,This study examines antibody with 459 word abstract...,"Author4428_1, Author4428_2",BMJ,2020-03-06,WHO,10.1000/sample.4428,PMC1004428,https://example.com/paper_4428,2020.0,3.0,71,10,True,54.0,8.0,True
cord-004429,Analysis of SARS-CoV-2 and immunity and antiviral in clinical settings,,"Author4429_1, Author4429_2",Nature Medicine,2020-09-14,Medline,10.1000/sample.4429,PMC1004429,https://example.com/paper_4429,2020.0,9.0,70,10,False,,,True
cord-004430,Analysis of antibody and pneumonia and treatment and lockdown in clinical settings,This study examines antibody with 325 word abstract...,"Author4430_1, Author4430_2",Journal of Virology,2020-02-10,ArXiv,10.1000/sample.4430,PMC1004430,https://example.com/paper_4430,2020.0,2.0,82,12,True,54.0,8.0,True
cord-004431,Analysis of epidemiology and therapeutic and pandemic and lockdown in clinical settings,This study examines epidemiology with 217 word abstract...,"Author4431_1, Author4431_2",JAMA,2020-09-20,Medline,10.1000/sample.4431,PMC1004431,https://example.com/paper_4431,2020.0,9.0,87,12,True,58.0,8.0,True
cord-004433,Analysis of lockdown and symptoms and transmission and respiratory in clinical settings,This study examines lockdown with 219 word abstract...,"Author4433_1, Author4433_2",,2020-07-18,WHO,10.1000/sample.4433,PMC1004433,https://example.com/paper_4433,2020.0,7.0,87,12,True,54.0,8.0,False
cord-004436,Analysis of clinical and treatment and symptoms and antibody in clinical settings,This study examines clinical with 452 word abstract...,Author4436_1,Nature,2020-12-26,medRxiv,10.1000/sample.4436,PMC1004436,https://example.com/paper_4436,2020.0,12.0,81,12,True,54.0,8.0,True
cord-004437,Analysis of SARS-CoV-2 and antibody and public health in clinical settings,This study examines SARS-CoV-2 with 198 word abstract...,"Author4437_1, Author4437_2",Journal of Virology,2020-09-01,bioRxiv,10.1000/sample.4437,PMC1004437,,2020.0,9.0,74,11,True,56.0,8.0,True
cord-004438,Analysis of COVID-19 and pandemic and antibody in clinical settings,This study examines COVID-19 with 312 word abstract...,"Author4438_1, Author4438_2",BMJ,2020-08-21,ArXiv,10.1000/sample.4438,PMC1004438,,2020.0,8.0,67,10,True,54.0,8.0,True
cord-004439,Analysis of clinical and diagnosis and antibody and treatment in clinical settings,This study examines clinical with 464 word abstract...,"Author4439_1, Author4439_2",,,medRxiv,10.1000/sample.4439,,https://example.com/paper_4439,,,82,12,True,54.0,8.0,False
cord-004440,Analysis of outbreak and antibody and lockdown in clinical settings,This study examines outbreak with 341 word abstract...,Author4440_1,Clinical Infectious Diseases,2021-10-31,medRxiv,10.1000/sample.4440,PMC1004440,,2021.0,10.0,67,10,True,54.0,8.0,True
cord-004441,Analysis of lockdown and immunity and clinical and transmission in clinical settings,This study examines lockdown with 185 word abstract...,"Author4441_1, Author4441_2",New England Journal of Medicine,2020-01-21,WHO,10.1000/sample.4441,PMC1004441,,2020.0,1.0,84,12,True,54.0,8.0,True
cord-004442,Analysis of immunity and outbreak and diagnosis in clinical settings,This study examines immunity with 463 word abstract...,"Author4442_1, Author4442_2",Lancet,2021-11-22,ArXiv,10.1000/sample.4442,PMC1004442,,2021.0,11.0,68,10,True,54.0,8.0,True
cord-004448,Analysis of pneumonia and pandemic and clinical and immunity in clinical settings,This study examines pneumonia with 381 word abstract...,"Author4448_1, Author4448_2",,2020-11-01,WHO,10.1000/sample.4448,PMC1004448,https://example.com/paper_4448,2020.0,11.0,81,12,True,55.0,8.0,False
cord-004449,Analysis of antibody and lockdown and coronavirus and public health in clinical settings,This study examines antibody with 139 word abstract...,"Author4449_1, Author4449_2",PLoS ONE,2020-07-02,ArXiv,10.1000/sample.4449,PMC1004449,https://example.com/paper_4449,2020.0,7.0,88,13,True,54.0,8.0,True
cord-004452,Analysis of transmission and epidemiology and treatment and public health in clinical settings,This study examines transmission with 322 word abstract...,"Author4452_1, Author4452_2",PLoS ONE,2022-02-10,ArXiv,10.1000/sample.4452,PMC1004452,https://example.com/paper_4452,2022.0,2.0,94,13,True,58.0,8.0,True
cord-004459,Analysis of SARS-CoV-2 and antiviral and clinical in clinical settings,This study examines SARS-CoV-2 with 308 word abstract...,"Author4459_1, Author4459_2",Science,2020-10-11,WHO,10.1000/sample.4459,,https://example.com/paper_4459,2020.0,10.0,70,10,True,56.0,8.0,True
cord-004464,Analysis of pneumonia and COVID-19 and public health in clinical settings,This study examines pneumonia with 128 word abstract...,"Author4464_1, Author4464_2",BMJ,2019-12-12,ArXiv,,PMC1004464,https://example.com/paper_4464,2019.0,12.0,73,11,True,55.0,8.0,True
cord-004465,Analysis of immunity and outbreak and SARS-CoV-2 in clinical settings,This study examines immunity with 341 word abstract...,Author4465_1,Virology,2020-12-14,Medline,10.1000/sample.4465,PMC1004465,https://example.com/paper_4465,2020.0,12.0,69,10,True,54.0,8.0,True
cord-004466,Analysis of immunity and treatment and vaccination and outbreak in clinical settings,This study examines immunity with 225 word abstract...,"Author4466_1, Author4466_2",Clinical Infectious Diseases,2021-06-25,bioRxiv,,,,2021.0,6.0,84,12,True,54.0,8.0,True
cord-004468,Analysis of outbreak and epidemiology and antiviral and treatment in clinical settings,,"Author4468_1, Author4468_2",,2022-12-22,medRxiv,10.1000/sample.4468,PMC1004468,https://example.com/paper_4468,2022.0,12.0,86,12,False,,,False
cord-004470,Analysis of treatment and therapeutic and vaccination and epidemiology in clinical settings,This study examines treatment with 408 word abstract...,"Author4470_1, Author4470_2",Clinical Infectious Diseases,2020-07-29,bioRxiv,10.1000/sample.4470,PMC1004470,,2020.0,7.0,91,12,True,55.0,8.0,True
cord-004471,Analysis of lockdown and COVID-19 and transmission in clinical settings,This study examines lockdown with 334 word abstract...,"Author4471_1, Author4471_2",Clinical Infectious Diseases,2022-11-05,WHO,10.1000/sample.4471,,,2022.0,11.0,71,10,True,54.0,8.0,True
cord-004474,Analysis of antibody and lockdown and pneumonia and outbreak in clinical settings,,"Author4474_1, Author4474_2",Nature,2020-12-27,WHO,10.1000/sample.4474,PMC1004474,,2020.0,12.0,81,12,False,,,True
cord-004476,Analysis of treatment and epidemiology and antibody and therapeutic in clinical settings,This study examines treatment with 113 word abstract...,"Author4476_1, Author4476_2",Clinical Infectious Diseases,,bioRxiv,10.1000/sample.4476,PMC1004476,https://example.com/paper_4476,,,88,12,True,55.0,8.0,True
cord-004477,Analysis of pandemic and antiviral and lockdown and immunity in clinical settings,This study examines pandemic with 406 word abstract...,"Author4477_1, Author4477_2",Science Translational Medicine,2021-11-08,medRxiv,10.1000/sample.4477,PMC1004477,https://example.com/paper_4477,2021.0,11.0,81,12,True,54.0,8.0,True
cord-004478,Analysis of epidemiology and treatment and clinical in clinical settings,This study examines epidemiology with 284 word abstract...,"Author4478_1, Author4478_2",Clinical Infectious Diseases,2020-02-29,PMC,10.1000/sample.4478,,https://example.com/paper_4478,2020.0,2.0,72,10,True,58.0,8.0,True
cord-004481,Analysis of outbreak and public health and pneumonia and treatment in clinical settings,This study examines outbreak with 471 word abstract...,"Author4481_1, Author4481_2",New England Journal of Medicine,,WHO,10.1000/sample.4481,PMC1004481,https://example.com/paper_4481,,,87,13,True,54.0,8.0,True
cord-004483,Analysis of antiviral and pneumonia and treatment and coronavirus in clinical settings,This study examines antiviral with 131 word abstract...,"Author4483_1, Author4483_2",Lancet,2021-10-08,bioRxiv,10.1000/sample.4483,,https://example.com/paper_4483,2021.0,10.0,86,12,True,55.0,8.0,True
cord-004485,Analysis of immunity and outbreak and public health in clinical settings,This study examines immunity with 429 word abstract...,Author4485_1,Nature Medicine,2021-08-14,Medline,10.1000/sample.4485,,https://example.com/paper_4485,2021.0,8.0,72,11,True,54.0,8.0,True
cord-004490,Analysis of clinical and lockdown and respiratory in clinical settings,This study examines clinical with 469 word abstract...,"Author4490_1, Author4490_2",Lancet,2021-11-23,medRxiv,10.1000/sample.4490,,https://example.com/paper_4490,2021.0,11.0,70,10,True,54.0,8.0,True
cord-004491,Analysis of symptoms and pandemic and outbreak and public health in clinical settings,This study examines symptoms with 388 word abstract...,"Author4491_1, Author4491_2",Clinical Infectious Diseases,2020-06-30,bioRxiv,10.1000/sample.4491,PMC1004491,,2020.0,6.0,85,13,True,54.0,8.0,True
cord-004492,Analysis of coronavirus and vaccination and antibody and pandemic in clinical settings,This study examines coronavirus with 240 word abstract...,"Author4492_1, Author4492_2",PLoS ONE,2019-12-05,WHO,10.1000/sample.4492,PMC1004492,https://example.com/paper_4492,2019.0,12.0,86,12,True,57.0,8.0,True
cord-004493,Analysis of diagnosis and clinical and vaccination in clinical settings,This study examines diagnosis with 147 word abstract...,"Author4493_1, Author4493_2",Emerging Infectious Diseases,2020-06-20,medRxiv,10.1000/sample.4493,,https://example.com/paper_4493,2020.0,6.0,71,10,True,55.0,8.0,True
cord-004496,Analysis of transmission and vaccination and epidemiology in clinical settings,,"Author4496_1, Author4496_2",Lancet,2019-12-25,medRxiv,10.1000/sample.4496,,https://example.com/paper_4496,2019.0,12.0,78,10,False,,,True
cord-004498,Analysis of therapeutic and antiviral and treatment and pandemic in clinical settings,This study examines therapeutic with 421 word abstract...,"Author4498_1, Author4498_2",Clinical Infectious Diseases,2020-11-22,bioRxiv,10.1000/sample.4498,,,2020.0,11.0,85,12,True,57.0,8.0,True
cord-004499,Analysis of pneumonia and coronavirus and COVID-19 and symptoms in clinical settings,This study examines pneumonia with 173 word abstract...,"Author4499_1, Author4499_2",BMJ,2022-07-18,PMC,10.1000/sample.4499,PMC1004499,https://example.com/paper_4499,2022.0,7.0,84,12,True,55.0,8.0,True
cord-004500,Analysis of transmission and treatment and clinical and epidemiology in clinical settings,This study examines transmission with 481 word abstract...,"Author4500_1, Author4500_2",Cell,,WHO,10.1000/sample.4500,PMC1004500,https://example.com/paper_4500,,,89,12,True,58.0,8.0,True
cord-004502,Analysis of lockdown and coronavirus and transmission and clinical in clinical settings,This study examines lockdown with 365 word abstract...,"Author4502_1, Author4502_2",Clinical Infectious Diseases,2020-02-02,Medline,10.1000/sample.4502,PMC1004502,https://example.com/paper_4502,2020.0,2.0,87,12,True,54.0,8.0,True
cord-004503,Analysis of respiratory and pandemic and symptoms and immunity in clinical settings,,"Author4503_1, Author4503_2",Virology,2020-10-16,bioRxiv,10.1000/sample.4503,PMC1004503,https://example.com/paper_4503,2020.0,10.0,83,12,False,,,True
cord-004510,Analysis of treatment and coronavirus and pandemic and transmission in clinical settings,This study examines treatment with 115 word abstract...,"Author4510_1, Author4510_2",Journal of Virology,2020-01-04,WHO,10.1000/sample.4510,PMC1004510,https://example.com/paper_4510,2020.0,1.0,88,12,True,55.0,8.0,True
cord-004512,Analysis of coronavirus and transmission and immunity and symptoms in clinical settings,This study examines coronavirus with 331 word abstract...,Author4512_1,Virology,2021-10-18,PMC,10.1000/sample.4512,,https://example.com/paper_4512,2021.0,10.0,87,12,True,57.0,8.0,True
cord-004513,Analysis of pandemic and coronavirus and lockdown in clinical settings,This study examines pandemic with 271 word abstract...,"Author4513_1, Author4513_2",New England Journal of Medicine,2021-11-09,PMC,10.1000/sample.4513,,https://example.com/paper_4513,2021.0,11.0,70,10,True,54.0,8.0,True
cord-004516,Analysis of symptoms and clinical and antiviral and antibody in clinical settings,This study examines symptoms with 147 word abstract...,"Author4516_1, Author4516_2",,2021-01-28,Medline,,,https://example.com/paper_4516,2021.0,1.0,81,12,True,54.0,8.0,False
cord-004518,Analysis of SARS-CoV-2 and symptoms and coronavirus in clinical settings,This study examines SARS-CoV-2 with 239 word abstract...,"Author4518_1, Author4518_2",JAMA,2020-02-25,Medline,10.1000/sample.4518,PMC1004518,https://example.com/paper_4518,2020.0,2.0,72,10,True,56.0,8.0,True
cord-004519,Analysis of pandemic and outbreak and epidemiology in clinical settings,This study examines pandemic with 422 word abstract...,"Author4519_1, Author4519_2",Science Translational Medicine,2021-04-23,bioRxiv,,PMC1004519,https://example.com/paper_4519,2021.0,4.0,71,10,True,54.0,8.0,True
cord-004520,Analysis of respiratory and pandemic and pneumonia and coronavirus in clinical settings,This study examines respiratory with 209 word abstract...,"Author4520_1, Author4520_2",Science,2021-04-30,Medline,10.1000/sample.4520,,https://example.com/paper_4520,2021.0,4.0,87,12,True,57.0,8.0,True
cord-004521,Analysis of antibody and respiratory and pneumonia and diagnosis in clinical settings,This study examines antibody with 350 word abstract...,"Author4521_1, Author4521_2",Virology,2020-05-31,ArXiv,10.1000/sample.4521,,https://example.com/paper_4521,2020.0,5.0,85,12,True,54.0,8.0,True
cord-004524,Analysis of symptoms and transmission and COVID-19 in clinical settings,This study examines symptoms with 150 word abstract...,"Author4524_1, Author4524_2",PLoS ONE,2019-12-12,medRxiv,10.1000/sample.4524,,https://example.com/paper_4524,2019.0,12.0,71,10,True,54.0,8.0,True
cord-004526,Analysis of immunity and transmission and antiviral and therapeutic in clinical settings,This study examines immunity with 497 word abstract...,"Author4526_1, Author4526_2",BMJ,2021-07-13,WHO,,PMC1004526,https://example.com/paper_4526,2021.0,7.0,88,12,True,54.0,8.0,True
cord-004527,Analysis of COVID-19 and respiratory and SARS-CoV-2 in clinical settings,This study examines COVID-19 with 383 word abstract...,Author4527_1,Cell,2021-07-16,PMC,10.1000/sample.4527,PMC1004527,https://example.com/paper_4527,2021.0,7.0,72,10,True,54.0,8.0,True
cord-004528,Analysis of respiratory and lockdown and epidemiology and SARS-CoV-2 in clinical settings,This study examines respiratory with 419 word abstract...,Author4528_1,Nature Medicine,2019-12-07,Medline,10.1000/sample.4528,PMC1004528,https://example.com/paper_4528,2019.0,12.0,89,12,True,57.0,8.0,True
cord-004529,Analysis of respiratory and pneumonia and vaccination and symptoms in clinical settings,This study examines respiratory with 472 word abstract...,"Author4529_1, Author4529_2",Virology,2019-12-13,WHO,10.1000/sample.4529,PMC1004529,https://example.com/paper_4529,2019.0,12.0,87,12,True,57.0,8.0,True
cord-004531,Analysis of transmission and clinical and COVID-19 and respiratory in clinical settings,This study examines transmission with 156 word abstract...,"Author4531_1, Author4531_2",Nature,2022-08-17,WHO,10.1000/sample.4531,PMC1004531,https://example.com/paper_4531,2022.0,8.0,87,12,True,58.0,8.0,True
cord-004533,Analysis of SARS-CoV-2 and epidemiology and clinical in clinical settings,This study examines SARS-CoV-2 with 450 word abstract...,"Author4533_1, Author4533_2",Virology,2020-12-26,bioRxiv,10.1000/sample.4533,,https://example.com/paper_4533,2020.0,12.0,73,10,True,56.0,8.0,True
cord-004534,Analysis of clinical and public health and symptoms in clinical settings,This study examines clinical with 266 word abstract...,"Author4534_1, Author4534_2",Nature Medicine,2020-10-30,Medline,10.1000/sample.4534,PMC1004534,https://example.com/paper_4534,2020.0,10.0,72,11,True,54.0,8.0,True
cord-004535,Analysis of respiratory and pandemic and clinical and lockdown in clinical settings,This study examines respiratory with 377 word abstract...,"Author4535_1, Author4535_2",Emerging Infectious Diseases,,bioRxiv,10.1000/sample.4535,,,,,83,12,True,57.0,8.0,True
cord-004538,Analysis of SARS-CoV-2 and respiratory and treatment in clinical settings,This study examines SARS-CoV-2 with 472 word abstract...,"Author4538_1, Author4538_2",Virology,2022-01-11,bioRxiv,10.1000/sample.4538,PMC1004538,,2022.0,1.0,73,10,True,56.0,8.0,True
cord-004540,Analysis of clinical and transmission and outbreak and public health in clinical settings,This study examines clinical with 433 word abstract...,"Author4540_1, Author4540_2",Lancet,2021-07-11,bioRxiv,10.1000/sample.4540,PMC1004540,https://example.com/paper_4540,2021.0,7.0,89,13,True,54.0,8.0,True
cord-004541,Analysis of clinical and antibody and pandemic in clinical settings,This study examines clinical with 257 word abstract...,Author4541_1,Emerging Infectious Diseases,2020-12-16,ArXiv,,PMC1004541,https://example.com/paper_4541,2020.0,12.0,67,10,True,54.0,8.0,True
cord-004543,Analysis of clinical and epidemiology and symptoms in clinical settings,This study examines clinical with 472 word abstract...,"Author4543_1, Author4543_2",Virology,2021-07-29,Medline,,PMC1004543,https://example.com/paper_4543,2021.0,7.0,71,10,True,54.0,8.0,True
cord-004544,Analysis of outbreak and transmission and pandemic and lockdown in clinical settings,,Author4544_1,BMJ,2022-11-16,ArXiv,10.1000/sample.4544,PMC1004544,,2022.0,11.0,84,12,False,,,True
cord-004545,Analysis of public health and transmission and pandemic in clinical settings,This study examines public health with 318 word abstract...,"Author4545_1, Author4545_2",Lancet,2021-06-11,ArXiv,10.1000/sample.4545,,,2021.0,6.0,76,11,True,59.0,9.0,True
cord-004546,Analysis of therapeutic and COVID-19 and vaccination and clinical in clinical settings,This study examines therapeutic with 115 word abstract...,"Author4546_1, Author4546_2",Science Translational Medicine,2021-07-27,medRxiv,10.1000/sample.4546,PMC1004546,https://example.com/paper_4546,2021.0,7.0,86,12,True,57.0,8.0,True
cord-004547,Analysis of symptoms and diagnosis and public health and respiratory in clinical settings,This study examines symptoms with 326 word abstract...,"Author4547_1, Author4547_2",,2019-12-05,bioRxiv,10.1000/sample.4547,PMC1004547,https://example.com/paper_4547,2019.0,12.0,89,13,True,54.0,8.0,False
cord-004549,Analysis of vaccination and outbreak and antiviral in clinical settings,This study examines vaccination with 270 word abstract...,"Author4549_1, Author4549_2",Cell,2019-12-06,Medline,10.1000/sample.4549,PMC1004549,https://example.com/paper_4549,2019.0,12.0,71,10,True,57.0,8.0,True
cord-004550,Analysis of vaccination and pandemic and lockdown in clinical settings,This study examines vaccination with 376 word abstract...,"Author4550_1, Author4550_2",Virology,2020-02-26,Medline,,,,2020.0,2.0,70,10,True,57.0,8.0,True
cord-004552,Analysis of therapeutic and transmission and respiratory in clinical settings,This study examines therapeutic with 407 word abstract...,"Author4552_1, Author4552_2",Nature,,PMC,,PMC1004552,https://example.com/paper_4552,,,77,10,True,57.0,8.0,True
cord-004554,Analysis of immunity and respiratory and transmission in clinical settings,This study examines immunity with 109 word abstract...,"Author4554_1, Author4554_2",Lancet,2020-04-13,medRxiv,,PMC1004554,,2020.0,4.0,74,10,True,54.0,8.0,True
cord-004556,Analysis of therapeutic and COVID-19 and transmission and SARS-CoV-2 in clinical settings,This study examines therapeutic with 462 word abstract...,"Author4556_1, Author4556_2",Journal of Medical Virology,2020-12-30,PMC,10.1000/sample.4556,,https://example.com/paper_4556,2020.0,12.0,89,12,True,57.0,8.0,True
cord-004557,Analysis of coronavirus and clinical and transmission in clinical settings,This study examines coronavirus with 450 word abstract...,"Author4557_1, Author4557_2",PLoS ONE,2020-05-26,ArXiv,10.1000/sample.4557,PMC1004557,,2020.0,5.0,74,10,True,57.0,8.0,True
cord-004558,Analysis of vaccination and pneumonia and clinical and treatment in clinical settings,This study examines vaccination with 356 word abstract...,"Author4558_1, Author4558_2",New England Journal of Medicine,2021-01-28,medRxiv,10.1000/sample.4558,PMC1004558,https://example.com/paper_4558,2021.0,1.0,85,12,True,57.0,8.0,True
cord-004559,Analysis of coronavirus and pandemic and vaccination in clinical settings,This study examines coronavirus with 103 word abstract...,"Author4559_1, Author4559_2",PLoS ONE,2020-07-05,bioRxiv,,PMC1004559,https://example.com/paper_4559,2020.0,7.0,73,10,True,57.0,8.0,True
cord-004561,Analysis of therapeutic and outbreak and SARS-CoV-2 and transmission in clinical settings,This study examines therapeutic with 240 word abstract...,"Author4561_1, Author4561_2",Nature,2021-06-10,bioRxiv,,PMC1004561,,2021.0,6.0,89,12,True,57.0,8.0,True
cord-004564,Analysis of immunity and transmission and lockdown and epidemiology in clinical settings,This study examines immunity with 332 word abstract...,"Author4564_1, Author4564_2",,2019-12-11,ArXiv,10.1000/sample.4564,,https://example.com/paper_4564,2019.0,12.0,88,12,True,54.0,8.0,False
cord-004567,Analysis of coronavirus and symptoms and pneumonia in clinical settings,,"Author4567_1, Author4567_2",Clinical Infectious Diseases,2020-03-15,WHO,,PMC1004567,https://example.com/paper_4567,2020.0,3.0,71,10,False,,,True
cord-004568,Analysis of SARS-CoV-2 and antibody and vaccination in clinical settings,This study examines SARS-CoV-2 with 455 word abstract...,"Author4568_1, Author4568_2",Nature Medicine,2020-07-18,bioRxiv,10.1000/sample.4568,PMC1004568,https://example.com/paper_4568,2020.0,7.0,72,10,True,56.0,8.0,True
cord-004569,Analysis of symptoms and antibody and public health and therapeutic in clinical settings,,"Author4569_1, Author4569_2",Journal of Medical Virology,2020-12-07,Medline,10.1000/sample.4569,,https://example.com/paper_4569,2020.0,12.0,88,13,False,,,True
cord-004570,Analysis of outbreak and SARS-CoV-2 and respiratory in clinical settings,This study examines outbreak with 176 word abstract...,Author4570_1,JAMA,2021-09-24,WHO,10.1000/sample.4570,PMC1004570,,2021.0,9.0,72,10,True,54.0,8.0,True
cord-004571,Analysis of diagnosis and SARS-CoV-2 and coronavirus and symptoms in clinical settings,This study examines diagnosis with 109 word abstract...,"Author4571_1, Author4571_2",Nature Medicine,2021-05-14,bioRxiv,10.1000/sample.4571,PMC1004571,https://example.com/paper_4571,2021.0,5.0,86,12,True,55.0,8.0,True
cord-004576,Analysis of transmission and antibody and therapeutic and lockdown in clinical settings,This study examines transmission with 382 word abstract...,"Author4576_1, Author4576_2",Science Translational Medicine,2022-05-08,ArXiv,10.1000/sample.4576,PMC1004576,,2022.0,5.0,87,12,True,58.0,8.0,True
cord-004577,Analysis of transmission and lockdown and coronavirus in clinical settings,This study examines transmission with 274 word abstract...,"Author4577_1, Author4577_2",Nature,2020-09-29,bioRxiv,10.1000/sample.4577,PMC1004577,https://example.com/paper_4577,2020.0,9.0,74,10,True,58.0,8.0,True
cord-004578,Analysis of epidemiology and symptoms and SARS-CoV-2 in clinical settings,This study examines epidemiology with 297 word abstract...,"Author4578_1, Author4578_2",Journal of Virology,2020-03-17,WHO,10.1000/sample.4578,PMC1004578,https://example.com/paper_4578,2020.0,3.0,73,10,True,58.0,8.0,True
cord-004579,Analysis of symptoms and vaccination and treatment and SARS-CoV-2 in clinical settings,This study examines symptoms with 274 word abstract...,Author4579_1,New England Journal of Medicine,2021-06-05,ArXiv,10.1000/sample.4579,,https://example.com/paper_4579,2021.0,6.0,86,12,True,54.0,8.0,True
cord-004581,Analysis of therapeutic and transmission and lockdown in clinical settings,This study examines therapeutic with 203 word abstract...,"Author4581_1, Author4581_2",Clinical Infectious Diseases,2020-11-27,PMC,10.1000/sample.4581,PMC1004581,https://example.com/paper_4581,2020.0,11.0,74,10,True,57.0,8.0,True
cord-004582,Analysis of pneumonia and antibody and antiviral and pandemic in clinical settings,This study examines pneumonia with 491 word abstract...,"Author4582_1, Author4582_2",Science,2020-05-11,WHO,10.1000/sample.4582,PMC1004582,https://example.com/paper_4582,2020.0,5.0,82,12,True,55.0,8.0,True
cord-004583,Analysis of outbreak and pneumonia and clinical in clinical settings,This study examines outbreak with 354 word abstract...,"Author4583_1, Author4583_2",Journal of Medical Virology,2022-12-05,bioRxiv,10.1000/sample.4583,PMC1004583,https://example.com/paper_4583,2022.0,12.0,68,10,True,54.0,8.0,True
cord-004585,Analysis of COVID-19 and epidemiology and lockdown and respiratory in clinical settings,This study examines COVID-19 with 380 word abstract...,"Author4585_1, Author4585_2",Emerging Infectious Diseases,2020-04-15,Medline,10.1000/sample.4585,,https://example.com/paper_4585,2020.0,4.0,87,12,True,54.0,8.0,True
cord-004589,Analysis of lockdown and immunity and treatment and COVID-19 in clinical settings,,"Author4589_1, Author4589_2",BMJ,2020-01-31,bioRxiv,10.1000/sample.4589,PMC1004589,https://example.com/paper_4589,2020.0,1.0,81,12,False,,,True
cord-004591,Analysis of pandemic and therapeutic and diagnosis and antibody in clinical settings,This study examines pandemic with 210 word abstract...,"Author4591_1, Author4591_2",Lancet,2021-12-24,WHO,10.1000/sample.4591,,,2021.0,12.0,84,12,True,54.0,8.0,True
cord-004592,Analysis of epidemiology and therapeutic and SARS-CoV-2 and COVID-19 in clinical settings,This study examines epidemiology with 113 word abstract...,"Author4592_1, Author4592_2",,2019-12-06,PMC,10.1000/sample.4592,PMC1004592,https://example.com/paper_4592,2019.0,12.0,89,12,True,58.0,8.0,False
cord-004593,Analysis of clinical and epidemiology and antiviral and public health in clinical settings,This study examines clinical with 424 word abstract...,"Author4593_1, Author4593_2",Nature,2021-09-22,Medline,10.1000/sample.4593,PMC1004593,https://example.com/paper_4593,2021.0,9.0,90,13,True,54.0,8.0,True
cord-004594,Analysis of transmission and public health and antibody in clinical settings,This study examines transmission with 231 word abstract...,"Author4594_1, Author4594_2",Nature Medicine,2020-10-20,ArXiv,10.1000/sample.4594,PMC1004594,https://example.com/paper_4594,2020.0,10.0,76,11,True,58.0,8.0,True
cord-004595,Analysis of clinical and coronavirus and outbreak in clinical settings,This study examines clinical with 289 word abstract...,"Author4595_1, Author4595_2",Nature,2020-09-16,medRxiv,10.1000/sample.4595,PMC1004595,https://example.com/paper_4595,2020.0,9.0,70,10,True,54.0,8.0,True
cord-004596,Analysis of symptoms and diagnosis and antiviral and lockdown in clinical settings,This study examines symptoms with 321 word abstract...,"Author4596_1, Author4596_2",BMJ,2021-06-14,Medline,10.1000/sample.4596,,,2021.0,6.0,82,12,True,54.0,8.0,True
cord-004598,Analysis of antiviral and vaccination and treatment and public health in clinical settings,This study examines antiviral with 389 word abstract...,"Author4598_1, Author4598_2",Nature,2019-12-30,Medline,,PMC1004598,https://example.com/paper_4598,2019.0,12.0,90,13,True,55.0,8.0,True
cord-004601,Analysis of diagnosis and lockdown and therapeutic in clinical settings,This study examines diagnosis with 180 word abstract...,"Author4601_1, Author4601_2",Journal of Medical Virology,2020-12-22,bioRxiv,10.1000/sample.4601,,https://example.com/paper_4601,2020.0,12.0,71,10,True,55.0,8.0,True
cord-004603,Analysis of transmission and antiviral and lockdown and respiratory in clinical settings,This study examines transmission with 353 word abstract...,"Author4603_1, Author4603_2",BMJ,,ArXiv,10.1000/sample.4603,PMC1004603,https://example.com/paper_4603,,,88,12,True,58.0,8.0,True
cord-004606,Analysis of diagnosis and outbreak and public health and immunity in clinical settings,This study examines diagnosis with 164 word abstract...,"Author4606_1, Author4606_2",,2021-02-23,ArXiv,,PMC1004606,https://example.com/paper_4606,2021.0,2.0,86,13,True,55.0,8.0,False
cord-004607,Analysis of epidemiology and pandemic and transmission and coronavirus in clinical settings,This study examines epidemiology with 429 word abstract...,Author4607_1,Cell,2021-11-14,ArXiv,10.1000/sample.4607,PMC1004607,https://example.com/paper_4607,2021.0,11.0,91,12,True,58.0,8.0,True
cord-004608,Analysis of antibody and diagnosis and immunity and COVID-19 in clinical settings,This study examines antibody with 445 word abstract...,"Author4608_1, Author4608_2",BMJ,2022-04-05,Medline,10.1000/sample.4608,PMC1004608,,2022.0,4.0,81,12,True,54.0,8.0,True
cord-004609,Analysis of lockdown and vaccination and antibody and symptoms in clinical settings,This study examines lockdown with 290 word abstract...,"Author4609_1, Author4609_2",Clinical Infectious Diseases,2020-04-12,medRxiv,10.1000/sample.4609,PMC1004609,,2020.0,4.0,83,12,True,54.0,8.0,True
cord-004610,Analysis of coronavirus and SARS-CoV-2 and immunity and lockdown in clinical settings,,"Author4610_1, Author4610_2",Virology,2020-06-07,WHO,10.1000/sample.4610,PMC1004610,https://example.com/paper_4610,2020.0,6.0,85,12,False,,,True
cord-004612,Analysis of symptoms and diagnosis and antiviral in clinical settings,This study examines symptoms with 137 word abstract...,"Author4612_1, Author4612_2",Science,2020-05-11,Medline,,,https://example.com/paper_4612,2020.0,5.0,69,10,True,54.0,8.0,True
cord-004613,Analysis of immunity and treatment and outbreak in clinical settings,This study examines immunity with 130 word abstract...,"Author4613_1, Author4613_2",Emerging Infectious Diseases,2020-08-18,PMC,10.1000/sample.4613,,https://example.com/paper_4613,2020.0,8.0,68,10,True,54.0,8.0,True
cord-004614,Analysis of antiviral and vaccination and outbreak in clinical settings,This study examines antiviral with 146 word abstract...,"Author4614_1, Author4614_2",BMJ,2020-01-10,PMC,10.1000/sample.4614,PMC1004614,https://example.com/paper_4614,2020.0,1.0,71,10,True,55.0,8.0,True
cord-004615,Analysis of outbreak and COVID-19 and treatment in clinical settings,This study examines outbreak with 294 word abstract...,"Author4615_1, Author4615_2",Journal of Medical Virology,2021-01-08,WHO,,PMC1004615,,2021.0,1.0,68,10,True,54.0,8.0,True
cord-004616,Analysis of respiratory and treatment and coronavirus and clinical in clinical settings,This study examines respiratory with 258 word abstract...,"Author4616_1, Author4616_2",BMJ,2021-06-22,WHO,10.1000/sample.4616,,https://example.com/paper_4616,2021.0,6.0,87,12,True,57.0,8.0,True
cord-004617,Analysis of respiratory and treatment and pandemic and pneumonia in clinical settings,This study examines respiratory with 476 word abstract...,"Author4617_1, Author4617_2",Journal of Virology,2020-01-19,medRxiv,10.1000/sample.4617,,https://example.com/paper_4617,2020.0,1.0,85,12,True,57.0,8.0,True
cord-004618,Analysis of symptoms and clinical and outbreak and diagnosis in clinical settings,This study examines symptoms with 495 word abstract...,"Author4618_1, Author4618_2",Journal of Virology,2019-12-31,medRxiv,10.1000/sample.4618,PMC1004618,https://example.com/paper_4618,2019.0,12.0,81,12,True,54.0,8.0,True
cord-004620,Analysis of SARS-CoV-2 and transmission and lockdown and vaccination in clinical settings,This study examines SARS-CoV-2 with 313 word abstract...,"Author4620_1, Author4620_2",,2022-12-08,WHO,,PMC1004620,,2022.0,12.0,89,12,True,56.0,8.0,False
cord-004621,Analysis of pneumonia and transmission and respiratory in clinical settings,This study examines pneumonia with 380 word abstract...,"Author4621_1, Author4621_2",JAMA,2020-07-07,medRxiv,,PMC1004621,https://example.com/paper_4621,2020.0,7.0,75,10,True,55.0,8.0,True
cord-004623,Analysis of antiviral and transmission and diagnosis and pandemic in clinical settings,This study examines antiviral with 450 word abstract...,"Author4623_1, Author4623_2",Virology,2020-06-15,Medline,10.1000/sample.4623,,https://example.com/paper_4623,2020.0,6.0,86,12,True,55.0,8.0,True
cord-004624,Analysis of clinical and coronavirus and antibody in clinical settings,This study examines clinical with 144 word abstract...,"Author4624_1, Author4624_2",PLoS ONE,2020-08-16,bioRxiv,10.1000/sample.4624,PMC1004624,https://example.com/paper_4624,2020.0,8.0,70,10,True,54.0,8.0,True
cord-004625,Analysis of diagnosis and outbreak and treatment in clinical settings,This study examines diagnosis with 493 word abstract...,Author4625_1,Lancet,2021-08-22,Medline,10.1000/sample.4625,,https://example.com/paper_4625,2021.0,8.0,69,10,True,55.0,8.0,True
cord-004629,Analysis of transmission and clinical and lockdown in clinical settings,This study examines transmission with 258 word abstract...,Author4629_1,Science Translational Medicine,2020-03-15,bioRxiv,10.1000/sample.4629,PMC1004629,https://example.com/paper_4629,2020.0,3.0,71,10,True,58.0,8.0,True
cord-004630,Analysis of vaccination and outbreak and treatment and clinical in clinical settings,This study examines vaccination with 457 word abstract...,Author4630_1,Nature,2020-07-14,Medline,10.1000/sample.4630,PMC1004630,https://example.com/paper_4630,2020.0,7.0,84,12,True,57.0,8.0,True
cord-004631,Analysis of antibody and antiviral and epidemiology and SARS-CoV-2 in clinical settings,This study examines antibody with 132 word abstract...,"Author4631_1, Author4631_2",Science,2020-12-27,PMC,10.1000/sample.4631,PMC1004631,,2020.0,12.0,87,12,True,54.0,8.0,True
cord-004633,Analysis of symptoms and clinical and epidemiology and outbreak in clinical settings,This study examines symptoms with 332 word abstract...,"Author4633_1, Author4633_2",Journal of Virology,2019-12-01,medRxiv,10.1000/sample.4633,PMC1004633,https://example.com/paper_4633,2019.0,12.0,84,12,True,54.0,8.0,True
cord-004635,Analysis of SARS-CoV-2 and epidemiology and coronavirus and pneumonia in clinical settings,This study examines SARS-CoV-2 with 304 word abstract...,"Author4635_1, Author4635_2",Clinical Infectious Diseases,2020-08-25,bioRxiv,10.1000/sample.4635,PMC1004635,https://example.com/paper_4635,2020.0,8.0,90,12,True,56.0,8.0,True
cord-004637,Analysis of public health and therapeutic and clinical and vaccination in clinical settings,This study examines public health with 139 word abstract...,"Author4637_1, Author4637_2",Virology,2019-12-01,PMC,10.1000/sample.4637,,https://example.com/paper_4637,2019.0,12.0,91,13,True,59.0,9.0,True
cord-004638,Analysis of coronavirus and treatment and SARS-CoV-2 and therapeutic in clinical settings,This study examines coronavirus with 294 word abstract...,"Author4638_1, Author4638_2",Lancet,2021-04-21,Medline,10.1000/sample.4638,,https://example.com/paper_4638,2021.0,4.0,89,12,True,57.0,8.0,True
cord-004640,Analysis of transmission and outbreak and lockdown in clinical settings,This study examines transmission with 474 word abstract...,"Author4640_1, Author4640_2",New England Journal of Medicine,2021-04-06,medRxiv,10.1000/sample.4640,PMC1004640,https://example.com/paper_4640,2021.0,4.0,71,10,True,58.0,8.0,True
cord-004642,Analysis of epidemiology and antibody and COVID-19 and therapeutic in clinical settings,This study examines epidemiology with 150 word abstract...,Author4642_1,Clinical Infectious Diseases,2021-01-23,bioRxiv,10.1000/sample.4642,,https://example.com/paper_4642,2021.0,1.0,87,12,True,58.0,8.0,True
cord-004650,Analysis of SARS-CoV-2 and clinical and public health and treatment in clinical settings,This study examines SARS-CoV-2 with 206 word abstract...,,Clinical Infectious Diseases,2020-03-16,ArXiv,10.1000/sample.4650,PMC1004650,https://example.com/paper_4650,2020.0,3.0,88,13,True,56.0,8.0,True
cord-004651,Analysis of immunity and treatment and therapeutic and public health in clinical settings,This study examines immunity with 393 word abstract...,Author4651_1,JAMA,2021-11-14,WHO,10.1000/sample.4651,PMC1004651,https://example.com/paper_4651,2021.0,11.0,89,13,True,54.0,8.0,True
cord-004652,Analysis of pandemic and COVID-19 and symptoms in clinical settings,This study examines pandemic with 465 word abstract...,"Author4652_1, Author4652_2",PLoS ONE,2022-09-24,medRxiv,10.1000/sample.4652,PMC1004652,https://example.com/paper_4652,2022.0,9.0,67,10,True,54.0,8.0,True
cord-004653,Analysis of respiratory and clinical and antibody in clinical settings,This study examines respiratory with 476 word abstract...,"Author4653_1, Author4653_2",Journal of Medical Virology,,Medline,10.1000/sample.4653,,https://example.com/paper_4653,,,70,10,True,57.0,8.0,True
cord-004654,Analysis of public health and vaccination and COVID-19 in clinical settings,This study examines public health with 245 word abstract...,"Author4654_1, Author4654_2",Science Translational Medicine,2020-02-04,medRxiv,10.1000/sample.4654,,https://example.com/paper_4654,2020.0,2.0,75,11,True,59.0,9.0,True
cord-004655,Analysis of lockdown and SARS-CoV-2 and symptoms in clinical settings,This study examines lockdown with 374 word abstract...,"Author4655_1, Author4655_2",New England Journal of Medicine,2021-03-25,bioRxiv,10.1000/sample.4655,,https://example.com/paper_4655,2021.0,3.0,69,10,True,54.0,8.0,True
cord-004657,Analysis of therapeutic and pneumonia and coronavirus and vaccination in clinical settings,This study examines therapeutic with 258 word abstract...,"Author4657_1, Author4657_2",BMJ,2021-12-27,PMC,10.1000/sample.4657,,https://example.com/paper_4657,2021.0,12.0,90,12,True,57.0,8.0,True
cord-004659,Analysis of epidemiology and immunity and clinical in clinical settings,This study examines epidemiology with 373 word abstract...,"Author4659_1, Author4659_2",Lancet,2021-08-25,Medline,10.1000/sample.4659,,https://example.com/paper_4659,2021.0,8.0,71,10,True,58.0,8.0,True
cord-004664,Analysis of pneumonia and coronavirus and epidemiology and SARS-CoV-2 in clinical settings,This study examines pneumonia with 348 word abstract...,"Author4664_1, Author4664_2",Nature,2020-07-06,ArXiv,10.1000/sample.4664,PMC1004664,https://example.com/paper_4664,2020.0,7.0,90,12,True,55.0,8.0,True
cord-004666,Analysis of pandemic and SARS-CoV-2 and COVID-19 and therapeutic in clinical settings,,Author4666_1,Emerging Infectious Diseases,2021-03-03,medRxiv,10.1000/sample.4666,PMC1004666,https://example.com/paper_4666,2021.0,3.0,85,12,False,,,True
cord-004670,Analysis of coronavirus and public health and antibody and antiviral in clinical settings,This study examines coronavirus with 445 word abstract...,"Author4670_1, Author4670_2",Clinical Infectious Diseases,2019-12-31,WHO,10.1000/sample.4670,PMC1004670,https://example.com/paper_4670,2019.0,12.0,89,13,True,57.0,8.0,True
cord-004671,Analysis of outbreak and immunity and epidemiology and COVID-19 in clinical settings,This study examines outbreak with 274 word abstract...,"Author4671_1, Author4671_2",Science Translational Medicine,2020-01-05,medRxiv,10.1000/sample.4671,PMC1004671,,2020.0,1.0,84,12,True,54.0,8.0,True
cord-004673,Analysis of public health and coronavirus and treatment in clinical settings,This study examines public health with 213 word abstract...,"Author4673_1, Author4673_2",,2020-04-09,ArXiv,10.1000/sample.4673,,https://example.com/paper_4673,2020.0,4.0,76,11,True,59.0,9.0,False
cord-004674,Analysis of public health and lockdown and treatment and pneumonia in clinical settings,This study examines public health with 477 word abstract...,"Author4674_1, Author4674_2",Journal of Medical Virology,2022-04-12,medRxiv,10.1000/sample.4674,PMC1004674,,2022.0,4.0,87,13,True,59.0,9.0,True
cord-004679,Analysis of vaccination and SARS-CoV-2 and COVID-19 in clinical settings,This study examines vaccination with 234 word abstract...,"Author4679_1, Author4679_2",Cell,2020-06-04,medRxiv,,PMC1004679,https://example.com/paper_4679,2020.0,6.0,72,10,True,57.0,8.0,True
cord-004683,Analysis of lockdown and antiviral and immunity and COVID-19 in clinical settings,This study examines lockdown with 344 word abstract...,,Nature Medicine,2021-01-03,bioRxiv,10.1000/sample.4683,PMC1004683,https://example.com/paper_4683,2021.0,1.0,81,12,True,54.0,8.0,True
cord-004685,Analysis of coronavirus and transmission and SARS-CoV-2 and immunity in clinical settings,This study examines coronavirus with 273 word abstract...,Author4685_1,Clinical Infectious Diseases,2020-08-14,medRxiv,10.1000/sample.4685,PMC1004685,https://example.com/paper_4685,2020.0,8.0,89,12,True,57.0,8.0,True
cord-004687,Analysis of antiviral and treatment and symptoms and clinical in clinical settings,This study examines antiviral with 118 word abstract...,Author4687_1,Science Translational Medicine,2019-12-16,ArXiv,10.1000/sample.4687,PMC1004687,https://example.com/paper_4687,2019.0,12.0,82,12,True,55.0,8.0,True
cord-004690,Analysis of transmission and pandemic and treatment and pneumonia in clinical settings,This study examines transmission with 394 word abstract...,"Author4690_1, Author4690_2",Virology,2020-04-17,WHO,10.1000/sample.4690,PMC1004690,https://example.com/paper_4690,2020.0,4.0,86,12,True,58.0,8.0,True
cord-004691,Analysis of diagnosis and antiviral and antibody and SARS-CoV-2 in clinical settings,This study examines diagnosis with 134 word abstract...,"Author4691_1, Author4691_2",BMJ,2020-10-12,PMC,10.1000/sample.4691,PMC1004691,,2020.0,10.0,84,12,True,55.0,8.0,True
cord-004692,Analysis of outbreak and immunity and lockdown and SARS-CoV-2 in clinical settings,This study examines outbreak with 452 word abstract...,Author4692_1,,2021-12-05,Medline,10.1000/sample.4692,PMC1004692,https://example.com/paper_4692,2021.0,12.0,82,12,True,54.0,8.0,False
cord-004693,Analysis of respiratory and clinical and pneumonia in clinical settings,This study examines respiratory with 498 word abstract...,"Author4693_1, Author4693_2",Virology,2020-06-02,medRxiv,,PMC1004693,,2020.0,6.0,71,10,True,57.0,8.0,True
cord-004695,Analysis of antiviral and epidemiology and clinical and transmission in clinical settings,This study examines antiviral with 486 word abstract...,"Author4695_1, Author4695_2",New England Journal of Medicine,2020-08-30,medRxiv,10.1000/sample.4695,PMC1004695,https://example.com/paper_4695,2020.0,8.0,89,12,True,55.0,8.0,True
cord-004697,Analysis of immunity and clinical and pneumonia and pandemic in clinical settings,This study examines immunity with 235 word abstract...,"Author4697_1, Author4697_2",Journal of Medical Virology,2020-02-22,Medline,10.1000/sample.4697,PMC1004697,,2020.0,2.0,81,12,True,54.0,8.0,True
cord-004699,Analysis of COVID-19 and treatment and therapeutic in clinical settings,This study examines COVID-19 with 356 word abstract...,"Author4699_1, Author4699_2",BMJ,2020-11-28,ArXiv,10.1000/sample.4699,PMC1004699,https://example.com/paper_4699,2020.0,11.0,71,10,True,54.0,8.0,True
cord-004700,Analysis of outbreak and antiviral and coronavirus and lockdown in clinical settings,This study examines outbreak with 139 word abstract...,"Author4700_1, Author4700_2",,2020-10-24,bioRxiv,10.1000/sample.4700,,https://example.com/paper_4700,2020.0,10.0,84,12,True,54.0,8.0,False
cord-004702,Analysis of pneumonia and public health and epidemiology in clinical settings,This study examines pneumonia with 481 word abstract...,"Author4702_1, Author4702_2",New England Journal of Medicine,2021-12-22,bioRxiv,10.1000/sample.4702,,,2021.0,12.0,77,11,True,55.0,8.0,True
cord-004703,Analysis of SARS-CoV-2 and immunity and treatment and respiratory in clinical settings,This study examines SARS-CoV-2 with 173 word abstract...,"Author4703_1, Author4703_2",New England Journal of Medicine,2019-12-23,medRxiv,10.1000/sample.4703,,https://example.com/paper_4703,2019.0,12.0,86,12,True,56.0,8.0,True
cord-004704,Analysis of SARS-CoV-2 and lockdown and COVID-19 in clinical settings,This study examines SARS-CoV-2 with 276 word abstract...,"Author4704_1, Author4704_2",,2021-07-26,Medline,,PMC1004704,https://example.com/paper_4704,2021.0,7.0,69,10,True,56.0,8.0,False
cord-004705,Analysis of epidemiology and clinical and SARS-CoV-2 and COVID-19 in clinical settings,This study examines epidemiology with 121 word abstract...,"Author4705_1, Author4705_2",Emerging Infectious Diseases,,ArXiv,10.1000/sample.4705,,https://example.com/paper_4705,,,86,12,True,58.0,8.0,True
cord-004706,Analysis of pandemic and transmission and antibody and respiratory in clinical settings,This study examines pandemic with 419 word abstract...,,BMJ,2020-01-15,ArXiv,10.1000/sample.4706,,,2020.0,1.0,87,12,True,54.0,8.0,True
cord-004708,Analysis of coronavirus and lockdown in clinical settings,This study examines coronavirus with 221 word abstract...,"Author4708_1, Author4708_2",Virology,2022-01-16,PMC,10.1000/sample.4708,PMC1004708,https://example.com/paper_4708,2022.0,1.0,57,8,True,57.0,8.0,True
cord-004709,Analysis of COVID-19 and treatment and antibody and pandemic in clinical settings,This study examines COVID-19 with 444 word abstract...,"Author4709_1, Author4709_2",Science,2021-04-29,ArXiv,10.1000/sample.4709,,,2021.0,4.0,81,12,True,54.0,8.0,True
cord-004710,Analysis of treatment and respiratory and pneumonia in clinical settings,This study examines treatment with 464 word abstract...,"Author4710_1, Author4710_2",Clinical Infectious Diseases,2020-11-19,Medline,10.1000/sample.4710,,https://example.com/paper_4710,2020.0,11.0,72,10,True,55.0,8.0,True
cord-004711,Analysis of pneumonia and clinical and immunity and vaccination in clinical settings,This study examines pneumonia with 443 word abstract...,"Author4711_1, Author4711_2",Nature Medicine,2019-12-04,bioRxiv,10.1000/sample.4711,PMC1004711,https://example.com/paper_4711,2019.0,12.0,84,12,True,55.0,8.0,True
cord-004712,Analysis of treatment and therapeutic and clinical in clinical settings,This study examines treatment with 114 word abstract...,"Author4712_1, Author4712_2",PLoS ONE,2020-06-05,medRxiv,10.1000/sample.4712,,https://example.com/paper_4712,2020.0,6.0,71,10,True,55.0,8.0,True
cord-004714,Analysis of respiratory and antibody and public health in clinical settings,,"Author4714_1, Author4714_2",Cell,2021-01-12,medRxiv,10.1000/sample.4714,PMC1004714,,2021.0,1.0,75,11,False,,,True
cord-004715,Analysis of coronavirus and respiratory and antibody and antiviral in clinical settings,This study examines coronavirus with 225 word abstract...,"Author4715_1, Author4715_2",Emerging Infectious Diseases,2022-04-21,medRxiv,10.1000/sample.4715,PMC1004715,,2022.0,4.0,87,12,True,57.0,8.0,True
cord-004719,Analysis of immunity and epidemiology and diagnosis and public health in clinical settings,This study examines immunity with 498 word abstract...,Author4719_1,Emerging Infectious Diseases,2020-12-22,Medline,10.1000/sample.4719,,https://example.com/paper_4719,2020.0,12.0,90,13,True,54.0,8.0,True
cord-004720,Analysis of antibody and clinical and immunity and respiratory in clinical settings,This study examines antibody with 226 word abstract...,Author4720_1,,2021-11-16,WHO,10.1000/sample.4720,PMC1004720,https://example.com/paper_4720,2021.0,11.0,83,12,True,54.0,8.0,False
cord-004723,Analysis of diagnosis and transmission and treatment and vaccination in clinical settings,This study examines diagnosis with 430 word abstract...,"Author4723_1, Author4723_2",Virology,2021-07-03,Medline,,PMC1004723,https://example.com/paper_4723,2021.0,7.0,89,12,True,55.0,8.0,True
cord-004728,Analysis of SARS-CoV-2 and lockdown and immunity and outbreak in clinical settings,This study examines SARS-CoV-2 with 289 word abstract...,Author4728_1,Cell,2020-12-20,PMC,10.1000/sample.4728,PMC1004728,https://example.com/paper_4728,2020.0,12.0,82,12,True,56.0,8.0,True
cord-004729,Analysis of clinical and lockdown and SARS-CoV-2 in clinical settings,This study examines clinical with 138 word abstract...,"Author4729_1, Author4729_2",Science Translational Medicine,2020-07-31,WHO,10.1000/sample.4729,PMC1004729,https://example.com/paper_4729,2020.0,7.0,69,10,True,54.0,8.0,True
cord-004730,Analysis of clinical and pandemic and diagnosis and pneumonia in clinical settings,This study examines clinical with 288 word abstract...,"Author4730_1, Author4730_2",BMJ,2020-06-27,PMC,,,https://example.com/paper_4730,2020.0,6.0,82,12,True,54.0,8.0,True
cord-004731,Analysis of lockdown and SARS-CoV-2 and respiratory and treatment in clinical settings,This study examines lockdown with 388 word abstract...,"Author4731_1, Author4731_2",BMJ,,medRxiv,10.1000/sample.4731,PMC1004731,,,,86,12,True,54.0,8.0,True
cord-004732,Analysis of treatment and outbreak and antiviral and clinical in clinical settings,This study examines treatment with 193 word abstract...,"Author4732_1, Author4732_2",Emerging Infectious Diseases,2020-04-25,ArXiv,10.1000/sample.4732,,,2020.0,4.0,82,12,True,55.0,8.0,True
cord-004733,Analysis of antiviral and diagnosis and therapeutic in clinical settings,This study examines antiviral with 207 word abstract...,"Author4733_1, Author4733_2",Journal of Virology,2020-10-04,medRxiv,10.1000/sample.4733,,https://example.com/paper_4733,2020.0,10.0,72,10,True,55.0,8.0,True
cord-004734,Analysis of transmission and therapeutic and pandemic and treatment in clinical settings,This study examines transmission with 440 word abstract...,"Author4734_1, Author4734_2",New England Journal of Medicine,2021-07-03,WHO,10.1000/sample.4734,PMC1004734,https://example.com/paper_4734,2021.0,7.0,88,12,True,58.0,8.0,True
cord-004735,Analysis of clinical and vaccination and diagnosis in clinical settings,This study examines clinical with 490 word abstract...,"Author4735_1, Author4735_2",Lancet,2021-08-28,medRxiv,10.1000/sample.4735,PMC1004735,https://example.com/paper_4735,2021.0,8.0,71,10,True,54.0,8.0,True
cord-004736,Analysis of SARS-CoV-2 and pandemic and therapeutic and pneumonia in clinical settings,This study examines SARS-CoV-2 with 476 word abstract...,"Author4736_1, Author4736_2",JAMA,2022-12-05,ArXiv,,,https://example.com/paper_4736,2022.0,12.0,86,12,True,56.0,8.0,True
cord-004739,Analysis of COVID-19 and coronavirus and treatment in clinical settings,This study examines COVID-19 with 273 word abstract...,"Author4739_1, Author4739_2",New England Journal of Medicine,2019-12-03,WHO,,PMC1004739,https://example.com/paper_4739,2019.0,12.0,71,10,True,54.0,8.0,True
cord-004745,Analysis of respiratory and COVID-19 and antibody and lockdown in clinical settings,This study examines respiratory with 131 word abstract...,"Author4745_1, Author4745_2",New England Journal of Medicine,2020-12-27,medRxiv,,PMC1004745,,2020.0,12.0,83,12,True,57.0,8.0,True
cord-004750,Analysis of COVID-19 and SARS-CoV-2 and clinical and lockdown in clinical settings,This study examines COVID-19 with 220 word abstract...,"Author4750_1, Author4750_2",Virology,2020-08-15,bioRxiv,10.1000/sample.4750,PMC1004750,https://example.com/paper_4750,2020.0,8.0,82,12,True,54.0,8.0,True
cord-004751,Analysis of COVID-19 and epidemiology and SARS-CoV-2 and treatment in clinical settings,This study examines COVID-19 with 258 word abstract...,"Author4751_1, Author4751_2",Journal of Virology,2021-05-04,Medline,10.1000/sample.4751,PMC1004751,https://example.com/paper_4751,2021.0,5.0,87,12,True,54.0,8.0,True
cord-004753,Analysis of respiratory and therapeutic and immunity and clinical in clinical settings,This study examines respiratory with 228 word abstract...,Author4753_1,Nature Medicine,2021-08-21,WHO,,,https://example.com/paper_4753,2021.0,8.0,86,12,True,57.0,8.0,True
cord-004754,Analysis of antibody and immunity and SARS-CoV-2 and public health in clinical settings,This study examines antibody with 331 word abstract...,"Author4754_1, Author4754_2",,2019-12-01,ArXiv,10.1000/sample.4754,,,2019.0,12.0,87,13,True,54.0,8.0,False
cord-004755,Analysis of treatment and coronavirus and respiratory and pneumonia in clinical settings,This study examines treatment with 357 word abstract...,"Author4755_1, Author4755_2",BMJ,2022-03-30,medRxiv,10.1000/sample.4755,PMC1004755,https://example.com/paper_4755,2022.0,3.0,88,12,True,55.0,8.0,True
cord-004756,Analysis of respiratory and pneumonia and therapeutic and diagnosis in clinical settings,This study examines respiratory with 479 word abstract...,"Author4756_1, Author4756_2",Science,2020-10-08,bioRxiv,10.1000/sample.4756,PMC1004756,,2020.0,10.0,88,12,True,57.0,8.0,True
cord-004757,Analysis of therapeutic and symptoms and pandemic and clinical in clinical settings,This study examines therapeutic with 365 word abstract...,"Author4757_1, Author4757_2",Science Translational Medicine,2020-10-24,WHO,10.1000/sample.4757,,https://example.com/paper_4757,2020.0,10.0,83,12,True,57.0,8.0,True
cord-004760,Analysis of SARS-CoV-2 and symptoms and antiviral in clinical settings,This study examines SARS-CoV-2 with 388 word abstract...,"Author4760_1, Author4760_2",Nature Medicine,2020-11-13,ArXiv,10.1000/sample.4760,PMC1004760,,2020.0,11.0,70,10,True,56.0,8.0,True
cord-004763,Analysis of epidemiology and COVID-19 and vaccination and lockdown in clinical settings,This study examines epidemiology with 136 word abstract...,"Author4763_1, Author4763_2",JAMA,2020-10-13,Medline,10.1000/sample.4763,,https://example.com/paper_4763,2020.0,10.0,87,12,True,58.0,8.0,True
cord-004764,Analysis of transmission and SARS-CoV-2 and lockdown and pneumonia in clinical settings,This study examines transmission with 289 word abstract...,"Author4764_1, Author4764_2",Emerging Infectious Diseases,2019-12-04,ArXiv,10.1000/sample.4764,PMC1004764,https://example.com/paper_4764,2019.0,12.0,87,12,True,58.0,8.0,True
cord-004766,Analysis of clinical and diagnosis and pneumonia in clinical settings,This study examines clinical with 156 word abstract...,"Author4766_1, Author4766_2",New England Journal of Medicine,2020-08-30,Medline,10.1000/sample.4766,PMC1004766,https://example.com/paper_4766,2020.0,8.0,69,10,True,54.0,8.0,True
cord-004769,Analysis of COVID-19 and respiratory and vaccination and treatment in clinical settings,This study examines COVID-19 with 436 word abstract...,"Author4769_1, Author4769_2",PLoS ONE,2020-07-19,bioRxiv,10.1000/sample.4769,PMC1004769,https://example.com/paper_4769,2020.0,7.0,87,12,True,54.0,8.0,True
cord-004771,Analysis of diagnosis and epidemiology and antibody and respiratory in clinical settings,This study examines diagnosis with 338 word abstract...,"Author4771_1, Author4771_2",Nature,2020-11-11,PMC,,,https://example.com/paper_4771,2020.0,11.0,88,12,True,55.0,8.0,True
cord-004774,Analysis of symptoms and pneumonia and antiviral and SARS-CoV-2 in clinical settings,This study examines symptoms with 240 word abstract...,"Author4774_1, Author4774_2",Science,2020-10-08,WHO,10.1000/sample.4774,PMC1004774,https://example.com/paper_4774,2020.0,10.0,84,12,True,54.0,8.0,True
cord-004776,Analysis of diagnosis and pneumonia and coronavirus and pandemic in clinical settings,This study examines diagnosis with 290 word abstract...,Author4776_1,Cell,2021-06-23,ArXiv,10.1000/sample.4776,,,2021.0,6.0,85,12,True,55.0,8.0,True
cord-004777,Analysis of outbreak and immunity and diagnosis and symptoms in clinical settings,This study examines outbreak with 111 word abstract...,"Author4777_1, Author4777_2",Emerging Infectious Diseases,2021-07-11,medRxiv,10.1000/sample.4777,,https://example.com/paper_4777,2021.0,7.0,81,12,True,54.0,8.0,True
cord-004778,Analysis of pandemic and outbreak and immunity in clinical settings,This study examines pandemic with 127 word abstract...,"Author4778_1, Author4778_2",Science,2020-01-13,ArXiv,10.1000/sample.4778,PMC1004778,,2020.0,1.0,67,10,True,54.0,8.0,True
cord-004779,Analysis of vaccination and coronavirus and transmission and COVID-19 in clinical settings,This study examines vaccination with 326 word abstract...,"Author4779_1, Author4779_2",Journal of Medical Virology,2021-02-13,PMC,10.1000/sample.4779,,https://example.com/paper_4779,2021.0,2.0,90,12,True,57.0,8.0,True
cord-004781,Analysis of pandemic and symptoms and antibody in clinical settings,This study examines pandemic with 170 word abstract...,"Author4781_1, Author4781_2",,2020-10-09,WHO,,PMC1004781,https://example.com/paper_4781,2020.0,10.0,67,10,True,54.0,8.0,False
cord-004784,Analysis of outbreak and transmission and therapeutic and lockdown in clinical settings,This study examines outbreak with 221 word abstract...,Author4784_1,Lancet,2020-09-10,medRxiv,10.1000/sample.4784,PMC1004784,https://example.com/paper_4784,2020.0,9.0,87,12,True,54.0,8.0,True
cord-004786,Analysis of antibody and clinical and immunity in clinical settings,This study examines antibody with 193 word abstract...,"Author4786_1, Author4786_2",PLoS ONE,,PMC,10.1000/sample.4786,,https://example.com/paper_4786,,,67,10,True,54.0,8.0,True
cord-004787,Analysis of epidemiology and therapeutic and treatment in clinical settings,This study examines epidemiology with 287 word abstract...,"Author4787_1, Author4787_2",Emerging Infectious Diseases,2021-09-22,medRxiv,10.1000/sample.4787,,,2021.0,9.0,75,10,True,58.0,8.0,True
cord-004788,Analysis of antiviral and therapeutic and pandemic and antibody in clinical settings,,"Author4788_1, Author4788_2",New England Journal of Medicine,2020-12-28,medRxiv,,PMC1004788,https://example.com/paper_4788,2020.0,12.0,84,12,False,,,True
cord-004789,Analysis of therapeutic and COVID-19 and lockdown in clinical settings,This study examines therapeutic with 451 word abstract...,"Author4789_1, Author4789_2",Nature,2022-08-15,medRxiv,10.1000/sample.4789,PMC1004789,https://example.com/paper_4789,2022.0,8.0,70,10,True,57.0,8.0,True
cord-004794,Analysis of respiratory and pandemic and diagnosis and SARS-CoV-2 in clinical settings,This study examines respiratory with 473 word abstract...,"Author4794_1, Author4794_2",,2020-11-06,WHO,,PMC1004794,,2020.0,11.0,86,12,True,57.0,8.0,False
cord-004796,Analysis of diagnosis and pandemic and treatment in clinical settings,This study examines diagnosis with 325 word abstract...,"Author4796_1, Author4796_2",JAMA,2020-01-05,PMC,10.1000/sample.4796,PMC1004796,https://example.com/paper_4796,2020.0,1.0,69,10,True,55.0,8.0,True
cord-004797,Analysis of coronavirus and epidemiology and therapeutic and diagnosis in clinical settings,This study examines coronavirus with 220 word abstract...,"Author4797_1, Author4797_2",Virology,2021-06-20,PMC,10.1000/sample.4797,,,2021.0,6.0,91,12,True,57.0,8.0,True
cord-004799,Analysis of outbreak and treatment and epidemiology and antiviral in clinical settings,This study examines outbreak with 469 word abstract...,Author4799_1,Nature,2021-04-04,bioRxiv,10.1000/sample.4799,,https://example.com/paper_4799,2021.0,4.0,86,12,True,54.0,8.0,True
cord-004800,Analysis of pneumonia and antibody and epidemiology in clinical settings,This study examines pneumonia with 426 word abstract...,"Author4800_1, Author4800_2",Clinical Infectious Diseases,2020-03-17,WHO,10.1000/sample.4800,PMC1004800,,2020.0,3.0,72,10,True,55.0,8.0,True
cord-004804,Analysis of antibody and respiratory and symptoms in clinical settings,This study examines antibody with 172 word abstract...,"Author4804_1, Author4804_2",Emerging Infectious Diseases,2021-06-07,WHO,10.1000/sample.4804,,,2021.0,6.0,70,10,True,54.0,8.0,True
cord-004806,Analysis of transmission and antiviral and diagnosis in clinical settings,This study examines transmission with 198 word abstract...,Author4806_1,Science Translational Medicine,2020-07-31,WHO,10.1000/sample.4806,,https://example.com/paper_4806,2020.0,7.0,73,10,True,58.0,8.0,True
cord-004807,Analysis of respiratory and epidemiology and pandemic and antibody in clinical settings,This study examines respiratory with 276 word abstract...,"Author4807_1, Author4807_2",Virology,2021-09-09,WHO,10.1000/sample.4807,PMC1004807,https://example.com/paper_4807,2021.0,9.0,87,12,True,57.0,8.0,True
cord-004808,Analysis of COVID-19 and diagnosis and antiviral and clinical in clinical settings,This study examines COVID-19 with 196 word abstract...,"Author4808_1, Author4808_2",Cell,2021-12-27,Medline,10.1000/sample.4808,PMC1004808,https://example.com/paper_4808,2021.0,12.0,82,12,True,54.0,8.0,True
cord-004809,Analysis of lockdown and antiviral and epidemiology in clinical settings,This study examines lockdown with 270 word abstract...,"Author4809_1, Author4809_2",Journal of Medical Virology,2021-09-01,WHO,10.1000/sample.4809,,https://example.com/paper_4809,2021.0,9.0,72,10,True,54.0,8.0,True
cord-004812,Analysis of antibody and immunity and outbreak and vaccination in clinical settings,This study examines antibody with 272 word abstract...,"Author4812_1, Author4812_2",Nature,2020-12-22,ArXiv,,PMC1004812,https://example.com/paper_4812,2020.0,12.0,83,12,True,54.0,8.0,True
cord-004813,Analysis of outbreak and diagnosis and antiviral in clinical settings,This study examines outbreak with 313 word abstract...,"Author4813_1, Author4813_2",Lancet,2021-04-26,Medline,10.1000/sample.4813,PMC1004813,https://example.com/paper_4813,2021.0,4.0,69,10,True,54.0,8.0,True
cord-004814,Analysis of immunity and respiratory and vaccination and COVID-19 in clinical settings,This study examines immunity with 314 word abstract...,"Author4814_1, Author4814_2",Journal of Virology,,ArXiv,10.1000/sample.4814,PMC1004814,,,,86,12,True,54.0,8.0,True
cord-004817,Analysis of SARS-CoV-2 and public health and immunity and clinical in clinical settings,This study examines SARS-CoV-2 with 324 word abstract...,"Author4817_1, Author4817_2",PLoS ONE,2020-03-21,ArXiv,10.1000/sample.4817,PMC1004817,https://example.com/paper_4817,2020.0,3.0,87,13,True,56.0,8.0,True
cord-004818,Analysis of immunity and symptoms and epidemiology and vaccination in clinical settings,This study examines immunity with 254 word abstract...,"Author4818_1, Author4818_2",New England Journal of Medicine,2021-04-17,Medline,10.1000/sample.4818,PMC1004818,https://example.com/paper_4818,2021.0,4.0,87,12,True,54.0,8.0,True
cord-004821,Analysis of vaccination and COVID-19 and coronavirus and respiratory in clinical settings,This study examines vaccination with 189 word abstract...,"Author4821_1, Author4821_2",,2020-04-09,medRxiv,,PMC1004821,,2020.0,4.0,89,12,True,57.0,8.0,False
cord-004822,Analysis of clinical and respiratory and lockdown in clinical settings,This study examines clinical with 116 word abstract...,Author4822_1,Lancet,2020-02-03,WHO,10.1000/sample.4822,,,2020.0,2.0,70,10,True,54.0,8.0,True
cord-004825,Analysis of clinical and coronavirus and immunity and outbreak in clinical settings,This study examines clinical with 448 word abstract...,"Author4825_1, Author4825_2",Nature,2021-09-08,bioRxiv,10.1000/sample.4825,PMC1004825,,2021.0,9.0,83,12,True,54.0,8.0,True
cord-004828,Analysis of antiviral and public health and respiratory and epidemiology in clinical settings,This study examines antiviral with 443 word abstract...,"Author4828_1, Author4828_2",Clinical Infectious Diseases,2020-06-09,ArXiv,10.1000/sample.4828,PMC1004828,https://example.com/paper_4828,2020.0,6.0,93,13,True,55.0,8.0,True
cord-004829,Analysis of transmission and treatment and antiviral and coronavirus in clinical settings,This study examines transmission with 253 word abstract...,Author4829_1,Nature Medicine,2022-06-12,WHO,10.1000/sample.4829,PMC1004829,https://example.com/paper_4829,2022.0,6.0,89,12,True,58.0,8.0,True
cord-004830,Analysis of coronavirus and lockdown and pandemic in clinical settings,This study examines coronavirus with 357 word abstract...,"Author4830_1, Author4830_2",Clinical Infectious Diseases,2019-12-15,medRxiv,10.1000/sample.4830,PMC1004830,,2019.0,12.0,70,10,True,57.0,8.0,True
cord-004831,Analysis of coronavirus and lockdown and epidemiology in clinical settings,This study examines coronavirus with 289 word abstract...,Author4831_1,BMJ,2021-03-20,medRxiv,10.1000/sample.4831,PMC1004831,https://example.com/paper_4831,2021.0,3.0,74,10,True,57.0,8.0,True
cord-004834,Analysis of coronavirus and SARS-CoV-2 and COVID-19 and pandemic in clinical settings,This study examines coronavirus with 100 word abstract...,"Author4834_1, Author4834_2",Nature,2020-05-16,medRxiv,10.1000/sample.4834,PMC1004834,https://example.com/paper_4834,2020.0,5.0,85,12,True,57.0,8.0,True
cord-004835,Analysis of outbreak and SARS-CoV-2 and pandemic in clinical settings,This study examines outbreak with 137 word abstract...,"Author4835_1, Author4835_2",,2020-01-31,WHO,10.1000/sample.4835,,https://example.com/paper_4835,2020.0,1.0,69,10,True,54.0,8.0,False
cord-004836,Analysis of symptoms and vaccination and antibody in clinical settings,This study examines symptoms with 307 word abstract...,"Author4836_1, Author4836_2",Cell,2020-01-10,ArXiv,10.1000/sample.4836,PMC1004836,https://example.com/paper_4836,2020.0,1.0,70,10,True,54.0,8.0,True
cord-004837,Analysis of antibody and vaccination and coronavirus in clinical settings,This study examines antibody with 479 word abstract...,"Author4837_1, Author4837_2",JAMA,2022-10-04,medRxiv,10.1000/sample.4837,PMC1004837,https://example.com/paper_4837,2022.0,10.0,73,10,True,54.0,8.0,True
cord-004838,Analysis of pandemic and antibody and SARS-CoV-2 in clinical settings,This study examines pandemic with 495 word abstract...,"Author4838_1, Author4838_2",BMJ,,WHO,10.1000/sample.4838,PMC1004838,,,,69,10,True,54.0,8.0,True
cord-004839,Analysis of lockdown and treatment and symptoms and SARS-CoV-2 in clinical settings,This study examines lockdown with 292 word abstract...,"Author4839_1, Author4839_2",Nature Medicine,2020-11-16,medRxiv,,PMC1004839,https://example.com/paper_4839,2020.0,11.0,83,12,True,54.0,8.0,True
cord-004840,Analysis of outbreak and clinical and transmission and public health in clinical settings,This study examines outbreak with 416 word abstract...,"Author4840_1, Author4840_2",Cell,2021-01-31,PMC,10.1000/sample.4840,PMC1004840,https://example.com/paper_4840,2021.0,1.0,89,13,True,54.0,8.0,True
cord-004841,Analysis of immunity and diagnosis and coronavirus and SARS-CoV-2 in clinical settings,This study examines immunity with 428 word abstract...,"Author4841_1, Author4841_2",BMJ,2021-12-07,WHO,10.1000/sample.4841,PMC1004841,https://example.com/paper_4841,2021.0,12.0,86,12,True,54.0,8.0,True
cord-004842,Analysis of SARS-CoV-2 and lockdown and transmission in clinical settings,This study examines SARS-CoV-2 with 157 word abstract...,"Author4842_1, Author4842_2",,2021-04-17,WHO,10.1000/sample.4842,PMC1004842,https://example.com/paper_4842,2021.0,4.0,73,10,True,56.0,8.0,False
cord-004843,Analysis of public health and epidemiology and respiratory and vaccination in clinical settings,,"Author4843_1, Author4843_2",Lancet,2020-08-07,bioRxiv,10.1000/sample.4843,,,2020.0,8.0,95,13,False,,,True
cord-004844,Analysis of clinical and diagnosis and vaccination and symptoms in clinical settings,This study examines clinical with 110 word abstract...,"Author4844_1, Author4844_2",Science,2021-01-17,bioRxiv,10.1000/sample.4844,PMC1004844,https://example.com/paper_4844,2021.0,1.0,84,12,True,54.0,8.0,True
cord-004845,Analysis of diagnosis and vaccination and epidemiology and coronavirus in clinical settings,This study examines diagnosis with 336 word abstract...,"Author4845_1, Author4845_2",New England Journal of Medicine,2020-08-28,ArXiv,10.1000/sample.4845,PMC1004845,https://example.com/paper_4845,2020.0,8.0,91,12,True,55.0,8.0,True
cord-004846,Analysis of diagnosis and coronavirus and respiratory and antibody in clinical settings,This study examines diagnosis with 135 word abstract...,"Author4846_1, Author4846_2",,2021-03-15,ArXiv,10.1000/sample.4846,,https://example.com/paper_4846,2021.0,3.0,87,12,True,55.0,8.0,False
cord-004848,Analysis of therapeutic and transmission and coronavirus in clinical settings,This study examines therapeutic with 434 word abstract...,"Author4848_1, Author4848_2",Clinical Infectious Diseases,2022-06-02,ArXiv,10.1000/sample.4848,,https://example.com/paper_4848,2022.0,6.0,77,10,True,57.0,8.0,True
cord-004849,Analysis of SARS-CoV-2 and vaccination and clinical and transmission in clinical settings,This study examines SARS-CoV-2 with 117 word abstract...,"Author4849_1, Author4849_2",Lancet,2020-03-22,Medline,10.1000/sample.4849,PMC1004849,https://example.com/paper_4849,2020.0,3.0,89,12,True,56.0,8.0,True
cord-004851,Analysis of diagnosis and epidemiology and outbreak and respiratory in clinical settings,This study examines diagnosis with 359 word abstract...,Author4851_1,Nature Medicine,2021-03-26,PMC,10.1000/sample.4851,PMC1004851,https://example.com/paper_4851,2021.0,3.0,88,12,True,55.0,8.0,True
cord-004852,Analysis of treatment and antiviral and COVID-19 and pneumonia in clinical settings,This study examines treatment with 118 word abstract...,"Author4852_1, Author4852_2",New England Journal of Medicine,2021-09-02,WHO,,,https://example.com/paper_4852,2021.0,9.0,83,12,True,55.0,8.0,True
cord-004854,Analysis of diagnosis and epidemiology and public health and therapeutic in clinical settings,This study examines diagnosis with 330 word abstract...,"Author4854_1, Author4854_2",Science Translational Medicine,2021-07-20,ArXiv,10.1000/sample.4854,PMC1004854,https://example.com/paper_4854,2021.0,7.0,93,13,True,55.0,8.0,True
cord-004855,Analysis of antiviral and COVID-19 and antibody and immunity in clinical settings,This study examines antiviral with 197 word abstract...,"Author4855_1, Author4855_2",PLoS ONE,2021-01-21,ArXiv,10.1000/sample.4855,PMC1004855,https://example.com/paper_4855,2021.0,1.0,81,12,True,55.0,8.0,True
cord-004856,Analysis of coronavirus and diagnosis and outbreak and therapeutic in clinical settings,This study examines coronavirus with 307 word abstract...,"Author4856_1, Author4856_2",Journal of Medical Virology,2020-12-11,Medline,10.1000/sample.4856,PMC1004856,https://example.com/paper_4856,2020.0,12.0,87,12,True,57.0,8.0,True
cord-004857,Analysis of clinical and SARS-CoV-2 and pneumonia in clinical settings,This study examines clinical with 211 word abstract...,"Author4857_1, Author4857_2",Nature Medicine,2020-03-30,PMC,10.1000/sample.4857,PMC1004857,https://example.com/paper_4857,2020.0,3.0,70,10,True,54.0,8.0,True
cord-004858,Analysis of immunity and SARS-CoV-2 and symptoms and epidemiology in clinical settings,This study examines immunity with 327 word abstract...,"Author4858_1, Author4858_2",,2021-03-27,Medline,10.1000/sample.4858,PMC1004858,https://example.com/paper_4858,2021.0,3.0,86,12,True,54.0,8.0,False
cord-004860,Analysis of epidemiology and pandemic and clinical and lockdown in clinical settings,This study examines epidemiology with 176 word abstract...,"Author4860_1, Author4860_2",PLoS ONE,2020-10-28,WHO,10.1000/sample.4860,,https://example.com/paper_4860,2020.0,10.0,84,12,True,58.0,8.0,True
cord-004861,Analysis of symptoms and antiviral and coronavirus in clinical settings,This study examines symptoms with 220 word abstract...,"Author4861_1, Author4861_2",Journal of Medical Virology,2022-01-11,medRxiv,10.1000/sample.4861,PMC1004861,https://example.com/paper_4861,2022.0,1.0,71,10,True,54.0,8.0,True
cord-004862,Analysis of pneumonia and vaccination and COVID-19 in clinical settings,This study examines pneumonia with 104 word abstract...,"Author4862_1, Author4862_2",Nature Medicine,2021-05-25,PMC,10.1000/sample.4862,PMC1004862,https://example.com/paper_4862,2021.0,5.0,71,10,True,55.0,8.0,True
cord-004864,Analysis of transmission and COVID-19 and pneumonia and respiratory in clinical settings,This study examines transmission with 334 word abstract...,"Author4864_1, Author4864_2",Journal of Virology,2020-01-09,ArXiv,10.1000/sample.4864,PMC1004864,https://example.com/paper_4864,2020.0,1.0,88,12,True,58.0,8.0,True
cord-004865,Analysis of diagnosis and epidemiology and pandemic and pneumonia in clinical settings,This study examines diagnosis with 346 word abstract...,"Author4865_1, Author4865_2",,2020-05-17,Medline,,PMC1004865,,2020.0,5.0,86,12,True,55.0,8.0,False
cord-004866,Analysis of transmission and SARS-CoV-2 and lockdown in clinical settings,This study examines transmission with 336 word abstract...,"Author4866_1, Author4866_2",Science,2020-11-05,Medline,10.1000/sample.4866,PMC1004866,https://example.com/paper_4866,2020.0,11.0,73,10,True,58.0,8.0,True
cord-004867,Analysis of respiratory and outbreak and transmission and epidemiology in clinical settings,This study examines respiratory with 470 word abstract...,Author4867_1,PLoS ONE,2021-05-04,medRxiv,10.1000/sample.4867,PMC1004867,https://example.com/paper_4867,2021.0,5.0,91,12,True,57.0,8.0,True
cord-004869,Analysis of respiratory and epidemiology and COVID-19 in clinical settings,This study examines respiratory with 280 word abstract...,"Author4869_1, Author4869_2",Lancet,2021-05-29,WHO,10.1000/sample.4869,,https://example.com/paper_4869,2021.0,5.0,74,10,True,57.0,8.0,True
cord-004871,Analysis of lockdown and therapeutic and pneumonia and coronavirus in clinical settings,This study examines lockdown with 344 word abstract...,"Author4871_1, Author4871_2",Science,2019-12-30,bioRxiv,10.1000/sample.4871,PMC1004871,https://example.com/paper_4871,2019.0,12.0,87,12,True,54.0,8.0,True
cord-004873,Analysis of antibody and vaccination and immunity in clinical settings,This study examines antibody with 358 word abstract...,Author4873_1,JAMA,2021-10-24,ArXiv,10.1000/sample.4873,,https://example.com/paper_4873,2021.0,10.0,70,10,True,54.0,8.0,True
cord-004875,Analysis of respiratory and treatment and symptoms and pandemic in clinical settings,This study examines respiratory with 304 word abstract...,"Author4875_1, Author4875_2",Clinical Infectious Diseases,2021-01-28,ArXiv,10.1000/sample.4875,PMC1004875,https://example.com/paper_4875,2021.0,1.0,84,12,True,57.0,8.0,True
cord-004876,Analysis of antiviral and pneumonia and diagnosis in clinical settings,This study examines antiviral with 497 word abstract...,Author4876_1,,2020-01-02,WHO,10.1000/sample.4876,,https://example.com/paper_4876,2020.0,1.0,70,10,True,55.0,8.0,False
cord-004879,Analysis of coronavirus and pandemic and pneumonia in clinical settings,This study examines coronavirus with 274 word abstract...,"Author4879_1, Author4879_2",PLoS ONE,2022-06-28,ArXiv,10.1000/sample.4879,PMC1004879,https://example.com/paper_4879,2022.0,6.0,71,10,True,57.0,8.0,True
cord-004881,Analysis of antibody and SARS-CoV-2 and clinical and coronavirus in clinical settings,This study examines antibody with 291 word abstract...,"Author4881_1, Author4881_2",Virology,2021-01-19,PMC,10.1000/sample.4881,PMC1004881,,2021.0,1.0,85,12,True,54.0,8.0,True
cord-004883,Analysis of outbreak and public health and lockdown and symptoms in clinical settings,,"Author4883_1, Author4883_2",,2021-11-16,bioRxiv,10.1000/sample.4883,,,2021.0,11.0,85,13,False,,,False
cord-004884,Analysis of public health and therapeutic and vaccination and treatment in clinical settings,This study examines public health with 364 word abstract...,Author4884_1,BMJ,,WHO,10.1000/sample.4884,,https://example.com/paper_4884,,,92,13,True,59.0,9.0,True
cord-004888,Analysis of coronavirus and antiviral and treatment and public health in clinical settings,This study examines coronavirus with 208 word abstract...,"Author4888_1, Author4888_2",JAMA,2021-03-12,Medline,10.1000/sample.4888,,https://example.com/paper_4888,2021.0,3.0,90,13,True,57.0,8.0,True
cord-004889,Analysis of antiviral and vaccination and antibody in clinical settings,This study examines antiviral with 135 word abstract...,Author4889_1,Virology,2021-05-11,PMC,10.1000/sample.4889,PMC1004889,https://example.com/paper_4889,2021.0,5.0,71,10,True,55.0,8.0,True
cord-004891,Analysis of clinical and transmission and coronavirus and public health in clinical settings,This study examines clinical with 246 word abstract...,"Author4891_1, Author4891_2",Cell,2021-04-26,WHO,10.1000/sample.4891,PMC1004891,,2021.0,4.0,92,13,True,54.0,8.0,True
cord-004893,Analysis of coronavirus and antibody and pneumonia and treatment in clinical settings,This study examines coronavirus with 107 word abstract...,"Author4893_1, Author4893_2",Nature,2020-07-02,medRxiv,10.1000/sample.4893,PMC1004893,https://example.com/paper_4893,2020.0,7.0,85,12,True,57.0,8.0,True
cord-004896,Analysis of epidemiology and lockdown and treatment and coronavirus in clinical settings,This study examines epidemiology with 358 word abstract...,"Author4896_1, Author4896_2",Journal of Medical Virology,2022-01-29,medRxiv,10.1000/sample.4896,,,2022.0,1.0,88,12,True,58.0,8.0,True
cord-004897,Analysis of immunity and antibody and lockdown and public health in clinical settings,This study examines immunity with 237 word abstract...,"Author4897_1, Author4897_2",PLoS ONE,2021-12-31,WHO,10.1000/sample.4897,PMC1004897,https://example.com/paper_4897,2021.0,12.0,85,13,True,54.0,8.0,True
cord-004898,Analysis of immunity and respiratory and coronavirus in clinical settings,This study examines immunity with 399 word abstract...,"Author4898_1, Author4898_2",Cell,2021-06-24,WHO,10.1000/sample.4898,,https://example.com/paper_4898,2021.0,6.0,73,10,True,54.0,8.0,True
cord-004899,Analysis of lockdown and antiviral and respiratory and immunity in clinical settings,This study examines lockdown with 129 word abstract...,Author4899_1,Lancet,2021-06-06,Medline,10.1000/sample.4899,PMC1004899,https://example.com/paper_4899,2021.0,6.0,84,12,True,54.0,8.0,True
cord-004900,Analysis of symptoms and immunity and outbreak and diagnosis in clinical settings,This study examines symptoms with 430 word abstract...,"Author4900_1, Author4900_2",Nature,2022-03-28,medRxiv,10.1000/sample.4900,,https://example.com/paper_4900,2022.0,3.0,81,12,True,54.0,8.0,True
cord-004902,Analysis of coronavirus and clinical and pneumonia and respiratory in clinical settings,This study examines coronavirus with 127 word abstract...,"Author4902_1, Author4902_2",Science,2020-08-04,bioRxiv,10.1000/sample.4902,PMC1004902,https://example.com/paper_4902,2020.0,8.0,87,12,True,57.0,8.0,True
cord-004908,Analysis of transmission and immunity and pandemic in clinical settings,This study examines transmission with 490 word abstract...,"Author4908_1, Author4908_2",Nature,2021-03-16,medRxiv,10.1000/sample.4908,PMC1004908,https://example.com/paper_4908,2021.0,3.0,71,10,True,58.0,8.0,True
cord-004909,Analysis of therapeutic and pneumonia and antibody and lockdown in clinical settings,This study examines therapeutic with 354 word abstract...,"Author4909_1, Author4909_2",Journal of Virology,2020-01-26,Medline,10.1000/sample.4909,PMC1004909,https://example.com/paper_4909,2020.0,1.0,84,12,True,57.0,8.0,True
cord-004911,Analysis of COVID-19 and public health and treatment and immunity in clinical settings,This study examines COVID-19 with 243 word abstract...,"Author4911_1, Author4911_2",PLoS ONE,2021-12-26,medRxiv,10.1000/sample.4911,,https://example.com/paper_4911,2021.0,12.0,86,13,True,54.0,8.0,True
cord-004912,Analysis of pneumonia and immunity and public health in clinical settings,This study examines pneumonia with 371 word abstract...,Author4912_1,BMJ,2020-04-19,WHO,10.1000/sample.4912,PMC1004912,https://example.com/paper_4912,2020.0,4.0,73,11,True,55.0,8.0,True
cord-004914,Analysis of epidemiology and clinical and transmission in clinical settings,This study examines epidemiology with 222 word abstract...,"Author4914_1, Author4914_2",Journal of Medical Virology,2019-12-05,PMC,10.1000/sample.4914,,https://example.com/paper_4914,2019.0,12.0,75,10,True,58.0,8.0,True
cord-004915,Analysis of outbreak and pandemic and treatment and lockdown in clinical settings,,"Author4915_1, Author4915_2",PLoS ONE,2019-12-13,Medline,10.1000/sample.4915,PMC1004915,,2019.0,12.0,81,12,False,,,True
cord-004916,Analysis of COVID-19 and lockdown and therapeutic and immunity in clinical settings,This study examines COVID-19 with 124 word abstract...,"Author4916_1, Author4916_2",,2020-03-01,Medline,10.1000/sample.4916,PMC1004916,,2020.0,3.0,83,12,True,54.0,8.0,False
cord-004918,Analysis of coronavirus and lockdown and pneumonia and treatment in clinical settings,This study examines coronavirus with 252 word abstract...,"Author4918_1, Author4918_2",BMJ,2021-01-17,ArXiv,10.1000/sample.4918,PMC1004918,https://example.com/paper_4918,2021.0,1.0,85,12,True,57.0,8.0,True
cord-004919,Analysis of coronavirus and transmission and immunity and public health in clinical settings,This study examines coronavirus with 108 word abstract...,"Author4919_1, Author4919_2",Clinical Infectious Diseases,2020-07-14,medRxiv,10.1000/sample.4919,,https://example.com/paper_4919,2020.0,7.0,92,13,True,57.0,8.0,True
cord-004921,Analysis of antiviral and pandemic and SARS-CoV-2 and transmission in clinical settings,This study examines antiviral with 110 word abstract...,"Author4921_1, Author4921_2",PLoS ONE,2021-09-18,medRxiv,,,,2021.0,9.0,87,12,True,55.0,8.0,True
cord-004922,Analysis of antiviral and public health and coronavirus in clinical settings,This study examines antiviral with 482 word abstract...,"Author4922_1, Author4922_2",,2020-06-03,medRxiv,10.1000/sample.4922,,https://example.com/paper_4922,2020.0,6.0,76,11,True,55.0,8.0,False
cord-004923,Analysis of lockdown and pneumonia and vaccination and clinical in clinical settings,This study examines lockdown with 361 word abstract...,"Author4923_1, Author4923_2",New England Journal of Medicine,2020-07-17,medRxiv,10.1000/sample.4923,PMC1004923,,2020.0,7.0,84,12,True,54.0,8.0,True
cord-004925,Analysis of SARS-CoV-2 and COVID-19 and vaccination in clinical settings,This study examines SARS-CoV-2 with 463 word abstract...,Author4925_1,Journal of Medical Virology,2020-05-08,medRxiv,10.1000/sample.4925,,,2020.0,5.0,72,10,True,56.0,8.0,True
cord-004928,Analysis of treatment and vaccination and lockdown and coronavirus in clinical settings,,"Author4928_1, Author4928_2",,2021-02-05,ArXiv,10.1000/sample.4928,PMC1004928,https://example.com/paper_4928,2021.0,2.0,87,12,False,,,False
cord-004931,Analysis of diagnosis and antiviral and vaccination and pandemic in clinical settings,This study examines diagnosis with 134 word abstract...,"Author4931_1, Author4931_2",New England Journal of Medicine,2021-12-10,medRxiv,10.1000/sample.4931,PMC1004931,https://example.com/paper_4931,2021.0,12.0,85,12,True,55.0,8.0,True
cord-004932,Analysis of respiratory and pandemic and SARS-CoV-2 and clinical in clinical settings,This study examines respiratory with 409 word abstract...,"Author4932_1, Author4932_2",JAMA,2021-01-19,PMC,10.1000/sample.4932,PMC1004932,https://example.com/paper_4932,2021.0,1.0,85,12,True,57.0,8.0,True
cord-004933,Analysis of COVID-19 and antibody and treatment and SARS-CoV-2 in clinical settings,This study examines COVID-19 with 440 word abstract...,"Author4933_1, Author4933_2",,2021-05-31,WHO,10.1000/sample.4933,PMC1004933,https://example.com/paper_4933,2021.0,5.0,83,12,True,54.0,8.0,False
cord-004934,Analysis of pandemic and antibody and immunity in clinical settings,This study examines pandemic with 157 word abstract...,"Author4934_1, Author4934_2",,2020-11-08,ArXiv,10.1000/sample.4934,PMC1004934,https://example.com/paper_4934,2020.0,11.0,67,10,True,54.0,8.0,False
cord-004936,Analysis of lockdown and diagnosis and symptoms in clinical settings,This study examines lockdown with 474 word abstract...,"Author4936_1, Author4936_2",Lancet,2020-01-21,ArXiv,10.1000/sample.4936,PMC1004936,https://example.com/paper_4936,2020.0,1.0,68,10,True,54.0,8.0,True
cord-004937,Analysis of epidemiology and clinical and vaccination in clinical settings,This study examines epidemiology with 421 word abstract...,"Author4937_1, Author4937_2",,2020-03-21,ArXiv,10.1000/sample.4937,PMC1004937,https://example.com/paper_4937,2020.0,3.0,74,10,True,58.0,8.0,False
cord-004939,Analysis of SARS-CoV-2 and vaccination and immunity in clinical settings,This study examines SARS-CoV-2 with 337 word abstract...,Author4939_1,Journal of Medical Virology,2022-04-15,ArXiv,10.1000/sample.4939,PMC1004939,https://example.com/paper_4939,2022.0,4.0,72,10,True,56.0,8.0,True
cord-004940,Analysis of pandemic and symptoms and therapeutic and vaccination in clinical settings,This study examines pandemic with 453 word abstract...,"Author4940_1, Author4940_2",Virology,,ArXiv,10.1000/sample.4940,PMC1004940,https://example.com/paper_4940,,,86,12,True,54.0,8.0,True
cord-004943,Analysis of immunity and symptoms and antiviral and antibody in clinical settings,This study examines immunity with 131 word abstract...,"Author4943_1, Author4943_2",Cell,2022-01-27,Medline,10.1000/sample.4943,PMC1004943,,2022.0,1.0,81,12,True,54.0,8.0,True
cord-004944,Analysis of vaccination and therapeutic and symptoms and outbreak in clinical settings,This study examines vaccination with 197 word abstract...,"Author4944_1, Author4944_2",PLoS ONE,2021-12-13,bioRxiv,10.1000/sample.4944,PMC1004944,https://example.com/paper_4944,2021.0,12.0,86,12,True,57.0,8.0,True
cord-004945,Analysis of outbreak and diagnosis and public health and pneumonia in clinical settings,This study examines outbreak with 432 word abstract...,"Author4945_1, Author4945_2",JAMA,2021-05-28,ArXiv,10.1000/sample.4945,PMC1004945,https://example.com/paper_4945,2021.0,5.0,87,13,True,54.0,8.0,True
cord-004948,Analysis of coronavirus and treatment and antiviral and vaccination in clinical settings,This study examines coronavirus with 413 word abstract...,"Author4948_1, Author4948_2",Journal of Medical Virology,,Medline,10.1000/sample.4948,PMC1004948,https://example.com/paper_4948,,,88,12,True,57.0,8.0,True
cord-004949,Analysis of immunity and antibody and diagnosis and epidemiology in clinical settings,This study examines immunity with 250 word abstract...,"Author4949_1, Author4949_2",Clinical Infectious Diseases,2022-12-31,PMC,10.1000/sample.4949,PMC1004949,https://example.com/paper_4949,2022.0,12.0,85,12,True,54.0,8.0,True
cord-004951,Analysis of outbreak and pneumonia and pandemic and coronavirus in clinical settings,This study examines outbreak with 467 word abstract...,"Author4951_1, Author4951_2",Science Translational Medicine,2021-08-29,Medline,10.1000/sample.4951,,https://example.com/paper_4951,2021.0,8.0,84,12,True,54.0,8.0,True
cord-004952,Analysis of symptoms and lockdown and public health and pneumonia in clinical settings,This study examines symptoms with 216 word abstract...,"Author4952_1, Author4952_2",Clinical Infectious Diseases,2022-10-16,WHO,10.1000/sample.4952,,https://example.com/paper_4952,2022.0,10.0,86,13,True,54.0,8.0,True
cord-004953,Analysis of treatment and COVID-19 and clinical and symptoms in clinical settings,This study examines treatment with 308 word abstract...,"Author4953_1, Author4953_2",Clinical Infectious Diseases,2021-05-26,bioRxiv,10.1000/sample.4953,PMC1004953,https://example.com/paper_4953,2021.0,5.0,81,12,True,55.0,8.0,True
cord-004954,Analysis of diagnosis and outbreak and COVID-19 and symptoms in clinical settings,This study examines diagnosis with 475 word abstract...,"Author4954_1, Author4954_2",Cell,2021-01-14,WHO,10.1000/sample.4954,PMC1004954,https://example.com/paper_4954,2021.0,1.0,81,12,True,55.0,8.0,True
cord-004956,Analysis of coronavirus and COVID-19 and vaccination and pneumonia in clinical settings,This study examines coronavirus with 232 word abstract...,"Author4956_1, Author4956_2",,2020-09-07,ArXiv,10.1000/sample.4956,PMC1004956,https://example.com/paper_4956,2020.0,9.0,87,12,True,57.0,8.0,False
cord-004959,Analysis of pneumonia and treatment and antiviral in clinical settings,This study examines pneumonia with 252 word abstract...,"Author4959_1, Author4959_2",Emerging Infectious Diseases,2021-01-03,PMC,10.1000/sample.4959,PMC1004959,https://example.com/paper_4959,2021.0,1.0,70,10,True,55.0,8.0,True
cord-004960,Analysis of pneumonia and SARS-CoV-2 and immunity and coronavirus in clinical settings,This study examines pneumonia with 224 word abstract...,"Author4960_1, Author4960_2",Science Translational Medicine,2020-05-19,Medline,10.1000/sample.4960,PMC1004960,https://example.com/paper_4960,2020.0,5.0,86,12,True,55.0,8.0,True
cord-004961,Analysis of coronavirus and epidemiology and treatment and SARS-CoV-2 in clinical settings,This study examines coronavirus with 257 word abstract...,"Author4961_1, Author4961_2",Cell,2021-08-13,PMC,,PMC1004961,https://example.com/paper_4961,2021.0,8.0,90,12,True,57.0,8.0,True
cord-004962,Analysis of lockdown and diagnosis and antiviral and symptoms in clinical settings,,"Author4962_1, Author4962_2",BMJ,2021-06-21,Medline,10.1000/sample.4962,PMC1004962,https://example.com/paper_4962,2021.0,6.0,82,12,False,,,True
cord-004964,Analysis of treatment and lockdown and SARS-CoV-2 in clinical settings,This study examines treatment with 316 word abstract...,"Author4964_1, Author4964_2",Science Translational Medicine,2021-05-31,bioRxiv,10.1000/sample.4964,PMC1004964,https://example.com/paper_4964,2021.0,5.0,70,10,True,55.0,8.0,True
cord-004965,Analysis of transmission and antiviral and SARS-CoV-2 and pandemic in clinical settings,This study examines transmission with 190 word abstract...,"Author4965_1, Author4965_2",,2019-12-10,WHO,10.1000/sample.4965,PMC1004965,,2019.0,12.0,87,12,True,58.0,8.0,False
cord-004966,Analysis of COVID-19 and pandemic and therapeutic and antiviral in clinical settings,This study examines COVID-19 with 449 word abstract...,Author4966_1,Cell,2021-03-26,PMC,10.1000/sample.4966,PMC1004966,https://example.com/paper_4966,2021.0,3.0,84,12,True,54.0,8.0,True
cord-004969,Analysis of epidemiology and public health and pandemic in clinical settings,This study examines epidemiology with 249 word abstract...,"Author4969_1, Author4969_2",Lancet,2020-11-21,Medline,10.1000/sample.4969,,,2020.0,11.0,76,11,True,58.0,8.0,True
cord-004971,Analysis of antiviral and respiratory and diagnosis and SARS-CoV-2 in clinical settings,This study examines antiviral with 358 word abstract...,"Author4971_1, Author4971_2",Journal of Virology,2020-04-08,ArXiv,,PMC1004971,,2020.0,4.0,87,12,True,55.0,8.0,True
cord-004972,Analysis of public health and pandemic and antibody in clinical settings,This study examines public health with 298 word abstract...,"Author4972_1, Author4972_2",Virology,2020-04-23,PMC,10.1000/sample.4972,PMC1004972,https://example.com/paper_4972,2020.0,4.0,72,11,True,59.0,9.0,True
cord-004973,Analysis of symptoms and antiviral and respiratory and treatment in clinical settings,This study examines symptoms with 460 word abstract...,"Author4973_1, Author4973_2",Nature,2020-12-12,medRxiv,,PMC1004973,https://example.com/paper_4973,2020.0,12.0,85,12,True,54.0,8.0,True
cord-004974,Analysis of diagnosis and clinical and coronavirus and pneumonia in clinical settings,This study examines diagnosis with 247 word abstract...,"Author4974_1, Author4974_2",Lancet,2020-05-14,Medline,10.1000/sample.4974,PMC1004974,https://example.com/paper_4974,2020.0,5.0,85,12,True,55.0,8.0,True
cord-004979,Analysis of lockdown and antibody and respiratory and treatment in clinical settings,This study examines lockdown with 233 word abstract...,"Author4979_1, Author4979_2",Clinical Infectious Diseases,2021-05-06,ArXiv,,,https://example.com/paper_4979,2021.0,5.0,84,12,True,54.0,8.0,True
cord-004981,Analysis of pandemic and vaccination and respiratory and COVID-19 in clinical settings,This study examines pandemic with 439 word abstract...,"Author4981_1, Author4981_2",JAMA,2020-03-28,medRxiv,10.1000/sample.4981,PMC1004981,https://example.com/paper_4981,2020.0,3.0,86,12,True,54.0,8.0,True
cord-004982,Analysis of vaccination and COVID-19 and SARS-CoV-2 in clinical settings,This study examines vaccination with 144 word abstract...,"Author4982_1, Author4982_2",,,ArXiv,10.1000/sample.4982,,https://example.com/paper_4982,,,72,10,True,57.0,8.0,False
cord-004984,Analysis of public health and immunity and pneumonia and symptoms in clinical settings,This study examines public health with 409 word abstract...,"Author4984_1, Author4984_2",Journal of Virology,2021-07-21,ArXiv,10.1000/sample.4984,PMC1004984,https://example.com/paper_4984,2021.0,7.0,86,13,True,59.0,9.0,True
cord-004986,Analysis of COVID-19 and pneumonia and antiviral in clinical settings,This study examines COVID-19 with 431 word abstract...,"Author4986_1, Author4986_2",JAMA,2020-08-06,PMC,10.1000/sample.4986,,https://example.com/paper_4986,2020.0,8.0,69,10,True,54.0,8.0,True
cord-004987,Analysis of SARS-CoV-2 and pandemic and COVID-19 in clinical settings,This study examines SARS-CoV-2 with 376 word abstract...,Author4987_1,JAMA,2021-03-04,PMC,10.1000/sample.4987,,https://example.com/paper_4987,2021.0,3.0,69,10,True,56.0,8.0,True
cord-004989,Analysis of lockdown and COVID-19 and pneumonia and antiviral in clinical settings,This study examines lockdown with 426 word abstract...,"Author4989_1, Author4989_2",JAMA,,ArXiv,10.1000/sample.4989,PMC1004989,https://example.com/paper_4989,,,82,12,True,54.0,8.0,True
cord-004992,Analysis of pneumonia and diagnosis and antiviral in clinical settings,This study examines pneumonia with 299 word abstract...,Author4992_1,Journal of Virology,2021-10-31,PMC,10.1000/sample.4992,PMC1004992,https://example.com/paper_4992,2021.0,10.0,70,10,True,55.0,8.0,True
cord-004994,Analysis of pandemic and vaccination and symptoms in clinical settings,This study examines pandemic with 434 word abstract...,"Author4994_1, Author4994_2",Clinical Infectious Diseases,2022-03-15,PMC,10.1000/sample.4994,PMC1004994,https://example.com/paper_4994,2022.0,3.0,70,10,True,54.0,8.0,True
cord-004996,Analysis of transmission and outbreak and epidemiology and treatment in clinical settings,This study examines transmission with 412 word abstract...,Author4996_1,Virology,2022-11-03,WHO,10.1000/sample.4996,PMC1004996,,2022.0,11.0,89,12,True,58.0,8.0,True
cord-004997,Analysis of pandemic and therapeutic and coronavirus in clinical settings,This study examines pandemic with 373 word abstract...,Author4997_1,Science,2020-11-25,Medline,,PMC1004997,https://example.com/paper_4997,2020.0,11.0,73,10,True,54.0,8.0,True
cord-004998,Analysis of coronavirus and treatment and pneumonia in clinical settings,This study examines coronavirus with 312 word abstract...,"Author4998_1, Author4998_2",New England Journal of Medicine,2021-09-14,WHO,10.1000/sample.4998,PMC1004998,https://example.com/paper_4998,2021.0,9.0,72,10,True,57.0,8.0,True
cord-004999,Analysis of pandemic and clinical and treatment in clinical settings,This study examines pandemic with 181 word abstract...,"Author4999_1, Author4999_2",Nature Medicine,2020-11-02,medRxiv,10.1000/sample.4999,PMC1004999,https://example.com/paper_4999,2020.0,11.0,68,10,True,54.0,8.0,True
